0001493152-23-030029.txt : 20230824 0001493152-23-030029.hdr.sgml : 20230824 20230823215501 ACCESSION NUMBER: 0001493152-23-030029 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230824 DATE AS OF CHANGE: 20230823 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viveon Health Acquisition Corp. CENTRAL INDEX KEY: 0001823857 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39827 FILM NUMBER: 231198811 BUSINESS ADDRESS: STREET 1: 3480 PEACHTREE ROAD NE STREET 2: 2ND FLOOR - SUITE #112 CITY: ATLANTA STATE: GA ZIP: 30326 BUSINESS PHONE: 4045797978 MAIL ADDRESS: STREET 1: 3480 PEACHTREE ROAD NE STREET 2: 2ND FLOOR - SUITE #112 CITY: ATLANTA STATE: GA ZIP: 30326 10-K 1 form10-k.htm
0001823857 false FY 0001823857 2022-01-01 2022-12-31 0001823857 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001823857 VHAQ:WarrantsMember 2022-01-01 2022-12-31 0001823857 VHAQ:UnitsMember 2022-01-01 2022-12-31 0001823857 us-gaap:RightsMember 2022-01-01 2022-12-31 0001823857 2022-06-30 0001823857 2023-08-22 0001823857 2022-12-31 0001823857 2021-12-31 0001823857 2021-01-01 2021-12-31 0001823857 us-gaap:CommonStockMember 2021-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001823857 us-gaap:RetainedEarningsMember 2021-12-31 0001823857 us-gaap:CommonStockMember 2020-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001823857 us-gaap:RetainedEarningsMember 2020-12-31 0001823857 2020-12-31 0001823857 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001823857 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001823857 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001823857 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001823857 us-gaap:CommonStockMember 2022-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001823857 us-gaap:RetainedEarningsMember 2022-12-31 0001823857 us-gaap:IPOMember VHAQ:PublicSharesMember 2020-12-28 2020-12-28 0001823857 us-gaap:IPOMember VHAQ:PublicSharesMember 2020-12-28 0001823857 us-gaap:IPOMember 2020-12-28 2020-12-28 0001823857 us-gaap:IPOMember VHAQ:PrivateWarrantsMember 2020-12-28 2020-12-28 0001823857 us-gaap:IPOMember VHAQ:PrivateWarrantsMember 2020-12-28 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-30 2020-12-30 0001823857 us-gaap:IPOMember 2022-01-01 2022-12-31 0001823857 us-gaap:IPOMember 2022-12-31 0001823857 2022-03-23 0001823857 2022-03-18 0001823857 2022-10-28 0001823857 2022-06-23 0001823857 2022-07-26 0001823857 2022-08-30 0001823857 2022-09-28 0001823857 2022-11-28 0001823857 2022-12-28 0001823857 srt:ScenarioForecastMember 2023-04-28 0001823857 srt:ScenarioForecastMember 2023-05-24 0001823857 us-gaap:SubsequentEventMember 2023-06-22 0001823857 us-gaap:SubsequentEventMember 2023-06-22 2023-06-22 0001823857 us-gaap:SubsequentEventMember 2023-06-27 0001823857 us-gaap:SubsequentEventMember 2023-07-27 0001823857 srt:MaximumMember 2022-07-13 2022-07-13 0001823857 srt:MinimumMember 2022-07-13 2022-07-13 0001823857 2022-07-13 2022-07-13 0001823857 2022-11-10 2022-11-10 0001823857 VHAQ:CleardayMember us-gaap:SubsequentEventMember 2023-04-05 0001823857 VHAQ:CleardayMember us-gaap:SubsequentEventMember VHAQ:EarnoutSharesMember 2023-04-05 2023-04-05 0001823857 VHAQ:SeriesFCumulativeConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-04-05 0001823857 us-gaap:SubsequentEventMember VHAQ:SeriesFCumulativeConvertiblePreferredStockMember 2023-04-05 2023-04-05 0001823857 VHAQ:SeriesACumulativeConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-04-05 0001823857 us-gaap:SubsequentEventMember VHAQ:SeriesACumulativeConvertiblePreferredStockMember 2023-04-05 2023-04-05 0001823857 us-gaap:SubsequentEventMember 2023-04-05 0001823857 us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 0001823857 us-gaap:SubsequentEventMember VHAQ:CleardayMember 2023-04-05 2023-04-05 0001823857 us-gaap:SubsequentEventMember VHAQ:NewMergerMember 2023-04-05 0001823857 us-gaap:SubsequentEventMember VHAQ:ViveonEquityIncentivePlanMember 2023-04-05 0001823857 2022-08-16 0001823857 2022-11-25 0001823857 2022-03-27 0001823857 VHAQ:PublicWarrantsMember 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember 2022-12-31 0001823857 VHAQ:RedeemableCommonStockMember 2022-01-01 2022-12-31 0001823857 VHAQ:NonRedeemableCommonStockMember 2022-01-01 2022-12-31 0001823857 VHAQ:RedeemableCommonStockMember 2021-01-01 2021-12-31 0001823857 VHAQ:NonRedeemableCommonStockMember 2021-01-01 2021-12-31 0001823857 us-gaap:IPOMember 2020-12-28 0001823857 2020-12-28 0001823857 us-gaap:PrivatePlacementMember 2022-12-31 0001823857 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001823857 VHAQ:FounderSharesMember 2020-08-01 2020-08-31 0001823857 VHAQ:FounderSharesMember 2020-08-31 0001823857 VHAQ:FounderSharesMember 2020-12-01 2020-12-03 0001823857 VHAQ:FounderSharesMember 2020-12-21 2020-12-22 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-21 2020-12-22 0001823857 VHAQ:FounderSharesMember 2020-12-30 2020-12-30 0001823857 VHAQ:FounderSharesMember 2022-01-01 2022-12-31 0001823857 VHAQ:FounderSharesMember VHAQ:SponsorMember 2020-12-23 2020-12-23 0001823857 VHAQ:FounderSharesMember VHAQ:TransfereeMember 2020-12-23 2020-12-23 0001823857 VHAQ:FounderSharesMember VHAQ:SponsorMember 2021-04-30 2021-04-30 0001823857 2021-04-29 2021-04-30 0001823857 2021-04-30 0001823857 srt:ChiefFinancialOfficerMember VHAQ:NoteAgreementsMember 2022-12-31 0001823857 VHAQ:SponsorMember VHAQ:PromissoryNoteMember 2022-01-01 2022-12-31 0001823857 srt:ChiefFinancialOfficerMember VHAQ:PromissoryNoteMember 2022-12-26 2022-12-27 0001823857 VHAQ:PromissoryNoteMember 2022-12-31 0001823857 VHAQ:PromissoryNoteMember 2021-12-31 0001823857 srt:ChiefFinancialOfficerMember VHAQ:PromissoryNoteMember us-gaap:SubsequentEventMember 2023-01-01 2023-04-28 0001823857 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-04-02 2023-04-02 0001823857 srt:ChiefExecutiveOfficerMember 2022-12-31 0001823857 srt:ChiefExecutiveOfficerMember 2021-12-31 0001823857 VHAQ:ThreeInvestorsMember us-gaap:SubsequentEventMember 2023-01-01 2023-04-07 0001823857 VHAQ:DipakVashirMember 2021-12-31 0001823857 VHAQ:SponsorMember 2022-01-01 2022-12-31 0001823857 VHAQ:SponsorMember 2021-01-01 2021-12-31 0001823857 VHAQ:SponsorMember 2022-12-31 0001823857 VHAQ:SponsorMember 2021-12-31 0001823857 VHAQ:UnsecuredSeniorPromissoryNoteAgreementsMember 2022-01-01 2022-12-31 0001823857 srt:ChiefFinancialOfficerMember 2022-12-31 0001823857 VHAQ:UnsecuredSeniorPromissoryNoteAgreementsMember 2022-12-31 0001823857 VHAQ:UnsecuredPromissoryNoteAgreementsMember 2022-12-31 0001823857 VHAQ:UnsecuredPromissoryNoteAgreementsMember 2022-01-01 2022-12-31 0001823857 us-gaap:SubsequentEventMember VHAQ:SubscriptionWarrantsMember 2023-08-16 0001823857 us-gaap:WarrantMember 2022-03-21 2022-03-21 0001823857 us-gaap:WarrantMember 2022-03-23 2022-03-23 0001823857 us-gaap:WarrantMember 2022-04-04 2022-04-04 0001823857 us-gaap:WarrantMember 2022-04-27 2022-04-27 0001823857 us-gaap:WarrantMember 2022-05-09 2022-05-09 0001823857 us-gaap:WarrantMember 2022-10-27 2022-10-27 0001823857 us-gaap:WarrantMember 2022-11-25 2022-11-25 0001823857 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001823857 VHAQ:StrategicAdvisorMember 2021-05-18 0001823857 VHAQ:StrategicAdviserMember 2021-11-01 0001823857 VHAQ:ExclusiveFinancialAdvisorMember 2021-10-08 0001823857 VHAQ:SecondFinancialAdvisorMember 2021-11-01 0001823857 VHAQ:ThirdFinancialAdvisorMember 2021-11-02 0001823857 2021-11-05 0001823857 VHAQ:PlacementAgentsMember 2021-11-15 2021-11-15 0001823857 2022-02-17 2022-02-17 0001823857 VHAQ:PlacementAgentsMember us-gaap:SubsequentEventMember 2023-05-09 2023-05-09 0001823857 us-gaap:SubsequentEventMember 2023-04-28 0001823857 us-gaap:SubsequentEventMember 2023-05-24 0001823857 us-gaap:CommonStockMember 2022-12-23 2022-12-23 0001823857 us-gaap:CommonStockMember 2022-12-23 0001823857 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-12-23 0001823857 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2023-12-23 0001823857 us-gaap:WarrantMember 2022-12-31 0001823857 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001823857 us-gaap:IPOMember 2021-12-31 0001823857 us-gaap:PrivatePlacementMember 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember 2022-01-01 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:MoneyMarketFundsHeldInTrustAccountMember 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:MoneyMarketFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:MoneyMarketFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:MoneyMarketFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:PrivateWarrantLiabilityMember 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:SubscriptionWarrantLiabilityMember 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:SubscriptionWarrantLiabilityMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:SubscriptionWarrantLiabilityMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:SubscriptionWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:PrivateWarrantLiabilityMember 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001823857 us-gaap:FairValueMeasurementsRecurringMember VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-21 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-11-25 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-10-27 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-05-09 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-04-27 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-04-04 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-03-23 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-03-21 2022-03-21 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-11-25 0001823857 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-21 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-03-21 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2022-03-21 0001823857 VHAQ:PrivateWarrantMember 2022-01-01 2022-12-31 0001823857 VHAQ:PrivateWarrantMember VHAQ:UnsucessfulBusinessCombinationMember 2022-01-01 2022-12-31 0001823857 VHAQ:PrivateWarrantMember VHAQ:UnsuccessfulBusinessCombinationMember 2022-12-31 0001823857 VHAQ:PrivateWarrantMember VHAQ:SuccessfulBusinessCombinationMember 2022-01-01 2022-12-31 0001823857 VHAQ:PrivateWarrantMember VHAQ:SuccessfulBusinessCombinationMember 2022-12-31 0001823857 VHAQ:PrivateAndSubscriptionWarrantsMember 2022-01-01 2022-12-31 0001823857 VHAQ:PrivateAndSubscriptionWarrantsMember 2021-01-01 2021-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnMarchTwentyOneTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnMarchTwentyThreeTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnAprilFourTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnAprilTwentySevenTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnMayNineTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnOctoberTwentySevenTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnNovemberTwentyFiveTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 us-gaap:DomesticCountryMember 2022-12-31 0001823857 us-gaap:DomesticCountryMember 2021-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2022

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _________ to _________

 

Commission file number 001-39827

 

VIVEON HEALTH ACQUISITION CORP.

(Exact name of registrant as specified in its charter)

 

Delaware   85-2788202

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S Employer

Identification No.)

 

3480 Peachtree Road NE

2nd Floor - Suite #112

Atlanta, Georgia 30326

(Address of principal executive offices and zip code)

 

(404)-861-5393

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   VHAQ   NYSE American, LLC
Warrants   VHAQW   NYSE American, LLC
Units   VHAQ   NYSE American, LLC
Rights   VHAQR   NYSE American, LLC

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
  Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that require a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

 

The aggregate market value of the outstanding shares of the registrant’s common stock, other than shares held by persons who may be deemed affiliates of the registrant, computed by reference to the closing price for the common stock on June 30, 2022, as reported on the Nasdaq Capital Market, was $103,157,271.

 

As of August 22, 2023, there were 6,648,665 shares of the registrant’s common stock, par value $0.0001 per share, issued and outstanding.

 

 

 

 
 

 

VIVEON HEALTH ACQUISITION CORP.

 

TABLE OF CONTENTS

 

PART I  
ITEM 1. BUSINESS 4
ITEM 1A. RISK FACTORS 20
ITEM 1B. UNRESOLVED STAFF COMMENTS 20
ITEM 2. PROPERTIES 20
ITEM 3. LEGAL PROCEEDINGS 20
ITEM 4. MINE SAFETY DISCLOSURES 20
     
PART II  
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 21
ITEM 6. [RESERVED] 22
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 22
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 34
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 34
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 34
ITEM 9A. CONTROLS AND PROCEDURES 34
ITEM 9B. OTHER INFORMATION 36
ITEM 9C DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION 36
     
PART III  
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 37
ITEM 11. EXECUTIVE COMPENSATION 44
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 44
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 46
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 48
     
PART IV  
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 49

 

2
 

 

FORWARD LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. The statements contained in this report that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this report may include, for example, statements about our:

 

  ● ability to complete our initial business combination;
     
  ● success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination;
     
  ● officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination, as a result of which they would then receive expense reimbursements;
     
  ● potential ability to obtain additional financing to complete our initial business combination;
     
  ● pool of prospective target businesses;
     
  ● the ability of our officers and directors to generate a number of potential investment opportunities;
     
  ● potential change in control if we acquire one or more target businesses for stock;
     
  ● the potential liquidity and trading of our securities;
     
  ● the lack of a market for our securities;
     
  ● use of proceeds not held in the trust account established at Continental Stock Transfer & Trust Company in connection with its initial public offering (the “Trust Account”). or available to us from interest income on the Trust Account balance; and
     
  ● financial performance following our initial public offering.

 

The forward-looking statements contained in this report are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors.” Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws and/or if and when management knows or has a reasonable basis on which to conclude that previously disclosed projections are no longer reasonably attainable.

 

3
 

 

PART I

 

ITEM 1. BUSINESS

 

Introduction

 

Viveon Health Acquisition Corp. (“Viveon,” “we,” “us,” or “our”) is a Delaware company incorporated on August 7, 2020 as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination, with one or more target businesses.

 

On December 28, 2020, Viveon consummated its initial public offering (the “IPO”) of 17,500,000 units (the “Units”), each Unit consisting of one share of common stock of the Company, par value $0.0001 per share (the “Common Stock”) and one redeemable warrant (“Warrant”), entitling the holder thereof to purchase one-half of a share of Common Stock at a price of $11.50 per whole share, and one right to receive one-twentieth (1/20) of a share of Common Stock. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $175,000,000. On December 28, 2020, the underwriters of the IPO, Chardan Capital Markets, LLC (“Chardan” or the “underwriters”) exercised the over-allotment option in full, and the closing occurred on December 30, 2020 when Viveon sold 2,625,000 Over-Allotment Option Units at a price of $10.00 per unit, generating additional gross proceeds of $26,250,000.

 

On December 28, 2020, simultaneously with the consummation of the IPO, we consummated a private placement (“Private Placement”) with Viveon Health, LLC (the “Sponsor”) of 18,000,000 warrants (the “Private Warrants”) at a price of $0.50 per Private Warrant, generating total proceeds of $9,000,000. The Private Warrants are identical to the Warrants (as defined below) sold in the IPO except that the Private Warrants are non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the Sponsor, or its permitted transferees. Additionally, our Sponsor agreed not to transfer, assign, or sell any of the Private Warrants or underlying securities (except in limited circumstances, as described in the Private Placement Warrants Subscription Statement) until the date we complete our initial business combination. The Sponsor was granted certain demand and piggyback registration rights in connection with the purchase of the Private Warrants.

 

A total of $203,262,500 of the net proceeds from the sale of Units in the IPO and the private placement were placed in a trust account (the “Trust Account”) established for the benefit of the Company’s public stockholders at J.P. Morgan Chase Bank, N.A. maintained by Continental Stock Transfer & Trust Company, acting as trustee. At the time of the IPO, the Company’s amended and restated certificate of incorporation provided, among other things that none of the funds held in trust will be released from the Trust Account, other than interest income to pay any tax obligations, until the earlier of (i) the consummation of the Company’s initial business combination, (ii) the Company’s failure to consummate a business combination by 15 months from the consummation of the IPO (March 18, 2022), and (iii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend Viveon’s amended and restated certificate of incorporation (a) to modify the substance or timing of the ability of holders of Viveon’s public shares to seek redemption in connection with Viveon’s initial business combination or Viveon’s obligation to redeem 100% of its public shares if Viveon does not complete its initial business combination by 15 months from the consummation of the IPO (March 28, 2022) or (b) with respect to any other provision relating to stockholders’ rights or pre-business combination activity.

 

Extensions of Business Combination Period and Amendment to Our Certificate of Incorporation

 

First Extension and First Amendment

 

On March 18, 2022, the Company held a stockholder meeting to seek approval to amend the Company’s amended and restated certificate of incorporation (the “First Amendment”) to extend the date by which the Company has to consummate a business combination from March 28, 2022 (the “Original Termination Date”) to June 28, 2022. The First Amendment (i) extends the date by which we have to consummate a business combination for three months, from the Original Termination Date to June 30, 2022 and (ii) allows us, without another stockholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time after June 30, 2023, upon five days’ advance notice and the deposit of $240,000 per month prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed business combination with Suneva Medical, Inc. or any potential alternative initial business combination shall have occurred.

 

The stockholders approved the First Amendment at the meeting.

 

On March 23, 2022, we filed the First Amendment with the Delaware Secretary of State. A copy of the First Amendment, as filed, is incorporated by reference into this Annual Report as Exhibit 3.2.

 

As a result of the First Amendment, on March 23, 2022, we also entered into an amendment (the “IMTA Amendment”) to the Investment Management Trust Agreement, dated as of December 22, 2020, with Continental Stock Transfer & Trust Company, as trustee (the “IMTA”). This IMTA Amendment amends and restates Sections 1(i), 7(c) and 7(j) of the IMTA to reflect the changes based on the First Amendment. A copy of the IMTA Amendment, is incorporated by reference into this Annual Report as Exhibit 10.18.

 

In connection with the First Amendment, the Company made a deposit into the Trust Account of $720,000 on March 23, 2022 and stockholders redeemed 15,092,126 shares resulting in redemption payments out of the Trust Account to such redeeming stockholders totaling approximately $152,451,819, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date.

 

4
 

 

On each of June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022 and November 25, 2022, the Company deposited $240,000 into the Trust Account to extend the date to consummate a Business Combination through July 28, 2022, August 28, 2022, September 28, 2022, October 28, 2022, November 28, 2022 and December 28, 2022, respectively.

 

Second Extension and Second Amendment

 

Viveon held its 2022 Annual Meeting of Stockholders (“Annual Meeting”) on December 23, 2022 to seek approval to, among other things, amend the Company’s amended and restated certificate of incorporation (the “Second Amendment”), to allow the Company to extend the date to consummate a business combination from December 28, 2022 until June 30, 2023 (the “Second Extended Date”). The Second Amendment allows us to elect to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time after December 28, 2022, upon three calendar days’ advance notice and the deposit of $100,000 per month prior to the applicable deadline, until June 30, 2023, unless the closing of the proposed business combination with Suneva Medical, Inc. or any potential alternative initial business combination shall have occurred. The Stockholders approved the Second Amendment at the Annual Meeting.

 

On December 23, 2022, we filed the Second Amendment with the Delaware Secretary of State. A copy of the Second Amendment, as filed is incorporated by reference into this Annual Report as Exhibit 3.3.

 

In connection with the Second Amendment stockholders redeemed 3,188,100 shares resulting in redemption payments out of the Trust Account to pay such redeeming stockholders, totaling approximately $34,004,514, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date.

 

As a result of the Second Amendment, on January 20, 2023 we also entered into an IMTA amendment that amends and restates Sections 1(i), 7(c) and 7(j) of the original IMTA to reflect the changes based on the Second Amendment. A copy of the amendment, is included as Exhibit 10.19 to this Annual Report.

 

In connection with the Second Amendment, on each of December 27, 2022, January 26, 2023, February 27, 2023, March 27, 2023 and April 28, 2023, the Company deposited $100,000 into the Trust Account to extend the date to consummate a Business Combination through January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023, respectively. Viveon made a final deposit of $100,000 on May 24, 2023 for a one month extension until June 30, 2023.

 

Third Extension and Third Amendment

 

On June 22, 2023, the Company held a stockholder meeting (the “June 2023 Stockholders Meeting”) to seek approval to, among other things, to amend the Company’s amended and restated certificate of incorporation (the “Third Amendment”), to allow the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to the Trustee, prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date; and (B) to amend the Company’s IMTA, allowing the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, each such extension for an additional one month period, with no additional deposits to be made into the Trust Account during such period from January 1, 2024 through March 31, 2024. The Stockholders approved the Third Amendment at the June 2023 Stockholders Meeting.

 

On June 27, 2023, we filed the Third Amendment with the Delaware Secretary of State. A copy of the Third Amendment, as filed is incorporated by reference into this Annual Report as Exhibit 3.4.   

 

In connection with the Third Amendment stockholders redeemed 227,359 shares resulting in redemption payments out of the Trust Account to pay such redeeming stockholders, totaling $2,498,947, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date.

 

On June 27, 2023 and July 27, 2023, the Company deposited $85,000 in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023 and August 31, 2023, respectively.

 

As a result of the Third Amendment, we also entered into an amendment to the IMTA, dated as of July 27, 2023, that amends and restates Sections 1(i), 7(c) and 7(j) of the original IMTA to reflect the change based on the Third Amendment. A copy of the amendment, is included as Exhibit 10.20 to this Annual Report.

 

Following all of the prior redemptions, the Company has 1,617,415 shares of public common stock outstanding, and approximately $17,777,323 remaining in the Trust Account as of the date hereof.

  

Termination of Merger Agreement

 

As disclosed in a Current Report on Form 8-K on January 12, 2022, Viveon Health Acquisition Corp., a Delaware corporation (“Viveon”), entered into a Merger Agreement (the “Old Merger Agreement”) by and among Viveon, VHAC Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Viveon (“Old Merger Sub”), and Suneva Medical, Inc., a Delaware corporation (“Suneva”). Pursuant to the terms of the Merger Agreement, a business combination between Viveon and Suneva was proposed to be effected through the merger of Merger Sub with and into Suneva, with Suneva surviving the merger as a wholly owned subsidiary of Viveon (the “Old Merger”). At the time of the signing of the Merger Agreement, the board of directors of Viveon had (i) approved and declared advisable the Merger Agreement, the Old Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Old Merger Agreement and related transactions by the stockholders of Viveon.

 

On February 2, 2023, legal counsel for Viveon sent a letter informing Suneva’s legal counsel that Viveon decided, effective immediately, to unilaterally terminate the Old Merger Agreement pursuant to Sections 10.2(a) and 10.2 thereof, based upon material breaches of the Old Merger Agreement by Suneva. The termination letter was sent without prejudice and reserved all of Viveon, Old Merger Sub and Viveon Health, LLC (Viveon’s sponsor) rights, claims and remedies, specifically including those within the Old Merger Agreement, against Suneva and others associated with Suneva who participated in the merger discussions and arrangements, and waived none.

 

5
 

 

Funding for Extension and Working Capital

 

On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, we entered into subscription agreements with several lenders for a loan of up to $4,000,000, in the aggregate (the “Subscription Agreements”).

 

Pursuant to the Subscription Agreements, we issued a series of unsecured senior promissory notes in the aggregate principal amount of up to $4,000,000 (the “Notes”) to the subscribers. Of the $4,000,000 in Notes, $1,955,000 was subscribed for by several related parties affiliated with our sponsor, Viveon Health LLC, and the balance in the amount of $2,045,000 was subscribed for by parties that are not related to our sponsor.

 

Pursuant to the terms of the Subscription Agreements, the subscribers also received warrants to purchase one share of our common stock for every $2.00 of the funded principal amount of the Notes up to 2,000,000 shares of our common stock, in the aggregate, at an exercise price of $11.50 per share, subject to adjustment (the “Subscription Warrants”). The Subscription Warrant term commences on the Exercise Date (as hereinafter defined) for a period of 49 months. The Subscription Warrants are exercisable commencing on the date of the initial business combination (the “Exercise Date”) and have a cashless exercise feature that is available at any time on or after the Exercise Date. Commencing on the date 13 months following the Exercise Date, the subscribers have the right, but not the obligation, to put the Subscription Warrants to us at a purchase price of $5.00 per share. We have agreed to file, within thirty (30) calendar days after the consummation of an initial business combination, a registration statement with the Securities and Exchange Commission to register for resale the shares of common stock underlying the Subscription Warrants.

 

The Notes do not bear interest and mature upon the earlier of (i) the closing of our initial business combination, and (ii) December 31, 2022 (the “Maturity Date”). The Notes provide for a credit line up to the maximum amount of $4,000,000. We will not have the right to re-borrow any portion of any loans made under the Notes once repaid. As of December 31, 2022, a commitment fee in the amount of $400,000, equal to 10% of the maximum principal amount of the Note, had been paid to the subscribers, on a pro rata basis. In the event that we do not consummate a business combination by the Maturity Date, the Notes will be repaid only from amounts remaining outside of our Trust Account, if any. Subsequent to December 31, 2022, in connection with the Merger Agreement (as defined below) a majority of the holders of the Notes and Subscription Warrants have agreed to exchange such Notes and Subscription Warrants pursuant to the terms of an exchange agreement with Viveon dated as of May 1, 2023 (the Exchange Agreement”) for a separate series of Clearday senior convertible promissory notes (the “Clearday Senior Convertible Notes”). The Clearday Senior Convertible Notes bear 8% interest per annum and mature upon the earlier of (i) June 30, 2024, or (ii) the date of any Change in Control. Upon the consummation of the business combination and the exchange of the Subscription Agreements for the Clearday Senior Convertible Notes, the lenders will forfeit their Subscription Warrants as part of the exchange. One lender has chosen not to convert to Clearday Senior Convertible Notes. The balance owed to this lender under the Notes is considered due upon demand by the lender. As of the date of this filing of this Annual Report the lender has not requested payment of the Note.

 

On March 21, 2022, an initial amount of $2,700,000 was drawn down from the Notes. $720,000 of the loan proceeds was deposited into our Trust Account in connection with extending the business combination completion window from March 28, 2022 until June 28, 2022. After June 28, 2022, we elected to continue to extend such date until December 28, 2022 by making a monthly deposit of $240,000 into the Trust Account each month for each monthly period until December 28, 2022. See section titled “Extensions of Business Combination Period and Amendments to Our Certificate of Incorporation” of this Annual Report for further detail.

 

The entry into the Subscription Agreement and the terms of the Notes and Subscription Warrants was approved by the Audit Committee of the Board of Directors of the Company at a meeting held on March 21, 2022.

 

The foregoing descriptions of the Note, the Subscription Warrant and the Subscription Agreement are qualified in their entirety by reference to the full text of the Note, the Subscription Warrant and the Subscription Agreement, which are incorporated by reference into this Annual Report as Exhibit 10.15, Exhibit 10.16 and Exhibit 10.17, respectively. The foregoing description of the Exchange Agreement is qualified in its entirety by reference to the full text of the Exchange Agreement which filed as Exhibit 10.21 to this Annual Report.

 

Our Sponsor agreed to loan the Company an aggregate of up to $500,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “IPO Note”). This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the Initial Public Offering. On January 13, 2021, we paid the $228,758 balance on the note from the proceeds of the Initial Public Offering. We no longer have the ability to borrow under the IPO Note.

 

Our Chief Financial Officer loaned the Company $75,000 to cover expenses related to ongoing operations, which was funded on December 27, 2022. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on December 27, 2022.

 

As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $75,000 and $0, respectively. Subsequent to December 31, 2022, our Chief Financial Officer loaned the Company an additional $555,000 through the date of this filing. These loans will be exchanged for Clearday Senior Convertible Notes upon consummation of the Company’s initial Business Combination.

 

Our Chief Executive Officer of the Company loaned the Company $100,000 to cover expenses related to ongoing operations, which was funded on April 2, 2023. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on April 2, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $0, respectively.

 

Subsequent to December 31, 2022, three investors in our Sponsor, loaned the Company $100,000 in the aggregate, to cover expenses related to ongoing operations, funded on April 5, 2023, and April 7, 2023. These loans are non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreements were entered into on April 5, 2023, and April 7, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loans was $0, respectively.

 

On May 12, 2023, the Company entered into an unsecured promissory note with Clearday (the “Clearday Note”). The Clearday Note is non-interest bearing mature upon the earlier of (i) the first anniversary of the issuance date and (ii) December 31, 2022. Proceeds provided to us under the Clearday Note through the filing date were approximately $881,710 during fiscal year 2023. Funds in the Trust Account may not be used to repay the obligations under the Clearday Note. We used such funds for general working capital purposes. A copy of the Clearday Note is incorporated as Exhibit 10.22 of this Annual Report, and all references herein to the Clearday Note are qualified in their entirety by reference to the full text of such agreement.

 

Delinquent SEC Filings

 

As previously reported in a Form 12b-25 Notification of Late Filing filed the Company on May 16, 2022, the Company was delayed in filing with the Securities and Exchange Commission (the “SEC”) its Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 (the “Form 10-Q”) because the financial statements could not be completed in sufficient time to solicit and obtain the necessary review of the Form 10-Q in a timely fashion prior to the due date of the report.

 

As of May 23, 2022 the Company remained unable to file the Form 10-Q. As a result, on May 24, 2022, in accordance with standard procedures related to the delayed filing of the Form 10-Q with the SEC, the Company received a late filer notification from the New York Stock Exchange stating that the Company is not in compliance with the NYSE American’s continued listing requirements under the timely filing criteria established in the NYSE American Company Guide. Under Section 1007 of the NYSE American Company Guide, the Company could be granted up to 12 months to cure the late filer deficiency. The initial six month period to regain compliance is automatic and the additional six months is only granted upon request by the Company and approval by the NYSE. The NYSE notice has no immediate effect on the listing or trading of the Company’s securities on the NYSE American. On June 13, 2022, the Company filed its 10-Q and fully regained compliance with the NYSE American’s continued listing requirements.

 

On April 18, 2023, the Company received a notice letter (the “Notice”) from the NYSE Regulation Department (the “Staff”) notifying the Company that, based upon the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”) by the filing due date, April 17, 2023 (the “Filing Delinquency”), it was not in compliance with the New York Stock Exchange American’s continued listing requirements. The Company is now subject to the procedures and requirements set forth in Section 1007 of the New York Stock Exchange American (“NYSE American” or the “Exchange”) Company Guide (the “Company Guide”).

 

As indicated in the Notice, during the six-month period from the date of the Filing Delinquency (the “Initial Cure Period”), the Exchange will monitor the Company and the status of the Delinquent Report and any subsequent delayed filings, including through contact with the Company, until the Filing Delinquency is cured. If the Company fails to cure the Filing Delinquency within the Initial Cure Period, the Exchange may, in the Exchange’s sole discretion, allow the Company’s securities to be traded for up to an additional six-month period (the “Additional Cure Period”) depending on the Company’s specific circumstances. If the Exchange determines that an Additional Cure Period is not appropriate, suspension and delisting procedures will commence in accordance with the procedures set out in Section 1010 of the Company Guide. If the Exchange determines that an Additional Cure Period of up to six months is appropriate and the Company fails to file its delinquent report and any subsequent delayed filings by the end of that period, suspension and delisting procedures will generally commence.

 

The NYSE American may in its sole discretion decide (i) not to afford an issuer any Initial Cure Period or Additional Cure Period, as the case may be, at all or (ii) at any time during the Initial Cure Period or Additional Cure Period, to truncate the Initial Cure Period or Additional Cure Period, as the case may be, and immediately commence suspension and delisting procedures if the issuer is subject to delisting pursuant to any other provision of the Company Guide, including if the Exchange believes, in the Exchange’s sole discretion, that continued listing and trading of an issuer’s securities on the Exchange is inadvisable or unwarranted in accordance with Sections 1001-1006 of the Company Guide.

 

During the Initial Cure Period and the Additional Cure Period, if applicable, the Company’s securities will continue to trade on the Exchange, subject to the Company’s compliance with other continued listing requirements, with a late filer (“.LF”) indicator. The .LF indicator will be removed when the Company has regained compliance with all applicable continued listing standards.

 

As previously reported by the Company in its Form 12b-25 filed with the SEC on each of March 31, 2023, May 15, 2023 and August 14, 2023, the Company required additional time to finalize its financial statements.

 

6
 

 

Recent Developments

 

Merger Agreement with Clearday

 

On April 5, 2023, we entered into a Merger Agreement (the “Merger Agreement”), with Clearday, Inc., a Delaware corporation (“Clearday”) VHAC2 Merger Sub, Inc., a Delaware corporation (“New Merger Sub”), and our Sponsor in the capacity as the representative from and after the Effective Time (as defined in the Merger Agreement) for the stockholders of Viveon (other than the Clearday Stockholders (as defined in the Merger Agreement)) as of immediately prior to the Effective Time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement, and Clearday SR LLC, a Delaware limited liability company, in the capacity as the representative from and after the Effective Time for the holders of Clearday Preferred Stock (as defined in the Merger Agreement) as of immediately prior to the Effective Time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement. Pursuant to the terms of the Merger Agreement, a business combination between us and Clearday will be effected through the merger of New Merger Sub with and into Clearday, with Clearday surviving the merger as a wholly owned subsidiary of ours and we will change our name to “Clearday Holdings, Inc.” (the “Merger”). Our board of directors has (i) approved and declared advisable the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement, the Merger and related transactions by our stockholders. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Merger Agreement.

 

Consideration

 

Merger Consideration

 

The total consideration to be paid at Closing (the “Merger Consideration”) by us to Clearday security holders (and holders who have the right to acquire Clearday capital stock) will be an amount equal to $250 Million (plus the aggregate exercise price for all Clearday options and warrants). The Merger Consideration will be payable in shares of common stock, par value $0.0001 per share, of our common stock, valued at $10 per share.

 

Earnout Payments

 

In addition, the holders of Clearday preferred stock will have the contingent right to earn up to 5,000,000 shares of our common stock, in the aggregate (the “Earnout Shares”), if at any time during the period beginning on the date of the Closing (the “Closing Date”) and ending on the fifth anniversary of the Closing Date (the “Earnout Eligibility Period”), the Adjusted Net Income (as defined below) for any Earnout Period is a positive number for the first time during the Earnout Eligibility Period (the “Earnout Milestone”). Under the Merger Agreement, Adjusted Net Income means for any Earnout Period, the consolidated net income or loss for such period calculated in accordance with U.S. GAAP applied on a basis consistent with past practice, of (a) for periods prior to the Closing, the Company and its subsidiaries (the “Company Group”), and (b) for periods from and after the Closing, of us and our subsidiaries (including the Company Group), in each case before adjusting for the following to the extent deducted/added in calculating consolidated net income or loss: (1) interest expense/income; (2) income tax expense/tax credits; (3) depreciation and amortization; (4) transaction expenses; (5) extraordinary items; (6) any income or loss attributable to us that accrues in accordance with U.S. GAAP on or prior to the Closing Date; and (7) all gains or losses in connection with sales or dispositions of assets and investments not in the ordinary course of business.

 

If, following the Closing Date and prior to end of the Earnout Eligibility Period, there is a Change of Control, then, immediately prior to such Change of Control, all the Earnout Shares not yet earned shall be earned by the Clearday Earnout Holders and shall be released from escrow and delivered to the Clearday Earnout Holders, and the Clearday Earnout Holders shall be eligible to participate in such Change of Control transaction with respect to such Earnout Shares.

 

7
 

 

The Earnout Shares will be placed in escrow and will not be released from escrow until they are earned as a result of the occurrence of the Earnout Milestone or a Change of Control, if applicable. The Earnout Shares that are not earned on or before the expiration of the Earnout Eligibility Period shall be automatically forfeited and cancelled.

 

Treatment of Clearday Securities

 

Cancellation of Securities. Each share of Clearday capital stock, if any, that is owned by Viveon, New Merger Sub, Clearday, or any of their subsidiaries (as treasury stock or otherwise) immediately prior to the effective time of the Merger (the “Effective Time”), will automatically be cancelled and retired without any conversion or consideration.

 

Preferred Stock. At the Effective Time, each issued and outstanding share of Clearday’s Series F Cumulative Convertible Preferred Stock, par value $0.001 per share (“Clearday Series F Preferred Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: (A) one (1) share of Parent New Series F Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement.

 

Each issued and outstanding share of Clearday’s Series A Convertible Preferred Stock, par value $0.001 per share (“Clearday Series A Preferred Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: (A) one (1) share of Parent New Series A Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement.

 

Common Stock. At the Effective Time, each issued and outstanding share of Clearday’s common stock, par value $0.001 per share (“Clearday Common Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares) will be converted into the right to receive a number of shares of Viveon Common Stock equal to the Conversion Ratio. The “Conversion Ratio” as defined in the Merger Agreement means an amount equal to (a)(i) the sum of $250 Million, plus the aggregate exercise or conversion price of outstanding Clearday’s stock options and warrants (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more), divided by (ii) the number of fully diluted Clearday capital stock (including Company Preferred Stock, warrants, stock options, convertible notes, and any other convertible securities) (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more and assuming a conversion price of Clearday subsidiary securities as provided in the Merger Agreement); divided by (b) $10.00.

 

Merger Sub Securities. Each share of common stock, par value $0.0001 per share, of New Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and become one newly issued share of common stock of the surviving corporation.

 

Stock Options. At the Effective Time, each outstanding option to purchase shares of Clearday Common Stock will be converted into an option to purchase, subject to substantially the same terms and conditions as were applicable under such options prior to the Effective Time, shares of Viveon Common Stock equal to the number of shares subject to such option prior to the Effective Time multiplied by the Conversion Ratio, at an exercise price per share of Viveon Common Stock equal to the exercise price per share of Clearday Common Stock subject to such option divided by the Conversion Ratio.

 

Warrants. Contingent on and effective as of immediately prior to the Effective Time, each outstanding warrant to purchase shares of Clearday Preferred Stock or Clearday Common Stock will be treated in accordance with the terms thereof.

 

8
 

 

Convertible Notes. Contingent on and effective as of immediately prior to the Effective Time, Clearday’s convertible notes outstanding as of immediately prior to the Effective Time, will be treated in accordance with the terms of the relevant agreements governing such convertible notes.

 

Subsidiary Capital Stock. At and as of the Effective Time, the Subsidiary Capital Stock will remain in full force and effect with the right to acquire the Company Common Stock with such adjustments noted in the terms of such Subsidiary Capital Stock.

 

Representations and Warranties

 

The Merger Agreement contains customary representations and warranties of the parties thereto with respect to, among other things, (a) corporate existence and power, (b) authorization to enter into the Merger Agreement and related transactions; subsidiaries, (c) governmental authorization, (d) non-contravention, (e) capitalization, (f) corporate records, (g) consents, (h) financial statements, (i) internal accounting controls, (j) absence of certain changes, (k) properties; title to assets, (l) litigation, (m) material contracts, (n) licenses and permits, (o) compliance with laws, (p) intellectual property, (q) privacy and data security, (r) employee matters and benefits, (s) tax matters, (t) real property, (u) environmental laws, (v) finders’ fees, (w) directors and officers, (x) anti-money laundering laws, (y) insurance, (z) related party transactions, and (aa) certain representations related to securities law and activity. Viveon has additional representations and warranties, including (a) issuance of shares, (b) trust fund, (c) listing, (d) board approval, (e) SEC documents and financial statements, (f) certain business practices, (g) expenses, indebtedness and other liabilities and (h) brokers and other advisors.

 

Covenants

 

The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the Registration Statement and Proxy Statement (as each such terms are defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party’s respective stockholders. Viveon and Clearday have each also agreed to include in the Proxy Statement the recommendation of its respective board that its stockholders approve all of the proposals to be presented at its respective special meeting. In addition, each of Viveon and Clearday have agreed to use commercially reasonable efforts to solicit and finalize definitive documentation for a committed equity in an aggregate amount that, together with the funds in the Trust Account after giving effect to potential redemptions from Viveon’s public stockholders, together with financing programs available to Clearday after the Closing, will provide to Clearday working capital to meet its short-term commercial development goals.

 

Viveon has also agreed to prepare a proxy statement to seek the approval of its stockholders (the “Extension Proposal”) to amend its organizational documents to extend the period of time Viveon is afforded under its organizational documents and IPO prospectus to consummate an initial business combination for an additional three months, from June 30,2023 to September 30, 2023 (or such earlier date as Viveon and Clearday may agree in writing).

 

Each party’s representations, warranties and pre-Closing covenants will not survive Closing and no party has any post-Closing indemnification obligations.

 

Viveon Equity Incentive Plan

 

Viveon has agreed to approve and adopt an equity incentive plan (the “Incentive Plan”) to be effective as of the Closing and in a form mutually acceptable to Viveon and Clearday, subject to approval of the Incentive Plan by the Viveon stockholders. The Incentive Plan will provide for an initial aggregate share reserve equal to 8% of the number of shares of Viveon Common Stock issued and outstanding at the Closing and an “evergreen” provision that is mutually agreeable to Viveon and Clearday will provide for an automatic increase on the first day of each fiscal year in the number of shares available for issuance under the Incentive Plan as mutually determined by Viveon and Clearday.

 

9
 

 

Non-Solicitation Restrictions

 

Each of Viveon and Clearday has agreed that from the date of the Merger Agreement to the Effective Time or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate any negotiations with any party relating to an Alternative Transaction (as such term is defined in the Merger Agreement) or enter into any agreement relating to such a proposal, other than as expressly excluded from the definition of an Alternative Transaction. Each of Viveon and Clearday has also agreed to be responsible for any acts or omissions of any of its respective representatives that, if they were the acts or omissions of Viveon and Clearday, as applicable, would be deemed a breach of the party’s obligations with respect to these non-solicitation restrictions.

 

Conditions to Closing

 

The consummation of the Merger is conditioned upon, among other things, (i) the absence of any applicable law or order restraining, prohibiting or imposing any condition on the consummation of the Merger and related transactions, (ii) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (iii) receipt of any consent, approval or authorization required by any Authority (as defined in the Merger Agreement), (iv) Viveon having net tangible assets of at least $5,000,001 (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act), unless Viveon’s amended and restated certificate of incorporation shall have been amended to remove such requirement prior to or concurrently with the Closing, (v) approval by Clearday’s stockholders of the Merger and related transactions, (vi) approval by Viveon’s stockholders of the Merger and related transactions, (vii) the conditional approval for listing by NYSE American (or an alternate exchange) of the shares of Viveon Common Stock to be issued in connection with the transactions contemplated by the Merger Agreement and satisfaction of initial and continued listing requirements, and (viii) the Registration Statement becoming effective in accordance with the provisions of the Securities Act of 1933, as amended (“Securities Act”).

 

Solely with respect to Viveon and New Merger Sub, the consummation of the Merger is conditioned upon, among other things, (i) Clearday having duly performed or complied with all of its obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of Clearday, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure would not have or reasonably be expected to have a Material Adverse Effect (as defined in the Merger Agreement) on Clearday or any of its subsidiaries, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a Material Adverse Effect on Clearday or any of its subsidiaries, (v) Clearday and its securityholders having executed and delivered to Viveon each Additional Agreement (as defined in the Merger Agreement) to which they each are a party and (vi) Clearday delivering certain certificates to Viveon.

 

Solely with respect to Clearday, the consummation of the Merger is conditioned upon, among other things, (i) Viveon and New Merger Sub having duly performed or complied with all of their respective obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of Viveon and New Merger Sub, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a Material Adverse Effect on Viveon or New Merger Sub and their ability to consummate the Merger and related transactions, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a Material Adverse Effect on Viveon or New Merger Sub, (v) the Amended Parent Charter (as defined in the Merger Agreement) being filed with, and declared effective by, the Delaware Secretary of State, (vi) Viveon delivering certain certificates to Clearday, (vii) the size and composition of the post-Closing board of directors of Viveon having been appointed as set forth in the Merger Agreement and (viii) Viveon, Viveon Health LLC and other stockholders, as applicable, having executed and delivered to Clearday each Additional Agreement to which they each are a party.

 

10
 

 

Termination

 

The Merger Agreement may be terminated at any time prior to the Effective Time as follows:

 

(i) by either Viveon or Clearday, if (A) the Merger and related transactions are not consummated on or before the latest of (i) June 30, 2023, (ii) if the Extension Proposal is approved, September 30, 2023 and (iii) if one or more extensions to a date following September 30, 2023 are obtained at the election of Viveon, with Viveon stockholder vote, in accordance with the Viveon’s amended and restated certificate of incorporation, the last date for Viveon to consummate a business combination pursuant to such extensions; and (B) the material breach or violation of any representation, warranty, covenant or obligation under the Merger Agreement by the party seeking to terminate the Merger Agreement was not the cause of, or resulted in, the failure of the Closing to occur on or before the Outside Closing Date, without liability to the other party;

 

(ii) by either Viveon or Clearday, if any Authority has issued any final decree, order, judgment, award, injunction, rule or consent or enacted any law, having the effect of permanently enjoining or prohibiting the consummation of the Merger, provided that, the party seeking to terminate cannot have breached its obligations under the Merger Agreement and such breach was a substantial cause of, or substantially resulted in, such action by the Authority; and

 

(iii) by mutual written consent of Viveon and Clearday duly authorized by each of their respective boards of directors.

 

The Merger Agreement and other agreements described below have been included to provide investors with information regarding their respective terms. They are not intended to provide any other factual information about Viveon, Clearday or the other parties thereto. In particular, the assertions embodied in the representations and warranties in the Merger Agreement were made as of a specified date, are modified or qualified by information in one or more disclosure letters prepared in connection with the execution and delivery of the Merger Agreement, may be subject to a contractual standard of materiality different from what might be viewed as material to investors, or may have been used for the purpose of allocating risk between the parties. Accordingly, the representations and warranties in the Merger Agreement are not necessarily characterizations of the actual state of facts about Viveon, Clearday or the other parties thereto at the time they were made or otherwise and should only be read in conjunction with the other information that Viveon or Clearday makes publicly available in reports, statements and other documents filed with the SEC. Viveon and Clearday investors and securityholders are not third-party beneficiaries under the Merger Agreement.

 

Certain Related Agreements

 

Parent Support Agreements. Concurrently with the execution of the Merger Agreement, Viveon, Clearday and the Sponsor and the officers and directors of Viveon entered into a support agreement (the “Parent Support Agreement”) pursuant to which the Sponsor and the officers and directors of Viveon have agreed to vote all shares of Viveon common stock beneficially owned by them, including any additional shares of Viveon they acquire ownership of or the power to vote: (i) in favor of the Merger and related transactions, (ii) against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions, and (iii) in favor of an extension of the period of time Viveon is afforded to consummate an initial business combination.

 

Company Support Agreements. Concurrently with the execution of the Merger Agreement, Viveon, Clearday and certain stockholders of Clearday entered into a support agreement (the “Company Support Agreement”), pursuant to which such Clearday stockholders have agreed to vote all common and preferred stock of Clearday beneficially owned by them, including any additional shares of Clearday they acquire ownership of or the power to vote, in favor of the Merger and related transactions and against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions.

 

11
 

 

Lock-Up Agreements. In connection with the Closing, certain Clearday stockholders will each agree, subject to certain customary exceptions, not to (i) offer, sell contract to sell, pledge or otherwise dispose of, directly or indirectly, any Lockup Shares, (ii) enter into a transaction that would have the same effect, (iii) enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up Shares or otherwise, (iv) engage in any short sales or other arrangement with respect to the Lock-Up Shares or (v) publicly announce any intention to effect any transaction specified in clause (i), (ii) or (iii) until the date that is six months after the Closing Date (the “Lock-Up Period”). The term “Lockup Shares” mean the Merger Consideration Shares and the Earnout Shares, if any, whether or not earned prior to the end of the Lock-up Period, together with any other shares of Viveon Common Stock, and including any securities convertible into, or exchangeable for, or representing the rights to receive Viveon Common Stock, if any, acquired during the Lock-up Period. If the closing price of Viveon Common Stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period following the Closing Date, 50% of the Lock-up Shares will be released from the lock-up. The existing escrow provisions of Viveon Common Stock held by certain stockholders will remain in effect.

 

Amended and Restated Registration Rights Agreement. At the Closing, Viveon will enter into an amended and restated registration rights agreement (the “Amended and Restated Registration Rights Agreement”) with certain existing stockholders of Viveon and Clearday with respect to their shares of Viveon Common Stock acquired before or pursuant to the Merger, and including the shares issuable on conversion of the warrants issued to the Sponsor in connection with Viveon’s initial public offering and any shares issuable on conversion of loans or other convertible securities. The agreement amends and restates the registration rights agreement Viveon entered into on December 22, 2020 in connection with its initial public offering. Subject to the Lock-Up Agreements described above, the holders of a majority of the shares held by the existing Viveon stockholders, and the holders of a majority of the shares held by the Clearday stockholders will each be entitled to make one demand that the Company register such securities for resale under the Securities Act, or two demands each if Viveon is eligible to use Form S-3 or a similar short-form registration statement. In addition, the holders will have certain “piggy-back” registration rights that require Viveon to include such securities in registration statements that Viveon otherwise files. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering Viveon’s securities. Viveon will bear the expenses incurred in connection with the filing of any such registration statements.

 

The foregoing descriptions of agreements and the transactions and documents contemplated thereby are not complete and are subject to and qualified in their entirety by reference to the Merger Agreement, form of Parent Support Agreement, form of Company Support Agreement, form of Lock-Up Agreement, and form of Amended and Restated Registration Rights Agreement, copies of which were filed on April 11, 2023 with a Current Report on Form 8-K as Exhibits 2.1, 10.1, 10.2, 10.3, and 10.4, respectively, and the terms of which are incorporated by reference herein.

 

General

 

We are a Delaware blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this Annual Report as our initial business combination. Although we are not limited to a particular industry or geographic region for purposes of consummating an initial business combination, we intend to focus on businesses that have their primary operations located in North America in the healthcare industry, and specifically in the medical technology and medical device sectors. As disclosed in our prospectus, although our management has significant experience in the orthopedic and spine marketplace, they also have extensive operating and transaction experiences in the medical technology sector as managers, investors, acquirors, and sellers and will use that experience to consider target companies in emerging growth medical technology and medical device companies that may be focused in areas outside of orthopedics and spine.

 

12
 

 

Consistent with our strategy, we have identified the following criteria to evaluate prospective target businesses. Although we may decide to enter into our initial business combination with a target business that does not meet the criteria described below, it is our intention to acquire companies that we believe:

 

  ● have a clinical or other competitive advantage in the markets in which they operate and which can benefit from access to additional capital as well as our industry relationships and expertise;
     
  ● will likely be well received by public investors and experience substantial increase in valuation as a result of a public listing and access to the public markets;
     
  ● are ready to be public, with strong management, corporate governance and reporting policies in place;
     
  ● have significant embedded and/or underexploited growth opportunities that will drive value;
     
  ● growing at or above industry market rates;
     
  ● will offer attractive risk-adjusted equity returns for our stockholders.

 

We may use other criteria as well. Any evaluation relating to the merits of a particular initial business combination may be based on these general criteria as well as other considerations, factors and criteria that our management may deem relevant.

 

We believe that emerging growth medical technology companies will realize a material benefit from being publicly-traded, including greater access to capital to support innovation and sales channel expansion, having available liquid securities which can be utilized for acquisitions, and increased market and customer awareness.

 

Many of these companies that are highly innovative and are experiencing high growth have few options to reach their full potential. While a traditional IPO could, in theory, provide a meaningful avenue for these companies to access capital and accelerate their growth, the relatively high risk and expense associated with a traditional initial public offering and the negative consequences of an unsuccessful public offering represent meaningful barriers to many companies in our target sector to pursuing a traditional IPO. Accordingly, we believe that the increased visibility and acceptance of going-public mergers with special purpose acquisition companies like us may enhance our ability to consummate an initial business combination.

 

We believe an acquisition by a special purpose acquisition company, like ours, can provide an efficient liquidity and capital-raising mechanism while materially reducing the risks and expenses associated with a traditional IPO. Furthermore, we believe our management team is well-known to, and respected by, the founders, management, and shareholders of private medical technology companies and that our leadership’s reputation will be a competitive advantage in attracting high quality targets for our business combination. Our management team and board of directors have an extensive operating and transaction experiences in the medical technology sector as manager, investors, acquirors, and sellers. We intend to leverage this experience and network to identify a target company and to deliver operational and economic benefit from a business combination.

 

Our Management Team

 

Jagi Gill, PhD is our Chief Executive Officer. Dr. Gill has more than 20 years of healthcare investment and general management experience. From 2017 to 2020, he served as the Vice-President of Business Development and General Manager of AcuVentures, a business unit within Acumed LLC, a Berkshire Hathaway Company. Acumed LLC is a market leader in the orthopedic sector with particular strength in the upper extremity fracture repair and trauma market segments. As the General Manager, Dr. Gill led two business units, Rib Fixation and the Soft Tissue Repair, with responsibilities for product development, sales, marketing and profitability. Under his leadership, the business units grew 2-3x faster than their market segment. In addition to general management responsibilities, Dr. Gill was involved in sourcing, closing and integrating four acquisitions within the orthopedic sector for Acumed. These transactions ranged from technology acquisitions serving as tuck-in product integrations to stand alone companies with global revenue. From 2009 to 2017, he was the Founder, Chief Executive Officer and Board Member of Tenex Health a privately held orthopedic sports medicine company. In this capacity he patented, designed and developed the initial platform technology intended to treat chronic tendon pain. Under his leadership, Tenex Health launched commercially, generated positive operating income, secured FDA regulatory approval, developed a manufacturing and operations infrastructure, and established sales channels serving the outpatient Ambulatory Surgery Centers. Before founding Tenex Health, Dr. Gill was the Founder and Chief Executive Officer of OrthoCor, a company providing non-invasive pain management technology, from 2007 to 2009, while also serving on an advisory and consulting capacity to a number of medical technology companies. OrthoCor developed and commercialized orthopedic knee braces integrating pulsed electromagnetic technology to address chronic pain associated with trauma or osteoarthritis. Prior to this, he served in executive business development roles for Boston Scientific Corporation from 2001 to 2007 where he was involved in sourcing and supporting the acquisition of private companies which collectively accounted for more than $750 million in enterprise value. While at Boston Scientific, he was involved in the investments in, and acquisition of, the following private companies: Advanced Bionics (implantable neurostimulation), Cameron Health (implantable cardiac rhythm management), Innercool (systemic hypothermia for recovery from cardiac arrest), Orqis Medical (heart failure treatment) and Kerberos (endovascular thrombectomy). Dr. Gill completed his BSc and MSc in Anatomy from McGill University and PhD in Neuroscience from Mayo Clinic College of Medicine. We believe we will be able to capitalize on Dr. Gill’s experience and accomplishments in the orthopedic and spine markets, along with his relationships among executives in the target companies, their supply chains, and their customer networks, to successfully close a business combination.

 

13
 

 

Rom Papadopoulos, M.D. is our Chief Financial Officer. Dr. Papadopoulos has more than 25 years of healthcare investment and operational experience. From 2006 to June 2020, Dr. Papadopoulos was the Founder and Sole Proprietor of Intuitus Capital, a private equity firm actively investing in the healthcare sector. At Intuitus, he led investments in more than 30 companies with a total of more than $700 million in enterprise value. Prior to founding Intuitus Capital, Dr. Papadopoulos was Chief Financial Officer, Chief Operations Officer, Corporate Executive Vice President and Corporate Secretary of Global Energy Holdings (NYSE Amex: GNH). While at GNH, he created and executed the company’s repositioning from traditional markets to renewable energy. He was responsible for coordinating all aspects of the financial management of the company including cash management and treasury, risk management, audit functions, SEC reporting and compliance as well as HR functions and employee policies. Dr. Papadopoulos was an early investor in Tenex Health Inc., a medical device company engaged in the manufacturing and sale of minimally invasive high frequency technology used to perform percutaneous tenotomy and fasciotomy. He eventually became the interim CFO for the company until September 2013. In this capacity, he was an integral part of the team seeking and completing acquisitions for the company. From 2002 to 2006, Dr. Papadopoulos was the Managing Director and head of healthcare investment banking for Caymus Partners, a middle market investment banking firm. Dr. Papadopoulos received his medical degree (M.D.) from the Aristotelian University of Thessaloniki, Greece, Medical School in 1985 and conducted his post-graduate training in Pediatrics at Emory University in 1986. We believe that Dr. Papadopoulos is qualified to sit on our board due to his years of experience in the healthcare industry, as a clinician as well as an investor who possesses unique insight into medical technology assets, in addition to his strong financial credentials.

 

Demetrios (Jim) G. Logothetis, is one of our directors and served as Senior Advisor in the Department of Housing and Urban Development (HUD) Office of the Assistant Secretary and Chief Financial Officer where he led the Audit Coordination Committee for Ginnie Mae, a government corporation within HUD from May 2020 to November 2020. Mr. Logothetis retired from Ernst & Young (EY) effective in June 2019 extending three years beyond normal retirement at the request of the EY Executive Board. Throughout his forty-year career with EY, from January 1979 to June 2019, Mr. Logothetis served some of EY’s largest global clients as lead audit partner, and fulfilled senior leadership roles within the firm, from offices in Chicago, Frankfurt Germany, New York, London England, and Atlanta. As of May 2023, Mr. Logothetis has served as a member of the Board of Directors of the Republic Bank of Chicago. Mr. Logothetis has served over the years on the boards of several non-profit organizations, including The National Board of the Boys & Girls Clubs of Americas where he served on the audit committee; The Archbishop Lakovos Leadership 100 Endowment Fund where he serves as Chairman, The American College of Greece where he served as Chairman of the Board of Trustees; Global Economics where he serves as a member of the advisory board and Cross-Country Consulting where he serves as a member of the advisory board, National Hellenic Museum where he serves on the Board. Mr. Logothetis is the founder and Chairman of the Board of Trustees of the Hellenic American Academy, one of the largest Greek American schools in the United States; and founding Chairman of the Foundation for Hellenic Education and Culture. Mr. Logothetis holds an M.B.A. degree in Accounting, Finance and International Business from The University of Chicago Booth Graduate School of Business and a B.S.C degree in Accountancy from DePaul University. Mr. Logothetis is also a Certified Public Accountant and a Certified Management Accountant. Mr. Logothetis has taught many EY training programs as well as graduate accounting classes at DePaul University. Mr. Logothetis served for several years on the DePaul University, Richard H. Driehaus College of Business advisory council, and since 2017 on the board of Trustees of the University as vice-chair, and then chair of the audit committee and member of the finance committee. Mr. Logothetis has also served as a member of the Trusteeship and Finance Committees for DePaul University.

 

14
 

 

Brian Cole MD, MBA is one of our directors, and the Managing Partner of Midwest Orthopedics at Rush in Chicago, the lead executive for this large specialty practice which is consistently ranked as one of the top orthopedic groups by US News & World Report. Dr. Cole is a Professor in the Department of Orthopedics with a conjoint appointment in the Department of Anatomy and Cell Biology at Rush University Medical Center. In 2015, he was appointed as an Associate-Chairman of the Department of Orthopedics at Rush. In 2011, he was appointed as Chairman of Surgery at Rush Oak Park Hospital. He is the Section Head of the Cartilage Research and Restoration Center at Rush specializing in the treatment of arthritis in young active patients with a focus on regenerative medicine and biologic alternatives to surgery. He also serves as the head of the Orthopedic Master’s Training Program and trains residents and fellows in sports medicine and research. He lectures nationally and internationally and holds several leadership positions in prominent sports medicine societies. Through his basic science and clinical research, he has developed several innovative techniques with several patents for the treatment of shoulder, elbow and knee conditions. He has published more than 1,000 articles and 10 widely read textbooks in orthopedics and regenerative medicine. In addition to his academic accomplishments, Dr. Cole currently serves in many senior leadership roles in organizations such as President of the Arthroscopy Association of North America, President of the Ortho-regeneration Network Foundation, and Secretary General (Presidential-line) International Cartilage Repair Society. Dr. Cole is frequently chosen as one of the “Best Doctors in America” since 2004 and as a “Top Doctor” in the Chicago metro area since 2003. In 2006, he was featured on the cover of Chicago Magazine as “Chicago’s Top Doctor” and was selected as NBA Team Physician of the Year in 2009. Orthopedics This Week has named Dr. Cole as one of the top 20 sports medicine, knee and shoulder specialists repeatedly over the last 5 years as selected by his peers. He is the head team physician for the Chicago Bulls NBA team, co-team physician for the Chicago White Sox MLB team and DePaul University in Chicago. Dr. Cole was awarded his medical degree from the University of Chicago Pritzker School of Medicine and his MBA from the University of Chicago Booth School of Business. He completed his residency in Orthopedic Surgery at the Hospital for Special Surgery — Cornell Medical Center in New York and his fellowship in Sports Medicine at the University of Pittsburgh.

 

Doug Craft is one of our directors, and the Chief Executive Officer of Atlanta-based Medicraft, Inc., which is one of the largest independent agents for Medtronic, the world leader in medical technology and pioneering therapies. He has devoted his entire career to the medical industry, initially concentrating in the sale of spinal implants, which he continues today. Mr. Craft has extensive relationships with health care systems, surgeons and other senior health care professionals across the nation. Over the past three decades his commercial interests have expanded to include evaluating, consulting and developing businesses in the medical field generally, including but not limited to neuro-intraoperative monitoring, biologic agents, orthopedic reconstruction implants, surgical navigation systems, regenerative kidney technology, trans-catheter cardiac valves and spinal implant device design. He has funded and started over 12 businesses in the Orthopedic, Spine and Neurological segments such as Biocraft Inc, Orthocraft Inc, Neurocraft Inc, Pharmacraft, Premier Medical Systems, and Diamond Orthopedics. Early in his career, he was one of the first agents for Danek a publicly traded spinal implant company which merged with Sofamor to become Sofamor-Danek and relisting on the NYSE. Sofamor-Danek was acquired by Medtronic in 1999 for $3.7 billion. Mr. Craft is a highly experienced entrepreneur who is continually exploring opportunities to multiply investments in medical businesses and technologies. Mr. Craft earned a B.S. degree in biomedical engineering from Mississippi State University, and is a Distinguished Fellow of the College of Engineering at Mississippi State University.

 

Acquisition Strategy

 

We believe our management team is well positioned to identify unique opportunities within the healthcare industry, and more specifically in the medical technology and medical device industry. Our selection process will leverage our relationships within the industry particularly with leading venture capitalists and growth equity funds, executives of private and public companies, as well as leading investment banking firms, which we believe should provide us with a key competitive advantage in sourcing potential business combination targets. Furthermore, members of our board of directors will augment the selection process through their robust relationships. Given our profile and dedicated industry approach, we anticipate that target business candidates may be brought to our attention from various unaffiliated sources, and in particular investors in other private and public companies in our networks.

 

Our strategy is to utilize the experience and relationships of our management and board to identify target businesses that are exhibiting rapid growth, technology and service innovation, and positive income that would benefit from the opportunity for substantial revenue and profit expansion.

 

15
 

 

We believe that target companies under this indicative will experience a substantial increase in value as a result of a public listing which brings access to the public markets to capitalize innovation, achieve added public visibility that can help expand sales channels, and provide flexibility to support additional substantial acquisitions in the highly fragmented medical technology and medical device market.

 

We believe an acquisition by a special purpose acquisition company, like us, can provide an efficient liquidity and capital-raising mechanism while materially reducing the risks and expenses associated with a traditional IPO. Furthermore, we believe our management team is well-known to, and respected by, the founders, management, and shareholders of private medical technology companies and that our leadership’s reputations will be a competitive advantage in attracting high quality targets for our business combination. Our management team and board of directors have extensive operating and transaction experiences in the medical technology sector as manager, investors, acquirors, and sellers. We intend to leverage this experience and network to identify a target company and to deliver operational and economic benefit from a business combination.

 

Investment Criteria

 

Consistent with our strategy, we have identified the following criteria to evaluate prospective target businesses. Although we may decide to enter into our initial business combination with a target business that does not meet the criteria described below, it is our intention to acquire companies that we believe:

 

  ● have a clinical or other competitive advantage in the markets in which they operate and which can benefit from access to additional capital as well as our industry relationships and expertise;
     
  ● will likely be well received by public investors and experience substantial increase in valuation as a result of a public listing and access to the public markets;
     
  ● are ready to be public, with strong management, corporate governance and reporting policies in place;
     
  ● will be able to take full advantage of the use of public securities as a means to engage in further substantial acquisitions in the highly fragmented medical technology and device industry;
     
  ● have significant embedded and/or underexploited growth opportunities that will drive value;
     
  ● growing at or above industry market rates; and
     
  ● will offer attractive risk-adjusted equity returns for our stockholders.

 

We may use other criteria as well. Any evaluation relating to the merits of a particular initial business combination may be based on these general criteria as well as other considerations, factors and criteria that our management may deem relevant.

 

Industry Opportunity

 

We believe the healthcare industry, particularly the life sciences and medical technology sectors, represents an enormous and growing target market with a large number of potential target acquisition opportunities. In 2018, total U.S. national health expenditures exceeded $3.6 trillion, and the Center for Medicare and Medicaid Services estimated that total healthcare spending accounted for approximately 18% of total U.S. Gross Domestic Product.

 

While most of the companies in our target sector of medical technology companies are domiciled in the United States, many have also begun to expand their commercial footprint globally, which delivers an opportunity to further extend their commercial reach. The regional distribution of the global market is primarily divided into North America (44%), Asia/Pacific (23%), Western Europe (22%), and all other areas (11%), according to 2020 analysis by MarketResearch.com. Of these segments, the Asia/Pacific market is expected to grow most rapidly at more than 6% CAGR. The enhanced growth rate in the Asia/Pacific segment is attributed to the increase in healthcare facilities primarily in emerging markets as well as expansion by local medical technology companies serving the region that also have expansion plans to enter the North American and Western European markets. These regionally based medical technology companies will serve as targets for our business combination.

 

16
 

 

Effecting a Business Combination

 

General

 

We are not presently engaged in, and we will not engage in, any operations for an indefinite period of time. We intend to effectuate our initial business combination using cash from the proceeds of the IPO and the private placement of the private warrants, our shares, new debt, or a combination of these, as the consideration to be paid in our initial business combination. We may seek to consummate our initial business combination with a company or business that may be financially unstable or in its early stages of development or growth (such as a company that has begun operations but is not yet at the stage of commercial manufacturing and sales), which would subject us to the numerous risks inherent in such companies and businesses, although we will not be permitted to effectuate our initial business combination with another blank check company or a similar company with nominal operations.

 

If our initial business combination is paid for using shares or debt securities, or not all of the funds released from the Trust Account are used for payment of the purchase price in connection with our business combination or used for redemptions of purchases of our Common Stock, we may apply the cash released to us from the Trust Account that is not applied to the purchase price for general corporate purposes, including for maintenance or expansion of operations of acquired businesses, the payment of principal or interest due on indebtedness incurred in consummating our initial business combination, to fund the purchase of other companies or for working capital.

 

Since the consummation of the IPO, we have focused on identifying, doing due diligence on and speaking to management of potential target companies in a variety of markets within the medical technology sector of the healthcare industry in the United States and other developed countries. Subject to the requirement that our initial business combination must be with one or more target businesses or assets having an aggregate fair market value of at least 80% of the value of the Trust Account (excluding any taxes payable) at the time of the agreement to enter into such initial business combination, we have virtually unrestricted flexibility in identifying and selecting one or more prospective target businesses.

 

We may seek to raise additional funds through a private offering of debt or equity securities in connection with the consummation of our initial business combination, and we may effectuate our initial business combination using the proceeds of such offering rather than using the amounts held in the Trust Account. Subject to compliance with applicable securities laws, we would consummate such financing only simultaneously with the consummation of our business combination. In the case of an initial business combination funded with assets other than the Trust Account assets, our tender offer documents or proxy materials disclosing the business combination would disclose the terms of the financing and, only if required by law or the NYSE American stock exchange, we would seek stockholder approval of such financing. There are no prohibitions on our ability to raise funds privately or through loans in connection with our initial business combination.

 

Sources of Target Businesses

 

Our process of identifying acquisition targets leverages our management team’s unique industry experiences, proven deal sourcing capabilities and broad and deep network of relationships in numerous industries, including executives and management teams, private equity groups and other institutional investors, large business enterprises, lenders, investment bankers and other investment market participants, restructuring advisers, consultants, attorneys and accountants, which we believe should provide us with a number of business combination opportunities. We expect that the collective experience, capability and network of our founders, directors and officers, combined with their individual and collective reputations in the investment community, will help to create prospective business combination opportunities.

 

We anticipate that target business candidates will be brought to our attention from various unaffiliated sources, including investment bankers, venture capital funds, private equity groups, leveraged buyout funds, management buyout funds and other members of the financial community. Target businesses may be brought to our attention by such unaffiliated sources as a result of being solicited by us through calls or mailings. These sources also may introduce us to target businesses in which they think we may be interested on an unsolicited basis, since many of these sources will have read this Annual Report and know what types of businesses we are targeting. Our officers and directors, as well as their affiliates, also may bring to our attention target business candidates that they become aware of through their business contacts as a result of formal or informal inquiries or discussions they may have, as well as attending trade shows or conventions.

 

17
 

 

In addition, we expect to receive a number of proprietary deal flow opportunities that would not otherwise necessarily be available to us as a result of the business relationships of our officers and directors. While we do not presently anticipate engaging the services of professional firms or other individuals that specialize in business acquisitions on any formal basis, we may engage these firms or other individuals in the future, in which event we may pay a finder’s fee, consulting fee or other compensation to be determined in an arm’s length negotiation based on the terms of the transaction. We will engage a finder only to the extent our management determines that the use of a finder may bring opportunities to us that may not otherwise be available to us or if finders approach us on an unsolicited basis with a potential transaction that our management determines is in our best interest to pursue. Payment of finder’s fees is customarily tied to completion of a transaction, in which case any such fee will be paid out of the funds held in the Trust Account. Although some of our officers and directors may enter into employment or consulting agreements with the acquired business following our initial business combination, the presence or absence of any such arrangements will not be used as a criterion in our selection process of an acquisition candidate.

 

We are not prohibited from pursuing an initial business combination with a company that is affiliated with our sponsor, officers or directors. In the event we seek to complete our initial business combination with such a company, we, or a committee of independent directors, would obtain (i) an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions on the type of target business we seek to acquire that such an initial business combination is fair to our unaffiliated stockholders from a financial point of view and (ii) the approval of a majority of our disinterested and of our independent directors.

 

Selection of a Target Business and Structuring of a Business Combination

 

Subject to the requirement that our initial business combination must be with one or more target businesses or assets having an aggregate fair market value of at least 80% of the value of the Trust Account (excluding any taxes payable) at the time of the agreement to enter into such initial business combination, our management will have virtually unrestricted flexibility in identifying and selecting one or more prospective target businesses. In any case, we will only consummate an initial business combination in which we become the majority shareholder of the target (or control the target through contractual arrangements in limited circumstances for regulatory compliance purposes as discussed below) or are otherwise not required to register as an investment company under the Investment Company Act or to the extent permitted by law we may acquire interests in a variable interest entity, in which we may have less than a majority of the voting rights in such entity, but in which we are the primary beneficiary. There is no basis for our stockholders to evaluate the possible merits or risks of any target business with which we may ultimately complete our initial business combination. To the extent we effect our initial business combination with a company or business that may be financially unstable or in its early stages of development or growth (such as a company that has begun operations but is not yet at the stage of commercial manufacturing and sales), we may be affected by numerous risks inherent in such company or business. Although our management will endeavor to evaluate the risks inherent in a particular target business, we may not properly ascertain or assess all significant risk factors.

 

In evaluating a prospective target business, we expect to conduct a thorough due diligence review that will encompass, among other things, meetings with incumbent management and employees, document reviews, interviews of customers and suppliers, inspection of facilities, as well as a review of financial and other information which will be made available to us.

 

The time required to select and evaluate a target business and to structure and complete our initial business combination, and the costs associated with this process, are not currently ascertainable with any degree of certainty. Any costs incurred with respect to the identification and evaluation of a prospective target business with which a business combination is not ultimately completed will result in our incurring losses and will reduce the funds we can use to complete another business combination. We will not pay any finders or consulting fees to members of our management team, or any of their respective affiliates, for services rendered to or in connection with our initial business combination.

 

18
 

 

Fair Market Value of Target Business or Businesses

 

The target business or businesses or assets with which we effect our initial business combination must have a collective fair market value equal to at least 80% of the value of the Trust Account (excluding any taxes payable) at the time of the agreement to enter into such initial business combination. If we acquire less than 100% of one or more target businesses in our initial business combination, the aggregate fair market value of the portion or portions we acquire must equal at least 80% of the value of the Trust Account (excluding taxes payable) at the time of the agreement to enter into such initial business combination. However, we will always acquire at least a controlling interest in a target business. The fair market value of a portion of a target business or assets will likely be calculated by multiplying the fair market value of the entire business by the percentage of the target we acquire. We may seek to consummate our initial business combination with an initial target business or businesses with a collective fair market value in excess of the balance in the Trust Account. In order to consummate such an initial business combination, we may issue a significant amount of debt, equity or other securities to the sellers of such business and/or seek to raise additional funds through a private offering of debt, equity or other securities. If we issue securities in order to consummate such an initial business combination, our stockholders could end up owning a minority of the combined company’s voting securities as there is no requirement that our stockholders own a certain percentage of our company (or, depending on the structure of the initial business combination, an ultimate parent company that may be formed) after our business combination. Because we have no specific business combination under consideration, we have not entered into any such arrangement to issue our debt or equity securities and have no current intention of doing so.

 

The fair market value of a target business or businesses or assets will be determined by our board of directors based upon standards generally accepted by the financial community, such as actual and potential gross margins, the values of comparable businesses, earnings and cash flow, book value, enterprise value and, where appropriate, upon the advice of appraisers or other professional consultants. Investors will be relying on the business judgment of our board of directors, which will have significant discretion in choosing the standard used to establish the fair market value of a particular target business. If our board of directors is not able to independently determine that the target business or assets has a sufficient fair market value to meet the threshold criterion, we will obtain an opinion from an unaffiliated, independent investment banking firm or another independent entity that commonly renders valuation opinions on the type of target business we seek to acquire with respect to the satisfaction of such criterion. Notwithstanding the foregoing, unless we consummate a business combination with an affiliated entity, we are not required to obtain an opinion from an independent investment banking firm, or another independent entity that commonly renders valuation opinions on the type of target business we seek to acquire, that the price we are paying is fair to our stockholders.

 

Competition

 

In identifying, evaluating and selecting a target business for our initial business combination, we may encounter intense competition from other entities having a business objective similar to ours, including other blank check companies, private equity groups and leveraged buyout funds, and operating businesses seeking strategic acquisitions. Many of these entities are well established and have significant experience identifying and effecting business combinations directly or through affiliates. Moreover, many of these competitors possess greater financial, technical, human and other resources than us. Our ability to acquire larger target businesses will be limited by our available financial resources. This inherent limitation gives others an advantage in pursuing the acquisition of a target business. Furthermore, the requirement that we acquire a target business or businesses having a fair market value equal to at least 80% of the value of the Trust Account (excluding any taxes payable) at the time of the agreement to enter into the business combination, our obligation to pay cash in connection with our public stockholders who exercise their redemption rights and the number of our outstanding warrants and the future dilution they potentially represent, may not be viewed favorably by certain target businesses. Any of these factors may place us at a competitive disadvantage in successfully negotiating our initial business combination.

 

Management Operating and Investment Experience

 

We believe that our executive officers possess the experience, skills and contacts necessary to source, evaluate, and execute an attractive business combination. See the section titled “Management” for complete information on the experience of our officers and directors. Notwithstanding the foregoing, our officers and directors are not required to commit their full time to our affairs and will allocate their time to other businesses. We presently expect each of our employees to devote such amount of time as they reasonably believe is necessary to our business (which could range from only a few hours a week while we are trying to locate a potential target business to a majority of their time as we move into serious negotiations with a target business for a business combination). The past successes of our executive officers and directors do not guarantee that we will successfully consummate an initial business combination.

 

19
 

 

As more fully discussed in “Conflicts of Interest,” if any of our officers or directors becomes aware of a business combination opportunity that falls within the line of business of any entity to which he has pre-existing fiduciary or contractual obligations, he may be required to present such business combination opportunity to such entity, subject to his or her fiduciary duties under Delaware law, prior to presenting such business combination opportunity to us. Most of our officers and directors currently have certain pre-existing fiduciary duties or contractual obligations.

 

Emerging Growth Company Status and Other Information

 

We are an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. If some investors find our securities less attractive as a result, there may be a less active trading market for our securities and the prices of our securities may be more volatile.

 

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period.

 

We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of the IPO, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our Common Stock that is held by non-affiliates exceeds $700 million as of the prior December 31, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. References herein to “emerging growth company” shall have the meaning associated with it in the JOBS Act.

 

Employees

 

We currently have two executive officers. These individuals are not obligated to devote any specific number of hours to our matters but they intend to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination. The amount of time they will devote in any time period will vary based on whether a target business has been selected for our initial business combination and the stage of the business combination process we are in. We do not intend to have any full time employees prior to the consummation of our initial business combination.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company, we are not required to make disclosures under this Item.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

Not applicable.

 

ITEM 2. PROPERTIES

 

We currently maintain our executive offices at 3480 Peachtree Road NE 2nd Floor - Suite #112 Atlanta, Georgia 30326. Our sponsor is making this space available to us for a monthly fee of $20,000. We consider our current office space adequate for our current operations.

 

ITEM 3. LEGAL PROCEEDINGS

 

We may be subject to legal proceedings, investigations and claims incidental to the conduct of our business from time to time. We are not currently a party to any material litigation or other legal proceedings brought against us. We are also not aware of any legal proceeding, investigation or claim, or other legal exposure that has a more than remote possibility of having a material adverse effect on our business, financial condition or results of operations.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not Applicable.

 

20
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Our units began to trade on The NYSE American stock exchange, or the NYSE American, under the symbol “VHAQU” on December 23, 2020. The shares of Common Stock, warrants and rights comprising the units began separate trading on NYSE American on February 4, 2021, under the symbols “VHAQ,” “VHAQW,” and “VHAQR”, respectively.

 

Holders of Record

 

As of the date of this filing, there was an aggregate of 5,031,250 shares of Common Stock issued and outstanding held by our sponsor, Viveon Health LLC, our independent directors, and a former independent director as the only stockholders of record. The number of record holders does not include beneficial owners of shares of Common Stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies held through Cede & Co.

 

Dividends

 

We have not paid any cash dividends on our Common Stock to date and do not intend to pay cash dividends prior to the completion of an initial business combination. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of a business combination. The payment of any dividends subsequent to a business combination will be within the discretion of our board of directors at such time. It is the present intention of our board of directors to retain all earnings, if any, for use in our business operations and, accordingly, our board of directors does not anticipate declaring any dividends in the foreseeable future. In addition, our board of directors is not currently contemplating and does not anticipate declaring any share dividends in the foreseeable future. Further, if we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

None.

 

Recent Sales of Unregistered Securities

 

None.

 

Use of Proceeds

 

On December 28, 2020, we consummated our IPO of 17,500,000 Units, each Unit consisting of one share of Common Stock of the Company, and one redeemable Warrant, entitling the holder thereof to purchase one-half of a share of Common Stock at a price of $11.50 per whole share, and one right to receive one-twentieth (1/20) of a share of Common Stock. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $175,000,000. On December 28, 2020, the underwriters exercised the over-allotment option in full, and the closing occurred on December 30, 2020 when we sold 2,625,000 Over-Allotment Option Units at a price of $10.00 per unit, generating additional gross proceeds of $26,250,000.

 

On December 28, 2020, simultaneously with the consummation of the IPO, we sold to our Sponsor 18,000,000 Private Warrants at a price of $0.50 per Private Warrant, generating total proceeds of $9,000,000. The Private Warrants are identical to the Warrants (as defined below) sold in the IPO except that the Private Warrants are non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the Sponsor, or its permitted transferees. Additionally, our Sponsor agreed not to transfer, assign, or sell any of the Private Warrants or underlying securities (except in limited circumstances, as described in the Private Placement Warrants Subscription Statement) until the date we complete our initial business combination.

 

A total of $203,262,500 of the net proceeds from the sale of Units in the IPO and the private placement were placed in a trust account established for the benefit of our public stockholders at J.P. Morgan Chase Bank, N.A. maintained by Continental Stock Transfer & Trust Company, acting as trustee (the “Trust Account”). At the time of the IPO, our initial amended and restated certificate of incorporation provided that, none of the funds held in trust will be released from the Trust Account, other than interest income to pay any tax obligations until the earlier of (i) the consummation of our initial business combination, (ii) our failure to consummate a business combination by 15 months after the IPO, and (iii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend our amended and restated certificate of incorporation (a) to modify the substance or timing of the ability of holders of our public shares to seek redemption in connection with our initial business combination or our obligation to redeem 100% of our public shares if we do not complete our initial business combination by 15 months after the IPO, or (b) with respect to any other provision relating to stockholders’ rights or pre-business combination activity.

 

As previously disclosed under the section titled “Extensions of Business Combination Period and Amendments to Our Certificate of Incorporation” to this Annual Report, our stockholders voted to amend our amended and restated certificate on three occasions resulting in 18,507,585 shares being redeemed since the IPO and $188,955,280 paid from the Trust Account to the redeeming stockholders.

 

As of the date of this filing, the Company has 1,617,415 shares of public common stock outstanding, and approximately $17,777,323 remains in the Trust Account.

 

21
 

 

Purchases of Equity Securities by the Issuer and Affiliated Purchasers

 

None.

 

ITEM 6. [RESERVED]

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This Annual Report includes “forward-looking statements” that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Annual Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to “Cautionary Note Regarding Forward-Looking Statements and Risk Factor Summary,” “Item 1A. Risk Factors” and elsewhere in this Annual Report on Form 10-K. The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

 

Overview

 

We are a blank check company formed under the laws of the State of Delaware on August 7, 2020 for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses. Although we are not limited to a particular industry or geographic region for purposes of consummating an initial business combination, we intend to focus on businesses that have their primary operations located in North America in the healthcare industry. We intend to utilize cash derived from the proceeds of our initial public offering in effecting our initial business combination.

 

22
 

 

The issuance of additional shares in connection with an initial business combination:

 

  ● may significantly dilute the equity interest of our investors in this offering who would not have pre-emption rights in respect of any such issuance;
     
  ● may subordinate the rights of holders of shares of common stock if we issue shares of preferred stock with rights senior to those afforded to our shares of common stock;
     
  ● will likely cause a change in control if a substantial number of our shares of common stock are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and most likely will also result in the resignation or removal of our present officers and directors; and
     
  ● may adversely affect prevailing market prices for our securities.
     
  ● Similarly, if we issue debt securities, it could result in:
     
  ● default and foreclosure on our assets if our operating revenues after our Initial Business Combination are insufficient to pay our debt obligations;
     
  ● acceleration of our obligations to repay the indebtedness even if we have made all principal and interest payments when due if the debt security contains covenants that required the maintenance of certain financial ratios or reserves and we breach any such covenant without a waiver or renegotiation of that covenant;
     
  ● our immediate payment of all principal and accrued interest, if any, if the debt security is payable on demand
     
  ● our inability to obtain additional financing, if necessary, if the debt security contains covenants restricting our ability to obtain additional financing while such security is outstanding; and
     
  ● limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages compared to our competitors who have less debt.

 

We expect to continue to incur significant costs in the pursuit of our acquisition plans. We cannot assure you that our plans to complete our initial business combination will be successful.

 

On January 12, 2022, we entered into a merger agreement (the “Old Merger Agreement”) with VHAC Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Old Merger Sub”), and Suneva Medical, Inc., a Delaware corporation (“Suneva”). Pursuant to the terms of the Old Merger Agreement, a business combination between the Company and Suneva will be consummated through the merger of Old Merger Sub with and into Suneva, with Suneva surviving the merger as a wholly owned subsidiary of the Company (the “Old Merger”). On February 2, 2023, legal counsel for Viveon sent a letter informing Suneva’s legal counsel that Viveon decided, effective immediately, to unilaterally terminate the Old Merger Agreement pursuant to Sections 10.2(a) and 10.3 thereof, based upon material breaches of the Old Merger Agreement by Suneva. The termination letter was sent without prejudice and reserved all of Viveon, Old Merger Sub and Viveon Health, LLC (Viveon’s sponsor) rights, claims and remedies, specifically including those within the Old Merger Agreement, against Suneva and others associated with Suneva who participated in the merger discussions and arrangements, and waived none.

 

23
 

 

On March 18, 2022, we held our 2022 Annual Meeting of Stockholders for the purpose of approving: (i) a proposal to approve an amendment to our amended and restated certificate of incorporation to (i) extend the date by which the Company has to consummate a business combination for three months, from March 28, 2022 (the “Original Termination Date”) to June 28, 2022, and (ii) allow us, without another stockholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed business combination with Suneva or any potential alternative initial business combination shall have occurred (the “Extension Proposal”); (ii) a proposal to re-elect five current directors to our Board of Directors (the “Director Election Proposal”); and (iii) a proposal to ratify the appointment of Marcum LLP as our independent registered certified public accountants for fiscal year 2020 (the “Auditor Ratification Proposal”). Stockholders voted to approve the Extension Proposal, Director Election Proposal and Auditor Ratification Proposal.

 

On March 18, 2022, stockholders elected to redeem 15,092,126 shares of our common stock, resulting in redemption payments out of the trust account totaling approximately $152,451,819. Subsequent to the redemptions, 5,032,874 shares of common stock remained in the trust account.

 

On March 21, 2022, an initial amount of $2,700,000 was drawn down from the Notes. $720,000 of the loan proceeds was deposited into our trust account in connection with extending the business combination completion window from the Original Termination Date until June 28, 2022. After June 28, 2022, we elected to continue to extend such date until December 28, 2022 (the “December Extension Date”), by making a monthly deposit of $240,000 into the trust account each month for each monthly period, until the December Extension Date. We deposited $240,000 into the trust account on each of June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 to extend the business combination completion window to July 28, 2022, August 28, 2022, September 28, 2022, October 28, 2022, November 28, 2022, and December 28, 2022, respectively.

 

On December 23, 2022, the Company held its 2022 Annual Meeting of the Stockholders in which they voted to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time for a total of up to six months from December 28, 2022 until June 30, 2023 (the “Second Extended Date”), upon three calendar days’ advance notice prior to the applicable monthly deadline, unless the closing of any potential initial business combination shall have occurred prior to the Second Extended Date.

 

On each of December 27, 2022, January 26, 2023, February 27, 2023, March 27, 2023 and April 28, 2023, the Company deposited $100,000 into the Trust Account to extend the date to consummate a Business Combination through January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023 (the “Extended Date”), respectively. Viveon made a final deposit of $100,000 on May 24, 2023 for a one month extension until June 30, 2023.

 

On December 23, 2022, stockholders elected to redeem 3,188,100 Public Shares, resulting in a redemption payable as of December 31, 2022 of $34,004,514 included in common stock tendered for redemption on the consolidated balance sheet. On January 25, 2023, redemption payments out of the trust account totaled $34,004,514. Subsequent to the redemptions, 1,844,774 shares of common stock remained in the trust account.

 

On June 22, 2023, the Company held a stockholder meeting to amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company, without another stockholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month until December 31, 2023, by depositing $85,000 into the trust account  and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”). The Company has deposited the initial payment of $85,000 into the Trust Account to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023.

 

On June 22, 2023, stockholders elected to redeem 227,359 Public Shares, resulting in a redemption of $2,498,947 from the Trust Account. Subsequent to the redemptions, 1,617,415 Public Shares remained.

 

The entry into the Subscription Agreement and the terms of the Notes and Subscription Warrants was approved by the Audit Committee of the Board of Directors of the Company at a meeting held on March 21, 2022.

 

On March 23, 2022, we filed an amendment to our amended and restated certificate of incorporation with the Delaware Secretary of State (the “Amendment”) The Amendment (i) extends the date by which we have to consummate a business combination for three months, from the Original Termination Date to the Extended Date and (ii) allows us, without another stockholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice and the deposit of $240,000 prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed business combination with Suneva Medical, Inc. or any potential alternative initial business combination shall have occurred. As disclosed in the Current Report on Form 8-K filed on March 18, 2022, the Amendment was approved by our stockholders at our Annual Meeting of Stockholders held on March 18, 2022.

 

On December 28, 2022, we filed an amendment to our amended and restated certificate of incorporation with the Delaware Secretary of State (the “Second Amendment”) The Second Amendment extends the date by which we have to consummate a business combination on a monthly basis for a total of up to six months from December 28, 2022 until June 30, 2023 unless the closing of the proposed Business Combination with Suneva, or any potential alternative initial business combination shall have occurred prior to June 30, 2023. Thereafter, we deposited $100,000 for each such monthly period. As disclosed in the Current Report on Form 8-K filed on December 28, 2022, the Amendment was approved by our stockholders at our Annual Meeting of Stockholders held on December 28, 2022.

 

On June 27, 2023, we filed a third amendment to our amended and restated certificate of incorporation with the Delaware Secretary of State (the “Third Amendment”). The Third Amendment allows us, to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the trust account established in connection with the Company’s initial public offering (the “Trust Account”) the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to Continental Stock Transfer & Trust Company (the “Trustee”), prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date.

 

On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, we entered into subscription agreements with several lenders for a loan of up to $4,000,000, in the aggregate (the “Subscription Agreements”).

 

Pursuant to the Subscription Agreements, we issued a series of unsecured senior promissory notes in the aggregate principal amount of up to $4,000,000 (the “Notes”) to the subscribers. Of the $4,000,000 in Notes, $1,955,000   was subscribed for by several related parties affiliated with our sponsor, Viveon Health LLC, and the balance in the amount of $2,045,000 was subscribed for by parties that are not related to our sponsor.

 

Pursuant to the terms of the Subscription Agreements, the subscribers also received warrants to purchase one share of our common stock for every $2.00 of the funded principal amount of the Notes up to 2,000,000 shares of our common stock, in the aggregate, at an exercise price of $11.50 per share, subject to adjustment (the “Subscription Warrants”). The Subscription Warrant term commences on the Exercise Date (as hereinafter defined) for a period of 49 months. The Subscription Warrants are exercisable commencing on the date of the initial business combination (the “Exercise Date”) and have a cashless exercise feature that is available at any time on or after the Exercise Date. Commencing on the date 13 months following the Exercise Date, the subscribers have the right, but not the obligation, to put the Subscription Warrants to us at a purchase price of $5.00 per share. We have agreed to file, within thirty (30) calendar days after the consummation of an initial business combination, a registration statement with the Securities and Exchange Commission to register for resale the shares of common stock underlying the Subscription Warrants.

 

The Notes do not bear interest and mature upon the earlier of (i) the closing of our initial business combination, and (ii) December 31, 2022 (the “Maturity Date”). The Notes provide for a credit line up to the maximum amount of $4,000,000. We will not have the right to re-borrow any portion of any loans made under the Notes once repaid  . As of December 31, 2022, a commitment fee in the amount of $400,000, equal to 10% of the maximum principal amount of the Note, had been paid to the subscribers, on a pro rata basis. In the event that we do not consummate a business combination by the Maturity Date, the Notes will be repaid only from amounts remaining outside of our Trust Account, if any. Subsequent to December 31, 2022, in connection with the Merger Agreement (as defined below) a majority of the holders of the Notes and Subscription Warrants have agreed to exchange such Notes and Subscription Warrants pursuant to the terms of an exchange agreement with Viveon dated as of May 1, 2023 (the Exchange Agreement”) for a separate series of Clearday senior convertible promissory notes (the “Clearday Senior Convertible Notes”). The Clearday Senior Convertible Notes bear 8% interest per annum and mature upon the earlier of (i) June 30, 2024, or (ii) the date of any Change in Control. Upon the consummation of the business combination and the exchange of the Subscription Agreements for the Clearday Senior Convertible Notes, the lenders will forfeit their Subscription Warrants as part of the exchange. One lender has chosen not to convert to Clearday Senior Convertible Notes. The balance owed to this lender under the Notes is considered due upon demand by the lender. As of the date of this filing of this Annual Report the lender has not requested payment of the Note. Pursuant to a warrant cancellation and forfeiture agreement dated as of August 16, 2023, one of the Company’s directors agreed to forfeit for cancellation 89,029 of the warrant shares underlying the warrant issued to an affiliate that he controls in connection with the Notes described above.

 

24
 

 

In accordance with ASC 470-20-25-2, Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants, the proceeds from the issuance of the Notes were allocated to the Notes and Subscription Warrants using the with-and-without method. Under this method, the Company first allocated the proceeds from the issuance of the Notes to the Subscription Warrants based on their initial fair value measurement. The measurement of the Subscription Warrants fair value was determined utilizing a Monte Carlo simulation model considering all relevant assumptions current at the dates of issuance. See Note 10 to the consolidated financial statements for more details on the assumptions used. The initial fair value of certain Subscription Warrants exceeded the proceeds received from the issuance of the Notes. In these instances, the proceeds allocated to the Notes were nil, and the Company recognized a loss on the issuance of those Subscription Warrants. In other instances, the fair value of Subscription Warrants did not exceed the proceeds received from the issuance of the Notes. As such a portion of the proceeds equal to the fair value of the Subscription Warrants on the date of issuance was allocated to the Subscription Warrants. The remaining proceeds were allocated to the Notes issued.

 

Discounts to the principal amounts are included in the carrying value of the Notes and amortized to “Interest expense” over the remaining term of the underlying debt to the Original Maturity Date. During the years ended December 31, 2022 and 2021, we recorded a $3,645,777 and $0 debt discount upon issuance of the Notes. The discount is amortized to interest expense over the term of the debt to the Original Maturity Date. For the years ended December 31, 2022 and 2021, the amortization of the discount resulted in interest expense of $3,645,777 and $0, respectively.

 

Our Sponsor agreed to loan the Company an aggregate of up to $500,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “IPO Note”). This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the Initial Public Offering. On January 13, 2021, we paid the $228,758 balance on the note from the proceeds of the Initial Public Offering. We no longer have the ability to borrow under the IPO Note.

 

Our Chief Financial Officer loaned the Company $75,000 to cover expenses related to ongoing operations, which was funded on December 27, 2022. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on December 27, 2022.

 

As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $75,000 and $0, respectively. Subsequent to December 31, 2022, our Chief Financial Officer loaned the Company an additional $555,000 through the date of this filing. These loans will be exchanged for Clearday Senior Convertible Notes upon consummation of the Company’s initial Business Combination

 

Our Chief Executive Officer of the Company loaned the Company $100,000 to cover expenses related to ongoing operations, which was funded on April 2, 2023. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on April 2, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $0, respectively.

 

Subsequent to December 31, 2022, three investors in our Sponsor, loaned the Company $100,000 in the aggregate, to cover expenses related to ongoing operations, funded on April 5, 2023, and April 7, 2023  . These loans are non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreements were entered into on April 5, 2023, and April 7, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loans was $0, respectively.

 

On May 12, 2023, we entered into an unsecured promissory note with Clearday (the “Clearday Note”). The Clearday Note is non-interest bearing mature upon the earlier of (i) the first anniversary of the issuance date and (ii) December 31, 2022. Proceeds provided to us under the Clearday Note through the filing date were approximately $881,710 during fiscal year 2023. Funds in the Trust Account may not be used to repay the obligations under the Clearday Note. We used such funds for general working capital purposes. A copy of the Clearday Note is incorporated as Exhibit 10.22 of this Annual Report, and all references herein to the Clearday Note are qualified in their entirety by reference to the full text of such agreement.

 

Recent Developments

 

Merger Agreement with Clearday

 

On April 5, 2023, the Company entered into a Merger Agreement (the “Merger Agreement”), by and among Viveon, Clearday, Inc., a Delaware corporation (the “Clearday”), VHAC2 Merger Sub, Inc., a Delaware corporation (“New Merger Sub”), Viveon Health LLC, a Delaware limited liability Company, in the capacity as the representative from and after the effective time for the stockholders of the Company (other than the Company Stockholders (as defined in the Merger Agreement)) as of immediately prior to the effective time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement, and Clearday SR LLC, a Delaware limited liability company, in the capacity as the representative from and after the effective time for the holders of Company preferred stock as of immediately prior to the effective time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement. Pursuant to the terms of the Merger Agreement, a business combination between the Company and Clearday will be consummated through the merger of New Merger Sub with and into Clearday, with Clearday surviving the merger as a wholly owned subsidiary of the Company and the Company will change its name to “Clearday Holdings, Inc.” (the “Merger”). The board of directors of the Company has (i) approved and declared advisable the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement, the Merger and related transactions by the stockholders of Company. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Merger Agreement.

 

Consideration

 

Merger Consideration

 

The total consideration to be paid at closing (the “Merger Consideration”) by the Company to Clearday security holders (and holders who have the right to acquire Clearday capital stock) will be an amount equal to $250 Million (plus the aggregate exercise price for all Clearday options and warrants). The Merger Consideration will be payable in shares of the Company’s common stock, par value $0.0001 per share, valued at $10 per share.

 

25
 

 

Earnout Payments

 

In addition, the holders of Clearday preferred stock will have the contingent right to earn up to 5,000,000 shares of the Company’s common stock, in the aggregate (the “Earnout Shares”), if at any time during the period beginning on the date of the Closing (the “Closing Date”) and ending on the fifth anniversary of the Closing Date (the “Earnout Eligibility Period”), the Adjusted Net Income for any Earnout Period is a positive number for the first time during the Earnout Eligibility Period (the “Earnout Milestone”).

 

If, following the Closing Date and prior to end of the Earnout Eligibility Period, there is a change of control, then, immediately prior to such change of control, all the Earnout Shares not yet earned shall be earned by the Clearday earnout holders and shall be released from escrow and delivered to the Clearday earnout holders, and the Clearday earnout holders shall be eligible to participate in such change of control transaction with respect to such Earnout Shares.

 

The Earnout Shares will be placed in escrow and will not be released from escrow until they are earned as a result of the occurrence of the Earnout Milestone or a change of control, if applicable. The Earnout Shares that are not earned on or before the expiration of the Earnout Eligibility Period shall be automatically forfeited and cancelled.

 

Treatment of Clearday Securities

 

Cancellation of Securities.

 

Each share of Clearday capital stock, if any, that is owned by the Company, New Merger Sub, Clearday, or any of their subsidiaries (as treasury stock or otherwise) immediately prior to the effective time of the Merger (the “Effective Time”), will automatically be cancelled and retired without any conversion or consideration.

 

Preferred Stock.

 

At the Effective Time, each issued and outstanding share of Clearday’s Series F Cumulative Convertible Preferred Stock, par value $0.001 per share (“Clearday Series F Preferred Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: (A) one (1) share of Parent New Series F Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement.

 

Each issued and outstanding share of Clearday’s Series A Convertible Preferred Stock, par value $0.001 per share (“Clearday Series A Preferred Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: (A) one (1) share of Parent New Series A Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement.

 

Common Stock.

 

At the Effective Time, each issued and outstanding share of Clearday’s common stock, par value $0.001 per share (“Clearday Common Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares) will be converted into the right to receive a number of shares of the Company’s common stock equal to the conversion ratio. The “Conversion Ratio” as defined in the Merger Agreement means an amount equal to (a)(i) the sum of $250 Million, plus the aggregate exercise or conversion price of outstanding Clearday’s stock options and warrants (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more), divided by (ii) the number of fully diluted Clearday capital stock (including Clearday preferred stock, warrants, stock options, convertible notes, and any other convertible securities) (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more and assuming a conversion price of Clearday subsidiary securities as provided in the Merger Agreement); divided by (b) $10.00.

 

Merger Sub Securities.

 

Each share of common stock, par value $0.0001 per share, of New Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and become one newly issued share of common stock of the surviving corporation.

 

26
 

 

Stock Options.

 

At the Effective Time, each outstanding option to purchase shares of Clearday Common Stock will be converted into an option to purchase, subject to substantially the same terms and conditions as were applicable under such options prior to the Effective Time, shares of the Company’s common stock equal to the number of shares subject to such option prior to the effective time multiplied by the Conversion Ratio, at an exercise price per share of the Company’s common stock equal to the exercise price per share of Clearday Common Stock subject to such option divided by the Conversion Ratio.

 

Warrants.

 

Contingent on and effective as of immediately prior to the effective time, each outstanding warrant to purchase shares of Clearday Preferred Stock or Clearday Common Stock will be treated in accordance with the terms thereof.

 

Convertible Notes.

 

Contingent on and effective as of immediately prior to the Effective Time, Clearday’s convertible notes outstanding as of immediately prior to the effective time, will be treated in accordance with the terms of the relevant agreements governing such convertible notes.

 

Subsidiary Capital Stock.

 

At and as of the effective time, the subsidiary capital stock will remain in full force and effect with the right to acquire the Clearday Common Stock with such adjustments noted in the terms of such subsidiary capital stock.

 

Representations and Warranties

 

The Merger Agreement contains customary representations and warranties of the parties thereto with respect to, among other things, (a) corporate existence and power, (b) authorization to enter into the Merger Agreement and related transactions; subsidiaries, (c) governmental authorization, (d) non-contravention, (e) capitalization, (f) corporate records, (g) consents, (h) financial statements, (i) internal accounting controls, (j) absence of certain changes, (k) properties; title to assets, (l) litigation, (m) material contracts, (n) licenses and permits, (o) compliance with laws, (p) intellectual property, (q) privacy and data security, (r) employee matters and benefits, (s) tax matters, (t) real property, (u) environmental laws, (v) finders’ fees, (w) directors and officers, (x) anti-money laundering laws, (y) insurance, (z) related party transactions, and (aa) certain representations related to securities law and activity. The Company has additional representations and warranties, including (a) issuance of shares, (b) trust fund, (c) listing, (d) board approval, (e) SEC documents and financial statements, (f) certain business practices, (g) expenses, indebtedness and other liabilities and (h) brokers and other advisors.

 

Covenants

 

The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the registration statement and proxy statement (as each such terms are defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party’s respective stockholders. The Company and Clearday have each also agreed to include in the proxy statement the recommendation of its respective board that its stockholders approve all of the proposals to be presented at its respective special meeting. In addition, each of the Company and Clearday have agreed to use commercially reasonable efforts to solicit and finalize definitive documentation for a committed equity in an aggregate amount that, together with the funds in the Trust Account after giving effect to potential redemptions from the Company’s public stockholders, together with financing programs available to Clearday after the Closing, will provide to Clearday working capital to meet its short-term commercial development goals.

 

27
 

 

The Company has also agreed to prepare a proxy statement to seek the approval of its stockholders (the “Extension Proposal”) to amend its organizational documents to extend the period of time the Company is afforded under its organizational documents and IPO prospectus to consummate an initial business combination for an additional three months, from June 30,2023 to September 30, 2023 (or such earlier date as the Company and Clearday may agree in writing).

 

Each party’s representations, warranties and pre-Closing covenants will not survive Closing and no party has any post-Closing indemnification obligations.

 

Viveon Equity Incentive Plan

 

The Company has agreed to approve and adopt an equity incentive plan (the “Incentive Plan”) to be effective as of the Closing and in a form mutually acceptable to the Company and Clearday, subject to approval of the Incentive Plan by the Company’s stockholders. The Incentive Plan will provide for an initial aggregate share reserve equal to 8% of the number of shares of the Company’s common stock issued and outstanding at the Closing and an “evergreen” provision that is mutually agreeable to the Company and Clearday will provide for an automatic increase on the first day of each fiscal year in the number of shares available for issuance under the Incentive Plan as mutually determined by the Company and Clearday.

 

Non-Solicitation Restrictions

 

Each of the Company and Clearday has agreed that from the date of the Merger Agreement to the effective time or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate any negotiations with any party relating to an alternative transaction (as such term is defined in the Merger Agreement) or enter into any agreement relating to such a proposal, other than as expressly excluded from the definition of an alternative transaction. Each of the Company and Clearday has also agreed to be responsible for any acts or omissions of any of its respective representatives that, if they were the acts or omissions of the Company and Clearday, as applicable, would be deemed a breach of the party’s obligations with respect to these non-solicitation restrictions.

 

Conditions to Closing

 

The consummation of the Merger is conditioned upon, among other things, (i) the absence of any applicable law or order restraining, prohibiting or imposing any condition on the consummation of the Merger and related transactions, (ii) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (iii) receipt of any consent, approval or authorization required by any Authority (as defined in the Merger Agreement), (iv) the Company having net tangible assets of at least $5,000,001 (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act), unless the Company’s amended and restated certificate of incorporation shall have been amended to remove such requirement prior to or concurrently with the Closing, (v) approval by Clearday’s stockholders of the Merger and related transactions, (vi) approval by the Company’s stockholders of the Merger and related transactions, (vii) the conditional approval for listing by NYSE American (or an alternate exchange) of the shares of the Company’s common stock to be issued in connection with the transactions contemplated by the Merger Agreement and satisfaction of initial and continued listing requirements, and (viii) the registration statement becoming effective in accordance with the provisions of the Securities Act of 1933, as amended (“Securities Act”).

 

Solely with respect to the Company and New Merger Sub, the consummation of the Merger is conditioned upon, among other things, (i) Clearday having duly performed or complied with all of its obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of Clearday, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure would not have or reasonably be expected to have a material adverse effect (as defined in the Merger Agreement) on Clearday or any of its subsidiaries, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a material adverse effect on Clearday or any of its subsidiaries, (v) Clearday and its securityholders having executed and delivered to the Company each additional agreement (as defined in the Merger Agreement) to which they each are a party and (vi) Clearday delivering certain certificates to the Company.

 

28
 

 

Solely with respect to Clearday, the consummation of the Merger is conditioned upon, among other things, (i) Viveon and New Merger Sub having duly performed or complied with all of their respective obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of the Company and Merger Sub, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a material adverse effect on the Company or New Merger Sub and their ability to consummate the Merger and related transactions, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a Material Adverse Effect on the Company or New Merger Sub, (v) the amended parent charter (as defined in the Merger Agreement) being filed with, and declared effective by, the Delaware Secretary of State, (vi) the Company delivering certain certificates to Clearday, (vii) the size and composition of the post-Closing board of directors of the Company having been appointed as set forth in the Merger Agreement and (viii) the Company, Viveon Health LLC and other stockholders, as applicable, having executed and delivered to Clearday each additional agreement to which they each are a party.

 

Termination

 

The Merger Agreement may be terminated at any time prior to the effective time as follows:

 

(i) by either the Company or Clearday, if (A) the Merger and related transactions are not consummated on or before the latest of (i) June 30, 2023, (ii) if the Extension Proposal is approved, September 30, 2023 and (iii) if one or more extensions to a date following September 30, 2023 are obtained at the election of the Company, with the Company’s stockholder vote, in accordance with the Company’s amended and restated certificate of incorporation, the last date for the Company to consummate a business combination pursuant to such extensions; and (B) the material breach or violation of any representation, warranty, covenant or obligation under the Merger Agreement by the party seeking to terminate the Merger Agreement was not the cause of, or resulted in, the failure of the closing to occur on or before the outside Closing Date, without liability to the other party;

 

(ii) by either the Company or Clearday, if any authority has issued any final decree, order, judgment, award, injunction, rule or consent or enacted any law, having the effect of permanently enjoining or prohibiting the consummation of the Merger, provided that, the party seeking to terminate cannot have breached its obligations under the Merger Agreement and such breach was a substantial cause of, or substantially resulted in, such action by the authority; and

 

(iii) by mutual written consent of the Company and Clearday duly authorized by each of their respective boards of directors.

 

The Merger Agreement and other agreements described below have been included to provide investors with information regarding their respective terms. They are not intended to provide any other factual information about the Company, Clearday or the other parties thereto. In particular, the assertions embodied in the representations and warranties in the Merger Agreement were made as of a specified date, are modified or qualified by information in one or more disclosure letters prepared in connection with the execution and delivery of the Merger Agreement, may be subject to a contractual standard of materiality different from what might be viewed as material to investors, or may have been used for the purpose of allocating risk between the parties. Accordingly, the representations and warranties in the Merger Agreement are not necessarily characterizations of the actual state of facts about the Company, Clearday or the other parties thereto at the time they were made or otherwise and should only be read in conjunction with the other information that the Company or Clearday makes publicly available in reports, statements and other documents filed with the SEC. The Company and Clearday investors and securityholders are not third-party beneficiaries under the Merger Agreement.

 

29
 

 

Certain Related Agreements

 

Parent Support Agreements.

 

Concurrently with the execution of the Merger Agreement, the Company, Clearday and the Sponsor and the officers and directors of the Company entered into a support agreement (the “Parent Support Agreement”) pursuant to which the Sponsor and the officers and directors of the Company have agreed to vote all shares of the Company’s common stock beneficially owned by them, including any additional shares of the Company they acquire ownership of or the power to vote: (i) in favor of the Merger and related transactions, (ii) against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions, and (iii) in favor of an extension of the period of time the Company is afforded to consummate an initial business combination.

 

Company Support Agreements.

 

Concurrently with the execution of the Merger Agreement, the Company, Clearday and certain stockholders of Clearday entered into a support agreement (the “Company Support Agreement”), pursuant to which such Clearday stockholders have agreed to vote all common and preferred stock of Clearday beneficially owned by them, including any additional shares of Clearday they acquire ownership of or the power to vote, in favor of the Merger and related transactions and against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions.

 

Lock-Up Agreements.

 

In connection with the closing, certain Clearday stockholders will each agree, subject to certain customary exceptions, not to (i) offer, sell contract to sell, pledge or otherwise dispose of, directly or indirectly, any lockup shares, (ii) enter into a transaction that would have the same effect, (iii) enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the lock-up shares or otherwise, (iv) engage in any short sales or other arrangement with respect to the lock-up shares or (v) publicly announce any intention to effect any transaction specified in clause (i), (ii) or (iii) until the date that is six months after the Closing Date (the “Lock-Up Period”). The term “Lockup Shares” mean the Merger Consideration Shares and the Earnout Shares, if any, whether or not earned prior to the end of the Lock-up Period, together with any other shares of the Company’s common stock, and including any securities convertible into, or exchangeable for, or representing the rights to receive the Company’s common stock, if any, acquired during the Lock-up Period. If the closing price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period following the Closing Date, 50% of the Lock-up Shares will be released from the lock-up. The existing escrow provisions of the Company’s common stock held by certain stockholders will remain in effect.

 

Amended and Restated Registration Rights Agreement.

 

At the Closing, the Company will enter into an amended and restated registration rights agreement (the “Amended and Restated Registration Rights Agreement”) with certain existing stockholders of the Company and Clearday with respect to their shares of the Company’s common stock acquired before or pursuant to the Merger, and including the shares issuable on conversion of the warrants issued to the Sponsor in connection with the Company’s initial public offering and any shares issuable on conversion of loans or other convertible securities. The agreement amends and restates the registration rights agreement the Company entered into on December 22, 2020 in connection with its initial public offering. Subject to the Lock-Up Agreements described above, the holders of a majority of the shares held by the Company’s existing stockholders, and the holders of a majority of the shares held by the Clearday stockholders will each be entitled to make one demand that Clearday register such securities for resale under the Securities Act, or two demands each if the Company is eligible to use Form S-3 or a similar short-form registration statement. In addition, the holders will have certain “piggy-back” registration rights that require the Company to include such securities in registration statements that the Company otherwise files. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

30
 

 

Results of Operations

 

We have neither engaged in any operations nor generated any revenues to date. Our only activities for the years ended December 31, 2022 and 2021 were organizational activities, identifying target companies for a business combination, conducting due diligence on such target companies and negotiating the Business Combination Agreement with Suneva, which was terminated on February 2, 2023. We do not expect to generate any operating revenues until after the completion of our business combination. We generate non-operating income in the form of interest income on marketable securities held after our initial public offering. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses.

 

For the year ended December 31, 2022, we had a net loss of $486,788, which consisted of loss on issuance of subscription warrants of $3,209,183 amortization of the debt discount of $3,645,777, professional fees of $1,368,699, operating costs of $756,386, expensed issuance costs of $392,642, franchise tax expense of $246,216 and income tax expense of $61,310, partially offset by a gain on the change in fair value of warrant liability of $8,468,308 interest and dividend income on investments held in Trust Account of $724,225, and interest income on the operating bank account of $892.

 

For the year ended December 31, 2021, we had net income of $2,489,829, which consisted of a change in fair value of warrant liability of $6,575,140, interest income on investments held in Trust Account of $20,329 and interest income on the operating bank account of $147, partially offset by formation and operating costs of $1,050,016, professional fees of $2,701,431, franchise tax expense of $197,200, and stock compensation expense of $157,140. The gains on the change in fair value of warrant liabilities was due in large part to the decrease in the public traded price of the public warrants.

 

Liquidity, Capital Resources, and Going Concern

 

For the year ended December 31, 2022, net cash used in operating activities was $1,753,388, which was primarily due to operational costs and franchise taxes paid during the period.

 

For the year ended December 31, 2021, net cash used in operating activities was $2,082,334, which was due to the change in fair value of warrant liability of $6,575,140 and interest earned on investments held in Trust Account of $20,329, offset in part by net income of $2,489,829, changes in working capital of $1,866,166, and stock compensation expense of $157,140.

 

For the year ended December 31, 2022, net cash provided by investing activities was $150,191,819 which resulted from cash withdrawn from Trust Account to pay redeeming stockholders of $152,451,819, offset in part by cash deposited for the extension contribution of $2,260,000.

 

There were no cash flows from investing activities for the year ended December 31, 2021.

 

For the year ended December 31, 2022, net cash used in financing activities was $148,813,819, which was due to the redemption of common stock of $152,451,819 and the payment of issuance costs of $437,000, offset in part by proceeds from note agreements payable of $2,045,000, proceeds from note agreements payable - related party of $1,955,000 and proceeds from promissory note - related party of $75,000.

 

For the year ended December 31, 2021, net cash used in financing activities was $619,387, which was due to payment of other payable – related party of $364,880, payment of the promissory note – related party of $228,758 and offering costs paid of $25,749.

 

As of December 31, 2022, we had cash and marketable securities in the trust account of $53,815,395. We intend to use substantially all of the funds held in the trust account, including any amounts representing interest earned on the trust account (less taxes payable and deferred underwriting commissions) to complete our initial business combination. We may withdraw interest to pay taxes. During the year ended December 31, 2022, we did not withdraw any of the interest income from the Trust Account to pay for franchise and income taxes. In June 2023, we withdrew approximately $429,305 to make payments for delinquent franchise taxes. To the extent that our capital stock or debt is used, in whole or in part, as consideration to complete our Initial Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies.

 

31
 

 

As of December 31, 2022, we had cash and cash equivalents of $19,847 outside of the Trust Account and a working capital deficit of $40,841,257.

 

In connection with our assessment of going concern considerations in accordance with FASB’s ASC Subtopic 205-40, Presentation of Financial Statements - Going Concern, management has determined that if we are unable to raise additional funds to alleviate liquidity needs, or complete a business combination by March 31, 2024, then we will cease all operations except for the purpose of liquidating, unless we seek stockholder approval to amend our current charter to extend the date by which we complete a business combination. The liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about our ability to continue as a going concern one year from the date that these consolidated financial statements are issued. No adjustments have been made to the carrying amounts of assets or liabilities should we be unable to continue as a going concern. We intend to complete a business combination before the mandatory liquidation date or obtain approval from our stockholders to amend our current charter for an extension.

 

Off-Balance Sheet Arrangements

 

We did not have any off-balance sheet arrangements as of December 31, 2022 and December 31, 2021.

 

Contractual Obligations

 

We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities other than an agreement to pay an affiliate of our sponsor a monthly fee of $20,000 for office space, utilities and secretarial and administrative support and the series of unsecured senior promissory note agreements we entered into with several lenders affiliated with our Sponsor. We began incurring these fees on December 22, 2020 and will continue to incur these fees monthly until the earlier of the completion of the Business Combination and our liquidation.

 

Chardan is entitled to a deferred fee of $0.35 per Unit, or $7,043,750. The deferred fee will become payable Chardan from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the Underwriting Agreement, dated as of December 22, 2020, between the Company and Chardan (the “Underwriting Agreement”). A copy of the Underwriting Agreement is incorporated by reference in Exhibit 1.1 of this Annual Report, and all references herein to the Underwriting Agreement are qualified in their entirety by reference to the full text of such agreement.

 

In addition, pursuant to the Underwriting Agreement, we granted Chardan for a period of 12 months after the date of the consummation of a Business Combination, a right of first refusal to act as book-running managing underwriter or placement agent, with at least 30% of the economics, for any and all future public and private equity, convertible and debt offerings (the “ROFR”). On April 20, 2021, pursuant to the terms of an Addendum to the Underwriting Agreement, Chardan waived and released the ROFR. Subsequently, on July 12, 2021, we entered into a Letter Agreement with Chardan (the “Letter Agreement”) that reinstates the ROFR in the event Chardan introduces us to a target that results in a Business Combination and entitles Chardan to a fee equal to 0.5% of the aggregate value of the target measured prior to the Business Combination, paid in cash or shares at the close of the Business Combination. A copy of the Letter Agreement is filed as Exhibit 10.23 of this Annual Report, and all references herein to the Letter Agreement are qualified in their entirety by reference to the full text of such agreement.

 

On May 18, 2021, the Company entered into an agreement with a transactional and strategic advisory firm (the “Strategic Advisor”) for advisory services as needed by the Company in connection with a Business Combination. Pursuant to this agreement, the Company incurred approximately $875,000 in fees. As of December 31, 2022 and December 31, 2021, $500,000 of such fees remain unpaid and are included in accrued costs and expenses on the consolidated balance sheets. On November 1, 2021, the Company and the Strategic Advisor entered into an amendment to the agreement. Pursuant to this amendment, the Company will pay the Strategic Advisor a fee of $2,625,000, inclusive of the $500,000 accrued as of December 31, 2022 and December 31, 2021. The remaining $2,125,000 is contingent upon the consummation of the Business Combination.

 

On October, 8, 2021, the Company entered into an agreement with a financial advisor (the “Exclusive Financial Advisor”) for financial advisory services such as financial and transaction feasibility analysis, assistance in negotiations, assistance in capital planning, and other customary services in connection with a Business Combination, pursuant to which the Company will pay the Exclusive Financial Advisor a fee of $1,500,000 contingent upon the consummation of the Business Combination. This agreement was terminated on January 31, 2023 as a result of the termination of the merger agreement between the Company and Suneva.

 

On November 1, 2021, the Company entered into an agreement with a financial advisor (the “Second Financial Advisor”) for financial advisory services such as guidance on valuation and transaction structure and terms, assistance in negotiations, coordination of due diligence, documentation, and transaction closing, and introduction of the Company to institutional investors in connection with a Business Combination, pursuant to which the Company will pay the Second Financial Advisor a fee of $400,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on January 31, 2023, and there are no related contingent fees for the agreement.

 

On November 2, 2021, the Company entered into an agreement with a financial advisor (the “Third Financial Advisor”) for financial advisory services such as market related advice and assistance in connection with a Business Combination, pursuant to which the Company will pay the Third Financial Advisor a fee of $500,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on June 9, 2023, and there are no related contingent fees for the agreement.

 

On November 5, 2021, the Company entered into an agreement with an advisor (the “Advisor”) for services such as assistance in refining strategic objectives, preparation or refinement of solicitation materials, identification, contact, and solicitation of or potential investors and other sources of capital, and assistance in review, selection, negotiation, and closing of a transaction in connection with a Business Combination, pursuant to which the Company will pay the Advisor a fee of $200,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on June 19, 2023, and there are no related contingent fees for the agreement.

 

On November 15, 2021, the Company entered into an agreement with two placement agents (the “Placement Agents”) for services such as analysis of potential contributions and assets of a target to the Company’s future prospects, assistance in negotiations, and assistance in preparation of presentations to investors, lenders, and/or other financial sources in connection with a Business Combination, pursuant to which the Company will pay the Placement Agents a fee equal to the difference between 5% of the total aggregate sales price of the securities sold as part of the Business Combination and 5% of any securities sold as part of the Business Combination to investors identified by the Advisor, contingent upon the consummation of the Business Combination. This agreement was terminated on February 15, 2022, as a result of an automatic termination provision upon the earlier to occur of three months or the final closing of Business Combination and there are no related contingent fees for the agreement.

 

On February 17, 2022, the Company entered into an agreement with a broker-dealer (the “Broker-Dealer”) for services such as providing the Company with capital markets advisory services with regard to a forward purchase agreement, convertible private investment in public equity (“PIPE”), secured credit facility, and any other capital structure topics in connection with a Business Combination, pursuant to which the Company will pay the Broker-Dealer a fee of $250,000. This agreement was terminated on June 9, 2023, as a result of the termination of the merger agreement between the Company and Suneva. Pursuant to the terms of the agreement the Broker-Dealer will remain entitled to the fee of $250,000 if a Business Combination is consummated within 24 months after the termination date. The Company is pursuing a waiver from the Broker-Dealer to waive the $250,000 fee upon a Business Combination. As such, the fee remains contingent upon the consummation of the Business Combination.

 

32
 

 

On May 9, 2023, the Company entered into an agreement with a placement agent (the “Placement Agent”) for services such as advising and assisting the Company in identifying one or more investors that are “accredited” or “qualified institutional buyers. Pursuant to which the Company will pay the Placement Agents a cash fee upon closing equal to eight percent (8.0%) of the gross proceeds received by the Company, contingent upon the consummation of the Business Combination.

 

Critical Accounting Policies

 

The preparation of consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and income and expenses during the periods reported. Actual results could materially differ from those estimates. We have identified the following critical accounting policies:

 

Common Stock Subject to Possible Redemption

 

All of the 1,844,774 public shares sold as part of the units in our initial public offering and subsequent full exercise of the underwriters’ over-allotment option that have not been redeemed by stockholders, contain a redemption feature which allows for the redemption of such redeemable common stock in connection with our liquidation, if there is a stockholder vote or tender offer in connection with our initial business combination and in connection with certain amendments to our amended and restated certificate of incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”), redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Therefore, all redeemable common stock have been classified outside of permanent equity.

 

We recognize changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit.

 

Net (Loss) Income per Common Share

 

Net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The calculation of diluted (loss) income per common share does not consider the effect of the warrants and rights issued in connection with the (i) initial public offering, (ii) exercise of over-allotment, (iii) Private Placement, and (iv) extension financing since the exercise of the warrants and rights are contingent upon the occurrence of future events and the inclusion of such warrants and rights would be anti-dilutive. The warrants and rights are exercisable to purchase 22,068,750 shares of common stock in the aggregate.

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, Derivatives and Hedging. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified on the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument’ could be required within 12 months of the balance sheet date. The Company has determined that the public warrants qualify for equity treatment and are not derivative instruments. The public warrants were measured at fair value and recorded as a component of additional paid-in capital at the time of issuance. The Company has determined that the private warrants and subscription warrants are derivative instruments. As the private warrants and subscription warrants meet the definition of a derivative the private warrants and subscription warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the statement of operations in the period of change. In accordance with ASC Topic 825, Financial Instruments, the Company has concluded that a portion of the transaction costs which directly related to the initial public offering and the private placement, should be allocated to the private warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the statement of operations.

 

Debt with Conversion and Other Options

 

The Company accounts for a series of unsecured senior promissory note agreements under ASC Topic ASC 470-20-25-2, Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants (“ASC 470-20-25-2”).  In accordance with ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants (detachable call options) are allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance.

 

Recent Accounting Standards

 

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements.

 

33
 

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

As a smaller reporting company we are not required to make disclosures under this Item.

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

Our financial statements and the notes thereto begin on page F-1 of this Annual Report.

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None.

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Evaluation of Disclosure Controls and Procedures

 

As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures. During the fiscal year ended December 31, 2021, the Company restated its audited financial statements as of December 31, 2020 to provide for the reclassification of the private warrants as a liability for the affected period and restated its audited financial statements as of December 31, 2020 and condensed financial statements as of and for the periods ended March 31, 2021 and June 30, 2021 to reclassify the Company’s redeemable common stock. In connection with the restatements, the Company identified a material weakness in its internal controls related to accounting for complex financial instruments. Subsequent to the aforementioned restatements, the Company determined that it had inappropriately accounted for the allocation of proceeds received in its initial public offering and did not appropriately recognize stock-based compensation related to the transfer of shares of common stock to members of the Company’s board of directors. This resulted in the restatement of the Company’s audited financial statement as of December 31, 2020 and condensed financial statements as of and for the periods ended June 30, 2021 and September 30, 2021. Subsequent to the aforementioned restatements, the Company determined it had inappropriately accounted for the remeasurement of common stock subject to possible redemption in connection with the Company’s deposit into the Trust Account on March 23, 2022 for the extension of the Company’s business combination period. This resulted in the restatement of the Company’s condensed consolidated financial statements as of and for the three months ended March 31, 2022. The control deficiencies related to the allocation of proceeds, stock-based compensation, and remeasurement of common stock subject to possible redemption represent a continuation of the previously identified material weakness related to accounting for complex financial instruments.

 

In addition, management identified deficiencies in internal control over financial reporting relating to the process of recording accounts payable, accrued expenses, tax liabilities and concluded that the failure to properly account for such accrued expenses constituted a material weakness as defined in the SEC regulations. The deficiencies related to accounts payable and accrued expenses resulted in the restatement of the Company’s condensed financial statements as of and for the periods ended March 31, 2021, June 30, 2021, and September 30, 2021. As such, our Chief Executive Officer and Chief Financial Officer determined that the Company’s disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d-15 (e) under the Exchange Act) were not effective as of December 31, 2022.

 

34
 

 

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

Management’s Annual Report on Internal Controls Over Financial Reporting

 

As required by SEC rules and regulations implementing Section 404 of the Sarbanes-Oxley Act, (as defined in Rules 13a-15(e) and 15- d-15(e) under the Exchange Act) our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our consolidated financial statements for external reporting purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that:

 

(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of our company;

 

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

 

(3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of our internal control over financial reporting at December 31, 2022. In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013). Based on our assessments and those criteria, management determined that our internal control over financial reporting was not effective, due to the material weaknesses described elsewhere in this Report.

 

Notwithstanding these material weaknesses, management has concluded that our audited consolidated financial statements included in this Report are fairly stated in all material respects in accordance with GAAP for each of the periods presented therein.

 

This Report does not include an attestation report of internal controls from our independent registered public accounting firm due to our status as an emerging growth company under the JOBS Act.

 

35
 

 

Changes in Internal Control Over Financial Reporting

 

During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. In light of the restatement of our financial statements as described above, we plan to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. In addition, we plan to enhance our processes to identify and record potential accruals. Our plans at this time include increased communication with third-party service providers and additional procedures to identify and review subsequent invoices and disbursements. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

36
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The following table sets forth information about our directors and executive officers as of the date of this Annual Report.

 

Name   Age   Position
Jagi Gill   57   Chief Executive Officer, President and Director
Rom Papadopoulos   64   Chief Financial Officer, Treasurer, Secretary and Director
Demetrios (Jim) G. Logothetis   66   Director
Brian Cole   60   Director
Doug Craft   61   Director

 

Below is a summary of the business experience of each our executive officers and directors:

 

Jagi Gill, PhD is our Chief Executive Officer. Dr. Gill has more than 20 years of healthcare investment and general management experience. From 2017 to 2020, he served as the Vice-President of Business Development and General Manager of AcuVentures, a business unit within Acumed LLC, a Berkshire Hathaway Company. Acumed LLC is a market leader in the orthopedic sector with particular strength in the upper extremity fracture repair and trauma market segments. As the General Manager, Dr. Gill led two business units, Rib Fixation and the Soft Tissue Repair, with responsibilities for product development, sales, marketing and profitability. Under his leadership, the business units grew 2-3x faster than their market segment. In addition to general management responsibilities, Dr. Gill was involved in sourcing, closing and integrating four acquisitions within the orthopedic sector for Acumed. These transactions ranged from technology acquisitions serving as tuck-in product integrations to stand alone companies with global revenue. From 2009 to 2017, he was the Founder, Chief Executive Officer and Board Member of Tenex Health a privately held orthopedic sports medicine company. In this capacity he patented, designed and developed the initial platform technology intended to treat chronic tendon pain. Under his leadership, Tenex Health launched commercially, generated positive operating income, secured FDA regulatory approval, developed a manufacturing and operations infrastructure, and established sales channels serving the outpatient Ambulatory Surgery Centers. Before founding Tenex Health, Dr. Gill was the Founder and Chief Executive Officer of OrthoCor, a company providing non-invasive pain management technology, from 2007 to 2009, while also serving on an advisory and consulting capacity to a number of medical technology companies. OrthoCor developed and commercialized orthopedic knee braces integrating pulsed electromagnetic technology to address chronic pain associated with trauma or osteoarthritis. Prior to this, he served in executive business development roles for Boston Scientific Corporation from 2001 to 2007 where he was involved in sourcing and supporting the acquisition of private companies which collectively accounted for more than $750 million in enterprise value. While at Boston Scientific, he was involved in the investments in, and acquisition of, the following private companies: Advanced Bionics (implantable neurostimulation), Cameron Health (implantable cardiac rhythm management), Innercool (systemic hypothermia for recovery from cardiac arrest), Orqis Medical (heart failure treatment) and Kerberos (endovascular thrombectomy). Dr. Gill completed his BSc and MSc in Anatomy from McGill University and PhD in Neuroscience from Mayo Clinic College of Medicine. We believe we will be able to capitalize on Dr. Gill’s experience and accomplishments in the orthopedic and spine markets, along with his relationships among executives in the target companies, their supply chains, and their customer networks, to successfully close a business combination.

 

Rom Papadopoulos, M.D. is our Chief Financial Officer. Dr. Papadopoulos has more than 25 years of healthcare investment and operational experience. From 2006 to June 2020, Dr. Papadopoulos was the Founder and Sole Proprietor of Intuitus Capital, a private equity firm actively investing in the healthcare sector. At Intuitus, he led investments in more than 30 companies with a total of more than $700 million in enterprise value. Prior to founding Intuitus Capital, Dr. Papadopoulos was Chief Financial Officer, Chief Operations Officer, Corporate Executive Vice President and Corporate Secretary of Global Energy Holdings (NYSE Amex: GNH). While at GNH, he created and executed the company’s repositioning from traditional markets to renewable energy. He was responsible for coordinating all aspects of the financial management of the company including cash management and treasury, risk management, audit functions, SEC reporting and compliance as well as HR functions and employee policies. Dr. Papadopoulos was an early investor in Tenex Health Inc., a medical device company engaged in the manufacturing and sale of minimally invasive high frequency technology used to perform percutaneous tenotomy and fasciotomy. He eventually became the interim CFO for the company until September 2013. In this capacity, he was an integral part of the team seeking and completing acquisitions for the company. From 2002 to 2006, Dr. Papadopoulos was the Managing Director and head of healthcare investment banking for Caymus Partners, a middle market investment banking firm. Dr. Papadopoulos received his medical degree (M.D.) from the Aristotelian University of Thessaloniki, Greece, Medical School in 1985 and conducted his post-graduate training in Pediatrics at Emory University in 1986. We believe that Dr. Papadopoulos is qualified to sit on our board due to his years of experience in the healthcare industry, as a clinician as well as an investor who possesses unique insight into medical technology assets, in addition to his strong financial credentials.

 

37
 

 

Demetrios (Jim) G. Logothetis, is one of our directors and served as Senior Advisor in the Department of Housing and Urban Development (HUD) Office of the Assistant Secretary and Chief Financial Officer where he led the Audit Coordination Committee for Ginnie Mae, a government corporation within HUD from May 2020 to November 2020. Mr. Logothetis retired from Ernst & Young (EY) effective in June 2019 extending three years beyond normal retirement at the request of the EY Executive Board. Throughout his forty-year career with EY, from January 1979 to June 2019, Mr. Logothetis served some of EY’s largest global clients as lead audit partner, and fulfilled senior leadership roles within the firm, from offices in Chicago, Frankfurt Germany, New York, London England, and Atlanta. Mr. Logothetis has served over the years on the boards of several non-profit organizations, including The National Board of the Boys & Girls Clubs of Americas where he served on the audit committee; The Archbishop Lakovos Leadership 100 Endowment Fund where he serves as Vice Chair, The American College of Greece where he serves as Chairman of the Board of Trustees; The Board of National Hellenic Museum; Founder and Chairman of the Board of Trustees of the Hellenic American Academy, one of the largest Greek American schools in the United States; and founding Chairman of the Foundation for Hellenic Education and Culture. Mr. Logothetis holds an M.B.A. degree in Accounting, Finance and International Business from The University of Chicago Booth Graduate School of Business and a B.S.C degree in Accountancy from DePaul University. Mr. Logothetis is also a Certified Public Accountant and a Certified Management Accountant. Mr. Logothetis has taught many EY training programs as well as graduate accounting classes at DePaul University. Mr. Logothetis served for several years on the DePaul University, Richard H. Driehaus College of Business advisory council, and since 2017 on the board of Trustees of the University as vice-chair, and then chair of the audit committee and member of the finance committee. Mr. Logothetis has also served as a member of the Trusteeship and Finance Committees for DePaul University.

 

Brian Cole MD, MBA is one of our directors, and the Managing Partner of Midwest Orthopedics at Rush in Chicago, the lead executive for this large specialty practice which is consistently ranked as one of the top orthopedic groups by US News & World Report. Dr. Cole is a Professor in the Department of Orthopedics with a conjoint appointment in the Department of Anatomy and Cell Biology at Rush University Medical Center. In 2015, he was appointed as an Associate-Chairman of the Department of Orthopedics at Rush. In 2011, he was appointed as Chairman of Surgery at Rush Oak Park Hospital. He is the Section Head of the Cartilage Research and Restoration Center at Rush specializing in the treatment of arthritis in young active patients with a focus on regenerative medicine and biologic alternatives to surgery. He also serves as the head of the Orthopedic Master’s Training Program and trains residents and fellows in sports medicine and research. He lectures nationally and internationally and holds several leadership positions in prominent sports medicine societies. Through his basic science and clinical research, he has developed several innovative techniques with several patents for the treatment of shoulder, elbow and knee conditions. He has published more than 1,000 articles and 10 widely read textbooks in orthopedics and regenerative medicine. In addition to his academic accomplishments, Dr. Cole currently serves in many senior leadership roles in organizations such as President of the Arthroscopy Association of North America, President of the Ortho-regeneration Network Foundation, and Secretary General (Presidential-line) International Cartilage Repair Society. Dr. Cole is frequently chosen as one of the “Best Doctors in America” since 2004 and as a “Top Doctor” in the Chicago metro area since 2003. In 2006, he was featured on the cover of Chicago Magazine as “Chicago’s Top Doctor” and was selected as NBA Team Physician of the Year in 2009. Orthopedics This Week has named Dr. Cole as one of the top 20 sports medicine, knee and shoulder specialists repeatedly over the last 5 years as selected by his peers. He is the head team physician for the Chicago Bulls NBA team, co-team physician for the Chicago White Sox MLB team and DePaul University in Chicago. Dr. Cole was awarded his medical degree from the University of Chicago Pritzker School of Medicine and his MBA from the University of Chicago Booth School of Business. He completed his residency in Orthopedic Surgery at the Hospital for Special Surgery — Cornell Medical Center in New York and his fellowship in Sports Medicine at the University of Pittsburgh.

 

38
 

 

Doug Craft is one of our directors, and the Chief Executive Officer of Atlanta-based Medicraft, Inc., which is one of the largest independent agents for Medtronic, the world leader in medical technology and pioneering therapies. He has devoted his entire career to the medical industry, initially concentrating in the sale of spinal implants, which he continues today. Mr. Craft has extensive relationships with health care systems, surgeons and other senior health care professionals across the nation. Over the past three decades his commercial interests have expanded to include evaluating, consulting and developing businesses in the medical field generally, including but not limited to neuro-intraoperative monitoring, biologic agents, orthopedic reconstruction implants, surgical navigation systems, regenerative kidney technology, trans-catheter cardiac valves and spinal implant device design. He has funded and started over 12 businesses in the Orthopedic, Spine and Neurological segments such as Biocraft Inc, Orthocraft Inc, Neurocraft Inc, Pharmacraft, Premier Medical Systems, and Diamond Orthopedics. Early in his career, he was one of the first agents for Danek a publicly traded spinal implant company which merged with Sofamor to become Sofamor-Danek and relisting on the NYSE. Sofamor-Danek was acquired by Medtronic in 1999 for $3.7 billion. Mr. Craft is a highly experienced entrepreneur who is continually exploring opportunities to multiply investments in medical businesses and technologies. Mr. Craft earned a B.S. degree in biomedical engineering from Mississippi State University, and is a Distinguished Fellow of the College of Engineering at Mississippi State University.

 

Our directors and officers have played a key role in identifying, evaluating, and selecting target businesses, and structuring, negotiating and consummating our initial Business Consummation. Except as described below and under “Conflicts of Interest,” none of these individuals is currently a principal of or affiliated with a public company or blank check company that executed a business plan similar to our business plan. We believe that the skills and experience of these individuals, their collective access to acquisition opportunities and ideas, their contacts, and their transaction expertise should enable them to identify successfully and effect an acquisition transaction, although we cannot assure you that they will, in fact, be able to do so.

 

Family Relationships

 

There are no family relationships among the officers and directors, nor are there any arrangements or understanding between any of the Directors or Officers of our Company or any other person pursuant to which any Officer or Director was or is to be selected as an officer or director.

 

Involvement in Certain Legal Proceedings

 

During the last ten years, none of our officers, directors, promoters or control persons have been involved in any legal proceedings as described in Item 401(f) of Regulation S-K.

 

Board Meetings; Committee Meetings; and Annual Meeting Attendance

 

In 2022, the Board of Directors held board meetings on two occasions: November 7, 2022 and November 16, 2022.

 

Officer and Director Qualifications

 

Our officers and board of directors are composed of a diverse group of leaders with a wide array of professional roles. In these roles, they have gained experience in core management skills, such as strategic and financial planning, financial reporting, compliance, risk management, and leadership development. Many of our officers and directors also have experience serving on boards of directors and board committees of other companies, and have an understanding of corporate governance practices and trends, which provides an understanding of different business processes, challenges, and strategies. Further, our officers and directors also have other experience that makes them valuable, managing and investing assets or facilitating the consummation of business combinations.

 

39
 

 

We, along with our officers and directors, believe that the above-mentioned attributes, along with the leadership skills and other experiences of our officers and board members described below, provide us with a diverse range of perspectives and judgment necessary to facilitate our goals of consummating an acquisition transaction.

 

Board Committees

 

The Board has a standing audit, nominating and compensation committee. The independent directors oversee director nominations. Each audit committee, nominating committee and compensation committee has a charter, which were filed with the SEC as exhibits to the Registration Statement on Form S-1 in connection with our IPO on December 21, 2020.

 

Audit Committee

 

The Audit Committee, which is established in accordance with Section 3(a)(58)(A) of the Exchange Act, engages Company’s independent accountants, reviewing their independence and performance; reviews the Company’s accounting and financial reporting processes and the integrity of its financial statements; the audits of the Company’s financial statements and the appointment, compensation, qualifications, independence and performance of the Company’s independent auditors; the Company’s compliance with legal and regulatory requirements; and the performance of the Company’s internal audit function and internal control over financial reporting. During 2022, the Audit Committee held six meetings on March 15, 2022, March 21, 2022, March 25, 2022, June 10, 2022, August 19, 2022 and November 18, 2022.

 

The Audit Committee consists of Demetrios (Jim) G. Logothetis and Doug Craft, each of whom is an independent director under NYSE American’s listing standards. Mr. Logothetis serves as the Chairperson of the Audit Committee and at the time of his appointment as an independent director, the Board has determined that Mr. Logothetis qualifies as an “audit committee financial expert,” as defined under the rules and regulations of the SEC.

 

Mr. Brian Cole previously served as a member of the Audit Committee, however due to his receipt of warrants in connection with the Subscription Agreement, he no longer meets the qualification to serve as an Audit Committee Member under Rule 10A-3 of the Securities Exchange Act of 1934, as amended.

 

Nominating Committee

 

The Nominating Committee is responsible for overseeing the selection of persons to be nominated to serve on our Board. Specifically, the Nominating Committee makes recommendations to the Board regarding the size and composition of the Board, establishes procedures for the director nomination process and screens and recommends candidates for election to the Board. On an annual basis, the Nominating Committee recommends for approval by the Board certain desired qualifications and characteristics for board membership. Additionally, the Nominating Committee establishes and administers a periodic assessment procedure relating to the performance of the Board as a whole and its individual members. The Nominating Committee will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person’s candidacy for membership on the Board. The Nominating Committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The Nominating Committee does not distinguish among nominees recommended by stockholders and other persons. During 2022, the Nominating Committee acted by unanimous written consent on one occasion.

 

The Nominating Committee consists of Demetrios (Jim) G. Logothetis, Brian Cole and Doug Craft, each of whom is an independent director under NYSE American’s listing standards. Dr. Cole is the Chairperson of the Nominating Committee.

 

40
 

 

Compensation Committee

 

The Compensation Committee reviews annually the Company’s corporate goals and objectives relevant to the officers’ compensation, evaluates the officers’ performance in light of such goals and objectives, determines and approves the officers’ compensation level based on this evaluation; makes recommendations to the Board regarding approval, disapproval, modification, or termination of existing or proposed employee benefit plans, makes recommendations to the Board with respect to non-CEO and non-CFO compensation and administers the Company’s incentive-compensation plans and equity-based plans. The Compensation Committee has the authority to delegate any of its responsibilities to subcommittees as it may deem appropriate in its sole discretion. The chief executive officer of the Company may not be present during voting or deliberations of the Compensation Committee with respect to his compensation. The Company’s executive officers do not play a role in suggesting their own salaries. Neither the Company nor the Compensation Committee has engaged any compensation consultant who has a role in determining or recommending the amount or form of executive or director compensation. During 2022, the Compensation Committee did not hold any meetings.

 

Notwithstanding the foregoing, as indicated above, no compensation of any kind, including finders, consulting or other similar fees, will be paid to any of our executive officers existing stockholders, our directors, or any of their respective affiliates, prior to, or for any services they render in order to effectuate, the consummation of a business combination. Accordingly, it is likely that prior to the consummation of an initial business combination, the compensation committee will only be responsible for the review and recommendation of any compensation arrangements to be entered into in connection with such initial business combination.

 

The Compensation Committee consists of Demetrios (Jim) G. Logothetis, Brian Cole and Doug Craft, each of whom is an independent director under NYSE American’s listing standards. Mr. Craft is the Chairperson of the Compensation Committee.

 

Conflicts of Interest

 

Investors should be aware of the following potential conflicts of interest:

 

  ● None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating their time among various business activities.
     
  ● In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to our company as well as the other entities with which they are affiliated. Our management has pre-existing fiduciary duties and contractual obligations and may have conflicts of interest in determining to which entity a particular business opportunity should be presented.
     
  ● Our officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business activities similar to those intended to be conducted by our company.
     
  ● The insider shares owned by our officers and directors will be released from escrow only if a business combination is successfully completed and subject to certain other limitations. Additionally, our officers and directors will not receive distributions from the Trust Account with respect to any of their insider shares if we do not complete a business combination. In addition, our officers and directors may loan funds to us after the IPO and may be owed reimbursement for expenses incurred in connection with certain activities on our behalf which would only be repaid if we complete an initial business combination. For the foregoing reasons, the personal and financial interests of our directors and executive officers may influence their motivation in identifying and selecting a target business, completing a business combination in a timely manner and securing the release of their shares.

 

In general, officers and directors of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities to a corporation if:

 

  ● the corporation could financially undertake the opportunity;
     
  ● the opportunity is within the corporation’s line of business; and
     
  ● it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.

 

41
 

 

In addition, when exercising powers or performing duties as a director, the director is required to exercise the care, diligence and skill that a reasonable director would exercise in the same circumstances taking into account, without limitation the nature of the company, the nature of the decision and the position of the director and the nature of the responsibilities undertaken by him. A director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience.

 

As set out above, directors have a duty not to engage in self-dealing, or to otherwise benefit as a result of their position. A director shall, forthwith after becoming aware of the fact that he is interested in a transaction entered into or to be entered into by the company, disclose the interest to the board of the company. However, in some instances what would otherwise be a breach of this duty can be forgiven and/or authorized in advance by the stockholders provided that there is full disclosure by the directors. This can be done by way of stockholder approval at a meeting of stockholders.

 

Accordingly, as a result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities meeting the above-listed criteria to multiple entities. In addition, conflicts of interest may arise when our board evaluates a particular business opportunity with respect to the above-listed criteria. We cannot assure you that any of the above mentioned conflicts will be resolved in our favor. Furthermore, most of our officers and directors have pre-existing fiduciary obligations to other businesses of which they are officers or directors. To the extent they identify business opportunities which may be suitable for the entities to which they owe pre-existing fiduciary obligations, our officers and directors will honor those fiduciary obligations. Accordingly, it is possible they may not present opportunities to us that otherwise may be attractive to us unless the entities to which they owe pre-existing fiduciary obligations and any successors to such entities have declined to accept such opportunities.

 

In order to minimize potential conflicts of interest which may arise from multiple corporate affiliations, each of our officers and directors has contractually agreed, pursuant to a written agreement with us, until the earliest of a business combination, our liquidation or such time as he ceases to be an officer or director, to present to our company for our consideration, prior to presentation to any other entity, any suitable business opportunity which may reasonably be required to be presented to us, subject to any pre-existing fiduciary or contractual obligations he might have.

 

The following table summarizes the current pre-existing fiduciary or contractual obligations of our officers and directors.

 

Individual   Entity   Entity’s Business   Affiliation
Doug Craft   Medicraft, Inc.   medical technology company   Chairman and CEO
             
Brian Cole   Midwest Orthopedics at Rush   specialty medical practice   Managing Partner

 

In connection with the vote required for any business combination, all of our existing stockholders, including all of our officers and directors, have agreed to vote their respective insider shares in favor of any proposed business combination. In addition, they have agreed to waive their respective rights to participate in any liquidation distribution with respect to the insider shares acquired by them prior to the IPO. If they purchased shares of Common Stock in the IPO or in the open market, however, they would be entitled to participate in any liquidation distribution in respect of such shares but have agreed not to redeem such shares (or sell their shares in any tender offer) in connection with the consummation of our initial business combination or an amendment to our amended and restated certificate of incorporation relating to pre-business combination activity.

 

All ongoing and future transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to be no less favorable to us than are available from unaffiliated third parties. Any such related party transactions, as defined under the rules and regulations of the Exchange Act, will require prior approval by our audit committee and a majority of our uninterested “independent” directors, or the members of our board who do not have an interest in the transaction, in either case who had access, at our expense, to our attorneys or independent legal counsel. We will not enter into any such transaction unless our audit committee and a majority of our disinterested “independent” directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated third parties.

 

42
 

 

With respect to possible initial business combinations that may be entered into between us and an entity that is affiliated with any of our officers, directors or initial stockholders, to further minimize conflicts of interest, we have agreed not to consummate such an affiliated initial business combination unless we have obtained (i) an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions on the type of target business we seek to acquire that such an initial business combination is fair to our unaffiliated stockholders from a financial point of view and (ii) the approval of a majority of our disinterested and of our independent directors. Furthermore, in no event will any of our initial stockholders, officers, directors, special advisors or their respective affiliates be paid any finder’s fee, consulting fee or other similar compensation prior to, or for any services they render in order to effectuate, the consummation of our initial business combination.

 

Code of Ethics

 

We adopted a code of conduct and ethics applicable to our directors, officers and employees in accordance with applicable federal securities laws. The code of ethics codifies the business and ethical principles that govern all aspects of our business.

 

Delinquent Section 16(a) Reports

 

Section 16(a) of the Exchange Act requires the Company’s directors, officers and stockholders who beneficially own more than 10% of any class of equity securities of the Company registered pursuant to Section 12 of the Exchange Act, collectively referred to herein as the “Reporting Persons,” to file initial statements of beneficial ownership of securities and statements of changes in beneficial ownership of securities with respect to the Company’s equity securities with the SEC. All Reporting Persons are required by SEC regulation to furnish us with copies of all reports that such Reporting Persons file with the SEC pursuant to Section 16(a). Based solely on our review of the copies of such reports and upon written representations of the Reporting Persons received by us, we believe that all filing requirements applicable to our executive officers, directors and greater than 10% beneficial owners were filed in a timely manner.

 

43
 

 

ITEM 11. EXECUTIVE COMPENSATION

 

Employment Agreements

 

We have not entered into any employment agreements with our executive officers and have not made any agreements to provide benefits upon termination of employment.

 

Executive Officers and Director Compensation

 

No executive officer has received any cash compensation for services rendered to us. Except as set forth below, no compensation of any kind, including finders, consulting or other similar fees, will be paid to any of our existing stockholders, including our directors, or any of their respective affiliates, prior to, or for any services they render in order to effectuate, the consummation of a business combination. However, such individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. There is no limit on the amount of these out-of-pocket expenses and there will be no review of the reasonableness of the expenses by anyone other than our board of directors and audit committee, which includes persons who may seek reimbursement, or a court of competent jurisdiction if such reimbursement is challenged.

 

Pursuant to the Subscription Agreements, the Company’s Chief Financial Officer, Rom Papadopoulos, as Sole Proprietor of Intuitus has funded $580,000 of the principal amount of the Notes. In connection with such loan, Intuitus has received Subscription Warrants exercisable for up to 290,000 shares. The warrants were not issued for services rendered. Pursuant to the Subscription Agreements, one of our directors, Brian Cole as an affiliate and control person of EAC Enterprises, L.P. Series D, has funded $250,000 of the principal amount of the Notes. In connection with such loan, EAC Enterprises, L.P. Series D has received Subscription Warrants exercisable for up to $125,000 shares. The warrants were not issued for services rendered. See section entitled “Item 13. Certain Relationships and Related Transactions, and Director Independence” of this Annual Report for further detail.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The following table sets forth as of the date of this Annual Report, the number of shares of Common Stock beneficially owned by (i) each person who is known by us to be the beneficial owner of more than five percent of our issued and outstanding shares of Common Stock, (ii) each of our officers and directors; and (iii) all of our officers and directors as a group. As of the date of this Annual Report, as a result of the redemptions by public stockholders in connection with the Amendment, we have 6,648,665 shares of Common Stock issued and outstanding.

 

Unless otherwise indicated, we believe that all persons named in the table have sole voting and investment power with respect to all shares of Common Stock beneficially owned by them. The following table does not reflect record of beneficial ownership of any shares of Common Stock issuable upon exercise of the warrants, as the warrants are not exercisable within 60 days of the date of this Annual Report.

 

Name and Address of Beneficial Owner(1) 

Number of Shares

Beneficially Owned

  

Approximate

Percentage of
Outstanding

Common Stock

 
Jagi Gill(2)   4,923,250    74.04%
Rom Papadopoulos(2) (3)   4,923,250    74.04%
Brian Cole   27,000    * 
Doug Craft   27,000    * 
Demetrios G. Logothetis   27,000    * 
All current directors and executive officers as a group (five individuals)   5,004,250    75.27%
           
Holders of 5% or more of our Common Stock          
Viveon Health, LLC(2) (3)   4,923,250    74.04%
Meteora Capital, LLC(4)   892,807    13.43 
Karpus Investment Management(5)   2,027,285    30.49%
Mizuho Financial Group, Inc.(6)   543,000    8.17%
Polar Asset Management Partners, Inc. (7)   650,000    9.78%
Fir Tree Capital Management LP (8)   518,742    7.80%

 

* Less than 1%
   
(1) Unless otherwise indicated, the business address of each of the individuals is c/o Viveon Health Acquisition Corp., 3480 Peachtree Road NE 2nd Floor - Suite #112 Atlanta, Georgia 30326.
   
(2) Consists of shares of Common Stock owned by Viveon Health, LLC, for which Jagi Gill is a member and Rom Papadopoulos is the managing member. Mr. Papadopoulos has sole voting and dispositive control over those shares.

 

44
 

 

(3) Rom Papadopoulos is the managing member of Viveon Health, LLC.
   
(4) Based on a Schedule 13G filed by the reporting persons on February 10, 2023, the address for the reporting person is 840 Park Drive East, Boca Raton, Florida 33444.The number of shares of Common Stock owned is as of February 10, 2022, the date of filing of the Schedule 13G. The Schedule 13G was filed by the following reporting persons: (i) Meteora Capital, LLC, a Delaware limited liability company (“Meteora Capital”) with respect to the common stock held by certain funds and managed accounts to which Meteora Capital serves as investment manager (collectively, the “Meteora Funds”); and (ii) Vik Mittal, who serves as the Managing Member of Meteora Capital, with respect to the common stock held by the Meteora Funds. The filing of the Schedule 13G by the reporting persons should not be construed as an admission that any of the reporting persons is, for the purposes of Section 13 of the Act, the beneficial owner of the common stock reported herein.
   
(5) Based on a Schedule 13G filed by the reporting person on February 14, 2022, the address for the reporting person is 183 Sully’s Trail, Pittsford, New York 14534.The number of shares of Common Stock owned is as of February 14, 2022, the date of filing of the Schedule 13G. The reporting person has not amended such schedule to report changes in ownership due to any redemption of its shares of Common Stock in connection with the Amendment. As a result, the number of shares and percentage ownership may not be accurate as of the date of the filing of this Annual Report.
   
(6) Based on a Schedule 13G filed by the reporting person on February 14, 2023, the address for the reporting person is 1-5-5. Otemachi, Chiyoda-ku, Tokyo 100-8176, Japan. Mizuho Financial Group, Inc., Mizuho Bank, Ltd. and Mizuho Americas LLC may be deemed to be indirect beneficial owners of said equity securities directly held by Mizuho Securities USA LLC which is their wholly-owned subsidiary.
   
(7) Based on a Schedule 13G/A filed by the reporting person on February 10, 2023, the address for the reporting person is 16 York Street, Suite 2900, Toronto, ON, Canada M5J 0E6. The Schedule 13G was filed by Polar Asset Management Partners Inc., which serves as the investment advisor to Polar Multi-Strategy Master Fund (“PMSMF”) with respect to the shares of common stock directly held by PMSMF.
   
(8) Based on a Schedule 13G filed by the reporting person on February 14, 2023, the address for the reporting person is 500 5th Avenue, 9th Floor, New York, New York 10110.

 

All of the insider shares issued and outstanding prior to the IPO were placed in escrow with Continental Stock Transfer & Trust Company, as escrow agent, until (1) with respect to 50% of the insider shares, the earlier of six months after the date of the consummation of our initial business combination and the date on which the closing price of our shares of Common Stock equals or exceeds $12.50 per share (as adjusted for share splits, share capitalizations, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after our initial business combination and (2) with respect to the remaining 50% of the insider shares, six months after the date of the consummation of our initial business combination, or earlier, in either case, if, subsequent to our initial business combination, we consummate a liquidation, merger, share exchange or other similar transaction which results in all of our stockholders having the right to exchange their shares for cash, securities or other property.

 

During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) to any persons (including their affiliates and stockholders) participating in the private placement of the private warrants, officers, directors, stockholders, employees and members of the Company’s sponsor and its affiliates, (2) amongst initial stockholders or their respective affiliates, or to the Company’s officers, directors, advisors and employees, (3) if a holder is an entity, as a distribution to its, partners, stockholders or members upon its liquidation, (4) by bona fide gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of the Company’s securities, or (8) by private sales at prices no greater than the price at which the shares were originally purchased, in each case where the transferee agrees to the terms of the escrow agreement and the insider letter.

 

Our initial stockholders, officers and directors or their affiliates may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory note. The notes would be repaid upon consummation of our initial business combination, without interest.

 

45
 

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

2020 Transactions

 

In August 2020, our sponsor purchased 3,593,750 shares for an aggregate purchase price of $25,000, or approximately $0.007 per share. We subsequently declared a share dividend of 0.36 for each outstanding share, resulting in 4,887,500 shares outstanding, and on December 22, 2020 declared another share dividend of 0.03 for each outstanding share, resulting in 5,031,250 shares outstanding, which shares are referred to herein as “founder shares” or “insider shares.” Prior to the initial investment in the company of $25,000 by our sponsor, we had no assets, tangible or intangible.

 

On December 23, 2020, our Sponsor transferred 81,000 of its founder shares to three board members 27,000 Founder Shares to each board member, for a nominal fee. On April 30, 2021, our Sponsor subsequently transferred 27,000 of its founder shares to a new board member.

 

On December 28, 2020, simultaneously with the consummation of the IPO, we sold to our Sponsor 18,000,000 Private Warrants at a price of $0.50 per Private Warrant, generating total proceeds of $9,000,000. The Private Warrants are identical to the Warrants sold in the IPO except that the Private Warrants are non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the Sponsor, or its permitted transferees. Additionally, our Sponsor agreed not to transfer, assign, or sell any of the Private Warrants or underlying securities (except in limited circumstances, as described in the Private Placement Warrants Subscription Statement) until the date we complete our initial business combination. The Sponsor was granted certain demand and piggyback registration rights in connection with the purchase of the Private Warrants.

 

The holders of our insider shares issued and outstanding on the date of this Annual Report, as well as the holders of the Private Warrants (and all underlying securities) are entitled to registration rights pursuant to the registration rights agreement, dated December 22, 2020. The holders of a majority of these securities are entitled to make up to two demands that we register such securities. The holders of the majority of the insider shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of Common Stock are to be released from escrow. The holders of a majority of the private warrants can elect to exercise these registration rights at any time after we consummate a business combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our consummation of a business combination. We will bear the expenses incurred in connection with the filing of any such registration statements.

 

In order to meet our working capital needs following the consummation of our IPO, our initial stockholders, officers and directors and their respective affiliates may, but are not obligated to, loan us funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory note. The notes would be repaid upon consummation of our initial business combination, without interest.

 

2022 Transactions

 

On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, we entered into subscription agreements with several lenders for a loan of up to $4,000,000, in the aggregate (the “Subscription Agreements”).

 

Pursuant to the Subscription Agreements, we issued a series of unsecured senior promissory notes in the aggregate principal amount of up to $4,000,000 (the “Notes”) to the subscribers. Of the $4,000,000 in Notes, $1,955,000   was subscribed for by several related parties affiliated with our sponsor, Viveon Health LLC, and the balance in the amount of $2,045,000 was subscribed for by parties that are not related to our sponsor.

 

Pursuant to the terms of the Subscription Agreements, the subscribers also received warrants to purchase one share of our common stock for every $2.00 of the funded principal amount of the Notes up to 2,000,000 shares of our common stock, in the aggregate, at an exercise price of $11.50 per share, subject to adjustment (the “Subscription Warrants”). The Subscription Warrant term commences on the Exercise Date (as hereinafter defined) for a period of 49 months. The Subscription Warrants are exercisable commencing on the date of the initial business combination (the “Exercise Date”) and have a cashless exercise feature that is available at any time on or after the Exercise Date. Commencing on the date 13 months following the Exercise Date, the subscribers have the right, but not the obligation, to put the Subscription Warrants to us at a purchase price of $5.00 per share. We have agreed to file, within thirty (30) calendar days after the consummation of an initial business combination, a registration statement with the Securities and Exchange Commission to register for resale the shares of common stock underlying the Subscription Warrants.

 

The Notes do not bear interest and mature upon the earlier of (i) the closing of our initial business combination, and (ii) December 31, 2022 (the “Maturity Date”). The Notes provide for a credit line up to the maximum amount of $4,000,000. We will not have the right to re-borrow any portion of any loans made under the Notes once repaid  . As of December 31, 2022, a commitment fee in the amount of $400,000, equal to 10% of the maximum principal amount of the Note, had been paid to the subscribers, on a pro rata basis. In the event that we do not consummate a business combination by the Maturity Date, the Notes will be repaid only from amounts remaining outside of our Trust Account, if any. Subsequent to December 31, 2022, in connection with the Merger Agreement (as defined below) a majority of the holders of the Notes and Subscription Warrants have agreed to exchange such Notes and Subscription Warrants pursuant to the terms of an exchange agreement with Viveon dated as of May 1, 2023 (the Exchange Agreement”) for a separate series of Clearday senior convertible promissory notes (the “Clearday Senior Convertible Notes”). The Clearday Senior Convertible Notes bear 8% interest per annum and mature upon the earlier of (i) June 30, 2024, or (ii) the date of any Change in Control. . Upon the consummation of the business combination and the exchange of the Subscription Agreements for the Clearday Senior Convertible Notes, the lenders will forfeit their Subscription Warrants as part of the exchange. One lender has chosen not to convert to Clearday Senior Convertible Notes. The balance owed to this lender under the Notes is considered due upon demand by the lender. As of the date of this filing of this Annual Report the lender has not requested payment of the Note.

 

Of the $4,000,000 in notes, $1,955,000 was subscribed for by several related parties affiliated with our sponsor, Viveon Health LLC. $250,000 of the principal amount of the Notes was funded by Brian Cole, one of our directors pursuant to a Subscription Agreement dated as of April 4, 2022, between the Company and EAC Enterprises, L.P. Series D(the “Cole Warrant Holder”), an entity that is an affiliate of, and controlled by Brian Cole (the “Cole Subscription Agreement”), and the balance of the Notes was subscribed for by parties that are not related to our sponsor. The entry into the subscription agreements and the terms of the notes and warrants was approved by the Audit Committee at a meeting held on March 21, 2022. Pursuant to the Cole Subscription Agreement, the Company also issued the Cole Warrant Holder, a warrant to purchase 125,000 shares of common stock, at an exercise price of $11.50 per share.

 

On May 10, 2022, Suneva entered into a subordinated convertible promissory note (the “Subordinated Convertible Promissory Note”) with Intuitus Suneva Debt LLC (“Intuitus”), pursuant to which Suneva borrowed an aggregate of $1,500,000 to be used to fund working capital. The Subordinated Convertible Promissory Note bears interest at a rate of 10.0% per annum and is payable upon the earlier of: (i) December 31, 2022 or (ii) the voluntary or involuntary liquidation, dissolution or winding up of Suneva. In addition, Intuitus may elect by written notice to Suneva to convert all (but not less than all) of the then-outstanding principal and interest on the Note into shares of Suneva Series AA Stock as is determined by dividing the total principal and accrued but unpaid interest balance on the Note by the $0.80. The Company’s Chief Financial Officer, Rom Papadopoulos, as Sole Proprietor of Intuitus, has contributed $200,000 of the $1,500,000 available under the Subordinated Convertible Promissory Note.

 

Commencing on the date of the Company’s final prospectus, the Company has agreed to pay an affiliate of the Sponsor a total of $20,000 per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company incurred $240,000 and $240,000 of administrative service fees for the year ended December 31, 2022 and 2021, respectively. The accrued amounts are included in Due to related party on the balance consolidated balance sheets. For the year ended December 31, 2022 and 2021, $50,000 and $10,000 of such expenses were recorded in Due to related party, respectively.

 

2023 Transactions

 

We have an agreement to pay an affiliate of our sponsor a monthly fee of $20,000 for office space, utilities and secretarial and administrative support and the series of unsecured senior promissory note agreements we entered into with several lenders affiliated with our Sponsor. We began incurring these fees on December 22, 2020 and will continue to incur these fees monthly until the earlier of the completion of the Business Combination and our liquidation.

 

On February 2, 2023, the Merger Agreement between Viveon and Suneva was terminated. From the point of termination, the Subordinated Convertible Promissory Note is no longer considered a related party transaction to Viveon as the Company will no longer be entering into a Business Combination with Suneva.

 

Pursuant to a Warrant Cancellation and Forfeiture Agreement dated as of August 16, 2023, the Cole Warrant Holder agreed to forfeit for cancellation 89,029 of the warrant shares underlying the warrant issued pursuant to the Cole Subscription Agreement described above. At initial issuance the value of the warrants exceeded $120,000. As a result, Mr. Cole agreed to forfeit certain of the warrants so that the value would be reduced to $120,000 and would not impact the determination that he is an independent director.

 

46
 

 

We reimburse our officers and directors for any reasonable out-of-pocket business expenses incurred by them in connection with certain activities on our behalf such as identifying and investigating possible target businesses and business combinations. There is no limit on the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in the Trust Account and the interest income earned on the amounts held in the Trust Account, such expenses would not be reimbursed by us unless we consummate an initial business combination. Our audit committee reviews and approves all reimbursements and payments made to any initial stockholder or member of our management team, or our or their respective affiliates, and any reimbursements and payments made to members of our audit committee are reviewed and approved by our Board of Directors, with any interested director abstaining from such review and approval.

 

No compensation or fees of any kind, including finder’s fees, consulting fees or other similar compensation, will be paid to any of our initial stockholders, officers or directors who owned our shares of Common Stock, or to any of their respective affiliates, prior to or with respect to the business combination (regardless of the type of transaction that it is).

 

All ongoing and future transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to be no less favorable to us than are available from unaffiliated third parties. Such transactions, including the payment of any compensation, will require prior approval by a majority of our uninterested “independent” directors (to the extent we have any) or the members of our board who do not have an interest in the transaction, in either case who had access, at our expense, to our attorneys or independent legal counsel. We will not enter into any such transaction unless our disinterested “independent” directors (or, if there are no “independent” directors, our disinterested directors) determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated third parties.

 

Related Party Policy

 

Our code of ethics requires us to avoid, wherever possible, all related party transactions that could result in actual or potential conflicts of interests, except under guidelines approved by the board of directors (or the audit committee). Related-party transactions are defined as transactions in which (1) the aggregate amount involved will or may be expected to exceed $120,000 in any calendar year, (2) we or any of our subsidiaries is a participant, and (3) any (a) executive officer, director or nominee for election as a director, (b) greater than 5% beneficial owner of our Common Stock, or (c) immediate family member, of the persons referred to in clauses (a) and (b), has or will have a direct or indirect material interest (other than solely as a result of being a director or a less than 10% beneficial owner of another entity). A conflict of interest situation can arise when a person takes actions or has interests that may make it difficult to perform his or her work objectively and effectively. Conflicts of interest may also arise if a person, or a member of his or her family, receives improper personal benefits as a result of his or her position.

 

Our audit committee, pursuant to its written charter, is responsible for reviewing and approving related-party transactions to the extent we enter into such transactions. All ongoing and future transactions between us and any of our officers and directors or their respective affiliates will be on terms believed by us to be no less favorable to us than are available from unaffiliated third parties. Such transactions require prior approval by our audit committee and a majority of our uninterested “independent” directors, or the members of our board who do not have an interest in the transaction, in either case who had access, at our expense, to our attorneys or independent legal counsel. We will not enter into any such transaction unless our audit committee and a majority of our disinterested “independent” directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated third parties. Additionally, we require each of our directors and executive officers to complete a directors’ and officers’ questionnaire that elicits information about related party transactions.

 

These procedures are intended to determine whether any such related party transaction impairs the independence of a director or presents a conflict of interest on the part of a director, employee or officer.

 

In furtherance of our policies with respect to related party transactions, with respect to any initial business combination that we consider with an entity that is affiliated with any of our initial stockholders, directors or officers, to further minimize potential conflicts of interest, we have agreed not to consummate a business combination with an entity affiliated with such parties unless (i) an opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions on the type of target business we seek to acquire that such an initial business combination is fair to our unaffiliated stockholders from a financial point of view and (ii) the approval of a majority of our disinterested and of our independent directors. Furthermore, in no event will any of our existing officers, directors or initial stockholders, or any entity with which they are affiliated, be paid any finder’s fee, consulting fee or other compensation prior to, or for any services they render in order to effectuate, the consummation of a business combination.

 

Director Independence

 

NYSE American’s listing standards require that a majority of our board of directors be independent. For a description of the director independence, see above Part III, Item 10 - Directors, Executive Officers and Corporate Governance.

 

47
 

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

Public Accounting Fees

 

During the year ended December 31, 2022, Marcum LLP, has acted as our principal independent registered public accounting firm. The following is a summary of fees paid or to be paid to Marcum LLP for services rendered.

 

Audit Fees. Audit fees consist of fees billed for professional services rendered for the audit of our year-end financial statements and services that are normally provided by Marcum LLP in connection with regulatory filings, such as registration statements filed with the SEC. The aggregate fees billed by Marcum LLP for professional services rendered for the audit of our annual financial statements, review of the financial information included in our Forms 10-Q for the respective periods, registration statements filed in connection with the pursuit of a business combination, and other required filings with the SEC for the year ended December 31 2022 totaled approximately $473,903. Audit fees for the year ended December 31, 2021 totaled $149,000. The above amount includes interim procedures and audit fees, as well as attendance at audit committee meetings.

 

Audit-Related Fees. We did not pay Marcum LLP for consultations concerning financial accounting and reporting standards for the years ended December 31, 2021 or 2022.

 

Tax Fees. We did not pay Marcum LLP for tax planning and tax advice for the years ended December 31, 2021 or 2022.

 

All Other Fees. We did not pay Marcum LLP for other services for the years ended December 31, 2021 or 2022.

 

Pre-Approval of Services

 

All services for the year ended December 31, 2022 have been approved by the audit committee.

 

48

 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

  (a) The following are filed with this report:

 

  (1) The financial statements listed on the Financial Statements Table of Contents

 

  (2) Not applicable

 

  (b) Exhibits

 

The following exhibits are filed with this report. Exhibits which are incorporated herein by reference can be obtained from the SEC’s website at sec.gov.

 

Exhibit No.   Description
     
1.1   Underwriting Agreement, dated December 22, 2020, by and between Registrant and Chardan Capital Markets, LLC (incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
3.1   Amended & Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
3.2   Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on March 24, 2022)
3.3   Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on June 27, 2023)
3.4   Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 28, 2022)
4.1   Specimen Unit Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on December 21, 2020)
4.2   Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on December 21, 2020)
4.3   Specimen Warrant Certificate (incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on December 21, 2020)
4.4   Specimen Right Certificate (incorporated by reference to Exhibit 4.6 to the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on December 21, 2020)
4.5   Warrant Agreement, dated December 22, 2020 between Continental Stock Transfer & Trust Company and the Registrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
4.6   Rights Agreement, dated December 22, 2020 between Continental Stock Transfer & Trust Company and the Registrant (incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
4.7   Description of Securities
10.1   Letter Agreements, dated December 22, 2020, among the Registrant and each of the initial stockholders, officer and directors of Registrant (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
10.2   Investment Management Trust Agreement, dated December 22, 2020, between Continental Stock Transfer & Trust Company and the Registrant. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
10.3   Registration Rights Agreement, dated December 22, 2020, among the Registrant and each of the initial stockholders, officer and directors of Registrant (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
10.4   A Private Placement Warrants Subscription Agreement, dated December 22, 2020, among the Registrant and Viveon Health LLC (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
10.5   Stock Escrow Agreement, dated December 22, 2020, by and among the Registrant, Continental Stock Transfer & Trust Company and the Initial Stockholders (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
10.6   Indemnity Agreement, dated December 22, 2020, among the Registrant and each of the initial stockholders, officer and directors of Registrant (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
10.7   Administrative Services Agreement, dated December 22, 2020, by and between the Registrant and Viveon Health LLC (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on December 29, 2020)
10.8   Letter Agreement, dated April 30, 2021, between the Registrant and Mr. Demetrios G. Logothetis (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on April 30, 2021)
10.9   Joinder Agreement, dated May 5, 2021, to the Stock Escrow Agreement, dated December 22, 2020, by and among the Registrant, Continental Stock Transfer & Trust Company and the Initial Stockholders (incorporated by reference to Exhibit 10.9 to the Annual Report on Form 10K/A filed with the Securities & Exchange Commission on December 17, 2021)
10.15   Form of Promissory Note (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on March 24, 2022)
10.16   Form of Warrant (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on March 24, 2022)
10.17   Form of Subscription Agreement (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on March 24, 2022)
10.18   Amendment to the Investment Management Trust Agreement, dated as of March 23, 2022 (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed with the Securities & Exchange Commission on March 24, 2022)
10.19   Amendment to the Investment Management Trust Agreement, dated as of January 20, 2023.
10.20   Amendment to the Investment Management Trust Agreement, dated as of June 27, 2023.
10.21   Form of Exchange Agreement
10.22   Unsecured Promissory Note (Clearday, Inc.)
10.23   Letter Agreement, dated as of July 12, 2021, between Viveon Health Acquisition Corp. and Chardan Capital Markets, LLC.
14   Form of Code of Ethics (incorporated by reference to Exhibit 14 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on December 21, 2020)
31.1   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
99.1   Form of Audit Committee Charter (incorporated by reference to Exhibit 99.1 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on December 21, 2020)
99.2   Form of Compensation Committee Charter (incorporated by reference to Exhibit 99.2 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on December 21, 2020)
99.3   Form of Nominating Committee Charter (incorporated by reference to Exhibit 99.3 to the Registration Statement on Form S-1/A filed with the Securities & Exchange Commission on December 21, 2020)
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

49

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VIVEON HEALTH ACQUISITION CORP.
     
Dated: August 23, 2023 By: /s/ Jagi Gill
  Name: Jagi Gill
  Title: Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Jagi Gill   Chief Executive Officer, President and Director   August 23, 2023
Jagi Gill   (Principal Executive Officer)    
         
/s/ Rom Papadopoulos   Chief Financial Officer, Treasurer, Secretary and Director   August 23, 2023
Rom Papadopoulos   (Principal Accounting and Financial Officer)    
         
/s/ Demetrios (Jim) G. Logothetis   Director   August 23, 2023
Demetrios (Jim) G. Logothetis        
         
/s/ Brian Cole   Director   August 23, 2023
Brian Cole        
         
/s/ Doug Craft   Director   August 23, 2023
Doug Craft        

 

 

50

 

 

INDEX TO FINANCIAL STATEMENTS

 

  Page
Report of Independent Registered Public Accounting Firm (PCAOB ID 688) F-2
Consolidated Balance Sheets as of December 31, 2022 and 2021 F-3
Consolidated Statements of Operations for the years ended December 31, 2022 and 2021 F-4
Consolidated Statements of Changes in Stockholders’ Deficit for the years ended December 31, 2022 and 2021 F-5
Consolidated Statements of Cash Flows for the years ended December 31, 2022 and 2021 F-6
Notes to Consolidated Financial Statements F-7

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Stockholders and Board of Directors of

Viveon Health Acquisition Corp.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Viveon Health Acquisition Corp. (the “Company”) as of December 31, 2022 and 2021, the related consolidated statements of operations, stockholders’ deficit and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America

 

Explanatory Paragraph – Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 to the financial statements, the Company’s business plan is dependent on the completion of a business combination and the Company’s cash and working capital as of December 31, 2022 are not sufficient to complete its planned activities for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ Marcum llp

 

Marcum LLP

 

We have served as the Company’s auditor since 2020

 

New York, NY

August 23, 2023

 

F-2

 

 

PART 1 – FINANCIAL INFORMATION

Item 1. FINANCIAL STATEMENTS

 

VIVEON HEALTH ACQUISITION CORP.

CONSOLIDATED BALANCE SHEETS

 

   December 31, 2022   December 31, 2021 
         
Assets:          
Current assets:          
Cash and cash equivalents  $19,847   $395,235 
Prepaid expenses   48,726    3,863 
Due from related party   —    15,000 
Total current assets   68,573    414,098 
Investment held in Trust Account   53,815,395    203,282,989 
Deferred tax asset   39,259    — 
Total Assets  $53,923,227   $203,697,087 
           
Liabilities and Stockholders’ Deficit:          
Current liabilities:          
Accounts payable  $226,796   $47,720 
Accrued costs and expenses   2,150,712    1,927,662 
Franchise tax payable   397,002    197,200 
Note Agreements payable   2,045,000    — 
Note Agreements payable – related party   1,955,000    — 
Due to related party   55,806    15,850 
Promissory note - related party   75,000    — 
Common stock tendered for redemption   34,004,514    — 
Total current liabilities   40,909,830    2,188,432 
Deferred underwriting fee   7,043,750    7,043,750 
Warrant liabilities   2,535,515    4,188,221 
Uncertain tax position   100,569    — 
Total Liabilities   50,589,664    13,420,403 
           
Commitments and Contingencies (see Note 7)   -     -  
Common Stock subject to possible redemption, 1,844,774 and 20,125,000 shares at redemption value as of December 31, 2022 and 2021, respectively   19,413,879    203,262,500 
           
Stockholders’ Deficit:          
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding   —    — 
Common stock not subject to possible redemption, $0.0001 par value; 60,000,000 shares authorized; 5,031,250 issued and outstanding (excluding 1,844,774 and 20,125,000 shares subject to redemption as of December 31, 2022 and 2021, respectively)   503    503 
Additional paid-in capital   —    157,140 
Accumulated deficit   (16,080,819)   (13,143,459)
Total Stockholders’ Deficit   (16,080,316)   (12,985,816)
Total Liabilities and Stockholders’ Deficit  $53,923,227   $203,697,087 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

 

 

VIVEON HEALTH ACQUISITION CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   2022   2021 
   For the years ended December 31, 
   2022   2021 
Operating costs  $756,386   $1,050,016 
Professional fees   1,368,699    2,701,431 
Franchise tax   246,216    197,200 
Stock compensation expense   —    157,140 
Loss from operations   (2,371,301)   (4,105,787)
           
Other income (expenses):          
Expensed issuance costs on issuance of subscription warrants   (392,642)   — 
Interest and dividends earned on investments held in Trust Account   724,225    20,329 
Interest earned on money market account   892    147 
Interest expense - amortization of debt discount   (3,645,777)   — 
Gain on change in fair value of warrant liabilities   8,468,308    6,575,140 
Loss on issuance of subscription warrants   (3,209,183)   — 
Total other income   1,945,823    6,595,616 
(Loss) income before income taxes   (425,478)   2,489,829 
Income tax expense   (61,310)   — 
Net (loss) income  $(486,788)  $2,489,829 
           
Weighted average shares outstanding, basic and diluted   12,224,223    24,150,000 
Basic and diluted net (loss) income per common share  $(0.04)  $0.10 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

 

VIVEON HEALTH ACQUISITION CORP.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

 

                          
   For the Year ended December 31, 2022 
   Common Stock  

Additional

Paid-in

   Accumulated   Total Stockholders’ 
   Shares   Amount   Capital   Deficit   Deficit 
Balance as of December 31, 2021   5,031,250   $503   $157,140   $(13,143,459)  $(12,985,816)
Remeasurement of common stock subject to possible redemption, to redemption amount   —    —    (157,140)   (2,450,572)   (2,607,712)
Net loss   —    —    —    (486,788)   (486,788)
Balance as of December 31, 2022   5,031,250   $503   $—   $(16,080,819)  $(16,080,316)

 

   For the Year ended December 31, 2021 
   Common Stock   Additional Paid-in   Accumulated   Total Stockholders’ 
   Shares   Amount   Capital   Deficit   Deficit 
Balance as of December 31, 2020   5,031,250   $503    —   $(15,607,539)  $(15,607,036)
Additional offering costs related to the Initial Public Offering   —    —    —    (25,749)   (25,749)
Stock compensation expense   —    —    157,140    —    157,140 
Net income   —    —    —    2,489,829    2,489,829 
Balance as of December 31, 2021   5,031,250    503    157,140    (13,143,459)   (12,985,816)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

 

VIVEON HEALTH ACQUISITION CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   2022   2021 
   For the years ended December 31, 
   2022   2021 
Cash Flows from Operating Activities:          
Net (loss) income  $(486,788)  $2,489,829 
Adjustments to reconcile net (loss) income to net cash used in operating activities:          
Expensed issuance costs on issuance of subscription warrants   392,642    — 
Interest and dividends earned on investments held in Trust Account   (724,225)   (20,329)
Interest expense - amortization of debt discount   3,645,777    — 
Gain on change in fair value of warrant liabilities   (8,468,308)   (6,575,140)
Loss on issuance of subscription warrants   3,209,183    — 
Stock compensation expense   —    157,140 
Deferred tax expense   (39,259)   — 
Changes in operating assets and liabilities:          
Prepaid expenses   (44,863)   656,832 
Due from related party   15,000    (15,000)
Accounts payable   179,076    47,720 
Accrued costs and expenses   228,050    969,370 
Franchise tax payable   199,802    197,200 
Due to related party   39,956    10,044 
Uncertain tax position   100,569    - 
Net cash used in operating activities   (1,753,388)   (2,082,334)
           
Cash Flows from Investing Activities:          
Cash withdrawn from Trust Account for payment to redeeming stockholders   152,451,819    — 
Cash deposited to Trust Account for extension contribution   (2,260,000)   — 
Net cash provided by investing activities   150,191,819    — 
           
Cash Flows from Financing Activities:          
Proceeds from Note Agreements payable   2,045,000    — 
Proceeds from Note Agreements payable – related party   1,955,000      
Proceeds from promissory note- related party   75,000    — 
Payment to redeeming stockholders   (152,451,819)   — 
Payment of issuance costs   (437,000)   — 
Payment of promissory note - related party   —    (228,758)
Payment of other payable - related party   —    (364,880)
Offering costs paid   —    (25,749)
Net cash used in financing activities   (148,813,819)   (619,387)
           
Net change in cash   (375,388)   (2,701,721)
Cash - beginning of period   395,235    3,096,956 
Cash - end of period  $19,847   $395,235 
           
Supplemental disclosure of noncash investing and financing activities:          
Common stock tendered for redemption  $34,004,514    

—

 
Remeasurement of common stock subject to possible redemption, to redemption amount  $2,607,712   $— 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-6

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

 

Viveon Health Acquisition Corp. (the “Company” or “Viveon”) is a newly organized blank check company incorporated as a Delaware company on August 7, 2020. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (“Business Combination”).

 

The Company has neither engaged in any operations nor generated any revenues to date. The Company’s only activities for the years ended December 31, 2022 and 2021 were organizational activities, those necessary to prepare for the Company’s initial public offering (the “Initial Public Offering”), described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company does not expect to generate any operating revenues until after the completion of our Business Combination. The Company generates non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. The Company incurs expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. The Company’s sponsor is Viveon Health, LLC, a Delaware limited liability company (the “Sponsor”).

 

The registration statement for the Initial Public Offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on December 22, 2020. On December 28, 2020, the Company consummated the Initial Public Offering of 17,500,000 units (the “Units” and, with respect to the common stock included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $175,000,000, which is discussed in Note 3. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 18,000,000 warrants (the “Private Warrants”), at a price of $0.50 per Private Warrant, which is discussed in Note 4.

 

On December 30, 2020, the underwriters fully exercised the over-allotment option by purchasing 2,625,000 Units (the “Over-Allotment Units”), generating aggregate of gross proceeds of $26,250,000.

 

Upon closing of the Initial Public Offering and the sale of the Over-Allotment Units, $203,262,500 (approximately $10.10 per Unit) from net offering proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, with a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act 1940, as amended (the “Investment Company Act”), which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its tax obligations, the proceeds from the Initial Public Offering will not be released from the Trust Account until the earliest to occur of (1) the completion of the initial Business Combination within 15 months, unless extended to a total of 24 months, pursuant to the terms of an amendment to the Company’s amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”), and (2) the Company’s redemption of 100% of the outstanding Public Shares if the Company has not completed a Business Combination in the required time period.

 

While the Company’s management has broad discretion with respect to the specific application of the cash held outside of the Trust Account, substantially all of the net proceeds from the Initial Public Offering and the sale of the Private Warrants, which are placed in the Trust Account, are intended to be applied generally toward completing a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

 

F-7

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

In connection with any proposed initial Business Combination, the Company will either (1) seek stockholder approval of such initial Business Combination at a meeting called for such purpose at which public stockholders may seek to convert their Public Shares, regardless of whether they vote for or against the proposed Business Combination, into their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable) or (2) provide its public stockholders with the opportunity to sell their Public Shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable), in each case subject to the limitations described herein. The Public Shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC 480”).

 

If the Company determines to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its Public Shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that the Company is unable to satisfy any applicable closing condition set forth in the definitive agreement related to its initial Business Combination, or the Company is unable to maintain net tangible assets of at least $5,000,001, the Company will not consummate such initial Business Combination. The decision as to whether it will seek stockholder approval of a proposed Business Combination or will allow stockholders to sell their shares to the Company in a tender offer will be made by the Company based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval.

 

If the Company provides stockholders with the opportunity to sell their shares to it by means of a tender offer, it will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial Business Combination as is required under the SEC’s proxy rules. If the Company seeks stockholder approval of its initial Business Combination, the Company will consummate the Business Combination only if a majority of the outstanding shares of common stock present in person or by proxy at a meeting of the Company are voted in favor of the Business Combination.

 

Notwithstanding the foregoing redemption rights, if the Company seeks stockholder approval of its initial Business Combination and the Company does not conduct redemptions in connection with its initial Business Combination pursuant to the tender offer rules,(the Amended and Restated Certificate of Incorporation will provide that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its Public Shares with respect to more than an aggregate of 20% of the shares sold in the Initial Public Offering, without the Company’s prior consent. The Company’s Sponsor, officers and directors (the “initial stockholders”) have agreed not to propose any amendment to the Amended and Restated Certificate of Incorporation (a) that would modify the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with an initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete its initial Business Combination within 15 months from the closing of the Initial Public Offering or (b) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity, unless the Company provide its public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

 

F-8

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

On March 18, 2022, the Company held a stockholder meeting to seek approval to extend the date by which the Company has to consummate a business combination from March 28, 2022 (the “Original Termination Date”) to June 28, 2022. In connection with the extension, the Company made a deposit into the Trust Account of $720,000 on March 23, 2022. As part of the meeting, stockholders redeemed 15,092,126 shares resulting in redemption payments out of the Trust Account totaling approximately $152,451,819. In addition, stockholders approved a proposal to allow the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with Suneva Medical, Inc. as described below or any potential alternative initial Business Combination shall have occurred. On each of June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 the Company deposited $240,000 into the Trust Account to extend the date to consummate a Business Combination through July 28, 2022, August 28, 2022, September 28, 2022, October 28, 2022, November 28, 2022, and December 28, 2022, respectively.

 

On December 23, 2022, the Company held its 2022 Annual Meeting of Stockholders, to among other things, seek approval to amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time for a total of up to six months from December 28, 2022 until June 30, 2023 (the “Second Extended Date”), upon three calendar days’ advance notice prior to the applicable monthly deadline unless the closing of any potential initial business combination shall have occurred prior to the Second Extended Date. On each of December 27, 2022, January 26, 2023, February 27, 2023, March 27, 2023, and April 28, 2023, the Company deposited $100,000 into the Trust Account to extend the date to consummate a Business Combination through January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023, respectively. Viveon made a final deposit of $100,000 on May 24, 2023 for a one month extension until June 30, 2023.

 

On June 22, 2023, the Company held a stockholder meeting to amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company, without another stockholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month until December 31, 2023, by depositing $85,000 into the trust account and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”).

 

On June 22, 2023, the Company held a stockholder meeting (the “June 2023 Stockholders Meeting”) in which stockholders voted to (A) amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to the Trustee, prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date; and (B) to amend the Company’s Investment Management Trust Agreement, dated as of December 22, 2020, by and between the Company and the Trustee, allowing the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, each such extension for an additional one month period, with no additional deposits to be made into the Trust Account during such period from January 1, 2024 through March 31, 2024. In connection with the stockholders’ vote at the June 2023 Stockholders Meeting, 227,359 shares of common stock were tendered for redemption. As a result, approximately $2,498,947 (approximately $10.99 per share) were removed from the Company’s Trust Account to pay such holders, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date. Following redemptions, the Company has 1,617,415 shares of public common stock outstanding, and approximately $17,777,324 will remain in the Trust Account. On June 27, 2023, and July 27, 2023, the Company deposited $85,000 in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023 and August 31, 2023, respectively.

 

If the Company is unable to complete its initial Business Combination by the Third Extended Date (the “Combination Period”), the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding Public Shares (including any Units or Public Shares that its initial stockholders or their affiliates purchased in the Initial Public Offering or later acquired in the open market or in private transactions), which will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of the Company’s remaining holders of common stock and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law.

 

The Company’s initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares (as defined in Note 5) held by them if the Company fails to complete its initial Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination within the Combination Period.

 

Merger Agreement

 

On January 12, 2022, the Company entered into a Merger Agreement (the “Old Merger Agreement”) by and among the Company, VHAC Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Old Merger Sub”), and Suneva Medical, Inc., a Delaware corporation (“Suneva”). Pursuant to the terms of the Merger Agreement, a Business Combination between the Company and Suneva will be effected through the merger of Old Merger Sub with and into Suneva, with Suneva surviving the merger as a wholly owned subsidiary of the Company (the “Old Merger”). The board of directors of the Company has (i) approved and declared advisable the Old Merger Agreement, the Old Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Old Merger Agreement and related transactions by the stockholders of the Company.

 

F-9

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

On July 13, 2022, the Company, Old Merger Sub, and Suneva entered into the Second Amendment to Old Merger Agreement (the “Second Amendment”) that amended and modified the Old Merger Agreement to extend the outside closing date to December 31, 2022 and to reduce the amount of parent closing cash required as a closing condition from $50 million to $30 million, net of Suneva expenses and Viveon expenses (“Parent Expenses”) and net of repayment of the $1.5 million Subordinated Convertible Promissory Note (as defined in Note 5) issued by Suneva to Intuitus Suneva Debt LLC (an entity affiliated with Viveon’s Chief Financial Officer), dated May 10, 2022 (unless converted into Suneva capital stock at the consummation of the business combination, which conversion is mandatory except in the case of a default by Suneva). Further, the defined term Parent Expenses was amended to include the Viveon’s operating expenses, severance payments and deferred compensation.

 

On November 10, 2022, the Company, Old Merger Sub, and Suneva entered into the Third Amendment to Old Merger Agreement (the “Third Amendment”) that amended and modified the Old Merger Agreement to (i) fix the aggregate exercise price for all of the in-the-money Suneva options and warrants at $2,582,075, representing the aggregate exercise price for all the in-the-money Suneva options and warrants outstanding as of the date of the Third Amendment, and extend the outside closing date from December 31, 2022 to March 31, 2023, to the extent the Company’s stockholders approve an amendment to its Amended and Restated Certificate of Incorporation to extend the date by which the Company has to consummate a business combination to June 30, 2023.

 

On February 2, 2023, legal counsel for Viveon sent a letter informing Suneva’s legal counsel that Viveon decided, effective immediately, to unilaterally terminate the Old Merger Agreement pursuant to Sections 10.2(a) and 10.3 thereof, based upon material breaches of the Old Merger Agreement by Suneva. The termination letter was sent without prejudice and reserved all of Viveon, Old Merger Sub and Viveon Health, LLC (Viveon’s sponsor) rights, claims and remedies, specifically including those within the Merger Agreement, against Suneva and others associated with Suneva who participated in the merger discussions and arrangements, and waived none.

 

Merger Agreement with Clearday 

 

On April 5, 2023, the Company entered into a Merger Agreement (the “Merger Agreement”), by and among Viveon, Clearday, Inc., a Delaware corporation (“Clearday”), VHAC2 Merger Sub, Inc., a Delaware corporation (“New Merger Sub”), Viveon Health LLC, a Delaware limited liability Company, in the capacity as the representative from and after the effective time for the stockholders of the Company (other than the Company Stockholders (as defined in the Merger Agreement)) as of immediately prior to the effective time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement, and Clearday SR LLC, a Delaware limited liability company, in the capacity as the representative from and after the effective time for the holders of Company preferred stock as of immediately prior to the effective time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement. Pursuant to the terms of the Merger Agreement, a business combination between the Company and Clearday will be effected through the merger of New Merger Sub with and into Clearday, with Clearday surviving the merger as a wholly owned subsidiary of the Company and the Company will change its name to “Clearday Holdings, Inc.” (the “Merger”). The board of directors of the Company has (i) approved and declared advisable the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement, the Merger and related transactions by the stockholders of Company. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Merger Agreement.

 

F-10

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Consideration

 

Merger Consideration

 

The total consideration to be paid at closing (the “Merger Consideration”) by the Company to Clearday security holders (and holders who have the right to acquire Clearday capital stock) will be an amount equal to $250 Million (plus the aggregate exercise price for all Clearday options and warrants). The Merger Consideration will be payable in shares of the Company’s common stock, par value $0.0001 per share, valued at $10 per share.

 

Earnout Payments

 

In addition, the holders of Clearday preferred stock will have the contingent right to earn up to 5,000,000 shares of the Company’s common stock, in the aggregate (the “Earnout Shares”), if at any time during the period beginning on the date of the Closing (the “Closing Date”) and ending on the fifth anniversary of the Closing Date (the “Earnout Eligibility Period”), the Adjusted Net Income (as defined below) for any Earnout Period is a positive number for the first time during the Earnout Eligibility Period (the “Earnout Milestone”). Under the Merger Agreement, Adjusted Net Income means for any Earnout Period, the consolidated net income or loss for such period calculated in accordance with U.S. GAAP applied on a basis consistent with past practice, of (a) for periods prior to the Closing, the Company and its subsidiaries (the “Company Group”), and (b) for periods from and after the Closing, of us and our subsidiaries (including the Company Group), in each case before adjusting for the following to the extent deducted/added in calculating consolidated net income or loss: (1) interest expense/income; (2) income tax expense/tax credits; (3) depreciation and amortization; (4) transaction expenses; (5) extraordinary items; (6) any income or loss attributable to us that accrues in accordance with U.S. GAAP on or prior to the Closing Date; and (7) all gains or losses in connection with sales or dispositions of assets and investments not in the ordinary course of business.

 

If, following the Closing Date and prior to end of the Earnout Eligibility Period, there is a change of control, then, immediately prior to such change of control, all the Earnout Shares not yet earned shall be earned by the Clearday earnout holders and shall be released from escrow and delivered to the Clearday earnout holders, and the Clearday earnout holders shall be eligible to participate in such change of control transaction with respect to such Earnout Shares.

 

The Earnout Shares will be placed in escrow and will not be released from escrow until they are earned as a result of the occurrence of the Earnout Milestone or a change of control, if applicable. The Earnout Shares that are not earned on or before the expiration of the Earnout Eligibility Period shall be automatically forfeited and cancelled.

  

Treatment of Clearday Securities

 

Cancellation of Securities.

 

Each share of Clearday capital stock, if any, that is owned by the Company, New Merger Sub, Clearday, or any of their subsidiaries (as treasury stock or otherwise) immediately prior to the effective time of the Merger (the “Effective Time”), will automatically be cancelled and retired without any conversion or consideration.

 

Preferred Stock.

 

At the Effective Time, each issued and outstanding share of Clearday’s Series F Cumulative Convertible Preferred Stock, par value $0.001 per share (“Clearday Series F Preferred Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: (A) one (1) share of Parent New Series F Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement.

 

Each issued and outstanding share of Clearday’s Series A Convertible Preferred Stock, par value $0.001 per share (“Clearday Series A Preferred Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: (A) one (1) share of Parent New Series A Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement.

 

F-11

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Common Stock.

 

At the Effective Time, each issued and outstanding share of Clearday’s common stock, par value $0.001 per share (“Clearday Common Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares) will be converted into the right to receive a number of shares of the Company’s common stock equal to the conversion ratio. The “Conversion Ratio” as defined in the Merger Agreement means an amount equal to (a)(i) the sum of $250 Million, plus the aggregate exercise or conversion price of outstanding Clearday’s stock options and warrants (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more), divided by (ii) the number of fully diluted Clearday capital stock (including Clearday preferred stock, warrants, stock options, convertible notes, and any other convertible securities) (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more and assuming a conversion price of Clearday subsidiary securities as provided in the Merger Agreement); divided by (b) $10.00.

 

Merger Sub Securities.

 

Each share of common stock, par value $0.0001 per share, of New Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and become one newly issued share of common stock of the surviving corporation.

 

Stock Options.

 

At the Effective Time, each outstanding option to purchase shares of Clearday Common Stock will be converted into an option to purchase, subject to substantially the same terms and conditions as were applicable under such options prior to the Effective Time, shares of the Company’s common stock equal to the number of shares subject to such option prior to the effective time multiplied by the Conversion Ratio, at an exercise price per share of the Company’s common stock equal to the exercise price per share of Clearday Common Stock subject to such option divided by the Conversion Ratio.

 

Warrants.

 

Contingent on and effective as of immediately prior to the effective time, each outstanding warrant to purchase shares of Clearday Preferred Stock or Clearday Common Stock will be treated in accordance with the terms thereof.

 

Convertible Notes.

 

Contingent on and effective as of immediately prior to the Effective Time, Clearday’s convertible notes outstanding as of immediately prior to the effective time, will be treated in accordance with the terms of the relevant agreements governing such convertible notes.

 

Subsidiary Capital Stock.

 

At and as of the effective time, the subsidiary capital stock will remain in full force and effect with the right to acquire the Clearday Common Stock with such adjustments noted in the terms of such subsidiary capital stock.

 

F-12

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Representations and Warranties

 

The Merger Agreement contains customary representations and warranties of the parties thereto with respect to, among other things, (a) corporate existence and power, (b) authorization to enter into the Merger Agreement and related transactions; subsidiaries, (c) governmental authorization, (d) non-contravention, (e) capitalization, (f) corporate records, (g) consents, (h) financial statements, (i) internal accounting controls, (j) absence of certain changes, (k) properties; title to assets, (l) litigation, (m) material contracts, (n) licenses and permits, (o) compliance with laws, (p) intellectual property, (q) privacy and data security, (r) employee matters and benefits, (s) tax matters, (t) real property, (u) environmental laws, (v) finders’ fees, (w) directors and officers, (x) anti-money laundering laws, (y) insurance, (z) related party transactions, and (aa) certain representations related to securities law and activity. The Company has additional representations and warranties, including (a) issuance of shares, (b) trust fund, (c) listing, (d) board approval, (e) SEC documents and financial statements, (f) certain business practices, (g) expenses, indebtedness and other liabilities and (h) brokers and other advisors.

 

Covenants

 

The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the registration statement and proxy statement (as each such terms are defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party’s respective stockholders. The Company and Clearday have each also agreed to include in the proxy statement the recommendation of its respective board that its stockholders approve all of the proposals to be presented at its respective special meeting. In addition, each of the Company and Clearday have agreed to use commercially reasonable efforts to solicit and finalize definitive documentation for a committed equity in an aggregate amount that, together with the funds in the Trust Account after giving effect to potential redemptions from the Company’s public stockholders, together with financing programs available to Clearday after the Closing, will provide to Clearday working capital to meet its short term commercial development goals.

 

The Company has also agreed to prepare a proxy statement to seek the approval of its stockholders (the “Extension Proposal”) to amend its organizational documents to extend the period of time the Company is afforded under its organizational documents and IPO prospectus to consummate an initial business combination for an additional three months, from June 30,2023 to September 30, 2023 (or such earlier date as the Company and Clearday may agree in writing).

 

Each party’s representations, warranties and pre-Closing covenants will not survive Closing and no party has any post-Closing indemnification obligations.

 

Viveon Equity Incentive Plan

 

The Company has agreed to approve and adopt an equity incentive plan (the “Incentive Plan”) to be effective as of the Closing and in a form mutually acceptable to the Company and Clearday, subject to approval of the Incentive Plan by the Company’s stockholders. The Incentive Plan will provide for an initial aggregate share reserve equal to 8% of the number of shares of the Company’s common stock issued and outstanding at the Closing and an “evergreen” provision that is mutually agreeable to the Company and Clearday will provide for an automatic increase on the first day of each fiscal year in the number of shares available for issuance under the Incentive Plan as mutually determined by the Company and Clearday.

 

Non-Solicitation Restrictions

 

Each of the Company and Clearday has agreed that from the date of the Merger Agreement to the effective time or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate any negotiations with any party relating to an alternative transaction (as such term is defined in the Merger Agreement) or enter into any agreement relating to such a proposal, other than as expressly excluded from the definition of an alternative transaction. Each of the Company and Clearday has also agreed to be responsible for any acts or omissions of any of its respective representatives that, if they were the acts or omissions of the Company and Clearday, as applicable, would be deemed a breach of the party’s obligations with respect to these non-solicitation restrictions.

 

F-13

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Conditions to Closing

 

The consummation of the Merger is conditioned upon, among other things, (i) the absence of any applicable law or order restraining, prohibiting or imposing any condition on the consummation of the Merger and related transactions, (ii) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (iii) receipt of any consent, approval or authorization required by any Authority (as defined in the Merger Agreement), (iv) the Company having net tangible assets of at least $5,000,001 (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act), unless the Company’s amended and restated certificate of incorporation shall have been amended to remove such requirement prior to or concurrently with the Closing, (v) approval by Clearday’s stockholders of the Merger and related transactions, (vi) approval by the Company’s stockholders of the Merger and related transactions, (vii) the conditional approval for listing by NYSE American (or an alternate exchange) of the shares of the Company’s common stock to be issued in connection with the transactions contemplated by the Merger Agreement and satisfaction of initial and continued listing requirements, and (viii) the registration statement becoming effective in accordance with the provisions of the Securities Act of 1933, as amended (“Securities Act”).

 

Solely with respect to the Company and New Merger Sub, the consummation of the Merger is conditioned upon, among other things, (i) Clearday having duly performed or complied with all of its obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of Clearday, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure would not have or reasonably be expected to have a material adverse effect (as defined in the Merger Agreement) on Clearday or any of its subsidiaries, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a material adverse effect on Clearday or any of its subsidiaries, (v) Clearday and its securityholders having executed and delivered to the Company each additional agreement (as defined in the Merger Agreement) to which they each are a party and (vi) Clearday delivering certain certificates to the Company.

 

Solely with respect to Clearday, the consummation of the Merger is conditioned upon, among other things, (i) Viveon and New Merger Sub having duly performed or complied with all of their respective obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of the Company and Merger Sub, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a material adverse effect on the Company or New Merger Sub and their ability to consummate the Merger and related transactions, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a Material Adverse Effect on the Company or New Merger Sub, (v) the amended parent charter (as defined in the Merger Agreement) being filed with, and declared effective by, the Delaware Secretary of State, (vi) the Company delivering certain certificates to Clearday, (vii) the size and composition of the post-Closing board of directors of the Company having been appointed as set forth in the Merger Agreement and (viii) the Company, Viveon Health LLC and other stockholders, as applicable, having executed and delivered to Clearday each additional agreement to which they each are a party.

 

Termination

 

The Merger Agreement may be terminated at any time prior to the effective time as follows:

 

(i) by either the Company or Clearday, if (A) the Merger and related transactions are not consummated on or before the latest of (i) June 30, 2023, (ii) if the Extension Proposal is approved, September 30, 2023 and (iii) if one or more extensions to a date following September 30, 2023 are obtained at the election of the Company, with the Company’s stockholder vote, in accordance with the Company’s amended and restated certificate of incorporation, the last date for the Company to consummate a business combination pursuant to such extensions; and (B) the material breach or violation of any representation, warranty, covenant or obligation under the Merger Agreement by the party seeking to terminate the Merger Agreement was not the cause of, or resulted in, the failure of the closing to occur on or before the outside Closing Date, without liability to the other party;

 

F-14

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

(ii) by either the Company or Clearday, if any authority has issued any final decree, order, judgment, award, injunction, rule or consent or enacted any law, having the effect of permanently enjoining or prohibiting the consummation of the Merger, provided that, the party seeking to terminate cannot have breached its obligations under the Merger Agreement and such breach was a substantial cause of, or substantially resulted in, such action by the authority; and

 

(iii) by mutual written consent of the Company and Clearday duly authorized by each of their respective boards of directors.

 

The Merger Agreement and other agreements described below have been included to provide investors with information regarding their respective terms. They are not intended to provide any other factual information about the Company, Clearday or the other parties thereto. In particular, the assertions embodied in the representations and warranties in the Merger Agreement were made as of a specified date, are modified or qualified by information in one or more disclosure letters prepared in connection with the execution and delivery of the Merger Agreement, may be subject to a contractual standard of materiality different from what might be viewed as material to investors, or may have been used for the purpose of allocating risk between the parties. Accordingly, the representations and warranties in the Merger Agreement are not necessarily characterizations of the actual state of facts about the Company, Clearday or the other parties thereto at the time they were made or otherwise and should only be read in conjunction with the other information that the Company or Clearday makes publicly available in reports, statements and other documents filed with the SEC. The Company and Clearday investors and securityholders are not third-party beneficiaries under the Merger Agreement.

 

Certain Related Agreements

 

Parent Support Agreements.

 

Concurrently with the execution of the Merger Agreement, the Company, Clearday and the Sponsor and the officers and directors of the Company entered into a support agreement (the “Parent Support Agreement”) pursuant to which the Sponsor and the officers and directors of the Company have agreed to vote all shares of the Company’s common stock beneficially owned by them, including any additional shares of the Company they acquire ownership of or the power to vote: (i) in favor of the Merger and related transactions, (ii) against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions, and (iii) in favor of an extension of the period of time the Company is afforded to consummate an initial business combination.

 

Company Support Agreements.

 

Concurrently with the execution of the Merger Agreement, the Company, Clearday and certain stockholders of Clearday entered into a support agreement (the “Company Support Agreement”), pursuant to which such Clearday stockholders have agreed to vote all common and preferred stock of Clearday beneficially owned by them, including any additional shares of Clearday they acquire ownership of or the power to vote, in favor of the Merger and related transactions and against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions.

 

Lock-Up Agreements.

 

In connection with the closing, certain Clearday stockholders will each agree, subject to certain customary exceptions, not to (i) offer, sell contract to sell, pledge or otherwise dispose of, directly or indirectly, any lockup shares, (ii) enter into a transaction that would have the same effect, (iii) enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the lock-up shares or otherwise, (iv) engage in any short sales or other arrangement with respect to the lock-up shares or (v) publicly announce any intention to effect any transaction specified in clause (i), (ii) or (iii) until the date that is six months after the Closing Date (the “Lock-Up Period”). The term “Lockup Shares” mean the Merger Consideration Shares and the Earnout Shares, if any, whether or not earned prior to the end of the Lock-up Period, together with any other shares of the Company’s common stock, and including any securities convertible into, or exchangeable for, or representing the rights to receive the Company’s common stock, if any, acquired during the Lock-up Period. If the closing price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period following the Closing Date, 50% of the Lock-up Shares will be released from the lock-up. The existing escrow provisions of the Company’s common stock held by certain stockholders will remain in effect.

 

F-15

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Amended and Restated Registration Rights Agreement.

 

At the Closing, the Company will enter into an amended and restated registration rights agreement (the “Amended and Restated Registration Rights Agreement”) with certain existing stockholders of the Company and Clearday with respect to their shares of the Company’s common stock acquired before or pursuant to the Merger, and including the shares issuable on conversion of the warrants issued to the Sponsor in connection with the Company’s initial public offering and any shares issuable on conversion of loans or other convertible securities. The agreement amends and restates the registration rights agreement the Company entered into on December 22, 2020 in connection with its initial public offering. Subject to the Lock-Up Agreements described above, the holders of a majority of the shares held by the Company’s existing stockholders, and the holders of a majority of the shares held by the Clearday stockholders will each be entitled to make one demand that Clearday register such securities for resale under the Securities Act, or two demands each if the Company is eligible to use Form S-3 or a similar short-form registration statement. In addition, the holders will have certain “piggy-back” registration rights that require the Company to include such securities in registration statements that the Company otherwise files. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Going Concern

 

As of December 31, 2022, the Company had $19,847 of cash and cash equivalents held outside the Trust Account available for working capital needs. In connection with the Company’s assessment of going concern considerations in accordance with FASB’s ASC Subtopic 205-40, Presentation of Financial Statements - Going Concern, management has determined that if the Company is unable to raise additional funds to alleviate liquidity needs or complete a Business Combination by March 31, 2024, then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern one year from the date that these consolidated financial statements are issued. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to continue as a going concern. The Company intends to complete a Business Combination before the mandatory liquidation date or obtain approval for an extension.

 

Risks & Uncertainties

 

Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

The credit and financial markets have experienced extreme volatility and disruptions due to the current conflict between Ukraine and Russia. The conflict is expected to have further global economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability. In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences, including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our common stock to be adversely affected.

 

F-16

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Inflation Reduction Act of 2022 and Excise Tax

 

On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, imposes a 1% excise tax on the fair market value of stock repurchased by publicly traded U.S. corporations and certain U.S. subsidiaries of publicly traded non-U.S. corporations beginning in 2023, with certain exceptions (the “Excise Tax”). Because we are a Delaware corporation and our securities trade on the New York Stock Exchange, we will likely be considered a “covered corporation” within the meaning of the Inflation Reduction Act. While not free from doubt, absent any further guidance from Congress or the U.S. Department of the Treasury, there is significant risk that the Excise Tax will apply to any redemptions of our common stock after December 31, 2022, including redemptions in connection with an initial Business Combination and any amendment to our certificate of incorporation to extend the time to consummate an initial Business Combination, unless an exemption is available. In addition, the Excise Tax may make a transaction with us less appealing to potential business combination targets, and thus, potentially hinder our ability to enter into and consummate an initial Business Combination. Further, the application of the Excise Tax in the event of a liquidation after December 31, 2022 is uncertain, and could impact the per-share amount that would otherwise be received by our stockholders in connection with our liquidation.

 

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its majority-owned and controlled operating subsidiary, Old Merger Sub after elimination of all intercompany transactions and balances as of December 31, 2022 and 2021.

 

Emerging Growth Company

 

The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. The Company has elected to implement the aforementioned exemptions.

 

In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period.

 

F-17

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.

 

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The initial valuation of the Public Warrants (as defined in Note 3), Rights (as defined in Note 3) common stock subject to redemption and the periodic valuation of the Private Warrants and Subscription Warrants (as defined in Note 6) required management to exercise significant judgement in its estimates.

 

Cash and Cash Equivalents

 

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $6,346 and $350,455, were held in money market funds as of December 31, 2022 and December 31, 2021, respectively.

 

Investments Held in Trust Account

 

As of December 31, 2022 and December 31, 2021, substantially all of the assets held in the Trust Account were held in a money market account and mutual funds which invested in U.S. Treasury securities, respectively. The assets were transferred from mutual funds to a money market account on December 21, 2022. The assets in the amount of $53,815,395 and $203,282,989 were held in the Trust Account as of December 31, 2022 and December 31, 2021, respectively. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in Interest and dividends earned on investments held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in Trust Account are determined using available market information.

 

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

 

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. In accordance with guidance contained in ASC 815, the Public Warrants (as defined in Note 3) qualify for equity treatment. The Private Warrants and Subscription Warrants (as defined in Note 6) do not qualify as equity and are recorded as liabilities at fair value. Changes in the estimated fair value of the Private Warrants and Subscription Warrants are recognized as non-cash gains or losses on the consolidated statements of operations.

 

Debt with Conversion and Other Options

 

The Company accounts for a series of unsecured senior promissory note agreements under ASC Topic ASC 470-20-25-2, Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants (“ASC 470-20-25-2”).  In accordance with ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants (detachable call options) are allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance.

 

F-18

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Common Stock Subject to Possible Redemption

 

All of the 5,032,874 Public Shares sold as part of the Units in the Initial Public Offering and subsequent full exercise of the underwriters’ over-allotment option that have not been redeemed by stockholders, contain a redemption feature which allows for the redemption of such redeemable common stock in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Therefore, all Public Shares been classified outside of permanent equity.

 

The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. There was no change in redemption value for the year ended December 31, 2021. In connection with extending the Company’s Original Termination Date to the Extended Date, the Company deposited $720,000, $240,000, $240,000, $240,000, $240,000, and $240,000 into the Trust Account on March 23, 2022, June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 respectively. In connection to the Company’s Second Extended Date, the Company deposited $100,000 into the Trust Account on December 27, 2022. The Company recorded increases in the redemption value of common stock subject to redemption of $2,607,712 during the year ended December 31, 2022.

 

In connection to the Company’s Third Extended Date, On June 27, 2023, the Company deposited the payment of $85,000 in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023.

 

As of December 31, 2022 and December 31, 2021, the redeemable common stock reflected in the consolidated balance sheets are reconciled in the following table:

 

Gross proceeds  $201,250,000 
Less:     
Fair value of Public Warrants at issuance   (10,384,500)
Fair value of Rights at issuance   (9,136,750)
Issuance costs allocated to common stock subject to possible redemption   (10,660,961)
Plus:     
Remeasurement of carrying value to redemption value   32,194,711 
Common stock subject to possible redemption as of December 31, 2021   203,262,500 
Redemption of common stock by stockholders   (152,451,819)
Common stock tendered for redemption   (34,004,514)
Remeasurement of carrying value to redemption value   2,607,712 
Common stock subject to possible redemption as of December 31, 2022  $19,413,879 

 

Offering Costs associated with the Initial Public Offering

 

The Company complies with the requirements of ASC Topic 340, Other Assets and Deferred Costs (“ASC 340”) and SEC Staff Accounting Bulletin Topic 5A - Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $11,830,356 as a result of the Initial Public Offering (consisting of a $4,025,000 cash underwriting fee, $7,043,750 of deferred underwriting fees, and $761,606 of other offering costs). The Company recorded $10,660,961 of offering costs as a reduction of temporary equity in connection with the redeemable common stock included in the Units. The Company recorded $1,144,422 of offering costs as a reduction of permanent equity in connection with the Public Warrants and Rights classified as equity instruments. The Company immediately expensed $24,973 of offering costs in connection with the Private Warrants that were classified as liabilities.

 

F-19

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Share-Based Payment Arrangements

 

The Company accounts for stock awards in accordance with ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), which requires that all equity awards be accounted for at their fair value. Fair value is measured on the grant date and is equal to the underlying value of the stock.

 

Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, or in the period of grant for awards that vest immediately and have no future service condition. For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company’s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.

 

Income Taxes

 

The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were unrecognized tax benefits as of December 31, 2022 and 2021 of $765,613 and $0, respectively. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the years ended December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 

See Note 11 for additional information on income taxes for the periods presented.

 

Net (Loss) Income Per Common Share

 

Net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The calculation of diluted (loss) income per common share does not consider the effect of the Public Warrants (as defined in Note 3), Private Warrants, Subscription Warrants (as defined in Note 6), and Rights (as defined in Note 3) since the exercise of the warrants and Rights are contingent upon the occurrence of future events and the inclusion of such warrants and Rights would be anti-dilutive. The warrants and Rights are exercisable to purchase 22,068,750 shares of common stock in the aggregate.

 

F-20

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

The following table reflects the calculation of basic and diluted net (loss) income per common share (in dollars, except per share amounts):

 

   Redeemable Common Stock   Non-redeemable Common Stock   Redeemable Common Stock   Non-redeemable Common Stock 
  

For the Year ended

December 31, 2022

  

For the Year ended

December 31, 2021

 
   Redeemable Common Stock   Non-redeemable Common Stock   Redeemable Common Stock   Non-redeemable Common Stock 
Basic and diluted net (loss) income per share:                    
Numerator:                    
Net (loss) income  $(326,506)  $(160,282)  $2,074,858   $414,971 
Denominator:                    
Weighted Average Common Stock   8,199,223    4,025,000    20,125,000    4,025,000 
Basic and diluted net (loss) income per common share  $(0.04)  $(0.04)  $0.10   $0.10 

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

 

Fair Value of Financial Instruments

 

The Company applies ASC Topic 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.

 

The carrying amounts reflected in the consolidated balance sheets for current assets and current liabilities approximate fair value due to their short-term nature.

 

Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.

 

Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

 

Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.

 

See Note 10 for additional information on assets and liabilities measured at fair value.

 

F-21

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Derivative Financial Instruments

 

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified on the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the Private Warrants and Subscription Warrants (as defined in Note 6) are derivative instruments. As the Private Warrants and Subscription Warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820 with changes in fair value recognized in the consolidated statements of operations in the period of change. In accordance with ASC Topic 825, Financial Instruments, the Company has concluded that a portion of the transaction costs which directly related to the Initial Public Offering and the Private Placement, should be allocated to the Private Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the consolidated statements of operations.

 

Recent Accounting Standards

 

The Company’s management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements. 

 

 

NOTE 3. INITIAL PUBLIC OFFERING

 

On December 28, 2020, the Company sold 17,500,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share, one redeemable warrant (the “Public Warrants”) and one right (the “Rights”). Each Public Warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share. Each Right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of an initial Business Combination.

 

On December 30, 2020, the Company sold 2,625,000 Over-Allotment Units pursuant to the underwriters’ full exercise of the over-allotment option (see Note 7), generating aggregate of gross proceeds of $26,250,000.

 

NOTE 4. PRIVATE PLACEMENT

 

Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 18,000,000 Private Warrants at a price of $0.50 per warrant ($9,000,000 in the aggregate), each exercisable to purchase one-half of one share common stock at a price of $11.50 per whole share, in a private placement that closed simultaneously with the closing of this offering. A portion of the purchase price of the Private Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account.

 

NOTE 5. RELATED PARTY TRANSACTIONS

 

Founder Shares

 

In August 2020, the Sponsor paid $25,000, or approximately $0.007 per share, to cover certain offering costs in consideration for 3,593,750 shares of common stock, par value $0.0001 (the “Founder Shares”). On December 3, 2020, the Company declared a share dividend of 0.36 for each outstanding share, resulting in 4,887,500 shares outstanding, and on December 22, 2020 the Company declared a share dividend of 0.03 resulting in 5,031,250 shares which includes an aggregate of up to 656,250 shares that are subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part, and up to an aggregate of 1,006,250 shares of common stock (or 875,000 shares of common stock to the extent that the underwriters’ over-allotment is not exercised, pro rata) that are subject to forfeiture to the extent that Rights are exercised upon consummation of an initial Business Combination. In connection with the underwriters’ fully exercise of their over-allotment option on December 30, 2020 (see Note 7), the 656,250 shares were no longer subject to forfeiture.

 

F-22

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

The Founder Shares were placed into an escrow account maintained by Continental Stock Transfer & Trust Company acting as escrow agent. 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the initial Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the initial Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to its initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.

 

During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) to any persons (including their affiliates and stockholders) participating in the Private Placement of the Private Warrants, officers, directors, stockholders, employees and members of the Company’s Sponsor and its affiliates, (2) amongst initial stockholders or their respective affiliates, or to the Company’s officers, directors, advisors and employees, (3) if a holder is an entity, as a distribution to its, partners, stockholders or members upon its liquidation, (4) by bona fide gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of the Company’s securities, (8) by private sales at prices no greater than the price at which the shares were originally purchased or (9) for the cancellation of up to 656,250 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part or in connection with the consummation of the Company’s initial Business Combination.

 

On December 23, 2020, the Sponsor transferred 81,000 of its Founder Shares of the Company to three board members (the “Transferees”) (27,000 Founder Shares to each Transferee) for a nominal fee. On April 30, 2021, the Sponsor subsequently transferred 27,000 of its Founder Shares of the Company to a new board member (the “Additional Transferee”, and, together with the Transferees, the “Directors”). These awards are subject to ASC 718.

 

Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Founder Shares vested immediately, and, as such, in accordance with ASC 718, the Company recognized compensation expense on the transfer date in an amount equal to the number of Founders Shares sold times the grant date fair value per share less the amount initially received for the purchase of the Founders Shares. The fair value of the Founder Shares transferred to the Additional Transferee was determined to be $157,140 ($5.82 per share) as of April 30, 2021. The Company recognized compensation expense of $157,140 within stock compensation expense in the Company’s statement of operations for the year ended December 31, 2021. The Company did not recognize compensation expense for the year ended December 31, 2022.

 

F-23

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Note Agreements Payable - Related Party

 

We entered into a series of Note Agreements with several lenders affiliated with our Sponsor, Viveon Health LLC and Intuitus Group LLC, for which the Chief Financial Officer of the Company is the Sole Proprietor for up to an aggregate amount totaling $1,955,000 (see Note 6). As of December 31, 2022, the balance on the Notes was $1,955,000.

 

Promissory Notes - Related Party

 

The Sponsor agreed to loan the Company an aggregate of up to $500,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the Initial Public Offering. On January 13, 2021, the Company paid the $228,758 balance on the note from the proceeds of the Initial Public Offering. The Company no longer has the ability to borrow under the Note.

 

The Chief Financial Officer of the Company loaned the Company $75,000 to cover expenses related to ongoing operations, which was funded on December 27, 2022. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on December 27, 2022.

 

As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $75,000 and $0, respectively. Subsequent to December 31, 2022, the Chief Financial Officer of the Company, loaned the Company an additional $555,000 through the date of this filing. These loans will be exchanged for Clearday Senior Convertible Notes upon consummation of the Company’s initial Business Combination.

 

The Chief Executive Officer of the Company loaned the Company $100,000 to cover expenses related to ongoing operations, which was funded on April 2, 2023. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on April 2, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $0, respectively.

 

Subsequent to December 31, 2022, three investors in the Sponsor, loaned the Company $100,000 in the aggregate, to cover expenses related to ongoing operations, funded on April 5, 2023, and April 7, 2023. These loans are non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreements were entered into on April 5, 2023, and April 7, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $0, respectively.

 

On May 12, 2023, the Company entered into an unsecured promissory note with Clearday (the “Clearday Note”). The Clearday Note is non-interest bearing mature upon the earlier of (i) the first anniversary of the issuance date and (ii) December 31, 2022. Proceeds provided to us under the Clearday Note through the filing date were approximately $881,710 during fiscal year 2023.Funds in the Trust Account may not be used to repay the obligations under the Clearday Note. We used such funds for general working capital purposes.

 

Working Capital Loans

 

In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would be repaid upon consummation of the Company’s initial Business Combination, without interest. As of December 31, 2022 and December 31, 2021, the Company had no borrowings under Working Capital Loans.

 

Administrative Service Fee

 

Commencing on the date of the Company’s final prospectus, the Company has agreed to pay an affiliate of the Sponsor a total of $20,000 per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company incurred $240,000 and $240,000 of administrative service fees for the year ended December 31, 2022 and 2021, respectively. The accrued amounts are included in Due to related party on the balance consolidated balance sheets. For the year ended December 31, 2022 and 2021, $50,000 and $10,000 of such expenses were recorded in Due to related party, respectively.

 

Due to Related Party

 

The Company’s directors and officers are reimbursed for any reasonable out-of-pocket expenses incurred by them in connection with certain activities on behalf of the Company, such as identifying and investigating possible target businesses and Business Combinations. For the years ended December 31, 2022 and 2021, $6,647 and $9,479 of such expenses were incurred, respectively. As of December 31, 2022 and 2021, $5,806 and $5,850 of such expenses were recorded in Due to related party, respectively.

 

Due from Related Party

 

As of December 31, 2021, the Company had a receivable of $15,000 in connection with a payment made by the Company to a vendor on behalf of a related party. During the year ended December 31, 2022, the Company was repaid for the receivable. As of December 31, 2022, the balance in Due from related party is $0.

 

F-24

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

NOTE 6. NOTE AGREEMENTS PAYABLE


On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, in connection with the extension of the date by which the Company has to consummate a Business Combination (see Note 7), the Company entered into a series of unsecured senior promissory note agreements (“Note Agreements”) for up to an aggregate amount totaling $4.0 million (the “Notes”). Of the total $4.0 million of the Notes, $1,955,000 is loaned by lenders who are affiliated with the sponsor and a director of the Company, and Intuitus Group LLC, for which the Chief Financial Officer of the Company is the Sole Proprietor. The Notes do not bear interest and were set to mature upon the earlier of (i) the closing of the Company’s initial Business Combination and (ii) December 31, 2022 (the “Original Maturity Date”). A commitment fee in the amount equal to 10% of all amounts funded under Notes (up to a maximum of $400,000), is due to the subscribers, on a pro rata basis, by the Company promptly following the initial funding. As of December 31, 2022, the Company has received $4 million of funding for the Notes. The Company has paid $400,000 in commitment fees as of December 31, 2022. Subsequent to December 31, 2022, in connection with the business combination a majority of the lenders of the Notes have agreed to exchange their Notes with the Company for Clearday Senior Convertible Notes. Upon the consummation of the business combination and the exchange of the Subscription Agreements for the Clearday Senior Convertible Notes, the lenders will forfeit their Subscription Warrants as part of the exchange. One lender has chosen not to convert to Clearday Senior Convertible Notes. The balance owed to this lender under the Notes is considered due upon demand by the lender. As of the date of this filing of this Annual Report the lender has not requested payment of the Note.

 

Pursuant to the terms of the Note Agreements, the subscribers shall receive warrants to purchase one share of Company common stock for every $2.00 of the funded principal amount of the Notes up to 2,000,000 shares of the Company common stock, in the aggregate, at an exercise price of $11.50 per share, subject to adjustment (the “Subscription Warrants”). See Note 9 for additional terms of the Subscription Warrants. Pursuant to a warrant cancellation and forfeiture agreement dated as of August 16, 2023, one of the Company’s directors agreed to forfeit for cancellation 89,029 of the warrant shares underlying the warrant issued to an affiliate that he controls in connection with the Notes described above.

 

In accordance with ASC 470-20-25-2, Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants, the proceeds from the issuance of the Notes were allocated to the Notes and Subscription Warrants using the with-and-without method. Under this method, the Company first allocated the proceeds from the issuance of the Notes to the Subscription Warrants based on their initial fair value measurement of $5,370,185 for the Subscription Warrants issued on March 21, 2022, $337,991 for the Subscription Warrants issued on March 23, 2022, $341,967 for the Subscription Warrants issued on April 4, 2022, $417,037 for the Subscription Warrants issued on April 27, 2022, $162,003 for the Subscription Warrants issued on May 9, 2022, $65,326 for the Subscription Warrants issued on October 27, 2022, and $121,093 for the Subscription Warrants issued on November 25, 2022. The measurement of the Subscription Warrants fair value was determined utilizing a Monte Carlo simulation model considering all relevant assumptions current at the dates of issuance. See Note 10 for additional details on the assumptions used. The initial fair value of the Subscription Warrants exceeded the proceeds received from the issuance of the Notes. As such, the proceeds allocated to the Notes were nil. The Company recognized a loss on issuance of the Subscription Warrants of $3,209,183 for the year ended December 31, 2022.

 

The Company complies with ASC Topic 835, Interest (“ASC 835”). In accordance with ASC 835-30, discounts to the principal amounts are included in the carrying value of the Notes and amortized to “Interest expense” over the remaining term of the underlying debt to the Original Maturity Date. During the year ended December 31, 2022, the Company recorded a $3,645,777 debt discount upon issuance of the Notes, respectively. The discount was amortized to interest expense over the term of the debt to the Original Maturity Date. For the year ended December 31, 2022, the amortization of the discount resulted in interest expense of $3,645,777.

 

F-25

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

The following table presents the Notes as of December 31, 2022:

 

      
Note  $4,000,000 
Debt discount  $— 
Carrying value of notes  $4,000,000 

 

NOTE 7. COMMITMENTS AND CONTINGENCIES

 

Underwriting Agreement

 

The Company granted the underwriter a 45-day option to purchase up to 2,625,000 additional shares of common stock to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. The underwriters exercised the over-allotment option in full on December 28, 2020.

 

The underwriter was paid a cash underwriting fee of $0.20 per share, or $4,025,000 in the aggregate, upon the closing of the Initial Public Offering. In addition, $0.35 per share, or $7,043,750 in the aggregate was payable to the underwriter for deferred underwriting commissions. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

 

In addition, subject to certain conditions, the Company granted the underwriters of the Initial Public Offering, for a period of 12 months after the date of the consummation of a Business Combination, a right of first refusal to act as book-running managing underwriter or placement agent, with at least 30% of the economics, for any and all future public and private equity, convertible and debt offerings. In accordance with FINRA Rule 5110(f)(2)(E)(i), such right of first refusal shall not have a duration of more than three years from the effective date of the registration statement related to our initial public offering. Subsequently this agreement was voided.

 

Registration Rights

 

The holders of the Company’s Founder Shares issued and outstanding on the date of this prospectus, as well as the holders of the Private Warrants (and underlying securities) will be entitled to registration rights pursuant to an agreement to be signed prior to or on the effective date of this offering. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants (and underlying securities) can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

 

Vendor Agreements

 

On May 18, 2021, the Company entered into an agreement with a transactional and strategic advisory firm (the “Strategic Advisor”) for advisory services as needed by the Company in connection with a Business Combination. Pursuant to this agreement, the Company incurred approximately $875,000 in fees. As of December 31, 2022 and December 31, 2021, $500,000 of such fees remain unpaid and are included in accrued costs and expenses on the consolidated balance sheets. On November 1, 2021, the Company and the Strategic Advisor entered into an amendment to the agreement. Pursuant to this amendment, the Company will pay the Strategic Advisor a fee of $2,625,000, inclusive of the $500,000 accrued as of December 31, 2022 and December 31, 2021. The remaining $2,125,000 is contingent upon the consummation of the Business Combination.

 

On October, 8, 2021, the Company entered into an agreement with a financial advisor (the “Exclusive Financial Advisor”) for financial advisory services such as financial and transaction feasibility analysis, assistance in negotiations, assistance in capital planning, and other customary services in connection with a Business Combination, pursuant to which the Company will pay the Exclusive Financial Advisor a fee of $1,500,000 contingent upon the consummation of the Business Combination. This agreement was terminated on January 31, 2023 as a result of the termination of the merger agreement between the Company and Suneva.

 

F-26

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

On November 1, 2021, the Company entered into an agreement with a financial advisor (the “Second Financial Advisor”) for financial advisory services such as guidance on valuation and transaction structure and terms, assistance in negotiations, coordination of due diligence, documentation, and transaction closing, and introduction of the Company to institutional investors in connection with a Business Combination, pursuant to which the Company will pay the Second Financial Advisor a fee of $400,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on January 31, 2023, and there are no related contingent fees for the agreement.

 

On November 2, 2021, the Company entered into an agreement with a financial advisor (the “Third Financial Advisor”) for financial advisory services such as market related advice and assistance in connection with a Business Combination, pursuant to which the Company will pay the Third Financial Advisor a fee of $500,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on June 9, 2023, and there are no related contingent fees for the agreement.

 

On November 5, 2021, the Company entered into an agreement with an advisor (the “Advisor”) for services such as assistance in refining strategic objectives, preparation or refinement of solicitation materials, identification, contact, and solicitation of or potential investors and other sources of capital, and assistance in review, selection, negotiation, and closing of a transaction in connection with a Business Combination, pursuant to which the Company will pay the Advisor a fee of $200,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on June 19, 2023, and there are no related contingent fees for the agreement.

 

On November 15, 2021, the Company entered into an agreement with two placement agents (the “Placement Agents”) for services such as analysis of potential contributions and assets of a target to the Company’s future prospects, assistance in negotiations, and assistance in preparation of presentations to investors, lenders, and/or other financial sources in connection with a Business Combination, pursuant to which the Company will pay the Placement Agents a fee equal to the difference between 5% of the total aggregate sales price of the securities sold as part of the Business Combination and 5% of any securities sold as part of the Business Combination to investors identified by the Advisor, contingent upon the consummation of the Business Combination. This agreement was terminated on February 15, 2022, as a result of an automatic termination provision upon the earlier to occur of three months or the final closing of Business Combination and there are no related contingent fees for the agreement.

 

On February 17, 2022, the Company entered into an agreement with a broker-dealer (the “Broker-Dealer”) for services such as providing the Company with capital markets advisory services with regard to a forward purchase agreement, convertible private investment in public equity (“PIPE”), secured credit facility, and any other capital structure topics in connection with a Business Combination, pursuant to which the Company will pay the Broker-Dealer a fee of $250,000. This agreement was terminated on June 9, 2023, as a result of the termination of the merger agreement between the Company and Suneva. Pursuant to the terms of the agreement the Broker-Dealer will remain entitled to the fee of $250,000 if a Business Combination is consummated within 24 months after the termination date. The Company is pursuing a waiver from the Broker-Dealer to waive the $250,000 fee upon a Business Combination. As such, the fee remains contingent upon the consummation of the Business Combination.

 

On May 9, 2023, the Company entered into an agreement with a placement agent (the “Placement Agent) for services such as advising and assisting the Company in identifying one or more investors that are “accredited” or “qualified institutional buyers. Pursuant to which the Company will pay the Placement Agents a cash fee upon closing equal to eight percent (8.0%) of the gross proceeds received by the Company, contingent upon the consummation of the Business Combination.

 

Extension

 

On March 18, 2022, the Company held its 2022 Annual Meeting of Stockholders for the purpose of approving: (i) a proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to (i) extend the date by which the Company has to consummate a Business Combination for three months, from March 28, 2022 (the “Original Termination Date”) to June 28, 2022 (the “Extended Date”), and (ii) allow the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with Suneva Medical, Inc. or any potential alternative initial Business Combination shall have occurred (the “Extension Proposal”); (ii) a proposal to re-elect five current directors to the Company’s Board of Directors (the “Director Election Proposal”); and (iii) a proposal to ratify the appointment of Marcum LLP as the Company’s independent registered certified public accountants for fiscal year 2020 (the “Auditor Ratification Proposal”). Stockholders voted to approve the Extension Proposal, Director Election Proposal and Auditor Ratification Proposal.

 

F-27

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

On March 18, 2022, stockholders elected to redeem 15,092,126 shares of the Company’s common stock, resulting in redemption payments out of the Trust Account totaling approximately $152,451,819. Subsequent to the redemptions, 5,032,874 shares of common stock remained in the Trust Account.

 

On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, the Company entered into the Note Agreements (see Note 6). The Note Agreements included Subscription Warrants (see Note 9). The entry into the Note Agreements and the terms of the Notes and Subscription Warrants was approved by the Audit Committee of the Board of Directors of the Company at a meeting held on March 21, 2022.

 

On March 23, 2022, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State (the “Amendment”) The Amendment (i) extends the date by which the Company has to consummate a Business Combination for three months, from the Original Termination Date to the Extended Date and (ii) allows the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice and the deposit of $240,000 prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with any potential initial Business Combination shall have occurred. The Amendment was approved by the Company’s stockholders at its Annual Meeting of Stockholders held on March 18, 2022.

 

On December 23, 2022, the Company held its 2022 Annual Meeting of the Stockholders in which they voted to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time for a total of up to six months from December 28, 2022 until June 30, 2023, upon three calendar days’ advance notice and the deposit of $100,000 prior to the applicable monthly deadline, unless the closing of any potential initial business combination shall have occurred prior to the Second Extended Date. On each of December 27, 2022, January 26, 2023, February 27, 2023, March 27, 2023 and April 28, 2023, the Company deposited $100,000 into the Trust Account to extend the date to consummate a Business Combination through January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023, respectively. The Company made a deposit of $100,000 on May 24, 2023 for a one month extension until the Second Extended Date.

 

On December 23, 2022, stockholders elected to redeem 3,188,100 Public Shares, resulting in a redemption payable as of December 31, 2022 of $34,004,514 included in common stock tendered for redemption on the consolidated balance sheet. On January 25, 2023, redemption payments out of the trust account totaled $34,004,514. Subsequent to the redemptions, 1,844,774 Public Shares remained.

 

On June 22, 2023, the Company held a stockholder meeting (the “June 2023 Stockholders Meeting”) in which stockholders voted to (A) amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to the Trustee, prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date; and (B) to amend the Company’s Investment Management Trust Agreement, dated as of December 22, 2020, by and between the Company and the Trustee, allowing the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, each such extension for an additional one month period, with no additional deposits to be made into the Trust Account during such period from January 1, 2024 through March 31, 2024. In connection with the stockholders’ vote at the June 2023 Stockholders Meeting, 227,359 shares of common stock were tendered for redemption. As a result, approximately $2,498,947.09 (approximately $10.99 per share) were removed from the Company’s Trust Account to pay such holders, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date. Following redemptions, the Company has 1,617,415 shares of public common stock outstanding, and approximately $17,777,323.54 will remain in the Trust Account. On June 27, 2023, and July 27, 2023, the Company deposited $85,000 in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023 and August 31, 2023, respectively.

 

NOTE 8. STOCKHOLDERS’ DEFICIT

 

Preferred stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2022 and December 31, 2021, there was no preferred stock issued or outstanding.

 

Common stock — The Company is authorized to issue 60,000,000 shares of common stock with a par value of $0.0001 per share. Holders are entitled to one vote for each share of common stock. As of December 31, 2022 and December 31, 2021, there were 5,031,250 shares of common stock issued and outstanding, excluding 1,844,774 and 20,125,000 shares of common stock subject to possible redemption, respectively.

 

Rights — Except in cases where the Company is not the surviving company in a Business Combination, each holder of a Right will automatically receive one-twentieth (1/20) of a share of common stock upon consummation of the initial Business Combination. In the event the Company will not be the surviving company upon completion of the initial Business Combination, each holder of a Right will be required to affirmatively convert his, her or its rights in order to receive the one-twentieth (1/20) of a share underlying each right upon consummation of the Business Combination. The Company will not issue fractional shares in connection with an exchange of Rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, holders must hold Rights in multiples of 20 in order to receive shares for all Rights upon closing of a Business Combination. If the Company is unable to complete an initial Business Combination within the required time period and the Company redeems the Public Shares for the funds held in the Trust Account, holders of Rights will not receive any of such funds for their Rights and the Rights will expire worthless.

 

F-28

 

 

NOTE 9. WARRANTS

 

Each Public Warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share, subject to adjustment. Pursuant to the warrant agreement, a warrant holder may exercise its s only for a whole number of shares. This means that only an even number of s may be exercised at any given time by a warrant holder.

The Company may call the Public Warrants for redemption (except the Private Warrants):

 

  ● in whole and not in part;
     
  ● at a price of $0.01 per warrant;
     
  ● upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and
     
  ● if and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.

 

If the Company calls the Public Warrants for redemption as described above, its management will have the option to require all holders that wish to exercise Public Warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the Public Warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the Public Warrants, multiplied by the difference between the exercise price of the Public Warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Company’s common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Public Warrants. Whether the Company will exercise its option to require all holders to exercise their Public Warrants on a “cashless basis” will depend on a variety of factors including the price of our common shares at the time the Public Warrants are called for redemption, its cash needs at such time and concerns regarding dilutive share issuances.

  

If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its Sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial Business Combination on the date of the consummation of our initial Business Combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. The Public Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their Public Warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

 

F-29

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

Private Warrants

 

The Private Warrants are identical to the Public Warrants except that the Private Warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees.

 

Subscription Warrants

 

The Subscription Warrant term commences on the Exercise Date (as hereinafter defined) for a period of 49 months. The Subscription Warrants are exercisable commencing on the date of the initial Business Combination (the “Exercise Date”) and have a cashless exercise feature that is available at any time on or after the Exercise Date. Commencing on the date 13 months following the Exercise Date, the subscribers have the right, but not the obligation, to put the Subscription Warrants to the Company at a purchase price of $5.00 per share. The Company has agreed to file, within thirty (30) calendar days after the consummation of an initial Business Combination, a registration statement with the Securities and Exchange Commission to register for resale the shares of common stock underlying the Subscription Warrants.

 

As of December 31, 2022 and December 31, 2021, there were 20,125,000 Public Warrants and 18,000,000 Private Warrants outstanding. As of December 31, 2022, there were 2,000,000 Subscription Warrants outstanding. The Company accounts for the Public Warrants, Private Warrants, and Subscription Warrants in accordance with the guidance contained in ASC 815-40. The Public Warrants qualify for equity treatment under ASC 815-40. Such guidance provides that because the Private Warrants and Subscription Warrants do not meet the criteria for equity treatment thereunder, the Private Warrants and Subscription Warrants must be recorded as a liability.

 

NOTE 10. FAIR VALUE MEASUREMENTS

 

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 and December 31, 2021, and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

 

Description 

Amount at

Fair Value

   Level 1   Level 2   Level 3 
December 31, 2022                    
Assets                    
Money Market Account  $6,346   $6,346   $—   $— 
Money Market Funds held in Trust Account  $53,815,395   $53,815,395   $—   $— 
Liabilities                    
Private Warrant Liability  $900,000   $—   $—   $900,000 
Subscription Warrant Liability  $1,635,515   $—   $—   $1,635,515 
                     
December 31, 2021                    
Assets                    
Money Market Account  $350,455   $350,455   $—   $— 
Mutual Funds held in Trust Account  $203,282,989   $203,282,989   $—   $— 
Liabilities                    
Private Warrant Liability  $4,188,221   $—   $—   $4,188,221 

 

The Private Warrants and Subscription Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the consolidated balance sheets. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated statements of operations.

 

The Company established the initial fair value of the Private Warrants on December 28, 2020, the date of the Company’s Initial Public Offering, and revalued on December 31, 2022 and on December 31, 2021, using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement date, on December 31, 2022 and on December 31, 2021 due to the use of unobservable inputs.

 

The key inputs into the Monte Carlo simulation for the Private Warrants as of December 31, 2022 and December 31, 2021 were as follows:

 

 

Inputs 

As of

December 31, 2022

  

As of

December 31, 2021

 
Risk-free interest rate   4.39%   1.30%
Expected term remaining (years)1   2.11    5.50 
Expected volatility   0.01%   7.6%
Stock price  $10.650   $10.020 

 

The Company established the initial fair value of the Subscription Warrants on March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9,2022, October 27,2022, and November 25,2022 the dates of issuance, and revalued on December 31, 2022, using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement dates, and on December 31, 2022 due to the use of unobservable inputs.

 

 

1 The contractual term of the Private Warrants is 5 years from the closing of a Business Combination. As of December 31, 2022 the expected term remaining of the Private Warrants was calculated based on assumptions for both a successful and unsuccessful Business Combination resulting in a weighted expected term remaining of 2.11. This was calculated using an expected term remaining with an unsuccessful Business Combination of 1.00 year (weighted at 75.5% probability) and a successful business combination term remaining of 5.52 years (weighted at 24.5% probability). Prior to December 31, 2022 the expected term was calculated using only assumptions for a successful Business Combination. The change in the calculation was made as using an expected term that was calculated based only on the assumption that the Business Combination would be successful as an input under the Monte Carlo simulation model resulted in an unsolvable expected volatility under the Monte Carlo simulation model.

 

F-30

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

The key inputs into the Monte Carlo simulation for the Subscription Warrants as of December 31, 2022 and the issuance dates were as follows:

 

Inputs 

As of

December 31,

2022

  

As of

November 25,

2022 (Initial Measurement)

  

As of

October 27,

2022 (Initial Measurement)

  

As of

May 9,

2022 (Initial Measurement)

  

As of

April 27,

2022 (Initial Measurement)

  

As of

April 4,

2022 (Initial Measurement)

  

As of

March 23,

2022 (Initial Measurement)

  

As of

March 21,

2022 (Initial Measurement)

 
Risk-free interest rate                  4.04%               3.90%               4.11%              2.92%              2.80%             2.57%             2.33%              2.33%
Market debt rate1   9.19%   8.70%   9.64%  7.49%   6.75%  6.09%  N/A   N/A 
Expected term remaining (years)   4.60    4.70    4.78   4.56    4.60   4.66   4.44   4.44 
Expected volatility   0.01%   1.38%   4.89%  1.0%   1.0%  1.0%  2.5%  2.4%
Probability of completing a Business Combination   24.5%   23.9%   14.4%   90%   90%  90%  90%   90%
Stock price  $10.650   $10.470   $10.400  $10.220   $10.220  $10.170   $10.080  $10.080 

 

1The Company changed its valuation technique to incorporate the market debt rate as a significant input to the Monte Carlo simulation for the valuation of the Subscription Warrants as of December 31, 2022, November 25, 2022, October 27, 2022, May 9, 2022, April 27, 2022, and April 4, 2022. In the case that the Subscription Warrants were exercised, the risk-free interest rate was used. In the case that the put option was exercised, the market debt rate was used. The risk-free interest rate was used in both scenarios in the Monte Carlo simulation for the valuation of the Subscription Warrants as of March 23, 2022 and March 21, 2022.

 

The following tables presents the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value:

 

 

Fair value as of December 31, 2020  $10,763,361 
Change in fair value   (6,575,140)
Fair value as of December 31, 2021  $4,188,221 

 

Fair value as of December 31, 2021  $4,188,221 
Fair value of Subscription Warrants at issuance on March 21, 2022   5,370,185 
Fair value of Subscription Warrants at issuance on March 23, 2022   337,991 
Fair value of Subscription Warrants at issuance on April 4, 2022   341,967 
Fair value of Subscription Warrants at issuance on April 27, 2022   417,037 
Fair value of Subscription Warrants at issuance on May 9, 2022   162,003 
Fair value of Subscription Warrants at issuance on October 27, 2022   65,326 
Fair value of Subscription Warrants at issuance on November 25, 2022   121,093 
Change in fair value   (8,468,308)
Fair value as of December 31, 2022  $2,535,515 

 

F-31

 

 

VIVEON HEALTH ACQUISITION CORP.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

The Company recognized a loss in connection with changes in the fair value of the Private and Subscription Warrants of $8,468,308 for the year ended December 31, 2022, within gain on change in fair value of warrant liabilities in the statements of operations. The Company recognized gains in connection with the changes in the fair value of the Private Warrants of $6,575,140 for the year ended December 31, 2021 within gain on change in fair value of warrant liabilities in the consolidated statements of operations.

 

NOTE 11. INCOME TAXES

 

The Company’s net deferred tax assets (liabilities) as of December 31, 2022 and December 31, 2021 are as follows:

 

   December 31, 2022   December 31, 2021 
Deferred tax assets:          
Start-up costs  $1,097,004   $791,079.00 
Accrued interest   100,569      
Transaction costs   —    — 
Net operating loss carryforwards   

704,303

    39,259 
Total deferred tax assets   1,901,876    830,338 
Valuation allowance   (1,862,617)   (830,338)
Deferred tax assets, net of allowance  $39,259   $— 

 

The income tax provision for the year ended December 31, 2022 and December 31, 2021 consist of the following:

 

 

   December 31, 2022   December 31, 2021 
Federal          
Current  $100,569   $— 
Deferred   (1,071,538)   (824,916)
           
State          
Current  $—   $— 
Deferred   —    — 
Change in valuation allowance   1,032,279    824,916 
Income tax provision  $61,310   $— 

 

As of December 31, 2022 and 2021, the Company has available U.S. federal operating loss carry forwards of approximately $3,354,000 and $187,000, respectively that may be carried forward indefinitely.

 

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a partial valuation allowance. For the year ended December 31, 2022 and December 31, 2021, the valuation allowance was $1,862,617 and 830,338, respectively.

 

A reconciliation of the federal income tax rate to the Company’s effective tax rate as of December 31, 2022 and December 31, 2021 are as follows:

 

 

   December 31, 2022   December 31, 2021 
Statutory federal income tax rate   21.0%   21.0%
State taxes, net of federal tax benefit   0.0%   0.0%
Change in fair value of derivative warrant liabilities   418.0%   (55.5)%
Non-deductible transaction costs   (32.8)%   0%
Stock compensation expense   0.0%   1.3%
Other permanent items, net   (0.2)%   0%
Warrant issuance costs   (177.8)%   0.0%
Change in valuation allowance   (242.6)%   33.2%
Income tax provision   (14.4)%   0.0%

 

ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were unrecognized tax benefits as of December 31, 2022 and December 31, 2021 of $765,613 and $0, respectively. The Company’s unrecognized tax benefits as of December 31, 2022 related to uncertain tax positions would impact the effective income tax rate if recognized. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the year ended December 31, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

 

Below is a tabular reconciliation of the total amount of unrecognized tax benefits as of the years:

 

 

   2022   2021 
   Year Ended December 31, 
   2022   2021 
Uncertain tax benefits - January 1  $—   $— 
Gross increases - Tax positions in prior period   765,613    — 
Uncertain tax benefits - December 31  $765,613   $— 

 

The Company files income tax returns in the U.S. federal jurisdiction and Georgia. Tax returns since inception remain open and subject to examination.

 

NOTE 12. SUBSEQUENT EVENTS

 

The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than as described in Note 1, Note 2, Note 5, Note 7, and below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements.

 

F-32

 EX-4.7 2 ex4-7.htm

 

Exhibit 4.7

 

 

DESCRIPTION OF SECURITIES OF VIVEON

 

The following description of capital stock of Viveon Health Acquisition Corp. (“Viveon”, or the “Company”) and provisions of Viveon’s current amended and restated certificate of incorporation, as amended (the “Existing Charter”), bylaws and the Delaware General Corporation Law (“DGCL”) are summaries and are qualified in their entirety by reference to Viveon’s Existing Charter and bylaws and the text of the DGCL. Copies of these documents have been filed with the U.S. Securities and Exchange Commission (“SEC”) as exhibits to the Annual Report on Form 10-K to which this description has been filed as an exhibit.

 

General

 

Viveon’s authorized capital stock consists of 60,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”) and 1,000,000 shares of preferred stock, par value $0.0001 per share. The authorized and unissued shares of Common Stock are available for issuance without further action by Viveon’s stockholders unless such action is required by applicable law or the rules of any stock exchange on which Viveon’s securities may be listed. Unless approval of stockholders is so required, the board of directors of Viveon (the “Board”) will not seek stockholder approval for the issuance and sale of Common Stock.

 

On December 28, 2020, Viveon consummated an initial public offering (“IPO”) of 17,500,000 units (the “Units” and, with respect to the Common Stock included in the Units being offered, the “public share”, the warrants included in the Units, the “Public Warrants” and the rights included in the Units, the “Rights”), at $10.00 per Unit, generating gross proceeds of $175,000,000.

 

Units

 

Each Unit consists of one share of Common Stock, one Public Warrant and one Right. Each Public Warrant entitles the holder thereof to purchase one-half (½) of a share of Common Stock at a price of $11.50 per whole share, subject to adjustment. Each Public Warrant will become exercisable on the later of one year after the closing of the IPO or the consummation of an initial business combination, and will expire five years after the completion of an initial business combination, or earlier upon redemption. Pursuant to the warrant agreement, a warrant holder may exercise its Public Warrants only for a whole number of shares. This means that only an even number of Public Warrants may be exercised at any given time by a warrant holder. For example, if a warrant holder holds one Public Warrant to purchase one-half (½) of one share, such Public Warrant shall not be exercisable. If a warrant holder holds two Public Warrants, such Public Warrants will be exercisable for one share. Each right entitles the holder thereof to receive one-twentieth (1/20) of a share of Common Stock upon consummation of our initial business combination.

 

Common Stock

 

Holders of record of Viveon’s Common Stock are entitled to one vote for each share held on all matters to be voted on by stockholders. In connection with any vote held to approve Viveon’s initial business combination, Viveon’s insiders, officers and directors, have agreed to vote their respective shares of Common Stock owned by them, and any shares acquired in the open market, in favor of the proposed business combination.

 

Viveon will consummate the business combination only if public stockholders do not exercise conversion rights in an amount that would cause its net tangible assets to be less than $5,000,001.

 

Pursuant to the Charter, Viveon has until June 30, 2023 to complete a business combination. In the event that Viveon does not consummate its initial business combination by June 30, 2023, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining stockholders and our board of directors, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to our obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. Our Initial Stockholders have agreed to waive their rights to share in any distribution with respect to their Founders Shares.

 

1

 

 

Viveon’s stockholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the shares of Common Stock, except that public stockholders have the right to sell their shares to Viveon in any tender offer or have their shares of Common Stock converted to cash equal to their pro rata share of the Trust Account if they vote on the proposed business combination and the business combination is completed.

 

If Viveon holds a stockholder vote to amend any provisions of the Existing Charter relating to stockholder’s rights or pre-business combination activity (including the substance or timing within which Viveon has to complete a business combination), Viveon will provide its public stockholders with the opportunity to redeem their shares of Common Stock upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to Viveon to pay its franchise and income taxes, divided by the number of then outstanding Public Shares, in connection with any such vote. In either of such events, converting stockholders would be paid their pro rata portion of the Trust Account promptly following consummation of the business combination or the approval of the amendment to the Existing Charter. If the business combination is not consummated or the amendment is not approved, stockholders will not be paid such amounts.

 

Preferred Stock

 

There are 1,000,000 shares of preferred stock authorized. Our Board is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of the holders of Common Stock. However, the underwriting agreement prohibits us, prior to a business combination, from issuing preferred stock which participates in any manner in the proceeds of the Trust Account, or which votes as a class with the Common Stock on our initial business combination. We may issue some or all of the preferred stock to consummate our initial business combination. In addition, the preferred stock could be utilized as a method of discouraging, delaying or preventing a change in control of us. Although we do not currently intend to issue any shares of preferred stock, we reserve the right to do so in the future.

 

Public Warrants

 

20,125,000 Public Warrants are currently outstanding. Each Public Warrant entitles the registered holder to purchase one-half (1/2) of a share of Common Stock at a price of $11.50 per whole share, subject to adjustment as discussed below, at any time commencing on the later of one year after the closing of Viveon’s initial public offering (“IPO”) or the consummation of an initial business combination. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares. This means that only an even number of Public Warrants may be exercised at any given time by a warrant holder. However, no Public Warrants will be exercisable for cash unless we have an effective and current registration statement covering the shares of Common Stock issuable upon exercise of the warrants and a current prospectus relating to such shares of Common Stock. Notwithstanding the foregoing, if a registration statement covering the shares of Common Stock issuable upon exercise of the Public Warrant is not effective within 120 days from the closing of our initial business combination, warrant holders may, until such time as there is an effective registration statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act. The warrants will expire five years from the closing of our initial business combination at 5:00 p.m., New York City time.

 

2

 

 

18,000,000 Private Warrants are current outstanding. The Private Warrants are identical to the Public Warrants underlying the Units except that such Private Warrants will not be redeemable and may be exercisable for cash (even if a registration statement covering the shares of Common Stock issuable upon exercise of such warrants is not effective) or on a cashless basis, at the holder’s option, and will not be redeemable by us, in each case so long as they are still held by the initial purchasers or their affiliates.

 

We may call the outstanding Public Warrants for redemption, in whole and not in part, at a price of $0.01 per warrant:

 

  ● at any time while the warrants are exercisable,

 

  ● upon not less than 30 days’ prior written notice of redemption to each warrant holder,

 

  ● if, and only if, the reported last sale price of the shares of Common Stock equals or exceeds $16.50 per share, for any 20 trading days within a 30-day trading period ending on the third business day prior to the notice of redemption to warrant holders, and

 

  ● if, and only if, there is a current registration statement in effect with respect to the shares of Common Stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.

 

The right to exercise will be forfeited unless the Public Warrants are exercised prior to the date specified in the notice of redemption. On and after the redemption date, a record holder of a Public Warrant will have no further rights except to receive the redemption price for such holder’s Public Warrant upon surrender of such Public Warrant.

 

The redemption criteria for our Public Warrants have been established at a price which is intended to provide warrant holders a reasonable premium to the initial exercise price and provide a sufficient differential between the then-prevailing share price and the warrant exercise price so that if the share price declines as a result of our redemption call, the redemption will not cause the share price to drop below the exercise price of the Public Warrants.

 

If we call the Public Warrants for redemption as described above, our management will have the option to require all holders that wish to exercise warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the Public Warrants for that number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Public Warrants, multiplied by the difference between the exercise price of the Public Warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of our Common Stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Public Warrants. Whether we will exercise our option to require all holders to exercise their Public Warrants on a “cashless basis” will depend on a variety of factors including the price of our Common Stock at the time the Public Warrants are called for redemption, our cash needs at such time and concerns regarding dilutive share issuances.

 

The Public Warrants will be issued in registered form under a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and us. The warrant agreement provides that the terms of the Public Warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but requires the approval, by written consent or vote, of the holders of a majority of the then outstanding Public Warrants in order to make any change that adversely affects the interests of the registered holders.

 

The exercise price and number of shares of Common Stock issuable on exercise of the Public Warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or our recapitalization, reorganization, merger or consolidation. However, except as described below, the Public Warrants will not be adjusted for issuances of shares of Common Stock at a price below their respective exercise prices.

 

3

 

 

If (x) we issue additional shares of Common Stock or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at an issue price or effective issue price of less than $9.50 per share of Common Stock (with such issue price or effective issue price to be determined in good faith by the Board, and in the case of any such issuance to our sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date of the consummation of our initial business combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which we issue the additional shares of Common Stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. The Public Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to us, for the number of Public Warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of Common Stock and any voting rights until they exercise their Public Warrants and receive shares of Common Stock. After the issuance of shares of Common Stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

 

Except as described above, no Public Warrants will be exercisable for cash and we will not be obligated to issue shares of Common Stock unless at the time a holder seeks to exercise such Public Warrant, a prospectus relating to the shares of Common Stock issuable upon exercise of the Public Warrants is current and the shares of Common Stock have been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of the warrant agreement, we have agreed to use our best efforts to meet these conditions and to maintain a current prospectus relating to the shares of Common Stock issuable upon exercise of the Public Warrants until the expiration of the Public Warrants. However, there is no assurance that we will be able to do so and, if we do not maintain a current prospectus relating to the shares of Common Stock issuable upon exercise of the Public Warrants, holders will be unable to exercise their Public Warrants and we will not be required to settle any such Public Warrants exercise. If the prospectus relating to the shares of Common Stock issuable upon the exercise of the Public Warrants is not current or if the Common Stock is not qualified or exempt from qualification in the jurisdictions in which the holders of the Public Warrants reside, we will not be required to net cash settle or cash settle the Public Warrants exercise, the Public Warrants may have no value, the market for the Public Warrants may be limited and the Public Warrants may expire worthless.

 

Warrant holders may elect to be subject to a restriction on the exercise of their Public Warrants such that an electing warrant holder would not be able to exercise their warrants to the extent that, after giving effect to such exercise, such holder would beneficially own in excess of 9.9% of the shares of Common Stock outstanding.

 

No fractional shares will be issued upon exercise of the Public Warrants. If, upon exercise of the Public Warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest whole number of shares of Common Stock to be issued to the warrant holder.

 

On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, we entered into subscription agreements with several lenders for a loan of up to $4,000,000, in the aggregate (the “Subscription Agreements”). Pursuant to the Subscription Agreement, we issued a series of unsecured senior promissory notes in the aggregate principal amount of up to $4,000,000 (the “Notes”) to the subscribers. Pursuant to the terms of the Subscription Agreements, the subscribers shall receive warrants to purchase one share of Company common stock for every $2.00 of the funded principal amount of the Notes up to 2,000,000 shares of the Company common stock, in the aggregate, at an exercise price of $11.50 per share, subject to adjustment (the “March 2022 Warrants”). The March 2022 Warrant term commences on the Exercise Date (as hereinafter defined) for a period of 49 months. The March 2022 Warrants are exercisable commencing on the date of the initial business combination (the “Exercise Date”) and have a cashless exercise feature that is available at any time on or after the Exercise Date. Commencing on the date 13 months following the Exercise Date, the subscribers have the right, but not the obligation, to put the March 2022 Warrants to the Company at a purchase price of $5.00 per share. The Company has agreed to file, within thirty (30) calendar days after the consummation of an initial business combination, a registration statement with the Securities and Exchange Commission to register for resale the shares of common stock underlying the March 2022 Warrants.

 

4

 

 

Contractual Arrangements with respect to the Certain Warrants

 

We have agreed that so long as the Private Warrants are still held by the initial purchasers or their affiliates, we will not redeem such warrants and we will allow the holders to exercise such warrants on a cashless basis (even if a registration statement covering the shares of Common Stock issuable upon exercise of such warrants is not effective). However, once any of the Private Warrants are transferred from the initial purchasers or their affiliates, these arrangements will no longer apply. The Private Warrants were issued in a private transaction. Accordingly, the holders and their transferees will be allowed to exercise the Private the Private Warrants is not effective and receive unregistered shares of Common Stock.

 

Rights included as part of Units

 

Each holder of a Right will automatically receive one twentieth (1/20) of a share of Common Stock upon consummation of the business combination, even if the holder of a Right converted all shares of Common Stock held by him, her or it in connection with the business combination or an amendment to the Existing Charter with respect to Viveon’s pre-business combination activities. No additional consideration will be required to be paid by a holder of Rights in order to receive his, her or its additional shares of Common Stock upon consummation of the business combination. The shares issuable upon exchange of the Rights will be freely tradable (except to the extent held by affiliates of Viveon).

 

Viveon will not issue fractional shares in connection with an exchange of Rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, holders must hold rights in multiples of 20 in order to receive shares for all of the holders’ Rights upon closing of the business combination. If Viveon is unable to complete an initial business combination within the required time period and it liquidates the funds held in the Trust Account, holders of Rights will not receive any of such funds with respect to their Rights, nor will they receive any distribution from Viveon’s assets held outside of the Trust Account with respect to such Rights, and the Rights will expire worthless. Further, there are no contractual penalties for failure to deliver securities to the holders of the Rights upon consummation of the business combination. Additionally, in no event will Viveon be required to net cash settle the Rights. Accordingly, the Rights may expire worthless.

 

5

 

 EX-10.19 3 ex10-19.htm

 

Exhibit 10.19

 

AMENDMENT TO THE

INVESTMENT MANAGEMENT TRUST AGREEMENT

 

This Amendment No. 2 (this “Amendment”), dated as of January 20, 2023, to the Investment Management Trust Agreement (as defined below) is made by and between Viveon Health Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein shall have the meanings assigned to them in the Trust Agreement.

 

WHEREAS, the Company and the Trustee entered into an Investment Management Trust Agreement dated as of December 22, 2020, as amended by Amendment No. 1 on March 23, 2022 (the “Trust Agreement”);

 

WHEREAS, Section 1(i) of the Trust Agreement sets forth the terms that govern the liquidation of the Trust Account under the circumstances described therein;

 

WHEREAS, at an annual meeting of shareholders of the Company held on December 23, 2022, the Company stockholders approved a proposal to amend (the “Second Extension Amendment”) the Company’s amended and restated certificate of incorporation, (the “Amended Charter”) to allow the Company to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time for a total of up to six months from December 28, 2022 (the “December Termination Date”) until June 30, 2023 (the “Second Extended Date”), upon three calendar days’ advance notice prior to the applicable monthly deadline, unless the closing of the proposed Business Combination with Suneva Medical Inc. (“Suneva”), or any potential alternative initial business combination shall have occurred prior to the Second Extended Date; and

 

WHEREAS, prior to the date hereof, the Company has deposited an additional $100,000 into the trust account and filed the Second Extension Amendment with the Secretary of State of the State of Delaware.

 

NOW THEREFORE, IT IS AGREED:

 

1. Section 1(i) of the Trust Agreement is hereby amended and restated to read in full as follows:

 

“(i) Commence liquidation of the Trust Account only after and promptly after receipt of, and only in accordance with, the terms of a letter (“Termination Letter”), in a form substantially similar to that attached hereto as either Exhibit A or Exhibit B, signed on behalf of the Company by its President, Chief Executive Officer or Chairman of the Board and Secretary or Assistant Secretary and, in the case of a Termination Letter in a form substantially similar to that attached hereto as Exhibit A, acknowledged and agreed to by Chardan, and complete the liquidation of the Trust Account and distribute the Property in the Trust Account only as directed in the Termination Letter and the other documents referred to therein; provided, however, that in the event (i) that a Termination Letter has not been received by the Trustee by June 30, 2023, or, (ii) prior to June 30, 2023, the Company fails to timely make the required additional monthly deposit into the trust account to extend the date to consummate an initial Business Combination on a monthly basis, upon three days’ advance notice prior to the applicable monthly deadline, commencing with the first additional monthly deposit to be made by December 28, 2022, and subsequent additional monthly deposits by January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023, the Trust Account shall be liquidated in accordance with the procedures set forth in the Termination Letter attached as Exhibit B hereto and distributed to the Public Shareholders.”

 

4. All other provisions of the Trust Agreement shall remain unaffected by the terms hereof.

 

5. This Amendment may be signed in any number of counterparts, each of which shall be an original and all of which shall be deemed to be one and the same instrument, with the same effect as if the signatures thereto and hereto were upon the same instrument. A facsimile signature shall be deemed to be an original signature for purposes of this Amendment.

 

6. This Amendment is intended to be in full compliance with the requirements for an Amendment to the Trust Agreement as required by Section 7(c) of the Trust Agreement, and every defect in fulfilling such requirements for an effective amendment to the Trust Agreement is hereby ratified, intentionally waived and relinquished by all parties hereto.

 

7. This Amendment shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, the parties have duly executed this Amendment to the Investment Management Trust Agreement as of the date first written above.

 

CONTINENTAL STOCK TRANSFER & TRUST COMPANY, AS TRUSTEE  
     
By: /s/ Francis Wolf  
Name: Francis Wolf  
Title: Vice President  

 

VIVEON HEALTH ACQUISITION CORP.  
     
By: /s/ Jagi Gill  
Name: Jagi Gill  
Title: Chief Executive Officer  

 

Acknowledged and Agreed:  
   
Chardan Capital Markets, LLC  
                    
By: /s/ George Kaufman  
Name: George Kaufman  
Title: Managing Director  

 

2

 

 EX-10.20 4 ex10-20.htm

 

Exhibit 10.20

 

AMENDMENT TO THE

INVESTMENT MANAGEMENT TRUST AGREEMENT

 

This Amendment No. 3 (this “Amendment”), dated as of June 27, 2023, to the Investment Management Trust Agreement (as defined below) is made by and between Viveon Health Acquisition Corp. (the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used but not defined herein shall have the meanings assigned to them in the Trust Agreement.

 

WHEREAS, the Company and the Trustee entered into an Investment Management Trust Agreement dated as of December 22, 2020, as amended by Amendment No. 1 on March 23, 2022, and Amendment No. 2 on January 20, 2023 (the “Trust Agreement”);

 

WHEREAS, Section 1(i) of the Trust Agreement sets forth the terms that govern the liquidation of the Trust Account under the circumstances described therein;

 

WHEREAS, at a special meeting of stockholders of the Company held on June 22, 2023, the Company stockholders approved a proposal to amend (the “Third Extension Amendment”) the Company’s amended and restated certificate of incorporation, (the “Amended Charter”) to allow the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the trust account established in connection with the Company’s initial public offering (the “Trust Account”) the amount of $85,000 for each one-month extension, until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to the Trustee, prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date; and

 

WHEREAS, prior to the date hereof, the Company has deposited an additional $85,000 into the trust account and filed the Third Extension Amendment with the Secretary of State of the State of Delaware.

 

NOW THEREFORE, IT IS AGREED:

 

1. Section 1(i) of the Trust Agreement is hereby amended and restated to read in full as follows:

 

“(i) Commence liquidation of the Trust Account only after and promptly after receipt of, and only in accordance with, the terms of a letter (“Termination Letter”), in a form substantially similar to that attached hereto as either Exhibit A or Exhibit B, signed on behalf of the Company by its President, Chief Executive Officer or Chairman of the Board and Secretary or Assistant Secretary and, in the case of a Termination Letter in a form substantially similar to that attached hereto as Exhibit A, acknowledged and agreed to by Chardan, and complete the liquidation of the Trust Account and distribute the Property in the Trust Account only as directed in the Termination Letter and the other documents referred to therein; provided, however, that in the event (i) that a Termination Letter has not been received by the Trustee by March 31, 2024, or, (ii) prior to December 31, 2023 the Company fails to timely make the required additional monthly deposit into the Trust Account to extend the date to consummate an initial Business Combination on a monthly basis, upon one day advance notice prior to the applicable monthly deadline, commencing with the first additional monthly deposit to be made by June 30, 2023, and subsequent additional monthly deposits by July 31, 2023, August 31, 2023, September 30, 2023, October 31, 2023, November 30, 2023 and December 31, 2023 (no additional deposits need to be made into the Trust Account during the period from January 1, 2024 through March 31, 2024), the Trust Account shall be liquidated in accordance with the procedures set forth in the Termination Letter attached as Exhibit B hereto and distributed to the Public Shareholders.”

 

 
 

 

2. All other provisions of the Trust Agreement shall remain unaffected by the terms hereof.

 

3. This Amendment may be signed in any number of counterparts, each of which shall be an original and all of which shall be deemed to be one and the same instrument, with the same effect as if the signatures thereto and hereto were upon the same instrument. A facsimile signature shall be deemed to be an original signature for purposes of this Amendment.

 

4. This Amendment is intended to be in full compliance with the requirements for an Amendment to the Trust Agreement as required by Section 7(c) of the Trust Agreement, and every defect in fulfilling such requirements for an effective amendment to the Trust Agreement is hereby ratified, intentionally waived and relinquished by all parties hereto.

 

5. This Amendment shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in the application of the substantive laws of another jurisdiction.

 

[Signature Page Follows]

 

2
 

 

IN WITNESS WHEREOF, the parties have duly executed this Amendment to the Investment Management Trust Agreement as of the date first written above.

 

CONTINENTAL STOCK TRANSFER & TRUST COMPANY, AS TRUSTEE

 

By: /s/ Francis Wolf  
Name: Francis Wolf  
Title: Vice President  

 

VIVEON HEALTH ACQUISITION CORP.

 

By: /s/ Jagi Gill  
Name: Jagi Gill  
Title: Chief Executive Officer  

 

Acknowledged and Agreed:

 

Chardan Capital Markets, LLC

 

By: /s/ George Kaufman  
Name: George Kaufman  
Title: Managing Director  

 

3

 

 EX-10.21 5 ex10-21.htm

 

Exhibit 10.21

 

Viveon Health Acquisition Corp.

 

As of May 1, 2023

 

Reference is made to the following documents:

 

  i. The Subscription Agreement (the “Subscription Agreement”) between you and Viveon Health Acquisition Corp., a Delaware corporation (“Viveon”), relating to the Extension Note (as hereinafter defined) and the Extension Warrant (as hereinafter defined);
     
  ii. Senior Note due 2022 (as heretofore amended and supplemented, the “Extension Note”) of Viveon in favor of you, issued pursuant to the Subscription Agreement;
     
  iii. Warrant, registered in your name (the “Extension Warrant”), issued pursuant to the Subscription Agreement;
     
  iv. Termsheet (the “Termsheet”) relating to the offering of 8% Senior Convertible Notes of Clearday, Inc., a Delaware corporation (“Clearday”); and
     
  v. Form of Senior Convertible Notes of Clearday (“Clearday Notes”).

 

As you know, on April 5, 2023, Viveon has entered into a Business Combination Agreement to acquire Clearday. In connection with the merger contemplated by such agreement (the “Merger”) and as set forth in the Termsheet, Clearday is conducting an offering (the “Clearday Bridge”) of securities in advance of the Merger of up to $16 million of Clearday Notes, including $4 million of Clearday Notes issuable to holders of Extension Notes and Extension Warrants in exchange for such securities. The purpose of the Clearday Bridge is to, among other things, permit Clearday and Viveon to pay expenses relating to, and in advance of, the Merger.

 

Viveon respectfully requests your consent to exchange your Extension Notes and Extension Warrants for a principal amount of Clearday Notes equal to the principal amount of your Extension Notes effective immediately prior to the consummation of the Merger.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

 
 

 

Please indicate your consent where indicated below to exchange your Extension Notes and Extension Warrants for Clearday Notes as described herein effective immediately prior to the consummation of the Merger. By executing this consent, you confirm that your representations and warranties set forth in the Subscription agreement are true and correct as of the date hereof and as of the date of the consummation of the Merger with respect to the Clearday Notes.

 

  VIVEON HEALTH ACQUISITION CORP.
     
  By:  
    Rom Papadopoulos
    Chief Financial Officer

 

CONSENTED TO AND AGREED AS OF  
THE DATE FIRST ABOVE WRITTEN:  
   
INVESTOR NAME:  
   
Name:  
Title:  

 

 

 

 EX-10.22 6 ex10-22.htm

 

Exhibit 10.22

 

THIS PROMISSORY NOTE (THE “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE FEDERAL OR STATE SECURITIES LAWS, AND HAS BEEN ISSUED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SUCH LAWS, INCLUDING, WITHOUT LIMITATION, THE EXEMPTION CONTAINED IN SECTION 4(a)(2) OF THE SECURITIES ACT. THIS NOTE MAY NOT BE SOLD OR TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT HAS BECOME AND IS THEN EFFECTIVE WITH RESPECT TO SUCH SECURITIES, (2) THIS NOTE IS TRANSFERRED PURSUANT TO RULE 144 PROMULGATED UNDER THE SECURITIES ACT (OR ANY SUCCESSOR RULE) OR (3) THE COMPANY (AS HEREINAFTER DEFINED) HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT, TO THE EFFECT THAT THE PROPOSED SALE OR TRANSFER OF SUCH SECURITIES IS EXEMPT FROM REGISTRATION UNDER THE SECURITIES ACT AND ALL OTHER APPLICABLE FEDERAL OR STATE SECURITIES LAWS.

 

Promissory Note

of

Viveon Health Acquisition Corp.

 

May 12, 2023 Atlanta, Georgia

 

Viveon Health Acquisition Corp., a Delaware corporation (the “Company”), for value received, hereby promises unconditionally to pay to the order of Clearday, Inc., a Delaware corporation, or such person’s assigns (collectively, the “Holder”), at the address set forth in Section 12 hereof, in lawful money of the United States of America (“Dollars” or “$”) and in immediately available funds, the aggregate principal amount of each loan (each, a “Loan”) that is from time to time recorded on the schedule attached to this Note as Annex A and initialed by an authorized signatory of the Company (the “Principal”), in full, on the Maturity Date (as defined below). Each Loan shall be binding on the Company and may be established by such other reasonable evidence such as a payment by the Holder or any of its subsidiaries or Affiliates or their respective related persons to the Company in addition to being evidenced by the notation of the Loan on Annex A.

 

The following is a statement of the rights of the Holder and the conditions to which this Note is subject, and to which the Holder hereof, by the acceptance of this Note, agrees:

 

1. Definitions. For the purposes of this Note:

 

“Affiliate(s)” means, with respect to any given Person other than a partnership or limited liability company, any other Person directly or indirectly controlling, controlled by or under common control with such Person and with respect to a partnership, the partners of such partnership and with respect to a limited liability company, the members of such limited liability company.

 

 
 

 

“Business Combination” means the business combination contemplated by Merger Agreement.

 

“Business Day” means any day that is not a Saturday, Sunday or a legal holiday in the State of New York.

 

“Event of Default” shall have the meaning assigned to such term in Section 5.

 

“Governmental Authority” means any Federal, state, local, foreign or other court, governmental department, commission, board, bureau, agency or instrumentality.

 

“Interest” shall have the meaning assigned to such term in Section 2(b).

 

“Issue Date” means May 12, 2023.

 

“Lien” means any mortgage, pledge, lien, security interest or other charge or encumbrance of any kind.

 

“Maturity Date” means the earlier of (i) first anniversary of the Issue Date and (ii) the date of the closing the Business Combination.

 

“Merger Agreement” means the Merger Agreement, dated as of April 5, 2023 (as amended or supplemented), by and among Company, Clearday SR LLC, in the capacity as the Company Representative, Viveon Health Acquisition Corp., VHAC2 Merger Sub, Inc. and Viveon Health LLC, in the capacity as the SPAC Representative.

 

“Person” means any individual, corporation, limited liability company, partnership, firm, joint venture, association, joint stock company, trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof.

 

2. Principal; Interest; Prepayment; Maturity Date Extension.

 

(a) Principal; Principal Increase. The entire unpaid Principal shall be paid in Dollars on the Maturity Date. Promptly following the payment in full of this Note, including all accrued and unpaid Interest and any other amounts owing hereunder, the Holder shall surrender this Note to the Company for cancellation.

 

(b) Interest. Subject to Section 2(c) hereof, Interest on the Note (“Interest”), during the period from the Issue Date (or with respect to any increase in the Principal during the term of this Note, from the date set forth opposite such increase in Principal in Annex A) through the Maturity Date, shall accrue on the Principal of the Note set forth in Annex A hereto at a rate 0.0% per annum and shall be payable on the Maturity Date. Interest shall be computed on the basis of a 360-day year applied to actual days elapsed. Interest shall accrue on each Loan (as set forth in Annex A hereto) commencing on the date thereof set forth in Annex A hereto and terminating on the Maturity Date and shall be paid in arrears on the Maturity Date. The rate of interest payable under the Note from time to time shall in no event exceed the maximum rate, if any, permissible under applicable law. If the rate of interest payable under the Note is ever reduced as a result of the preceding sentence and at any time thereafter the maximum rate permitted by applicable law shall exceed the rate of interest provided hereunder, then the rate provided for hereunder shall be increased to the maximum rate permitted by applicable law for such period as required so that the total amount of interest received by the Holder is that which would have been received by the Holder but for the operation of the preceding sentence.

 

-2-
 

 

(c) Prepayment. This Note may be prepaid, in whole or in part, at any time and from time to time, without penalty or premium.

 

(d) Maturity Extension. Upon no less than thirty (30) days written notice prior to the Maturity Date, the Holder may extend this Note for on a month-by-month basis, in which event that Maturity Date shall be deemed to be the last day of the last monthly extension thereof.

 

3. Covenants of the Company.

 

(a) The Company covenants and agrees with the Holder that the Company will comply with all applicable laws, rules, regulations and orders, such compliance to include, without limitation, paying before they become delinquent all taxes, assessments and governmental charges imposed on it or upon its property, except to the extent contested in good faith.

 

(b) The Company covenants and agrees with the Holder that the Company will use the proceeds of each Loan only in accordance with payments that are described and listed (and only in such amounts) as in the budget that has been approved by Holder or any amendment or supplement thereto that has been approved by Holder, in each case, in writing.

 

(c) The Company covenants and agrees with the Holder that the Company hereby waives any or all defaults or breaches by the Company that may have occurred under the terms of the Merger Agreement and accepts as a supplement to the Disclosure Schedules to the Merger Agreement by all of the disclosures made by Holder in its draft Form 10K that has been provided by Holder to the Company.

 

(d) The Company covenants and agrees with the Holder that each notation on Annex A is or will have been made by an executive of the Company that, prior to the date and time of such notation and in effect on the date and time of such notation, is an executive of the Company, duly authorized to execute Annex A by the Board of Directors of the Company and that the signature of such individual is the true and genuine signature of such individual.

 

4. Events of Default. If one or more of the following events (“Events of Default”) shall have occurred and be continuing:

 

(a) the Company shall fail to pay any Principal of, or Interest on, this Note, or any fees or any other amount payable hereunder within ten (10) days of the due date of such payment;

 

-3-
 

 

(b) the Company shall fail to observe or perform any covenant or agreement in this Note;

 

(c) any representation, warranty, certification or statement made by the Company in this Note, or in any document delivered pursuant to this Note shall prove to have been incorrect in any material respect when made (or deemed made);

 

(d) a judgment or order for the payment of money shall be rendered against the Company and such judgment or order shall continue unsatisfied and unstayed for a period of ten (10) days;

 

(e) the Company shall commence a voluntary case or other proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or shall fail generally to pay its debts as they become due, or shall take any corporate action to authorize any of the foregoing;

 

(f) an involuntary case or other proceeding shall be commenced against the Company seeking liquidation, reorganization or other relief with respect to it or its debts under any bankruptcy, insolvency or other similar law now or hereafter in effect or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, and such involuntary case or other proceeding shall remain undismissed for a period of 60 days; or an order for relief shall be entered against the Company under the federal bankruptcy laws as now or hereafter in effect;

 

then, and in every such event, the Holder may, by written notice to the Company, declare the Principal (together with accrued Interest thereon and all other amounts owing hereunder) to be, and the Principal (together with accrued Interest thereon and all other amounts owing hereunder) shall thereupon become, immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Company; provided, that in the case of any of the Events of Default specified in clause (e) or (f) above, without any notice to the Company or any other act by the Holder, the Principal (together with accrued Interest thereon and all other amounts owing hereunder) shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby waived by the Company.

 

5. Payments; Extension of Maturity. All payments of Principal and Interest (and all other amounts owing hereunder) to be made by the Company in respect of this Note shall be made in Dollars by wire transfer to an account designated by the Holder by written notice to the Company. All amounts payable under this Note shall be paid free and clear of, and without reduction by reason of, any deduction, setoff, or counterclaim. If the Principal and accrued and unpaid Interest become due and payable on any day other than a Business Day, the Maturity Date shall be extended to the next succeeding Business Day, and to such payable amounts shall be added the Interest which shall have accrued during such extension period at the rate per annum herein specified.

 

-4-
 

 

6. Replacement of Note. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Note, and (in case of loss, theft or destruction) of indemnity reasonably satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and (if mutilated) upon surrender and cancellation of this Note, the Company shall make and deliver to the Holder a new note of like tenor in lieu of this Note. Any replacement note made and delivered in accordance with this Section 6 shall be dated as of the date hereof.

 

7. Remedies.

 

(a) Upon the occurrence of an Event of Default, Principal then outstanding of, and the accrued and unpaid Interest on, this Note shall automatically become immediately due and payable without presentment, demand, protest, or other formalities of any kind, all of which are hereby expressly waived by the Company.

 

(b) The Holder may institute such actions or proceedings in law or equity as it shall deem expedient for the protection of its rights and may prosecute and enforce its claims against all assets of the Company, and in connection with any such action or proceeding shall be entitled to receive from the Company payment of the principal amount of this Note plus accrued interest to the date of payment plus reasonable expenses of collection, including, without limitation, attorneys’ fees and expenses.

 

8. Costs and Expenses. The Company shall be responsible for all expenses incurred by any Holder in connection with the conversion of the Principal and accrued and unpaid Interest under this Note.

 

9. No Waivers by Delay or Partial Exercise. No delay by the Holder in exercising any powers or rights hereunder shall operate as a waiver of such power or right, nor shall any single or partial exercise of any power or right preclude other or further exercise thereof, or the exercise of any other power or right hereunder or otherwise.

 

10. Further Assurances. Each party agrees to execute such other documents, instruments, agreements and consents, and take such other actions as may be reasonably requested by the other parties hereto to effectuate the purposes of this Note.

 

-5-
 

 

11. Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next Business Day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent as follows:

 

  If to the Company: Viveon Health Acquisition Corp.
    3480 Peachtree Road NE
    2nd Floor, Suite #112
    Atlanta, Georgia 30326
    Attention: Chief Executive Officer
    Telecopy:

 

  If to the Holder: Clearday, Inc.
    8800 Village Drive, Suite 106
    San Antonio, TX 78217
    Attention: James Walesa, Chief Executive Officer
    Telecopy:

 

or to such other address or telecopy number as the party to whom notice is to be given may have furnished to the other party in writing in accordance herewith.

 

12. Amendments and Waivers. No modification, amendment or waiver of any provision of, or consent required by, this Note, nor any consent to any departure herefrom, shall be effective unless it is in writing and signed by each of the Company and the Holder. Such modification, amendment, waiver or consent shall be effective only in the specific instance and for the purpose for which given.

 

13. Exclusivity and Waiver of Rights. No failure to exercise and no delay in exercising on the part of any party, any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any right, power or privilege preclude any other right, power or privilege. The rights and remedies herein provided are cumulative and are not exclusive of any other rights or remedies provided by law.

 

14. Invalidity. Any term or provision of this Note shall be ineffective to the extent it is declared invalid or unenforceable, without rendering invalid or enforceable the remaining terms and provisions of this Note.

 

15. Headings. Headings used in this Note are inserted for convenience only and shall not affect the meaning of any term or provision of this Note.

 

16. Assignment. This Note and the rights and obligations hereunder shall not be assignable or transferable by the Company without the prior written consent of the Holder. The Holder may assign this Note and the rights and obligations hereunder without the prior written consent of the Company. Any instrument purporting to make an assignment in violation of this Section 16 shall be void.

 

17. Survival. Unless otherwise expressly provided herein, all representations warranties, agreements and covenants contained in this Note shall survive the execution hereof and shall remain in full force and effect until the payment in full of all Principal and accrued and unpaid Interest and all other amounts owing under this Note.

 

-6-
 

 

18. Miscellaneous. This Note shall inure to the benefit of the Company and the Holder, and all their respective successors and permitted assigns. Nothing in this Note is intended or shall be construed to give to any other person, firm or corporation any legal or equitable right, remedy or claim under or in respect of this Note or any provision herein contained.

 

19. GOVERNING LAW. THIS NOTE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF TEXAS (WITHOUT GIVING EFFECT TO ANY CHOICE OR CONFLICT OF LAWS PROVISIONS).

 

20. CONSENT TO JURISDICTION. THE COMPANY HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF TEXAS AND OF THE FEDERAL COURTS SITTING IN THE STATE OF TEXAS. THE COMPANY AGREES THAT ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS NOTE OR THE TRANSACTIONS CONTEMPLATED HEREBY MUST BE LITIGATED EXCLUSIVELY IN ANY SUCH STATE OR FEDERAL COURT THAT SITS IN THE CITY OF SAN ANTONIO, TEXAS, AND ACCORDINGLY, THE COMPANY IRREVOCABLY WAIVES ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF THE VENUE OF ANY SUCH LITIGATION IN ANY SUCH COURT.

 

21. WAIVER OF JURY TRIAL. THE COMPANY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS NOTE. THE COMPANY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF THE HOLDER HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT THE HOLDER WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE HOLDER HAS BEEN INDUCED TO ENTER INTO THIS NOTE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 21.

 

22. Attorneys’ Fees. In the event that any suit or action is instituted to enforce any provision in this Note, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Note, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals.

 

23. Conversion. Principal of, and accrued and unpaid Interest on, this Note shall be convertible, at the option of the holder, into the securities heretofore offered in connection with the financing relating to the extension of the term of the Company or any other securities issued by the Company following the date hereof.

 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

-7-
 

 

In Witness Whereof, the undersigned has executed this Note as of the date first above written.

 

  VIVEON HEALTH ACQUISITION CORP.
   
  By: /s/ Jagi Gill
  Name:  Jagi Gill
  Title: Chief Executive Officer

 

 
 

 

ANNEX A

 

Advance #

  

Date

  

Amount Funded

  

Aggregate Principal Amount

  

Initials of

Authorized

Company Signatory

 
1   May 16, 2023   $167,616   $167,616     
2   May 22, 2023   $58,200   $225,816     
3   June 5, 2023   $46,560   $272,376         
4   June 19, 2023   $46,560   $318,936      
5   June 30, 2023   $34,920   $353,856      
6   July 14, 2023   $34,704   $388,560      
7   August 2, 2023   $256,080   $644,640      
8   August 7, 2023   $174,600   $819,240      
9   August 11, 2023   $58,416   $877,656      
10                    
11                    
12                    
13                    
14                    
15                    
16                    

 

 

 EX-10.23 7 ex10-23.htm

 

Exhibit 10.23

 

 

 

 

 

 

 

 

 EX-31.1 8 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Jagi Gill, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Viveon Health Acquisition Corp. for the annual period ended December 31, 2022;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 23, 2023    
  By: /s/ Jagi Gill
    Jagi Gill
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 EX-31.2 9 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Rom Papadopoulos, certify that:

 

1. I have reviewed this Annual Report on Form 10-K of Viveon Health Acquisition Corp. for the annual period ended December 31, 2022;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 23, 2023    
  By: /s/ Rom Papadopoulos
    Rom Papadopoulos
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

 

 EX-32 10 ex-32.htm

 

Exhibit 32

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Viveon Health Acquisition Corp. (the “Company”) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Date: August 23, 2023    
  By: /s/ Jagi Gill
    Jagi Gill
    Chief Executive Officer
    (Principal Executive Officer)

 

 

 

  

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report of Viveon Health Acquisition Corp. (the “Company”) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

 

Date: August 23, 2023    
  By: /s/ Rom Papadopoulos
    Rom Papadopoulos
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 

 

 GRAPHIC 11 ex10-23_001.jpg begin 644 ex10-23_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#0# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#S0A /FYIN MX=NE0--&%QNIAG4<@\5@::EHX/7IWJ,>W2H#<*1M!IC2X!7.*8$S, ,49JL' M_B)SBE%P#TH E(D)SBGC+#D5&+C H^TB@!Y7T&*4#BHC-\IP<\T@E)'6F(G' MRC(ZT'=[;>U5_-9>)!GKQ3$2 $'(I<>_/6HS*H[T"510!)_%UI-^ MXXIOF)W--,B*C=]*8"]Q2BF%Q2^8M M #N]&.:;YJ^U*)E% #@OS4%2#2><.M)YPQ20""-B^:<$/.#@TTW)'04><6&< M4P' 'LI!IF_+<!3L<=*A^T,.0M.$Y/44 /(XHP-M1E]Q MX-)N;/WAB@"48Q1Q41;'4T@;WHL!.,4HQWJ%9!GDT\NI/6@!2,'-&ZD++GK3 M9&!'&* ) 0:3O4*O@9)IWG ]: )!CKZTZH=X/^]09<=: )J..XJ W!_A&:7S M^.: )J *B\[/2D:4XP* )AR<4XK42/ZGFG>83QF@!P P,]*3(')Z=*:6..M( M6R,<4 2@#UHR/6H5.TY)H ]Z ):*:64#K2&9 * 'T5&)5)X-'F@4@)*.,,T@'8-+BH3,_KQ4(E/0BG;SP! M2 D"\9I ,BHRS#^*G(W'-,!^!W%&!VHW@"FF09H =TZT'!J-W]Z:).: )2<$ M49I@;!.: XS0 ^D]J;Y@IK2C/2@"0=:"N3Q3!.I[4++R<4 /" 'BG8S41D.> ME =CV(H >5)R*<%(7%-#TNXGO0 A% %-?=G(--WGI0!(5!.:,TSD]Z=P*!CO MO$'VH/3D5&"1WI2YQ0(=N4=5% 89'&*AWKGYJ<9%W<4 29!%&,\5&'!/%!DP M: N/49/-. Y]JAW,>11YC9P: )N,TM0^:2>E!EYI=0)OPI*CW'#<\FA7)3YN M* )R.!3=H/-1*S$<&I%.!R>: %X:CBH#+M)P,TY6YZ]:=A71+G-(6"C)J,OA MJ"X(Q0.Z%$NX].*D( (-1@H!2^8* N/[T4S?FC> ,]Z+,!^:0-C/)J,2C^(\ MX[4+(-O!XHLP) _*,C%56DP0.8N<8I"J$=ZB/R,.>*+ 6,YZ4A )YZU&LJ]!F MD\Q /F)'-)H"4.5&*0S=0.M1X+'CY5[>])M4-R30D!+DX'&::6(/3-19=1G> M<=JDWJ5!'!Z$>M,!Q8$XQVH0$'K4>[#M/60,#DTP),@@DFF@@MM%1[E VD@ $J:;MP"2. :+#)%?C)%()E((Q2,]#3FDV4G[P?\ +,D_2D(S]]6W M>F* %W$C(IJMN..]/" #!)SZ 4Y(=C;CD_A0%AH#*3FGXIV8[$8? S1O!Y/6IC8S;B"A_ 4]+-\X\ISGVH:8K% M;<,C%2D_+D59&G2 @^4X_"E^RRC*K$['_=I6"Q3+2%"!30SYR?2KPL[H?\L2 M/J*46%RX.(#N^AIV'8I@L:4J:L#2[[)R"/PJ==+NPN CL?I2:"Q0W$#Z4F_( MSS5N32KX'(A;\J4:5>LO (/<;:5@L4U91R>M-VACE36BNC7##+QL3[#%/_L6 MX$>3&RCZ4)!8S"K <&FG=@@GZ5I#1[DC #<^U#:-<$]\CU%59B,\+@ # /-V/;UK0_L:=A\RN3["FMHMV3A8W'X&BS H/\ (.M,:7>:Z. M/PGJ#M_J)/RJ5_!NID+BV;_OFCE86.7 I@ B%_\ OFED M\':D@!^SR$^RT^4+'(9P2II2!@"-2D.3:R#_@-3#P!?G_EWDS]*?*%C MC-O.-U.QT.[BNW7X=ZD1G[&](/AUJ2];9\?2CE"QQ!Y8A1QZT\1989KM&\ Z MGVMGQ]*=_P *]UB096!@/I1R <5A=V*4H,' S73&#]:>OPDU,M@Q@#UHY0MYGE9!89 MQB@0$G->N_\ "GKQ5ZY;W-,'P>U/G# "E9A9'D:]W7X,PE#F%@<@'/84OE2@ M;BA%?0D7PALP?G6$F 0A-*L3-P$?WXKZ(7X0:6 MISYI_*K,7PITI#RY(HY0T/F[[)/G=M.#VQ3_ ++/D_NS7TRGPQT,?>5F]JDC M^&VA(^?))^M'*+0^9%L9_P")"?;%2#3)W_Y8-^5?4:> ]!3_ )VVI5TRR7I:Q# M_@ IV0$-48\6LGX"I4\#:I+P+64'Z5]5+:VZ]((Q_P$4X00CI$@_X" M*+!S'RV/A[K+'BVE_*IH_ASK)(!M7_$5]0!%'11^5+M'H*+"YCYH3X8ZR1_Q M[D9]JE7X4ZJW6W/Y5])8]A2TPYCYR'PEU?\ YYU,OPCU3 _=BOH>B@.8^>O^ M%/:K(.8TQ4@^#VHKQY25] T4!S'@2?!R_8[BJKBK$?P;O<89KV;%&!Z4"YF>. M_P#"E(O^>ZU*GP5MP377T4 A6BR%S'Q"FG:L(\"PN2#_ -,S0+#4(R=V MGW(SZQD5]M_8+3_GVB_[Y%-;3K-OO6L)^J"BR'SGQ+Y&H=!I]Q_W[- @U#/. MGW('_7,_X5]LC3;$=+2'_O@4O]G67_/K#_WP*.5"YSXD:"^Z+9W ]O+--,6H M(039W/\ WZ-?;?\ 9=@3G['#_P!\"E_LNP/_ "YP_P#? I[ M[V\OX(?\*<9)0/F@G!_W#7VV-'TT=+&W_P"_8J&7PYH\YS)IML3Z^6*+(.8^ M*!*Z?\LI,>ZFC[3S]Q_RK[3/A;0R,'2[4_\ ;,5"?!GATGG2;4Y_V!1RH.8^ M+VNR,X5L^],-VYQG*BOM#_A!_#1.3H]J?J@IC^ _#$G71[;\$%/E071\;BZ4 M]S2_;D+!<''TK[%'P_\ "X_Y@]L?JM*/ /A=3D:+:@_[@HL@YD?&[W*[3@FF MK= #!.3]:^R)/A]X7DQNTBW_ 6@_#[PL5VG1K;'^X*7*/F78^/3=JJ\2<^E,-X.S8]L5]=?\*K\' MXP-'A'TI5^%WA)?^83#^5'*@N?(:WW(R#CUJ47T>>]?6\OPO\)2KM.E0CZ#% M5F^$?@]AC^S%_.CE0[GRHU]$1C/XU&;U>S9_"OJQ?A!X/5]W]FC/UIS?"'PB MW33P/QHY0NCY3^V*PX;'U%--XG9C^5?5?_"F_!V<_P!G#\Z5?@_X.7_F'?\ MCQHY0NCY1-XH/WC^5/%Y%C[QS7U0WP9\&NV3I_ZTA^#'@W&!IY'T:CE%='RV M+R/'7]:;]L3/6OJ _!'P=G/V1_\ OJA?@CX.7/\ HC\_[5'*.Z/F%;U.06!H M^V+_ 'ACZU].GX(^$.UH_P"=!^"7A$KC[*P_&GRH+H^8_M:9R''YTIO$QRP_ M.OIG_A1_A''_ ![/^=*/@?X/!YM7/_ J7*@NCYB-Y'ZTW[:A_B/Y5]2#X*^# M5Z6+?BU#?!;PHI/MJ;NI KZH'P9\'AMPL#],U,/A#X1 XL M*.1#N?*HOT]3^5(M[&7PWPE\(L>=.'YT^5"N?*1U*(8 )_*H_[1^;H<>W-? M68^$_A$?\PQ/SJP/AEX44 #2H1C_ &:.5!<^1QJ$>,9(/O3EO$/!;)]J^M#\ M,?"Q.3ID1_"IH_AUX60$#28.?:E8=SY%:\0'EB/PIKW\>,+DFOKL?#CPN&S_ M &7#^(H;X<^%V8'^RX01Z+3Y4.Z/D);OU5AZ$BE^VHIY8GZ5]>M\._#3 Z; M%@?[-(/AQX7_ .@5"?\ @-'*@NCY":_'4 @>]*NH+@=2:^O&^&_A9Q@Z5#^" MTJ?#KPO&'3_P P MJW'_ 4]?!OA]>FF0?]\T[(5SXZ69LG;$X_X":8TER3G[/)CV4U]F#PEH0 M_P")9;_]\"G'PKH9 ']F6_\ WP*5D%SXR\Z4$?Z-,/\ @)IV^Y4U]DKX5T13D:=!_WR*>?#.BL,'3H,?[@HY4/F1\<>9,$^>)Q_P$U$)93T MCD_[Y-?9+>%=#8^& MRNTZ=&1]*$^'GAI!@:;$?J*.5!<^2#.23\IQ[4JW#="C8]:^MQ\/O#0/_(,A M_*G?\(!X; XTR'_OFBR"Y\C2W"(F<-GZ5&MR9,, >/:OKB3X>>&Y!@Z=%CZ4 MW_A7/AO ']GQC'M1RH+H^2S<,<_(X/N*5'F;K^6:^L3\-?#1.38)^50R?"_P MTYS]DQ]*?*@;1\K>;Y;8D4BE:Y4*2.*^HW^%/AQSG[.?Q-0-\(O#CYS!2Y4% MSYA6YW+GK^---TH/)/X5]-_\*>\/[N$(7TQ1)\'/#C@8C8$>U/E7<+GS&;H. M=HR/>GI)CC=D^]?2$GP4T(_<=E_X#44OP0T9E 6=Q_P&ERH+GSPTV,$X/XT" M5<9R/SKZ#'P,T?O,_,6./I7T-_PH M[12W,[X'M3#\#=%SQ,^*.5#N?/9EBS\IH\U5Y!&:^@I?@?I+ ".=A^%+'\#] M+0#]^Q/TI\J"Y\^B[('W>E+Y[LN0.#7T&_P3TQP/WQ'T%!^!^D,/FG;/THY4 M%T?/A9UYVL/M ZD\4 MPSEN44_6OHW_ (4GH@7!E;\!4L?P:T-,9=R/I1RH+H^;$=V;C.?'*U M]+?\*@\/$?<88I[?"+P^R ;#D4^5#NCYG\Y2.IS1YPVD#!-?20^#?AX'.T_E M4D7P@\.HVXJY_"ERHFZ/F8(SC)P#[TWR9 ,@!OH:^I#\*O#N.(#^-(OPH\.* M7 +#@U]2_\ "M]!P/\ 1^E"?#;00=QM\DTG%$W/EGRG3H"10OF;L;&(^E?5 MO_"O?#_>S4_A2?\ "O?#V<_8DH20'RI]GD=N%P/<4\V.!^Z?_OFOKA?"6C+TLH_RJ8>&=(4 M8%C%_P!\T6B%SY&73[P''E/^1I_]DWIY$;?D:^MQX;TA>EC%_P!\U(-!TL# ML8/^^!3T"Y\C'0KUB"L#_P#?)J5= U'9@6TO_?-?6ZZ/IZC LX?^^!3QIED! M@6L7_?(HT"Y\D#PUJ3@?Z++_ -\&G'PQJH _T6;'_7,U]<"RMEZ6\8_X"*7[ M);_\\4_[YI!<^2(_"FM2?\N<^/\ 2?E2_9X? M^>2?E3T"Y\F_\(3KY/&GR$?2I!X%\0 ;VLY@/85]7"&,=(U_*E,2'^!?RI!< M^4T\":S, /L4V?\ =JU%\.=>*X6R?'TKZB$48Z(H_"G;1Z"@+GS"OPVU\=+- MORJ?_A5?B"3[T)KZ7VCTHQ3"Y\W)\)]? '^B''UJ=/A)K;$;K<#ZU]%8HQ2" MY\^CX,:LXW#RT]B:4?!?5NA,9_&OH'%% 7/ 5^"NJL1F2,8]ZM+\%=0Q_K8< M^YKW2C%,+GA3_!;47&#)" /0TT?!&_S_ *Z/\Z]WQ2T@N>%'X)7AP#+'^=!^ M"5\/NRQ?G7NM% V:^@L =!10',>'+\$;KC-S&/QJ>+X(.,^9=(: M]J_"C ]* YCQEO@FP'R7:BFCX(MCF[6O:,#TH_"@.8\>3X*A5Q]K3\J:?@H' M/-XF/I7L>!Z4N* YCR(?!.V5* M,4#YF>9_\*>P/KBG MI\(M*7&^=V'IBO2**+A=G ?\*FT+;@[\^N*C/PDT8G_628^E>AT4!S,\\_X5 M%HO9W(I4^$>A*^29#7H-+0',SAU^%^@K_ WY5,OPVT-0!Y;&NQQ1CG-%PNSD ME^'>@ GAG1T^[8 M1C\*UZ* NS);PWI#=;*,_A3/^$6T4?\ +A'^5;-% 7,E?#.CKR+&+\J>/#^E M8Q]AA_%:TZ*!7,IO#>D-_P N,(^BTS_A%]&'_+A$?PK8HH RU\.Z2O2QB_[Y MH;P[I3'_ (\XO^^:U** ,P:!I:]+.+\J>-%TY>EI'_WS6A10!1_LBP_Y]H_^ M^:1=&TY3D6<.?7;5^B@=RJ--L@.+:/\ [YH.G69&#;1_]\U:HH"[*HTVR4Y% MM&/PIXLK8?\ +!/RJ>B@5R'[';_\\4_*E^RP?\\4_P"^:EHH B^SP_\ /)/R MI?L\/_/)/RJ2B@",0Q#I&OY4IAC/5%_*GT4 ,\J/'W%_*E$:#HB_E3J* $V+ M_='Y48'I2T4 &**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "C%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>E &%K"%KQ3_ + _ MF:*GU-1]I7/]P?S-% &M1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 8HHHH ,48HHH ,48HHH ,4444 &**** "BBB@ P/2C%%% " M8%&*6B@ Q28I:* "C%%% !28I:* #%%%% !BDQ2T4 &*3%+10 F/>EHHH ,4 M8HHH ,4444 %&*** "C%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH *3%+10 8HHHH **** "BBB@ HHHH **** "BBB@ Q1BBB@!,4M%% M!1110 4444 %%%% !1110 F*6BB@ HHHH ,4F!2T4 )BC%+10 F*,"EHH ,# MTHHHH 3%+110 8I,4M% "8I<444 )BC%+10 F*6BB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ H/(HHH Q-6)6[4#^X/YFBF:R3]L7G^ ?S-%,#>HHHI %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z449H P- M84F\4Y_@'\S14&O70BU!5/\ SS!_4T4%6.FHHHH)"BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "DI:3M0!Q?BJ7;JZC_IDO\S13/%B M*VL@G.?*7^9HJ;E'<44451(4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 "+Q04!Z0I_6BE8L]: MHHHID!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M0: /%/B/,H\72@@9$2_UHK%^*5]Y?CBX0-C$:_UHH+/H6BBB@@**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6D/0T ?+7Q3NFD M\?7W/W<+_.BH_B+$#XWU L>2V:*91]54444B0HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ -)V-+3)#MB<^@H ^2_B3?X\=:B ,X?' M6BLCQ[,)/&FI$@D^:113&?9U%%%(04444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&: "BBB@ HH MHS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !44_&; MQO?^%H+&'39 L\IR: /6J*\M\'Z]XI;P->:YK"CB!I(%[FN>^$GQ(\0>*/%T MUAJ+K);&%I!QRN#Q0![G1110 4444 %%%% !1110 4444 %%%% !1110 9I, MUY/\9O&6L>$HM.DTR94\YR&!^E^*^8V^,GC&XG%G%<)N:0QH!U/- CZNHKG?!JZO_84, MFM.#=.H; ["NBH **** "BBB@ HR,XSS6/XHU0Z)X:U'4E(W00EESZUX#\/O M'/BGQ5\1[*.2Z)@+,\D8Z;,4 ?2U%1R2I#$TLCA449)/I69HGB&R\00S2V+[ MTCD,9/O0!K<>M (/0YKP3XV^.]7T/Q'::;IEV856W$DFWU)('\J[[X0RZI=> M"8KS5;AYIKARZEO2@+'?4444 %%%% !36=5QN8#)P,GK4<\\=M"\\SA8T!9F M/0 5\_7_ ,3;OQ%\5-.L=,F*Z?'<[" >'QQF@#Z'HI!TI: "BBB@ HHHH ** M** "BBB@!I(522< BU.)VB( M3'K7B?P<\)Z[;^+[K5]1$T<";E)8\,30!] T4W>HZD4H8'H: _7C%8T7BO1 M)M5.F1W\+78.WRPP.36G=AFM)53[Y0A?KBOGKP9X"UB3XHOJ%P^V&WG,I(;K MSTH ^B^]*>E<_P"*/%>F^%M->YOYU4X^1<\DUS7PW\>S>-;B^+)MBB;Y/>G8 M#L-<\0Z?X>LQI=(U>SUS3TO;&420OT(KS'XV:'=^((K"TM9@A MC)=E)ZUUWPW\.2^%_!]M8RS>9(?G8^F:0'844QY$1VUD@>YF6-?5C4EO<174(EA=70 M]"* ):**BN;B.UMI+B9@L<:EF)[ 4 /9E5"S$!1R2>@KD=6^)/AS29S UXMQ M-G&R$AN?PKQ#XD?%R_U^]ETW197@L$8IYB'!D-=E\*OA8EO;IKFN@RW,ZAHX MW.>/6@#MXOB/921F5K.X6+^\5-5=*^*^BZMKT>DVVXRN=OXUV,FD6+6[Q?9H MPI&/NUYAX4^&!T;XBW.L.!]G5B\0^M,#UZBJUW?6UA%YES,D2>K&LNZ\6Z+: M0B66_A5&^Z2W6D!NT57M+J*]M4N('#HXR"IK(UKQCHF@3+%J%XD;M_#F@#?R M**YJ7QWX=B\@MJ4?[[[@SUK3U'7+#2]+_M&[G5+?;N#'O0!I45P^G_%;PQJ4 MYBM[P,14"?%OPY)KBZ4LV96?8#[T =_1358,JE>01FG4 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6?KC, MNB7A7KY3?RK0K*\2N8_#M\PZB%OY4 ?%.K[CJ]T21GS#_.BH=4D,FISL>[FB M@H^\:***"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** /.OC9=?9_AQ>+WE8+7CGP%LQ/\1/-8 B"U=OQRHKU+]H"39X 1<_ M>N5%>6_!76+#0-4U?4[Z0 QVP6->[$D\#\A1U*Z'T3XI\467A?2VN[I@SD$1 MQ#JYQTKS;PSX3U#QUX@_X2KQ1"4A4YM;9AT'8UI:#X=O/&^LCQ'XA#K9QMFS MM#TQZD5ZDJ)'&$50JJ, 8P*"4:"#E(-MN".[5]&^!]!BT+P78:;L M&3%NDXZD]: 9S,'QIT*Z\2PZ/$C@O-Y1D;H#TKIO&WBV#P;X??5)XO-PVQ%' M9=2S*8XTY+4 =QX+\6V MWC+P['JEO$T8+%'1NQ'6G7WC+2++4/[/^TK+>'_EDAR17FEWJ[?"OX06%D0% MU2\5F*YY4MR?YUQ?P\N;73]/U3Q;JTIGO?F2$.-QW8SF@#T*3XYV,7BL:2;! MA%YHB,N>^<5ZM<7<%I:O,5\P_#OP-J/C/Q9_;-]$T-BD_GNQ7 M&\YS@5T?QU\<.;Q?#&FRLJP@&Z*$@D]E_+% VET/2;?XFZ7JFH2V6CQR7DL7 M+E.@_P XK%TGXT6-WXL&A7MH;5C)Y8\*Q^%O!!U.\14NKL?:)&( MY5 /E&?SKP<-)KGQ31[-2YFU)2N/0-S^E 6T/K?7]:M_#^BW&IW.3%"NX@=Z MX'PE\9+'Q7XBCTJ"R>+S%)#M3/CCK0TOP%]D 'G7CB( ^@ZFO*?@MH-_J?B* M:YMU*PP(%,IZ ]P#0(]@\:??"E^M@J&YG'WPO\-=AX6\0P>*/#UMJULI5 M)@<*?6OE+XEI#+\0+R"S8R$,L>#&ORH6>[D)8G^Z.E?/=T]YXN\9/L9GGOKK:N3G )_H*^F]*^'MWIUA;6 M\6M2Q1QHJF-%P*13>EB[\3O$,&@^";^1I$,LT9BC7/4FOG?X0Z$=<^(-F73= M%;9GD/8$=*M_&22YL_%(TF6^EN(X(U)#'C)YZ5Z9^S_X=-EX=NM9FCQ)>.$C M)'.Q>_ZTQ=#V":>*U@::9U2)!DL3@ 5S%W\0-&BL+J[MY#<+;J6)3D<5Y%\: MOB%=S:F_AK3)3'#&0)G4\L3QBFWU[!X;^&5OX?T^U>YU34%'F$+DC-.P6/0/ M /Q6M?&FL3:>L!A<(77(ZUU_B?Q3IOA/2S?:E*%7.U%[L:\N^#?@6Z\,0W7B M'6HQ$YCPBGJJCO7":SJUY\6/B;:Z:&=; 2F-$5C@(#DMCUQWI!8]:G^,%K;: M8=1ETZ5;4GY7/>I/ GQ5A\;Z[-806+0QQIN#&N.^/-Q9:3X=TGP_9HB?,&*H M,':!WJ[^SYX?-OH]YK4BX:X.R,D=A0%M+FC\?->.G>$H-.C?$E[(# M/AC%YV%%K:F5SZL1_P#7H'LCQOXG_%G4=3N[O0]-;R+-&,A_ RR> MP\ -+/&R>9*SG>,9&*\*\*:8WC#XB0Q;1MFN3*WTSFOIOQSJ]OX2\"WDL:I& MJQ>5$JC')&.U MCYJ\97\GC#XF7# _++.+9?]T&O:?%7Q&L_AWI&GZ/9PB>X M6)1CTP.M>0_"G0+CQ'XXAEV%H8"99G/8G.*3XNW4=QX[F@MSDP*(?J: >]CZ M.^'GBM_&/AP:I)$(W+E2HKK*XWX7:"?#_@6PMG&)9$$C_4UV1H$*>E1331V\ M3RS2!$499B< "EEE2")I)7"HHR6)P *\&^(_CG4_$ETVA^'H)GM%;;/+'GYO MQH T?B)X@U/Q-H=Y#HF\:="I\R8='%>1?"N/S?B+I*^CDUZOK6M1>'_A(VGI M9S1RO$%9B,IKRWQ7\6X+'6?[$T6(W M5\6VDKR :VOBMXFD\+^"KF>$XGG_ '49!P03W%>7_ /0$U'6K_7;U1-)%PA< M9^8]3SWH#H7_ !/\3_%'AR2UCN( DDA!*GTKU^RUV,>$X-:U K"OD"20FJ/B M3P#H_BB^ANM0C9FBP1@^E>3_ !W\43:?%:>%+ &&W6,/)M.-P' 'TZT@-C3_ M (D:UXV\2S6&@P!;6'DMZC-5 M$!QSC%?/GP9T5-=\=K=W./*M 9B3_>SD5('OWCKQ0W@_P1+J#,/M>P)$/5S7 M#?!?Q7XB\4:K?3:G.T]NBX#-V-<7\I_!715T M7P##<2KMENB96SV%,+:'/?'+QSJ.AS6VCZ;((Q-&7E8=>O%=-\'9KV3P"+[4 M,L\K%P3U8"O"?B!J;^+OB9<)$2R&86T7.0 #@U]3:#IL.E^&[+34PJ)"$XXR M<6U=@[;>F*\9 M^(_A:[\*^+9W)98II#)#(..^:]Z^#7B1_$7A11W_ E\*7'A/PA)>W;XFN(S,0>PQFO#?"MC)XS^),;N M"5FN#,V>> 1$/3C%"8Y'SUJ/B37?%GQ!1(;J1BU MUY<2KV7/-?2'BKQ=9^!_#*7-ZX:?RPL<8ZNV*\*^!.CG4O&S:C,N4MD8C_>- M5OC9KLVL>.&L1N\NT&Q%!ZL>_P!: 2UL=KX#O]?^(^I75]=SO#91MA<=#[5Q M7B+Q#JGA?XF2P6E](T,$R*5SQS7N7AJWM/!/PR@D<)&(K;S')X+,17SKX9T^ M[\>?$83^6S+-<^?*Q&0%SD"@5CZ<\4:O)I_P_O=3#B.46F]3_M$"OFCP!J^J M:A\0+2X>Z>23S-Y!;@UZE\>_$)TWPY::! <&XP7(/\*UC_ CP4DB3^)KY2(U MRL /&<=30(POC/XFU:X\01V$LQB@C7.V,]Z]8^!XO#\/XI;QW8R3,4W>G%> M>.=4/B?XAWC1 &-[CRH\?W0<5]8^%=.CTKPQIUG$ %2%E>9_' M#7#I/@.:WB,_M!6-S<^'+2:%&9(9/G(&<4A'D?PF\/P>( MO'EI;W2[H(?WK+ZD5]@(@C144850 .P%?+_ , )X8O&T>XU&[8".)2<="QJZU[;K((_-7>>, YKQO]H?4)(M!LK2, ML%D?+8/6D!QNFZYK?Q5^(:0I/-%IT;%@@/")FM7XXZ-8Z!H^EV]HS!GD.03R M1BMK]GK2;>VT'4-8?'FR/L+'LJUP?Q,U6\\=_$4:;8,9886\F$(,@'N33 ]9 M^!=U=77@#?=L2$E(1C_=%> _$#49-8\>:E(CF3,Y2,"OHIH(?AK\*)(FD)EC M@.3TRY%>)_"+PPWBOQF;NZ4M#;GSG+#(+$]#0-=S7\/_ ?\1:L=/O[NNZ==_;].M[L KY MJ!\>E %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ K$\7ML\*:B?^F+?RK;KE_B#,8/!>HL#@^410!\:3$-< M2G_;-%,/+,3U)HI%'WM1113)"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH \6_:*O OA_3+$$YEG+$#VZ5A?#7X23S65MK&J M*4$KJZ0G^Z.A->X:OX;TO79[:74;59VMSF/=T!K32)(T5$4*JC Z 4#N)#$ MD,2QH %48 'I6?XBOCIGA[4+U3AH8&,ECUK[.M65[6)E!"E1@'TQ7#^'OA'X=\/:Q_ M:4$;/("2@0\\UN8P,4 SYK_:*:8^*-.5@W MD"V^7TSN-;'PPUCP9%X&2SU9H3<*Q,B,.2:]6\7>!]*\8VR1:@K!H^%=3@BN M8TGX(^&],G$FZ>7!SAFX- CK_#6KZ9JUB3I47EV\? PFT5\M>*X99?BW?P7I MR6U$@D_W=W'Z8KZZLK"VTZV6WM85BB48"J*Y'Q-\,M#\2ZC_ &A+&8KOJ9$X MR?6@:.<^+/C.+0?!D&E:9(K7=X@B01G.U !G^8KF_@AX!F2[;Q)JD139D6RL M.CZ5\--'L+I;JZ!O)4 V>=R!791010Q".)%1!T51@"@$]#YB^.WB!]6 M\9+I4;DPV("[?]L]:]9\(Z9'X(^$IGV 3_96N)6Q@DD3_''Q M8FC^%3I4$P%U?':5!Y"5ZQVKSSQ+\)M*\4:N;^_N)F<_PYX ]J /%_@780WO MC^.650?L\3,N?7UKZAO;R'3[26ZN9%CBC4L23Z5QWAGX6Z-X6U0W]B\H?;MP M6XQ6_P")_#D7B?2'T^:>2*-NI0\F@&SY%\7:R/%'CF]U#),=Q< (3V4<#]!7 MUWX5LX=/\+:;:VZJ(X[=2-ON*X"U^ GARW96,]PS*'M%U)[V&-V9N-K'CK0"9\[?$SQ$_B/QM>7/F$PQMY40/8>U?1/@@KHWPF MMIX\#RK1I,^^*CO?@UX5O=4:_DMW#,\.:C]NMHV>0'*[SG%;_ (H\*:?XMTM;'44/EJV]=IZ&@&SP'X!6]I_PE,]U M.?WR)B+ ]:Z/]H;6T2'3M%B<@EC-(N>/:O3O"W@+1?"8;^SX3O/5FY-2>(/ M6@>)[Z*\U2T$LT0PISB@&]3C?@WHRZPT96ZNU:5RW=5!VUX%%(VN>/ MA-,K2-/>%F &>]?9D-A;06"V4<*K;A/+" <8KG-(^'/AS1M5DU"UL@)W).6Y M /M0!T>G@"QM]HP!&!5EF"J6) &230% & *;-$LT+Q/\ =88- CPCXE?$ MB36-9@\(Z'*56698IYU/7)Q@?G7J_A?PKI_A[28;>&!&EV@R2$=_";XBVWA1+FPN[=R)6W!E'.:^G)K:&X@:&6-7C M(P589%847@;PW%<>>FE0>9G.=M )E7PEXFN/$K33?9FBM0?D8C&:\'^/-E>) MX^6Y>-WADB41X&1QU_G7T_!;PVT0C@C6-!T"C%4M2T+3M5DBDO;5)GC/R%AG M% CY[\8>,+L?"C3-,2W:V\T"-^V15O\ 9Y\/K<:G>ZW,F1 HCB/OW-87QSUF MVO/%,6FV2HL5FFU@O W5[%\%=)72_ %LP.6N"9&^M &%^T!)J!\-6MO;12/ MSYE*C-<5\'-#UO\ TV2"%XDD3&6&,U](W5G;WL7E7,22IUVL,BBWL[>T39;P MI$OH@Q0,^-?$'AK65\67-G]DF>>24G(4D5].Z5:ZCI_PR6"1-M[':%0!U!Q7 M5M86KSB=K>,R_P!\KS4Y4$;2,@]J ;/CSP5H>JW7CFV+6&: M!7/G[XH7\WC/3;.VLM-D>[C(RVWD>M>C?"OP8_A+PF!,3]KN1YCC^Z<=*[:/ M3+*%]Z6T8;UVU: Q0!\B:MX-\0:I\0KV,6%PPDNB_FE3C&?6O=O&NBZB_P * M9=.MD+7*P!2B=2,5Z&(HPV[8N[UQ3BJD$$9!ZYH ^:O@]X3\0:?XKCO9]/DB MA"D%G&.U=M\>-*UG5M'LHM.MY)HE)>);3Q/XXT^TT.VMI+6U50)';@'%=W\/_A_9^"-+\I2LUY)S)+C]*[( M(J_=4#Z4[% CP'XG^!?$GBOQU$\4!-BH"J^> .]>NZ=H0TGP>NDV:JC);E ! M_>Q70%0:,"@#YA\._"3Q(?%'GW5N$A20MO)Z\U],6<)M[.&$]40*:FP*6@ J MCJNE6NL:?+97<8:*08.15ZB@#YYU3X-ZOX?US^T/#\S,@;2^#O!/B'0_#\VBF18X96)WJ>F:Z3P?\ #?2O"LTEV$$UXY), MAYP37;XI, 4 (!:PZG M>%K6#'[L'@XKMM.TRUTO3XK*TB6."-=H515M1P*6@#RK4_@GI>H>+3K)GVQ. MP=H<<$YKT^W@CMK>.&,82-0JCVJ7%&* %HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #7$?%*81>";P$_>7%= ML>E>=_&.0)X*G&<$XQ^="!;GRA(C*Y&T"BAXV9B2314&A]Z44459F%%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% "8%+154ZC:+?+9-/&+EAD1[N<4 6J*** #&.E%%% !28S03SQ2/(J#,=J,4M% "8HQ2TE !BEQ5"X MUG3[2;RI[N)']"PI\6J6,Z[H[N%A[.* +F*3'.:8DT+&YZ(.36AHFLVNO:7%J%F28),[2: -"D(R M"*6B@#SC4?@YX>U75I;^YWL\K;F^M=KH>D0:'ID5A;C;%$,**LWU];:=:/=7 M4JQPH,EF.*X6X^,?AB&3:)W*[L!\<&@#T.BJ>EZG;:OIT-]:/O@F7,?BEI?A"_6UNHY&=AG@50T?XSZ3K(<6]M,77JM 'IV:2O/[OXJ MZ?9V[32VDP53WXJ7P9\4--\9ZE/9V<$B-$NXECUH [O-'6O*/%?QIL-!UYM* MMX'FEC<)(W8$]J]-TR[^WZ=;W>W;YR!\'MF@"WBC%%% !114<%O#)O[) MU63=MYH [G-)G-?,G@_XB^,_$_BJVLA=[TMSX@?$/Q/X1UX69"E6 M7<,G&: /H"@BN)^&OC4>,O#GVIU"W$3;)$!SSCC^M4_B!\5-.\&1FWC N=0( MXB5L;?KQ0!Z"6"]6 ^II#-&#C>OYU\]^&]6\=?$743=1LUM8J>3G _\ KUWL M_A/Q':6DEQ'J9>1%)"\\\?6@#T83Q%@HD4L>V:DKP3X8:MXEU7X@SQ:G(XMX M5;*D=Z][H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** UYC\;6"^#FR<9.*]-/2O(_CNY/AV./=@9S0-'S9 MV8\FBFPD"/&.E%9E'WE1116A 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !GG%)N%175S#:6[SSNJ1H"69C@ 5XU)\5]7\3 M^(YM%\,6@,:MC[01^&: /:L^U+7SCXL\;^,?"7BNSL;F^$N65B@'7D<5]"17 M2MIZ74Q$8,8=LG[O&: ,[Q3XDLO"^@W&I7D@544A!W9O05Y-\*M-UCQ/XKN? M&6J/*MKDK;JV1N'M69XAO+OXM_$--%L78:'9/AW'0^IKT_7O%6A?#/P]:VTI MYC39# @Y8^I]* .W!SVHS7E.E>*_$OBCPQ?:Y;J+*U56,0/<"N<^%7Q7UG7/ M$R:/J[B83@^6^.010![U2$@&@=*9(ZQJSMT49- '.^,O&NF^#-+-W?/F0C]W M$#\SGVKY^N/'7C#XB>(EL=',L,;G&R,_=7/4US/Q \5W/BGQ;=7,DA:"*0I" MAZ #CI7O_P &O!L'A_PG#J$D7^GWJ^8[GJJGH*!VT*>C_".Z@5);_6;AYR/F MVL<5Y_\ %3PIK/A>6"YM+^Y>SG;R\!OXC7TC/>VMJ0)[B.,GIO8#-4;VUTG7 MXE@G\BY1'# @X- BOX0MKBS\'Z;!<,6F6W7<2>2<5X$UGXLO?C"77[2%6[W M C.P)FO8?B?XKF\&>$OM=G&AE9Q$@/:N-^#/B;4_%.LWT][&FR! "X'4GM0" M.^^).HR:7\/M4N(9O)G\H*CD]"2/_KUX)\'VU?7/B%:R27DTD4'[R7FWH13/BQ\4)_"$\&FZ:H-XZ^8Y8?=7/% MCUFDS[5XL_CSQ?;^";?7BD+?)G@#ZT" M-[(H!S7D\GQ>75?%*Z)H-NTQ+%6D*^G>LSQC\5-=\&^(;6TN;>-H)$#D'KMS M0![7GG%&:S-+UF+5- @U:('RY8?- _#->!WOQKUG4/%]O:VJ+#:+<"/ '+#. M*!GT?FC->8_$KXF_\(GIENMBBR7ER."?X:3X/^.=3\8VE_\ VB%+6[###WH M]0HH-% !29P:6JM]>0V%E<77Q?X]DD4%S>W>%_W2:^Q]'T^+ M2-(M;&%=L<,80?E0-GRKJ/B;Q7X#\4R6&[? M4H^'*[9%]&KYY^/4D87?Q-_M7Q4?#^@J7F0_/+V '6O+/&/Q \26'C9[6VU!BL,@7:O( M)]*!GU%FD+ '![]*YVX\3PZ+X)BUK5F\LBW#LIZLV.!^->4:%XP\6>.M1O-0 ML/W%A;'*CVH$>]9&,GB@MCKQ7R5>_$?Q7J_B**VCU"2-3.$5$/7FOI'7-6?0 M? DU]<-F>&T )/=]H_K0!\S?%;4&USXDWL,+%U5UAC .>>*^GO!.D?V'X0TZ MP)RR1 M]3UKYL^$VBMXJ^)"7=TOF10LUS*3Z]OUKZQ084#&/:@8ZD)XH-8.N M^+](T!0+N[02L=JQ Y8GZ4"/%?V@/%-W_:=OH5M*R0(F^7!^\>F/UKBO%5II MEOX.T*VL'6:\F4%]G)R>WUJK\3M4;6/%\UWL94887<,<5W/PPT+0[7PM-XJU M?_2?LN2L1YVD4T,]=^%VFWFD^ -,M;Y2LVS=M/4 \X-=E7!> OB-%XUDF6WL M6ACB. W;%=[2$%)GVI:I:E?)INFW-W+]R",N?RH ^9OCUJD-[XX%K"!_HT8# MMZDUWWP1\'6=OX5;6K^,-)<$E2W917A6IW%QXK\93RQKNFO;DA ?0GBO7?&; M^*?"7@NSTBVC.QD :2+J/RH&T>J_V7X8\56MS;10QRK&=CE1T-9'ASP+I?P[ MM-4U2%MS%&E>!_L\^'RU MQ?:Y*GRKB*(G\2:M?%_XD73:A'X9T.8QR,X6:5>#DG&*!L]&[S0_#5_JE]NB2Z!9(V[*!UIM"Z"_$[XOQ:/OTK1G$EV?E>0=$'^-7O M@7J&H:GH%[>:A,\KO-\I;TKP.YLV\4?$&6TM>3=7913TXSS7TCJNI:9\*O : MB%5$ZQXC3^^](#J]4\2Z7I$@CO+I$D/\&>:R/^%D>'A=PVSW(225MJ[N*\D^ M%7A^_P#'.LW/B/6IWEMT8JJLV+/A7>ZIX[L;FP!CL$VM(W]TBF+6YZ MYJFHQ6&BW6H,P\N*%I,^O'%?(OA^Q;QK\1XU8?)/<[W]ESWKW?XT:V- ^'OV M!7_?76V%?<#K7F?P-TJ6YUF\O@A$4*?ZR@?0]?\ $'Q/\.^#KF'27D,CQJ$Q M'@[0..:[73=1M]4TZ"^MG#0S*&4U\;:W;/K/Q N;:!BYGNB@)^M?5U@MOX,\ M#1"=L1V=ON8GN<4@-;5-:L=(A\R[G2// !/)KA/%'Q?TOP^8E6,N\G./:O(K M;Q-/X]^(7F:A.RV,9++&#@8%4_$%E<>-_'BV.DPMY*XC#8X [T[:%)(^G-)\ M06FJ^'8=9C1^$?@K;^'?$-OJTUT9I(&#J/>O7*0@KP;]HC7$%K8Z1'("S.7D4 M=@*]UDD$4;2,M>#O 6HV'@N"Q%X8/M";I M-I]:FT/X+Z'IFH1WUV3=SJ=WS],T#ZG+^"V/PS^%-[K-XA6]NFS&GU&!UKRG MPYI5]\1?'D<$\C.]Q(9)I#R%46CBV+QZFF![WH^D6NB:?#96<:QPQ*!P.OUJ^5R"#0*6D(S;/0[&PO MI+NWA5)9!AB!6E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 (:\3^/]P%TVWBRC6TIC>\):4C^X/_ *^: ML_ ;PW!IOA)M7(#7-\_4_P *KT_F:Q/V@O#FI7TNGZO:P/-!!$8W"#)!R3G' MXUA_#;XJW.@Z&F@MH\MRT3$QE.#SZT%=#V_5?!&@ZUK5OJM_9"6Z@(*L>AQ7 MGWQ;\873W$'@[0#NOKLA9C'U4>E:FH_$;4K'P?>ZK>:9);OM*P(1SN/2LCX0 M^$+FYN)/&6NYDOKDEH%<?$CXE1QRL[)=7(B1 ?NH#SC\ 37UKK-O)V\1S))"ZCZD5\M_#>,^&O MB;#-JUN\4?K0,]V\;W%EX+^%MW;0[45;8P1+T+,1BO%/@5HT MM_X[2^"MY5FA8MCC)Z5T/Q#N]9^)VNPZ/X>MFET^W.?,;Y59OL%6'3[>-% 18U Z8P*^7/BAX U#PWXBFO[.! MY+*=S*C(I.PYSSZ5ZKX$^+&EW/AR&'5)#%=6T05MPQN(%!4CB/V@KYD\3V%O M;W,BN+>,?'%[=01 M2S&1_+A"(3\HZ?S-?4W@30UT#P=IUALVLL89P1@[CS0#V/&OV@O$:76HVF@P M/D6X\R8#^\>F:]%^#?A^+0? 5K<,FV>\!FE8]1Z?I7SUXXN;O5?B1J#R0N9& MN=JH5.2 ?2OIE;F]M_AO+(MOYT&"1[:)_G%;PZG%XCB!>V:,12 #[F.]=[_9T'PG^&DKVR^;=(HWN!RS&J)\ M:Z7XF^%UT=0(%R82K1L.=W;% '.? [Q8FK6\OA;5%25(UWP!AUQVK4^.WBF; M0M'M=#T]Q ;M3OV<$(*XGX%:)=7'CAM0$;I;6\;#<5(!STJW^T+:71\46-VT M;_9C!M5\' /I0.QT?P!\(I:Z9/XCN5)EN3LASV4=3^>:\]^,FJ_\)'\2'@M? MG6W5+50.\-JJ1H@R0Y&>?SKC_A'\.[W5M:?Q1K MT+*@?S(UD'+N>2>?3B@1Z3?WI\&?!W?-B.:"Q$85O[Y& /UKYY^'&@7?B/QK M;+&A*1OYLSXX4=37JO[0^LF+1]-T=&(\Z7S) .Z@' _/%;7P.\-_V/X..HSP M[;J[8N2PYV]A0!P?Q]NK2#4]-TF"-#+;P[G;OSTKT;X(>'CHW@A;F12LUZWF M'/IVKP#QO=W>M_$;4#,KO(;G8B@$D*#P*^K_ S&UIX0L4$90Q6P^4C!SB@# M;\Q-V-PSZ4^ODQ/B#XID\>*L=_+M-X(Q%C(QNKZR7E1]*!"YKS'XW^(&T7P/ M);PMB6]?RA@\X[UZ7+(L,;R.V%4$D^@KY=^-/BMO$VOPVEFDC6EF#@[3RWK0 M-#?@1HG]I^.!>2)NBLD+9(XW=J^G+Z]AL+*:YG<)'$A=BW:O /@GKNG^&],O MVU!9(Y93P=AR<5)\0?%_B#QM.FB:%83Q6;-AI,'+_7VH \S\27]WXU\<7$UO M&TLMS+Y<2IR=H.!7KWC.63X;?""STBS)CN[YA&[]UR,G^5;WPL^%%K&?3Y-+DED= MLJZIR*]Q\':OK&M2SW5]:/;VQ \L-U- CQ[X^^))KK6K;P[ VVVMT#NHXRQX M _"NYT];?X=_!=KE"J7+VWF#=U=R.!7E_P 9-(OQ\1WN(K>1UE";"%)!.:U_ M'R>)=6\!Z:)K218HMH:-5.3CVH"QS?P=T0:[X^AFG7=';_O3]:]+_:"\0-:: M'9Z/$^UKIB[C/.T5D? GPYJMA?3WT]HT4+#&7&":Q?CCINKZC\0%6*VFE@,* M)#M4D ]Z ZG;_L_Z$MGX;N=5=/WMT^U3C^$5[&*XWX9Z3?Z-X0M;2]C$;!00 MHZBNS'2@&8GBS6#H'AJ^U(8+01DKGUKYF\!27'C/XI6UWJLHE!=I2LAX'H * M^EO&6AGQ%X7O=-5RK2I\I'K7RF_@_P 6^&=95[>RN%FC?"21*3D4!8]8^/OA M: :';:O9VZ1M#(!)L4#Y:\9\/:M?NB^'HI_+M+V4*XSZFO:3IOC3QWX?CT_4 M[?R;? #,W!->;ZS\)O%.@:DC6ENUPJMNC>/G% 'TIX0\*:?X3TF.RL8P#@%Y M.['%='7 _#>W\3C3TFU]RIV@!#UKOJ!!7F?QLUMM+\#2P12A9KAMF,\XKTMC MA217S]\0O!/C3QAKY981]D!RBEN!0-'+_ W0$U3QM]KE7='9)O\ 8MVKZBN; M.WO(O+N(ED7_ &ATKRKX1^ -8\'SW,NH+&/.&, ]*]<'2@;=QD<:Q1+&HPJC M %?+OQUUO^U?&XL8F!CM$$?MNKZF/2OGKQ1\']8UKQ]<7:/_ *)/-O9B.E!) MZ-X L8_#/PL@? W>0T[X]2*^:; '7O'ZM+*4::Z+%B>G-?7^G:)#9^'X]*D) M>,1>6WOQ7AFL? K6%\02W>D7"1PF3E-NX'A7P,TZ.^\>"\FP?LZ,RY[L>]=!^T7*YU32X\DQA22 M.Q-=C\-_A1+X1O'O+JYW2GH%KI/'W@&T\:Z>LGVNH6E_N^S3)+L^]M.<5XGI?P,U3392%U@+ 3RJYKUGPU MX;M_#FG?9XB7D;EY">2:"3Y[^.NNOK/C2+2X6WQVBA0H[NU>E:=IZ?#WX-32 ML5CNVMR[-WW,.E2W'P:L[SQJ_B"YO&<-*)3$1W%=IXH\,V_B?P]-I,[F..08 M!7M0,^6_A?#_ &C\0[.6?+GS/,;OSFO??C3)/'\/;LP \L%;'84SP-\)-.\' MW[7_ )S3W&,+GH!7;:WH]MKNDSZ==+F.5>?:@#YA^#^GZ5>:[.=3N5A C^3) MQFOH7PZWAJSN?L>DB)I0/FD503^=<)9? 2QMM0:;[=(L9/ 4XQ7HWASPAIGA MM/\ 1$9I".9'.33N!Y?^T)KOD:3::1&Y#R/O<9ZBIO@!X6%GI-QKL\6)KD[8 MRPZ+[5V?C'X:Z;XQU.WO+QW#1#H.AKK=/L(=,L(+.W0)%"H5548I"+=%%% ' M)?$3Q#;^'_"5Y+)*%FDC*1KGDY]*^6? NGIK?CFQCEY1I][9^N:^J?%?@:P\ M7/&-0=_*0?=6J.B_"GPUH5S'9_&7P7+XH\-I<6BDW=H2RJ/X@?_U5Y+\(O%__ ANOW-AJ4;1PS]6R"2DY+)QF@"5_'^@^4'2\5B1PM. MTO7;G6=15H8F2T'\1'!JG:?#'P]:2!UA=BIR-S5UUO;0VL2QPQA$48 H EH MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** ]*^=OC[<$ZK;1#L.:^B#TKYL^/;_\ %01@0B&X@22/.=K*"*ECC2)5CB5511@!>@J2B@!#TK(O_#&CZE+YMS91 MM)UW8YK8HH H:?H]AI<96SMTB!ZD#FK]%% !0:** *]U:6]["8KF)98SU5AF ML"[\ ^'+L '3XD]U&,UT]% &)IOA71=*8-::?#&X_CVC-;/I3J* ,B3PSHLV MH?;GTZ!KG.3(5&V%MJ-JUM=Q++$_56%8W_ A&@ ;5L(PAZJ!Q M71T4 4-.TFQTF(QV5M' IZA!C-0ZSH&G:_;"WU&V6:-3EK^JWJZ9I<]R5W>6A M(7U..!5^HIH8YT,)'9>A*@D5-10 @Z<4M%)0 'K3&AB*V4\X%?4%?*WQJ;/B^4 X- T>>A- MB@>U%2QJ=@R:*SN4?-=!TJX:WN]0BCE7JN.=;E\/>#=1U.+_6Q1?)[$\5\L^$8 M7\:?$*SCU:X9EN)[' K0LMN[>35-5ODE5PX@0.3VZ MT >ZT4T'/0\4$X[X^M #J*09H)]Z %HIN3Q2YR 1S0!2U35;+2+-KJ^N%@A' M&YO6L[0?%VD>))YX-,N/-,&-QKRC]HK5S'9:9I22$%R96 /X5H?L_:%-8^'; MO59E(^UN @/H* /9JJW^H6VF6KW5Y,L4"#EF[59) &2HFQT^^2>8*6(6K>O>(M,\.6@NM3N1!$3M&>I->& M_L\Z!(^HW^MR*?+C'E1D]SWKK?C3X3U#Q3;:>MA<1[HF.Z%WP#GC- 'IFCZS M9:[8)>V$HE@;HPK0KE/A[X:D\*>$+339F#3J"TA!R 373)-&[%5E1F'8-F@" M6BH9KB*W4-+(J _WCBGQN)$#*V5/(- #Z*:SJ@RS #U-0_;K7_GYB'U84 6* M*B%Q$6 616)Z8.:EH *YGQGXRM/!NG+>7<;.C' P:Z:O#_VC-0CCT?3+$-^\ MDD+D?[- &QI/QPTO5[R.TMK*8R,"3WJ[=_%RSM=W_$MN?E')8'%>??L_^%8[ MZ]N]=ND#I"/*B4CN>]>V26.A:A=26$D,$CX^9 !D56@'#^'?C-!XC\46VD6U MDV)20S>E>L"N!T'X7:3X?\62ZU: H3]R/LM;UYXST*POELIM1A6X9MOEYY!J M0.@HJO/>V]M:&ZEF1(%7<7)XQ65HWBS2->NIK;3KM9GB^]B@#=HJC?ZK9Z9& M'O+A(0WW=QY-,7 @C]^<4 ?17PR M\0:CXG\(QZKJ*;)9)& ]!7:#I7G]SXJT#X:>&M/T^[EVR) H$*#)SCFNA\) M^*['Q=I']H6!/EAMI!Z@T ;]%9NM:Y9:!8/>7\RQQKTR>37&-\6]*339-1:" M8VRG <+Q0!Z+17FWA'XOZ9XNU[^S+2WE1BI8,P[5K^._B!8>"+-)+I7>64X1 M%H [*BN!\&_$VP\3Z1<7\RFU6 G=N]!7)'X^6C^)AI\5H[6;2B,3_C0![714 M/VB/[)]H=]D>SS"Q[#&:\>U?XWEM?32M!L_M3^9L+'H: /9Z*\?\0?%V]\*7 M45MJU@1(ZAL)78^!?'=MXWLIKFWMY(5C;'S=Z .OHKC->^(.G:3JJ:5$_G7K MG&Q>=IKSGQ9\:=5T?6XK..V5$4@R'VH ]YHK.T'4QK&AVFH!=OGQA\5HT %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?)_Q<_?>+ MI\GHU?5[G"$^U?)'Q.F#^+KE2>=U)[#1R"C:H&:*0[P>!146*/NBBBBM" HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJKJ-['IVG7%W,<1PH78_2@"A MXHT5/$/AN^TN3I/$54_[7;]:^.-2L-2\'^(6@D#0W-L_R/TW"OK+P%XQ7QEI M5S=H%!AG,>!Z=JQ?BI\/K+Q1H=Q>QJL=_;Q,Z.!][ [T#)/AI\1+7QAIB6L[ M@7\:8D4_Q5UUXL.BZ)=RVZK"D<;R?\"Q7R%X O[O3?&FFO:$AWF6-@.XKZ.^ M,FM?V3\/KI-X6:Y(C49Y([T#:/#-+\>^,-2\56UM:ZA)(TMSM2(=",UTOQ1U MSQOH=Y:-"13_V?_"ZWNKW6OW$99+0>7#G^^?_ *U/_:!UB._U MO3M%MSYDL RX']YN@IW%8]4^&'B2Z\0?#^UU/4G_ 'J[U>0]PI(S^E>?Z]\1 M]2\4^.8- \,/B!&(DD_O<\U;UZ6;P!\"++30VR\G3:?4%R6/\ZK? 7P]!::/ M?^)[I06)*1LPSM502Q^IR/RI <_\1/&7B7PIK0TFVU-@?+!E/7%>J_"&[UB] M\#QWNLSM)),Y:,L.=E?.GB?4)/&WQ%E:,<7-R(4QZ9QFOI_7+B'P7\.9Y(R MMG:;$'JV,"@#YZ^)NK-XP^)[VEL2\44JVL8'?!Y_K7TC816'@WP?"LKB*ULH M S,QZG'-?.WP9T&3Q!X_&HS8,=F3.^>[-_\ KKN/VA/$LEKI]EH,) %P?-EP M3G [4 RMI'B[7_B5XSGM=-F:WTZ#)W+Q@>IKA_C!>7LGC :5+.TJ6RA%7/>O M5OA+86GA3X8RZY[-0![)\1M9N/ M#O@"]O+:41W"1A58C/->%?"3Q)J\_C@237,]PK(69"Q(KL?VA]?:*QL="0Y\ MW][(<\X'2E^ WA+[)IL_B6\3:9,B($<; .O\Z!G"_%/QGKMSXOGMOM4L,$ P MD:G&/\\5[_\ #*:\G\ :;-?.6G=,DMZ5\S^)&_X2KXHW2VX)6XO!&N/[H/-? M7&E6*:=HMM9C 6&$+GTXH#H?.7Q&^(VM:MXMETC2KB2*".;R5"=SG%:WC_0K MWPKX LKJ;4YOMTI4'YSU(R:X&9H]/^*4T_,T4-Z9"5YSSFNL^(6JZQ\3-:LK M'2K"X^S1=V7C)[F@5BS\$IM>UWQ-)++?S-9VJ ON8D$YZ5](5QGPW\$Q>"_# MB6IPUW+AYG]_2NSH 0G KY(^,/B0^(_'EQ'"=T%G_H\8'KGG]:^F_%NL1Z'X M8O[YW"^7$P7/=L<5\@^%K1]=\9V,4F6:>Y#R'KWS0-'J_A2[\2>"/AP[VVFL MQG)D#8SMXKHO@A;:A>0:CKFJ-(9IY<+OKU?[' U@+-XU,0385QQC%<]J/B;0 MO"C6VF1O$)I6"I#'C//K3N(ZH@8/O7RM\:]"FT/QHE]%(WEW(W(<]&'_ .NO MIY]3M(57SKB*-RNXJS,\BNJ^/>IRVO@800.<3R@.5/;- 'G^A7NI_%GXC2"2X=-/A)?8 M. $SQ7=\KSYGDSV%?-^JWJ^(?B1<7$A)CG MO2!_NAL#]!7U9K,KV/P]NGMEPR61" =OEQ0!\^^._$M]\1/'L6BV$C"T$XA1 M!W.<$UV?QDAL/#7@+3M%M519FPI"]3@OO0!V/[/'A]FN-1UR5<(NV&$D=3SG^E8OQ\UQ+_Q5#I\? M*VB?/]:]8^%(@TCX6VT[#:$#ROQUKP&VM9_B!\4"@SLN;K+'T0&@$>C_ Y\ M+FU^&.H:CJ!*1RQLZJ3C( KRWP%H1\1^.K.UCR(O.\QB.P!XKW?XRWT7AWX< M+IEH?+\W;$H7CY1UKA?V>K:(:_>7$B OY0"''2@$>Q_$.2:R^'FI_9BV];?8 M,=<8Q7@OP-L;2X\:-=WC+_H\;.H8_P 5>O?&/Q_F,.?RH^'/@_PF2=3M)([RZW;MS$$J?6L_]H:*XD\*V31H3$DQ+D?2 M@#S#X/?&TNI7EN\-BLNXAQC(!J'X1 MZ]X"[.K0[YFQMXSFOH#PUK5OK*M)90&.W[97&:.@&[:6\5I:Q6\"A8HU" MJ!T %34@ ' I:0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% #)>(G/L:^._B(XE\879ST=@XHI%'W#1115$A1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M "&N/^)YO&\ :E#8Q/+/,HC54'/-=C3616&&4$>AH ^:OAE>^)? -Q,;[1KD MV%UC.1]TCO7:^,OBN9- N+32]-N7NKE#&&*GY<\>G->NR6T,L>R2-67T(JL- M'TX,K"SAR#D'8*:L#/GWX1?#+4Y-=AUS5K9K>W@.Z-)!RY_I4'Q_\1I?^)K; M2(23'91YDVG(+-S7T5J%Y!IFGS7!6=X!^'>H:YXHF\4>)HSM\ MPO%&_.3GBO:;32K&.QMHTMH]D<8"C;TXJ\L:JH4* !V%.Z)ZGCWQ]T:_U'0K M"2S@>98I#O6,<^U5/ D.N1?!Z^T\64D,FV386&"<^U>V21K*I5PK*>Q&:%B5 M$V*JA>F .*0'R/\ #SPQK+^/+!I;"9%AEWLSI@<5[/\ '0:A-X$6"S@>17F7 MS1&,G KT]+>*,YCC13ZA:=)$DJE9$5U/9AF@#PC]G[2M2LGO[BXM'BAEP-SC M!.*A^/OAO4[[6-.U"RM7G3RVC.P9P:]\CACA3;$BHOHHQ0\,<@ =%8#H",T# M/"KNU\1W?P5&F"PDC=$"E1U9?3%+DU"2R=847;N<8Q7TP8E*[- MJ[,?=QQ38;:&W4B*)(P?[HQ0%SQW]H&SU*\T?38[.&66 2$R+&,\TGP'T'4] M-TZ\FNX&@CE<$!Q@D5[+)#',NV1%=1V89IR(L8PJA1Z 8H"Y\S_$;0M=\7?% M4VZV,P@RL:/C*A>YKW+4]-DTGP!<:;I:8>&T\N-5ZYQUKI/)3S/,VKO_ +V. M:<%'(P#GKF@#Y1^&_A#7I/&]M<2Z?,BPN6DDD&!G/6O>_B;X@/A[P)>S)*J7 M#Q^7'S@Y/'%=B(D3[B*OT&*^>OCK%J\_BC3XWCE?3,CA02N<]_PS0!Y'IVHZ MCI]TU]'"TC-RQ=<@^]>M> /C#;V^H0V6H6:QK,0HF0#@_E7HEJ/!O_",QJ]M M;+F##*5&[.*\*\.^";KQ#X],6GP2+I\=SO\ -*G"J#FF!]1?&.S\1:[8IIFDVC/!G+D?Q5YWX'\!>*M!UN+57 MT[YHCPC=Z^G]N1SC/TH"_3\J!IGD^KZA\1;^VD2SM$B# @;3S7+>#/A=XBO/ M%8U?Q*[CRCN7>=V37T%C%!&13N(\$UGX;^+]4\=2W"WCK8^9D-OX"^F*]0N/ M ^G7?AJ329UWO)%M:0C^+UKJ\48.:07/G[P]\$]=TCQ+]H%ZD=JK<,O!(_.O M7/$?@ZR\1>&6TBY7?A?E?#D&ZXO)+JY(Y9C75X/K2T >8_$'X6-XWURVOGO?)CC7:4QG/\ A7=Z M?HEKIN@QZ1;C;;QQ>4/IBM+%+0!X]HWP+LM,\4/JL][YL"R%XX@F,<^N:]7N M+**YTV6R8?NI(RF/8BK-% 'F?A[X.:3H6MR:B)7=FSA>@&:DU[X-:!KVN#4I M6EC/&Y%Z-BO2,4M &5!X?L;;03H\*%+4QF/ ZX-8'A+X9:)X0U*>_LP\D\H( M!?\ A!.>*[2B@#F?&/@K3?&>FI9W^Y0C;E=>HI?"_@K2/!]F$T^,[@N&=NIK MI,4,/E- 'S1XUOY?B7\3K7P^K"WM[=VCW=3[GM3?&/P/?P]HL^IVNI>:L*Y* MN,9_6O3]1^%=N?%8\0Z;(8K@MN(SCFK^L>#M5UW3VL;V]_\_**^D]9T6SUW39+&^C$D+]CVK)\'>"--\&Z>;>R0&1 MCEY2.373T"//+/X-^%K.Z\X0NV/X@%6J,T %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %;4'V:=< M-Z1M_*OC+Q( WB*\8'G>?YU]CZV_EZ+=N>T1KXOUR0MKETX/5SBCH!"LC*N, MT4(A90<44BC[EHHHIDA1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 &:,UQWBGXD:)X4E:&Y9I9QU2/DB ML#PY\;=!U_5XM/,4EJTAPC.>": /4**3<..:XKQ+\3M"\-:BFGRNT]TQ ,<1 MR1F@#MJ*\Z/Q=T:'5;>QO;>:W:L/ M#FE2ZCJ$H2&/\R?05YY_POSPMM.([@D=!CK0!ZO1FN?\(^+;+QCI/]H6*LL> M[:0WK5_6=9L]#L'N[V0)$@S]: -#-+FO))OCYX?AOA ;>8QY.9!TKTW2=5M- M;TR&_LY/,@E7U= MA0210 !5 '0<4N:X7Q)\4]!\+ZL;#4#(LF,_**D\,_$[1/%5\;33_->3U(H ML!VN:7-9>O:[:>'=*EU&^W"WB^\5&<5P*?'?PK)*D<27#,[;0,4 >I455T^^ MBU&T2YB!"N 0#UJU0 444UW"1LYZ*"30 I(%+7FI^-'AT:R--_>&4S"+<.G7 M%>E Y&: "BBB@ HHS10 56NK&VODV7,"2+_M#-6:* ,1/">C("!9H<]L- M*LM,399VZ0KWVCK5VC- "!K6W?[/YKS'"BL_X8_$ M2X\+[JYBMK2#$2[B0O2L.Y^-NO:5XB>UOX(F2&3:^WK0!]( M45GZ+JT&N:/:ZE;G]U.@<5H9H **,USOC?5+C1_"E[>6F?/5#LQV- '0AE;. M"#CTI:\+^!_B3Q!K>KWXU*266#&[YY % "YJ$W=NLHC,R!ST7=S65X MLU-])\,7]]$?GBB+"OF7P/J_B#Q3\1+(M>W# R^8ZAN%6@#ZUHI!QU^E+D4 M%%)D49% !VI:,BC- !111F@"A>ZSIVGOLNKR&)L9P[ &H(?$FDW&?*O8GP,\ M-7SQ\?[H#QC!%#,P819=5:MWX3>##J'@V[U&_EE_>!O(&XC&.]/06I[:FN6$ MMV+:.YC:4\[0:T@7)R-U?9>A7,MWH=E<3_ZV M2%6;ZXI#-"BD+*!DG HWKC.X4 +11D4TNH."P'UH =136D11EF 'N:4,&7<" M"/44 +3))4AC9Y&"JHR2>PH:5$ +, #TS7(?$G78-)\$W\OF+OD0HF#U- #$ M^)OA^;7$TFWN/,N6;;C'&:[0%]0E+2'IQ0!RVJ^$_#(^UZAJEM$RR#=(\IZ5\P:#I1U;XD)%H<$C6R7 MF]& /RH#WKK?C1-XIM=987LLJ:;,2L8C;Y6%=;^SW'82:/>R+"OVZ.3#N1SB M@9Z1XZU__A&?!VH:EGYT39&/1C7@GP;TJ3Q9\0[C5M3'GK;(9G+\C<>%KV'X MSV$U]\-KY+==SHZ2$#T%>8_ ;7=*T6'6C?3K#*RJP#=P,T$LS/CU=P?\)K!; MV^U)+> %C'QAJ]S^&=S/=_#O1IKEV:9X.6;J>:^5O$.H3^+_ !M<3IEFNI]D M?TS@5]?>&M+_ +&\-6.F$X:W@"-['% VCP3XU>*DUOQ=;>'ENC#8VIQ-(.06 M./Y8J30_@;8ZY"MQ:^($FA."=@R0*?\ $GX/ZC%/?Z_93?: [F5T[@5ROPG\ M47^C>,K&Q65S;7$HCD0G@4#L?2O@WPE9^#=%73K-VD7<69V[FKFMZ!9:_%'' M?*7B0Y*YP#6L#P,5YM\7-1\1Z=H+3:+Q"1MD9>JT"/&/B_I6@:7XD@L]"1=X M7]XB-NY]..]>Y?!_2[S2O -K'>A@[G>JMU -?/GPUNK2Y^)%A)K@-P)W*YDY MR_;]:^OT18XPB* H& !T H*?8?24M4M5ODTS2KN^D.$@B9S^ H)/ECXVWT5Y M\1+F*(?\>Z!&/OUKUCX&^#X]*\-)K,R_Z5>B65C'H\N(8U0\4Q[(9\:;^*R^'-XCD;IF"(">IKP M/X2>&1XC\=6\4J%K>U'GR'''; K<^,GCR?Q!J:Z.(&@@M&RZMU+5Z!\ ?#G] MG^'+C6)4Q+>N%4_[(S_C2#H>OPPQPQA(D"(!P!4;W]I$Y5[F)2.H+@5Y+\5/ MBVOAZ1]&TDB2^*XD=K XK*\8:JNC>$=4ORP!C@;;DXR<<5\\?![Q%J%O\1$L$F>6WNG8, M';. ,UWW[07B%;+PW:Z/&^);N3>P']Q?_P!= CRGX7:$WBKXB6S3(3#%(;B; M\.:^O, "O%_@'X;^P:%/K/_ (G7UWX@C\-^&6)E$@1Y1W- MSVJ74+.$D274*$=0S@8J:*6.9 \3JZGH5.17A_C[PGJ6E>!/MHFGN+]RIEVD M_*2.:Z/X2W=YI'PUDO==E=(H6:0-+U" 4 >G/*D0S(ZJ/-M=^)/CB#2M,D>WLO-XVG&4'>M3XUZ:OAW2],^Q7DJSR-@C<@ M#Z"#!E# Y!Z&LZ]US3-.E,=W>PQ,!G#N!7%_!G6[C6/A_%)=R,\L$K(SMW K MY\^)>LOJ7CG4GBN)&B638/FX% 'V!]NM?L?VOST^S[=WF9XQ]:IZ?XATG5I6 MBL;Z"=U&2L;AC^E?//B+5]>B^&MO%&[)8JBJ7Y^:N>^$6H75GXW@^SDDR(58 M9IM:@MKGU/JWB'2M$"_VC>Q0;N@9@":N6=Y;ZA:I3:LTWQ%^)UPMF&(N[C"9_A4 M&NB^+7@1/".E:9+'=,ZM^[*9[@#F@;1],V%];ZC:)!I1,S,(Y]JEO3%>K#IUI !Y-?+_ ,?]86_\9P:>C[ELX,-CU)S7TQ?W M:6-A<73](HRY_ 5\97TESXV\>2EW_"&/3_ G\-YM(6TZX@03W7$4IZ@^E4![UH]G!X.\&V]O,_[NR@^<_SKSBW M^.]GI-?-?PV\(3^+_$Z6L>5B MB4R2O_='3^M CWSPW\7K3Q'XN71;>U8!CC?VJE\5_B1:>'9!I'V4S3,-S GC M%:/@WX26'A#7CJRW)FD"D*I[9KPKXAZB?%GQ.N4B'RF<6Z?0'%(:/H+X3/!= M^#UU".V2%[B1B=H[55\7?%2RT75QHEA&;K4'^7"G(!]/K4NO7L7P[^%86 !) M([=8X\?\]".37E_P0\//XB\3WGB34_WJVY^4OSF1J8C1^*WCG4V\-0Z9-;FW MENQ\P)YQWJQ^SQX= M+W7I5&YF\F/([ /6 MO?O NAKX=\!6=FBXE$&]\=V(S0,XCX@_&1="U;^Q]'C\^Z1@LC=@>P%3:[X\ M\2^&O"\&LWMI'B50 C'!!->-Z/##??%__B9,!&+UFD+=, UV?QR\6VFL'3]$ MTN59XXVWN$]>@'ZT =K\.OBO>>--8DL9-/\ *5$W%QT%=9XL\>Z3X5:.WN)1 M)>2$!(4.6YKCOA=X>_X07P+=ZSJ<7EW,B&5MW7;C(%>.:)J$_BSXF1:A?[YE M:8RJIY^4'@4@L>L?$;XE:KH6C6;6JB*XN#D!AR%KL/A7XCOO$_A!+Z_'[W?M MR.]>8Z_X0U_XB>,8PUJ]MI=OA0S#M7N>@Z+:>']'@TVS0+#$N..Y]: L:E07 M=REI:RSR, L:%C^%3UP_Q4UY=!\#7TI8"2=?)C_&@#Y>\9:R?$GC2]OF&#XJ\906\BY@3,DAJ MI\0=&_L+QI>68.45@1]*8'5_#;X6ZGXEO;;5K\&*P5_,)<-O$GC_Q+.EN3!81'(8 XQG'-<[XW\;:_X9\>-8#4#);H M0&2O5/ACHMKX3^'T%S, KR1^?*V.>E?/EVL_C[XG2"W!<75UA?\ =!_PI@?5 MAURVM/"L>L7;A(A;K(Q)]A7C>A^+_$_Q#\73QV#^3IMNQ^8>F:=\=M:;2="T MKPS;2,O[I3*!W &*U?AC;0>#_A9=:S-A)IT9PQZ\ XH&>>_$'Q_K\/B&72[6 M^=8K<[3MZL:^AO#MS)IO@FRN=6E"/';AYF.C^"5T^V.U[HA#CLHH$<=J7C_6?'WCA-)\/&2.Q#8+CT!Y; MZ5SGQ?N-0L-0MM%GNG=(TW,,]378_ +2(M.T/4O$MS@+DJC'^ZHY_6O,?%VL M-XV^(KRQ\Q33K#'_ +N:$![C\"/#S:5X1>_E7$MX^1QSM%>L#I6=H5A'IFB6 MEG&H58HP,#UQ6C2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .-^)UR;?P1>D=QBOD0. M\ES)D]3VKZM^,$HC\#7&?XB!^AKY0@C_ -(;&0*;V MA>.:*<0!U-%96*/N* MBBBM"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH 0G )JO#=VUP[+%/&[+]X*P.*34XYYM+NH[8XF>-E0^^*^ M9M,\/?$CPUXAEN+6WN&S(Q8LY96&: /2?C]-;)X'6)]IG>9?+'>LW]GG29[7 M1;_4)5*QW,@">^*@;P5XH^(U[;S^)Y/LMK >(TXS^%>RZ5I5IHNG0V-E$L<$ M2X"@?K0.^A9GBCN('BE4-&ZX93T(KYA^,FC>'-"U"*+0PL=W,Q\](SVKW/QQ M/XB^RK::!"#),"&D/\->R)'M(B8C!!- 'L.HM&-+NC(1L\IL_E7RK\-M$;6?BO 8E)M;> MY>9B.P7/]:])L6^)&N>'$TVY@2W5EV/(PPQ'UKM?AWX"M_!>GNI*R7DQR\N. M?IF@#L6FBCD5&D0,>@)YJ/4?).G7/GA3%Y3%L],8KP[XL:9XS/BY;W17N3;! M1M6)SC\JLVE[\2M"39(P$] M[)MQ["O3Y&*1LP7<0,A?6OG7XK:+XL\6>(XWATNM;_P 4I=YTIQ%#,&9L]J^I[FW^V:=- V M09HBI^I&*!L^1-#LF\:?%**.4$K<799_]T'/]*]Z^+WB>/POX(>QM\"XNT\F M,>B]":\V\/>#O$'@CXBK??V>]S;([E2G<&NA\2>!_$7Q*\3075^OV'385PJ' MK0(P/@#X8DNMV4QQD]V/4US/Q7UMO%'Q$FABYBMV%K%CUSS7T[I' MA^T\.^&QIFG1JJ1Q$ @8+-CJ:^;M)^'7B.]\=--):.L271D,C]#SF@.I[G>/ M_P (5\)I6MCM>TL2R'_;VUXG\"K--2^(#W4YS)#&9!GU-?0^N^'QKWA&XT:Y M;F6'867CG%?-.CZ!XU\$^)O,T^RE,RMLW!?E84#1]82PQ3ILE0,IYP:\F^/> MM'2_!L.EV^%-[(%(']T)?X$&,U3^,?@VX\4>'$DL8] M]W:ME1W(H%U.7_9Z\.PQV%[K\@!E=C%$?[H[UQWQB\02^*_'R:38?O([4B"/ M;W<]37<> 4\2:/X,N-)BTQHKA@PC?I@FK?PW^$TFD:E)K?B'9/?ERT:=0">_ M- S%Y/'7C0139^S;C/<'_9STKWSXS: M9JNJ^"3::9&9&:8-(J]2!TJA\%O!%UX9TFXO-1B"7EU@;>X7TH!/0X[X\7%M MI5AI7AZS.U%7>Z^PZ5L_!'PC;:;X;?Q/=H#<3!C&6_A4=ZS_ !]\.?$?BWX@ M-=;,6)(4,3G:OM7KQT0V/@PZ-8@;HK;RDXQDXH%T/E/599/&7Q-DR 5N;L1G M_=!P?TKZ.^(6HQ^%/A?=+"VQQ;"WA^I&*\K\&?";Q%9^,XKV]C6.&*0ON_&O M5_B9X*N?&/A=+"UGVRQ,&&>C8H \I_9]T-;C6KW69?NVR[%^M1_&K6CXK\86 M7A_2U,S6WRMMY^=CS^5=/X0\%^+?"WA^YTVW6)9+DG=*IY%=)X#^%\'AR\EU M?4W^V:K,Q8N_(7WY[T ='X"\,KX4\)6>FK@N%WRGU8UTV*!THH$><_&;Q$FB M>"9X4<">['EJ.^*\=^!&CK?^-S>S$;;.,D ]R:]2\?\ PQU7QG?*[:FJ0J8#!Q0/H'QP\9V^G>&'T6"17NKWY7VG[JUYK M\%/"MUJGBV#5?+(L[0Y+D=37J9^"6F7U^+W5]0GNY*_M$:YN>PT1>W[]L?I76? [PS'H_A :C)&5N[XY8G^Z.E:GB MWX6:7XNUV'5+NXE5T4*4!X(%=M8V<.GV4-I H6*)0JB@1D^,]2?1_!^J7T9^ M>*W8K]<5\L?#("Z^(UA+/\Y,A<_6OKC5M-@U?2[C3[E MV;W*M(TEV'8?C7UCXMU\>'?!MSJ<:9,<>$![&J>D?#/PUHVK'4[:S!N,DJ6Y M"_2O./CIXBN3J5EX7@]>O?#=? M!=YK4=P&C:^8?()#W]JK7?P&TQO#Z7-I?R?:3")"7(QTKRGPOIUU#X^LK.$L M9(;H*7C] :+A8^I?B9;SW'P_U2"U!+F(@!1VKYI^&FNVGACQ3]HU*V9E*[ " M.AK[ ,:R0".4!U9<,#WKEW^''AA[_P"UMIJ&3.[CIFD!3T'QJ^O:G';Z=9%; M9?\ 6.1@5W%5K.PM=/B\NU@2)?\ 9'6K5 #6(523T%?-?QU\03:OK5OI=M&Y M@MQDX4\FOI4@$8(R*S)O#^DSW!GFL('D/=DS0!XY^SW:&V74&GA9)' VEACB MLKX^>&YSKMOJEI:LZR)MD9!7T%:Z;9V9+6UM'$3UV*!3[BTM[I-MQ"DB^C#- M [GDWP)U2Y/AY]+NH71H#F,LN.*X/XM^%]1A^((U%;>2:UF*,60<#!Y_G7TI M!9VUM_J((X\_W% I;BTM[I-D\*2+_M#.* /'?%NNW^J^#(-#T2UEWRPJC\=O M2M3X3?#4^%+5M0U)5:_F''^P#7I5OIUG;?ZJWC4CH=HXJW@>E CYR^//AO4K MCQ/!J%M;R30O$!E1G&*L:E:ZY>_!RWM1!(AB&2@&"17T#)#%, )8T<#IN4&D M:VA>$Q-$AC(P5QQ0,^8/@KHNHIXPCNVLI! G#.PKN_COX=U+5=/LKBR1YMAP MR**]@M+"ULE*VUO'"#U"#&:G>-)!AT5AZ,,T"/!/ NC^(A\-M0TDVKP@AF52 M.N:X3P'X.UIO&T)DL98Q#+EBR\=:^MU14&%4 >@%,2"*-RZ1(K'J0H!- "PK MLA12 " <4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ [TAI32=12 \O^-L^SPDL><9;/ MZ&OEZV=C,PR:^COCQ<,ND6\8[Y-?.MH@P9".IIR!%H 8Y%%2#I10,^X****! M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4FT'M2T4 )@ 8 I:** # I *6B@ I"H/44M% "!0.@I< 444 M-**W50?J*7 '04M% "8%+110 4A /44M% ";1Z48![4M% ";1Z4N*** &E%) MR5!/K2X%+10 F!2!%!R% /L*=10 4PQ1LP8HI([XI]% !BDP/2EHH :$4=% M^@I<"EHH 0J",$ CWH"@=!2T4 )@4N!0>** $(!HP*6B@!,"C I:* "BBB@ MP*3 ]**,T &!C&*,"EHH **3/O2T %&*3-1?:H!)L,J!_0F@"; I,"A2&&0< MBEH ,<8KD?%7P_TKQ7.EU=+LNHP L@'I7744 <1)X*OSIOV)=7?9C;GN!2^# M_AOI7A:XEN@HGNW/^L<9QSFNUP*6@ P**** "BBB@ HQ110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!HHI >(_'B94LK M<'WKP"T8LA!& .E>V_'J<-'OC'-XDNIX[+1I&CC_C&:EU_XU6&A@1R6(M:T^^TQ0I:0+<#MMSR: ZGIGAK6 M1X@T"UU,1F,3INVGM6M69#]A\.Z)%'+)'!:V\87). ,5#I/BG2-;NI;?3[M) MWC&6VF@#9H-9.L^)=)T Q#4KM(3+G8">3BKUK=P7MK'RENI M[C6_( LK7=)VYQTKYNT2.\^) M/Q3B>4LRRW'F-GD)&#G^5 'K-_<^)M.^'4GB>YOWBNO+$HB!X /_ .NNA^$7 MC6Y\8>'IGO,&XMG"LPSSFL;X[ZP-+\#0Z7$ INW$87/1%JI^S]"ECX)U/4)6 MVHTVYCCH%7)H Z7XG_$6'P;I1B@*OJ,PQ&F?N^YKC?"NG:GJO@2\\4ZK>3"= MD:2$;N-HZ&O+]:N;OXA_$@H"[>?<>7&HYVH#7N'Q6OH/"/PP72K+$7F(((P. M#CUH&9WP0\;WNOI=Z;?SM)-"-Z9_NU[,.E?.W[.>GE]4U74"3\B+$..M?1- M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHI#0!\V_'2;&KJ,YVUY2N&R0<*!7I7QH<3 M>)BK=!7FL'(.1P:4MRD3HORC#XHI0Z@8Q14CL?<-%%%60%%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "9 MKRGXQ_#Y_$]A_:EGC[7;)RISE@/3%2?$_P >3^&=*] BU*W9 M<-PP!Z&O _CSX>T[2-9M+VS"QRW*DR1@>_6NP_9U2<>&M3=R?),X" GVYH&R M;]H'6OLGAFUTR-]LES+S@\X%8_[/6C/#;:CKTQ81M^Z3)[#DG]:XSXV:X=6\ M?2VZ-F*U41J/0]Z]#N]:A\&?!6VM+3'VM[8_$K7;CQ?\17MX)6 M>&.06\"@\=>:^E8T3PU\/\2N%%I9$LQ/?;7S)\*-)_MOXA6)E.Y(G,[D_P!Z MO;OCIKPTKP$]E&P$M^XB _V1R?Y4 SQ#X?:?+XI^)=GN9S^_-PY). H K#_9ZTE!)?ZFZCU>Z> /B#<^-]5F2SMQ;V-J/F!'4'I MC\J8BG\>M5>Q\"?9(V*F[E5&QZ YQ7,?L\:"N;_7'QQ^YC]O6MS]H:T:;PI9 MS*K$13_-CMP:/ VH1>#O@X;QF19G5G SR2>E(JQYS\;-=?7O'K:=;N9(;0+" MJKS\YZUZ;=6A\#? 2XAQY=S);@,1_>?C^5>??"7P9<^+?%;^(M3C)M(Y3*2W M\;YSBO7/C)IUQ??#>]AM5),;HY4>@- ,\H_9^T47WBJYU.1=RVD?RD_WC3/C MYKQOO%L6EJY:&T3YE7^\:ZOX-7=AX<\ WVH7,BQS;_G!ZX^E<5X+\,7WQ#\> MS:Q?Q/\ 9/.\V1F& W/ H ]:^"?AZ71? \<\R!9KQ_-/'.WMFO3!TJ*"%+>% M(HD"QH JJ.@%2T""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "D8X4GVI:;)_JV^AH ^4/ MC#/YOBB4J>G%<- N0,'M78?%/!\3SN#D!JXZ(E^1\O%3(I%H1KCDFBD'3DT4 MAGW%1115D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110!X9\4/ASXF\8^+OM=L(Q:11A8R36OI-SXW\)Z0 MEE=6JW@1<(RKG%>N4F,CD#%,#YRUCP7XQ^(OB2.YU.+[/:K@K>-[N91BUN)B_G'L":]&\3? M#<3> &TJR/F7JHO[QSG.!VKT['/:EI >&_";X8:QX=UQ]4U!T50NT(!UK8^, MG@+5_&+Z>^FD,L.04/3GO7K0X[8HH'<\[^%_@2Y\(:.T5](&EJ*!&7I>D"QT2/3I7,@6/86/TQ7@FL_ W7HM=E MNM)ND6)G+H>A7FOH^B@=SRWP=\/-6LIC<:YJ,LV#E4+5ZBBA$51T P*6B@0F M.UM,LSGYW/4XZ5U5% &?JVD6>MZ?)97T(DA?J".E<9)\)].F@6UENIFM%; M*Q;N,>E>AT4 4=+TJST:QCL[&!(8(Q@!1UJS-!')[A W_+0US$2- M&,'\*Z;Q^H;Q=/Z!SFN;C82.W^S4LI$H/%%* /2BD,^XZ***L@**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH ***J:E=FQL)[E8S(8U+;1[4 6Z*\*D_:$BBN6B?3R-LFT_3->Q MZ%K%MKVCV^I6C;H9T##VH TJ*R/$VLKX?\/W>J-'O\A-VWUKE/ 'Q';QLSE= M.:)%."] 'H5%(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HJ.61(D,DC!449+$\"O.O$GQC\/Z),;>VE-Y=9V[(^0* /2:*\HM_'' MBW4XO.M-&*QGEE%O=V"QR/PN10![O165X=OYM3\/6-[<*%E MFB#D5JT %%%% !1110 4444 %%%% !1110!#<7,5K"TTSA$49)-+!-'<0K+$ MP97&0:\=^/%SK2:=:V^G^;Y#M\_EBNK^$EKJ5IX%M4U02B8G($G4"@#O***0 MD#J: %HHHH *S-3UW3M(C9[RZ2+:,X8UI')'!QQ7EWCKX?PZAIVH:I>:A()% MC9@"> ,4 =AI'C31-+]%=E7[8@+ M=,U\YP:IJGQ6^)D-N\\@LDD+*@Z+&#R/QKHOCPEMHL>DVNG_ +F7&6V]< 4 M?0JL&4%>:HZKK-EHMK]IOITACSC+'K6+X(U9[CX>Z;J=\_/V8/(Q]A7@7B_Q M1>?$WQ]:Z58;OL$.YA2:)@R. M,@BO#OC18V'ASP#I^GVJ*DSR*O'4X'-=7\&]4DF^&<5S=R%A 6&3Z"@#KO$/ MBO2?#$<;ZE=)%YGW5)Y-8[_$O0H+=+F6;9 _ >OGW4-0N_B7\4T5]S0//L1. MPC4UWOQWL-/TCPMI-E;HL;[\ #N !0![A8WUMJ5E'=6L@DAD&5855UO7;'P_ MIS7M_*(XE]>IKSG]G^[FN?!$\A^'_$%CXDTM+^PD#QM^E?.GQ6^&-CX-TFUOK*0E7? M8^>IKMOV=$E'AW47;.PS +^5 'M5%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %17!Q;RGT0_RJ7O5>]XLI_P#<- 'Q[XUFW>*[PG^^:P8D&2>F:V_&(!\1 MW9/_ #T-8J-D#%0]2R3-%(.E%.P'W)1115$!1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6)XK MU.#1O#&I7\YPD5N^!GJ2,"MNO(OC?J4EU;:7X5M6Q/J=PH//1$ZMX0U: MVT"'Q+<1,+:ZO?L_^*GGM)_#]PX(A^>'UQZ5Z)K'A&.^^'3>'CM9D MM@J''\0%?+_A'5KGP;XW@DD+1F*;RIEZ9&:!WT/ICXM:C]@^'U\%4-)&O!EC;%0)Y$$DAQR2:Y7Q9>Q>-_&6@:#:RB2T3_3)RIR#C& :Z MGX@>-+7P+X;\\C-Q(/*MX_4XH$=1<:C9V;!)YT0GL36>OB[0FNUM1J,(F8X" M%L&O$OA3:ZKX\\176MZO>RO:0-Q$2<$GL*YKXS^3IGQ(V:8?)\J*,D(>C4: M?59(V[PPQC.<\5DKXHT5KP6HU* SEMNP-SFLB#4)(_A4+^ZE(D732[.3SG:: M^3M'N-2NO$]O+9&6:[>;<@!)).: /LP^(=+755TTWL1NV_Y9@\UI,RH"S,%7 MN2<5\\^$/ ?BR3XCQ:OK*/''&Q=W9NM6/B1\0K_7O$T?A3PY*P7S!')+&>2V M>1^% 'M=UXDTBR#FXOHDV?>R>E6M/U*SU6U%S97"3PDX#(9>*/A^;?X: MW,4)ENM36$'=U+'N*G^"FCZIHG@N?^U0\6^4ND;]4 H [J^\3:/IMQY%U?PQ MR?W2W-17WBW1-/:W6XOXU-P<1\]:^0?%.H7&I^-=0F2:20O=L(_F)_BX%=H/ M GBW6=9TAYX9#;90@D_< ZT ?4BL&4,IRI&0:H3ZWIUM*TJAN:T+R\M["UDN+F9(8D&6=S@5\D^"KJX7XMVJ64S MB.2^=?E/5,FO6?VAK^]@\+6-O;>8L$T^9F7I@#@&@9Z+9>-- O\ S3;ZA&RQ M??;/ K1TW6-/U=7>PNHYUC.&*'H:^?O@C_9&IZ;J6C7KC[5<\)NZUZUX3\(K MX)T'4DCD,C2L\H[X]!0!H:EX^\-Z3>_8[O4HQ/G&U><'TI\7C;0Y;N&UCO \ MLQPHKY(BOUE\<_;-49GC-XQEW>[&OH^R\ Z7JNN:=XDTZ<"V50P5.C&@=CTL M=*:W'-*. !5/5IC;Z3=S X*1,<_A0(\"^,7Q0NIKVX\.:5+Y<,9Q-*C8)/ID M4OP4^'-MJJ/XAUB$RH&_^6K[3\/Z;%I. M@V-E$JHL42KA1[4#:L:,<44482-%1!P @P!7%>/_ #!XP>PD^5)() 6;'4> M]9'Q*^*4_@:^AM(;#SFE3<&)XJ'X;?%#4?&^HSP2Z<(XHP,NO:@1Z=;PQ65E M%"H5(XD"C' K&U'QEH^G6=QN2,TT@/7/!?Q-TGQI=RVMHKI*@W8;TKJ-6U MFQT6R:ZO[A((A_>/)KQGX&^%I]$L;SQ-J<30H\9,8<8.WN:X;QAXLU#XD^-8 MM-LW9; SB&%%/##/WC^%(#W";XHV'V62Y@M)Y;9 290O!JYX&^(FF^-1/':@ MQS0]48\D5G>*[*Q\(_"2]M0B#R[41*<M/Q3X>_X0_P"#FI:?IKME(OF= M>IYYKSK]G[3K6XUZ^U&Y9%:UCRFXXP3U- '<>*/C'=^$[^.PU#2?WI0,2&KK M? 7C8^,M(DOOL3PHN<$GK7SY\2+Z?QQ\3YH--1IPC+;Q^6,].I_G7O<-O;_# M[X7287:]O;;F/5^)?BYJ=[XM_LR"RB:**X\H*1G/.*]_:^BL-)%U>L MD*11!I"3@+Q7R]\)=(/BGXCK>7*[HX7:XDSW/:NX_: \4M%#9^'K69@\G[V? M:<<=@:0S=TCXC:GXR\275KH402RM<[I6&=P]:X7Q/\:/$,.NOI]DL2K!*(V8 M@DN:[;XE?2O\J\*_:%TC3(=*LM05$CO6FVD@?>�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�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�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�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�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end GRAPHIC 12 ex10-23_002.jpg begin 644 ex10-23_002.jpg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�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� ^BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3/UH 6BH7N(D8!Y% M!/09J84 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 44F1D@=J6@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBD.<<4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ***3F@!:**0G'>@!:*J7&HVMHFZXGCC'^TPKB]?^)UO MI]W]BTO3[G4;HC@1(2*:38'?9JA?:SIVFC-[?008[.X!_*N)C/CWQ+ DG[C1 M;=_O!\F3'TQ5^U^&VG&9+C59YM1G4[M\O'-%EU U+?Q=9ZEQI*2WIZ;D7" ^ MY-);)X@U*21KQHK&W(*JD9W-]236Y:6-K8PB&U@CAC_NH,"K% %*STR"V@1& MS*Z\EWY)-7:**0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 1K'L=FW$EJDHQ10 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%)SSF@!:*** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **,T4 %%%% !1110 4449H **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH ***,T %%%% !1110 4444 %%%% !1110 4 M44A.* %HIH;-+F@!:*0GCIS1F@!:*3-&>* %HHHH **3-&?:@!:*3- 8'IT] M: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDS[4F[VQ0 ZD[ MU%+:A;6$1E MNIDB7_::N,N]:\6:PS)HEE';Q@?,\_!!J&Q^'VHWTGVCQ#JYN6?DPHIVK^.: M?*NK$/O_ (M:+!));V<AM+89R5EX&LU\N6^D:XF!W-D_*3720:=: M6V##;QH0,9"C-6<&V\F>67>6\SL>U %BBBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "FD\<#FG4E "<@KS[QE\4]-\,7RZ7;0OJ&J/TMXAG'I^/M0!Z#F@D#K7E$'B+XIWZ+>VWA MRWBMR,B*9PKG\#S63??&[4]+Q8:GH$EIJ>\ !^%(SR: /;=W% .:X'Q]XGU_ M1O#$&JZ!8QSK+&)99"?N*0"./QK)^#?C'6?%UKJTVK2K)Y4J!,#IG.: /5:* M** "BC-% !11FC- !249%0W?G?9)?LQ7SMIV;NF>U B7G5\YWGBOQO:?$ M^PTK6;PQA;A"88""I4GC.*^BPF:4G R:\0T_PEXX\?01: MEK6MMIUK+\R6\6=V.U6-4\)>.?!-B][H&OS:A;0J7>WG/) ZX]: L>SY%+7E M?P7\37_B/3M4DU.Z,UTER24/&Q3TX_.O4R10#%HHS2;A0 M%)D4;A0 $XJG_ M &OIHO/L9OK<7.<>3YB[L_3-6RP) !%>)7GPJ\02?%8:U%.!I\EQ]H:8.,K_ M +..M )'MVX4N:C^Z!G/UK \/>+K7Q#JVJV-O#(IL)!&SMT?Z4 ='129HW#G MVH 6L35_%V@Z#QJ6IP0/G&PMEL_05M9%?-GQS\-VNC^(+34+??NO2S2AVR,^ MPH&M3Z0BE2>))8F#1N RL.A!J2LSP]'Y?AO3$&?EMHQSU^Z*TZ!&=>Z_I&FW M*VU[J5K;S,-P264*2/QJ:SU2QU!6:SNX;@+][RI V/KBN'^*_A'3]<\,WNH2 M0J+VUA+I-WP.U>)_"#Q1+X?\906\SM]EO<1..V3T- TM#ZOSFD)P*12.1Z42 M$*A9C@#DGTH$4=1UO3=)5&U"]AME,99$ MSQ^.*^:?BQXHD\3>+9Q%(38V>8H0#P3W-?0/P]T'3M*\*Z;/;V445Q+;(99% M'S,<<\T#:T.PHI-P]: P(R#D4"%HI-PQG-&10!0UG6[#0-/>^U&<0P+QN(SS M7,^$/B7I'C36+G3]-AN@8(C*9)44*P# <8)/>NGU:PMM4TZ6UNH5EA=3E7'? M%>%_ V)(/B)X@AC_ -7%!(B^P$JT#2/H,=**0L!P:,B@0M%)D9H# ]#F@!:3 M-1SW$5O"\LT@CC09+,< 5YWX$\7S^*O&_B1EN =/M2D5O'GKC.6H ])HI,C& M<\4P31%MHD4GTS0!)12!@>AS]*6@ J*=W2)WC3>X4[5SC)]*EIKVU7PE-;-R8V>XX<#\*Z;P1XWUGQ;*)9?#;6.GLFY;AY]VX\8 &/\ M.*X3]H50'T5L'?\ ,,]NU>M^#T*^$=*& I^S+G;TH*:T-OZ]JRO$5YJECI$M MQI%BMY>#[L3/M%:U)C/)H)/"[GXW^(+;56TJ7PY$+]9/*\GS.=W'M[UZGX3O M/$5]8/-XAL(+*1B#''')N('^U[UXGK4*R?M'K$H 4SQ'Z_NP37T;VH&T.I"P M%+7%_$OQ,WA?PC=741_?R?NHO8GO0(Q_&?Q5ATC4_P"P] M7U/66./+491/J M:J0-\7+B#[9C2X\C<+9B0?IZ?K63\"?#ZSVM]XENQYUS-,8T=^2. 3_.O:L= M<#K0,\,UKXM>+]!N8=.U70X;6[=U42$Y5AGG&*]OM93-:Q2G WHK8'N,UP?Q M<\)2^)/"QELX#)?6A\R/:/F..PKK?#7VD^&M--W&R7'V:/S%88(;:,@T ]4: MU%%% @HHHH **** "BBB@ HHHH **3-&0* %HIK.J#+,%'J:Q=3\6:-IA$)?$<0;5;H6D+X)A4_-BK5+2\G85S8U7XA>&]*E\F748GE/1$.>:QCXYO\ M55"Z+8RROZ[,*?Q-6](^%7AG29_/^RM*)VN/$&LRVULQ^2UA.2!Z,>*[;2_".C:5;PQ06:$Q#AV M&3GUK= XQ2U+G(=AH7'IBE Q2T4@"BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH ***.] '*_$+Q+_P (KX/O-17_ %VW9$/] MH]*\Q^!7AI=3FOO%>IQBXN'DQ"\@S@GEC_*M#]HJ:1/#FDPJY5)+ARP]< 5U M'P8C$?PVL" !O9V/YT[:%6TN=Z0>>N*\T^,OA%=>\*/?P6P>^LOG5P/F*#J* M].II&1BD2<4D\DWPA1WC:.7^RE#(PY!" '^5E8YP/I MUIC1]"V/C?PSJ5ZEG9:W9SW#G"QI)R:W2X R2,>M?,OQ-\!6OP]N-+U;0I;A M$\T!B[Y8,.>*]LU*_O\ 5OAB^H6*D7MU8+*BKU!9<\4@L2ZK\1?"ND3O#H0W! RRJWS+]17F/PD\&V=KX6NM4\26"&ZGF M;+7HP0@ ZYZK:_I>AV[3ZC> MPP1KC[[ ')Z5F3^/?#5MI-MJ(5>9;Q M&5"-Q*-SZ5S_ (+^%@\;>!(+N_U&>$C_V.I6>I:?'? M6=Q'+:R+N613QBN2UCXK^$M(O#:RZ@TLH.UO(3>%/N:X;QG-=_#CX<:9X4T^ M]+WUU*5,P7^ GD ?B/RKM?!7P_T/1_#T"W%C%M K'DOB3 M5]/U[XVZ5?Z;XCD5.RY/2O7?B_INK:MX'>UT=9))FF7>_ Z2./X@:K%:R'[(\;%1VQGB@FQZ[XC^(WAOPS* M;>^O@;A3AH8AN=?J*@U[XF>&O#MO;2WET6:XC$R1QKN?81P2*\K^._AG3[+5 M;'4;2(Q7-](WGON)W$GKBO0?#/PQ\/)H=I<:E:"_O9K=/,FF). 5X 'L,4%6 MTN=+X5\:Z+XPM'GTJYW%#AXW&UU]\>E=%7S?X%L6\+_'F;1K>4_9BTJL@/&- MA(%?1X.10)JQ%!O\EB,_6F5%:,^FHUVJ !@ 8 ]!3F4,A4C. M1C%*#2TB#S_P5X0O/#'C#Q'_.?YT_P 8?$W3_"]ZFGPP27^H MN<""(_=^M=[G%>/6_@FXTGXIW_B_6KJVBTQ.F#0!+%\:TLM1@L]>T M.XTXS$8=N@![UWNM>*]+T'04UF[E=[-P"CQIN+ ]*\/^,GC70_$ME:6VFQM/ M)#*':X*;?E] >]>N^#X(=1^&6E0WD2SI]A0;9 ".$H'8Y[2OCCX?U"ZO%EBD MM[:"/>DKG)D/H!ZUD1_M#:8=0$;Z1<+ 6P)"W;UKA/AGX6TS7?B-J%I?0F6V MMR[K'T7[QKUOXA?#G1]8\)3FQL8;:[M8S)"T:8R!U!_"@.IV<'B"RN]!.L6T MOGVI3>/+.3]*\YTOXV1:QXOM=%M]*=(I9?+,DA^8?A65\ -5G>VU/1IV\R* M!U4]N<$5B:Y:1:?^T7;101K'&98GVJ, 90&@&K,]*^)_B'Q-HVFO'H>DM/"\ M),MV.?*]>/I7DWPL\0^*+(:C+HVC'5'FD!N).X)KZ$\48;PGJN1G_1)/_037 MD_[.RYT_6F/_ #V3C\Z"EL=WXR\?0>#]"MKJ[MM]Y<@!+<'^+'?VKD;CQM\1 M;?05U]M LEL"-YB&=X3L36_\2/ 5OXJEL=0EU1;%;(Y=G *E>M9&O_$JUN-, MNM*\/Z3+L">F*\Y_: M)A;S=#GZJI88]34O[/0(AUPX/WX_ZTG[0Y^70P5.N>0X]:C^)?B1?#W@ZY:-Q]KN_P#1[=>Y M9N,X]J\G^"VKW/A[QA?^%[QOD9V49XPZGD_C75:E"?'GQ?BLP=VF:"@>4@Y5 MY#T'U_PH$UJ>=?$GPO%X9\*>'(T1!<2H[W#XY9C@U]$>$C_Q2.ED_P#/JG\J M\G_:("?8='0<,'; SVQZ5ZOX20KX2TI(]0; M28KG5-=U63>UM&P(3)/!QTYKSOXIR^+[Z.PU+Q%;165L7*P01G)!/K2!*[/< M_$NKZ[%X8CU+PY9P74[QB0B0]!CL*\;\,_%;QCJ4^HV\,,E_>SC]Q&@XA->X MZ#\O@JR4G/\ H@Y/^[7COP!C5]9UR4H"ZJNUB.F27^M6O MB03GRP#^^7&UN<@5SWP4Q_PLCQ,?2.3 /3_6K7N\H2."5PJ@;23CBODK3=:U MK1]6\37&B1!O.22.>0*2T49<9(]^E DKGJ/CG4M?\2^/;?1O!^MW<0B3;=&W ME*I&<]\=Z]*\,:#<^'[%A?ZS?:E.RC?)=3,X&/3/2N2^"U[H=[X4!L(HXM15 MB+K)/K7>:[*T&@7\B$@K Y!'TH%8\QFUK7OB'XJO-)T;4'TS1K%ME MQ/$V'<^@-JJ=2O;+[*$&;9]I?EN3^5>^:-X:L/"GA6 M32[!G:&-'^:1LG)%>6_L^(%U'Q'CLR#]6H&MC<^*WB*Z\'>$=/T>QNYQ<7!$ M7VEFRVT=>:I)\(+>70X[_2O$-\+\Q>8LHE^5CC/:NU^(G@:#QQH/VR?RKR']HNX?J*]?\ "XV^ M&-,7TMD_E3Z%/8UZ3(H-4-/U>QU.:[CM)A(]I*89L#[K#M2)/ M4?/[2"D=1 M<1C_ ,AU]&5\Z:M\G[1Z87.9XS_XY7T7394N@M>)?M$RD:/I,:DX:9BP_ 5[ M!J>I6ND:=/?7DJQ6\*EF9J\N^,M@GB;P#9:WI^9(HMLZG&,QL 0<4A+1_2N\%>1_ C7%O?"T^FM-N>UN"R(>R,.@_'->N+D*,]: M >X&A>_K45S/#;6[SW$BQPH"SNQP /6FV-Y!J%G'=VL@D@E&Y''0B@18HHHH M **** "BBB@ HHJ"XNX+9&>:5$51DY-%K[ 3TTD=ZX?6?B9I>G!EM5:ZE'&% M%<^;SQGXJG62T2>RA(^4E@JX]^,UO&A)ZO1";/1[W7-.L(V:>[C4+U^;D5QV MH?$N,R&+2[.6Y)X4AB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC-% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%!H \I^/>CMJ'@J&]0$M93;R!Z-P?Y5%\ ]=6_\(3Z8Q_>V,O&?[K< MC^5>GZE86^IZ?-9W:!X)5*LIKYSUCPWXB^$WBPZKHB2S:=(F2RQP1/+*ZI&@RS,< #W->2Z;\>M!N;\L/\ [/7:>+;NP\"^ #IMM;R-N@,$"1H6R<(;;PO\)-*U6ZRT<.GP MX4?Q,4&!7G7QP\0+JX@T.SM+F26VE#O*(R5-:<#R_$'X/_V!902V^H6$$2LD MR%0^P8X_*GT E\-:-K7Q/C_MWQ%?S6^D2.?LUE"V Z@XY_$&N0U_1M-T+XZ: M19:9 (;<20DJ/[V3G^E+X&\?^+= T\>&;;16NI8Y"L)D4@1Y))_4FL_Q+I?C M#3?B%8:OJ-B]U>221S1+$"R9SPI/M_6A CUGXW\_#2ZQ_P ]D_\ 0A6A\'B6 M^&.DGV?_ -#-+]#N' %M&@93[AAFO<]%NX]0T:S MNHR"DL*GCZ5S'Q-\#)XV\.K#$0E];DR0/Z\W MO7C^L^&_B#<^/+?6)--D>\W+(D@7Y$^M=W\2_!WB+Q+X$TRXG5)M:LN7-D-KSQ1DI,W=A[$UZ9X1UOQ!%X$/V[P]< H -(;V/. M]/S_ ,-.S9_YZR?^B6KZ"%?,:Z9X^C\?MXLB\-W0G:7>8BF0 1C%?26FSS7. MGP3W$#03.@+QL.5/I0)DUS$)[>2)ONNI4_B*^5K5C\.OC&HF;;!'<$,?^F;# MC^=?5IKAOB-\.;+QQ8(05@U"'_53[<\>A]NE )G9VUQ%=V\=Q"X>.10RD>E3 M'C.*\ TJU^*O@&9+2WM)-7L%X5%RZX^HY%;\S?%'Q>%C^RQZ#:,<2?-A\=^O M- CM[/QMI^H^*[W0;1)99;),S3A?D5NZY]:\HTF:3XI?$^_L]3NG33-/#.EJ MIXDVL%_K7K_A?PG8>%M(^Q6R[G;YIIC]Z1CU->.ZK\)/&6D^,I]5\,7";)': M19/.$97=U% &Y\;=.TG2? ]M;VMO#!-YRB((@R1]:[;X<2"X^&^EX()^S;"1 M[#%>>:Q\(/$&N>'6O-4U:6[U[&0C290>U='\,?!&N>&;!I=8OY00K+'9J^47 MWICZ6.+^#JF+XN:_">JK,/\ Q\5[9XKNTL/"NJW,C!%2TD^8GOM(%?./A'3= M:]!U/PU\2?&2QZ7KD]K::;N'GF$C,@%('H0_L M_P"F.MIJFLN.)W\I#ZC.:Q_%+!OVC;;UWP?^BUKVG3-#30/#B:7I 1##&1$7 M'&[U->.:C\(_&NI>(#K=QJMHU\9-X9?X<=*8;GLWB?H:]7L+&]G\-+I^N21S7,D1CF:/@$5Y'%\#=3L];E^PZY MY&G3,1(JDAMAZC\J 1!\:M=N)_$^G:!]J:WTV55:5E. V3WKT^[@T7PAX(N1 M$(+:S6V8;O[[,O\ 4U@^/?A7;^*=-L4LIQ!>6<8B1W_B0=C63X>^"QC7=XFU M.2_55VI K':M(+F5^S_=01IK(DN$4LZD*33OVA9$*Z(OF .6K0T;X%VVG^( M7O)=0=K /OCMTR#CT-2^*_A%J?BO6?M-UKV+./B",C[@IL;W/3O#S!O#>FL# MD&VC/_CHK2KE_!/A[4/#6C"POM4:_6/ A+?P(.@KIQTI$G.>/L_\('K8#;?] M$?G\*S/A.R-\.=*"R"3$?)]Z@\?^"=9\7/Y-GK[VEFR!9+7'#=>:A\!?#V^\ M&3@#7)9[4KAK;^'/K0!YA\8M$N?#/C:+7],8PB\^8,IY+]Z]1^$GAU]'\+?; MKHL;[4V\^8MU]OYUT7B;PEIOBJ&VCU"/=]FD$D9'8\5L_9P+7[/&QC4)L4KU M7C&13N-NZL>#?M&2C[9HJ9Y\J7^8KUKPX[K\/K*2/.\60*X]=M<7J?P.LM9N MVN]2\07\\K,2"^#@'MS73>#O ">#V=8-7OKJW88\B8C:*0-Z6/)_@SK6FCQ% MK-[K=Y M_(P:.6X8#')R!FD^-_C'3=:?L^W$0UO6HC*N]T4JOK\QYKT%_A#X8_L:/3XHY( M"/O31-AW^M0V7P:\,:==07-I]JAEB((*RGYOK0":V.ZU*:.#2[N:0X1(F+?E M7SY\&KBPN?'>N0W+IY5[!)&L;_Q@L,@?E7NGB#PQI_B;2DT[4!,8%.?DD*D_ M4BN7M_@QX0M+F.>WM[B.5&#!A.W44 G8\FU^"Y^$7Q(6[TYS)9RGS!%GJA/( M->^:%XATOQGX?\^RFC=)HRDD>>4)'(-4/$OP\\/>*;R*YU2WDEEC01J5E*\" MG^&?A]X>\*WSW6EV\D?'C2Y[%HM(L+N;4Y0%BB9/EWGCK7H7B7P9HGBR)4U2S61UX24<,!]: MS_#GPS\->&=0%]86I-P 0'=LX[4#NNI%X5TC5K'P+<#59GEU*ZC>616.?++# M[M>._"?QII7@F_UJ'63)$\I4+M0G)4D8KZ8. I]*XR^\!^$9=;_MVZL;<7"G M<22-I([XHM?1$WT.6\:_$B;1I?"FM6WFII][YIG@9<,RCSXC\7^"M:\(7 M$MUJ-G/$T)*1E@7#XXP/6G>*-?\ FH116^KF"Y2(DHH&0*P_#GAWX:>(=1D M73;17GC&[RV)Q5N$DKM!=$'P,L;C2O">HZC-"R03R-) &ZLJC_ZU5] ^.DFH M>*$L+S3A':3S>5$ZGYE^M>R116]E9")$2*WB3 7&%4#^E>*:UI.@>)?'FG6O MA2RC,L5S]HOKN(?N\#'&?6H"Y[HI#*".E-E=8T9V(55&23V%+&NU HZ#@4.H M<;6&5(P0>] 'S;\;/%^E>(;[3[?2Y_M/V7=YC*IQG/;\J] \-?%[PC!X>L(; MV_>VFBA6-U:!VY ]@:[?_A$/#QD+_P!C66XG=GRAG-2-X6T%G#-I%F2.G[H4 M#O=6/._%7QPT*#2KF+1#/>7;H5C<1,J GN215WP!/!X0^&PUG7)MC7CFYE?D MEBW2N]&@:0JX73;8?2,5=:")XA$\:,@X"8X% CY4N?&=O-\6CXI^SS-:"88 M7G:!C->MM\=O#2]+74S](*].^R6P 'V>(#TV"FFPM,_\>T7_ 'P*;8VSP+Q- M\0+SXDZC9>&='L98;6>==[RC&]0>:]XETJUET8Z4T0%J8O)V#H%QBK*6T"$, ML,:D="% J:D(^;M3\'>*_ACXE;5/#T4MW8,V<1C=\OHP[5U=E\>;$0B/4M#O MXKT'#)&NX$U[*0",$ CTJ$V=L6W&WC+>NP4#N>3K)XF^*%VD%Q97&C^'D;,O MFC:]P/0>U>KV-I!86<5I;((X84"(@[ <"IU P /:EH$%%%(>E( H[5G7^N M:?IL3O?ZW\6(ED2'14$[D\Y7-:0I2ELA-VW/3W=47+, /?BL; M6/%.E:-$6N+J,OV16&37GV?&GB\Q.L)LH.N\\5MZ5\+-.A9)]5FDOKD'=ECQ M6OLX1^-BO?8H7?CG5M6O1#HEI.Z.ORE4R!]31;^!O$6MW@FU_41%; ?+#$QW M'ZUZ/;6=O:0B*")8E P HJR.G-)UK:05@L&] M"CG,R:+IZRDYWK;(&SZYQ6DJ(@PJJH] ,4ZB@!" >H!I%C11A44#K@"G44 ( M44YRH.?:E Z"BB@!H10VX* 3WQ2[5SG SZXI:* # ]*3 SG'-+10 F!Z"EP M*** "C%%% "8'I2X [444 &!Z48'I110 8HP*** "C ]*** "BBB@ Q1110 MFT#L*Q?$NOZ=X;TF6^U*0I#@J !DDUMU7O+&TU"'R;RVBGCZ[9$##]: /F;X M9>*=/TGXCW][=F6*UO2Z1<$\E^*^GH]KHK#!!&0:H)X>T:,Y32K($'(/D+Q^ ME:( 48 P/2@&+BC ]*!10 8'I1BBB@ P/2C%%% !BC ]*** @'J**** "C% M%% !@>E&*** $P/04N!Z444 &!G.*,#THHH **C$F3C%))/'"I>6144=2QQ2 M6H$M)7/ZAXV\/Z;D7&J0;NNU&R17"ZQ\ M17WCOQ]XN['9$E%%% !1BBB@ HHHH M2BD)Y-5+S4[/3XB]U*,GJ@P /C6EE;64*Q6MO'#&O18P *7-3A\.H]>IY7IWPQU74SYWB#4G M;EHT.,_C7=:)X+T/0O\ CTL4+_\ /20;C^M=#@'M2X]JSE5G(=@P , "EHH MK(88&.E%%%, HHHH **** "BBB@ HHHH *",]:** $ & ,"EHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH *,#THHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDS[4M !112$X M[&@!:*:3QQS4;SK%EI'15[DMC%(":D)Q7-ZIX\\.Z0K&YU*'F64]PX'R,%R":UC2G+9"NCUK=[5!=7UM90O-.O6HY/AIXVU/=)K>L+! ?OF27M6ZPZ^U)(ER?1'JE MY\3?"MG&[G58GVCHASFN/N/CUII9TLM-N)F_A) -<2:EXU\1^,[C[-H\4WV=SC$(./Q-:FD_"&_NY8Y=:O (3R\2_>^A- M=:P\(J]27R,W)WLB#6_BGJ>K2BWT2*2/1)(,FNB$:JH"J !T %/%%:6F[!YF_/;% #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **,TF:0"T4A8#J14:5(T'\3M@4("0G M S3#*N<5SE[XX\,64;O/K%N-F^-7A[385&E!M2N'_A!VJ/QZUH MJ2G.%' K(TCX"6[%9]0KDHC$X/U-=GI/P MJ\)Z2X>/3EFD'5I3FHM0CYCU/-)OBOXP\0L8M#TQ(%;@;8R3_P!]4ZR^''CK MQ#*)=8UFYMX9#EE\TG'X"O<;/2[+3HREI:PQ G.%0"JFJ>)='T57:]OXXV7D MIGG\J/;]*<;"MW."L_@7X?CC7[9\0LUOX7TA]A'%S/P/K4&F_##4=7NOM_B[4VN'(XMHR=JGU M_P ^M2Y2?QL+%ZY^)=J[O:^']->Z<9&43"Y_*JD/@_Q1XJ+-XFU1K>T;E(+< MX.#V->@:7H.G:/;B&RMDC &,@6]K 9+F58HQU9SBN"\3_%'3]-A\O2WCN)@<$L< M*!_//2M(4IS^%";L>A22I'&7=@JCJ2<5Y]XL^*-GI"M!IB+/O&I)M(7@M7X\QQM3'MWKL_#_ ,)=+L!'<:I-)?7?WFW'"@UO[.G3_B.Y M-VSBED\?^.&9[65[:!OXL[5 KJ?#WP;LK5DN-=NWOYNK1]$S7IL-M%;Q+%"B MQQJ,!5&*E(S42KMZ0T1=BI8:59:7 (+&VBMXA_#&N*MXXI:*YWKN @&!2XHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHIH0*)-8;0=%FOTMGN70@")1R:\CU#XTZ MU!YFS284Q]TL?N_6M:=&=3X1-V/<\\4N:\3TSXYM-+&+S3E1LE&(P=TI8XJO8I?%(#V35_&?A_1;8W%[JENJCLK M@D_@*XJ_^.GABWC8VQFN'_A 4C-9UC\!+ Q@:IJ4]P MM=5I'PA\+:'OE6U-PX&09>:]"JK?S>183S$_<0G]*GVLY.UP/!_A_IQE^+EY M,L2"*/S-JX^X,X%?0 ],5Y!\++^QO?%&JR16S^?@EY<<#+=*[S6_&>D:(/+F MG66X8X6).6S]*VQ?-*I;LB8Z(Z/(KF?$?CW0?#2'[9>IYO01*9;CYN?QKFY%'/;-;&D_"ZS2<7VMW+ZA>GEBY^7/TKO4B6- B(%0=% P M!3QQ1[1]-!6(;>TAM(ECMX4C11@!1BI0,=J=14#"BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHI,T +29J.6XA@C,DLBH@Y)8X%>;^-/BWIN@*L.FO' M>7+-SMY JX0E/9 >EEU498X'J:XWQ+\1-(T*WD;SEDF0XVCUKS.+6/B#X^G" MV\4EG8.V/,1<#%=KX:^$6EZ;/]NU5FO[L\_O3E0?I6RITX:U&!PTUUXP^)&H MK':VLUO8L/= \ M/JRW5ZC3#CR8^33C&4M$@.I9U52S, HZDG@5P'B;XL:#X?-O%/CS4I;#0[>46N2H$8XQZDUTWA+X+6UNZ7WB&3S[C.X1 _+^-=4 M:5.&M5Z]B&V]$+_ (I:K(ENKVU@I.!D@ ?7O79^#_@SI^BRF[UF0:C< MYRB$?(E>FVEE;6%NL-K D4:C 5 !5D=*B==O2&B*2?4B@ACMXA'%&L:#@*BX M J4#%+17.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &[1NS3J** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#Q3XJLO"EK M#7>SR-_=6 DUWNKP17.D7<4T:R(T395AD= M*^>O@7! WQ"U:&2!&"6[E=R@X^<=*!I7/2!\;O"(D$6%ONE7:)EB42(?4-C(KYU\':E>> M ?BBVE0S%K7[5]GF7&=R;L9^M TKGU713,Y&U $E%1K(K$JL@)'4 C-2#I0 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%)2$T@'54U"_MM.MGN+J98HT&22:Y_P 1 M^.-/T)C I-Q>'A88^>:YZ'PUKGC"Y2^UZ;R;7JEJIXQ[BM53>\M!7(;SQ9KG MBZ?[%X9LWCL]Q$ET_&1[5T?A_P "V&EG[1=G[7>MRTDAS@^U=)I^GVVFVJ6U MK$L<2# &*M$#CBASMH@&#:B_+@ #H*^==0<^*OC8(6DW1Q7&T ?W5KWK7]2 MATG0KR]F;"Q1%OTKQWX)Z&NIZMJ/BBX7<_F-'%NY[]:WP[Y(RFP:/ M@& *?1BBN084444 %%%% !1110 4444 %%%% !1110 4444 %%)45Q-';Q&6 M618T49+,< 4 2MTK)USQ#IOA^Q:ZU&Z2%%Z GD^P%<7XE^+^CZ3(]K8[KRX M.&CY /\ 6O-=.\+>*/B3J9U"[DDCMF8G?-RJC_9!Z?A73##WUJ:(3?8U=?\ MBOJ_B.X_LS0K66(2DHAC&6;-6O#OP7OK^5;SQ)>G8YWF!3R?K7I'A/P#I'A1 M5DMXO,NR,--)R?P/:NNQ53Q"BN6EH))OQT6S2UL;>.&- ,"M"EHKD M=WJR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *; MEL].*=10 E%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07PW M6%P!WC;^5?,GPQ\1Z9X5^(>JW&IRO%"ZR1!@A;DL"!Q]#7TW><64Y_Z9M_*O MG?X-P0W?Q4UI9XDE00S$!U!&=ZT%)Z,]'U?XU^$K"PDEM[J6YF"G9&L1&X_4 MUY?\--'_ .$[^(5QXBO)8T6&<3F!3@LBR_"_QK;7>B73Q13_O8T0]!GI]*:'$]X^(&A:AKWAF:'2[^:TO(CYD; M1OMWX'0XKQ;X1W&HZCX_>UUK5KTRVJ,5ADG;#.#TZ^E?06@:@=7\/V%^PYN( M$D8>Y4$UX'\1--G^'_Q0L?$]LG^A7,N\X_O?Q#\J1/D>D?&>9K?P+)-%=36] MR)5$/DN5+,3TXJ_X \.:CH?@[%W?7%QJ-U%YC>=(6V,1T&?2N9\3W5OX^\7^ M&]&M9EFLMOVRXV'H!R!FO750!0!T P* /#OAMH7C:Q^(5[/K'G_906\QWDRC M$\@BO=_"!=.U&VO+UFC>\\PY3NHSUQ731A%1=270ENQM^$/ L=JZZIJ4AN M;R0;CO&<&N]50 !C I%PHXZ4X')-83FYN[*L+BD;I03BJ][=QV-E/=3, D2 M%CD^E1:^@'G/QIUY=.\(M8( \UXVS8.N#6Q\*](;1_ >GQ2Q>7/(#)(/4D]? MRKS'1H+GXH_$62^E9AIUF^2O;@]*^@8XUC144 *H &*ZJON05-?,"2BBBN8 MHHHH **** "BBB@ HHHH **** "BBB@ I"::\BQJS,P"J,DGL*\B\;?&FVTY MI-/T&,W=T,HTV/E0_P!:NG3E4=D!Z'XD\6:7X7L7NK^<# XB3EF/TKPK7O&' MB?XEW<5AI,+VMDS8"J#R#_>-:GA?X& M-,\-V*VMA % ZNP^9JZ4Z=#SD+5G ^"?@[;:+.M[K$OVJY7E(P/E7_&O488( M;:-8H8EC3LJ# %38%&*YZE251WDP2#'2EHHK,84444 %%%% !1110 4444 1 MAI/-(*C9ZU)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M449S0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !112(=+T?XDZE?:A=QVUM/'*B22' R74C^1KZ$\1^$='\51PQZ MM;M,D))51(RCGKG!YK!'P?\ X<'^Q$X[>:XS^34#-.;XA^$HHF4LF.Q/+&O9S\(/ ^\,-$0>WG28_]"K?T3PG MHGAQ&72=/BMBW5ER6/XGF@$[%K1]-32-(L].BIVC&:Y3XK>'H]? M\"7J[09K8?:(CZ%>OZ5UVI:I9Z18O>7\Z06Z=78UYQXX^).AWGA*ZLM$OTNK M^]Q;Q1Q D\]:!&9\ ]#:'1;K6)US+,WE1,>R#TKV*:80022$$A%+8'M6/X0T M5=!\+V&GKUCB!8XQDD5^!_BY)XJ\77>C3:<(54MY+H220#C MYLUZH#D5A:9X-T+1M5N-3L+".*\G)+R#WK= P,4"%HHHH **** "BDS1F@!: M*3<,49H 6BDS2YH **3/-&10 M%)NHSF@!:*0G':C/&: %HI-U&[V- "T4W> M"<4N: (;J!+F&2&5=T)? MA[J<-]97TFUSM^T0^WJ*Z(0I5$TGJ!]1EOS]*\<^,_BR3R$\,Z:Y%Q<,/-V] M<9X'YUQ,'Q@\9Z9&]M,UO=.1A2\1W#WXK,\&^*X+#Q3)K'B+39;R5R2K'/R$ M]\&KAA)P?-(5T?0/P_\ #$/A?PQ;6ZI_I$BAYGQR2:ZWC@5YU:_&;PA+.(FF MN(6.,EXL*/UKI;'QQX;U+'V75[9V/8O@UQR4F[M#N=#14"7<$@RDT; ],.#F MI0V5S4 .HIN\'I1O% #J*:&!Z4I8 X)'YT +132V.QH# F@!U%)GGM0#0 M% M%,,J?WEXZ\T .^E87B'Q;I/ABS:XU*Z2,@';'GYF^@KFOB%\1[?PQ9FULBLV MHRC"JK [<]Z\;L?"GBCQQJGVF]NT5TT:',N:>B$S<\0_$?Q1 MXWGEL/#=I+'9D[6\L'[2T0(FCC"* !@#@#TJ0#%5 MA?6F?^/J D_]-!37U.PB($E[;)_O2J/ZUR#+=%4?[9TSOJ-G_P!_U_QH_MK2 MO^@G9_\ ?]?\:8%ZBJ/]M:5_T$[/_O\ K_C2'7-)49;5+(?]MU_QH OT5G?V M_HX_YBEG_P!_U_QIO_"1:-_T%;/_ +_K_C0!IT5EGQ'HH&3JMD!_UW7_ !JI M)XW\,Q2,CZU:!EZ_/F@#?HKF6^(7A->NN6@_X%41^)7@Y>NOV@_$_P"% '5T M5R?_ LWP;G']OVGYG_"@_$SP8IY\06@_$_X47 ZRBN2_P"%G>"R\%;=W]KKC_< M- '=_\ "[/!@.#= M7(/_ %Q_^O4;_''P8C8$UXWNMOD?SH ](HKS0_'3P;_?O\?]>_\ ]>F-\=_! MZGC^T"/:W_\ KT >G45Y=_POGPEVBU _]L!_C2CX\^$>\>HCZ0 _UH'8]0H) MP":\N?X\^$Q_JX-2<_\ 7#']:C;X\^&]I_T'4#QTV#_&@1ZD9%";SD"GCD9K MR6/XY^'WC^73-1,@Z(%S^M.'QTTXG_D ZCCZ?_6H ]8HKR27XZ6X \CPQJ4N M??'_ ++4?_"\Y<9_X0S4\?[_ /\ 8T >OT5Y#_PO"2?\+KO3T\#:K_ -_/_L*5?C1?L<#P+JA/_73_ M .PH'8]:Z4A.!GM7EG_"VM9=,IX"U(9Z%IA_\30OQ1\1O]WP)>'ZR_\ UJ L M>IYHS7EY^)?BIT.SP!>!O4W Q_Z#4!^)'C.8D0>!94P.?,D)S_*@+'J^:,UY M0OCSX@AC_P 40"#T&\C^M1'QG\5-Q,?@RTVD\;BV1#QG\ M4\X;P79D_P# O_BZ#XQ^*_\ #X+L,>^[_P"+H ]=)HS7D)\7?%IB#_PB%BOL M W_Q= \5?%MWX\*V"C_:#?\ Q= 'KV>:"<#->3-KOQ>?&W0=,0>V[/ZM0FI? M&"7*_P!G:;&>S$?_ %Z /6=PP33/-7U'YUY(\/QHGR5NM,A![!1_\33!IWQI M/75M/'_ 4_\ B* /7_-'M^='F#V_.O(?[+^-!7/]LZ<#Z;4_^(I5T?XT$9;7 MM+'_ %?_B* /7?-'M^= D!/&/SKR4:+\92,GQ!IO_?*_P#Q% T+XQ/P_B/3 MU'J(T_\ B: /7,GTH)Q7D@\+_%=LEO%5MGV1?_B:>G@[XG2#,GC2-&]!"#_A M0%CUC=SC%&>:XKPIX8\4Z7JSWFN>*&U&(Q[1 (0H!]>M=J!B@!:*** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:J[<\YS3J* "BBB@ MHHHH **** "BBB@ H-)GFJ-Q?QM=BQBRTQY;'\(]Z +X.1D44U%"*%':G4 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 AX%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4'I110!SGC;PL/%WABYTDRB)I.4<] 1ZUP_P /O@M#X7O5U/5[ MB*[OXS^[$6?+7WY YKUJB@!>U%%% !1110 4444 %8_BC6_^$<\/76J_9);K MR-O[F+[S98#^N:V*:ZJRE64,#U!&: /'H_CW8LF'\.ZH7'4(F12?\+T\UOW/ MA74F7MD$'^5>L_8+,-Q;0C_MF*D%I;K]V",?1!0!X_/\<+U&^3PA>;<<[W(_ MDM-_X7;JQ^[X(O&_[:-_\37L9MX&'^IC_P"^!2B. ?\ +.,?\!% 'C__ N7 M7PNX>!+T ]][?_$4U?C/KYZ> [YV]G;_ .(KV/9&1PJX^E+Y:8X11]!0!XXW MQ@\4 \> +Y?JS'_V2E'Q@\4D9'@&^8^Q?_XBO82GHH-'E^P% 'D/_"VO%K*- MOP]O\_[S_P#Q%-D^*_C,+QX!NU]SO/\ [)7L(3!ZG\Z"F>A/YT >,_\ "U/' M3'$?@6Y)_P!U_P#XFF/\0/BA-\T/@[RP>SJ37M.SU)_ TH##C@CWH \8B\<_ M%)CM/A&+/J5('\ZL_P#"7?%ADRG@^V!]Y!_C7KY'X4=N: /%3XL^+Q8_\4Q: MK]$_^RJ:+Q!\9)?N^'+'!Y&\J/\ V>O9:0C- 'CQU?XSDY_X1[30/0.G_P 7 M36U/XT-RNAV*^PD3_P"+KV/'&!28(H \7DOOC6Z;?[)LT)[AT_\ BJ6>R^+> MH67V>\M=-=".0^TD?K7LQ09Z<^M!X//\JJ,G%W0'@6E>!OB/8W;RK9Z.Q<8) MN%# ?3%+J'@+XC7K,TMOHZY.,0KBO>PRM]U@?I2@@G&>>N#6OMY[W%8^<)O@ MOXRNI1YT]B W4GM^0JPO[/WB&/$B:S9(_HFX?TKZ(QZ"EI.M-C6AX!#\&_&\ M"$Q>)$5D^[^]?'\JAO/#7Q:\.J#:ZG+>+ZPN'Q^8!KZ%QFDP1Z5GSL=SY7OO M&GQ)T^8PWFIRPN#@[H\8/Y5/I7C;Q'AB"' M]:M/X \8WTP>#Q]!.@_B60Y_0&M34/@7H,Y'V1W@&>W:L:[^">J6"L^C:Y-O M'*JSE:F4:N(0US#:EP?[C?_ M !=<5XXTF3PBJ6UKXRU"ZOW/SQ9Z?7FN^^)'Q1AT=/[)T*5+C5)OE+(ZA_;OB=9&)(D593RY]_:MJ5/D7M)B;Z&!X1^#VH^*4_M#6+ZYM MXY%W)*WS,WT&:[*+X%S0ILB\9ZBB>BQD?^SUZXB+'&$B4*JC "CI27-W;V-L M]Q=3I#"@RTDC;0/J36$JKEZ%'E"? WD^;XMU)\^@_P#LJ4? FT*X?Q'J+>A( M_P#LJ[W_ (3GPL5+?V_IV!_T\+_C5[2=?TG78WDTN_@NUC.&,3AL?7%9CU/. MH?@9IR#,FO:F[=L/M_K3F^!.AR-NEU74W/O)G^==K<^-_#-E=R6MSK5G%/&< M/&\H!%2:5XP\/ZY<_9M-U:UN9L9V1R FBXCA4^ GAH-F2^U%U]!(!_2IO^%" M^$,Y,NI'_MX'_P 37IX8'I2TP/,#\!_"..)-2'_;0.=0'_ &\#_P")I?\ A1/@_P!=0_[_ (_^)KTV MB@#S1?@7X.4'Y+PY[^=_]:IE^"O@Y(@AM;@X_B,W)_2O1"P&H@^"_@M3G[#*?K+_ /6JROPB\%[-K:0I MQWWFH/!7Q5T?QE?G3TBFM+W:6$4V/FQU KOP* U.*'PC\$C_ )@Z?]]FI4^% M/@E1@Z!;M_O,W^-=C13L(Y'_ (5=X)'_ #+UK_WT_P#C2GX7^"C_ ,R]:_FW M^-==10!R8^&7@L=/#UI_X]_C0?AGX,(Q_P (_:_^/?XUUE% ')#X:^$@,?V' M:_K4Z?#[PJB!1H=H,?[)KIJ* .?C\$>&HP NBV8Q_L9J4>$= '32+,?]LA6W M10!BGPEH# AM(M"/^N8IT?A;0HL[-(LP/>$'^=;%% &8/#NB@_\ (*LO^_"_ MX4HT'2 .-+LO^_"_X5I44 4!HNE8Q_9EE_X#K_A2?V'I7_0,LO\ OPO^%:%% M %$:/IJ_=T^T'TA4?TJ3^S[3_GUM\?\ 7(5:HH KBQME'RV\ ^D8IWV:+&/+ M0#T"BIJ* (A!&!]Q1] *#"HZ#'T _P *EHH B\H>I_3_ H$0!]?RJ6B@0S: M/>E IU% "8H(XI:* $*\4TQC-/HH&,\OWH\L4^B@"/RA2^6*?10 T*<\D$?2 MG444 %)BEHH 3''4T$9I:* &[3ZT8[=J=10 F.,"@#%+10 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110!#=3QVUN\TK!40;B36;H,!>W>_D7$MT=_/4+V%-UA3J%Q!I@4F M*3YY6_V0>E;"((U"*,*!@#T% "@8I:** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ***0C./:@!:*** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ JCJ[7Z:7.VF)$]X%S&LOW2?>KU(>E 'A-]\8_$OAS7(K+Q% MH,$2[@6*@AMOJ*]GTG5[36=,M[^SE5X)T#*0<_A7DOQQTDZS?Z#IUNL8O;F3 M8KGCOWKDOAIXOO? GB>;PQK;,+(R%"7!'EMG@C/8T%6/HV_%TUC.+)HUNRA\ MEG&5#=LUXN_CSXBQ^*E\*M9V?]I/\ROMX*=<_E7MZ2))&KHRLK#((.017DEV M"W[2=G[6!_\ 0&H$CT_2/[0&EVZZKY1O=@\TQ_=W=\5>!'2H+FY@M+=YKB5( MHD&69S@"N1D^+'@R%PKZS&?5EC;&?KB@1VU%4-*UG3];LQ=Z;=1W$!.-R'H? M>L[5_&OAW1)(TOM5MT=VV!$;>V?H.E '09HS7(^(OB1X9\,.D=_?;I64-Y<0 MW, ?7TJ_H'C#1O$NF/J&G7BM!'_K-_RE/J* -^D!S7G\OQD\'0:N-/:]E+[] MAD$?R _6N[@GANK=9[>1)(G&593D$4 34F17.>)O&FB^$XU.I7)$K_<@C&YW M_"N>LOC-X6NM0BL9/MMG)(< W,(0?S- 'HF1G%+FHDECEB62-U9&&0RG((KD M-.^)WAW4_%$GA^W>X^V([)N9 $)!QP<\T =I1F@4UOTQ0!S/C?QG8^#-&-]< MG?(V5AB'5FKS31-.\<_$Q3J=_J\VE:7)_JHH?E+KZUS/CK4I/&OQ9M])AN#+ M9QS+%&H/'7DU](V5K#8VL=K H2*)0J*!T H':R/)[KX/ZIIUNT^A>*=0CNQS MB60D'_)Q67\,_$/B&7XFW.E^)+J5KE;077Q0\66MK_ &NW@^1=*Z@E_G"^ MI%=AX(^(6D^-K(O:$PW2?ZRWM '89IK$ 9/2O,O&OQ@M?"=Y+8QZ7< MW%TC;%[U2!8+"[?QQ\$5YC\1?A]X?\)Z-]LLI91>R.$B M3=RV?2M"V^.E]#,UAJ7AF5]1B)#I!(1T[X(S4NCZA'XPU*X\:Z]$;;2-.7,4 M#/NPP[UU4ZDXN\GH3)'):)\'_$4UA#J,;?9YY/G +88=QFMYYOBEX9;<]Q)= M0Q]=PW+BNA@\6?$#Q';RW_AW2+&WTQ21 ;G=OE4=\4O@GXJS:OKTGAWQ+8Q6 M>I!B@*_=8^G-.6*(8#9W%S M&BRC:\-RO!]JZF_T'3-3@\J\LXI$_P!W%<)JOP;TB[G::RFDMN>$90R_A4WH MSWT'JMCR3Q[X;T.S^)6GV6D(C6-WY9:*%AM&6P?T%?1FB:%I'AG2S'8VT%I$ M$R[@ $X'4FOFOQKX8N/"WC6RM?M2I.55XINPYK2U?QEXJUZWDT 7L=Q:H 9W MB&UF4=1FB5&[]TMO0VM=T&/XK?$)WTFW6/2[?"3WJ)CS#WY[U[)X:\'Z-X6M M5ATRQCB<+M:; WM^-<7X0^)'@[3M*@TQ(Y=-6)0I$J=3ZDUZ+IVLZ=JL7FV- M];W"9QF-LUC*$H[HFY>Z'FEX%>=_$_XAOX+@M;:R@CEU"[.(_,^ZHZ9_45S= M]IGQ)LO#T<49'//3K7GGPL\;W?C/P_,;U4 M6]MSL9U'#>^*XGQEXD\<>#_&%E8R>(!=6UVX>/%JHPI;&V@+'O/&:,C\*PM> ML=5U?PX8M,U$V%ZRJRS!,X/<8KRWX8^+O%NH^.[K1M9OQD0)L!&,$_P"]7*_"CPOXAUCPK]LTWQ9-ID*W!C\A8?,! MP%)ZGCK0'V3TW3OAIH6F>,3XDLUDBG(/[H'Y 2.3BNT4@9YKP?XIZUX_\-01 M%]3@33Y#Y*RP+AV..I]^#5F"Z^(WCGPW:_V25TRS6 W$SGS)SZC'04!8]OW M#U%&]%?-GA7X@>*_"7B.;0=8CFU&3/EK"Y)&OB9-:W7B* M;5O(11Y@M()FS&H]L8H"Q] Y%!( R2 *\X^$'C"\\5^'94U !KFS81M)W<>M MG74MA;F15DFBSN(/4T"L>U+-$Y(65"1UPP-/+ #K7@?Q M \#WW@C2$UKP_KVHCRV G2:*OAI#>6EREOJLL103NF0''? M% [=3M/,3>%WKN/09YIIGA#;3*@;TW#-?,>BZOXTM/B=+9->->ZLKM"?,8^6 MO'7:*T_%WP^\8:/I<_B:XU^2:\4^9<)$Q54[\>U -_!CX@G M4K;_ (1W5) MW N++-!5Q$9/ M,E"?\LF['Z4[X?\ BB7Q?\7M-U.=-LRV31/CN0AH*:.S^-]EKE[X;M(-'BFE M1I\3K%U([58N_#GAK1?A?%::G;VEL39 EIL"0RE?ZK(R%&<9K*T[X8KJVDOK/BN^FU&^EA,H1G(2/(R /TH$SC6]5 MT\.6M1;F4*?4. /YUD_&7PK9:'XJLI=/+(U_F1@S='W8R*U/@/&L7CK6XHQB M-+9U49SQYBU9^//_ "-/AX?[/_LXIHI/4ZG2_@_HLNA9U=I+S49X\M&;;49;>UWO'<%#]Y%]OQ%?4]J,6T8_V1_*O ?AL^/CEK M0QGFX_\ 1@H0C7^)7PR\.Z)\/YKNPMREW:E,2]WRP4Y_.ND^#.HS7'PWC>=B MQ@+*,^@K1^+OS?#+5O\ ME_Z,6N:^"8,_P .;J%?O;F _*CH'0X#1/&6GS>/ M-4\0^(;&\U!%8L:@XZ5+\3?%.E>,M-MFTKP_J$%S$V?/>VV_+^%7/@ MGK5GH_B/5='U+9%)<. HE ^5U)!'-?0C1VT<+2.D2Q@9)(& /6EJ&SN<)\&F MOV\ PIJ*3+(DC*HF!!*TND?"?2-)\9R^(H99&+,72 CA":ZGP_K^G^(K.6?3 M6)BCE,><8!(K46>.20HKJ6'4!AD4$DJ_=I&Z4HZ4'H>* /D_P!+%'\6[0S*" M#=L 3ZY-?5Z]>>M?+/Q+T:Z\&?$4ZO%$8[>:;[1"5'&<\BOHWPKXBM/%&@VV MI6LBMYB#>H/*MW%4QO9#O$^@IXBT9[%[JXM?FWK) ^UL@'OZ8Q9Y,'H371:1KWCFTTJVM+7P#$L"1!1_ID:C&.N#ZU@?' M^SF@FT?68U)$+;#@>^:](\%^,M+\5Z)!<6MPIF5 )(B<,K 8- =#Q_P_X$\; M0?$:WUR32ELXGN3)(!*I"H>HP*O:[<+XI^.UII-Z6:SM)-GE'H2.:]1USQK: MZ7KVFZ+:I]KO[N4*Z(<^4G=C7BGC*2Z\'_&Q-789CGG692>A4\&A#1]'R6\, M]HUM)&K1.NTH1QBOF<02_#_XWK!;!C"]P% 48!20 _H>/PKZ9@E2:WCEB(*. MH92.A!Z5\_:U9#Q)^T,(;<[XX)(WD9>0-BC^N:0+J=-^T#%&?"-E-Y2^:UV$ MWX^9?D8_TK9\"^!M NOAWIJ7EA%.;F%97=E^8DCUK+_:"8#P38CUOE_] :NV M^';A_A_H9'_/HG\J=] Z'!_&RQ;2?A]8V6F1B*PCF"RHO0#'']:[+X8M&?AO MHAB^Z83_ .A&CXG3Z/!X(O/[:3=;N-J@#/S]J\V^'NA^)[7PVCZ/XIL((+Q" MZP3C<8^2./0T=!=#FOB/Y=K\7F:UE\G./-93CCO70_$!TT'X5Z1INGCRXKN3 M#DG[XZ\UA^+/!BZ'J]CYNH?;]1O6_P!(E+9 R>U=A\;M#F;P/I4MK"2MDPW! M1]T8ZUU5&E3C874M:%8?$V/PYIW]GWFDK;"VC,:.#NQCO6*_PA\7:CXJCU[4 M-1L8IS,DK^23QBMSX9?%+2+OP[!I^KW4=I>6BB/,S8#J.AK7\0?$B%K^RT?P MO/#?:C%=0^%OB2/5[")KS2YNN\9 '<-6E\4WC_ M .%TZ8V\806^\G^'YS_C7N^JZ98Z[I,ME>1+-:SIAA]>XK3F:V'<\[TC2?!G MQ#T59=-*6USMS+&HRR'OQWK'U+X5:SH#-?>']1?*_,40[2?^ UP_B+0M6^$? MBZ&\TVX)MW):$YZKG[IKW7P1\0-)\8Z4DT>)M*O)K.X\<:?.\UB=JRH,%CZ$?A6_/XN\1^-M!O8O#FGVMMI2P/&TEQ*- MQ3:>U<[\9<+\1])AO4\O3"BEFQP>3FE\4:1I6CZ<;S0]6CF$J8^SPME@".>! M6S<)ZI6!)FS^SU Z6NL.S+#*\H*!NK58^.=M)9^)-#UHJSVJ(JL0.F&)KEDK,O[1[Q;\VL7^Z* M\,^'X,?QQUV/MF2NW/Q9\+V_AZ"^%ZLDCH MM'R^[TQ7D_@3QKIMA\3]1U;5 M&-K'=E@-_52?6I6P+9GLOQ3?9\/-6;U2L'X"X_X5ZV.OVML_]\I5_P"*NK6( M^'=Z1.C&X13&N>6!Z'%9GP*OX)/ IMA./-BN&!0GG! /2CH3T*?[0N/^$5TP M^E\/_0&KO_ 0 \!:(/\ ITC_ )5YI^T%>P'2--LQ,ID\_>R9Y'!']:]$\!W] MC/X*TPVEQ&\<%NJ/AON$#G- WL>4:V ?VEX1_P!-(?\ T4M>WZ^0OAS4R1D" MTE_]!->":AJ^F-^T,M^UX@M5D3]ZIRN0@'6O;_$VIV=OX3O[F:XC$,EJX1BV M V5/3\Z :V/+OV?#FVULC[OF+QZ=:WO&?B'2-"\51+I6D)J'BFXPB*#C;GN3 M7,?L^ZE91'5[1YHXYII5,<;-RV,]*R8]=M_!WQLU:_UU)%BDED,;LN!K^*:Z0R7EN1"JG.\'H10QM:F3^S_ /\ )/)O^O\ D_\ 0$KU M:O%O@!K5I_PC=SHIE O4N&GV'J5(4?TKV@8 XI$RW%%% HH$%%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 444AS@XZT +15>-KDRD2(NSL0 M:L#WH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F3.(XF<[L*,G:,FG MT4 ?.WQ*\;C5?$VD2Z?I=T?[.FWDR1'YL'I7MWAGQ%#XFTA;^&VF@4G!29<' M-:CV5I(X=[:%F']M)K6XB62&52CHPX8&O$_" MW@FZ\)?&M$M[9SICI(\#7NF!2>6A.2HSC&>] [GC7QS\*ZCJ4=AK.G M0R3&T!5XT&2!G.<5B:/XG^(7C+2%\/VMG]E54V2WI0H=O0#ZX]*^@2H88(R/ M0TU(8XAB-%0>BC% 7/E[PCIWC;PIXSO+/2+(O^)%SXC M\7:M9/%X>O(I;!=CMMR'.FD,2@JA;D<"I 10%SP#XG_"G43K4OB'PZK2^<^^2).&1O45E:)H MGQ/\10_V7<7M_;6!.V62XE;)7TZ]*^E=HZXHP,=* N8?ACPW:^%M ATRQSA! MEF;DLQZDUY%X4\(>,;+XJSWUR)EM//=I9A(=LHR><>E>]8%(0#0(!TI<444 M8/BKPKIOBW26L-1AW _$+TWME(>82H/Y@U[^0# MUH Z"@#R"37_BU>6*VZ:#;6TK\&XQ\P_#./TJWX"^%EUH_B#_A)=?OC?3K^)7CD4@,0"4/J/0UX!=? _Q7IV MIRMI%RGD;\HXD*-CMR*^EJ",]: ///AW\.5\*&34]2N6O-8G7#RL<[!_=%:/ MCWP#8^-])\B4+%=1\PS #(]L^E=C@>E&* /%M(\,?%G1M/73;?5[-K0?(KR' M>ZK[9'&*[3P/\/;7PE]HO)IFO-3NSNGN9.N>IP>N*[3:/2EP,8[4!<\F\?\ MP[\3^-;[;+K$,>F1/NAA"]#C&3ZFMWX?^%?$?A.$66HZTEYI\:;88A'ROISZ M5WN*:1R* /-?C1>:?_PB(TN[+-=74BFW13C+"O/K3X :K M5\2FSU31YMUQ9ICR&/7!R"/>N.LOB-\3M(MTL;C0&N&B&WS9+- MR3^*D"F,R_$_PGUWPEI2ZQ;:L;M+4AR.1C![!K=[R..?S8_+ MN(F&>?>N'M8/B%\1(XTUF.WTG2@X&#GO3+)[SX5:V()8RVDW39.W MD+]/>MDG.-KZB;(=9_9Y@N=2DFTW5_LULYW"*1-VWV!STKLO GPNTOP2QN0S M7=^XVF9QPOT]*Z[2M9L=TBNY M[1Y!@30MM9?H15^BD!XU=_ B+4=0:\O_ !'?7,[8S+*=SG'3)/->@>$O"]QX M9M9;:;6+O4(V(\O[0VXQ^P)Z#VKI:* ."\9_#*P\9ZA'@HP/04 <5XK^&^E>+=(L[.^ MGN?.M5"QW(8%V'OD8-5O"_PE\/>&FD=%ENY70H7N"#M!&#@8KO\ %(1Q1<#Q M+Q)\%8+);C5-&G9I5)D\N7YAQS@9K7\,:A9?$OPW/H.N1E[BV^5FSA@1QD5W MGB3Q)IOAO2Y+K4ID1-IVHW5SZ"O(_A;/+K7C[4-7LK3R+*0DNJ_='I75%3KRAN<-L/J!CK6A;?##PQ#K%SJDE@MQ-<-N*S M_.JGV!KL\"EKE&<+XB^%7A[Q-J27UZLZ[0!Y448=#&#N^I-;^** .33X;>#D.1H%FW M.?F7//XUJW/A;0+V"&*ZT:PG6! D0EMU?8HZ 9'%:^** ,C3O#&A:1=O=:?I M-E;3L-IDBA56QZ9 Z5KT8%&,4 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !@4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1129]J # MG-+7!^)O&.JZ1J@AM+-)(,?Q#DFM_P -:U=ZS9F2[LC;..W.#0!NT444 %%% M(3@4 +16?)KFF1$B2_ME([&04JZUITBYCO;=AZB04 7Z:Y<*2HR>U9ORZ)# MJ$;7\3%6C'KZ5T()]* %H-(21BN>\0^-M#\,8&J7T<3XSY>1SA44L3["N(B^+W M@Z9R@U,*RG!#*0: .[HJ&UNH;RVCN('#Q2*&1AT(J:@ I*;+(L4;.Y"JHR2> M@%E 'H5%5=.OX]2L8+N)76.9 ZAUP0/>K5 M !1110 4444 %%%% !2$9I:* $VC%(57TIU(: &X'3CZ5GZOHECKEJ+>^A61 M X->?_%#XEW_@G4+*ULK2.02J7=I ><=A7H.AZD=6T2SOVB,1N(E3:UX5UCP7>+J&CRS26@?<$0\#V(KKO#/Q*T_5FCM+S-M?$[2I'RD_ M6NX=4=2KJ"I['D5PGBKX9VVL3&]TN;[#>#H5'!-=*G&:Y:GWD6MJCOMV1GC' MO2[N*\"EA^*'A&X5EDGO[5#R$RP(K8L?C7=6X:/6/#]U'*K;3Y:'%1*B^CN5 M<]F'2BO.K7XQ:!/A7AN8W[AD/%7O^%I:"Z$Q?:)&_NK&:RY6,[8YHW '&1GT MKSR;XH2.A^Q^&M3F?.!\F :YK4=>^*FK3R2Z7IIL+8#(22,9_ GFGRL#V.:Y MC@0O+(B*!DEF KB_$WQ"CTRTD.FVSW4@XW[2$'T/>O!;37/%6J>*Q83B6\U M/>R&%VPN1[>E>@/#\0].87=WXRU[)X5\+6/A325L;,$]W<]6->?Z-\:H$OH]-\1Z1)I=P3M MS@A!^=>L07,5W;I/;R+)$XR&4Y!%1.JY:= V)F^&[B\N_#>GSZ@A6[D@4RJ?[V*SL%C6HHHH **** "B MBB@ HI"<"FL^U2Q( R2: 'T50TS5[+6+=I[&=9HEA!Q5^@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD/M M0,D#/6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ I,4M% $,EK;RN'D@C=AT+*#4J MJ%& !Z 4M% !1110 56U"1HM-NI%0R,L3,$7JQ /%6:#0!X+X!^$\.OVL^K M^)%O$>65BD#.5(&:X_XK>$K#PAXAL;72Y+E+>XB\QD:4GOC%?5.,=*^=OV@1 MM\5:0#U^RC_T(C^E T=YIWP?\(7^@6DDMBXFFMD9I!*V=:+\'5TOQ[)X@DU,S0K,TL<'EX().<%L\XKTZ\O([&SFN9CB.%"[ M$GL*\9\-?%GQ#X@^(4.CR6$-G;-(0\; [UQV/O6O\:QXH70I'T^:"/2 @\_! M(D+9/3MC&.]"'8ZKP)XR/C2SO;I;4P0PSF.-MV=XKSCX_>'=/AM+378H=M[) M+Y#%B22V'^DWDOW4/MC/K0]R7N>J9.>E&?:O ]<\0_$7X:W=IE?,WQR\/V6F>*K0V%HD1N83(ZH, G) M']*^FJ\?^(=M%>_%_P )VEP@>*:,H0>X+&@:T'_ CQ2^J>&9='GDW36+?N\G MGRSS^AS7K8:OF#2Y;CX:?&&6S8A;>28)QG#1OROY9KZ=5U9 X(*$9!![4#EH M<%\6O$KZ+X5:TM2?MM]^YB5?O8/4BO'O@C9Q3?$'RKJ$M+%"[?/@X8=*[KPGX/:ZL@/M$THA4G^'(//UXKC=#^&VJ^(O"D6JW7BB_ M74;E/,C D.Q?K4DGMN>*1I%098@#W.*\3^#/BS6;S6;_ ,/ZI<272VX.R5QR M,''-8OQD?Q3H^K6\DNMNUE!V_A#X@>.-$M+E]62QMHXPL4U(+'OY<#KVZU674K)I/+6[@+?W1(,UY3\:O%6J:8=.T73I)+< MWI^>X [9QC/K575?A!9VOA1KZVU*^CU6& 2O,TY"LV,F@#VD-D ^M(\J1@L[ M!5 R6)P!7E?P-\2:AK>@7]M?RM.]E,JK(YR3NSQ_X[63\1];O]>\>V/@NSN9 M+:T=E%R8^K9]\T!8]@35]-DD$:7]JSGHHF4G^=6]P/ /6O(_&_PJT2Q\)S7F MBQS6M]9)Y@F24[GQZU@_!G3[WQ#<2:I<^(;\O92*&M\DJ^0>"2?Z4"L>N^(] M$\/ZK#&VO06SI$P*/*<;3GUK7MO)2TC$&P0A0$V'Y=OM7SQ\;]!U32+R/4FU MJ>XL[N7 MV)'ED<\=CTKUW2M(DUCX:Z?IZWLMJ\EDBF:/[P..M 6.E&IV$EU M]E6ZA:X_YYAP35>?7](M)?)FU&VCE'!1I1Q7S'9^'M=L?BC+HEAJ3M>JY7[4 M6)^4]S[XKL?&7P8;3?#EYK/]LS7E]"GF2;TP#ZXYICL>^(P9 RD$$9!!R"*J M7K:=;P-<7JVR1C[SR@ ?K7#?!?7+G6? Z)=.7EM7,6]NX[5R7C2[F\7?%NV\ M*37#1Z7 R^9$IP)&QDTA'H=KXG\#7MX;>&XTUIR<8**,_I6[;+HIN9[PW]K+ ML&)?E([9]:?0JVA[N$4 * /0<4UQM7(S3A0X)7BD2?-7A.1I_V@',G7[9*, M8]$:OI0 J.3D^M?-7@YRWQ]8D#F\G_16%?2]-E3W/-OB[X+@U_PO<7\4*?;[ M13(' Y8#M7)? 3Q9+(+CPYIHKZ5=*P!4Q-G/TKY@^#A ME3XEVXBZ,) ^/[N::V&MCZ)UOQ=X=T9 =3U"VC(;:%R&(/T[5KB^MOL2WGGQ MK;LH82,<#%?/GQQ\*Z;HMW8ZE9+(L][*_G!GW*?I7L^G:/::WX%L;#4(RT,E ML@958CM4D]"2T\<^';[5VTNUU**6Z0$LJG@8Z\TFE^//#FL:I)IMEJ4E?.VD^%'N/BY>^'M/GFM;>*XEC,BM\WEJ<8SCKBO7M"^$6E>$_$IU^V MOII(X8V(AD4<'')+9Y]: :1V7B+Q=H_A:W6;5;CRRWW(UY=OH*Y_3/C!X3U. M_6S2XG@E8X7[1'L!_6O+M(\9Z3<^,=4USQ)I^H:FUO+Y=FL$(DCC7)&2"0,U M6^)'B/0/%]A:C1M U&VOTE_UIM!'E?\ @)- 'THLBN@=2&4C((/!%C_!>:\U:&:*[MRT$9E7!/H:T/@]X M;MF\*_V[>PQW%]J+M(\DHW$#/09H$;WAOXI^'/$U\+&VEDANCTCG7:37,_%3 MXFKHME=:+I]I.;R0&-IV4A8P>X/ NOFE#L*$'.2 M!_2MGXTVR+\.+B5HXWE22,>9MPQ]Z!K/\ 2--\.66C36UW]LDF;'97!T^RF4F+.1(0-QS^%(;5V=C)\:M&B9)6TG518N.+HP8 M'Y5VN@>)M+\3:K>(?BSX7\.W#6L]R\]RK;3%"N M<'CJ?QJEKOQG\-Z*UHH\RZ:=59A$1^[4^M<7^T#IEE;1:/"].6_MS]JDB61YXF(8D\XYH*25KL]+TW4(=5TZ"^M\F& M= Z$]<&K=5-,T^'2M-M["W!$,"!$R.U9^@,K>'=,*D$?98 M^?\ @(K1R*!'SKI$:Q_M&WB@];N4X^K&O5/BO%YOPWU8G.$0,?S_ /KUYA:S M6L?[1T[I*A1IV!;/&[N/SKU7XH M\-M;4#),(P!W^84QLYKX"2[_ $ZX/RW M+U-;@]S7^'DYC^$%C.KDE+-\$]B,UY-\--$\0^)9- M8O=$\0#3KL3 S94_,&SCD#_9KUGX8+'??"NQM0ZN'A>-@#TR3_C7B_A_7;SX M3?$*]M+N%VLW?RW0C^#.0X_6D]PMJ=]J_P */&FOVZVVJ^+HKB!3N".&.#^5 M=[\/_"4O@WPVFERW/GL&+;E&!6/??&3PG;:8]S!>&XF"Y2$#YB?2MGP+>ZKJ M'AI=2U@LDMRS2K&1C8A.1^E GH=&EE;)+I M-!@BD64,424]'(ZXKT"D 5Y+XY&?C9X,[84?^AFO620!DG KQGQSJVGCXS>% M9?MD/EVX E;<,)\QZT 0?'WPOYUE;>)+=2LUN1'(5].H-6=*^(7E?!1[V24' M4(U-I&NZ\ MPV6G3-))&_W3C[O%-6*NFK,]I^&OAG_A'O!Z>;DW5Y^^G)Y.37EGPH"Q?&?5 M% Z?:/\ T*O?;_4++2;(RWEQ%;0J#RYP *^<_ASKVFV7Q=U"^N;V**TF,H25 MCA6R>.::V!;'NGCFYT"U\.O<^(HHI;6)PZ)(,[GP<8_6N&L+SQGXYM%71(X] M!T,+MCRT*]M9#+I^YRY0Y0GY2/ZULZ-\8= M_"]G#;0 MSS:@D046D<>>:0NAROP4MWM/B+K%O+,9)8T96<_QD'K6I^T*IV:&<'EF'Y8_ MQKC?A_XU@\/>.]1O]6MIU:[S\BCYE)/3%;GQP\2V&L0:'':3;I$!EDC/WH\X MX(H8UHSW7P^NWP[IF/\ GUC_ /017B6C)YG[2EYQDK/+@GCHIKUSPWXATFX\ M)6EW'J$#0VUM&)G#<(0HSFO"M&\4:9#\=)=8:XQ82SR8E;H,@C-(1Z]\2/$6 MBZ#:6TE[817^HLX%I;LN23Z^U%O&'B+1;J_U[6S96SP/,EA"<;1U )^F M/SKD_BY>S:=\1-+U\#[38F..6!@,J0 .E=7JGQ M'K^\TG^S+BZGO)4R(ARI&<_EFMGXJ^++G3_']E:ZE9-=:- J3"V/20D<_E30 M^IVOB_XC>&I/!-R]KJ=O/<7<&(H(G#/DCH5'(J+X*>';C0O"$EQ=Q&*:^E\W M:W7;V_K7!67Q5\#V5R9XO T2/NW!PJ;@?KMKTOP;\6- \87WV"%9+2\QE(I> MC#V/K0Q7.3_:%8?V1I*'J;@G]#7J7A7 \*Z8 ./LZ?RKP[XY^)[#5KJTTRT> M1Y;1V,I X!]*]/\ !WC/2)_ D=Z)G$=C %F!!R"!TH>PWL>>^&76\_:'U5XF MR$=\_P# >#^M>L>/V=? FM,G7[,:\&\+^*[.Q^+][KC0SBQNY9 &\LY 8]37 MK/Q0\3VMKX,GM8$DGGU"+$(1">/6@3,CX _\(E>$CK<5S_Q)T^Z\(?$FR\8 MHGF6DTJY7/.X=>*N? [Q#!864FA7D$T5Q)+N0F,@-69\3M>UG2OBC$QLUO[2 M!$>"UD3[O[U!&(!$PV$^I(KI?A;X6F\*> M#HK:Z(-S.YF?'\.<8%>41?&W5K!CY?A*RA&>=L;*:[[P+\8;/Q5J:Z9>6ALK MU_N DX;V&:0CT^AB .:!6'XH\1P>&].%U/;7$X8D*L*;CF@1X'X-!3X_-O4@ M?:[CDCCD,:^EU8,!BOD[0]5U+2_B*WB,:+>2(UQ)($VL#@C']:]4F^,UPR". MT\*:BURQ"JLF=N3^%-E2U9VGQ#\01>'_ ;?W#OMEDC:.(>K$<5Y-\ ?#MQ+ MJ=YX@FC(BV^7&Q[L3DXJU=>#O&WQ,U6*Y\1Q?V9IJ'BVS@X^E>SZ-HUKH.D6 MVFV4>R"!=J@#J>Y-%]!7T/'?VAR?)T)>>9)#^@KU_P .<>'=.S_S[I_*O&/C M##XB\4ZE;VMCX?O3!8,Q\X#A\XZ5W7A;Q-K2^"&DNO#EXMY8HD:PXYF]Q2&] MCA/![*/VA]:)Z^='[]X MUG>4F)'7.Y@3D9KW0VUK$"[0Q*JC.2@ %>%_$?X3ZO%KY\0>%8G*X/XN7IU#X0-=F%HC.8GV/P5R(Z9'UQ7HWCOPQ)XJ\(W6E0R>5*0&C]"1T!H$MS'^#+ _#/3AW!D_\ M0C7F$X/A[]HE)96VI+-E2WHZD9K0\$>&/B7:'^Q'EFTW2DES)(>,C/.P^]=G M\2OAD_BFWM+[3)1'JEHH57;K(!ZF@M/4]+!R 1R*\#EA;6_VCFDM%WQV IO#3YTW\DKU7PF^_P )Z6WK;I_*O+OBAX.\;>,- M7CBM[:V_L^UR8&$F"*;+3(]/\065M%';QA(I8I,LV.Q% GL= MH*6BB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)8 M_-C*9(SW%$<2Q($7[HI]% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% $5S')+:RQQ2F*1E(60#.T^N*\9UCX'ZGKU\;O4O%4D\IR%+VX.T9Z= M:]KHH XGP1X-U3PD)(KOQ%/J=KMVQQ/'M"=.G)KJM1LWO]-N+5)W@:5"HD3J MON*N44 >+K\!(UO4NQXBO1<[M[3!1N+=S7JHTQ)-$_LR\D:ZC,7E222#E_1Z9\"-%LO$)OY[J2:U#[TM2,#/7DUN^)_A7IOBJ^\^]U'4%A4 );)( M!&F!V&*[^B@1QG@WX?VG@MI39W][-%(N/)F?*K[@5-XO^'VB>-(8AJ,3+/'] MR>+Y7 ]#ZBNMHH \LT+X&>'M'U2.\EFN+P1MN6*4C:?3->F^4HB\H+\F-N%X M 'I4U% '!Z+\*= T3Q0^O6QN&N"Y=4=OE4GK7>444 13PI/!)$^=LBE6P<<& MO-3\#/"C2/(S7[,>[39(^G%>GT4 9>@:):^'=(ATVS,IABSM,K;FY.>M3V^F M65O>37D-K''<3?ZR0#EJNT4 87B/PII'BJVC@U:V::.,Y4!RO\JPO^%1^"0F MW^Q$/_;1N/UKNJ* ,-O"VCRZ"FBS6*26$?W8G8G'OG\:K:'X$\.>&[DW&EZ5 M%#,?^6F26&?3-=+10!S\W@S0)]<&LR:7!)?C_EJ^?SQTHG\&>';K4)+Z?1[: M2X<8+.F?TKH** ,>W\+Z':0306^EVT<4W#H$X/X56'@?PP#D:%8Y]?*%=#10 M!F7F@:5J%I':W>GV\T$2[41TX4>@I-+T'2M#A,.F:?!;(WWA&@!;ZGO6I10! MFV^BZ99W3W-M86L4\AR[I$ 37CFG^*=+UGXPWZ^(S (+93!:)<(-J\]\U[IC MFO/_ !1\(/#GB6\DO766VNGY+Q'J?7% S7EL_!$@^>+0>.<@1#^5>>'3?#NL M_%72&\*6B*;$M)>30*1'Z >G>IK?]G[34N5-SK5W- /^683'ZUZ;X<\,:5X8 MLOLFEVPB0\LQY9C[F@18FT+1YYFEFTFRED;EF>W1B?S%30Z98VT+0P6-O%$_ MWHTB4*WU JY10!0CT?38B"FGVJD>D*U:>&.0 -&I"],J#BI:* ($MX8SN2%% M8=P@!KP?P_XZL;3XMZW=>)6:V#,T=NTJG$2@X QBO?ZXOQ7\-/#_ (NG$]] MT=QGF6$X)^M R"7QW\.[@%YM1TV4^KP$Y_-:Y"W@L_&OQ,TW4/#EG'!IFF$O M+=1Q>6)2>W Y[5LVWP*\)6[ LMS-@YP9.*]"TK2;'1[);2P@2&%?X5]?>@1> M'2D89&, _6G"B@"/;CH.?\^U+@D\T^B@!H!S[4ZBB@!N,FCG-.HH 0#'8"E' M2BB@!.] XI:* "DZTM% !1110 E%+10 E+110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,T444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444@!'>@!: M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C-!JI=QW;O%]FFC MC <>8&7.5]J +=%(.*4]* "BF L6(/3BGT %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4F.:6B@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0L P',XYT4 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)4,D3*#M)& ?2 MGT4 ,B4I$J,!UC;:Y'!H EHID8944,U.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%,EC$L90 MDC/<4 /ZT5#!!Y VAV8?[1J:@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,+M&\)VGVG5;I(R?N1CEW^@K>) MP#7D5M\.[OQ5X\U;6/%D;OI\4[)8P%_E9 ?E./IB@+%G3_CSX5O+DQ3)G6=[;W]I%=6TBR0RCW>BZI97,CR16LJA-QSC(.?Y4%-*UT>S44BTM!(4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117%?$:[UZ/2H;+P M_!(UU=/M\Q#C8* .UHKYJUN7XD>!6LM1U+5)Y(99 I5I=RYZX/Y5[,?&,4?@ M"/Q'>,O[4G@ND8M;HI."%X_I7I_PY\8 MOXD\*M(=:^)'BR;0]'NWM=)CY MFE0X) /K[]*]3\.^'+'PUI_V2S#D'EV9LEC2 UY)8X\>8ZKGIDXI_!%>!?$^ MSU:/XAV#27\LMK+(ABA!P%&1FO;[Q+EM%E6Q8+=>01"Q[-CBFU8!ESKNDV5R MMM=:G9P3M]V.6=58_AFM!'5T#J0RD9!!R#7B%S\%)[VWN-0UG69'OR&D CZ9 M S3O@;?ZA*^IZ9<74LD%NHV;CG!S2';0]5O?%6A:;<:W\(M#OH+_4+Z:66^??+YI; 'I^F*J? MR"ZMM'U2.1V:T2?;%N.>1G)_E1T!(])U76],T2)9=2OH;5&. 9& S5FSO+>^ MM8[FUE66%QE70Y!KR?X\Z3#-X?M]3)(FA?8H]0:[3X=-N\!:/D_\L!18+:$? MBKXC>'O",HAU"XD:<_\ +*)=S8]?I5[PMXST7Q=#)+I5SYA3[Z,,,/PJM?\ M@7PU=7UUJ>H6,4\DPS(\O( %>=?"G28[?XCZW-IXV:=$&5%3[O)H ]O/W:Y' MQC\0=(\'"-;PR2SN,B&'EJZX]*Q[[P]HMS>G4KRQ@>=5P99%' I,1RO@[XL: M/XNU)M/CAFM+CJBRC[]>AUX;X8TC3[KXWWEUI@B%K:JS@(>-Q !Q7N54QL** M**0@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHJ&>9+>)YI'"1J-S,QX44 8OC74[72?"6I7-Y(( MXS \:D]V92 *XKX%Z%/I7A&>_N$*-J$OF*#W49P?UJEJ4ES\5O%<%G9!QX:T MZ7,\IZ3./2O7;>&.WMXX8E"QQJ%4#L!0!(.E+110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %'6BB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#Q2UA>*?$UEX7TB6]O)54@ M'RTSRYQ0!PWQKN1/HMAH]L!)=W5R/W:\D#!Y_6J_Q"TYM&^#%MI[$GRA$IS] M17/^$?$^E7OBB;Q+XEU:$M&A^SQ,.8P?I79^.Y4\:_#.ZFT4&89WKGC..>*H M9L>"HHX_A;9#8N#8[F&.I*UXKX4UBXTOPAXND@8KGRU&#C&XMD_I7HGAOQMI M,/PJ*FX6.>VMS T3-\VX#'2N2T#P?=7?PDUJ[6!SF54D_U-'4$5?! MWAGQA%X9DUW0M1B@+*S,H7!8=:],^%/C2_\ %6E3QZF ;NU;8[ 8S6)\,O%^ MEV_@22ROKN&WGMMZM%(P!/'3%2_!B.5Y--HSS7L']MV=KX:&KO* M#:1P"4NO.1BB6R!F?XU\00Z#X>N9I%,DKH4CC3J2>*Y;X.>&;C1M)N=0O(RD M]XW"D8(6O/9/BA::AXSFU'5([F738QB*)%!%=OIGQE35;^5;#1IS801EW?'S M#\!0]@9TGQ)TWQ)J7AYXO#UVL'!\Y23WOAV^4![=-X.,'( M(!S^=:A^.6@3V.[)$A Y/!(/YBNEN/C#K=KJUQ92>%;APCE4* G..]2^"_#FK M>(/%Q\9:S#]C8$B*W(Y(P1_6DM@Z'K@_2J6J:=#JVFSV,Y=8IE*L8V*L/<$5 MRESXE\2Q>/1I,>C[M*(&+K:?\:Q/$'BOXAZ1KD\5IX=@N[!<>6ZJ22/SJ1'! MMH4_P\^+&FV=A=S/#HS7T@,[1GKBO(_#?A37O$_BQ/%/BJV2 MT\E0+>W0\\'(S^->NTQMA1110(**** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]#SBO"_BG\5+=;Z7P MS9[FMT?9>RJ<'KRHKW7 QBN5N/AMX/N[Z6]GT*WDN)7,CNS/\S$Y)ZXH \TT M7XU>%= TN/3M-T2XC@B'&"!N//+>WTV#[-I4,;-<)(,D\ M>M=G)\,/!%-"\.^8=)TV*U,@PY0DDC\2:!FPIR,YI: M0 =J6@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !7->+?!&D^,H[>/4Q-B!BR^6^WKZUTM(3B@#S+_ (47X1_Z?/\ O]_]:N\T M?0[+1-(BTRT0_9XQ@!NO;3([OO:..7"$_3 M%=C!906UI':PQA(47:$'3%3YHS2 Y&Y^&?A6[OC=R::HE+;CM. 3]*Z>TLK> MQMU@M85BC48"J,5-O&<9'YTI)[8H PM3\&^']9NC@IJ2K(NZ-E93T(.10!CQ^#O#T,WG1Z1:J_J M$K91%10JJ HZ =J@NM2L[(@75S%#D<;V S4L-S%<1B2&1)$/1E.10 DMM!<< M31)(!T#*#3HH(H%VQ1HB^BC%2 YILDBQ(7=@J@9))Z4 ,^S0;]_DIN/?:,T\ M(HZ#I5&PUO3=4DDCLKV&=X_OB-LXJW<7$=M"TLK!8U&68]J )"H-&*Y&S^)G MAB^U3^SXM103[MHW# )^M=/?&&^83W>E^'Y+G3;=BLEP2>W7%=YX M2\56?BW1UO[3*]F0]5- &_1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QOQ$\5/X6T/S+9E^ MVW#B. -SSZUV5>0?'-3;QZ#J3\P6]R3(N"3C@TUN-&/J&H?$[0M-37[F^CEM M%P\D6T<*3]*]9\*:_%XE\/P:C&02XPP'K7/:UXGT35_AI>7$%W$T;VH'EL0& M!XXQ5+X(@GP,6R=K3MMSV%%M ,)_%'BP?%O^RKF[6&R\[*1!1AD[5ZEXDN-0 MMM"N9-,A,UX5VQH#T)[UY?XB02?'/3L<$0C\:]DQP.,TY*P'SQXGT?X@>'+ M>(;G7' + R0JY^3)P!COUKUGPYXFGG\!P:O?8\T0[F8]ZX/XV>+)8H/[".FS MI'(0S7+?<.#GC&?3VI=9UN";X&QM8.5 $<38Z]<&BP&?:Z9XA\>IJVO_ -MW M%E#;.X@6'(#!?QKKOA-XRN->TM["_?S+NU.W>?O,/>K7PFB'_"L(-P_UGF[A MZ\D5Y=X%UV#PWXTU>XG<1VZ^8![G/ ^O%%M1GH/QC\5S:5H@T^SD9)YR0S(V M"HI_P;O+G_A I;J]N))0LK$%SD@"N5OK>+Q%X>U;Q)>RI)))S%'O&54'T)ZU MN?#*[B;X47R1N/-02L4SR.M%M L4-+T!OB7XEO\ 4=5N99-.AD:.*.,E,$=. M]+\/K^\\.?$:^\*,TC69+&-96W%<#-;?P5\MO#M])&Q+/(LNX8.,=Z@+'COP0MDM?$.N11!MD;[1DY/ M4]?RKH_C1J=U'HUAI-G,8Y+^Y6)MIP2/_P!=8_P8!7Q+XDR5QYQ'OU_^O2_& M'CQMX4W$K%YX)/;[ZUH]9:@/\7^ -/T?X9K-;0(E_:!9&G ^=CWYK!\0>-[K M5OAYH]@DC*]SB.1\=E.VO4OB0X3X?:DP.,19S7@TT;1^&/#$G*J\TBDXZCS* M2L-'J^O>"M+M?A1)%%;IYL,"S^:HPQ;'6MOX57"<3^()XYOCUIT)#J8G1,]B2,UZQXJUI/ M#_AJ^U)XRXAC/ ]3P*)66P,^?/#'BJ'3?!FL>'+[;'.Q/E@CYBQZC]/UKUWX M1>'KG0O"2F[0)-<-YFWT':O'_P#A =1\1^%;KQA!-'%*LCR&$CJHYR/?FO6_ MA!XKN?$?AF2&^YNK)Q&S8QN&.*';H!Z+THHHJ1!1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;K6B M6.O6+V>H0++">GJ*TJS=M>R7%Y;VB;[F M:.%2< R,%S^=>=W?PA@O/%)UV36+PSF7S<$],=JZCQ=X.M?%VBQZ?=S2QF-@ MRRHV&R!BANX'/?%.ZTJY\&W):>VEDV_NQN!;/M7(Z#X=EN_@A>)*C)P\J KS M@QS7]_<7T4;96*1CCVKTV.RABM%M4B40JNP1CIBBX'EGPS\ M4V-G\,7BDF03V?FAE9L'J2.M%F,<.]>W3K]*]&U;PAH6N3^?J6F6\\N,;V M3D_4UH:?IMGI=HMI96\<$"]$1<"G<1S/Y3R,UVOQ> M\.W6KZ!#J-BA:ZTY_-"@]=Y!IMC;2F6"SACD(^\D8!JT5X/OUS3N#=SQ" M;QC-X[\.0>%[6UN$U"9469V0XXZY/:NF\4_#E;GP%;:7IRJMW9 /$Y[GJ?UK MT80(K[U10WKCFI*+BN>%3:SXLU[P]:>$CHMW#.66&6X:,@;1U.37KOAO14\/ M:!::=&/]2@#'U/>M?'S9Z4ZBX'A6I:!XKN/BW'X@309F@BG7G(VL%XSFO5_% M&AOXG\*W.F,WD27$8YZ[3UQ6Z1GB@# X%)Z@>%Z7HGQ!\.^'K[P]%I,=S:SA ME6;S5.-W&>M>@?#7P=+X0\/M!IH =29S2TWUH =29%,%13LP0X8CZ&@"P6 ..?RHR*PKBXF M5>)I!]&->?>+-1ODDPEY<+\IZ2L/ZT#L>N&6,'EU_,45\JWFJ:AYQ_TZYZ_\ )]F_QHH'RG__9 end EX-101.SCH 13 vhaq-20221231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - INITIAL PUBLIC OFFERING link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PRIVATE PLACEMENT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NOTE AGREEMENTS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ DEFICIT link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - NOTE AGREEMENTS PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - PRIVATE PLACEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - NOTE AGREEMENTS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCKHOLDERS’ DEFICIT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 vhaq-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 15 vhaq-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 16 vhaq-20221231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Warrants [Member] Units [Member] Rights [Member] Equity Components [Axis] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] IPO [Member] Public Shares [Member] Private Warrants [Member] Over-Allotment Option [Member] Scenario [Axis] Forecast [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] Business Acquisition [Axis] Clearday [Member] Earnout Shares [Member] Series F Cumulative Convertible Preferred Stock [Member] Series A Cumulative Convertible Preferred Stock [Member] New Merger [Member] Plan Name [Axis] Viveon Equity Incentive Plan [Member] Public Warrants [Member] Redeemable Common Stock [Member] Non Redeemable Common Stock [Member] Private Placement [Member] Founder Shares [Member] Title of Individual [Axis] Sponsor [Member] Transferee [Member] Chief Financial Officer [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Note Agreements [Member] Debt Instrument [Axis] Promissory Note [Member] Chief Executive Officer [Member] Three Investors [Member] Dipak Vashir [Member] Unsecured Senior Promissory Note Agreements [Member] Unsecured Promissory Note Agreements [Member] Subscription Warrants [Member] Warrant [Member] Related Party Transaction [Axis] Strategic Advisor [Member] Strategic Adviser [Member] Exclusive Financial Advisor [Member] Second Financial Advisor [Member] Third Financial Advisor [Member] Placement Agents [Member] Common Class A [Member] Class of Warrant or Right [Axis] Measurement Frequency [Axis] Fair Value, Recurring [Member] Asset Class [Axis] Money Market Funds [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Money Market Funds Held In Trust Account [Member] Liability Class [Axis] Private Warrant Liability [Member] Subscription Warrant Liability [Member] Mutual Fund [Member] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Share Price [Member] Measurement Input Market Debt Rate [Member] Measurement Input Probability Of Completing A Business Combination [Member] Private Warrant [Member] Unsucessful Business Combination [Member] Unsuccessful Business Combination [Member] Successful Business Combination [Member] Private And Subscription Warrants [Member] Subscription Warrants At Issuance On March 21, 2022 [Member] Subscription Warrants At Issuance On March 23, 2023 [Member] Subscription Warrants At Issuance On April 4, 2022 [Member] Subscription Warrants At Issuance On April 27, 2022 [Member] Subscription Warrants At Issuance On May 9, 2022 [Member] Subscription Warrants At Issuance On October 27, 2022 [Member] Subscription Warrants At Issuance On November 25, 2022 [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] Assets: Current assets: Cash and cash equivalents Prepaid expenses Due from related party Total current assets Investment held in Trust Account Deferred tax asset Total Assets Liabilities and Stockholders’ Deficit: Current liabilities: Accounts payable Accrued costs and expenses Franchise tax payable Note Agreements payable Note Agreements payable – related party Due to related party Promissory note - related party Common stock tendered for redemption Total current liabilities Deferred underwriting fee Warrant liabilities Uncertain tax position Total Liabilities Commitments and Contingencies (see Note 7) Common Stock subject to possible redemption, 1,844,774 and 20,125,000 shares at redemption value as of December 31, 2022 and 2021, respectively Stockholders’ Deficit: Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding Common stock not subject to possible redemption, $0.0001 par value; 60,000,000 shares authorized; 5,031,250 issued and outstanding (excluding 1,844,774 and 20,125,000 shares subject to redemption as of December 31, 2022 and 2021, respectively) Additional paid-in capital Accumulated deficit Total Stockholders’ Deficit Total Liabilities and Stockholders’ Deficit Temporary equity, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating costs Professional fees Franchise tax Stock compensation expense Loss from operations Other income (expenses): Expensed issuance costs on issuance of subscription warrants Interest and dividends earned on investments held in Trust Account Interest earned on money market account Interest expense - amortization of debt discount Gain on change in fair value of warrant liabilities Loss on issuance of subscription warrants Total other income (Loss) income before income taxes Income tax expense Net (loss) income Weighted average shares outstanding, basic and diluted Basic and diluted net (loss) income per common share Balance, value Balance, shares Remeasurement of common stock subject to possible redemption, to redemption amount Net income (loss) Additional offering costs related to the Initial Public Offering Stock compensation expense Balance, value Balance, shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities: Net (loss) income Adjustments to reconcile net (loss) income to net cash used in operating activities: Expensed issuance costs on issuance of subscription warrants Interest and dividends earned on investments held in Trust Account Interest expense - amortization of debt discount Gain on change in fair value of warrant liabilities Loss on issuance of subscription warrants Deferred tax expense Changes in operating assets and liabilities: Prepaid expenses Due from related party Accounts payable Accrued costs and expenses Franchise tax payable Due to related party Uncertain tax position Net cash used in operating activities Cash Flows from Investing Activities: Cash withdrawn from Trust Account for payment to redeeming stockholders Cash deposited to Trust Account for extension contribution Net cash provided by investing activities Cash Flows from Financing Activities: Proceeds from Note Agreements payable Proceeds from Note Agreements payable – related party Proceeds from promissory note- related party Payment to redeeming stockholders Payment of issuance costs Payment of promissory note - related party Payment of other payable - related party Offering costs paid Net cash used in financing activities Net change in cash Cash - beginning of period Cash - end of period Supplemental disclosure of noncash investing and financing activities: Common stock tendered for redemption Remeasurement of common stock subject to possible redemption, to redemption amount Accounting Policies [Abstract] DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Initial Public Offering INITIAL PUBLIC OFFERING Private Placement PRIVATE PLACEMENT Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Debt Disclosure [Abstract] NOTE AGREEMENTS PAYABLE Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Equity [Abstract] STOCKHOLDERS’ DEFICIT Warrants WARRANTS Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principles of Consolidation Emerging Growth Company Use of Estimates Cash and Cash Equivalents Investments Held in Trust Account Warrants Debt with Conversion and Other Options Common Stock Subject to Possible Redemption Offering Costs associated with the Initial Public Offering Share-Based Payment Arrangements Income Taxes Net (Loss) Income Per Common Share Concentration of Credit Risk Fair Value of Financial Instruments Derivative Financial Instruments Recent Accounting Standards SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE SCHEDULE OF NOTES Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES SCHEDULE OF INCOME TAX PROVISION SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION SCHEDULE OF UNRECOGNIZED TAX BENEFITS Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Sale of shares Share price Gross proceeds Purchase units Gross proceeds of options Sale of units, value Redemption percentage of outstanding public shares Initial business combination percentage of trust account Percentage of outstanding voting securities Business combination net tangible assets Aggregate percent of shares sold Redemption of public shares percentage Deposits Redemption payment shares Repayments of related party debt Share price Common stock, shares, outstanding Asset, held-in-trust Outstanding public shares percentage Company expenses and parent expenses Net of repayment subordinated convertible promissory note Agreegate warrants value Business Combination, Contingent Consideration, Liability Shares Issued, Price Per Share Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Preferred Stock, Par or Stated Value Per Share Preferred Stock, Conversion Basis Common Stock, Conversion Basis Common Stock, Convertible, Conversion Price, Increase Percentage of common stock issued and outstanding Percentage of lock up shares Percentage of excise tax Fair value of Public Warrants at issuance Fair value of Rights at issuance Issuance costs allocated to common stock subject to possible redemption Remeasurement of carrying value to redemption value Common stock subject to possible redemption as of December 31, 2021 Redemption of common stock by stockholders Redemption of common share, value Common stock subject to possible redemption as of December 31, 2022 Numerator: Denominator: Weighted Average Common Stock Subsequent Event [Table] Subsequent Event [Line Items] Cash equivalents Investment held in Trust Account Temporary equity, shares issued Offering costs Cash underwriting fee Deferred underwriting fees Other offering costs Other offering costs Unrecognized tax benefits Warrants exercisable to purchase shares of common stock Federal depository insurance coverage amount Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary, Sale of Stock [Line Items] Sale of stock Exercise price of warrants Sale of stock Warrent purchases Warrent purchases price Number of shares issued to sponsor Number of shares issued to sponsor, shares Common stock dividend declared per share Common stock dividend declared shares Shares cancellation common stock subject to forfeiture Share issued Founder shares related description Number of stock transferred Fair value of founder shares Founder shares, per share Share based compensation Notes payable, related party Costs and expenses, related party Proceeds from initial public offering Loans payable Proceeds from Loans Proceeds from (Repayments of) Notes Payable Rent paid Administrative service fees Due to related party Incurred expenses Due to related party Note Debt discount Carrying value of notes Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Debt instrument description Interest rate Line of credit facility maximum borrowing capacity Notes receivable Commitment fee amount Common Stock, Dividends, Per Share, Declared Debt Instrument, Face Amount Class of Warrant or Right, Exercise Price of Warrants or Rights Debt forfeit for cancellation Subscription warrants Fair Value Adjustment of Warrants Debt discount Interest expense Additional Shares granted Underwriting fee Underwriting expense Underwriting expense Agreement fees Accrued costs and expenses Advisor fees Accrued advisor fee Business combination consideration transferred Business combination assets description Floor Brokerage Broker dealer fee Redemption payment shares (in Shares) Temporary equity shares issued Deposit amount Redemption of common share, value Temporary equity shares outstanding Common stock outstanding, shares Voting rights Price per warrant Business combination equity description Shares issued price Redemption price per share Purchase price per warrant Warrants outstanding Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets Liabilities Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Warrants and rights outstanding, measurement input Warrants and rights term Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair value as of beginning Change in fair value Fair value as of ending Fair value of Subscription Warrants Contractual term Exercise price Contractual term Probability Contractual term Recognized gain (loss) in fair value Deferred tax assets: Start-up costs Accrued interest Transaction costs Net operating loss carryforwards Total deferred tax assets Valuation allowance Deferred tax assets, net of allowance Federal Current Deferred State Current Deferred Change in valuation allowance Income tax provision Statutory federal income tax rate State taxes, net of federal tax benefit Change in fair value of derivative warrant liabilities Non-deductible transaction costs Stock compensation expense Other permanent items, net Warrant issuance costs Change in valuation allowance Income tax provision Uncertain tax benefits - January 1 Gross increases - Tax positions in prior period Uncertain tax benefits - December 31 Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Operating loss carry forwards Valuation allowance Clearday [Member] Earnout Shares [Member] Offering costs paid. Percentage of common stock issued and outstanding. Viveon Equity Incentive Plan [Member] Remeasurement of common stock subject to possible redemption to redemption amount. Percentage of lock up shares released from the lockup. Percentage of excise tax. Emerging Growth Company [Policy Text Block] Redeemable Common Stock [Member] Units [Member] Warrants [Member] Percentage of redemption of companys outstanding public shares. Initial business combination percentage of trust account. Redemption of public shares percentage. Outstanding public shares percentage. Expensed issuance costs on issuance of subscription warrants. Fair value of warrants at issaunce. Fair value of rights at issuance. Initial Public Offering Disclosure [Text Block] Private placement disclosure [Text Block] Non Redeemable Common Stock [Member] Offering costs. Other offering costs. Stock issued issuance costs common stock subject to possible redemption. Founder Shares [Member] Sponsor [Member] Transferee [Member] Promissory Note [Member] Unsecured Promissory Note Agreements [Member] Private Warrant Liability [Member] Subscription Warrant Liability [Member] Agreement fees. Strategic Advisor [Member] Private Warrants [Member] Strategic advisor accrued fees. Subscription Warrants [Member] Measurement Input Market Debt Rate [Member] Measurement Input Probability Of Completing A Business Combination [Member] Warrants and rights disclosure text block Underwriting fee per share. Subscription Warrants At Issuance On March Twenty One Twenty Twenty Two [Member] Subscription Warrants At Issuance On March Twenty Three Twenty Twenty Two [Member] Subscription Warrants At Issuance On April Four Twenty Twenty Two [Member] Subscription Warrants At Issuance On April Twenty Seven Twenty Twenty Two [Member] Subscription Warrants At Issuance On May Nine Twenty Twenty Two [Member] Subscription Warrants At Issuance On October Twenty Seven Twenty Twenty Two [Member] Subscription Warrants At Issuance On November Twenty Five Twenty Twenty Two [Member] Private And Subscription Warrants [Member] Deferred tax assets gross transaction costs. Effective income tax rate reconciliation change in fair value of derivative warrant liabilities. Effective income tax rate reconciliation warrant issuance costs. Series F Cumulative Convertible Preferred Stock [Member] Series A Cumulative Convertible Preferred Stock [Member] Deferred underwriting fees. Public Warrants [Member] Public Shares [Member] Unsecured Senior Promissory Note Agreements [Member] Advisor fees. Strategic Adviser [Member] Exclusive Financial Advisor [Member] Third Financial Advisor [Member] Second Financial Advisor [Member] Warrants and rights term. Percentage of voting equity interests acquired at the acquisition date in the business combination. Placement Agents [Member] New Merger [Member] Promissory note related party. Dipak Vashir [Member] Effective income tax rate reconciliation nondeductible transaction costs. Common stock tendered for redemption. Common stock tendered for redemptions. Deferred tax assets accrued interest. Uncertain tax position. Increase decrease in uncertain tax position. Note Agreements [Member] Three Investors [Member] Debt with Conversion and Other Options [Policy Text Block] Money Market Funds Held In Trust Account [Member] Interest earned on money market account. Unsecured Promissory Note [Member] Debt instrument, forfeit for cancellation shares. Assets, Current Assets [Default Label] Liabilities, Current Liabilities [Default Label] Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) ExpensedIssuanceCostsOnIssuanceOfSubscriptionWarrants Interest Expense Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Shares, Outstanding APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Issuance of Stock and Warrants for Services or Claims Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Due from Related Parties Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Accrued Liabilities Increase (Decrease) in Property and Other Taxes Payable Increase (Decrease) in Due to Related Parties Increase decrease in uncertain tax position Net Cash Provided by (Used in) Operating Activities Payments to Acquire Investments Net Cash Provided by (Used in) Investing Activities Payments for Repurchase of Common Stock Payments of Stock Issuance Costs Repayments of Other Debt OfferingCostsPaid Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents CommonStockTenderedForRedemptions Derivatives, Policy [Policy Text Block] Share Price StockIssuedIssuanceCostsCommonStockSubjectToPossibleRedemption Offering Costs, Partnership Interests Due to Related Parties, Current Related Party Tax Expense, Due to Affiliates, Deferred Debt Instrument, Unamortized Discount, Current Notes Payable Costs and Expenses Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Deferred Tax Assets, Gross Deferred Tax Assets, Net of Valuation Allowance Current State and Local Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent EX-101.PRE 17 vhaq-20221231_pre.xml XBRL PRESENTATION FILE XML 18 R1.htm IDEA: XBRL DOCUMENT v3.23.2
    Cover - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Aug. 22, 2023
    Jun. 30, 2022
    Document Type 10-K    
    Amendment Flag false    
    Document Annual Report true    
    Document Transition Report false    
    Document Period End Date Dec. 31, 2022    
    Document Fiscal Period Focus FY    
    Document Fiscal Year Focus 2022    
    Current Fiscal Year End Date --12-31    
    Entity File Number 001-39827    
    Entity Registrant Name VIVEON HEALTH ACQUISITION CORP.    
    Entity Central Index Key 0001823857    
    Entity Tax Identification Number 85-2788202    
    Entity Incorporation, State or Country Code DE    
    Entity Address, Address Line One 3480 Peachtree Road NE    
    Entity Address, Address Line Two 2nd Floor - Suite #112    
    Entity Address, City or Town Atlanta,    
    Entity Address, State or Province GA    
    Entity Address, Postal Zip Code 30326    
    City Area Code (404)    
    Local Phone Number 861-5393    
    Entity Well-known Seasoned Issuer No    
    Entity Voluntary Filers No    
    Entity Current Reporting Status No    
    Entity Interactive Data Current Yes    
    Entity Filer Category Non-accelerated Filer    
    Entity Small Business true    
    Entity Emerging Growth Company true    
    Elected Not To Use the Extended Transition Period false    
    Entity Shell Company true    
    Entity Public Float     $ 103,157,271
    Entity Common Stock, Shares Outstanding   6,648,665  
    ICFR Auditor Attestation Flag false    
    Auditor Firm ID 688    
    Auditor Name Marcum LLP    
    Auditor Location New York, NY    
    Common Stock [Member]      
    Title of 12(b) Security Common Stock    
    Trading Symbol VHAQ    
    Security Exchange Name NYSEAMER    
    Warrants [Member]      
    Title of 12(b) Security Warrants    
    Trading Symbol VHAQW    
    Security Exchange Name NYSEAMER    
    Units [Member]      
    Title of 12(b) Security Units    
    Trading Symbol VHAQ    
    Security Exchange Name NYSEAMER    
    Rights [Member]      
    Title of 12(b) Security Rights    
    Trading Symbol VHAQR    
    Security Exchange Name NYSEAMER    

    XML 19 R2.htm IDEA: XBRL DOCUMENT v3.23.2
    Consolidated Balance Sheets - USD ($)
    Dec. 31, 2022
    Dec. 31, 2021
    Current assets:    
    Cash and cash equivalents $ 19,847 $ 395,235
    Prepaid expenses 48,726 3,863
    Due from related party 15,000
    Total current assets 68,573 414,098
    Investment held in Trust Account 53,815,395 203,282,989
    Deferred tax asset 39,259
    Total Assets 53,923,227 203,697,087
    Current liabilities:    
    Accounts payable 226,796 47,720
    Accrued costs and expenses 2,150,712 1,927,662
    Franchise tax payable 397,002 197,200
    Note Agreements payable 2,045,000
    Note Agreements payable – related party 1,955,000
    Due to related party 55,806 15,850
    Promissory note - related party 75,000
    Common stock tendered for redemption 34,004,514
    Total current liabilities 40,909,830 2,188,432
    Deferred underwriting fee 7,043,750 7,043,750
    Warrant liabilities 2,535,515 4,188,221
    Uncertain tax position 100,569 0
    Total Liabilities 50,589,664 13,420,403
    Commitments and Contingencies (see Note 7)
    Common Stock subject to possible redemption, 1,844,774 and 20,125,000 shares at redemption value as of December 31, 2022 and 2021, respectively 19,413,879 203,262,500
    Stockholders’ Deficit:    
    Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
    Common stock not subject to possible redemption, $0.0001 par value; 60,000,000 shares authorized; 5,031,250 issued and outstanding (excluding 1,844,774 and 20,125,000 shares subject to redemption as of December 31, 2022 and 2021, respectively) 503 503
    Additional paid-in capital 157,140
    Accumulated deficit (16,080,819) (13,143,459)
    Total Stockholders’ Deficit (16,080,316) (12,985,816)
    Total Liabilities and Stockholders’ Deficit $ 53,923,227 $ 203,697,087
    XML 20 R3.htm IDEA: XBRL DOCUMENT v3.23.2
    Consolidated Balance Sheets (Parenthetical) - $ / shares
    Dec. 31, 2022
    Dec. 31, 2021
    Statement of Financial Position [Abstract]    
    Temporary equity, shares outstanding 1,844,774 20,125,000
    Preferred stock, par value $ 0.0001 $ 0.0001
    Preferred stock, shares authorized 1,000,000 1,000,000
    Preferred stock, shares issued 0 0
    Preferred stock, shares outstanding 0 0
    Common stock, par value $ 0.0001 $ 0.0001
    Common stock, shares authorized 60,000,000 60,000,000
    Common stock, shares issued 5,031,250 5,031,250
    Common stock, shares outstanding 5,031,250 5,031,250
    XML 21 R4.htm IDEA: XBRL DOCUMENT v3.23.2
    Consolidated Statements of Operations - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Income Statement [Abstract]    
    Operating costs $ 756,386 $ 1,050,016
    Professional fees 1,368,699 2,701,431
    Franchise tax 246,216 197,200
    Stock compensation expense 157,140
    Loss from operations (2,371,301) (4,105,787)
    Other income (expenses):    
    Expensed issuance costs on issuance of subscription warrants (392,642)
    Interest and dividends earned on investments held in Trust Account 724,225 20,329
    Interest earned on money market account 892 147
    Interest expense - amortization of debt discount (3,645,777)
    Gain on change in fair value of warrant liabilities 8,468,308 6,575,140
    Loss on issuance of subscription warrants (3,209,183)
    Total other income 1,945,823 6,595,616
    (Loss) income before income taxes (425,478) 2,489,829
    Income tax expense (61,310)
    Net (loss) income $ (486,788) $ 2,489,829
    Weighted average shares outstanding, basic and diluted 12,224,223 24,150,000
    Basic and diluted net (loss) income per common share $ (0.04) $ 0.10
    XML 22 R5.htm IDEA: XBRL DOCUMENT v3.23.2
    Consolidated Statements of Changes in Stockholders' Deficit - USD ($)
    Common Stock [Member]
    Additional Paid-in Capital [Member]
    Retained Earnings [Member]
    Total
    Balance, value at Dec. 31, 2020 $ 503 $ (15,607,539) $ (15,607,036)
    Balance, shares at Dec. 31, 2020 5,031,250      
    Remeasurement of common stock subject to possible redemption, to redemption amount       (32,194,711)
    Net income (loss) 2,489,829 2,489,829
    Additional offering costs related to the Initial Public Offering (25,749) (25,749)
    Stock compensation expense 157,140 157,140
    Balance, value at Dec. 31, 2021 $ 503 157,140 (13,143,459) (12,985,816)
    Balance, shares at Dec. 31, 2021 5,031,250      
    Remeasurement of common stock subject to possible redemption, to redemption amount (157,140) (2,450,572) (2,607,712)
    Net income (loss) (486,788) (486,788)
    Balance, value at Dec. 31, 2022 $ 503 $ (16,080,819) $ (16,080,316)
    Balance, shares at Dec. 31, 2022 5,031,250      
    XML 23 R6.htm IDEA: XBRL DOCUMENT v3.23.2
    Consolidated Statements of Cash Flows - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Cash Flows from Operating Activities:    
    Net (loss) income $ (486,788) $ 2,489,829
    Adjustments to reconcile net (loss) income to net cash used in operating activities:    
    Expensed issuance costs on issuance of subscription warrants 392,642
    Interest and dividends earned on investments held in Trust Account (724,225) (20,329)
    Interest expense - amortization of debt discount 3,645,777
    Gain on change in fair value of warrant liabilities (8,468,308) (6,575,140)
    Loss on issuance of subscription warrants 3,209,183
    Stock compensation expense 157,140
    Deferred tax expense (39,259)
    Changes in operating assets and liabilities:    
    Prepaid expenses (44,863) 656,832
    Due from related party 15,000 (15,000)
    Accounts payable 179,076 47,720
    Accrued costs and expenses 228,050 969,370
    Franchise tax payable 199,802 197,200
    Due to related party 39,956 10,044
    Uncertain tax position 100,569
    Net cash used in operating activities (1,753,388) (2,082,334)
    Cash Flows from Investing Activities:    
    Cash withdrawn from Trust Account for payment to redeeming stockholders 152,451,819
    Cash deposited to Trust Account for extension contribution (2,260,000)
    Net cash provided by investing activities 150,191,819
    Cash Flows from Financing Activities:    
    Proceeds from Note Agreements payable 2,045,000
    Proceeds from Note Agreements payable – related party 1,955,000  
    Proceeds from promissory note- related party 75,000
    Payment to redeeming stockholders (152,451,819)
    Payment of issuance costs (437,000)
    Payment of promissory note - related party (228,758)
    Payment of other payable - related party (364,880)
    Offering costs paid (25,749)
    Net cash used in financing activities (148,813,819) (619,387)
    Net change in cash (375,388) (2,701,721)
    Cash - beginning of period 395,235 3,096,956
    Cash - end of period 19,847 395,235
    Supplemental disclosure of noncash investing and financing activities:    
    Common stock tendered for redemption 34,004,514
    Remeasurement of common stock subject to possible redemption, to redemption amount $ 2,607,712
    XML 24 R7.htm IDEA: XBRL DOCUMENT v3.23.2
    DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN
    		 12 Months Ended
    Dec. 31, 2022
    Accounting Policies [Abstract]  
    DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

    NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN

     

    Viveon Health Acquisition Corp. (the “Company” or “Viveon”) is a newly organized blank check company incorporated as a Delaware company on August 7, 2020. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (“Business Combination”).

     

    The Company has neither engaged in any operations nor generated any revenues to date. The Company’s only activities for the years ended December 31, 2022 and 2021 were organizational activities, those necessary to prepare for the Company’s initial public offering (the “Initial Public Offering”), described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company does not expect to generate any operating revenues until after the completion of our Business Combination. The Company generates non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. The Company incurs expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. The Company’s sponsor is Viveon Health, LLC, a Delaware limited liability company (the “Sponsor”).

     

    The registration statement for the Initial Public Offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on December 22, 2020. On December 28, 2020, the Company consummated the Initial Public Offering of 17,500,000 units (the “Units” and, with respect to the common stock included in the Units being offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $175,000,000, which is discussed in Note 3. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 18,000,000 warrants (the “Private Warrants”), at a price of $0.50 per Private Warrant, which is discussed in Note 4.

     

    On December 30, 2020, the underwriters fully exercised the over-allotment option by purchasing 2,625,000 Units (the “Over-Allotment Units”), generating aggregate of gross proceeds of $26,250,000.

     

    Upon closing of the Initial Public Offering and the sale of the Over-Allotment Units, $203,262,500 (approximately $10.10 per Unit) from net offering proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, with a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act 1940, as amended (the “Investment Company Act”), which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its tax obligations, the proceeds from the Initial Public Offering will not be released from the Trust Account until the earliest to occur of (1) the completion of the initial Business Combination within 15 months, unless extended to a total of 24 months, pursuant to the terms of an amendment to the Company’s amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”), and (2) the Company’s redemption of 100% of the outstanding Public Shares if the Company has not completed a Business Combination in the required time period.

     

    While the Company’s management has broad discretion with respect to the specific application of the cash held outside of the Trust Account, substantially all of the net proceeds from the Initial Public Offering and the sale of the Private Warrants, which are placed in the Trust Account, are intended to be applied generally toward completing a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    In connection with any proposed initial Business Combination, the Company will either (1) seek stockholder approval of such initial Business Combination at a meeting called for such purpose at which public stockholders may seek to convert their Public Shares, regardless of whether they vote for or against the proposed Business Combination, into their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable) or (2) provide its public stockholders with the opportunity to sell their Public Shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable), in each case subject to the limitations described herein. The Public Shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, Distinguishing Liabilities from Equity (“ASC 480”).

     

    If the Company determines to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its Public Shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that the Company is unable to satisfy any applicable closing condition set forth in the definitive agreement related to its initial Business Combination, or the Company is unable to maintain net tangible assets of at least $5,000,001, the Company will not consummate such initial Business Combination. The decision as to whether it will seek stockholder approval of a proposed Business Combination or will allow stockholders to sell their shares to the Company in a tender offer will be made by the Company based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval.

     

    If the Company provides stockholders with the opportunity to sell their shares to it by means of a tender offer, it will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial Business Combination as is required under the SEC’s proxy rules. If the Company seeks stockholder approval of its initial Business Combination, the Company will consummate the Business Combination only if a majority of the outstanding shares of common stock present in person or by proxy at a meeting of the Company are voted in favor of the Business Combination.

     

    Notwithstanding the foregoing redemption rights, if the Company seeks stockholder approval of its initial Business Combination and the Company does not conduct redemptions in connection with its initial Business Combination pursuant to the tender offer rules,(the Amended and Restated Certificate of Incorporation will provide that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its Public Shares with respect to more than an aggregate of 20% of the shares sold in the Initial Public Offering, without the Company’s prior consent. The Company’s Sponsor, officers and directors (the “initial stockholders”) have agreed not to propose any amendment to the Amended and Restated Certificate of Incorporation (a) that would modify the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with an initial Business Combination or to redeem 100% of its Public Shares if the Company does not complete its initial Business Combination within 15 months from the closing of the Initial Public Offering or (b) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity, unless the Company provide its public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    On March 18, 2022, the Company held a stockholder meeting to seek approval to extend the date by which the Company has to consummate a business combination from March 28, 2022 (the “Original Termination Date”) to June 28, 2022. In connection with the extension, the Company made a deposit into the Trust Account of $720,000 on March 23, 2022. As part of the meeting, stockholders redeemed 15,092,126 shares resulting in redemption payments out of the Trust Account totaling approximately $152,451,819. In addition, stockholders approved a proposal to allow the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with Suneva Medical, Inc. as described below or any potential alternative initial Business Combination shall have occurred. On each of June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 the Company deposited $240,000 into the Trust Account to extend the date to consummate a Business Combination through July 28, 2022, August 28, 2022, September 28, 2022, October 28, 2022, November 28, 2022, and December 28, 2022, respectively.

     

    On December 23, 2022, the Company held its 2022 Annual Meeting of Stockholders, to among other things, seek approval to amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time for a total of up to six months from December 28, 2022 until June 30, 2023 (the “Second Extended Date”), upon three calendar days’ advance notice prior to the applicable monthly deadline unless the closing of any potential initial business combination shall have occurred prior to the Second Extended Date. On each of December 27, 2022, January 26, 2023, February 27, 2023, March 27, 2023, and April 28, 2023, the Company deposited $100,000 into the Trust Account to extend the date to consummate a Business Combination through January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023, respectively. Viveon made a final deposit of $100,000 on May 24, 2023 for a one month extension until June 30, 2023.

     

    On June 22, 2023, the Company held a stockholder meeting to amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company, without another stockholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month until December 31, 2023, by depositing $85,000 into the trust account and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”).

     

    On June 22, 2023, the Company held a stockholder meeting (the “June 2023 Stockholders Meeting”) in which stockholders voted to (A) amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to the Trustee, prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date; and (B) to amend the Company’s Investment Management Trust Agreement, dated as of December 22, 2020, by and between the Company and the Trustee, allowing the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, each such extension for an additional one month period, with no additional deposits to be made into the Trust Account during such period from January 1, 2024 through March 31, 2024. In connection with the stockholders’ vote at the June 2023 Stockholders Meeting, 227,359 shares of common stock were tendered for redemption. As a result, approximately $2,498,947 (approximately $10.99 per share) were removed from the Company’s Trust Account to pay such holders, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date. Following redemptions, the Company has 1,617,415 shares of public common stock outstanding, and approximately $17,777,324 will remain in the Trust Account. On June 27, 2023, and July 27, 2023, the Company deposited $85,000 in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023 and August 31, 2023, respectively.

     

    If the Company is unable to complete its initial Business Combination by the Third Extended Date (the “Combination Period”), the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding Public Shares (including any Units or Public Shares that its initial stockholders or their affiliates purchased in the Initial Public Offering or later acquired in the open market or in private transactions), which will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of the Company’s remaining holders of common stock and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law.

     

    The Company’s initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares (as defined in Note 5) held by them if the Company fails to complete its initial Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination within the Combination Period.

     

    Merger Agreement

     

    On January 12, 2022, the Company entered into a Merger Agreement (the “Old Merger Agreement”) by and among the Company, VHAC Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Old Merger Sub”), and Suneva Medical, Inc., a Delaware corporation (“Suneva”). Pursuant to the terms of the Merger Agreement, a Business Combination between the Company and Suneva will be effected through the merger of Old Merger Sub with and into Suneva, with Suneva surviving the merger as a wholly owned subsidiary of the Company (the “Old Merger”). The board of directors of the Company has (i) approved and declared advisable the Old Merger Agreement, the Old Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Old Merger Agreement and related transactions by the stockholders of the Company.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    On July 13, 2022, the Company, Old Merger Sub, and Suneva entered into the Second Amendment to Old Merger Agreement (the “Second Amendment”) that amended and modified the Old Merger Agreement to extend the outside closing date to December 31, 2022 and to reduce the amount of parent closing cash required as a closing condition from $50 million to $30 million, net of Suneva expenses and Viveon expenses (“Parent Expenses”) and net of repayment of the $1.5 million Subordinated Convertible Promissory Note (as defined in Note 5) issued by Suneva to Intuitus Suneva Debt LLC (an entity affiliated with Viveon’s Chief Financial Officer), dated May 10, 2022 (unless converted into Suneva capital stock at the consummation of the business combination, which conversion is mandatory except in the case of a default by Suneva). Further, the defined term Parent Expenses was amended to include the Viveon’s operating expenses, severance payments and deferred compensation.

     

    On November 10, 2022, the Company, Old Merger Sub, and Suneva entered into the Third Amendment to Old Merger Agreement (the “Third Amendment”) that amended and modified the Old Merger Agreement to (i) fix the aggregate exercise price for all of the in-the-money Suneva options and warrants at $2,582,075, representing the aggregate exercise price for all the in-the-money Suneva options and warrants outstanding as of the date of the Third Amendment, and extend the outside closing date from December 31, 2022 to March 31, 2023, to the extent the Company’s stockholders approve an amendment to its Amended and Restated Certificate of Incorporation to extend the date by which the Company has to consummate a business combination to June 30, 2023.

     

    On February 2, 2023, legal counsel for Viveon sent a letter informing Suneva’s legal counsel that Viveon decided, effective immediately, to unilaterally terminate the Old Merger Agreement pursuant to Sections 10.2(a) and 10.3 thereof, based upon material breaches of the Old Merger Agreement by Suneva. The termination letter was sent without prejudice and reserved all of Viveon, Old Merger Sub and Viveon Health, LLC (Viveon’s sponsor) rights, claims and remedies, specifically including those within the Merger Agreement, against Suneva and others associated with Suneva who participated in the merger discussions and arrangements, and waived none.

     

    Merger Agreement with Clearday 

     

    On April 5, 2023, the Company entered into a Merger Agreement (the “Merger Agreement”), by and among Viveon, Clearday, Inc., a Delaware corporation (“Clearday”), VHAC2 Merger Sub, Inc., a Delaware corporation (“New Merger Sub”), Viveon Health LLC, a Delaware limited liability Company, in the capacity as the representative from and after the effective time for the stockholders of the Company (other than the Company Stockholders (as defined in the Merger Agreement)) as of immediately prior to the effective time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement, and Clearday SR LLC, a Delaware limited liability company, in the capacity as the representative from and after the effective time for the holders of Company preferred stock as of immediately prior to the effective time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement. Pursuant to the terms of the Merger Agreement, a business combination between the Company and Clearday will be effected through the merger of New Merger Sub with and into Clearday, with Clearday surviving the merger as a wholly owned subsidiary of the Company and the Company will change its name to “Clearday Holdings, Inc.” (the “Merger”). The board of directors of the Company has (i) approved and declared advisable the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement, the Merger and related transactions by the stockholders of Company. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Merger Agreement.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Consideration

     

    Merger Consideration

     

    The total consideration to be paid at closing (the “Merger Consideration”) by the Company to Clearday security holders (and holders who have the right to acquire Clearday capital stock) will be an amount equal to $250 Million (plus the aggregate exercise price for all Clearday options and warrants). The Merger Consideration will be payable in shares of the Company’s common stock, par value $0.0001 per share, valued at $10 per share.

     

    Earnout Payments

     

    In addition, the holders of Clearday preferred stock will have the contingent right to earn up to 5,000,000 shares of the Company’s common stock, in the aggregate (the “Earnout Shares”), if at any time during the period beginning on the date of the Closing (the “Closing Date”) and ending on the fifth anniversary of the Closing Date (the “Earnout Eligibility Period”), the Adjusted Net Income (as defined below) for any Earnout Period is a positive number for the first time during the Earnout Eligibility Period (the “Earnout Milestone”). Under the Merger Agreement, Adjusted Net Income means for any Earnout Period, the consolidated net income or loss for such period calculated in accordance with U.S. GAAP applied on a basis consistent with past practice, of (a) for periods prior to the Closing, the Company and its subsidiaries (the “Company Group”), and (b) for periods from and after the Closing, of us and our subsidiaries (including the Company Group), in each case before adjusting for the following to the extent deducted/added in calculating consolidated net income or loss: (1) interest expense/income; (2) income tax expense/tax credits; (3) depreciation and amortization; (4) transaction expenses; (5) extraordinary items; (6) any income or loss attributable to us that accrues in accordance with U.S. GAAP on or prior to the Closing Date; and (7) all gains or losses in connection with sales or dispositions of assets and investments not in the ordinary course of business.

     

    If, following the Closing Date and prior to end of the Earnout Eligibility Period, there is a change of control, then, immediately prior to such change of control, all the Earnout Shares not yet earned shall be earned by the Clearday earnout holders and shall be released from escrow and delivered to the Clearday earnout holders, and the Clearday earnout holders shall be eligible to participate in such change of control transaction with respect to such Earnout Shares.

     

    The Earnout Shares will be placed in escrow and will not be released from escrow until they are earned as a result of the occurrence of the Earnout Milestone or a change of control, if applicable. The Earnout Shares that are not earned on or before the expiration of the Earnout Eligibility Period shall be automatically forfeited and cancelled.

      

    Treatment of Clearday Securities

     

    Cancellation of Securities.

     

    Each share of Clearday capital stock, if any, that is owned by the Company, New Merger Sub, Clearday, or any of their subsidiaries (as treasury stock or otherwise) immediately prior to the effective time of the Merger (the “Effective Time”), will automatically be cancelled and retired without any conversion or consideration.

     

    Preferred Stock.

     

    At the Effective Time, each issued and outstanding share of Clearday’s Series F Cumulative Convertible Preferred Stock, par value $0.001 per share (“Clearday Series F Preferred Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: (A) one (1) share of Parent New Series F Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement.

     

    Each issued and outstanding share of Clearday’s Series A Convertible Preferred Stock, par value $0.001 per share (“Clearday Series A Preferred Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: (A) one (1) share of Parent New Series A Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Common Stock.

     

    At the Effective Time, each issued and outstanding share of Clearday’s common stock, par value $0.001 per share (“Clearday Common Stock”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares) will be converted into the right to receive a number of shares of the Company’s common stock equal to the conversion ratio. The “Conversion Ratio” as defined in the Merger Agreement means an amount equal to (a)(i) the sum of $250 Million, plus the aggregate exercise or conversion price of outstanding Clearday’s stock options and warrants (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more), divided by (ii) the number of fully diluted Clearday capital stock (including Clearday preferred stock, warrants, stock options, convertible notes, and any other convertible securities) (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more and assuming a conversion price of Clearday subsidiary securities as provided in the Merger Agreement); divided by (b) $10.00.

     

    Merger Sub Securities.

     

    Each share of common stock, par value $0.0001 per share, of New Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and become one newly issued share of common stock of the surviving corporation.

     

    Stock Options.

     

    At the Effective Time, each outstanding option to purchase shares of Clearday Common Stock will be converted into an option to purchase, subject to substantially the same terms and conditions as were applicable under such options prior to the Effective Time, shares of the Company’s common stock equal to the number of shares subject to such option prior to the effective time multiplied by the Conversion Ratio, at an exercise price per share of the Company’s common stock equal to the exercise price per share of Clearday Common Stock subject to such option divided by the Conversion Ratio.

     

    Warrants.

     

    Contingent on and effective as of immediately prior to the effective time, each outstanding warrant to purchase shares of Clearday Preferred Stock or Clearday Common Stock will be treated in accordance with the terms thereof.

     

    Convertible Notes.

     

    Contingent on and effective as of immediately prior to the Effective Time, Clearday’s convertible notes outstanding as of immediately prior to the effective time, will be treated in accordance with the terms of the relevant agreements governing such convertible notes.

     

    Subsidiary Capital Stock.

     

    At and as of the effective time, the subsidiary capital stock will remain in full force and effect with the right to acquire the Clearday Common Stock with such adjustments noted in the terms of such subsidiary capital stock.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Representations and Warranties

     

    The Merger Agreement contains customary representations and warranties of the parties thereto with respect to, among other things, (a) corporate existence and power, (b) authorization to enter into the Merger Agreement and related transactions; subsidiaries, (c) governmental authorization, (d) non-contravention, (e) capitalization, (f) corporate records, (g) consents, (h) financial statements, (i) internal accounting controls, (j) absence of certain changes, (k) properties; title to assets, (l) litigation, (m) material contracts, (n) licenses and permits, (o) compliance with laws, (p) intellectual property, (q) privacy and data security, (r) employee matters and benefits, (s) tax matters, (t) real property, (u) environmental laws, (v) finders’ fees, (w) directors and officers, (x) anti-money laundering laws, (y) insurance, (z) related party transactions, and (aa) certain representations related to securities law and activity. The Company has additional representations and warranties, including (a) issuance of shares, (b) trust fund, (c) listing, (d) board approval, (e) SEC documents and financial statements, (f) certain business practices, (g) expenses, indebtedness and other liabilities and (h) brokers and other advisors.

     

    Covenants

     

    The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the registration statement and proxy statement (as each such terms are defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party’s respective stockholders. The Company and Clearday have each also agreed to include in the proxy statement the recommendation of its respective board that its stockholders approve all of the proposals to be presented at its respective special meeting. In addition, each of the Company and Clearday have agreed to use commercially reasonable efforts to solicit and finalize definitive documentation for a committed equity in an aggregate amount that, together with the funds in the Trust Account after giving effect to potential redemptions from the Company’s public stockholders, together with financing programs available to Clearday after the Closing, will provide to Clearday working capital to meet its short term commercial development goals.

     

    The Company has also agreed to prepare a proxy statement to seek the approval of its stockholders (the “Extension Proposal”) to amend its organizational documents to extend the period of time the Company is afforded under its organizational documents and IPO prospectus to consummate an initial business combination for an additional three months, from June 30,2023 to September 30, 2023 (or such earlier date as the Company and Clearday may agree in writing).

     

    Each party’s representations, warranties and pre-Closing covenants will not survive Closing and no party has any post-Closing indemnification obligations.

     

    Viveon Equity Incentive Plan

     

    The Company has agreed to approve and adopt an equity incentive plan (the “Incentive Plan”) to be effective as of the Closing and in a form mutually acceptable to the Company and Clearday, subject to approval of the Incentive Plan by the Company’s stockholders. The Incentive Plan will provide for an initial aggregate share reserve equal to 8% of the number of shares of the Company’s common stock issued and outstanding at the Closing and an “evergreen” provision that is mutually agreeable to the Company and Clearday will provide for an automatic increase on the first day of each fiscal year in the number of shares available for issuance under the Incentive Plan as mutually determined by the Company and Clearday.

     

    Non-Solicitation Restrictions

     

    Each of the Company and Clearday has agreed that from the date of the Merger Agreement to the effective time or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate any negotiations with any party relating to an alternative transaction (as such term is defined in the Merger Agreement) or enter into any agreement relating to such a proposal, other than as expressly excluded from the definition of an alternative transaction. Each of the Company and Clearday has also agreed to be responsible for any acts or omissions of any of its respective representatives that, if they were the acts or omissions of the Company and Clearday, as applicable, would be deemed a breach of the party’s obligations with respect to these non-solicitation restrictions.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Conditions to Closing

     

    The consummation of the Merger is conditioned upon, among other things, (i) the absence of any applicable law or order restraining, prohibiting or imposing any condition on the consummation of the Merger and related transactions, (ii) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (iii) receipt of any consent, approval or authorization required by any Authority (as defined in the Merger Agreement), (iv) the Company having net tangible assets of at least $5,000,001 (as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act), unless the Company’s amended and restated certificate of incorporation shall have been amended to remove such requirement prior to or concurrently with the Closing, (v) approval by Clearday’s stockholders of the Merger and related transactions, (vi) approval by the Company’s stockholders of the Merger and related transactions, (vii) the conditional approval for listing by NYSE American (or an alternate exchange) of the shares of the Company’s common stock to be issued in connection with the transactions contemplated by the Merger Agreement and satisfaction of initial and continued listing requirements, and (viii) the registration statement becoming effective in accordance with the provisions of the Securities Act of 1933, as amended (“Securities Act”).

     

    Solely with respect to the Company and New Merger Sub, the consummation of the Merger is conditioned upon, among other things, (i) Clearday having duly performed or complied with all of its obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of Clearday, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure would not have or reasonably be expected to have a material adverse effect (as defined in the Merger Agreement) on Clearday or any of its subsidiaries, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a material adverse effect on Clearday or any of its subsidiaries, (v) Clearday and its securityholders having executed and delivered to the Company each additional agreement (as defined in the Merger Agreement) to which they each are a party and (vi) Clearday delivering certain certificates to the Company.

     

    Solely with respect to Clearday, the consummation of the Merger is conditioned upon, among other things, (i) Viveon and New Merger Sub having duly performed or complied with all of their respective obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of the Company and Merger Sub, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a material adverse effect on the Company or New Merger Sub and their ability to consummate the Merger and related transactions, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a Material Adverse Effect on the Company or New Merger Sub, (v) the amended parent charter (as defined in the Merger Agreement) being filed with, and declared effective by, the Delaware Secretary of State, (vi) the Company delivering certain certificates to Clearday, (vii) the size and composition of the post-Closing board of directors of the Company having been appointed as set forth in the Merger Agreement and (viii) the Company, Viveon Health LLC and other stockholders, as applicable, having executed and delivered to Clearday each additional agreement to which they each are a party.

     

    Termination

     

    The Merger Agreement may be terminated at any time prior to the effective time as follows:

     

    (i) by either the Company or Clearday, if (A) the Merger and related transactions are not consummated on or before the latest of (i) June 30, 2023, (ii) if the Extension Proposal is approved, September 30, 2023 and (iii) if one or more extensions to a date following September 30, 2023 are obtained at the election of the Company, with the Company’s stockholder vote, in accordance with the Company’s amended and restated certificate of incorporation, the last date for the Company to consummate a business combination pursuant to such extensions; and (B) the material breach or violation of any representation, warranty, covenant or obligation under the Merger Agreement by the party seeking to terminate the Merger Agreement was not the cause of, or resulted in, the failure of the closing to occur on or before the outside Closing Date, without liability to the other party;

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    (ii) by either the Company or Clearday, if any authority has issued any final decree, order, judgment, award, injunction, rule or consent or enacted any law, having the effect of permanently enjoining or prohibiting the consummation of the Merger, provided that, the party seeking to terminate cannot have breached its obligations under the Merger Agreement and such breach was a substantial cause of, or substantially resulted in, such action by the authority; and

     

    (iii) by mutual written consent of the Company and Clearday duly authorized by each of their respective boards of directors.

     

    The Merger Agreement and other agreements described below have been included to provide investors with information regarding their respective terms. They are not intended to provide any other factual information about the Company, Clearday or the other parties thereto. In particular, the assertions embodied in the representations and warranties in the Merger Agreement were made as of a specified date, are modified or qualified by information in one or more disclosure letters prepared in connection with the execution and delivery of the Merger Agreement, may be subject to a contractual standard of materiality different from what might be viewed as material to investors, or may have been used for the purpose of allocating risk between the parties. Accordingly, the representations and warranties in the Merger Agreement are not necessarily characterizations of the actual state of facts about the Company, Clearday or the other parties thereto at the time they were made or otherwise and should only be read in conjunction with the other information that the Company or Clearday makes publicly available in reports, statements and other documents filed with the SEC. The Company and Clearday investors and securityholders are not third-party beneficiaries under the Merger Agreement.

     

    Certain Related Agreements

     

    Parent Support Agreements.

     

    Concurrently with the execution of the Merger Agreement, the Company, Clearday and the Sponsor and the officers and directors of the Company entered into a support agreement (the “Parent Support Agreement”) pursuant to which the Sponsor and the officers and directors of the Company have agreed to vote all shares of the Company’s common stock beneficially owned by them, including any additional shares of the Company they acquire ownership of or the power to vote: (i) in favor of the Merger and related transactions, (ii) against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions, and (iii) in favor of an extension of the period of time the Company is afforded to consummate an initial business combination.

     

    Company Support Agreements.

     

    Concurrently with the execution of the Merger Agreement, the Company, Clearday and certain stockholders of Clearday entered into a support agreement (the “Company Support Agreement”), pursuant to which such Clearday stockholders have agreed to vote all common and preferred stock of Clearday beneficially owned by them, including any additional shares of Clearday they acquire ownership of or the power to vote, in favor of the Merger and related transactions and against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions.

     

    Lock-Up Agreements.

     

    In connection with the closing, certain Clearday stockholders will each agree, subject to certain customary exceptions, not to (i) offer, sell contract to sell, pledge or otherwise dispose of, directly or indirectly, any lockup shares, (ii) enter into a transaction that would have the same effect, (iii) enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the lock-up shares or otherwise, (iv) engage in any short sales or other arrangement with respect to the lock-up shares or (v) publicly announce any intention to effect any transaction specified in clause (i), (ii) or (iii) until the date that is six months after the Closing Date (the “Lock-Up Period”). The term “Lockup Shares” mean the Merger Consideration Shares and the Earnout Shares, if any, whether or not earned prior to the end of the Lock-up Period, together with any other shares of the Company’s common stock, and including any securities convertible into, or exchangeable for, or representing the rights to receive the Company’s common stock, if any, acquired during the Lock-up Period. If the closing price of the Company’s common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period following the Closing Date, 50% of the Lock-up Shares will be released from the lock-up. The existing escrow provisions of the Company’s common stock held by certain stockholders will remain in effect.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Amended and Restated Registration Rights Agreement.

     

    At the Closing, the Company will enter into an amended and restated registration rights agreement (the “Amended and Restated Registration Rights Agreement”) with certain existing stockholders of the Company and Clearday with respect to their shares of the Company’s common stock acquired before or pursuant to the Merger, and including the shares issuable on conversion of the warrants issued to the Sponsor in connection with the Company’s initial public offering and any shares issuable on conversion of loans or other convertible securities. The agreement amends and restates the registration rights agreement the Company entered into on December 22, 2020 in connection with its initial public offering. Subject to the Lock-Up Agreements described above, the holders of a majority of the shares held by the Company’s existing stockholders, and the holders of a majority of the shares held by the Clearday stockholders will each be entitled to make one demand that Clearday register such securities for resale under the Securities Act, or two demands each if the Company is eligible to use Form S-3 or a similar short-form registration statement. In addition, the holders will have certain “piggy-back” registration rights that require the Company to include such securities in registration statements that the Company otherwise files. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

     

    Going Concern

     

    As of December 31, 2022, the Company had $19,847 of cash and cash equivalents held outside the Trust Account available for working capital needs. In connection with the Company’s assessment of going concern considerations in accordance with FASB’s ASC Subtopic 205-40, Presentation of Financial Statements - Going Concern, management has determined that if the Company is unable to raise additional funds to alleviate liquidity needs or complete a Business Combination by March 31, 2024, then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern one year from the date that these consolidated financial statements are issued. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to continue as a going concern. The Company intends to complete a Business Combination before the mandatory liquidation date or obtain approval for an extension.

     

    Risks & Uncertainties

     

    Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

     

    The credit and financial markets have experienced extreme volatility and disruptions due to the current conflict between Ukraine and Russia. The conflict is expected to have further global economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability. In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences, including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our common stock to be adversely affected.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Inflation Reduction Act of 2022 and Excise Tax

     

    On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, imposes a 1% excise tax on the fair market value of stock repurchased by publicly traded U.S. corporations and certain U.S. subsidiaries of publicly traded non-U.S. corporations beginning in 2023, with certain exceptions (the “Excise Tax”). Because we are a Delaware corporation and our securities trade on the New York Stock Exchange, we will likely be considered a “covered corporation” within the meaning of the Inflation Reduction Act. While not free from doubt, absent any further guidance from Congress or the U.S. Department of the Treasury, there is significant risk that the Excise Tax will apply to any redemptions of our common stock after December 31, 2022, including redemptions in connection with an initial Business Combination and any amendment to our certificate of incorporation to extend the time to consummate an initial Business Combination, unless an exemption is available. In addition, the Excise Tax may make a transaction with us less appealing to potential business combination targets, and thus, potentially hinder our ability to enter into and consummate an initial Business Combination. Further, the application of the Excise Tax in the event of a liquidation after December 31, 2022 is uncertain, and could impact the per-share amount that would otherwise be received by our stockholders in connection with our liquidation.

     
    XML 25 R8.htm IDEA: XBRL DOCUMENT v3.23.2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    		 12 Months Ended
    Dec. 31, 2022
    Accounting Policies [Abstract]  
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     

    Basis of Presentation

     

    The accompanying consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).

     

    Principles of Consolidation

     

    The consolidated financial statements include the accounts of the Company and its majority-owned and controlled operating subsidiary, Old Merger Sub after elimination of all intercompany transactions and balances as of December 31, 2022 and 2021.

     

    Emerging Growth Company

     

    The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. The Company has elected to implement the aforementioned exemptions.

     

    In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Use of Estimates

     

    The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.

     

    Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The initial valuation of the Public Warrants (as defined in Note 3), Rights (as defined in Note 3) common stock subject to redemption and the periodic valuation of the Private Warrants and Subscription Warrants (as defined in Note 6) required management to exercise significant judgement in its estimates.

     

    Cash and Cash Equivalents

     

    The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $6,346 and $350,455, were held in money market funds as of December 31, 2022 and December 31, 2021, respectively.

     

    Investments Held in Trust Account

     

    As of December 31, 2022 and December 31, 2021, substantially all of the assets held in the Trust Account were held in a money market account and mutual funds which invested in U.S. Treasury securities, respectively. The assets were transferred from mutual funds to a money market account on December 21, 2022. The assets in the amount of $53,815,395 and $203,282,989 were held in the Trust Account as of December 31, 2022 and December 31, 2021, respectively. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in Interest and dividends earned on investments held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in Trust Account are determined using available market information.

     

    Warrants

     

    The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

     

    For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. In accordance with guidance contained in ASC 815, the Public Warrants (as defined in Note 3) qualify for equity treatment. The Private Warrants and Subscription Warrants (as defined in Note 6) do not qualify as equity and are recorded as liabilities at fair value. Changes in the estimated fair value of the Private Warrants and Subscription Warrants are recognized as non-cash gains or losses on the consolidated statements of operations.

     

    Debt with Conversion and Other Options

     

    The Company accounts for a series of unsecured senior promissory note agreements under ASC Topic ASC 470-20-25-2, Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants (“ASC 470-20-25-2”).  In accordance with ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants (detachable call options) are allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Common Stock Subject to Possible Redemption

     

    All of the 5,032,874 Public Shares sold as part of the Units in the Initial Public Offering and subsequent full exercise of the underwriters’ over-allotment option that have not been redeemed by stockholders, contain a redemption feature which allows for the redemption of such redeemable common stock in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Therefore, all Public Shares been classified outside of permanent equity.

     

    The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. There was no change in redemption value for the year ended December 31, 2021. In connection with extending the Company’s Original Termination Date to the Extended Date, the Company deposited $720,000, $240,000, $240,000, $240,000, $240,000, and $240,000 into the Trust Account on March 23, 2022, June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 respectively. In connection to the Company’s Second Extended Date, the Company deposited $100,000 into the Trust Account on December 27, 2022. The Company recorded increases in the redemption value of common stock subject to redemption of $2,607,712 during the year ended December 31, 2022.

     

    In connection to the Company’s Third Extended Date, On June 27, 2023, the Company deposited the payment of $85,000 in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023.

     

    As of December 31, 2022 and December 31, 2021, the redeemable common stock reflected in the consolidated balance sheets are reconciled in the following table:

     

    Gross proceeds  $201,250,000 
    Less:     
    Fair value of Public Warrants at issuance   (10,384,500)
    Fair value of Rights at issuance   (9,136,750)
    Issuance costs allocated to common stock subject to possible redemption   (10,660,961)
    Plus:     
    Remeasurement of carrying value to redemption value   32,194,711 
    Common stock subject to possible redemption as of December 31, 2021   203,262,500 
    Redemption of common stock by stockholders   (152,451,819)
    Common stock tendered for redemption   (34,004,514)
    Remeasurement of carrying value to redemption value   2,607,712 
    Common stock subject to possible redemption as of December 31, 2022  $19,413,879 

     

    Offering Costs associated with the Initial Public Offering

     

    The Company complies with the requirements of ASC Topic 340, Other Assets and Deferred Costs (“ASC 340”) and SEC Staff Accounting Bulletin Topic 5A - Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $11,830,356 as a result of the Initial Public Offering (consisting of a $4,025,000 cash underwriting fee, $7,043,750 of deferred underwriting fees, and $761,606 of other offering costs). The Company recorded $10,660,961 of offering costs as a reduction of temporary equity in connection with the redeemable common stock included in the Units. The Company recorded $1,144,422 of offering costs as a reduction of permanent equity in connection with the Public Warrants and Rights classified as equity instruments. The Company immediately expensed $24,973 of offering costs in connection with the Private Warrants that were classified as liabilities.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Share-Based Payment Arrangements

     

    The Company accounts for stock awards in accordance with ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), which requires that all equity awards be accounted for at their fair value. Fair value is measured on the grant date and is equal to the underlying value of the stock.

     

    Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, or in the period of grant for awards that vest immediately and have no future service condition. For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company’s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.

     

    Income Taxes

     

    The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

     

    ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were unrecognized tax benefits as of December 31, 2022 and 2021 of $765,613 and $0, respectively. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the years ended December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

     

    See Note 11 for additional information on income taxes for the periods presented.

     

    Net (Loss) Income Per Common Share

     

    Net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The calculation of diluted (loss) income per common share does not consider the effect of the Public Warrants (as defined in Note 3), Private Warrants, Subscription Warrants (as defined in Note 6), and Rights (as defined in Note 3) since the exercise of the warrants and Rights are contingent upon the occurrence of future events and the inclusion of such warrants and Rights would be anti-dilutive. The warrants and Rights are exercisable to purchase 22,068,750 shares of common stock in the aggregate.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    The following table reflects the calculation of basic and diluted net (loss) income per common share (in dollars, except per share amounts):

     

       Redeemable Common Stock   Non-redeemable Common Stock   Redeemable Common Stock   Non-redeemable Common Stock 
      

    For the Year ended

    December 31, 2022

    		  

    For the Year ended

    December 31, 2021

    		 
       Redeemable Common Stock   Non-redeemable Common Stock   Redeemable Common Stock   Non-redeemable Common Stock 
    Basic and diluted net (loss) income per share:                    
    Numerator:                    
    Net (loss) income  $(326,506)  $(160,282)  $2,074,858   $414,971 
    Denominator:                    
    Weighted Average Common Stock   8,199,223    4,025,000    20,125,000    4,025,000 
    Basic and diluted net (loss) income per common share  $(0.04)  $(0.04)  $0.10   $0.10 

     

    Concentration of Credit Risk

     

    Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

     

    Fair Value of Financial Instruments

     

    The Company applies ASC Topic 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.

     

    The carrying amounts reflected in the consolidated balance sheets for current assets and current liabilities approximate fair value due to their short-term nature.

     

    Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.

     

    Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

     

    Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.

     

    See Note 10 for additional information on assets and liabilities measured at fair value.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Derivative Financial Instruments

     

    The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified on the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the Private Warrants and Subscription Warrants (as defined in Note 6) are derivative instruments. As the Private Warrants and Subscription Warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820 with changes in fair value recognized in the consolidated statements of operations in the period of change. In accordance with ASC Topic 825, Financial Instruments, the Company has concluded that a portion of the transaction costs which directly related to the Initial Public Offering and the Private Placement, should be allocated to the Private Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the consolidated statements of operations.

     

    Recent Accounting Standards

     

    The Company’s management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements. 

     

     
    XML 26 R9.htm IDEA: XBRL DOCUMENT v3.23.2
    INITIAL PUBLIC OFFERING
    		 12 Months Ended
    Dec. 31, 2022
    Initial Public Offering  
    INITIAL PUBLIC OFFERING

    NOTE 3. INITIAL PUBLIC OFFERING

     

    On December 28, 2020, the Company sold 17,500,000 Units, at a purchase price of $10.00 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share, one redeemable warrant (the “Public Warrants”) and one right (the “Rights”). Each Public Warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share. Each Right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of an initial Business Combination.

     

    On December 30, 2020, the Company sold 2,625,000 Over-Allotment Units pursuant to the underwriters’ full exercise of the over-allotment option (see Note 7), generating aggregate of gross proceeds of $26,250,000.

     
    XML 27 R10.htm IDEA: XBRL DOCUMENT v3.23.2
    PRIVATE PLACEMENT
    		 12 Months Ended
    Dec. 31, 2022
    Private Placement  
    PRIVATE PLACEMENT

    NOTE 4. PRIVATE PLACEMENT

     

    Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of 18,000,000 Private Warrants at a price of $0.50 per warrant ($9,000,000 in the aggregate), each exercisable to purchase one-half of one share common stock at a price of $11.50 per whole share, in a private placement that closed simultaneously with the closing of this offering. A portion of the purchase price of the Private Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account.

     
    XML 28 R11.htm IDEA: XBRL DOCUMENT v3.23.2
    RELATED PARTY TRANSACTIONS
    		 12 Months Ended
    Dec. 31, 2022
    Related Party Transactions [Abstract]  
    RELATED PARTY TRANSACTIONS

    NOTE 5. RELATED PARTY TRANSACTIONS

     

    Founder Shares

     

    In August 2020, the Sponsor paid $25,000, or approximately $0.007 per share, to cover certain offering costs in consideration for 3,593,750 shares of common stock, par value $0.0001 (the “Founder Shares”). On December 3, 2020, the Company declared a share dividend of 0.36 for each outstanding share, resulting in 4,887,500 shares outstanding, and on December 22, 2020 the Company declared a share dividend of 0.03 resulting in 5,031,250 shares which includes an aggregate of up to 656,250 shares that are subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part, and up to an aggregate of 1,006,250 shares of common stock (or 875,000 shares of common stock to the extent that the underwriters’ over-allotment is not exercised, pro rata) that are subject to forfeiture to the extent that Rights are exercised upon consummation of an initial Business Combination. In connection with the underwriters’ fully exercise of their over-allotment option on December 30, 2020 (see Note 7), the 656,250 shares were no longer subject to forfeiture.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    The Founder Shares were placed into an escrow account maintained by Continental Stock Transfer & Trust Company acting as escrow agent. 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the initial Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the initial Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to its initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.

     

    During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) to any persons (including their affiliates and stockholders) participating in the Private Placement of the Private Warrants, officers, directors, stockholders, employees and members of the Company’s Sponsor and its affiliates, (2) amongst initial stockholders or their respective affiliates, or to the Company’s officers, directors, advisors and employees, (3) if a holder is an entity, as a distribution to its, partners, stockholders or members upon its liquidation, (4) by bona fide gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of the Company’s securities, (8) by private sales at prices no greater than the price at which the shares were originally purchased or (9) for the cancellation of up to 656,250 shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part or in connection with the consummation of the Company’s initial Business Combination.

     

    On December 23, 2020, the Sponsor transferred 81,000 of its Founder Shares of the Company to three board members (the “Transferees”) (27,000 Founder Shares to each Transferee) for a nominal fee. On April 30, 2021, the Sponsor subsequently transferred 27,000 of its Founder Shares of the Company to a new board member (the “Additional Transferee”, and, together with the Transferees, the “Directors”). These awards are subject to ASC 718.

     

    Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Founder Shares vested immediately, and, as such, in accordance with ASC 718, the Company recognized compensation expense on the transfer date in an amount equal to the number of Founders Shares sold times the grant date fair value per share less the amount initially received for the purchase of the Founders Shares. The fair value of the Founder Shares transferred to the Additional Transferee was determined to be $157,140 ($5.82 per share) as of April 30, 2021. The Company recognized compensation expense of $157,140 within stock compensation expense in the Company’s statement of operations for the year ended December 31, 2021. The Company did not recognize compensation expense for the year ended December 31, 2022.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Note Agreements Payable - Related Party

     

    We entered into a series of Note Agreements with several lenders affiliated with our Sponsor, Viveon Health LLC and Intuitus Group LLC, for which the Chief Financial Officer of the Company is the Sole Proprietor for up to an aggregate amount totaling $1,955,000 (see Note 6). As of December 31, 2022, the balance on the Notes was $1,955,000.

     

    Promissory Notes - Related Party

     

    The Sponsor agreed to loan the Company an aggregate of up to $500,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the Initial Public Offering. On January 13, 2021, the Company paid the $228,758 balance on the note from the proceeds of the Initial Public Offering. The Company no longer has the ability to borrow under the Note.

     

    The Chief Financial Officer of the Company loaned the Company $75,000 to cover expenses related to ongoing operations, which was funded on December 27, 2022. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on December 27, 2022.

     

    As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $75,000 and $0, respectively. Subsequent to December 31, 2022, the Chief Financial Officer of the Company, loaned the Company an additional $555,000 through the date of this filing. These loans will be exchanged for Clearday Senior Convertible Notes upon consummation of the Company’s initial Business Combination.

     

    The Chief Executive Officer of the Company loaned the Company $100,000 to cover expenses related to ongoing operations, which was funded on April 2, 2023. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on April 2, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $0, respectively.

     

    Subsequent to December 31, 2022, three investors in the Sponsor, loaned the Company $100,000 in the aggregate, to cover expenses related to ongoing operations, funded on April 5, 2023, and April 7, 2023. These loans are non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreements were entered into on April 5, 2023, and April 7, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $0, respectively.

     

    On May 12, 2023, the Company entered into an unsecured promissory note with Clearday (the “Clearday Note”). The Clearday Note is non-interest bearing mature upon the earlier of (i) the first anniversary of the issuance date and (ii) December 31, 2022. Proceeds provided to us under the Clearday Note through the filing date were approximately $881,710 during fiscal year 2023.Funds in the Trust Account may not be used to repay the obligations under the Clearday Note. We used such funds for general working capital purposes.

     

    Working Capital Loans

     

    In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). Each loan would be evidenced by a promissory note. The notes would be repaid upon consummation of the Company’s initial Business Combination, without interest. As of December 31, 2022 and December 31, 2021, the Company had no borrowings under Working Capital Loans.

     

    Administrative Service Fee

     

    Commencing on the date of the Company’s final prospectus, the Company has agreed to pay an affiliate of the Sponsor a total of $20,000 per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company incurred $240,000 and $240,000 of administrative service fees for the year ended December 31, 2022 and 2021, respectively. The accrued amounts are included in Due to related party on the balance consolidated balance sheets. For the year ended December 31, 2022 and 2021, $50,000 and $10,000 of such expenses were recorded in Due to related party, respectively.

     

    Due to Related Party

     

    The Company’s directors and officers are reimbursed for any reasonable out-of-pocket expenses incurred by them in connection with certain activities on behalf of the Company, such as identifying and investigating possible target businesses and Business Combinations. For the years ended December 31, 2022 and 2021, $6,647 and $9,479 of such expenses were incurred, respectively. As of December 31, 2022 and 2021, $5,806 and $5,850 of such expenses were recorded in Due to related party, respectively.

     

    Due from Related Party

     

    As of December 31, 2021, the Company had a receivable of $15,000 in connection with a payment made by the Company to a vendor on behalf of a related party. During the year ended December 31, 2022, the Company was repaid for the receivable. As of December 31, 2022, the balance in Due from related party is $0.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     
    XML 29 R12.htm IDEA: XBRL DOCUMENT v3.23.2
    NOTE AGREEMENTS PAYABLE
    		 12 Months Ended
    Dec. 31, 2022
    Debt Disclosure [Abstract]  
    NOTE AGREEMENTS PAYABLE

    NOTE 6. NOTE AGREEMENTS PAYABLE


    On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, in connection with the extension of the date by which the Company has to consummate a Business Combination (see Note 7), the Company entered into a series of unsecured senior promissory note agreements (“Note Agreements”) for up to an aggregate amount totaling $4.0 million (the “Notes”). Of the total $4.0 million of the Notes, $1,955,000 is loaned by lenders who are affiliated with the sponsor and a director of the Company, and Intuitus Group LLC, for which the Chief Financial Officer of the Company is the Sole Proprietor. The Notes do not bear interest and were set to mature upon the earlier of (i) the closing of the Company’s initial Business Combination and (ii) December 31, 2022 (the “Original Maturity Date”). A commitment fee in the amount equal to 10% of all amounts funded under Notes (up to a maximum of $400,000), is due to the subscribers, on a pro rata basis, by the Company promptly following the initial funding. As of December 31, 2022, the Company has received $4 million of funding for the Notes. The Company has paid $400,000 in commitment fees as of December 31, 2022. Subsequent to December 31, 2022, in connection with the business combination a majority of the lenders of the Notes have agreed to exchange their Notes with the Company for Clearday Senior Convertible Notes. Upon the consummation of the business combination and the exchange of the Subscription Agreements for the Clearday Senior Convertible Notes, the lenders will forfeit their Subscription Warrants as part of the exchange. One lender has chosen not to convert to Clearday Senior Convertible Notes. The balance owed to this lender under the Notes is considered due upon demand by the lender. As of the date of this filing of this Annual Report the lender has not requested payment of the Note.

     

    Pursuant to the terms of the Note Agreements, the subscribers shall receive warrants to purchase one share of Company common stock for every $2.00 of the funded principal amount of the Notes up to 2,000,000 shares of the Company common stock, in the aggregate, at an exercise price of $11.50 per share, subject to adjustment (the “Subscription Warrants”). See Note 9 for additional terms of the Subscription Warrants. Pursuant to a warrant cancellation and forfeiture agreement dated as of August 16, 2023, one of the Company’s directors agreed to forfeit for cancellation 89,029 of the warrant shares underlying the warrant issued to an affiliate that he controls in connection with the Notes described above.

     

    In accordance with ASC 470-20-25-2, Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants, the proceeds from the issuance of the Notes were allocated to the Notes and Subscription Warrants using the with-and-without method. Under this method, the Company first allocated the proceeds from the issuance of the Notes to the Subscription Warrants based on their initial fair value measurement of $5,370,185 for the Subscription Warrants issued on March 21, 2022, $337,991 for the Subscription Warrants issued on March 23, 2022, $341,967 for the Subscription Warrants issued on April 4, 2022, $417,037 for the Subscription Warrants issued on April 27, 2022, $162,003 for the Subscription Warrants issued on May 9, 2022, $65,326 for the Subscription Warrants issued on October 27, 2022, and $121,093 for the Subscription Warrants issued on November 25, 2022. The measurement of the Subscription Warrants fair value was determined utilizing a Monte Carlo simulation model considering all relevant assumptions current at the dates of issuance. See Note 10 for additional details on the assumptions used. The initial fair value of the Subscription Warrants exceeded the proceeds received from the issuance of the Notes. As such, the proceeds allocated to the Notes were nil. The Company recognized a loss on issuance of the Subscription Warrants of $3,209,183 for the year ended December 31, 2022.

     

    The Company complies with ASC Topic 835, Interest (“ASC 835”). In accordance with ASC 835-30, discounts to the principal amounts are included in the carrying value of the Notes and amortized to “Interest expense” over the remaining term of the underlying debt to the Original Maturity Date. During the year ended December 31, 2022, the Company recorded a $3,645,777 debt discount upon issuance of the Notes, respectively. The discount was amortized to interest expense over the term of the debt to the Original Maturity Date. For the year ended December 31, 2022, the amortization of the discount resulted in interest expense of $3,645,777.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    The following table presents the Notes as of December 31, 2022:

     

          
    Note  $4,000,000 
    Debt discount  $— 
    Carrying value of notes  $4,000,000 

     
    XML 30 R13.htm IDEA: XBRL DOCUMENT v3.23.2
    COMMITMENTS AND CONTINGENCIES
    		 12 Months Ended
    Dec. 31, 2022
    Commitments and Contingencies Disclosure [Abstract]  
    COMMITMENTS AND CONTINGENCIES

    NOTE 7. COMMITMENTS AND CONTINGENCIES

     

    Underwriting Agreement

     

    The Company granted the underwriter a 45-day option to purchase up to 2,625,000 additional shares of common stock to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. The underwriters exercised the over-allotment option in full on December 28, 2020.

     

    The underwriter was paid a cash underwriting fee of $0.20 per share, or $4,025,000 in the aggregate, upon the closing of the Initial Public Offering. In addition, $0.35 per share, or $7,043,750 in the aggregate was payable to the underwriter for deferred underwriting commissions. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.

     

    In addition, subject to certain conditions, the Company granted the underwriters of the Initial Public Offering, for a period of 12 months after the date of the consummation of a Business Combination, a right of first refusal to act as book-running managing underwriter or placement agent, with at least 30% of the economics, for any and all future public and private equity, convertible and debt offerings. In accordance with FINRA Rule 5110(f)(2)(E)(i), such right of first refusal shall not have a duration of more than three years from the effective date of the registration statement related to our initial public offering. Subsequently this agreement was voided.

     

    Registration Rights

     

    The holders of the Company’s Founder Shares issued and outstanding on the date of this prospectus, as well as the holders of the Private Warrants (and underlying securities) will be entitled to registration rights pursuant to an agreement to be signed prior to or on the effective date of this offering. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants (and underlying securities) can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

     

    Vendor Agreements

     

    On May 18, 2021, the Company entered into an agreement with a transactional and strategic advisory firm (the “Strategic Advisor”) for advisory services as needed by the Company in connection with a Business Combination. Pursuant to this agreement, the Company incurred approximately $875,000 in fees. As of December 31, 2022 and December 31, 2021, $500,000 of such fees remain unpaid and are included in accrued costs and expenses on the consolidated balance sheets. On November 1, 2021, the Company and the Strategic Advisor entered into an amendment to the agreement. Pursuant to this amendment, the Company will pay the Strategic Advisor a fee of $2,625,000, inclusive of the $500,000 accrued as of December 31, 2022 and December 31, 2021. The remaining $2,125,000 is contingent upon the consummation of the Business Combination.

     

    On October, 8, 2021, the Company entered into an agreement with a financial advisor (the “Exclusive Financial Advisor”) for financial advisory services such as financial and transaction feasibility analysis, assistance in negotiations, assistance in capital planning, and other customary services in connection with a Business Combination, pursuant to which the Company will pay the Exclusive Financial Advisor a fee of $1,500,000 contingent upon the consummation of the Business Combination. This agreement was terminated on January 31, 2023 as a result of the termination of the merger agreement between the Company and Suneva.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    On November 1, 2021, the Company entered into an agreement with a financial advisor (the “Second Financial Advisor”) for financial advisory services such as guidance on valuation and transaction structure and terms, assistance in negotiations, coordination of due diligence, documentation, and transaction closing, and introduction of the Company to institutional investors in connection with a Business Combination, pursuant to which the Company will pay the Second Financial Advisor a fee of $400,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on January 31, 2023, and there are no related contingent fees for the agreement.

     

    On November 2, 2021, the Company entered into an agreement with a financial advisor (the “Third Financial Advisor”) for financial advisory services such as market related advice and assistance in connection with a Business Combination, pursuant to which the Company will pay the Third Financial Advisor a fee of $500,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on June 9, 2023, and there are no related contingent fees for the agreement.

     

    On November 5, 2021, the Company entered into an agreement with an advisor (the “Advisor”) for services such as assistance in refining strategic objectives, preparation or refinement of solicitation materials, identification, contact, and solicitation of or potential investors and other sources of capital, and assistance in review, selection, negotiation, and closing of a transaction in connection with a Business Combination, pursuant to which the Company will pay the Advisor a fee of $200,000 contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on June 19, 2023, and there are no related contingent fees for the agreement.

     

    On November 15, 2021, the Company entered into an agreement with two placement agents (the “Placement Agents”) for services such as analysis of potential contributions and assets of a target to the Company’s future prospects, assistance in negotiations, and assistance in preparation of presentations to investors, lenders, and/or other financial sources in connection with a Business Combination, pursuant to which the Company will pay the Placement Agents a fee equal to the difference between 5% of the total aggregate sales price of the securities sold as part of the Business Combination and 5% of any securities sold as part of the Business Combination to investors identified by the Advisor, contingent upon the consummation of the Business Combination. This agreement was terminated on February 15, 2022, as a result of an automatic termination provision upon the earlier to occur of three months or the final closing of Business Combination and there are no related contingent fees for the agreement.

     

    On February 17, 2022, the Company entered into an agreement with a broker-dealer (the “Broker-Dealer”) for services such as providing the Company with capital markets advisory services with regard to a forward purchase agreement, convertible private investment in public equity (“PIPE”), secured credit facility, and any other capital structure topics in connection with a Business Combination, pursuant to which the Company will pay the Broker-Dealer a fee of $250,000. This agreement was terminated on June 9, 2023, as a result of the termination of the merger agreement between the Company and Suneva. Pursuant to the terms of the agreement the Broker-Dealer will remain entitled to the fee of $250,000 if a Business Combination is consummated within 24 months after the termination date. The Company is pursuing a waiver from the Broker-Dealer to waive the $250,000 fee upon a Business Combination. As such, the fee remains contingent upon the consummation of the Business Combination.

     

    On May 9, 2023, the Company entered into an agreement with a placement agent (the “Placement Agent) for services such as advising and assisting the Company in identifying one or more investors that are “accredited” or “qualified institutional buyers. Pursuant to which the Company will pay the Placement Agents a cash fee upon closing equal to eight percent (8.0%) of the gross proceeds received by the Company, contingent upon the consummation of the Business Combination.

     

    Extension

     

    On March 18, 2022, the Company held its 2022 Annual Meeting of Stockholders for the purpose of approving: (i) a proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to (i) extend the date by which the Company has to consummate a Business Combination for three months, from March 28, 2022 (the “Original Termination Date”) to June 28, 2022 (the “Extended Date”), and (ii) allow the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with Suneva Medical, Inc. or any potential alternative initial Business Combination shall have occurred (the “Extension Proposal”); (ii) a proposal to re-elect five current directors to the Company’s Board of Directors (the “Director Election Proposal”); and (iii) a proposal to ratify the appointment of Marcum LLP as the Company’s independent registered certified public accountants for fiscal year 2020 (the “Auditor Ratification Proposal”). Stockholders voted to approve the Extension Proposal, Director Election Proposal and Auditor Ratification Proposal.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    On March 18, 2022, stockholders elected to redeem 15,092,126 shares of the Company’s common stock, resulting in redemption payments out of the Trust Account totaling approximately $152,451,819. Subsequent to the redemptions, 5,032,874 shares of common stock remained in the Trust Account.

     

    On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, the Company entered into the Note Agreements (see Note 6). The Note Agreements included Subscription Warrants (see Note 9). The entry into the Note Agreements and the terms of the Notes and Subscription Warrants was approved by the Audit Committee of the Board of Directors of the Company at a meeting held on March 21, 2022.

     

    On March 23, 2022, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State (the “Amendment”) The Amendment (i) extends the date by which the Company has to consummate a Business Combination for three months, from the Original Termination Date to the Extended Date and (ii) allows the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice and the deposit of $240,000 prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with any potential initial Business Combination shall have occurred. The Amendment was approved by the Company’s stockholders at its Annual Meeting of Stockholders held on March 18, 2022.

     

    On December 23, 2022, the Company held its 2022 Annual Meeting of the Stockholders in which they voted to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time for a total of up to six months from December 28, 2022 until June 30, 2023, upon three calendar days’ advance notice and the deposit of $100,000 prior to the applicable monthly deadline, unless the closing of any potential initial business combination shall have occurred prior to the Second Extended Date. On each of December 27, 2022, January 26, 2023, February 27, 2023, March 27, 2023 and April 28, 2023, the Company deposited $100,000 into the Trust Account to extend the date to consummate a Business Combination through January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023, respectively. The Company made a deposit of $100,000 on May 24, 2023 for a one month extension until the Second Extended Date.

     

    On December 23, 2022, stockholders elected to redeem 3,188,100 Public Shares, resulting in a redemption payable as of December 31, 2022 of $34,004,514 included in common stock tendered for redemption on the consolidated balance sheet. On January 25, 2023, redemption payments out of the trust account totaled $34,004,514. Subsequent to the redemptions, 1,844,774 Public Shares remained.

     

    On June 22, 2023, the Company held a stockholder meeting (the “June 2023 Stockholders Meeting”) in which stockholders voted to (A) amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to the Trustee, prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date; and (B) to amend the Company’s Investment Management Trust Agreement, dated as of December 22, 2020, by and between the Company and the Trustee, allowing the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $85,000 for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, each such extension for an additional one month period, with no additional deposits to be made into the Trust Account during such period from January 1, 2024 through March 31, 2024. In connection with the stockholders’ vote at the June 2023 Stockholders Meeting, 227,359 shares of common stock were tendered for redemption. As a result, approximately $2,498,947.09 (approximately $10.99 per share) were removed from the Company’s Trust Account to pay such holders, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date. Following redemptions, the Company has 1,617,415 shares of public common stock outstanding, and approximately $17,777,323.54 will remain in the Trust Account. On June 27, 2023, and July 27, 2023, the Company deposited $85,000 in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023 and August 31, 2023, respectively.

     
    XML 31 R14.htm IDEA: XBRL DOCUMENT v3.23.2
    STOCKHOLDERS’ DEFICIT
    		 12 Months Ended
    Dec. 31, 2022
    Equity [Abstract]  
    STOCKHOLDERS’ DEFICIT

    NOTE 8. STOCKHOLDERS’ DEFICIT

     

    Preferred stock — The Company is authorized to issue 1,000,000 shares of preferred stock with a par value of $0.0001 and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2022 and December 31, 2021, there was no preferred stock issued or outstanding.

     

    Common stock — The Company is authorized to issue 60,000,000 shares of common stock with a par value of $0.0001 per share. Holders are entitled to one vote for each share of common stock. As of December 31, 2022 and December 31, 2021, there were 5,031,250 shares of common stock issued and outstanding, excluding 1,844,774 and 20,125,000 shares of common stock subject to possible redemption, respectively.

     

    Rights — Except in cases where the Company is not the surviving company in a Business Combination, each holder of a Right will automatically receive one-twentieth (1/20) of a share of common stock upon consummation of the initial Business Combination. In the event the Company will not be the surviving company upon completion of the initial Business Combination, each holder of a Right will be required to affirmatively convert his, her or its rights in order to receive the one-twentieth (1/20) of a share underlying each right upon consummation of the Business Combination. The Company will not issue fractional shares in connection with an exchange of Rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, holders must hold Rights in multiples of 20 in order to receive shares for all Rights upon closing of a Business Combination. If the Company is unable to complete an initial Business Combination within the required time period and the Company redeems the Public Shares for the funds held in the Trust Account, holders of Rights will not receive any of such funds for their Rights and the Rights will expire worthless.

     

     
    XML 32 R15.htm IDEA: XBRL DOCUMENT v3.23.2
    WARRANTS
    		 12 Months Ended
    Dec. 31, 2022
    Warrants  
    WARRANTS

    NOTE 9. WARRANTS

     

    Each Public Warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share, subject to adjustment. Pursuant to the warrant agreement, a warrant holder may exercise its s only for a whole number of shares. This means that only an even number of s may be exercised at any given time by a warrant holder.

    The Company may call the Public Warrants for redemption (except the Private Warrants):

     

      ● in whole and not in part;
         
      ● at a price of $0.01 per warrant;
         
      ● upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and
         
      ● if and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.

     

    If the Company calls the Public Warrants for redemption as described above, its management will have the option to require all holders that wish to exercise Public Warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the Public Warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the Public Warrants, multiplied by the difference between the exercise price of the Public Warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Company’s common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Public Warrants. Whether the Company will exercise its option to require all holders to exercise their Public Warrants on a “cashless basis” will depend on a variety of factors including the price of our common shares at the time the Public Warrants are called for redemption, its cash needs at such time and concerns regarding dilutive share issuances.

      

    If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its Sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial Business Combination on the date of the consummation of our initial Business Combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. The Public Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their Public Warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    Private Warrants

     

    The Private Warrants are identical to the Public Warrants except that the Private Warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees.

     

    Subscription Warrants

     

    The Subscription Warrant term commences on the Exercise Date (as hereinafter defined) for a period of 49 months. The Subscription Warrants are exercisable commencing on the date of the initial Business Combination (the “Exercise Date”) and have a cashless exercise feature that is available at any time on or after the Exercise Date. Commencing on the date 13 months following the Exercise Date, the subscribers have the right, but not the obligation, to put the Subscription Warrants to the Company at a purchase price of $5.00 per share. The Company has agreed to file, within thirty (30) calendar days after the consummation of an initial Business Combination, a registration statement with the Securities and Exchange Commission to register for resale the shares of common stock underlying the Subscription Warrants.

     

    As of December 31, 2022 and December 31, 2021, there were 20,125,000 Public Warrants and 18,000,000 Private Warrants outstanding. As of December 31, 2022, there were 2,000,000 Subscription Warrants outstanding. The Company accounts for the Public Warrants, Private Warrants, and Subscription Warrants in accordance with the guidance contained in ASC 815-40. The Public Warrants qualify for equity treatment under ASC 815-40. Such guidance provides that because the Private Warrants and Subscription Warrants do not meet the criteria for equity treatment thereunder, the Private Warrants and Subscription Warrants must be recorded as a liability.

     

    XML 33 R16.htm IDEA: XBRL DOCUMENT v3.23.2
    FAIR VALUE MEASUREMENTS
    		 12 Months Ended
    Dec. 31, 2022
    Fair Value Disclosures [Abstract]  
    FAIR VALUE MEASUREMENTS

    NOTE 10. FAIR VALUE MEASUREMENTS

     

    The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 and December 31, 2021, and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

     

    Description 

    Amount at

    Fair Value

    		   Level 1   Level 2   Level 3 
    December 31, 2022                    
    Assets                    
    Money Market Account  $6,346   $6,346   $—   $— 
    Money Market Funds held in Trust Account  $53,815,395   $53,815,395   $—   $— 
    Liabilities                    
    Private Warrant Liability  $900,000   $—   $—   $900,000 
    Subscription Warrant Liability  $1,635,515   $—   $—   $1,635,515 
                         
    December 31, 2021                    
    Assets                    
    Money Market Account  $350,455   $350,455   $—   $— 
    Mutual Funds held in Trust Account  $203,282,989   $203,282,989   $—   $— 
    Liabilities                    
    Private Warrant Liability  $4,188,221   $—   $—   $4,188,221 

     

    The Private Warrants and Subscription Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the consolidated balance sheets. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated statements of operations.

     

    The Company established the initial fair value of the Private Warrants on December 28, 2020, the date of the Company’s Initial Public Offering, and revalued on December 31, 2022 and on December 31, 2021, using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement date, on December 31, 2022 and on December 31, 2021 due to the use of unobservable inputs.

     

    The key inputs into the Monte Carlo simulation for the Private Warrants as of December 31, 2022 and December 31, 2021 were as follows:

     

     

    Inputs 

    As of

    December 31, 2022

    		  

    As of

    December 31, 2021

    		 
    Risk-free interest rate   4.39%   1.30%
    Expected term remaining (years)1   2.11    5.50 
    Expected volatility   0.01%   7.6%
    Stock price  $10.650   $10.020 

     

    The Company established the initial fair value of the Subscription Warrants on March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9,2022, October 27,2022, and November 25,2022 the dates of issuance, and revalued on December 31, 2022, using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement dates, and on December 31, 2022 due to the use of unobservable inputs.

     

     

    1 The contractual term of the Private Warrants is 5 years from the closing of a Business Combination. As of December 31, 2022 the expected term remaining of the Private Warrants was calculated based on assumptions for both a successful and unsuccessful Business Combination resulting in a weighted expected term remaining of 2.11. This was calculated using an expected term remaining with an unsuccessful Business Combination of 1.00 year (weighted at 75.5% probability) and a successful business combination term remaining of 5.52 years (weighted at 24.5% probability). Prior to December 31, 2022 the expected term was calculated using only assumptions for a successful Business Combination. The change in the calculation was made as using an expected term that was calculated based only on the assumption that the Business Combination would be successful as an input under the Monte Carlo simulation model resulted in an unsolvable expected volatility under the Monte Carlo simulation model.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    The key inputs into the Monte Carlo simulation for the Subscription Warrants as of December 31, 2022 and the issuance dates were as follows:

     

    Inputs 

    As of

    December 31,

    2022

    		  

    As of

    November 25,

    2022 (Initial Measurement)

    		  

    As of

    October 27,

    2022 (Initial Measurement)

    		  

    As of

    May 9,

    2022 (Initial Measurement)

    		  

    As of

    April 27,

    2022 (Initial Measurement)

    		  

    As of

    April 4,

    2022 (Initial Measurement)

    		  

    As of

    March 23,

    2022 (Initial Measurement)

    		  

    As of

    March 21,

    2022 (Initial Measurement)

    		 
    Risk-free interest rate                  4.04%               3.90%               4.11%              2.92%              2.80%             2.57%             2.33%              2.33%
    Market debt rate1   9.19%   8.70%   9.64%  7.49%   6.75%  6.09%  N/A   N/A 
    Expected term remaining (years)   4.60    4.70    4.78   4.56    4.60   4.66   4.44   4.44 
    Expected volatility   0.01%   1.38%   4.89%  1.0%   1.0%  1.0%  2.5%  2.4%
    Probability of completing a Business Combination   24.5%   23.9%   14.4%   90%   90%  90%  90%   90%
    Stock price  $10.650   $10.470   $10.400  $10.220   $10.220  $10.170   $10.080  $10.080 

     

    1The Company changed its valuation technique to incorporate the market debt rate as a significant input to the Monte Carlo simulation for the valuation of the Subscription Warrants as of December 31, 2022, November 25, 2022, October 27, 2022, May 9, 2022, April 27, 2022, and April 4, 2022. In the case that the Subscription Warrants were exercised, the risk-free interest rate was used. In the case that the put option was exercised, the market debt rate was used. The risk-free interest rate was used in both scenarios in the Monte Carlo simulation for the valuation of the Subscription Warrants as of March 23, 2022 and March 21, 2022.

     

    The following tables presents the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value:

     

     

    Fair value as of December 31, 2020  $10,763,361 
    Change in fair value   (6,575,140)
    Fair value as of December 31, 2021  $4,188,221 

     

    Fair value as of December 31, 2021  $4,188,221 
    Fair value of Subscription Warrants at issuance on March 21, 2022   5,370,185 
    Fair value of Subscription Warrants at issuance on March 23, 2022   337,991 
    Fair value of Subscription Warrants at issuance on April 4, 2022   341,967 
    Fair value of Subscription Warrants at issuance on April 27, 2022   417,037 
    Fair value of Subscription Warrants at issuance on May 9, 2022   162,003 
    Fair value of Subscription Warrants at issuance on October 27, 2022   65,326 
    Fair value of Subscription Warrants at issuance on November 25, 2022   121,093 
    Change in fair value   (8,468,308)
    Fair value as of December 31, 2022  $2,535,515 

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    The Company recognized a loss in connection with changes in the fair value of the Private and Subscription Warrants of $8,468,308 for the year ended December 31, 2022, within gain on change in fair value of warrant liabilities in the statements of operations. The Company recognized gains in connection with the changes in the fair value of the Private Warrants of $6,575,140 for the year ended December 31, 2021 within gain on change in fair value of warrant liabilities in the consolidated statements of operations.

     
    XML 34 R17.htm IDEA: XBRL DOCUMENT v3.23.2
    INCOME TAXES
    		 12 Months Ended
    Dec. 31, 2022
    Income Tax Disclosure [Abstract]  
    INCOME TAXES

    NOTE 11. INCOME TAXES

     

    The Company’s net deferred tax assets (liabilities) as of December 31, 2022 and December 31, 2021 are as follows:

     

       December 31, 2022   December 31, 2021 
    Deferred tax assets:          
    Start-up costs  $1,097,004   $791,079.00 
    Accrued interest   100,569      
    Transaction costs   —    — 
    Net operating loss carryforwards   

    704,303

    		    39,259 
    Total deferred tax assets   1,901,876    830,338 
    Valuation allowance   (1,862,617)   (830,338)
    Deferred tax assets, net of allowance  $39,259   $— 

     

    The income tax provision for the year ended December 31, 2022 and December 31, 2021 consist of the following:

     

     

       December 31, 2022   December 31, 2021 
    Federal          
    Current  $100,569   $— 
    Deferred   (1,071,538)   (824,916)
               
    State          
    Current  $—   $— 
    Deferred   —    — 
    Change in valuation allowance   1,032,279    824,916 
    Income tax provision  $61,310   $— 

     

    As of December 31, 2022 and 2021, the Company has available U.S. federal operating loss carry forwards of approximately $3,354,000 and $187,000, respectively that may be carried forward indefinitely.

     

    In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a partial valuation allowance. For the year ended December 31, 2022 and December 31, 2021, the valuation allowance was $1,862,617 and 830,338, respectively.

     

    A reconciliation of the federal income tax rate to the Company’s effective tax rate as of December 31, 2022 and December 31, 2021 are as follows:

     

     

       December 31, 2022   December 31, 2021 
    Statutory federal income tax rate   21.0%   21.0%
    State taxes, net of federal tax benefit   0.0%   0.0%
    Change in fair value of derivative warrant liabilities   418.0%   (55.5)%
    Non-deductible transaction costs   (32.8)%   0%
    Stock compensation expense   0.0%   1.3%
    Other permanent items, net   (0.2)%   0%
    Warrant issuance costs   (177.8)%   0.0%
    Change in valuation allowance   (242.6)%   33.2%
    Income tax provision   (14.4)%   0.0%

     

    ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were unrecognized tax benefits as of December 31, 2022 and December 31, 2021 of $765,613 and $0, respectively. The Company’s unrecognized tax benefits as of December 31, 2022 related to uncertain tax positions would impact the effective income tax rate if recognized. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the year ended December 31, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

     

    Below is a tabular reconciliation of the total amount of unrecognized tax benefits as of the years:

     

     

       2022   2021 
       Year Ended December 31, 
       2022   2021 
    Uncertain tax benefits - January 1  $—   $— 
    Gross increases - Tax positions in prior period   765,613    — 
    Uncertain tax benefits - December 31  $765,613   $— 

     

    The Company files income tax returns in the U.S. federal jurisdiction and Georgia. Tax returns since inception remain open and subject to examination.

     
    XML 35 R18.htm IDEA: XBRL DOCUMENT v3.23.2
    SUBSEQUENT EVENTS
    		 12 Months Ended
    Dec. 31, 2022
    Subsequent Events [Abstract]  
    SUBSEQUENT EVENTS

    NOTE 12. SUBSEQUENT EVENTS

     

    The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than as described in Note 1, Note 2, Note 5, Note 7, and below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements.
    XML 36 R19.htm IDEA: XBRL DOCUMENT v3.23.2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
    		 12 Months Ended
    Dec. 31, 2022
    Accounting Policies [Abstract]  
    Basis of Presentation

    Basis of Presentation

     

    The accompanying consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).

     
    Principles of Consolidation

    Principles of Consolidation

     

    The consolidated financial statements include the accounts of the Company and its majority-owned and controlled operating subsidiary, Old Merger Sub after elimination of all intercompany transactions and balances as of December 31, 2022 and 2021.

     
    Emerging Growth Company

    Emerging Growth Company

     

    The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. The Company has elected to implement the aforementioned exemptions.

     

    In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     
    Use of Estimates

    Use of Estimates

     

    The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.

     

    Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The initial valuation of the Public Warrants (as defined in Note 3), Rights (as defined in Note 3) common stock subject to redemption and the periodic valuation of the Private Warrants and Subscription Warrants (as defined in Note 6) required management to exercise significant judgement in its estimates.

     
    Cash and Cash Equivalents

    Cash and Cash Equivalents

     

    The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $6,346 and $350,455, were held in money market funds as of December 31, 2022 and December 31, 2021, respectively.

     
    Investments Held in Trust Account

    Investments Held in Trust Account

     

    As of December 31, 2022 and December 31, 2021, substantially all of the assets held in the Trust Account were held in a money market account and mutual funds which invested in U.S. Treasury securities, respectively. The assets were transferred from mutual funds to a money market account on December 21, 2022. The assets in the amount of $53,815,395 and $203,282,989 were held in the Trust Account as of December 31, 2022 and December 31, 2021, respectively. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in Interest and dividends earned on investments held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in Trust Account are determined using available market information.

     
    Warrants

    Warrants

     

    The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC Topic 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

     

    For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. In accordance with guidance contained in ASC 815, the Public Warrants (as defined in Note 3) qualify for equity treatment. The Private Warrants and Subscription Warrants (as defined in Note 6) do not qualify as equity and are recorded as liabilities at fair value. Changes in the estimated fair value of the Private Warrants and Subscription Warrants are recognized as non-cash gains or losses on the consolidated statements of operations.

     
    Debt with Conversion and Other Options

    Debt with Conversion and Other Options

     

    The Company accounts for a series of unsecured senior promissory note agreements under ASC Topic ASC 470-20-25-2, Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants (“ASC 470-20-25-2”).  In accordance with ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants (detachable call options) are allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     
    Common Stock Subject to Possible Redemption

    Common Stock Subject to Possible Redemption

     

    All of the 5,032,874 Public Shares sold as part of the Units in the Initial Public Offering and subsequent full exercise of the underwriters’ over-allotment option that have not been redeemed by stockholders, contain a redemption feature which allows for the redemption of such redeemable common stock in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Therefore, all Public Shares been classified outside of permanent equity.

     

    The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. There was no change in redemption value for the year ended December 31, 2021. In connection with extending the Company’s Original Termination Date to the Extended Date, the Company deposited $720,000, $240,000, $240,000, $240,000, $240,000, and $240,000 into the Trust Account on March 23, 2022, June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 respectively. In connection to the Company’s Second Extended Date, the Company deposited $100,000 into the Trust Account on December 27, 2022. The Company recorded increases in the redemption value of common stock subject to redemption of $2,607,712 during the year ended December 31, 2022.

     

    In connection to the Company’s Third Extended Date, On June 27, 2023, the Company deposited the payment of $85,000 in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023.

     

    As of December 31, 2022 and December 31, 2021, the redeemable common stock reflected in the consolidated balance sheets are reconciled in the following table:

     

    Gross proceeds  $201,250,000 
    Less:     
    Fair value of Public Warrants at issuance   (10,384,500)
    Fair value of Rights at issuance   (9,136,750)
    Issuance costs allocated to common stock subject to possible redemption   (10,660,961)
    Plus:     
    Remeasurement of carrying value to redemption value   32,194,711 
    Common stock subject to possible redemption as of December 31, 2021   203,262,500 
    Redemption of common stock by stockholders   (152,451,819)
    Common stock tendered for redemption   (34,004,514)
    Remeasurement of carrying value to redemption value   2,607,712 
    Common stock subject to possible redemption as of December 31, 2022  $19,413,879 

     
    Offering Costs associated with the Initial Public Offering

    Offering Costs associated with the Initial Public Offering

     

    The Company complies with the requirements of ASC Topic 340, Other Assets and Deferred Costs (“ASC 340”) and SEC Staff Accounting Bulletin Topic 5A - Expenses of Offering. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $11,830,356 as a result of the Initial Public Offering (consisting of a $4,025,000 cash underwriting fee, $7,043,750 of deferred underwriting fees, and $761,606 of other offering costs). The Company recorded $10,660,961 of offering costs as a reduction of temporary equity in connection with the redeemable common stock included in the Units. The Company recorded $1,144,422 of offering costs as a reduction of permanent equity in connection with the Public Warrants and Rights classified as equity instruments. The Company immediately expensed $24,973 of offering costs in connection with the Private Warrants that were classified as liabilities.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     
    Share-Based Payment Arrangements

    Share-Based Payment Arrangements

     

    The Company accounts for stock awards in accordance with ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), which requires that all equity awards be accounted for at their fair value. Fair value is measured on the grant date and is equal to the underlying value of the stock.

     

    Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, or in the period of grant for awards that vest immediately and have no future service condition. For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company’s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.

     
    Income Taxes

    Income Taxes

     

    The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, Income Taxes (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

     

    ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were unrecognized tax benefits as of December 31, 2022 and 2021 of $765,613 and $0, respectively. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the years ended December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.

     

    See Note 11 for additional information on income taxes for the periods presented.

     
    Net (Loss) Income Per Common Share

    Net (Loss) Income Per Common Share

     

    Net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The calculation of diluted (loss) income per common share does not consider the effect of the Public Warrants (as defined in Note 3), Private Warrants, Subscription Warrants (as defined in Note 6), and Rights (as defined in Note 3) since the exercise of the warrants and Rights are contingent upon the occurrence of future events and the inclusion of such warrants and Rights would be anti-dilutive. The warrants and Rights are exercisable to purchase 22,068,750 shares of common stock in the aggregate.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     

    The following table reflects the calculation of basic and diluted net (loss) income per common share (in dollars, except per share amounts):

     

       Redeemable Common Stock   Non-redeemable Common Stock   Redeemable Common Stock   Non-redeemable Common Stock 
      

    For the Year ended

    December 31, 2022

    		  

    For the Year ended

    December 31, 2021

    		 
       Redeemable Common Stock   Non-redeemable Common Stock   Redeemable Common Stock   Non-redeemable Common Stock 
    Basic and diluted net (loss) income per share:                    
    Numerator:                    
    Net (loss) income  $(326,506)  $(160,282)  $2,074,858   $414,971 
    Denominator:                    
    Weighted Average Common Stock   8,199,223    4,025,000    20,125,000    4,025,000 
    Basic and diluted net (loss) income per common share  $(0.04)  $(0.04)  $0.10   $0.10 

     
    Concentration of Credit Risk

    Concentration of Credit Risk

     

    Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

     
    Fair Value of Financial Instruments

    Fair Value of Financial Instruments

     

    The Company applies ASC Topic 820, Fair Value Measurement (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.

     

    The carrying amounts reflected in the consolidated balance sheets for current assets and current liabilities approximate fair value due to their short-term nature.

     

    Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.

     

    Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

     

    Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.

     

    See Note 10 for additional information on assets and liabilities measured at fair value.

     

     

    VIVEON HEALTH ACQUISITION CORP.

    NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

     
    Derivative Financial Instruments

    Derivative Financial Instruments

     

    The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified on the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the Private Warrants and Subscription Warrants (as defined in Note 6) are derivative instruments. As the Private Warrants and Subscription Warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820 with changes in fair value recognized in the consolidated statements of operations in the period of change. In accordance with ASC Topic 825, Financial Instruments, the Company has concluded that a portion of the transaction costs which directly related to the Initial Public Offering and the Private Placement, should be allocated to the Private Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the consolidated statements of operations.

     
    Recent Accounting Standards

    Recent Accounting Standards

     

    The Company’s management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements. 
    XML 37 R20.htm IDEA: XBRL DOCUMENT v3.23.2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
    		 12 Months Ended
    Dec. 31, 2022
    Accounting Policies [Abstract]  
    SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS

    Gross proceeds  $201,250,000 
    Less:     
    Fair value of Public Warrants at issuance   (10,384,500)
    Fair value of Rights at issuance   (9,136,750)
    Issuance costs allocated to common stock subject to possible redemption   (10,660,961)
    Plus:     
    Remeasurement of carrying value to redemption value   32,194,711 
    Common stock subject to possible redemption as of December 31, 2021   203,262,500 
    Redemption of common stock by stockholders   (152,451,819)
    Common stock tendered for redemption   (34,004,514)
    Remeasurement of carrying value to redemption value   2,607,712 
    Common stock subject to possible redemption as of December 31, 2022  $19,413,879 
    SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE

    The following table reflects the calculation of basic and diluted net (loss) income per common share (in dollars, except per share amounts):

     

       Redeemable Common Stock   Non-redeemable Common Stock   Redeemable Common Stock   Non-redeemable Common Stock 
      

    For the Year ended

    December 31, 2022

    		  

    For the Year ended

    December 31, 2021

    		 
       Redeemable Common Stock   Non-redeemable Common Stock   Redeemable Common Stock   Non-redeemable Common Stock 
    Basic and diluted net (loss) income per share:                    
    Numerator:                    
    Net (loss) income  $(326,506)  $(160,282)  $2,074,858   $414,971 
    Denominator:                    
    Weighted Average Common Stock   8,199,223    4,025,000    20,125,000    4,025,000 
    Basic and diluted net (loss) income per common share  $(0.04)  $(0.04)  $0.10   $0.10 
    XML 38 R21.htm IDEA: XBRL DOCUMENT v3.23.2
    NOTE AGREEMENTS PAYABLE (Tables)
    		 12 Months Ended
    Dec. 31, 2022
    Debt Disclosure [Abstract]  
    SCHEDULE OF NOTES

    The following table presents the Notes as of December 31, 2022:

     

          
    Note  $4,000,000 
    Debt discount  $— 
    Carrying value of notes  $4,000,000 
    XML 39 R22.htm IDEA: XBRL DOCUMENT v3.23.2
    FAIR VALUE MEASUREMENTS (Tables)
    		 12 Months Ended
    Dec. 31, 2022
    Class of Warrant or Right [Line Items]  
    SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS

    Description 

    Amount at

    Fair Value

    		   Level 1   Level 2   Level 3 
    December 31, 2022                    
    Assets                    
    Money Market Account  $6,346   $6,346   $—   $— 
    Money Market Funds held in Trust Account  $53,815,395   $53,815,395   $—   $— 
    Liabilities                    
    Private Warrant Liability  $900,000   $—   $—   $900,000 
    Subscription Warrant Liability  $1,635,515   $—   $—   $1,635,515 
                         
    December 31, 2021                    
    Assets                    
    Money Market Account  $350,455   $350,455   $—   $— 
    Mutual Funds held in Trust Account  $203,282,989   $203,282,989   $—   $— 
    Liabilities                    
    Private Warrant Liability  $4,188,221   $—   $—   $4,188,221 
    SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS

    The following tables presents the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value:

     

     

    Fair value as of December 31, 2020  $10,763,361 
    Change in fair value   (6,575,140)
    Fair value as of December 31, 2021  $4,188,221 

     

    Fair value as of December 31, 2021  $4,188,221 
    Fair value of Subscription Warrants at issuance on March 21, 2022   5,370,185 
    Fair value of Subscription Warrants at issuance on March 23, 2022   337,991 
    Fair value of Subscription Warrants at issuance on April 4, 2022   341,967 
    Fair value of Subscription Warrants at issuance on April 27, 2022   417,037 
    Fair value of Subscription Warrants at issuance on May 9, 2022   162,003 
    Fair value of Subscription Warrants at issuance on October 27, 2022   65,326 
    Fair value of Subscription Warrants at issuance on November 25, 2022   121,093 
    Change in fair value   (8,468,308)
    Fair value as of December 31, 2022  $2,535,515 
    Private Warrants [Member]  
    Class of Warrant or Right [Line Items]  
    SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES

    The key inputs into the Monte Carlo simulation for the Private Warrants as of December 31, 2022 and December 31, 2021 were as follows:

     

     

    Inputs 

    As of

    December 31, 2022

    		  

    As of

    December 31, 2021

    		 
    Risk-free interest rate   4.39%   1.30%
    Expected term remaining (years)1   2.11    5.50 
    Expected volatility   0.01%   7.6%
    Stock price  $10.650   $10.020 
    Subscription Warrants [Member]  
    Class of Warrant or Right [Line Items]  
    SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES

    The key inputs into the Monte Carlo simulation for the Subscription Warrants as of December 31, 2022 and the issuance dates were as follows:

     

    Inputs 

    As of

    December 31,

    2022

    		  

    As of

    November 25,

    2022 (Initial Measurement)

    		  

    As of

    October 27,

    2022 (Initial Measurement)

    		  

    As of

    May 9,

    2022 (Initial Measurement)

    		  

    As of

    April 27,

    2022 (Initial Measurement)

    		  

    As of

    April 4,

    2022 (Initial Measurement)

    		  

    As of

    March 23,

    2022 (Initial Measurement)

    		  

    As of

    March 21,

    2022 (Initial Measurement)

    		 
    Risk-free interest rate                  4.04%               3.90%               4.11%              2.92%              2.80%             2.57%             2.33%              2.33%
    Market debt rate1   9.19%   8.70%   9.64%  7.49%   6.75%  6.09%  N/A   N/A 
    Expected term remaining (years)   4.60    4.70    4.78   4.56    4.60   4.66   4.44   4.44 
    Expected volatility   0.01%   1.38%   4.89%  1.0%   1.0%  1.0%  2.5%  2.4%
    Probability of completing a Business Combination   24.5%   23.9%   14.4%   90%   90%  90%  90%   90%
    Stock price  $10.650   $10.470   $10.400  $10.220   $10.220  $10.170   $10.080  $10.080 

     

    1The Company changed its valuation technique to incorporate the market debt rate as a significant input to the Monte Carlo simulation for the valuation of the Subscription Warrants as of December 31, 2022, November 25, 2022, October 27, 2022, May 9, 2022, April 27, 2022, and April 4, 2022. In the case that the Subscription Warrants were exercised, the risk-free interest rate was used. In the case that the put option was exercised, the market debt rate was used. The risk-free interest rate was used in both scenarios in the Monte Carlo simulation for the valuation of the Subscription Warrants as of March 23, 2022 and March 21, 2022.
    XML 40 R23.htm IDEA: XBRL DOCUMENT v3.23.2
    INCOME TAXES (Tables)
    		 12 Months Ended
    Dec. 31, 2022
    Income Tax Disclosure [Abstract]  
    SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

    The Company’s net deferred tax assets (liabilities) as of December 31, 2022 and December 31, 2021 are as follows:

     

       December 31, 2022   December 31, 2021 
    Deferred tax assets:          
    Start-up costs  $1,097,004   $791,079.00 
    Accrued interest   100,569      
    Transaction costs   —    — 
    Net operating loss carryforwards   

    704,303

    		    39,259 
    Total deferred tax assets   1,901,876    830,338 
    Valuation allowance   (1,862,617)   (830,338)
    Deferred tax assets, net of allowance  $39,259   $— 
    SCHEDULE OF INCOME TAX PROVISION

    The income tax provision for the year ended December 31, 2022 and December 31, 2021 consist of the following:

     

     

       December 31, 2022   December 31, 2021 
    Federal          
    Current  $100,569   $— 
    Deferred   (1,071,538)   (824,916)
               
    State          
    Current  $—   $— 
    Deferred   —    — 
    Change in valuation allowance   1,032,279    824,916 
    Income tax provision  $61,310   $— 
    SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION

    A reconciliation of the federal income tax rate to the Company’s effective tax rate as of December 31, 2022 and December 31, 2021 are as follows:

     

     

       December 31, 2022   December 31, 2021 
    Statutory federal income tax rate   21.0%   21.0%
    State taxes, net of federal tax benefit   0.0%   0.0%
    Change in fair value of derivative warrant liabilities   418.0%   (55.5)%
    Non-deductible transaction costs   (32.8)%   0%
    Stock compensation expense   0.0%   1.3%
    Other permanent items, net   (0.2)%   0%
    Warrant issuance costs   (177.8)%   0.0%
    Change in valuation allowance   (242.6)%   33.2%
    Income tax provision   (14.4)%   0.0%
    SCHEDULE OF UNRECOGNIZED TAX BENEFITS

     

       2022   2021 
       Year Ended December 31, 
       2022   2021 
    Uncertain tax benefits - January 1  $—   $— 
    Gross increases - Tax positions in prior period   765,613    — 
    Uncertain tax benefits - December 31  $765,613   $— 
    XML 41 R24.htm IDEA: XBRL DOCUMENT v3.23.2
    DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative) - USD ($)
    		 12 Months Ended
    Jun. 22, 2023
    Apr. 05, 2023
    Dec. 23, 2022
    Nov. 10, 2022
    Jul. 13, 2022
    Apr. 30, 2021
    Dec. 30, 2020
    Dec. 28, 2020
    Dec. 22, 2020
    Dec. 31, 2022
    Dec. 31, 2021
    Jul. 27, 2023
    Jun. 27, 2023
    May 24, 2023
    Apr. 28, 2023
    Dec. 28, 2022
    Nov. 28, 2022
    Nov. 25, 2022
    Oct. 28, 2022
    Sep. 28, 2022
    Aug. 30, 2022
    Aug. 16, 2022
    Jul. 26, 2022
    Jun. 23, 2022
    Mar. 27, 2022
    Mar. 23, 2022
    Mar. 18, 2022
    Property, Plant and Equipment [Line Items]                                                      
    Share price           $ 5.82                                          
    Gross proceeds                     $ 201,250,000                                
    Sale of units, value           $ 157,140                                          
    Initial business combination percentage of trust account                   80.00%                                  
    Percentage of outstanding voting securities                   50.00%                                  
    Business combination net tangible assets                   $ 5,000,001                                  
    Aggregate percent of shares sold                   20.00%                                  
    Redemption of public shares percentage                   100.00%                                  
    Deposits                               $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000   $ 240,000 $ 240,000 $ 100,000 $ 720,000 $ 152,451,819
    Redemption payment shares                                                     15,092,126
    Repayments of related party debt                   $ 228,758                                
    Common stock, shares, outstanding                   5,031,250 5,031,250                                
    Asset, held-in-trust                   $ 53,815,395 $ 203,282,989                               $ 152,451,819
    Outstanding public shares percentage                   100.00%                                  
    Net of repayment subordinated convertible promissory note         $ 1,500,000                                            
    Agreegate warrants value       $ 2,582,075                                              
    Common stock, par value                   $ 0.0001 $ 0.0001                                
    Preferred Stock, Par or Stated Value Per Share                   $ 0.0001 $ 0.0001                                
    Percentage of lock up shares                   50.00%                                  
    Cash and cash equivalents                   $ 19,847 $ 395,235                                
    Percentage of excise tax                                           1.00%          
    Common Stock [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Purchase units     3,188,100                                                
    Share price                   $ 12.50                                  
    Maximum [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Company expenses and parent expenses         50,000,000                                            
    Minimum [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Company expenses and parent expenses         $ 30,000,000                                            
    Subsequent Event [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Deposits $ 85,000                     $ 85,000 $ 85,000 $ 100,000 $ 100,000                        
    Redemption payment shares 227,359                                                    
    Repayments of related party debt $ 2,498,947.09                                                    
    Share price $ 10.99                                                    
    Common stock, shares, outstanding 1,617,415                                                    
    Asset, held-in-trust $ 17,777,323.54                                                    
    Common stock, par value   $ 0.001                                                  
    Common Stock, Conversion Basis   the sum of $250 Million, plus the aggregate exercise or conversion price of outstanding Clearday’s stock options and warrants (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more),                                                  
    Subsequent Event [Member] | Viveon Equity Incentive Plan [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Percentage of common stock issued and outstanding   8.00%                                                  
    Subsequent Event [Member] | Clearday [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Business combination net tangible assets   $ 5,000,001                                                  
    Business Combination, Contingent Consideration, Liability   $ 250,000,000                                                  
    Common stock, par value   $ 0.0001                                                  
    Shares Issued, Price Per Share   10                                                  
    Common Stock, Convertible, Conversion Price, Increase   $ 5.00                                                  
    Subsequent Event [Member] | Clearday [Member] | Earnout Shares [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Business Acquisition, Equity Interest Issued or Issuable, Number of Shares   5,000,000                                                  
    Subsequent Event [Member] | New Merger [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Common stock, par value   $ 0.0001                                                  
    Forecast [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Deposits                           $ 100,000 $ 100,000                        
    Series F Cumulative Convertible Preferred Stock [Member] | Subsequent Event [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Preferred Stock, Par or Stated Value Per Share   $ 0.001                                                  
    Preferred Stock, Conversion Basis   (A) one (1) share of Parent New Series F Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement                                                  
    Series A Cumulative Convertible Preferred Stock [Member] | Subsequent Event [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Preferred Stock, Par or Stated Value Per Share   $ 0.001                                                  
    Preferred Stock, Conversion Basis   (A) one (1) share of Parent New Series A Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement                                                  
    IPO [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Sale of shares               17,500,000                                      
    Share price               $ 10.00   $ 10.10                                  
    Gross proceeds               $ 175,000,000                                      
    Sale of units, value                   $ 203,262,500                                  
    Redemption percentage of outstanding public shares                   100.00%                                  
    Common stock, par value               $ 0.0001                                      
    IPO [Member] | Public Shares [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Sale of shares               17,500,000                                      
    Share price               $ 10.00                                      
    IPO [Member] | Private Warrants [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Sale of shares               18,000,000                                      
    Share price               $ 0.50                                      
    Over-Allotment Option [Member]                                                      
    Property, Plant and Equipment [Line Items]                                                      
    Purchase units             2,625,000   875,000                                    
    Gross proceeds of options             $ 26,250,000                                        
    XML 42 R25.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Accounting Policies [Abstract]    
    Gross proceeds   $ 201,250,000
    Fair value of Public Warrants at issuance   (10,384,500)
    Fair value of Rights at issuance   (9,136,750)
    Issuance costs allocated to common stock subject to possible redemption   (10,660,961)
    Remeasurement of carrying value to redemption value $ 2,607,712 32,194,711
    Common stock subject to possible redemption as of December 31, 2021 203,262,500  
    Redemption of common stock by stockholders (152,451,819)  
    Redemption of common share, value (34,004,514)
    Common stock subject to possible redemption as of December 31, 2022 $ 19,413,879 $ 203,262,500
    XML 43 R26.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Numerator:    
    Net (loss) income $ (486,788) $ 2,489,829
    Denominator:    
    Weighted Average Common Stock 12,224,223 24,150,000
    Basic and diluted net (loss) income per common share $ (0.04) $ 0.10
    Redeemable Common Stock [Member]    
    Numerator:    
    Net (loss) income $ (326,506) $ 2,074,858
    Denominator:    
    Weighted Average Common Stock 8,199,223 20,125,000
    Basic and diluted net (loss) income per common share $ (0.04) $ 0.10
    Non Redeemable Common Stock [Member]    
    Numerator:    
    Net (loss) income $ (160,282) $ 414,971
    Denominator:    
    Weighted Average Common Stock 4,025,000 4,025,000
    Basic and diluted net (loss) income per common share $ (0.04) $ 0.10
    XML 44 R27.htm IDEA: XBRL DOCUMENT v3.23.2
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Jul. 27, 2023
    Jun. 27, 2023
    Jun. 22, 2023
    May 24, 2023
    Apr. 28, 2023
    Dec. 28, 2022
    Nov. 28, 2022
    Nov. 25, 2022
    Oct. 28, 2022
    Sep. 28, 2022
    Aug. 30, 2022
    Jul. 26, 2022
    Jun. 23, 2022
    Mar. 27, 2022
    Mar. 23, 2022
    Mar. 18, 2022
    Dec. 31, 2020
    Subsequent Event [Line Items]                                      
    Cash equivalents $ 6,346 $ 350,455                                  
    Investment held in Trust Account $ 53,815,395 203,282,989                               $ 152,451,819  
    Temporary equity, shares issued 5,032,874                                 5,032,874  
    Deposits               $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 100,000 $ 720,000 $ 152,451,819  
    Remeasurement of carrying value to redemption value $ 2,607,712 32,194,711                                  
    Offering costs 11,830,356                                    
    Cash underwriting fee 4,025,000                                    
    Deferred underwriting fees 7,043,750                                    
    Other offering costs 761,606                                    
    Other offering costs 10,660,961                                    
    Unrecognized tax benefits $ 765,613                                
    Warrants exercisable to purchase shares of common stock 22,068,750                                    
    Federal depository insurance coverage amount $ 250,000                                    
    Public Warrants [Member]                                      
    Subsequent Event [Line Items]                                      
    Other offering costs 1,144,422                                    
    Private Warrants [Member]                                      
    Subsequent Event [Line Items]                                      
    Other offering costs $ 24,973                                    
    Subsequent Event [Member]                                      
    Subsequent Event [Line Items]                                      
    Investment held in Trust Account         $ 17,777,323.54                            
    Deposits     $ 85,000 $ 85,000 $ 85,000 $ 100,000 $ 100,000                        
    XML 45 R28.htm IDEA: XBRL DOCUMENT v3.23.2
    INITIAL PUBLIC OFFERING (Details Narrative) - USD ($)
    Dec. 30, 2020
    Dec. 28, 2020
    Dec. 22, 2020
    Dec. 31, 2022
    Dec. 31, 2021
    Apr. 30, 2021
    Subsidiary, Sale of Stock [Line Items]            
    Share price           $ 5.82
    Common stock, par value       $ 0.0001 $ 0.0001  
    Exercise price of warrants   $ 11.50   11.50    
    IPO [Member]            
    Subsidiary, Sale of Stock [Line Items]            
    Sale of stock   17,500,000        
    Share price   $ 10.00   $ 10.10    
    Common stock, par value   $ 0.0001        
    Over-Allotment Option [Member]            
    Subsidiary, Sale of Stock [Line Items]            
    Sale of stock 2,625,000   875,000      
    Gross proceeds of options $ 26,250,000          
    XML 46 R29.htm IDEA: XBRL DOCUMENT v3.23.2
    PRIVATE PLACEMENT (Details Narrative) - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 28, 2020
    Subsidiary, Sale of Stock [Line Items]    
    Warrent purchases 22,068,750  
    Exercise price of warrants $ 11.50 $ 11.50
    Private Placement [Member]    
    Subsidiary, Sale of Stock [Line Items]    
    Warrent purchases 18,000,000  
    Exercise price of warrants $ 0.50  
    Warrent purchases price $ 9,000,000  
    XML 47 R30.htm IDEA: XBRL DOCUMENT v3.23.2
    RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
    		 1 Months Ended 3 Months Ended 4 Months Ended 12 Months Ended
    Apr. 02, 2023
    Dec. 27, 2022
    Apr. 30, 2021
    Apr. 30, 2021
    Dec. 30, 2020
    Dec. 23, 2020
    Dec. 22, 2020
    Dec. 03, 2020
    Aug. 31, 2020
    Apr. 07, 2023
    Apr. 28, 2023
    Dec. 31, 2022
    Dec. 31, 2021
    Jun. 22, 2023
    Apr. 05, 2023
    Subsidiary, Sale of Stock [Line Items]                              
    Common stock, par value                       $ 0.0001 $ 0.0001    
    Common stock dividend declared per share                       $ 2.00      
    Fair value of founder shares       $ 157,140                      
    Founder shares, per share     $ 5.82 $ 5.82                      
    Share based compensation                       $ 157,140    
    Notes payable, related party                       1,955,000    
    Proceeds from initial public offering                         201,250,000    
    Incurred expenses                       6,647 9,479    
    Due to related party                       5,806 5,850    
    Due from related party                       15,000    
    Subsequent Event [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Share price                           $ 10.99  
    Common stock, par value                             $ 0.001
    Promissory Note [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Loans payable                       75,000 0    
    Sponsor [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Rent paid                       20,000      
    Administrative service fees                       240,000 240,000    
    Due to related party                       50,000 10,000    
    Sponsor [Member] | Promissory Note [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Costs and expenses, related party                       500,000      
    Proceeds from initial public offering                       228,758      
    Chief Financial Officer [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Loans payable                       1,955,000      
    Chief Financial Officer [Member] | Promissory Note [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Costs and expenses, related party   $ 75,000                          
    Chief Financial Officer [Member] | Promissory Note [Member] | Subsequent Event [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Proceeds from Loans                     $ 555,000        
    Chief Financial Officer [Member] | Note Agreements [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Notes payable, related party                       1,955,000      
    Chief Executive Officer [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Loans payable                       $ 0 0    
    Chief Executive Officer [Member] | Subsequent Event [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Proceeds from Loans $ 100,000                            
    Three Investors [Member] | Subsequent Event [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Proceeds from (Repayments of) Notes Payable                   $ 100,000          
    Dipak Vashir [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Loans payable                         $ 0    
    Founder Shares [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Number of shares issued to sponsor                 $ 25,000            
    Share price                 $ 0.007            
    Number of shares issued to sponsor, shares                 3,593,750            
    Common stock, par value                 $ 0.0001            
    Common stock dividend declared per share             $ 0.03 $ 0.36              
    Common stock dividend declared shares             5,031,250 4,887,500              
    Shares cancellation common stock subject to forfeiture         656,250   656,250         656,250      
    Share issued             1,006,250                
    Founder shares related description                       50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the initial Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the initial Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to its initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.      
    Founder Shares [Member] | Sponsor [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Number of stock transferred     27,000     81,000                  
    Founder Shares [Member] | Transferee [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Number of stock transferred           27,000                  
    Over-Allotment Option [Member]                              
    Subsidiary, Sale of Stock [Line Items]                              
    Share issued         2,625,000   875,000                
    XML 48 R31.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF NOTES (Details)
    Dec. 31, 2022
    USD ($)
    Debt Disclosure [Abstract]  
    Note $ 4,000,000
    Debt discount
    Carrying value of notes $ 4,000,000
    XML 49 R32.htm IDEA: XBRL DOCUMENT v3.23.2
    NOTE AGREEMENTS PAYABLE (Details Narrative) - USD ($)
    		 12 Months Ended
    Nov. 25, 2022
    Oct. 27, 2022
    May 09, 2022
    Apr. 27, 2022
    Apr. 04, 2022
    Mar. 23, 2022
    Mar. 21, 2022
    Dec. 31, 2022
    Dec. 31, 2021
    Aug. 16, 2023
    Dec. 28, 2020
    Short-Term Debt [Line Items]                      
    Common Stock, Dividends, Per Share, Declared               $ 2.00      
    Debt Instrument, Face Amount               $ 2,000,000      
    Class of Warrant or Right, Exercise Price of Warrants or Rights               $ 11.50     $ 11.50
    Fair Value Adjustment of Warrants               $ (8,468,308) $ (6,575,140)    
    Debt discount               3,645,777      
    Interest expense               3,645,777      
    Warrant [Member]                      
    Short-Term Debt [Line Items]                      
    Subscription warrants $ 121,093 $ 65,326 $ 162,003 $ 417,037 $ 341,967 $ 337,991 $ 5,370,185        
    Fair Value Adjustment of Warrants               3,209,183      
    Subsequent Event [Member] | Subscription Warrants [Member]                      
    Short-Term Debt [Line Items]                      
    Debt forfeit for cancellation                   89,029  
    Chief Financial Officer [Member]                      
    Short-Term Debt [Line Items]                      
    Loans payable               $ 1,955,000      
    Unsecured Senior Promissory Note Agreements [Member]                      
    Short-Term Debt [Line Items]                      
    Debt instrument description               On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, in connection with the extension of the date by which the Company has to consummate a Business Combination (see Note 7), the Company entered into a series of unsecured senior promissory note agreements (“Note Agreements”) for up to an aggregate amount totaling $4.0 million (the “Notes”). Of the total $4.0 million of the Notes, $1,955,000 is loaned by lenders who are affiliated with the sponsor and a director of the Company, and Intuitus Group LLC, for which the Chief Financial Officer of the Company is the Sole Proprietor      
    Interest rate               10.00%      
    Line of credit facility maximum borrowing capacity               $ 400,000      
    Unsecured Promissory Note Agreements [Member]                      
    Short-Term Debt [Line Items]                      
    Notes receivable               4,000,000      
    Commitment fee amount               $ 400,000      
    XML 50 R33.htm IDEA: XBRL DOCUMENT v3.23.2
    COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
    		 12 Months Ended
    Jun. 22, 2023
    May 09, 2023
    Dec. 23, 2022
    Feb. 17, 2022
    Nov. 15, 2021
    Dec. 30, 2020
    Dec. 22, 2020
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 23, 2023
    Jul. 27, 2023
    Jun. 27, 2023
    May 24, 2023
    Apr. 28, 2023
    Dec. 28, 2022
    Nov. 28, 2022
    Nov. 25, 2022
    Oct. 28, 2022
    Sep. 28, 2022
    Aug. 30, 2022
    Jul. 26, 2022
    Jun. 23, 2022
    Mar. 27, 2022
    Mar. 23, 2022
    Mar. 18, 2022
    Nov. 05, 2021
    Nov. 02, 2021
    Nov. 01, 2021
    Oct. 08, 2021
    May 18, 2021
    Underwriting fee               $ 0.35                                            
    Underwriting expense               $ 4,025,000                                            
    Underwriting expense               7,043,750                                            
    Accrued costs and expenses               500,000 $ 500,000                                          
    Advisor fees                                                   $ 200,000        
    Accrued advisor fee               500,000 500,000                                          
    Business combination consideration transferred               2,125,000                                            
    Floor Brokerage       $ 250,000                                                    
    Broker dealer fee       $ 250,000                                                    
    Redemption payment shares (in Shares)                                                 15,092,126          
    Asset, held-in-trust               $ 53,815,395 203,282,989                               $ 152,451,819          
    Temporary equity shares issued               5,032,874                                 5,032,874          
    Deposit amount               $ 100,000                               $ 240,000            
    Deposits                             $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 240,000 $ 100,000 $ 720,000 $ 152,451,819          
    Redemption of common share, value               $ 34,004,514                                          
    Temporary equity shares outstanding               1,844,774 20,125,000                                          
    Redemption payment shares                                                 15,092,126          
    Repayments of related party debt               $ 228,758                                          
    Common stock outstanding, shares               5,031,250 5,031,250                                          
    Common Stock [Member]                                                            
    Purchase units     3,188,100                                                      
    Redemption of common share, value     $ 34,004,514                                                      
    Share price               $ 12.50                                            
    Subsequent Event [Member]                                                            
    Asset, held-in-trust $ 17,777,323.54                                                          
    Deposits $ 85,000                   $ 85,000 $ 85,000 $ 100,000 $ 100,000                                
    Redemption payment shares 227,359                                                          
    Repayments of related party debt $ 2,498,947.09                                                          
    Share price $ 10.99                                                          
    Common stock outstanding, shares 1,617,415                                                          
    Subsequent Event [Member] | Common Class A [Member]                                                            
    Temporary equity shares outstanding                   1,844,774                                        
    Subsequent Event [Member] | Common Stock [Member]                                                            
    Redemption of common share, value                   $ 34,004,514                                        
    Placement Agents [Member]                                                            
    Business combination assets description         On November 15, 2021, the Company entered into an agreement with two placement agents (the “Placement Agents”) for services such as analysis of potential contributions and assets of a target to the Company’s future prospects, assistance in negotiations, and assistance in preparation of presentations to investors, lenders, and/or other financial sources in connection with a Business Combination, pursuant to which the Company will pay the Placement Agents a fee equal to the difference between 5% of the total aggregate sales price of the securities sold as part of the Business Combination and 5% of any securities sold as part of the Business Combination to investors identified by the Advisor, contingent upon the consummation of the Business Combination. This agreement was terminated on February 15, 2022, as a result of an automatic termination provision upon the earlier to occur of three months or the final closing of Business Combination and there are no related contingent fees for the agreement.                                                  
    Placement Agents [Member] | Subsequent Event [Member]                                                            
    Business combination assets description   On May 9, 2023, the Company entered into an agreement with a placement agent (the “Placement Agent) for services such as advising and assisting the Company in identifying one or more investors that are “accredited” or “qualified institutional buyers. Pursuant to which the Company will pay the Placement Agents a cash fee upon closing equal to eight percent (8.0%) of the gross proceeds received by the Company, contingent upon the consummation of the Business Combination.                                                        
    Strategic Adviser [Member]                                                            
    Advisor fees                                                       $ 2,625,000    
    Exclusive Financial Advisor [Member]                                                            
    Advisor fees                                                         $ 1,500,000  
    Second Financial Advisor [Member]                                                            
    Advisor fees                                                       $ 400,000    
    Third Financial Advisor [Member]                                                            
    Advisor fees                                                     $ 500,000      
    Strategic Advisor [Member]                                                            
    Agreement fees                                                           $ 875,000
    Over-Allotment Option [Member]                                                            
    Additional Shares granted           2,625,000                                                
    Purchase units           2,625,000 875,000                                              
    IPO [Member]                                                            
    Underwriting fee               $ 0.20                                            
    Underwriting expense               $ 4,025,000                                            
    XML 51 R34.htm IDEA: XBRL DOCUMENT v3.23.2
    STOCKHOLDERS’ DEFICIT (Details Narrative) - $ / shares
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Equity [Abstract]    
    Preferred stock, shares authorized 1,000,000 1,000,000
    Preferred stock, par value $ 0.0001 $ 0.0001
    Preferred stock, shares issued 0 0
    Preferred stock, shares outstanding 0 0
    Common stock, shares authorized 60,000,000 60,000,000
    Common stock, par value $ 0.0001 $ 0.0001
    Voting rights Holders are entitled to one vote for each share  
    Common stock, shares issued 5,031,250 5,031,250
    Common stock, shares outstanding 5,031,250 5,031,250
    Temporary equity shares outstanding 1,844,774 20,125,000
    XML 52 R35.htm IDEA: XBRL DOCUMENT v3.23.2
    WARRANTS (Details Narrative) - $ / shares
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Apr. 30, 2021
    Dec. 28, 2020
    Price per warrant $ 11.50     $ 11.50
    Business combination equity description If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its Sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial Business Combination on the date of the consummation of our initial Business Combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value.      
    Purchase price per warrant     $ 5.82  
    Warrants outstanding 2,000,000      
    IPO [Member]        
    Purchase price per warrant $ 10.10     $ 10.00
    Warrants outstanding 20,125,000 20,125,000    
    Private Placement [Member]        
    Price per warrant $ 0.50      
    Warrants outstanding 18,000,000 18,000,000    
    Warrant [Member]        
    Price per warrant $ 0.01      
    Shares issued price 9.50      
    Redemption price per share 16.50      
    Purchase price per warrant $ 5.00      
    XML 53 R36.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - Fair Value, Recurring [Member] - USD ($)
    Dec. 31, 2022
    Dec. 31, 2021
    Private Warrant Liability [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Liabilities $ 900,000 $ 4,188,221
    Subscription Warrant Liability [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Liabilities 1,635,515  
    Fair Value, Inputs, Level 1 [Member] | Private Warrant Liability [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Liabilities
    Fair Value, Inputs, Level 1 [Member] | Subscription Warrant Liability [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Liabilities  
    Fair Value, Inputs, Level 2 [Member] | Private Warrant Liability [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Liabilities
    Fair Value, Inputs, Level 2 [Member] | Subscription Warrant Liability [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Liabilities  
    Fair Value, Inputs, Level 3 [Member] | Private Warrant Liability [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Liabilities 900,000 4,188,221
    Fair Value, Inputs, Level 3 [Member] | Subscription Warrant Liability [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Liabilities 1,635,515  
    Money Market Funds [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets 6,346 350,455
    Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets 6,346 350,455
    Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets
    Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets
    Money Market Funds Held In Trust Account [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets 53,815,395  
    Money Market Funds Held In Trust Account [Member] | Fair Value, Inputs, Level 1 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets 53,815,395  
    Money Market Funds Held In Trust Account [Member] | Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets  
    Money Market Funds Held In Trust Account [Member] | Fair Value, Inputs, Level 3 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets  
    Mutual Fund [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets   203,282,989
    Mutual Fund [Member] | Fair Value, Inputs, Level 1 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets   203,282,989
    Mutual Fund [Member] | Fair Value, Inputs, Level 2 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets  
    Mutual Fund [Member] | Fair Value, Inputs, Level 3 [Member]    
    Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
    Assets  
    XML 54 R37.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES (Details)
    		 12 Months Ended
    Nov. 25, 2022
    $ / shares
    Oct. 27, 2022
    $ / shares
    May 09, 2022
    $ / shares
    Apr. 27, 2022
    $ / shares
    Apr. 04, 2022
    shares
    Mar. 23, 2022
    $ / shares
    Mar. 21, 2022
    Dec. 31, 2022
    $ / shares
    Dec. 31, 2021
    $ / shares
    Measurement Input, Price Volatility [Member] | Fair Value, Inputs, Level 3 [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input   4.89              
    Private Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input               4.39 1.30
    Private Warrants [Member] | Measurement Input, Expected Term [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights term                 5 years 6 months
    Private Warrants [Member] | Measurement Input, Expected Term [Member] | Fair Value, Inputs, Level 3 [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights term               2 years 1 month 9 days  
    Private Warrants [Member] | Measurement Input, Price Volatility [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input               0.01 7.6
    Private Warrants [Member] | Measurement Input, Share Price [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input               10.650 10.020
    Subscription Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input 3.90 4.11 2.92 2.80 2.57   2.33 4.04  
    Subscription Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | Fair Value, Inputs, Level 3 [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input           2.33      
    Subscription Warrants [Member] | Measurement Input, Expected Term [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights term   4 years 9 months 10 days 4 years 6 months 21 days 4 years 7 months 6 days 4 years 7 months 28 days 4 years 5 months 8 days   4 years 7 months 6 days  
    Subscription Warrants [Member] | Measurement Input, Expected Term [Member] | Fair Value, Inputs, Level 3 [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights term 4 years 8 months 12 days           4 years 5 months 8 days    
    Subscription Warrants [Member] | Measurement Input, Price Volatility [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input 1.38   1.0 1.0 1.0 2.5 2.4 0.01  
    Subscription Warrants [Member] | Measurement Input, Share Price [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input 10.470 10.400 10.220 10.220 10.170 10.080   10.650  
    Subscription Warrants [Member] | Measurement Input, Share Price [Member] | Fair Value, Inputs, Level 3 [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input             10.080    
    Subscription Warrants [Member] | Measurement Input Market Debt Rate [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input [1] 8.70 9.64 7.49 6.75 6.09     9.19  
    Subscription Warrants [Member] | Measurement Input Probability Of Completing A Business Combination [Member]                  
    Fair Value Measurement Inputs and Valuation Techniques [Line Items]                  
    Warrants and rights outstanding, measurement input 23.9 14.4 90 90 90 90 90 24.5  
    [1] The Company changed its valuation technique to incorporate the market debt rate as a significant input to the Monte Carlo simulation for the valuation of the Subscription Warrants as of December 31, 2022, November 25, 2022, October 27, 2022, May 9, 2022, April 27, 2022, and April 4, 2022. In the case that the Subscription Warrants were exercised, the risk-free interest rate was used. In the case that the put option was exercised, the market debt rate was used. The risk-free interest rate was used in both scenarios in the Monte Carlo simulation for the valuation of the Subscription Warrants as of March 23, 2022 and March 21, 2022.
    XML 55 R38.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Fair value as of beginning $ 4,188,221 $ 10,763,361
    Change in fair value (8,468,308) (6,575,140)
    Fair value as of ending 2,535,515 $ 4,188,221
    Subscription Warrants At Issuance On March 21, 2022 [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Fair value of Subscription Warrants 5,370,185  
    Subscription Warrants At Issuance On March 23, 2023 [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Fair value of Subscription Warrants 337,991  
    Subscription Warrants At Issuance On April 4, 2022 [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Fair value of Subscription Warrants 341,967  
    Subscription Warrants At Issuance On April 27, 2022 [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Fair value of Subscription Warrants 417,037  
    Subscription Warrants At Issuance On May 9, 2022 [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Fair value of Subscription Warrants 162,003  
    Subscription Warrants At Issuance On October 27, 2022 [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Fair value of Subscription Warrants 65,326  
    Subscription Warrants At Issuance On November 25, 2022 [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Fair value of Subscription Warrants $ 121,093  
    XML 56 R39.htm IDEA: XBRL DOCUMENT v3.23.2
    FAIR VALUE MEASUREMENTS (Details Narrative)
    		 12 Months Ended
    Dec. 31, 2022
    USD ($)
    $ / shares
    Dec. 31, 2021
    USD ($)
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Recognized gain (loss) in fair value $ 8,468,308 $ 6,575,140
    Private And Subscription Warrants [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Recognized gain (loss) in fair value $ 8,468,308 $ 6,575,140
    Private Warrant [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Contractual term 5 years  
    Exercise price | $ / shares $ 2.11  
    Private Warrant [Member] | Unsucessful Business Combination [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Contractual term 1 year  
    Private Warrant [Member] | Unsuccessful Business Combination [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Probability 75.5  
    Private Warrant [Member] | Successful Business Combination [Member]    
    Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]    
    Probability 24.5  
    Contractual term 5 years 6 months 7 days  
    XML 57 R40.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)
    Dec. 31, 2022
    Dec. 31, 2021
    Deferred tax assets:    
    Start-up costs $ 1,097,004 $ 791,079.00
    Accrued interest 100,569  
    Transaction costs
    Net operating loss carryforwards 704,303 39,259
    Total deferred tax assets 1,901,876 830,338
    Valuation allowance (1,862,617) (830,338)
    Deferred tax assets, net of allowance $ 39,259
    XML 58 R41.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF INCOME TAX PROVISION (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Federal    
    Current $ 100,569
    Deferred (1,071,538) (824,916)
    State    
    Current
    Deferred
    Change in valuation allowance 1,032,279 824,916
    Income tax provision $ 61,310
    XML 59 R42.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]    
    Statutory federal income tax rate 21.00% 21.00%
    State taxes, net of federal tax benefit 0.00% 0.00%
    Change in fair value of derivative warrant liabilities 418.00% (55.50%)
    Non-deductible transaction costs (32.80%) 0.00%
    Stock compensation expense 0.00% 1.30%
    Other permanent items, net (0.20%) 0.00%
    Warrant issuance costs (177.80%) 0.00%
    Change in valuation allowance (242.60%) 33.20%
    Income tax provision (14.40%) 0.00%
    XML 60 R43.htm IDEA: XBRL DOCUMENT v3.23.2
    SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details) - USD ($)
    		 12 Months Ended
    Dec. 31, 2022
    Dec. 31, 2021
    Income Tax Disclosure [Abstract]    
    Uncertain tax benefits - January 1
    Gross increases - Tax positions in prior period 765,613
    Uncertain tax benefits - December 31 $ 765,613
    XML 61 R44.htm IDEA: XBRL DOCUMENT v3.23.2
    INCOME TAXES (Details Narrative) - USD ($)
    Dec. 31, 2022
    Dec. 31, 2021
    Dec. 31, 2020
    Operating Loss Carryforwards [Line Items]      
    Valuation allowance $ 1,862,617 $ 830,338  
    Unrecognized tax benefits 765,613
    Domestic Tax Authority [Member]      
    Operating Loss Carryforwards [Line Items]      
    Operating loss carry forwards $ 3,354,000 $ 187,000  
    XML 62 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001823857 2022-01-01 2022-12-31 0001823857 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001823857 VHAQ:WarrantsMember 2022-01-01 2022-12-31 0001823857 VHAQ:UnitsMember 2022-01-01 2022-12-31 0001823857 us-gaap:RightsMember 2022-01-01 2022-12-31 0001823857 2022-06-30 0001823857 2023-08-22 0001823857 2022-12-31 0001823857 2021-12-31 0001823857 2021-01-01 2021-12-31 0001823857 us-gaap:CommonStockMember 2021-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001823857 us-gaap:RetainedEarningsMember 2021-12-31 0001823857 us-gaap:CommonStockMember 2020-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001823857 us-gaap:RetainedEarningsMember 2020-12-31 0001823857 2020-12-31 0001823857 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001823857 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001823857 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001823857 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001823857 us-gaap:CommonStockMember 2022-12-31 0001823857 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001823857 us-gaap:RetainedEarningsMember 2022-12-31 0001823857 VHAQ:PublicSharesMember us-gaap:IPOMember 2020-12-28 2020-12-28 0001823857 VHAQ:PublicSharesMember us-gaap:IPOMember 2020-12-28 0001823857 us-gaap:IPOMember 2020-12-28 2020-12-28 0001823857 VHAQ:PrivateWarrantsMember us-gaap:IPOMember 2020-12-28 2020-12-28 0001823857 VHAQ:PrivateWarrantsMember us-gaap:IPOMember 2020-12-28 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-30 2020-12-30 0001823857 us-gaap:IPOMember 2022-01-01 2022-12-31 0001823857 us-gaap:IPOMember 2022-12-31 0001823857 2022-03-23 0001823857 2022-03-18 0001823857 2022-10-28 0001823857 2022-06-23 0001823857 2022-07-26 0001823857 2022-08-30 0001823857 2022-09-28 0001823857 2022-11-28 0001823857 2022-12-28 0001823857 srt:ScenarioForecastMember 2023-04-28 0001823857 srt:ScenarioForecastMember 2023-05-24 0001823857 us-gaap:SubsequentEventMember 2023-06-22 0001823857 us-gaap:SubsequentEventMember 2023-06-22 2023-06-22 0001823857 us-gaap:SubsequentEventMember 2023-06-27 0001823857 us-gaap:SubsequentEventMember 2023-07-27 0001823857 srt:MaximumMember 2022-07-13 2022-07-13 0001823857 srt:MinimumMember 2022-07-13 2022-07-13 0001823857 2022-07-13 2022-07-13 0001823857 2022-11-10 2022-11-10 0001823857 VHAQ:CleardayMember us-gaap:SubsequentEventMember 2023-04-05 0001823857 VHAQ:CleardayMember VHAQ:EarnoutSharesMember us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 0001823857 VHAQ:SeriesFCumulativeConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-04-05 0001823857 VHAQ:SeriesFCumulativeConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 0001823857 VHAQ:SeriesACumulativeConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-04-05 0001823857 VHAQ:SeriesACumulativeConvertiblePreferredStockMember us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 0001823857 us-gaap:SubsequentEventMember 2023-04-05 0001823857 us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 0001823857 VHAQ:CleardayMember us-gaap:SubsequentEventMember 2023-04-05 2023-04-05 0001823857 VHAQ:NewMergerMember us-gaap:SubsequentEventMember 2023-04-05 0001823857 VHAQ:ViveonEquityIncentivePlanMember us-gaap:SubsequentEventMember 2023-04-05 0001823857 2022-08-16 0001823857 2022-11-25 0001823857 2022-03-27 0001823857 VHAQ:PublicWarrantsMember 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember 2022-12-31 0001823857 VHAQ:RedeemableCommonStockMember 2022-01-01 2022-12-31 0001823857 VHAQ:NonRedeemableCommonStockMember 2022-01-01 2022-12-31 0001823857 VHAQ:RedeemableCommonStockMember 2021-01-01 2021-12-31 0001823857 VHAQ:NonRedeemableCommonStockMember 2021-01-01 2021-12-31 0001823857 us-gaap:IPOMember 2020-12-28 0001823857 2020-12-28 0001823857 us-gaap:PrivatePlacementMember 2022-12-31 0001823857 us-gaap:PrivatePlacementMember 2022-01-01 2022-12-31 0001823857 VHAQ:FounderSharesMember 2020-08-01 2020-08-31 0001823857 VHAQ:FounderSharesMember 2020-08-31 0001823857 VHAQ:FounderSharesMember 2020-12-01 2020-12-03 0001823857 VHAQ:FounderSharesMember 2020-12-21 2020-12-22 0001823857 us-gaap:OverAllotmentOptionMember 2020-12-21 2020-12-22 0001823857 VHAQ:FounderSharesMember 2020-12-30 2020-12-30 0001823857 VHAQ:FounderSharesMember 2022-01-01 2022-12-31 0001823857 VHAQ:SponsorMember VHAQ:FounderSharesMember 2020-12-23 2020-12-23 0001823857 VHAQ:TransfereeMember VHAQ:FounderSharesMember 2020-12-23 2020-12-23 0001823857 VHAQ:SponsorMember VHAQ:FounderSharesMember 2021-04-30 2021-04-30 0001823857 2021-04-29 2021-04-30 0001823857 2021-04-30 0001823857 srt:ChiefFinancialOfficerMember VHAQ:NoteAgreementsMember 2022-12-31 0001823857 VHAQ:SponsorMember VHAQ:PromissoryNoteMember 2022-01-01 2022-12-31 0001823857 srt:ChiefFinancialOfficerMember VHAQ:PromissoryNoteMember 2022-12-26 2022-12-27 0001823857 VHAQ:PromissoryNoteMember 2022-12-31 0001823857 VHAQ:PromissoryNoteMember 2021-12-31 0001823857 srt:ChiefFinancialOfficerMember VHAQ:PromissoryNoteMember us-gaap:SubsequentEventMember 2023-01-01 2023-04-28 0001823857 srt:ChiefExecutiveOfficerMember us-gaap:SubsequentEventMember 2023-04-02 2023-04-02 0001823857 srt:ChiefExecutiveOfficerMember 2022-12-31 0001823857 srt:ChiefExecutiveOfficerMember 2021-12-31 0001823857 VHAQ:ThreeInvestorsMember us-gaap:SubsequentEventMember 2023-01-01 2023-04-07 0001823857 VHAQ:DipakVashirMember 2021-12-31 0001823857 VHAQ:SponsorMember 2022-01-01 2022-12-31 0001823857 VHAQ:SponsorMember 2021-01-01 2021-12-31 0001823857 VHAQ:SponsorMember 2022-12-31 0001823857 VHAQ:SponsorMember 2021-12-31 0001823857 VHAQ:UnsecuredSeniorPromissoryNoteAgreementsMember 2022-01-01 2022-12-31 0001823857 srt:ChiefFinancialOfficerMember 2022-12-31 0001823857 VHAQ:UnsecuredSeniorPromissoryNoteAgreementsMember 2022-12-31 0001823857 VHAQ:UnsecuredPromissoryNoteAgreementsMember 2022-12-31 0001823857 VHAQ:UnsecuredPromissoryNoteAgreementsMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:SubsequentEventMember 2023-08-16 0001823857 us-gaap:WarrantMember 2022-03-21 2022-03-21 0001823857 us-gaap:WarrantMember 2022-03-23 2022-03-23 0001823857 us-gaap:WarrantMember 2022-04-04 2022-04-04 0001823857 us-gaap:WarrantMember 2022-04-27 2022-04-27 0001823857 us-gaap:WarrantMember 2022-05-09 2022-05-09 0001823857 us-gaap:WarrantMember 2022-10-27 2022-10-27 0001823857 us-gaap:WarrantMember 2022-11-25 2022-11-25 0001823857 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001823857 VHAQ:StrategicAdvisorMember 2021-05-18 0001823857 VHAQ:StrategicAdviserMember 2021-11-01 0001823857 VHAQ:ExclusiveFinancialAdvisorMember 2021-10-08 0001823857 VHAQ:SecondFinancialAdvisorMember 2021-11-01 0001823857 VHAQ:ThirdFinancialAdvisorMember 2021-11-02 0001823857 2021-11-05 0001823857 VHAQ:PlacementAgentsMember 2021-11-15 2021-11-15 0001823857 2022-02-17 2022-02-17 0001823857 VHAQ:PlacementAgentsMember us-gaap:SubsequentEventMember 2023-05-09 2023-05-09 0001823857 us-gaap:SubsequentEventMember 2023-04-28 0001823857 us-gaap:SubsequentEventMember 2023-05-24 0001823857 us-gaap:CommonStockMember 2022-12-23 2022-12-23 0001823857 us-gaap:CommonStockMember 2022-12-23 0001823857 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2023-12-23 0001823857 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2023-12-23 0001823857 us-gaap:WarrantMember 2022-12-31 0001823857 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001823857 us-gaap:IPOMember 2021-12-31 0001823857 us-gaap:PrivatePlacementMember 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember 2022-01-01 2022-12-31 0001823857 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 VHAQ:MoneyMarketFundsHeldInTrustAccountMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 VHAQ:MoneyMarketFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 VHAQ:MoneyMarketFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 VHAQ:MoneyMarketFundsHeldInTrustAccountMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:FairValueInputsLevel1Member VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:FairValueInputsLevel2Member VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:FairValueInputsLevel3Member VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:FairValueInputsLevel1Member VHAQ:SubscriptionWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:FairValueInputsLevel2Member VHAQ:SubscriptionWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:FairValueInputsLevel3Member VHAQ:SubscriptionWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001823857 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:MutualFundMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:MutualFundMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:FairValueInputsLevel1Member VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:FairValueInputsLevel2Member VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 us-gaap:FairValueInputsLevel3Member VHAQ:PrivateWarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2021-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001823857 VHAQ:PrivateWarrantsMember us-gaap:MeasurementInputSharePriceMember 2021-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-03-21 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputMarketDebtRateMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-11-25 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-10-27 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-05-09 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-04-27 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-04-04 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-03-23 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2022-03-21 2022-03-21 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-11-25 0001823857 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-03-21 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember VHAQ:MeasurementInputProbabilityOfCompletingABusinessCombinationMember 2022-03-21 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-11-25 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-10-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-05-09 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-04-27 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-04-04 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:MeasurementInputSharePriceMember 2022-03-23 0001823857 VHAQ:SubscriptionWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2022-03-21 0001823857 VHAQ:PrivateWarrantMember 2022-01-01 2022-12-31 0001823857 VHAQ:UnsucessfulBusinessCombinationMember VHAQ:PrivateWarrantMember 2022-01-01 2022-12-31 0001823857 VHAQ:UnsuccessfulBusinessCombinationMember VHAQ:PrivateWarrantMember 2022-12-31 0001823857 VHAQ:SuccessfulBusinessCombinationMember VHAQ:PrivateWarrantMember 2022-01-01 2022-12-31 0001823857 VHAQ:SuccessfulBusinessCombinationMember VHAQ:PrivateWarrantMember 2022-12-31 0001823857 VHAQ:PrivateAndSubscriptionWarrantsMember 2022-01-01 2022-12-31 0001823857 VHAQ:PrivateAndSubscriptionWarrantsMember 2021-01-01 2021-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnMarchTwentyOneTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnMarchTwentyThreeTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnAprilFourTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnAprilTwentySevenTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnMayNineTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnOctoberTwentySevenTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 VHAQ:SubscriptionWarrantsAtIssuanceOnNovemberTwentyFiveTwentyTwentyTwoMember 2022-01-01 2022-12-31 0001823857 us-gaap:DomesticCountryMember 2022-12-31 0001823857 us-gaap:DomesticCountryMember 2021-12-31 iso4217:USD shares iso4217:USD shares pure 0001823857 false FY 10-K true 2022-12-31 --12-31 2022 false 001-39827 VIVEON HEALTH ACQUISITION CORP. DE 85-2788202 3480 Peachtree Road NE 2nd Floor - Suite #112 Atlanta, GA 30326 (404) 861-5393 Common Stock VHAQ NYSEAMER Warrants VHAQW NYSEAMER Units VHAQ NYSEAMER Rights VHAQR NYSEAMER No No No Yes Non-accelerated Filer true true false false true 103157271 6648665 688 Marcum LLP New York, NY 19847 395235 48726 3863 15000 68573 414098 53815395 203282989 39259 53923227 203697087 226796 47720 2150712 1927662 397002 197200 2045000 1955000 55806 15850 75000 34004514 40909830 2188432 7043750 7043750 2535515 4188221 100569 0 50589664 13420403 1844774 20125000 19413879 203262500 0.0001 0.0001 1000000 1000000 0 0 0 0 0.0001 0.0001 60000000 60000000 5031250 5031250 5031250 5031250 1844774 20125000 503 503 157140 -16080819 -13143459 -16080316 -12985816 53923227 203697087 756386 1050016 1368699 2701431 246216 197200 157140 -2371301 -4105787 392642 724225 20329 892 147 3645777 -8468308 -6575140 -3209183 1945823 6595616 -425478 2489829 61310 -486788 2489829 12224223 24150000 -0.04 0.10 5031250 503 157140 -13143459 -12985816 157140 2450572 2607712 -486788 -486788 5031250 503 -16080819 -16080316 5031250 503 -15607539 -15607036 5031250 503 -15607539 -15607036 -25749 -25749 157140 157140 2489829 2489829 2489829 2489829 5031250 503 157140 -13143459 -12985816 5031250 503 157140 -13143459 -12985816 -486788 2489829 392642 724225 20329 3645777 -8468308 -6575140 3209183 157140 -39259 44863 -656832 -15000 15000 179076 47720 228050 969370 199802 197200 39956 10044 100569 -1753388 -2082334 152451819 2260000 150191819 2045000 1955000 75000 152451819 437000 228758 364880 25749 -148813819 -619387 -375388 -2701721 395235 3096956 19847 395235 34004514 2607712 <p id="xdx_80A_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zQeSqlrWYoQ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_82C_zBXI4qetvak8">DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Viveon Health Acquisition Corp. (the “Company” or “Viveon”) is a newly organized blank check company incorporated as a Delaware company on August 7, 2020. The Company was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (“Business Combination”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has neither engaged in any operations nor generated any revenues to date. The Company’s only activities for the years ended December 31, 2022 and 2021 were organizational activities, those necessary to prepare for the Company’s initial public offering (the “Initial Public Offering”), described below, and, after the Initial Public Offering, identifying a target company for a Business Combination. The Company does not expect to generate any operating revenues until after the completion of our Business Combination. The Company generates non-operating income in the form of interest income on marketable securities held after the Initial Public Offering. The Company incurs expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as for due diligence expenses. The Company’s sponsor is Viveon Health, LLC, a Delaware limited liability company (the “Sponsor”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registration statement for the Initial Public Offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on December 22, 2020. On December 28, 2020, the Company consummated the Initial Public Offering of <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201228__20201228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_ziL6ILHAB6e4" title="Sale of shares">17,500,000</span> units (the “Units” and, with respect to the common stock included in the Units being offered, the “Public Shares”), at $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20201228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__custom--PublicSharesMember_zOSD1SHMkSbg" title="Share price">10.00</span> per Unit, generating gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20201228__20201228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zpMOoqNzVsu4" title="Gross proceeds">175,000,000</span>, which is discussed in Note 3. Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201228__20201228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_zGnlTCjeXIn9" title="Sale of shares">18,000,000</span> warrants (the “Private Warrants”), at a price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20201228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementClassOfStockAxis__custom--PrivateWarrantsMember_zjCUyxHLFGT6" title="Share price">0.50</span> per Private Warrant, which is discussed in Note 4.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2020, the underwriters fully exercised the over-allotment option by purchasing <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201230__20201230__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zkKZnEskKrFd" title="Purchase units">2,625,000</span> Units (the “Over-Allotment Units”), generating aggregate of gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromStockOptionsExercised_c20201230__20201230__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zERqUcDS1Wmj" title="Gross proceeds of options">26,250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon closing of the Initial Public Offering and the sale of the Over-Allotment Units, $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zmYqOQXGFHA5" title="Sale of units, value">203,262,500</span> (approximately $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zyHItc46RrMi" title="Share price">10.10</span> per Unit) from net offering proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Warrants was placed in a trust account (the “Trust Account”) and invested in U.S. government securities, with a maturity of 180 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act 1940, as amended (the “Investment Company Act”), which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its tax obligations, the proceeds from the Initial Public Offering will not be released from the Trust Account until the earliest to occur of (1) the completion of the initial Business Combination within 15 months, unless extended to a total of 24 months, pursuant to the terms of an amendment to the Company’s amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”), and (2) the Company’s redemption of <span id="xdx_908_ecustom--PercentageOfRedemptionOfCompanysOutstandingPublicShares_iI_pid_dp_uPure_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_z1BBticOVLWl" title="Redemption percentage of outstanding public shares">100</span>% of the outstanding Public Shares if the Company has not completed a Business Combination in the required time period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company’s management has broad discretion with respect to the specific application of the cash held outside of the Trust Account, substantially all of the net proceeds from the Initial Public Offering and the sale of the Private Warrants, which are placed in the Trust Account, are intended to be applied generally toward completing a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least <span id="xdx_905_ecustom--InitialBusinessCombinationPercentageOfTrustAccount_iI_pid_dp_uPure_c20221231_zqMCKdvsrudb" title="Initial business combination percentage of trust account">80</span>% of the assets held in the Trust Account (net of amounts disbursed to management for working capital purposes, if permitted, and excluding the amount of any deferred underwriting commissions) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires <span id="xdx_903_ecustom--BusinessAcquisitionPercentageOfVotingInterestsAcquired1_iI_pid_dp_uPure_c20221231_zxMh7bMGx9Ye" title="Percentage of outstanding voting securities">50</span>% or more of the outstanding voting securities of the target or otherwise acquires an interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with any proposed initial Business Combination, the Company will either (1) seek stockholder approval of such initial Business Combination at a meeting called for such purpose at which public stockholders may seek to convert their Public Shares, regardless of whether they vote for or against the proposed Business Combination, into their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable) or (2) provide its public stockholders with the opportunity to sell their Public Shares to the Company by means of a tender offer (and thereby avoid the need for a stockholder vote) for an amount equal to their pro rata share of the aggregate amount then on deposit in the Trust Account (net of taxes payable), in each case subject to the limitations described herein. The Public Shares subject to redemption were recorded at redemption value and classified as temporary equity upon the completion of the Initial Public Offering in accordance with the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, <i>Distinguishing Liabilities from Equity</i> (“ASC 480”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company determines to engage in a tender offer, such tender offer will be structured so that each public stockholder may tender any or all of his, her or its Public Shares rather than some pro rata portion of his, her or its shares. If enough stockholders tender their shares so that the Company is unable to satisfy any applicable closing condition set forth in the definitive agreement related to its initial Business Combination, or the Company is unable to maintain net tangible assets of at least $<span id="xdx_90B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_c20221231_zcEA90qBUssi" title="Business combination net tangible assets">5,000,001</span>, the Company will not consummate such initial Business Combination. The decision as to whether it will seek stockholder approval of a proposed Business Combination or will allow stockholders to sell their shares to the Company in a tender offer will be made by the Company based on a variety of factors such as the timing of the transaction or whether the terms of the transaction would otherwise require us to seek stockholder approval.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company provides stockholders with the opportunity to sell their shares to it by means of a tender offer, it will file tender offer documents with the SEC which will contain substantially the same financial and other information about the initial Business Combination as is required under the SEC’s proxy rules. If the Company seeks stockholder approval of its initial Business Combination, the Company will consummate the Business Combination only if a majority of the outstanding shares of common stock present in person or by proxy at a meeting of the Company are voted in favor of the Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding the foregoing redemption rights, if the Company seeks stockholder approval of its initial Business Combination and the Company does not conduct redemptions in connection with its initial Business Combination pursuant to the tender offer rules,(the Amended and Restated Certificate of Incorporation will provide that a public stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act), will be restricted from redeeming its Public Shares with respect to more than an aggregate of <span id="xdx_90E_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_uPure_c20220101__20221231_zXCh0m90wvqb" title="Aggregate percent of shares sold">20</span>% of the shares sold in the Initial Public Offering, without the Company’s prior consent. The Company’s Sponsor, officers and directors (the “initial stockholders”) have agreed not to propose any amendment to the Amended and Restated Certificate of Incorporation (a) that would modify the substance or timing of the Company’s obligation to provide for the redemption of its Public Shares in connection with an initial Business Combination or to redeem <span id="xdx_90F_ecustom--RedemptionOfPublicSharesPercentage_iI_pid_dp_uPure_c20221231_zcjJAk1IBNAh" title="Redemption of public shares percentage">100</span>% of its Public Shares if the Company does not complete its initial Business Combination within 15 months from the closing of the Initial Public Offering or (b) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity, unless the Company provide its public stockholders with the opportunity to redeem their Public Shares in conjunction with any such amendment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2022, the Company held a stockholder meeting to seek approval to extend the date by which the Company has to consummate a business combination from March 28, 2022 (the “Original Termination Date”) to June 28, 2022. In connection with the extension, the Company made a deposit into the Trust Account of $<span id="xdx_901_eus-gaap--Deposits_iI_c20220323_zr0Ggd3eXSP5" title="Deposits">720,000</span> on March 23, 2022. As part of the meeting, stockholders redeemed <span id="xdx_903_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_iI_c20220318_zloZyyuciCPl" title="Redemption payment shares">15,092,126</span> shares resulting in redemption payments out of the Trust Account totaling approximately $<span id="xdx_90E_eus-gaap--Deposits_iI_c20220318_zmGh9cmJRayg" title="Deposits">152,451,819</span>. In addition, stockholders approved a proposal to allow the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with Suneva Medical, Inc. as described below or any potential alternative initial Business Combination shall have occurred. On each of June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 the Company deposited $<span id="xdx_90C_eus-gaap--Deposits_iI_c20221028_z9b3mPxYRL3i" title="Deposits"><span id="xdx_904_eus-gaap--Deposits_iI_c20220623_zTSlPWOIMzMk" title="Deposits"><span id="xdx_906_eus-gaap--Deposits_iI_c20220726_zLTvwxdxm6Pa" title="Deposits"><span id="xdx_90A_eus-gaap--Deposits_iI_c20220830_zuyHexCWppA9" title="Deposits"><span id="xdx_907_eus-gaap--Deposits_iI_c20220928_zMU6hEwX0Jk2" title="Deposits"><span id="xdx_909_eus-gaap--Deposits_iI_c20221128_z1f0DFSUKqvg" title="Deposits"><span id="xdx_90A_eus-gaap--Deposits_iI_c20221228_zxlN2Fhy0JWe" title="Deposits">240,000</span></span></span></span></span></span></span> into the Trust Account to extend the date to consummate a Business Combination through July 28, 2022, August 28, 2022, September 28, 2022, October 28, 2022, November 28, 2022, and December 28, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2022, the Company held its 2022 Annual Meeting of Stockholders, to among other things, seek approval to amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time for a total of up to six months from December 28, 2022 until June 30, 2023 (the “Second Extended Date”), upon three calendar days’ advance notice prior to the applicable monthly deadline unless the closing of any potential initial business combination shall have occurred prior to the Second Extended Date. On each of December 27, 2022, January 26, 2023, February 27, 2023, March 27, 2023, and April 28, 2023, the Company deposited $<span id="xdx_900_eus-gaap--Deposits_iI_c20230428__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z3cKEWVFrkMf">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">into the Trust Account to extend the date to consummate a Business Combination through January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023, respectively. Viveon made a final deposit of $<span id="xdx_90D_eus-gaap--Deposits_iI_c20230524__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zrdgc5Csj9s" title="Deposits">100,000</span> on May 24, 2023 for a one month extension until June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2023, the Company held a stockholder meeting to amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company, without another stockholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month<span style="background-color: white"> until December 31, 2023, by depositing $<span id="xdx_90B_eus-gaap--Deposits_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z738OlsxBeq1" title="Deposits">85,000</span> into the trust account and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 22, 2023, the Company held a stockholder meeting (the “June 2023 Stockholders Meeting”) in which stockholders voted to (A) amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $<span id="xdx_909_eus-gaap--Deposits_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFMDo3hYKOJ" title="Deposits">85,000</span> for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to the Trustee, prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date; and (B) to amend the Company’s Investment Management Trust Agreement, dated as of December 22, 2020, by and between the Company and the Trustee, allowing the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $<span id="xdx_90F_eus-gaap--Deposits_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zhoGQAzD0xJ" title="Deposits">85,000</span> for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, each such extension for an additional one month period, with no additional deposits to be made into the Trust Account during such period from January 1, 2024 through March 31, 2024. In connection with the stockholders’ vote at the June 2023 Stockholders Meeting, <span id="xdx_906_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zExnQ33ndIn2" title="Redemption payment shares">227,359</span> shares of common stock were tendered for redemption. As a result, approximately $<span id="xdx_905_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230622__20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXeM1Pmbcj01" title="Repayments of related party debt">2,498,947</span> (approximately $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYtT0pZkVWy8" title="Share price">10.99</span> per share) were removed from the Company’s Trust Account to pay such holders, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date. Following redemptions, the Company has <span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z2rhpulWyaLj" title="Common stock, shares, outstanding">1,617,415</span> shares of public common stock outstanding, and approximately $<span id="xdx_900_eus-gaap--AssetsHeldInTrust_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAJuOneJU1g9" title="Asset, held-in-trust">17,777,324</span> will remain in the Trust Account. <span style="background-color: white">On June 27, 2023, and July 27, 2023, the Company deposited $<span id="xdx_907_eus-gaap--Deposits_iI_c20230627__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmZhEdfwYLO1" title="Deposits"><span id="xdx_901_eus-gaap--Deposits_iI_c20230727__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zuwsKzriq3x8" title="Deposits">85,000</span></span> in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023 and August 31, 2023, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is unable to complete its initial Business Combination by the Third Extended Date (the “Combination Period”), the Company will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than five business days thereafter, redeem <span id="xdx_903_ecustom--OutstandingPublicSharesPercentage_iI_pid_dp_uPure_c20221231_zvvHDXQlfIud" title="Outstanding public shares percentage">100</span>% of the outstanding Public Shares (including any Units or Public Shares that its initial stockholders or their affiliates purchased in the Initial Public Offering or later acquired in the open market or in private transactions), which will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably practicable following such redemption, subject to the approval of the Company’s remaining holders of common stock and its board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject (in the case of (ii) and (iii) above) to its obligations to provide for claims of creditors and the requirements of applicable law.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares (as defined in Note 5) held by them if the Company fails to complete its initial Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete its initial Business Combination within the Combination Period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Merger Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 12, 2022, the Company entered into a Merger Agreement (the “Old Merger Agreement”) by and among the Company, VHAC Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“Old Merger Sub”), and Suneva Medical, Inc., a Delaware corporation (“Suneva”). Pursuant to the terms of the Merger Agreement, a Business Combination between the Company and Suneva will be effected through the merger of Old Merger Sub with and into Suneva, with Suneva surviving the merger as a wholly owned subsidiary of the Company (the “Old Merger”). The board of directors of the Company has (i) approved and declared advisable the Old Merger Agreement, the Old Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Old Merger Agreement and related transactions by the stockholders of the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 13, 2022, the Company, Old Merger Sub, and Suneva entered into the Second Amendment to Old Merger Agreement (the “Second Amendment”) that amended and modified the Old Merger Agreement to extend the outside closing date to December 31, 2022 and to reduce the amount of parent closing cash required as a closing condition from $<span id="xdx_907_eus-gaap--HealthCareOrganizationExpensesNet_pn6n6_c20220713__20220713__srt--RangeAxis__srt--MaximumMember_zuOUrWH06HBi" title="Company expenses and parent expenses">50</span> million to $<span id="xdx_903_eus-gaap--HealthCareOrganizationExpensesNet_pn6n6_c20220713__20220713__srt--RangeAxis__srt--MinimumMember_zIgoQ2tEqR8g" title="Company expenses and parent expenses">30</span> million, net of Suneva expenses and Viveon expenses (“Parent Expenses”) and net of repayment of the $<span id="xdx_908_eus-gaap--EarlyRepaymentOfSubordinatedDebt_pn5n6_c20220713__20220713_zZXDSjji4YWd" title="Net of repayment subordinated convertible promissory note">1.5</span> million Subordinated Convertible Promissory Note (as defined in Note 5) issued by Suneva to Intuitus Suneva Debt LLC (an entity affiliated with Viveon’s Chief Financial Officer), dated May 10, 2022 (unless converted into Suneva capital stock at the consummation of the business combination, which conversion is mandatory except in the case of a default by Suneva). Further, the defined term Parent Expenses was amended to include the Viveon’s operating expenses, severance payments and deferred compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 10, 2022, the Company, Old Merger Sub, and Suneva entered into the Third Amendment to Old Merger Agreement (the “Third Amendment”) that amended and modified the Old Merger Agreement to (i) fix the aggregate exercise price for all of the in-the-money Suneva options and warrants at $<span id="xdx_906_eus-gaap--ProductWarrantyExpense_c20221110__20221110_zOAK8JafrDN2" title="Agreegate warrants value">2,582,075</span>, representing the aggregate exercise price for all the in-the-money Suneva options and warrants outstanding as of the date of the Third Amendment, and extend the outside closing date from December 31, 2022 to March 31, 2023, to the extent the Company’s stockholders approve an amendment to its Amended and Restated Certificate of Incorporation to extend the date by which the Company has to consummate a business combination to June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 2, 2023, legal counsel for Viveon sent a letter informing Suneva’s legal counsel that Viveon decided, effective immediately, to unilaterally terminate the Old Merger Agreement pursuant to Sections 10.2(a) and 10.3 thereof, based upon material breaches of the Old Merger Agreement by Suneva. The termination letter was sent without prejudice and reserved all of Viveon, Old Merger Sub and Viveon Health, LLC (Viveon’s sponsor) rights, claims and remedies, specifically including those within the Merger Agreement, against Suneva and others associated with Suneva who participated in the merger discussions and arrangements, and waived none.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Merger Agreement with Clearday</i> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2023, the Company entered into a Merger Agreement (the “<span style="text-decoration: underline">Merger Agreement</span>”), by and among Viveon, Clearday, Inc., a Delaware corporation (“<span style="text-decoration: underline">Clearday”<b>)</b></span>, VHAC2 Merger Sub, Inc., a Delaware corporation (“New <span style="text-decoration: underline">Merger Sub</span>”), Viveon Health LLC, a Delaware limited liability Company, in the capacity as the representative from and after the effective time for the stockholders of the Company (other than the Company Stockholders (as defined in the Merger Agreement)) as of immediately prior to the effective time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement, and Clearday SR LLC, a Delaware limited liability company, in the capacity as the representative from and after the effective time for the holders of Company preferred stock as of immediately prior to the effective time (and their successors and assigns) in accordance with the terms and conditions of the Merger Agreement. Pursuant to the terms of the Merger Agreement, a business combination between the Company and Clearday will be effected through the merger of New Merger Sub with and into Clearday, with Clearday surviving the merger as a wholly owned subsidiary of the Company and the Company will change its name to “Clearday Holdings, Inc.” (the “<span style="text-decoration: underline">Merger</span>”). The board of directors of the Company has (i) approved and declared advisable the Merger Agreement, the Merger and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement, the Merger and related transactions by the stockholders of Company. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Merger Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consideration</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Merger Consideration</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The total consideration to be paid at closing (the “<span style="text-decoration: underline">Merger Consideration</span>”) by the Company to Clearday security holders (and holders who have the right to acquire Clearday capital stock) will be an amount equal to $<span id="xdx_900_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn6n6_c20230405__us-gaap--BusinessAcquisitionAxis__custom--CleardayMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5WUuUvpJzv8">250 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Million (plus the aggregate exercise price for all Clearday options and warrants). The Merger Consideration will be payable in shares of the Company’s common stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230405__us-gaap--BusinessAcquisitionAxis__custom--CleardayMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHXszBR5wj74">0.0001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, valued at $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20230405__us-gaap--BusinessAcquisitionAxis__custom--CleardayMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0hHbSHZrC89">10 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Earnout Payments</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the holders of Clearday preferred stock will have the contingent right to earn up to <span id="xdx_90B_eus-gaap--BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_c20230405__20230405__us-gaap--BusinessAcquisitionAxis__custom--CleardayMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--EarnoutSharesMember_zMBLVcZ1VF0b">5,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock, in the aggregate (the “<span style="text-decoration: underline">Earnout Shares</span>”), if at any time during the period beginning on the date of the Closing (the “<span style="text-decoration: underline">Closing Date</span>”) and ending on the fifth anniversary of the Closing Date (the “<span style="text-decoration: underline">Earnout Eligibility Period</span>”), the Adjusted Net Income (as defined below) for any Earnout Period is a positive number for the first time during the Earnout Eligibility Period (the “<span style="text-decoration: underline">Earnout Milestone</span>”). Under the Merger Agreement, Adjusted Net Income means for any Earnout Period, the consolidated net income or loss for such period calculated in accordance with U.S. GAAP applied on a basis consistent with past practice, of (a) for periods prior to the Closing, the Company and its subsidiaries (the “Company Group”), and (b) for periods from and after the Closing, of us and our subsidiaries (including the Company Group), in each case before adjusting for the following to the extent deducted/added in calculating consolidated net income or loss: (1) interest expense/income; (2) income tax expense/tax credits; (3) depreciation and amortization; (4) transaction expenses; (5) extraordinary items; (6) any income or loss attributable to us that accrues in accordance with U.S. GAAP on or prior to the Closing Date; and (7) all gains or losses in connection with sales or dispositions of assets and investments not in the ordinary course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If, following the Closing Date and prior to end of the Earnout Eligibility Period, there is a change of control, then, immediately prior to such change of control, all the Earnout Shares not yet earned shall be earned by the Clearday earnout holders and shall be released from escrow and delivered to the Clearday earnout holders, and the Clearday earnout holders shall be eligible to participate in such change of control transaction with respect to such Earnout Shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Earnout Shares will be placed in escrow and will not be released from escrow until they are earned as a result of the occurrence of the Earnout Milestone or a change of control, if applicable. The Earnout Shares that are not earned on or before the expiration of the Earnout Eligibility Period shall be automatically forfeited and cancelled.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Treatment of Clearday Securities</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cancellation of Securities. </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each share of Clearday capital stock, if any, that is owned by the Company, New Merger Sub, Clearday, or any of their subsidiaries (as treasury stock or otherwise) immediately prior to the effective time of the Merger (the “<span style="text-decoration: underline">Effective Time</span>”), will automatically be cancelled and retired without any conversion or consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred Stock. </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Effective Time, each issued and outstanding share of Clearday’s Series F Cumulative Convertible Preferred Stock, par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230405__us-gaap--StatementClassOfStockAxis__custom--SeriesFCumulativeConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8lSTDlveY12">0.001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (“<span style="text-decoration: underline">Clearday Series F Preferred Stock</span>”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: <span id="xdx_90C_eus-gaap--PreferredStockConversionBasis_c20230405__20230405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesFCumulativeConvertiblePreferredStockMember_zFuNF9AiGs4d">(A) one (1) share of Parent New Series F Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each issued and outstanding share of Clearday’s Series A Convertible Preferred Stock, par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20230405__us-gaap--StatementClassOfStockAxis__custom--SeriesACumulativeConvertiblePreferredStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zorZTg1sTX7g">0.001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (“<span style="text-decoration: underline">Clearday Series A Preferred Stock</span>”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares), will be converted into the right to receive: <span id="xdx_902_eus-gaap--PreferredStockConversionBasis_c20230405__20230405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__custom--SeriesACumulativeConvertiblePreferredStockMember_zwAyfBGLBqW7">(A) one (1) share of Parent New Series A Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common Stock. </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Effective Time, each issued and outstanding share of Clearday’s common stock, par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQn9l43M02hl">0.001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (“<span style="text-decoration: underline">Clearday Common Stock</span>”) (other than any such shares of Clearday capital stock cancelled as described above and any dissenting shares) will be converted into the right to receive a number of shares of the Company’s common stock equal to the conversion ratio. The “Conversion Ratio” as defined in the Merger Agreement means an amount equal to (a)(i) <span id="xdx_90C_eus-gaap--CommonStockConversionBasis_c20230405__20230405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz6U4qzaZyjl">the sum of $250 Million, plus the aggregate exercise or conversion price of outstanding Clearday’s stock options and warrants (excluding unvested options and options or warrants with an exercise or conversion price of $<span id="xdx_902_eus-gaap--CommonStockConvertibleConversionPriceIncrease_c20230405__20230405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--CleardayMember_zapYAg0Uy4Z5">5.00</span> or more),</span> divided by (ii) the number of fully diluted Clearday capital stock (including Clearday preferred stock, warrants, stock options, convertible notes</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, and any other convertible securities) (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more and assuming a conversion price of Clearday subsidiary securities as provided in the Merger Agreement); divided by (b) $10.00.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Merger Sub Securities. </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each share of common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20230405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--NewMergerMember_zf4aKPOChhbj" title="Common stock, par value">0.0001</span> per share, of New Merger Sub issued and outstanding immediately prior to the Effective Time will be converted into and become one newly issued share of common stock of the surviving corporation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Options.</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Effective Time, each outstanding option to purchase shares of Clearday Common Stock will be converted into an option to purchase, subject to substantially the same terms and conditions as were applicable under such options prior to the Effective Time, shares of the Company’s common stock equal to the number of shares subject to such option prior to the effective time multiplied by the Conversion Ratio, at an exercise price per share of the Company’s common stock equal to the exercise price per share of Clearday Common Stock subject to such option divided by the Conversion Ratio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants. </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent on and effective as of immediately prior to the effective time, each outstanding warrant to purchase shares of Clearday Preferred Stock or Clearday Common Stock will be treated in accordance with the terms thereof.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Convertible Notes</i></b>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contingent on and effective as of immediately prior to the Effective Time, Clearday’s convertible notes outstanding as of immediately prior to the effective time, will be treated in accordance with the terms of the relevant agreements governing such convertible notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Subsidiary Capital Stock</i></b>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At and as of the effective time, the subsidiary capital stock will remain in full force and effect with the right to acquire the Clearday Common Stock with such adjustments noted in the terms of such subsidiary capital stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Representations and Warranties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Merger Agreement contains customary representations and warranties of the parties thereto with respect to, among other things, (a) corporate existence and power, (b) authorization to enter into the Merger Agreement and related transactions; subsidiaries, (c) governmental authorization, (d) non-contravention, (e) capitalization, (f) corporate records, (g) consents, (h) financial statements, (i) internal accounting controls, (j) absence of certain changes, (k) properties; title to assets, (l) litigation, (m) material contracts, (n) licenses and permits, (o) compliance with laws, (p) intellectual property, (q) privacy and data security, (r) employee matters and benefits, (s) tax matters, (t) real property, (u) environmental laws, (v) finders’ fees, (w) directors and officers, (x) anti-money laundering laws, (y) insurance, (z) related party transactions, and (aa) certain representations related to securities law and activity. The Company has additional representations and warranties, including (a) issuance of shares, (b) trust fund, (c) listing, (d) board approval, (e) SEC documents and financial statements, (f) certain business practices, (g) expenses, indebtedness and other liabilities and (h) brokers and other advisors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Covenants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Merger Agreement includes customary covenants of the parties with respect to operation of their respective businesses prior to consummation of the Merger and efforts to satisfy conditions to consummation of the Merger. The Merger Agreement also contains additional covenants of the parties, including, among others, access to information, cooperation in the preparation of the registration statement and proxy statement (as each such terms are defined in the Merger Agreement) required to be filed in connection with the Merger and to obtain all requisite approvals of each party’s respective stockholders. The Company and Clearday have each also agreed to include in the proxy statement the recommendation of its respective board that its stockholders approve all of the proposals to be presented at its respective special meeting. In addition, each of the Company and Clearday have agreed to use commercially reasonable efforts to solicit and finalize definitive documentation for a committed equity in an aggregate amount that, together with the funds in the Trust Account after giving effect to potential redemptions from the Company’s public stockholders, together with financing programs available to Clearday after the Closing, will provide to Clearday working capital to meet its short term commercial development goals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has also agreed to prepare a proxy statement to seek the approval of its stockholders (the “Extension Proposal”) to amend its organizational documents to extend the period of time the Company is afforded under its organizational documents and IPO prospectus to consummate an initial business combination for an additional three months, from June 30,2023 to September 30, 2023 (or such earlier date as the Company and Clearday may agree in writing).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each party’s representations, warranties and pre-Closing covenants will not survive Closing and no party has any post-Closing indemnification obligations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Viveon Equity Incentive Plan </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has agreed to approve and adopt an equity incentive plan (the “<span style="text-decoration: underline">Incentive Plan</span>”) to be effective as of the Closing and in a form mutually acceptable to the Company and Clearday, subject to approval of the Incentive Plan by the Company’s stockholders. The Incentive Plan will provide for an initial aggregate share reserve equal to <span id="xdx_90C_ecustom--PercentageOfCommonStockIssuedAndOutstanding_iI_pid_dp_uPure_c20230405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--ViveonEquityIncentivePlanMember_zgdajuNAVyql" title="Percentage of common stock issued and outstanding">8</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the number of shares of the Company’s common stock issued and outstanding at the Closing and an “evergreen” provision that is mutually agreeable to the Company and Clearday will provide for an automatic increase on the first day of each fiscal year in the number of shares available for issuance under the Incentive Plan as mutually determined by the Company and Clearday.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Solicitation Restrictions</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the Company and Clearday has agreed that from the date of the Merger Agreement to the effective time or, if earlier, the valid termination of the Merger Agreement in accordance with its terms, it will not initiate any negotiations with any party relating to an alternative transaction (as such term is defined in the Merger Agreement) or enter into any agreement relating to such a proposal, other than as expressly excluded from the definition of an alternative transaction. Each of the Company and Clearday has also agreed to be responsible for any acts or omissions of any of its respective representatives that, if they were the acts or omissions of the Company and Clearday, as applicable, would be deemed a breach of the party’s obligations with respect to these non-solicitation restrictions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Conditions to Closing</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consummation of the Merger is conditioned upon, among other things, (i) the absence of any applicable law or order restraining, prohibiting or imposing any condition on the consummation of the Merger and related transactions, (ii) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (iii) receipt of any consent, approval or authorization required by any Authority (as defined in the Merger Agreement), (iv) the Company having net tangible assets of at least $<span id="xdx_90C_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_c20230405__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--CleardayMember_zgTSUyKDrjfi">5,000,001 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(as determined in accordance with Rule 3a51-1(g)(1) of the Exchange Act), unless the Company’s amended and restated certificate of incorporation shall have been amended to remove such requirement prior to or concurrently with the Closing, (v) approval by Clearday’s stockholders of the Merger and related transactions, (vi) approval by the Company’s stockholders of the Merger and related transactions, (vii) the conditional approval for listing by NYSE American (or an alternate exchange) of the shares of the Company’s common stock to be issued in connection with the transactions contemplated by the Merger Agreement and satisfaction of initial and continued listing requirements, and (viii) the registration statement becoming effective in accordance with the provisions of the Securities Act of 1933, as amended (“<span style="text-decoration: underline">Securities Act</span>”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely with respect to the Company and New Merger Sub, the consummation of the Merger is conditioned upon, among other things, (i) Clearday having duly performed or complied with all of its obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of Clearday, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure would not have or reasonably be expected to have a material adverse effect (as defined in the Merger Agreement) on Clearday or any of its subsidiaries, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than de minimis inaccuracies, (iv) no event having occurred that would result in a material adverse effect on Clearday or any of its subsidiaries, (v) Clearday and its securityholders having executed and delivered to the Company each additional agreement (as defined in the Merger Agreement) to which they each are a party and (vi) Clearday delivering certain certificates to the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solely with respect to Clearday, the consummation of the Merger is conditioned upon, among other things, (i) Viveon and New Merger Sub having duly performed or complied with all of their respective obligations under the Merger Agreement in all material respects, (ii) the representations and warranties of the Company and Merger Sub, other than certain fundamental representations as defined in the Merger Agreement, being true and correct in all respects unless failure to be true and correct would not have or reasonably be expected to have a material adverse effect on the Company or New Merger Sub and their ability to consummate the Merger and related transactions, (iii) certain fundamental representations, as defined in the Merger Agreement, being true and correct in all respects, other than <i>de minimis</i> inaccuracies, (iv) no event having occurred that would result in a Material Adverse Effect on the Company or New Merger Sub, (v) the amended parent charter (as defined in the Merger Agreement) being filed with, and declared effective by, the Delaware Secretary of State, (vi) the Company delivering certain certificates to Clearday, (vii) the size and composition of the post-Closing board of directors of the Company having been appointed as set forth in the Merger Agreement and (viii) the Company, Viveon Health LLC and other stockholders, as applicable, having executed and delivered to Clearday each additional agreement to which they each are a party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Termination</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Merger Agreement may be terminated at any time prior to the effective time as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) by either the Company or Clearday, if (A) the Merger and related transactions are not consummated on or before the latest of (i) June 30, 2023, (ii) if the Extension Proposal is approved, September 30, 2023 and (iii) if one or more extensions to a date following September 30, 2023 are obtained at the election of the Company, with the Company’s stockholder vote, in accordance with the Company’s amended and restated certificate of incorporation, the last date for the Company to consummate a business combination pursuant to such extensions; and (B) the material breach or violation of any representation, warranty, covenant or obligation under the Merger Agreement by the party seeking to terminate the Merger Agreement was not the cause of, or resulted in, the failure of the closing to occur on or before the outside Closing Date, without liability to the other party;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) by either the Company or Clearday, if any authority has issued any final decree, order, judgment, award, injunction, rule or consent or enacted any law, having the effect of permanently enjoining or prohibiting the consummation of the Merger, provided that, the party seeking to terminate cannot have breached its obligations under the Merger Agreement and such breach was a substantial cause of, or substantially resulted in, such action by the authority; and</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) by mutual written consent of the Company and Clearday duly authorized by each of their respective boards of directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Merger Agreement and other agreements described below have been included to provide investors with information regarding their respective terms. They are not intended to provide any other factual information about the Company, Clearday or the other parties thereto. In particular, the assertions embodied in the representations and warranties in the Merger Agreement were made as of a specified date, are modified or qualified by information in one or more disclosure letters prepared in connection with the execution and delivery of the Merger Agreement, may be subject to a contractual standard of materiality different from what might be viewed as material to investors, or may have been used for the purpose of allocating risk between the parties. Accordingly, the representations and warranties in the Merger Agreement are not necessarily characterizations of the actual state of facts about the Company, Clearday or the other parties thereto at the time they were made or otherwise and should only be read in conjunction with the other information that the Company or Clearday makes publicly available in reports, statements and other documents filed with the SEC. The Company and Clearday investors and securityholders are not third-party beneficiaries under the Merger Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Certain Related Agreements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Parent Support Agreements</i>. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently with the execution of the Merger Agreement, the Company, Clearday and the Sponsor and the officers and directors of the Company entered into a support agreement (the “<span style="text-decoration: underline">Parent Support Agreement</span>”) pursuant to which the Sponsor and the officers and directors of the Company have agreed to vote all shares of the Company’s common stock beneficially owned by them, including any additional shares of the Company they acquire ownership of or the power to vote: (i) in favor of the Merger and related transactions, (ii) against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions, and (iii) in favor of an extension of the period of time the Company is afforded to consummate an initial business combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company Support Agreements</i>. </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently with the execution of the Merger Agreement, the Company, Clearday and certain stockholders of Clearday entered into a support agreement (the “<span style="text-decoration: underline">Company Support Agreement</span>”), pursuant to which such Clearday stockholders have agreed to vote all common and preferred stock of Clearday beneficially owned by them, including any additional shares of Clearday they acquire ownership of or the power to vote, in favor of the Merger and related transactions and against any action reasonably be expected to impede, delay, or materially and adversely affect the Merger and related transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Lock-Up Agreements. </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the closing, certain Clearday stockholders will each agree, subject to certain customary exceptions, not to (i) offer, sell contract to sell, pledge or otherwise dispose of, directly or indirectly, any lockup shares, (ii) enter into a transaction that would have the same effect, (iii) enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of the lock-up shares or otherwise, (iv) engage in any short sales or other arrangement with respect to the lock-up shares or (v) publicly announce any intention to effect any transaction specified in clause (i), (ii) or (iii) until the date that is six months after the Closing Date (the “<span style="text-decoration: underline">Lock-Up Period</span>”). The term “Lockup Shares” mean the Merger Consideration Shares and the Earnout Shares, if any, whether or not earned prior to the end of the Lock-up Period, together with any other shares of the Company’s common stock, and including any securities convertible into, or exchangeable for, or representing the rights to receive the Company’s common stock, if any, acquired during the Lock-up Period. If the closing price of the Company’s common stock equals or exceeds $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYhOAp5BUcjl">12.50 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period following the Closing Date, <span id="xdx_90D_ecustom--PercentageOfLockUpSharesReleasedFromTheLockUp_iI_pid_dp_uPure_c20221231_z8e32X3PDUMf" title="Percentage of lock up shares">50</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of the Lock-up Shares will be released from the lock-up. The existing escrow provisions of the Company’s common stock held by certain stockholders will remain in effect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Amended and Restated Registration Rights Agreement. </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the Closing, the Company will enter into an amended and restated registration rights agreement (the “<span style="text-decoration: underline">Amended and Restated Registration Rights Agreement</span>”) with certain existing stockholders of the Company and Clearday with respect to their shares of the Company’s common stock acquired before or pursuant to the Merger, and including the shares issuable on conversion of the warrants issued to the Sponsor in connection with the Company’s initial public offering and any shares issuable on conversion of loans or other convertible securities. The agreement amends and restates the registration rights agreement the Company entered into on December 22, 2020 in connection with its initial public offering. Subject to the Lock-Up Agreements described above, the holders of a majority of the shares held by the Company’s existing stockholders, and the holders of a majority of the shares held by the Clearday stockholders will each be entitled to make one demand that Clearday register such securities for resale under the Securities Act, or two demands each if the Company is eligible to use Form S-3 or a similar short-form registration statement. In addition, the holders will have certain “piggy-back” registration rights that require the Company to include such securities in registration statements that the Company otherwise files. The registration rights agreement does not contain liquidating damages or other cash settlement provisions resulting from delays in registering the Company’s securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Going Concern</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, the Company had $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_c20221231_zyYqtYwyihdl" title="Cash and cash equivalents">19,847</span> of cash and cash equivalents held outside the Trust Account available for working capital needs. In connection with the Company’s assessment of going concern considerations in accordance with FASB’s ASC Subtopic 205-40, <i>Presentation of Financial Statements - Going Concern</i>, management has determined that if the Company is unable to raise additional funds to alleviate liquidity needs or complete a Business Combination by March 31, 2024, then the Company will cease all operations except for the purpose of liquidating. The liquidity condition and date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern one year from the date that these consolidated financial statements are issued. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be unable to continue as a going concern. The Company intends to complete a Business Combination before the mandatory liquidation date or obtain approval for an extension.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks &amp; Uncertainties</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management continues to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations, and/or search for a prospective partner company, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The credit and financial markets have experienced extreme volatility and disruptions due to the current conflict between Ukraine and Russia. The conflict is expected to have further global economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability. In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences, including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our common stock to be adversely affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Inflation Reduction Act of 2022 and Excise Tax</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 16, 2022, President Biden signed into law the Inflation Reduction Act of 2022, which, among other things, imposes a <span id="xdx_90A_ecustom--PercentageOfExciseTax_iI_pid_dp_uPure_c20220816_zkb7zIOPXUA1" title="Percentage of excise tax">1</span>% excise tax on the fair market value of stock repurchased by publicly traded U.S. corporations and certain U.S. subsidiaries of publicly traded non-U.S. corporations beginning in 2023, with certain exceptions (the “Excise Tax”). Because we are a Delaware corporation and our securities trade on the New York Stock Exchange, we will likely be considered a “covered corporation” within the meaning of the Inflation Reduction Act. While not free from doubt, absent any further guidance from Congress or the U.S. Department of the Treasury, there is significant risk that the Excise Tax will apply to any redemptions of our common stock after December 31, 2022, including redemptions in connection with an initial Business Combination and any amendment to our certificate of incorporation to extend the time to consummate an initial Business Combination, unless an exemption is available. In addition, the Excise Tax may make a transaction with us less appealing to potential business combination targets, and thus, potentially hinder our ability to enter into and consummate an initial Business Combination. Further, the application of the Excise Tax in the event of a liquidation after December 31, 2022 is uncertain, and could impact the per-share amount that would otherwise be received by our stockholders in connection with our liquidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 17500000 10.00 175000000 18000000 0.50 2625000 26250000 203262500 10.10 1 0.80 0.50 5000001 0.20 1 720000 15092126 152451819 240000 240000 240000 240000 240000 240000 240000 100000 100000 85000 85000 85000 227359 2498947 10.99 1617415 17777324 85000 85000 1 50000000 30000000 1500000 2582075 250000000 0.0001 10 5000000 0.001 (A) one (1) share of Parent New Series F Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement 0.001 (A) one (1) share of Parent New Series A Preferred Stock plus (B) a number of Earnout Shares in accordance with, and subject to the contingencies, set forth in the Merger Agreement 0.001 the sum of $250 Million, plus the aggregate exercise or conversion price of outstanding Clearday’s stock options and warrants (excluding unvested options and options or warrants with an exercise or conversion price of $5.00 or more), 5.00 0.0001 0.08 5000001 12.50 0.50 19847 0.01 <p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_z5ue1jID6mcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2. <span id="xdx_82D_z0hBZaWYowYg">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zDscHMHo5FXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zrsOLhyvB2d1">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zq7ffDPT0oh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zuky9iYPRlfc">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its majority-owned and controlled operating subsidiary, Old Merger Sub after elimination of all intercompany transactions and balances as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_ecustom--EmergingGrowthCompanyPolicyTextBlock_zDWJDlMIoVgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zke21l7HXsPc">Emerging Growth Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. The Company has elected to implement the aforementioned exemptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--UseOfEstimates_z9NFdqspXXTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zLSHt7Shlxf8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The initial valuation of the Public Warrants (as defined in Note 3), Rights (as defined in Note 3) common stock subject to redemption and the periodic valuation of the Private Warrants and Subscription Warrants (as defined in Note 6) required management to exercise significant judgement in its estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRA9Ftce1xy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_ziCE2MLaXpWl">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $<span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20221231_zoW1OwjkBBeg" title="Cash equivalents">6,346</span> and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20211231_zUEzhspauAl6" title="Cash equivalents">350,455</span>, were held in money market funds as of December 31, 2022 and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--MarketableSecuritiesPolicy_zf6tm7Alg9Hl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zTlKqDxfk4ve">Investments Held in Trust Account</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and December 31, 2021, substantially all of the assets held in the Trust Account were held in a money market account and mutual funds which invested in U.S. Treasury securities, respectively. The assets were transferred from mutual funds to a money market account on December 21, 2022. The assets in the amount of $<span id="xdx_900_eus-gaap--AssetsHeldInTrust_iI_c20221231_zbVaB0EzZGod" title="Investment held in Trust Account">53,815,395</span> and $<span id="xdx_90A_eus-gaap--AssetsHeldInTrust_iI_c20211231_zW30QzTS5cOg" title="Investment held in Trust Account">203,282,989</span> were held in the Trust Account as of December 31, 2022 and December 31, 2021, respectively. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in Interest and dividends earned on investments held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in Trust Account are determined using available market information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zXaMj2ORMgx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zydBjDm7Gukj">Warrants</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC Topic 815, <i>Derivatives and Hedging</i> (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. In accordance with guidance contained in ASC 815, the Public Warrants (as defined in Note 3) qualify for equity treatment. The Private Warrants and Subscription Warrants (as defined in Note 6) do not qualify as equity and are recorded as liabilities at fair value. Changes in the estimated fair value of the Private Warrants and Subscription Warrants are recognized as non-cash gains or losses on the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--DebtWithConversionAndOtherOptionsPolicyTextBlock_zsWxMPjvEdYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zOLQ7biWIM6b">Debt with Conversion and Other Options</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for a series of unsecured senior promissory note agreements under ASC Topic ASC 470-20-25-2, <i>Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants </i>(“ASC 470-20-25-2”).  In accordance with ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants (detachable call options) are allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_zpBObilMc6v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zOI6fOzJQ157">Common Stock Subject to Possible Redemption</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the <span id="xdx_902_eus-gaap--TemporaryEquitySharesIssued_iI_c20221231_ziN3HSPevpBj" title="Temporary equity, shares issued">5,032,874</span> Public Shares sold as part of the Units in the Initial Public Offering and subsequent full exercise of the underwriters’ over-allotment option that have not been redeemed by stockholders, contain a redemption feature which allows for the redemption of such redeemable common stock in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Therefore, all Public Shares been classified outside of permanent equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. There was no change in redemption value for the year ended December 31, 2021. In connection with extending the Company’s Original Termination Date to the Extended Date, the Company deposited $<span id="xdx_906_eus-gaap--Deposits_iI_c20220323_zDGzeWs27Ucl" title="Cash deposited into trust account">720,000</span>, $<span id="xdx_90A_eus-gaap--Deposits_iI_c20220623_zv1w2mMEZZw8" title="Cash deposited into trust account">240,000</span>, $<span id="xdx_90B_eus-gaap--Deposits_iI_c20220726_zzz90NY52kwb" title="Cash deposited into trust account">240,000</span>, $<span id="xdx_90F_eus-gaap--Deposits_iI_c20220830_z2gXn5545O13" title="Cash deposited into trust account">240,000</span>, $<span id="xdx_905_eus-gaap--Deposits_iI_c20220928_zcElO6FsVMod" title="Cash deposited into trust account">240,000</span>, and $<span id="xdx_904_eus-gaap--Deposits_iI_c20221028_z5lx4SUtcTSg" title="Cash deposited into trust account"><span id="xdx_90C_eus-gaap--Deposits_iI_c20221125_z9MyDBRXHfY7" title="Cash deposited into trust account">240,000</span></span> into the Trust Account on March 23, 2022, June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 respectively. In connection to the Company’s Second Extended Date, the Company deposited $<span id="xdx_906_eus-gaap--Deposits_iI_c20220327_zN3YAa21L09f" title="Cash deposited into trust account">100,000</span> into the Trust Account on December 27, 2022. The Company recorded increases in the redemption value of common stock subject to redemption of $<span id="xdx_907_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_ztdcPHi13aec" title="Remeasurement of carrying value to redemption value">2,607,712</span> during the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection to the Company’s Third Extended Date, On June 27, 2023, <span style="background-color: white">the Company deposited the payment of $<span id="xdx_90B_eus-gaap--Deposits_iI_c20230627__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBkna8Eyi5sd" title="Deposits">85,000</span> in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and December 31, 2021, the redeemable common stock reflected in the consolidated balance sheets are reconciled in the following table:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--TemporaryEquityTableTextBlock_zr7woeZaUnMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zKSxWcQ9nbRi" style="display: none">SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross proceeds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20211231_zNePpQ7Q20T7" style="width: 16%; text-align: right" title="Gross proceeds">201,250,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Fair value of Public Warrants at issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueOfWarrantsAtIssaunce_c20210101__20211231_zr3J3Iv78gkh" style="text-align: right" title="Fair value of Public Warrants at issuance">(10,384,500</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fair value of Rights at issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueOfRightsAtIssuance_c20210101__20211231_zFg8EkPU2HB1" style="text-align: right" title="Fair value of Rights at issuance">(9,136,750</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Issuance costs allocated to common stock subject to possible redemption</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--StockIssuedIssuanceCostsCommonStockSubjectToPossibleRedemption_iN_di_c20210101__20211231_z1WTsserApN1" style="text-align: right" title="Issuance costs allocated to common stock subject to possible redemption">(10,660,961</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Remeasurement of carrying value to redemption value</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20210101__20211231_zR8wX17B5uT" style="border-bottom: Black 1.5pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">32,194,711</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption as of December 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zUSfeVlygjQ9" style="font-weight: bold; text-align: right" title="Common stock subject to possible redemption as of December 31, 2021">203,262,500</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Redemption of common stock by stockholders</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20221231_zIteQWqRqXzd" style="text-align: right" title="Redemption of common stock by stockholders">(152,451,819</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Common stock tendered for redemption</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--CommonStockTenderedForRedemption_iNI_di_c20221231_zpVelUfCSN78" style="text-align: right" title="Redemption of common share, value">(34,004,514</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Remeasurement of carrying value to redemption value</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_zpFEBhUGYMC6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">2,607,712</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption as of December 31, 2022</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20220101__20221231_zaeHbyl3ceWk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Common stock subject to possible redemption as of December 31, 2022">19,413,879</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zDJCnypGa5zg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--DeferredChargesPolicyTextBlock_zg5GPbUd98t1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zE1VXkowxAP4">Offering Costs associated with the Initial Public Offering</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of ASC Topic 340, <i>Other Assets and Deferred Costs</i> (“ASC 340”) and SEC Staff Accounting Bulletin Topic 5A - <i>Expenses of Offering</i>. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $<span id="xdx_907_ecustom--OfferingCosts_c20220101__20221231_zqKLlkTsUF19" title="Offering costs">11,830,356</span> as a result of the Initial Public Offering (consisting of a $<span id="xdx_904_eus-gaap--PaymentsForUnderwritingExpense_c20220101__20221231_zpCmd20uFA5g" title="Cash underwriting fee">4,025,000</span> cash underwriting fee, $<span id="xdx_90A_ecustom--DeferredUnderwritingFees_c20220101__20221231_z07TmG2dwbOh" title="Deferred underwriting fees">7,043,750</span> of deferred underwriting fees, and $<span id="xdx_904_ecustom--OtherOfferingCosts_c20220101__20221231_zuv6a4FYByq8" title="Other offering costs">761,606</span> of other offering costs). The Company recorded $<span id="xdx_904_eus-gaap--OfferingCostsPartnershipInterests_iI_c20221231_zLI0atOg0Jy5" title="Other offering costs">10,660,961</span> of offering costs as a reduction of temporary equity in connection with the redeemable common stock included in the Units. The Company recorded $<span id="xdx_90F_eus-gaap--OfferingCostsPartnershipInterests_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicWarrantsMember_zDWligi3egJg" title="Other offering costs">1,144,422</span> of offering costs as a reduction of permanent equity in connection with the Public Warrants and Rights classified as equity instruments. The Company immediately expensed $<span id="xdx_904_eus-gaap--OfferingCostsPartnershipInterests_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivateWarrantsMember_zQZFFIIgfDq4" title="Other offering costs">24,973</span> of offering costs in connection with the Private Warrants that were classified as liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zxNiGtwv98cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zg3d9KK5lL9f">Share-Based Payment Arrangements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock awards in accordance with ASC Topic 718, <i>Compensation - Stock Compensation</i> (“ASC 718”), which requires that all equity awards be accounted for at their fair value. Fair value is measured on the grant date and is equal to the underlying value of the stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, or in the period of grant for awards that vest immediately and have no future service condition. For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company’s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zr13RzBltgHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zSWZ3AVJeGL2">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, <i>Income Taxes</i> (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were unrecognized tax benefits as of December 31, 2022 and 2021 of $<span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_c20221231_zBsRfIVnpz1d" title="Unrecognized tax benefits">765,613</span> and $<span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iI_dxL_c20211231_zNJeZYhGlxia" title="Unrecognized tax benefits::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0640">0</span></span>, respectively. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the years ended December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 11 for additional information on income taxes for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zj6lwW9Zq1ri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zQpyErliYYS4">Net (Loss) Income Per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The calculation of diluted (loss) income per common share does not consider the effect of the Public Warrants (as defined in Note 3), Private Warrants, Subscription Warrants (as defined in Note 6), and Rights (as defined in Note 3) since the exercise of the warrants and Rights are contingent upon the occurrence of future events and the inclusion of such warrants and Rights would be anti-dilutive. The warrants and Rights are exercisable to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_zzJevrYV3bAa" title="Warrants exercisable to purchase shares of common stock">22,068,750</span> shares of common stock in the aggregate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zY58cCffkKv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reflects the calculation of basic and diluted net (loss) income per common share (in dollars, except per share amounts):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhUCwrYVb8m3" style="display: none">SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z2hSrhPwYSdj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableCommonStockMember_zJpxTUz9qjuh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z07obJNMQe6e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableCommonStockMember_zabgViVTrmf5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net (loss) income per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zpOVcc3OsbRj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_zbsyevxIr3ih" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 40%; text-align: left; padding-bottom: 2.5pt">Net (loss) income</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">(326,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">(160,282</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">2,074,858</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">414,971</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zY8VK2sGyrF7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_z4C85fDZuHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 1.5pt">Weighted Average Common Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,199,223</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,025,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,125,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,025,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasic_zPedzQe4LRBb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net (loss) income per common share</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zViAT3RRpsge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zCc0QHj6Z3Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zWKsCj7CEQ81">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zv6SYjJTKCP2" title="Federal depository insurance coverage amount">250,000</span>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zeUKBws12ndj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zQlVgCIo9ML5">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC Topic 820, <i>Fair Value Measurement</i> (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts reflected in the consolidated balance sheets for current assets and current liabilities approximate fair value due to their short-term nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 10 for additional information on assets and liabilities measured at fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--DerivativesReportingOfDerivativeActivity_zC5CfZJN75l5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_znyQ5Q3xYAoc">Derivative Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified on the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the Private Warrants and Subscription Warrants (as defined in Note 6) are derivative instruments. As the Private Warrants and Subscription Warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820 with changes in fair value recognized in the consolidated statements of operations in the period of change. In accordance with ASC Topic 825, Financial Instruments, the Company has concluded that a portion of the transaction costs which directly related to the Initial Public Offering and the Private Placement, should be allocated to the Private Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zeoM1oegp3p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zmccoxS3UsUh">Recent Accounting Standards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements. </span></p> <p id="xdx_853_zAhLENi87oG1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zDscHMHo5FXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zrsOLhyvB2d1">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements of the Company are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--ConsolidationPolicyTextBlock_zq7ffDPT0oh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zuky9iYPRlfc">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its majority-owned and controlled operating subsidiary, Old Merger Sub after elimination of all intercompany transactions and balances as of December 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_ecustom--EmergingGrowthCompanyPolicyTextBlock_zDWJDlMIoVgf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zke21l7HXsPc">Emerging Growth Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is an “emerging growth company”, as defined in Section 2(a) of the Securities Act of 1933, as amended, (the “Securities Act”), as modified by the Jumpstart Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. The Company has elected to implement the aforementioned exemptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company intends to take advantage of the benefits of this extended transition period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_eus-gaap--UseOfEstimates_z9NFdqspXXTg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_864_zLSHt7Shlxf8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ from those estimates. The initial valuation of the Public Warrants (as defined in Note 3), Rights (as defined in Note 3) common stock subject to redemption and the periodic valuation of the Private Warrants and Subscription Warrants (as defined in Note 6) required management to exercise significant judgement in its estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zRA9Ftce1xy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_ziCE2MLaXpWl">Cash and Cash Equivalents</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The cash equivalents in the amount of $<span id="xdx_901_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20221231_zoW1OwjkBBeg" title="Cash equivalents">6,346</span> and $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_c20211231_zUEzhspauAl6" title="Cash equivalents">350,455</span>, were held in money market funds as of December 31, 2022 and December 31, 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 6346 350455 <p id="xdx_84C_eus-gaap--MarketableSecuritiesPolicy_zf6tm7Alg9Hl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zTlKqDxfk4ve">Investments Held in Trust Account</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and December 31, 2021, substantially all of the assets held in the Trust Account were held in a money market account and mutual funds which invested in U.S. Treasury securities, respectively. The assets were transferred from mutual funds to a money market account on December 21, 2022. The assets in the amount of $<span id="xdx_900_eus-gaap--AssetsHeldInTrust_iI_c20221231_zbVaB0EzZGod" title="Investment held in Trust Account">53,815,395</span> and $<span id="xdx_90A_eus-gaap--AssetsHeldInTrust_iI_c20211231_zW30QzTS5cOg" title="Investment held in Trust Account">203,282,989</span> were held in the Trust Account as of December 31, 2022 and December 31, 2021, respectively. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in Interest and dividends earned on investments held in Trust Account in the accompanying statement of operations. The estimated fair values of investments held in Trust Account are determined using available market information.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 53815395 203282989 <p id="xdx_84C_eus-gaap--DerivativesPolicyTextBlock_zXaMj2ORMgx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zydBjDm7Gukj">Warrants</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in ASC 480 and ASC Topic 815, <i>Derivatives and Hedging</i> (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance and recorded as a warrant liability. In accordance with guidance contained in ASC 815, the Public Warrants (as defined in Note 3) qualify for equity treatment. The Private Warrants and Subscription Warrants (as defined in Note 6) do not qualify as equity and are recorded as liabilities at fair value. Changes in the estimated fair value of the Private Warrants and Subscription Warrants are recognized as non-cash gains or losses on the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_ecustom--DebtWithConversionAndOtherOptionsPolicyTextBlock_zsWxMPjvEdYj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zOLQ7biWIM6b">Debt with Conversion and Other Options</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for a series of unsecured senior promissory note agreements under ASC Topic ASC 470-20-25-2, <i>Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants </i>(“ASC 470-20-25-2”).  In accordance with ASC 470-20-25-2, proceeds from the sale of a debt instrument with stock purchase warrants (detachable call options) are allocated to the two elements based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock_zpBObilMc6v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zOI6fOzJQ157">Common Stock Subject to Possible Redemption</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the <span id="xdx_902_eus-gaap--TemporaryEquitySharesIssued_iI_c20221231_ziN3HSPevpBj" title="Temporary equity, shares issued">5,032,874</span> Public Shares sold as part of the Units in the Initial Public Offering and subsequent full exercise of the underwriters’ over-allotment option that have not been redeemed by stockholders, contain a redemption feature which allows for the redemption of such redeemable common stock in connection with the Company’s liquidation, if there is a stockholder vote or tender offer in connection with the Business Combination and in connection with certain amendments to the Amended and Restated Certificate of Incorporation. In accordance with SEC and its staff’s guidance on redeemable equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require common stock subject to redemption to be classified outside of permanent equity. Therefore, all Public Shares been classified outside of permanent equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable common stock to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid in capital and accumulated deficit. There was no change in redemption value for the year ended December 31, 2021. In connection with extending the Company’s Original Termination Date to the Extended Date, the Company deposited $<span id="xdx_906_eus-gaap--Deposits_iI_c20220323_zDGzeWs27Ucl" title="Cash deposited into trust account">720,000</span>, $<span id="xdx_90A_eus-gaap--Deposits_iI_c20220623_zv1w2mMEZZw8" title="Cash deposited into trust account">240,000</span>, $<span id="xdx_90B_eus-gaap--Deposits_iI_c20220726_zzz90NY52kwb" title="Cash deposited into trust account">240,000</span>, $<span id="xdx_90F_eus-gaap--Deposits_iI_c20220830_z2gXn5545O13" title="Cash deposited into trust account">240,000</span>, $<span id="xdx_905_eus-gaap--Deposits_iI_c20220928_zcElO6FsVMod" title="Cash deposited into trust account">240,000</span>, and $<span id="xdx_904_eus-gaap--Deposits_iI_c20221028_z5lx4SUtcTSg" title="Cash deposited into trust account"><span id="xdx_90C_eus-gaap--Deposits_iI_c20221125_z9MyDBRXHfY7" title="Cash deposited into trust account">240,000</span></span> into the Trust Account on March 23, 2022, June 23, 2022, July 26, 2022, August 30, 2022, September 28, 2022, October 28, 2022, and November 25, 2022 respectively. In connection to the Company’s Second Extended Date, the Company deposited $<span id="xdx_906_eus-gaap--Deposits_iI_c20220327_zN3YAa21L09f" title="Cash deposited into trust account">100,000</span> into the Trust Account on December 27, 2022. The Company recorded increases in the redemption value of common stock subject to redemption of $<span id="xdx_907_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_ztdcPHi13aec" title="Remeasurement of carrying value to redemption value">2,607,712</span> during the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection to the Company’s Third Extended Date, On June 27, 2023, <span style="background-color: white">the Company deposited the payment of $<span id="xdx_90B_eus-gaap--Deposits_iI_c20230627__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBkna8Eyi5sd" title="Deposits">85,000</span> in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and December 31, 2021, the redeemable common stock reflected in the consolidated balance sheets are reconciled in the following table:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--TemporaryEquityTableTextBlock_zr7woeZaUnMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zKSxWcQ9nbRi" style="display: none">SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross proceeds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20211231_zNePpQ7Q20T7" style="width: 16%; text-align: right" title="Gross proceeds">201,250,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Fair value of Public Warrants at issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueOfWarrantsAtIssaunce_c20210101__20211231_zr3J3Iv78gkh" style="text-align: right" title="Fair value of Public Warrants at issuance">(10,384,500</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fair value of Rights at issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueOfRightsAtIssuance_c20210101__20211231_zFg8EkPU2HB1" style="text-align: right" title="Fair value of Rights at issuance">(9,136,750</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Issuance costs allocated to common stock subject to possible redemption</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--StockIssuedIssuanceCostsCommonStockSubjectToPossibleRedemption_iN_di_c20210101__20211231_z1WTsserApN1" style="text-align: right" title="Issuance costs allocated to common stock subject to possible redemption">(10,660,961</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Remeasurement of carrying value to redemption value</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20210101__20211231_zR8wX17B5uT" style="border-bottom: Black 1.5pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">32,194,711</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption as of December 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zUSfeVlygjQ9" style="font-weight: bold; text-align: right" title="Common stock subject to possible redemption as of December 31, 2021">203,262,500</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Redemption of common stock by stockholders</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20221231_zIteQWqRqXzd" style="text-align: right" title="Redemption of common stock by stockholders">(152,451,819</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Common stock tendered for redemption</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--CommonStockTenderedForRedemption_iNI_di_c20221231_zpVelUfCSN78" style="text-align: right" title="Redemption of common share, value">(34,004,514</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Remeasurement of carrying value to redemption value</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_zpFEBhUGYMC6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">2,607,712</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption as of December 31, 2022</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20220101__20221231_zaeHbyl3ceWk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Common stock subject to possible redemption as of December 31, 2022">19,413,879</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zDJCnypGa5zg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5032874 720000 240000 240000 240000 240000 240000 240000 100000 2607712 85000 <p id="xdx_89D_eus-gaap--TemporaryEquityTableTextBlock_zr7woeZaUnMg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B8_zKSxWcQ9nbRi" style="display: none">SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Gross proceeds</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20210101__20211231_zNePpQ7Q20T7" style="width: 16%; text-align: right" title="Gross proceeds">201,250,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Fair value of Public Warrants at issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueOfWarrantsAtIssaunce_c20210101__20211231_zr3J3Iv78gkh" style="text-align: right" title="Fair value of Public Warrants at issuance">(10,384,500</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Fair value of Rights at issuance</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--FairValueOfRightsAtIssuance_c20210101__20211231_zFg8EkPU2HB1" style="text-align: right" title="Fair value of Rights at issuance">(9,136,750</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Issuance costs allocated to common stock subject to possible redemption</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--StockIssuedIssuanceCostsCommonStockSubjectToPossibleRedemption_iN_di_c20210101__20211231_z1WTsserApN1" style="text-align: right" title="Issuance costs allocated to common stock subject to possible redemption">(10,660,961</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Plus:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Remeasurement of carrying value to redemption value</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20210101__20211231_zR8wX17B5uT" style="border-bottom: Black 1.5pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">32,194,711</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption as of December 31, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_980_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iS_c20220101__20221231_zUSfeVlygjQ9" style="font-weight: bold; text-align: right" title="Common stock subject to possible redemption as of December 31, 2021">203,262,500</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Redemption of common stock by stockholders</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_c20220101__20221231_zIteQWqRqXzd" style="text-align: right" title="Redemption of common stock by stockholders">(152,451,819</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Common stock tendered for redemption</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_ecustom--CommonStockTenderedForRedemption_iNI_di_c20221231_zpVelUfCSN78" style="text-align: right" title="Redemption of common share, value">(34,004,514</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Remeasurement of carrying value to redemption value</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--TemporaryEquityAccretionToRedemptionValue_c20220101__20221231_zpFEBhUGYMC6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Remeasurement of carrying value to redemption value">2,607,712</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Common stock subject to possible redemption as of December 31, 2022</td><td style="font-weight: bold"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td id="xdx_985_eus-gaap--TemporaryEquityCarryingAmountAttributableToParent_iE_c20220101__20221231_zaeHbyl3ceWk" style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right" title="Common stock subject to possible redemption as of December 31, 2022">19,413,879</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> 201250000 -10384500 -9136750 10660961 32194711 203262500 -152451819 34004514 2607712 19413879 <p id="xdx_84B_eus-gaap--DeferredChargesPolicyTextBlock_zg5GPbUd98t1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zE1VXkowxAP4">Offering Costs associated with the Initial Public Offering</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of ASC Topic 340, <i>Other Assets and Deferred Costs</i> (“ASC 340”) and SEC Staff Accounting Bulletin Topic 5A - <i>Expenses of Offering</i>. Offering costs consist principally of professional and registration fees incurred through the balance sheet date that are related to the Initial Public Offering. Offering costs directly attributable to the issuance of an equity contract to be classified in equity are recorded as a reduction in equity. Offering costs for equity contracts that are classified as assets and liabilities are expensed immediately. The Company incurred offering costs amounting to $<span id="xdx_907_ecustom--OfferingCosts_c20220101__20221231_zqKLlkTsUF19" title="Offering costs">11,830,356</span> as a result of the Initial Public Offering (consisting of a $<span id="xdx_904_eus-gaap--PaymentsForUnderwritingExpense_c20220101__20221231_zpCmd20uFA5g" title="Cash underwriting fee">4,025,000</span> cash underwriting fee, $<span id="xdx_90A_ecustom--DeferredUnderwritingFees_c20220101__20221231_z07TmG2dwbOh" title="Deferred underwriting fees">7,043,750</span> of deferred underwriting fees, and $<span id="xdx_904_ecustom--OtherOfferingCosts_c20220101__20221231_zuv6a4FYByq8" title="Other offering costs">761,606</span> of other offering costs). The Company recorded $<span id="xdx_904_eus-gaap--OfferingCostsPartnershipInterests_iI_c20221231_zLI0atOg0Jy5" title="Other offering costs">10,660,961</span> of offering costs as a reduction of temporary equity in connection with the redeemable common stock included in the Units. The Company recorded $<span id="xdx_90F_eus-gaap--OfferingCostsPartnershipInterests_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicWarrantsMember_zDWligi3egJg" title="Other offering costs">1,144,422</span> of offering costs as a reduction of permanent equity in connection with the Public Warrants and Rights classified as equity instruments. The Company immediately expensed $<span id="xdx_904_eus-gaap--OfferingCostsPartnershipInterests_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivateWarrantsMember_zQZFFIIgfDq4" title="Other offering costs">24,973</span> of offering costs in connection with the Private Warrants that were classified as liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 11830356 4025000 7043750 761606 10660961 1144422 24973 <p id="xdx_84D_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zxNiGtwv98cj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zg3d9KK5lL9f">Share-Based Payment Arrangements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for stock awards in accordance with ASC Topic 718, <i>Compensation - Stock Compensation</i> (“ASC 718”), which requires that all equity awards be accounted for at their fair value. Fair value is measured on the grant date and is equal to the underlying value of the stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, or in the period of grant for awards that vest immediately and have no future service condition. For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company’s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--IncomeTaxPolicyTextBlock_zr13RzBltgHj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zSWZ3AVJeGL2">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the asset and liability method of accounting for income taxes under ASC Topic 740, <i>Income Taxes</i> (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were unrecognized tax benefits as of December 31, 2022 and 2021 of $<span id="xdx_90A_eus-gaap--UnrecognizedTaxBenefits_iI_c20221231_zBsRfIVnpz1d" title="Unrecognized tax benefits">765,613</span> and $<span id="xdx_903_eus-gaap--UnrecognizedTaxBenefits_iI_dxL_c20211231_zNJeZYhGlxia" title="Unrecognized tax benefits::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0640">0</span></span>, respectively. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the years ended December 31, 2022 and 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 11 for additional information on income taxes for the periods presented.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 765613 <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zj6lwW9Zq1ri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zQpyErliYYS4">Net (Loss) Income Per Common Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss) income per common share is computed by dividing net (loss) income by the weighted average number of common shares outstanding for the period. The calculation of diluted (loss) income per common share does not consider the effect of the Public Warrants (as defined in Note 3), Private Warrants, Subscription Warrants (as defined in Note 6), and Rights (as defined in Note 3) since the exercise of the warrants and Rights are contingent upon the occurrence of future events and the inclusion of such warrants and Rights would be anti-dilutive. The warrants and Rights are exercisable to purchase <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231_zzJevrYV3bAa" title="Warrants exercisable to purchase shares of common stock">22,068,750</span> shares of common stock in the aggregate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zY58cCffkKv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reflects the calculation of basic and diluted net (loss) income per common share (in dollars, except per share amounts):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhUCwrYVb8m3" style="display: none">SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z2hSrhPwYSdj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableCommonStockMember_zJpxTUz9qjuh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z07obJNMQe6e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableCommonStockMember_zabgViVTrmf5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net (loss) income per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zpOVcc3OsbRj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_zbsyevxIr3ih" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 40%; text-align: left; padding-bottom: 2.5pt">Net (loss) income</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">(326,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">(160,282</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">2,074,858</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">414,971</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zY8VK2sGyrF7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_z4C85fDZuHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 1.5pt">Weighted Average Common Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,199,223</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,025,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,125,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,025,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasic_zPedzQe4LRBb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net (loss) income per common share</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zViAT3RRpsge" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 22068750 <p id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zY58cCffkKv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table reflects the calculation of basic and diluted net (loss) income per common share (in dollars, except per share amounts):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zhUCwrYVb8m3" style="display: none">SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z2hSrhPwYSdj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableCommonStockMember_zJpxTUz9qjuh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_494_20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--RedeemableCommonStockMember_z07obJNMQe6e" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_499_20210101__20211231__us-gaap--StatementClassOfStockAxis__custom--NonRedeemableCommonStockMember_zabgViVTrmf5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Year ended</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Non-redeemable Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Basic and diluted net (loss) income per share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasicAbstract_iB_zpOVcc3OsbRj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--NetIncomeLoss_zbsyevxIr3ih" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 40%; text-align: left; padding-bottom: 2.5pt">Net (loss) income</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">(326,506</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">(160,282</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">2,074,858</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right">414,971</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasicAbstract_iB_zY8VK2sGyrF7" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_z4C85fDZuHRf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 1.5pt">Weighted Average Common Stock</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,199,223</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,025,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,125,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,025,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--EarningsPerShareBasic_zPedzQe4LRBb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Basic and diluted net (loss) income per common share</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table> -326506 -160282 2074858 414971 8199223 4025000 20125000 4025000 -0.04 -0.04 0.10 0.10 <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zCc0QHj6Z3Kc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zWKsCj7CEQ81">Concentration of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20221231_zv6SYjJTKCP2" title="Federal depository insurance coverage amount">250,000</span>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 250000 <p id="xdx_845_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zeUKBws12ndj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zQlVgCIo9ML5">Fair Value of Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies ASC Topic 820, <i>Fair Value Measurement</i> (“ASC 820”), which establishes a framework for measuring fair value and clarifies the definition of fair value within that framework. ASC 820 defines fair value as an exit price, which is the price that would be received for an asset or paid to transfer a liability in the Company’s principal or most advantageous market in an orderly transaction between market participants on the measurement date. The fair value hierarchy established in ASC 820 generally requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs reflect the assumptions that market participants would use in pricing the asset or liability and are developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the entity’s own assumptions based on market data and the entity’s judgments about the assumptions that market participants would use in pricing the asset or liability and are to be developed based on the best information available in the circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amounts reflected in the consolidated balance sheets for current assets and current liabilities approximate fair value due to their short-term nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 — Assets and liabilities with unadjusted, quoted prices listed on active market exchanges. Inputs to the fair value measurement are observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 — Inputs to the fair value measurement are determined using prices for recently traded assets and liabilities with similar underlying terms, as well as direct or indirect observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 — Inputs to the fair value measurement are unobservable inputs, such as estimates, assumptions, and valuation techniques when little or no market data exists for the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 10 for additional information on assets and liabilities measured at fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--DerivativesReportingOfDerivativeActivity_zC5CfZJN75l5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_znyQ5Q3xYAoc">Derivative Financial Instruments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815. The Company’s derivative instruments are recorded at fair value and re-valued at each reporting date, with changes in the fair value reported in the consolidated statements of operations. Derivative assets and liabilities are classified on the consolidated balance sheets as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the Private Warrants and Subscription Warrants (as defined in Note 6) are derivative instruments. As the Private Warrants and Subscription Warrants meet the definition of a derivative the warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820 with changes in fair value recognized in the consolidated statements of operations in the period of change. In accordance with ASC Topic 825, Financial Instruments, the Company has concluded that a portion of the transaction costs which directly related to the Initial Public Offering and the Private Placement, should be allocated to the Private Warrants based on their relative fair value against total proceeds, and recognized as transaction costs in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zeoM1oegp3p6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zmccoxS3UsUh">Recent Accounting Standards</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying consolidated financial statements. </span></p> <p id="xdx_80F_ecustom--InitialPublicOfferingDisclosureTextBlock_zzzbQEQczgPa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3. <span id="xdx_820_zlSt05tdmiQ8">INITIAL PUBLIC OFFERING</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 28, 2020, the Company sold <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201228__20201228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zvUCFDcY0p1j" title="Sale of stock">17,500,000</span> Units, at a purchase price of $<span id="xdx_901_eus-gaap--SaleOfStockPricePerShare_iI_c20201228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zWUflRvbdDPh" title="Share price">10.00</span> per Unit. Each Unit consists of one share of common stock, par value $<span id="xdx_907_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zV2sjw7gR9Re" title="Common stock, par value">0.0001</span> per share, one redeemable warrant (the “Public Warrants”) and one right (the “Rights”). Each Public Warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201228_zBhih0n3JGDi" title="Exercise price of warrants">11.50</span> per whole share. Each Right entitles the holder thereof to receive one-twentieth (1/20) of a share of common stock upon consummation of an initial Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 30, 2020, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201230__20201230__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zjrT8W4OdR23" title="Sale of stock">2,625,000</span> Over-Allotment Units pursuant to the underwriters’ full exercise of the over-allotment option (see Note 7), generating aggregate of gross proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromStockOptionsExercised_c20201230__20201230__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zG11zcmJem9c" title="Gross proceeds of options">26,250,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 17500000 10.00 0.0001 11.50 2625000 26250000 <p id="xdx_807_ecustom--PrivatePlacementDisclosureTextBlock_zDxz4fkuR2m1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4. <span id="xdx_822_z82zfDnoG4s8">PRIVATE PLACEMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneously with the closing of the Initial Public Offering, the Sponsor purchased an aggregate of <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6ChstxWLAQ9" title="Warrent purchases">18,000,000</span> Private Warrants at a price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zJ1hODjeBj9f" title="Warrent purchase price per share">0.50</span> per warrant ($<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfWarrants_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zGEFSOlVFbrl" title="Warrent purchases price">9,000,000</span> in the aggregate), each exercisable to purchase one-half of one share common stock at a price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zeeo9s0gKPQ6" title="Exercise price of warrants">11.50</span> per whole share, in a private placement that closed simultaneously with the closing of this offering. A portion of the purchase price of the Private Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 18000000 0.50 9000000 11.50 <p id="xdx_800_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOqvFM8t4KN8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5. <span id="xdx_822_zkWpOlPw56c1">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Founder Shares</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the Sponsor paid $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20200801__20200831__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zJC0c2MJlshi" title="Number of shares issued to sponsor">25,000</span>, or approximately $<span id="xdx_902_eus-gaap--SharePrice_iI_c20200831__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zkaTD3tuNYtd" title="Share price">0.007</span> per share, to cover certain offering costs in consideration for <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200801__20200831__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zWYIG1OQfcbf" title="Number of shares issued to sponsor, shares">3,593,750</span> shares of common stock, par value $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200831__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zRPC8Imy3oKj" title="Common stock, par value">0.0001</span> (the “Founder Shares”). On December 3, 2020, the Company declared a share dividend of <span id="xdx_909_eus-gaap--CommonStockDividendsPerShareDeclared_pid_c20201201__20201203__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_z4qaTcmRsCef" title="Common stock dividend declared per share">0.36</span> for each outstanding share, resulting in <span id="xdx_90A_eus-gaap--CommonStockDividendsShares_c20201201__20201203__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_z5xkZ8p7hSK6" title="Common stock dividend declared shares">4,887,500</span> shares outstanding, and on December 22, 2020 the Company declared a share dividend of <span id="xdx_90D_eus-gaap--CommonStockDividendsPerShareDeclared_c20201221__20201222__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zo46EwzopcIj" title="Common stock dividend declared per share">0.03</span> resulting in <span id="xdx_902_eus-gaap--CommonStockDividendsShares_c20201221__20201222__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zDlABVePpPp3" title="Common stock dividend declared shares">5,031,250</span> shares which includes an aggregate of up to <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20201221__20201222__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zP0oxpJ5JE2l" title="Shares subject to forfeiture">656,250</span> shares that are subject to forfeiture to the extent that the underwriters’ over-allotment option is not exercised in full or in part, and up to an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201221__20201222__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zEEmtqpyehn9">1,006,250</span> shares of common stock (or <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201221__20201222__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zL97oA1AbwV8" title="Share issued">875,000</span> shares of common stock to the extent that the underwriters’ over-allotment is not exercised, pro rata) that are subject to forfeiture to the extent that Rights are exercised upon consummation of an initial Business Combination. In connection with the underwriters’ fully exercise of their over-allotment option on December 30, 2020 (see Note 7), the <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20201230__20201230__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zK6ZghSrE9Ye" title="Shares cancellation common stock subject to forfeiture">656,250</span> shares were no longer subject to forfeiture.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Founder Shares were placed into an escrow account maintained by Continental Stock Transfer &amp; Trust Company acting as escrow agent. <span id="xdx_90C_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_zGM77TYKcGu8" title="Founder shares related description">50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the initial Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the initial Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to its initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the escrow period, the holders of these shares will not be able to sell or transfer their securities except (1) to any persons (including their affiliates and stockholders) participating in the Private Placement of the Private Warrants, officers, directors, stockholders, employees and members of the Company’s Sponsor and its affiliates, (2) amongst initial stockholders or their respective affiliates, or to the Company’s officers, directors, advisors and employees, (3) if a holder is an entity, as a distribution to its, partners, stockholders or members upon its liquidation, (4) by bona fide gift to a member of the holder’s immediate family or to a trust, the beneficiary of which is a holder or a member of a holder’s immediate family, for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations order, (7) by certain pledges to secure obligations incurred in connection with purchases of the Company’s securities, (8) by private sales at prices no greater than the price at which the shares were originally purchased or (9) for the cancellation of up to <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember_ztqC0CeTpCT9" title="Shares cancellation common stock subject to forfeiture">656,250</span> shares of common stock subject to forfeiture to the extent that the underwriters’ over-allotment is not exercised in full or in part or in connection with the consummation of the Company’s initial Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2020, the Sponsor transferred <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201223__20201223__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember__srt--TitleOfIndividualAxis__custom--SponsorMember_z7zWkyzTLwg1" title="Number of stock transferred">81,000</span> of its Founder Shares of the Company to three board members (the “Transferees”) (<span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20201223__20201223__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember__srt--TitleOfIndividualAxis__custom--TransfereeMember_zI2qVUOS78Xf" title="Number of stock transferred">27,000</span> Founder Shares to each Transferee) for a nominal fee. On April 30, 2021, the Sponsor subsequently transferred <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210430__20210430__us-gaap--SubsidiarySaleOfStockAxis__custom--FounderSharesMember__srt--TitleOfIndividualAxis__custom--SponsorMember_zPrSvKRoh9r5" title="Number of stock transferred">27,000</span> of its Founder Shares of the Company to a new board member (the “Additional Transferee”, and, together with the Transferees, the “Directors”). These awards are subject to ASC 718.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The Founder Shares vested immediately, and, as such, in accordance with ASC 718, the Company recognized compensation expense on the transfer date in an amount equal to the number of Founders Shares sold times the grant date fair value per share less the amount initially received for the purchase of the Founders Shares. The fair value of the Founder Shares transferred to the Additional Transferee was determined to be $<span id="xdx_909_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20210429__20210430_zes3FRpI8jy2" title="Fair value of founder shares">157,140</span> ($<span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_c20210430_z9wZkPLcW9g1" title="Founder shares, per share">5.82</span> per share) as of April 30, 2021. The Company recognized compensation expense of $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_c20210101__20211231_zRqieKOwQL5l" title="Share based compensation">157,140</span> within stock compensation expense in the Company’s statement of operations for the year ended December 31, 2021. The Company did not recognize compensation expense for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Note Agreements Payable - Related Party</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="margin: 0; text-align: justify">We entered into a series of Note Agreements with several lenders affiliated with our Sponsor, Viveon Health LLC and Intuitus Group LLC, for which the Chief Financial Officer of the Company is the Sole Proprietor for up to an aggregate amount totaling $<span id="xdx_906_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--TypeOfArrangementAxis__custom--NoteAgreementsMember_zFJxjd3Dph1j" title="Notes payable related party"><span title="Loans payable">1,955,000</span></span> (see Note 6). As of December 31, 2022, the balance on the Notes was $<span id="xdx_90F_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_c20221231_zCBMFAhE2FGa" title="Notes payable, related party">1,955,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Promissory Notes - Related Party</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sponsor agreed to loan the Company an aggregate of up to $<span id="xdx_90E_eus-gaap--CostsAndExpensesRelatedParty_c20220101__20221231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zjciDerx7Nb5" title="Costs and expenses, related party">500,000</span> to cover expenses related to the Initial Public Offering pursuant to a promissory note (the “Note”). This loan was non-interest bearing and payable on the earlier of March 31, 2021 or the completion of the Initial Public Offering. On January 13, 2021, the Company paid the $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20220101__20221231__srt--TitleOfIndividualAxis__custom--SponsorMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zkCDJOgGaNQg" title="Proceeds from initial public offering">228,758</span> balance on the note from the proceeds of the Initial Public Offering. The Company no longer has the ability to borrow under the Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chief Financial Officer of the Company loaned the Company $<span id="xdx_90D_eus-gaap--CostsAndExpensesRelatedParty_c20221226__20221227__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zznSg2evIDqg">75,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">to cover expenses related to ongoing operations, which was funded on December 27, 2022. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on December 27, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $<span id="xdx_903_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_z9DRfngUydg1">75,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--LoansPayable_iI_c20211231__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zgf4JjeSes77">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively. Subsequent to December 31, 2022, the Chief Financial Officer of the Company, loaned the Company an additional $<span id="xdx_90D_eus-gaap--ProceedsFromLoans_c20230101__20230428__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znvvv5X9lyPb" title="Additiona loansl">555,000</span> through the date of this filing. These loans will be exchanged for Clearday Senior Convertible Notes upon consummation of the Company’s initial Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chief Executive Officer of the Company loaned the Company $<span id="xdx_909_eus-gaap--ProceedsFromLoans_c20230402__20230402__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zsdPIxHCXvHa" title="Proceeds from Loans">100,000</span> to cover expenses related to ongoing operations, which was funded on April 2, 2023. This loan is non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreement was entered into on April 2, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $<span id="xdx_90F_eus-gaap--LoansPayable_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcx48daUu9Pa" title="Loans payable"><span id="xdx_90B_eus-gaap--LoansPayable_iI_c20211231__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zymPycTjxqlc" title="Loans payable">0</span></span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subsequent to December 31, 2022, three investors in the Sponsor, loaned the Company $<span id="xdx_906_eus-gaap--ProceedsFromRepaymentsOfNotesPayable_c20230101__20230407__srt--TitleOfIndividualAxis__custom--ThreeInvestorsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zscV7sh0Xraf">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the aggregate, to cover expenses related to ongoing operations, funded on April 5, 2023, and April 7, 2023. These loans are non-interest bearing and payable upon consummation of the Company’s initial Business Combination. The loan agreements were entered into on April 5, 2023, and April 7, 2023. As of December 31, 2022, and December 31, 2021, the outstanding balance of the loan was $<span id="xdx_90A_eus-gaap--LoansPayable_iI_c20211231__srt--TitleOfIndividualAxis__custom--DipakVashirMember_znsK7Zd2kjNg">0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 12, 2023, the Company entered into an unsecured promissory note with Clearday (the “<b><span style="text-decoration: underline">Clearday Note</span></b>”). The Clearday Note is non-interest bearing mature upon the earlier of (i) the first anniversary of the issuance date and (ii) December 31, 2022. Proceeds provided to us under the Clearday Note through the filing date were approximately $881,710 during fiscal year 2023.Funds in the Trust Account may not be used to repay the obligations under the Clearday Note. We used such funds for general working capital purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Working Capital Loans</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“<b><span style="text-decoration: underline">Working Capital Loans</span></b>”). Each loan would be evidenced by a promissory note. The notes would be repaid upon consummation of the Company’s initial Business Combination, without interest. As of December 31, 2022 and December 31, 2021, the Company had no borrowings under Working Capital Loans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Administrative Service Fee</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing on the date of the Company’s final prospectus, the Company has agreed to pay an affiliate of the Sponsor a total of $<span id="xdx_908_eus-gaap--PaymentsForRent_c20220101__20221231__srt--TitleOfIndividualAxis__custom--SponsorMember_zmOWMFYZEd1j" title="Rent paid">20,000</span> per month for office space, utilities and secretarial support. Upon completion of the initial Business Combination or the Company’s liquidation, the Company will cease paying these monthly fees. The Company incurred $<span id="xdx_90B_eus-gaap--AdministrativeFeesExpense_c20220101__20221231__srt--TitleOfIndividualAxis__custom--SponsorMember_zBgZlep9Izjf" title="Administrative service fees">240,000</span> and $<span id="xdx_902_eus-gaap--AdministrativeFeesExpense_c20210101__20211231__srt--TitleOfIndividualAxis__custom--SponsorMember_zlLOegPdqvGe" title="Administrative service fees">240,000</span> of administrative service fees for the year ended December 31, 2022 and 2021, respectively. The accrued amounts are included in Due to related party on the balance consolidated balance sheets. For the year ended December 31, 2022 and 2021, $<span id="xdx_909_eus-gaap--DueToRelatedPartiesCurrent_iI_c20221231__srt--TitleOfIndividualAxis__custom--SponsorMember_z19PzT70fphd" title="Due to related party">50,000</span> and $<span id="xdx_90A_eus-gaap--DueToRelatedPartiesCurrent_iI_c20211231__srt--TitleOfIndividualAxis__custom--SponsorMember_zfgTLWRtSmG" title="Due to related party">10,000</span> of such expenses were recorded in Due to related party, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Due to Related Party</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s directors and officers are reimbursed for any reasonable out-of-pocket expenses incurred by them in connection with certain activities on behalf of the Company, such as identifying and investigating possible target businesses and Business Combinations. For the years ended December 31, 2022 and 2021, $<span id="xdx_909_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c20220101__20221231_zSWO8T17ag15" title="Incurred expenses">6,647</span> and $<span id="xdx_900_eus-gaap--RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c20210101__20211231_zO2Rs7adjOif" title="Incurred expenses">9,479</span> of such expenses were incurred, respectively. As of December 31, 2022 and 2021, $<span id="xdx_902_eus-gaap--RelatedPartyTaxExpenseDueToAffiliatesDeferred_c20220101__20221231_zQ7rS4sV6Xde" title="Due to related party">5,806</span> and $<span id="xdx_909_eus-gaap--RelatedPartyTaxExpenseDueToAffiliatesDeferred_c20210101__20211231_zRgUZr5yVLP2" title="Due to related party">5,850</span> of such expenses were recorded in Due to related party, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Due from Related Party</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2021, the Company had a receivable of $<span id="xdx_90A_eus-gaap--DueFromRelatedPartiesCurrent_iI_c20211231_znQvuMjxXVFh" title="Due from related party">15,000</span> in connection with a payment made by the Company to a vendor on behalf of a related party. During the year ended December 31, 2022, the Company was repaid for the receivable. As of December 31, 2022, the balance in Due from related party is $<span id="xdx_903_eus-gaap--DueFromRelatedPartiesCurrent_iI_dxL_c20221231_zzcP5RC2oq3g" title="Due from related party::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0789">0</span></span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 25000 0.007 3593750 0.0001 0.36 4887500 0.03 5031250 656250 1006250 875000 656250 50% of these shares will not be transferred, assigned, sold or released from escrow until the earlier of (i) 6 months after the date of the consummation of the initial Business Combination or (ii) the date on which the closing price of the Company’s shares of common stock equals or exceeds $12.50 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing after the initial Business Combination and the remaining 50% of the Founder Shares will not be transferred, assigned, sold or released from escrow until 6 months after the date of the consummation of the initial Business Combination, or earlier, in either case, if, subsequent to its initial Business Combination, the Company consummates a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of its stockholders having the right to exchange their shares of common stock for cash, securities or other property. 656250 81000 27000 27000 157140 5.82 157140 1955000 1955000 500000 228758 75000 75000 0 555000 100000 0 0 100000 0 20000 240000 240000 50000 10000 6647 9479 5806 5850 15000 <p id="xdx_805_eus-gaap--DebtDisclosureTextBlock_zQTxu8gIMIq7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6. <span id="xdx_82A_zvooWksxLbb">NOTE AGREEMENTS PAYABLE</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><br/> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--DebtInstrumentDescription_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--UnsecuredSeniorPromissoryNoteAgreementsMember_zZCbFaWW6jG6" title="Debt instrument description">On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, in connection with the extension of the date by which the Company has to consummate a Business Combination (see Note 7), the Company entered into a series of unsecured senior promissory note agreements (“Note Agreements”) for up to an aggregate amount totaling $4.0 million (the “Notes”). Of the total $4.0 million of the Notes, $<span id="xdx_901_eus-gaap--LoansPayable_iI_c20221231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember_z8IoD6BhTPKa" title="Loans payable">1,955,000</span> is loaned by lenders who are affiliated with the sponsor and a director of the Company, and Intuitus Group LLC, for which the Chief Financial Officer of the Company is the Sole Proprietor</span>. The Notes do not bear interest and were set to mature upon the earlier of (i) the closing of the Company’s initial Business Combination and (ii) December 31, 2022 (the “Original Maturity Date”). A commitment fee in the amount equal to <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_uPure_c20221231__us-gaap--TypeOfArrangementAxis__custom--UnsecuredSeniorPromissoryNoteAgreementsMember_zD6GyGGia6rh" title="Interest rate">10%</span> of all amounts funded under Notes (up to a maximum of $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--UnsecuredSeniorPromissoryNoteAgreementsMember_z6bsP6HV4hWg" title="Line of credit facility maximum borrowing capacity">400,000</span>), is due to the subscribers, on a pro rata basis, by the Company promptly following the initial funding. As of December 31, 2022, the Company has received $<span id="xdx_90B_eus-gaap--AccountsAndNotesReceivableNet_iI_pn6n6_c20221231__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementsMember_zKtyZHjS4gxh" title="Notes receivable">4</span> million of funding for the Notes. The Company has paid $<span id="xdx_90B_eus-gaap--LineOfCreditFacilityCommitmentFeeAmount_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--UnsecuredPromissoryNoteAgreementsMember_z7BQ7RgzhHhh" title="Commitment fee amount">400,000</span> in commitment fees as of December 31, 2022. Subsequent to December 31, 2022, in connection with the business combination a majority of the lenders of the Notes have agreed to exchange their Notes with the Company for Clearday Senior Convertible Notes. Upon the consummation of the business combination and the exchange of the Subscription Agreements for the Clearday Senior Convertible Notes, the lenders will forfeit their Subscription Warrants as part of the exchange. One lender has chosen not to convert to Clearday Senior Convertible Notes. The balance owed to this lender under the Notes is considered due upon demand by the lender. As of the date of this filing of this Annual Report the lender has not requested payment of the Note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Note Agreements, the subscribers shall receive warrants to purchase one share of Company common stock for every $<span id="xdx_906_eus-gaap--CommonStockDividendsPerShareDeclared_c20220101__20221231_zhrEhgtkPbKg">2.00 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the funded principal amount of the Notes up to <span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231_zkxS2mEJhoo4">2,000,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company common stock, in the aggregate, at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_zNIa9fihsfdi">11.50 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, subject to adjustment (the “Subscription Warrants”). See Note 9 for additional terms of the Subscription Warrants. Pursuant to a warrant cancellation and forfeiture agreement dated as of August 16, 2023, one of the Company’s directors agreed to forfeit for cancellation <span id="xdx_906_ecustom--DebtInstrumentForfeitForCancellationShares_iI_c20230816__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--DebtInstrumentAxis__custom--SubscriptionWarrantsMember_zEyUPtp2t5Ol" title="Debt forfeit for cancellation">89,029</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> of the warrant shares underlying the warrant issued to an affiliate that he controls in connection with the Notes described above.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 470-20-25-2, <i>Debt with Conversion and Other Options - Debt Instruments with Detachable Warrants,</i> the proceeds from the issuance of the Notes were allocated to the Notes and Subscription Warrants using the with-and-without method. Under this method, the Company first allocated the proceeds from the issuance of the Notes to the Subscription Warrants based on their initial fair value measurement of $<span id="xdx_902_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220321__20220321__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zZfm1FcVoHUd" title="Subscription warrants">5,370,185</span> for the Subscription Warrants issued on March 21, 2022, $<span id="xdx_906_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220323__20220323__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zx5Ei7A3ztob" title="Subscription warrants">337,991</span> for the Subscription Warrants issued on March 23, 2022, $<span id="xdx_909_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220404__20220404__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zRsI2EPYYfj" title="Subscription warrants">341,967</span> for the Subscription Warrants issued on April 4, 2022, $<span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220427__20220427__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zzgut05AUzrk" title="Subscription warrants">417,037</span> for the Subscription Warrants issued on April 27, 2022, $<span id="xdx_906_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220509__20220509__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zRtJ29tzmHV4" title="Subscription warrants">162,003</span> for the Subscription Warrants issued on May 9, 2022, $<span id="xdx_900_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20221027__20221027__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zxZbcA8b33Af" title="Subscription warrants">65,326</span> for the Subscription Warrants issued on October 27, 2022, and $<span id="xdx_90A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20221125__20221125__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zMNUCMJLsLtd" title="Subscription warrants">121,093</span> for the Subscription Warrants issued on November 25, 2022. The measurement of the Subscription Warrants fair value was determined utilizing a Monte Carlo simulation model considering all relevant assumptions current at the dates of issuance. See Note 10 for additional details on the assumptions used. The initial fair value of the Subscription Warrants exceeded the proceeds received from the issuance of the Notes. As such, the proceeds allocated to the Notes were nil. The Company recognized a loss on issuance of the Subscription Warrants of $<span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_zv6j8l2LfCm4">3,209,183</span> for the year ended December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with ASC Topic 835, <i>Interest </i>(“ASC 835”). In accordance with ASC 835-30, discounts to the principal amounts are included in the carrying value of the Notes and amortized to “Interest expense” over the remaining term of the underlying debt to the Original Maturity Date. During the year ended December 31, 2022, the Company recorded a $<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20221231_zntR5IxbECF4" title="Debt discount">3,645,777</span> debt discount upon issuance of the Notes, respectively. The discount was amortized to interest expense over the term of the debt to the Original Maturity Date. For the year ended December 31, 2022, the amortization of the discount resulted in interest expense of $<span id="xdx_901_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_c20221231_zzSCDFyr4jj9" title="Interest expense">3,645,777</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_zvTKc4YrOmd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Notes as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_zCx9ZOA7TSpd" style="display: none">SCHEDULE OF NOTES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_493_20221231_zQHXm6LFNnFi" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_maNPzaHr_zeiZxYYV7x97" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Note</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_msNPzaHr_zIgMuZtUjjcg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesPayable_iTI_mtNPzaHr_zf9TaC6Cc8R4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Carrying value of notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zcvhSUBfqtx7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, in connection with the extension of the date by which the Company has to consummate a Business Combination (see Note 7), the Company entered into a series of unsecured senior promissory note agreements (“Note Agreements”) for up to an aggregate amount totaling $4.0 million (the “Notes”). Of the total $4.0 million of the Notes, $1,955,000 is loaned by lenders who are affiliated with the sponsor and a director of the Company, and Intuitus Group LLC, for which the Chief Financial Officer of the Company is the Sole Proprietor 1955000 0.10 400000 4000000 400000 2.00 2000000 11.50 89029 5370185 337991 341967 417037 162003 65326 121093 3209183 3645777 3645777 <p id="xdx_898_eus-gaap--ConvertibleDebtTableTextBlock_zvTKc4YrOmd5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents the Notes as of December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_8B2_zCx9ZOA7TSpd" style="display: none">SCHEDULE OF NOTES</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"> </td><td style="text-align: center"> </td> <td style="text-align: center"> </td><td id="xdx_493_20221231_zQHXm6LFNnFi" style="text-align: center"> </td><td style="text-align: center"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtInstrumentCarryingAmount_iI_maNPzaHr_zeiZxYYV7x97" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Note</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">4,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iNI_di_msNPzaHr_zIgMuZtUjjcg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Debt discount</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--NotesPayable_iTI_mtNPzaHr_zf9TaC6Cc8R4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Carrying value of notes</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,000,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 4000000 4000000 <p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zl7CyxbkN12h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7. <span id="xdx_826_z7yxCXQMnTYd">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Underwriting Agreement</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted the underwriter a 45-day option to purchase up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20201230__20201230__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zRCkGy3r6Tdk" title="Additional Shares granted">2,625,000</span> additional shares of common stock to cover over-allotments at the Initial Public Offering price, less the underwriting discounts and commissions. The underwriters exercised the over-allotment option in full on December 28, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underwriter was paid a cash underwriting fee of $<span id="xdx_90D_ecustom--UnderwritingFeePerShare_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zQ1SLfgaoJN7" title="Underwriting fee">0.20</span> per share, or $<span id="xdx_90E_eus-gaap--PaymentsForUnderwritingExpense_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zFtp480htacl" title="Underwriting expense">4,025,000</span> in the aggregate, upon the closing of the Initial Public Offering. In addition, $<span id="xdx_905_ecustom--UnderwritingFeePerShare_iI_c20221231_zK2XsugI7Cwc" title="Underwriting fee">0.35</span> per share, or $<span id="xdx_90D_ecustom--DeferredUnderwritingFees_c20220101__20221231_zELPdMYjGv98" title="Underwriting expense">7,043,750</span> in the aggregate was payable to the underwriter for deferred underwriting commissions. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, subject to certain conditions, the Company granted the underwriters of the Initial Public Offering, for a period of 12 months after the date of the consummation of a Business Combination, a right of first refusal to act as book-running managing underwriter or placement agent, with at least 30% of the economics, for any and all future public and private equity, convertible and debt offerings. In accordance with FINRA Rule 5110(f)(2)(E)(i), such right of first refusal shall not have a duration of more than three years from the effective date of the registration statement related to our initial public offering. Subsequently this agreement was voided.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration Rights</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The holders of the Company’s Founder Shares issued and outstanding on the date of this prospectus, as well as the holders of the Private Warrants (and underlying securities) will be entitled to registration rights pursuant to an agreement to be signed prior to or on the effective date of this offering. The holders of a majority of these securities are entitled to make up to two demands that the Company registers such securities. The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months prior to the date on which these shares of common stock are to be released from escrow. The holders of a majority of the Private Warrants (and underlying securities) can elect to exercise these registration rights at any time after the Company consummates a Business Combination. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s consummation of a Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vendor Agreements</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 18, 2021, the Company entered into an agreement with a transactional and strategic advisory firm (the “Strategic Advisor”) for advisory services as needed by the Company in connection with a Business Combination. Pursuant to this agreement, the Company incurred approximately $<span id="xdx_907_ecustom--AgreementFees_iI_c20210518__us-gaap--RelatedPartyTransactionAxis__custom--StrategicAdvisorMember_zvNG0V5QpQDi" title="Agreement fees">875,000</span> in fees. As of December 31, 2022 and December 31, 2021, $<span id="xdx_901_eus-gaap--CostsAndExpenses_c20220101__20221231_zMeUlt5I7Qtg" title="Accrued costs and expenses"><span id="xdx_900_eus-gaap--CostsAndExpenses_c20210101__20211231_zR6OqcD1l4ge" title="Accrued costs and expenses">500,000</span></span> of such fees remain unpaid and are included in accrued costs and expenses on the consolidated balance sheets. On November 1, 2021, the Company and the Strategic Advisor entered into an amendment to the agreement. Pursuant to this amendment, the Company will pay the Strategic Advisor a fee of $<span id="xdx_90C_ecustom--AdvisorFees_iI_c20211101__srt--TitleOfIndividualAxis__custom--StrategicAdviserMember_z5EeqWNIB8d" title="Advisor fees">2,625,000</span>, inclusive of the $<span id="xdx_901_ecustom--StrategicAdvisorAccruedFees_iI_c20221231_zSzKugsRFgM4" title="Accrued advisor fee"><span id="xdx_90D_ecustom--StrategicAdvisorAccruedFees_iI_c20211231_zx7aH4PT8eR" title="Accrued advisor fee">500,000</span></span> accrued as of December 31, 2022 and December 31, 2021. The remaining $<span id="xdx_900_eus-gaap--BusinessCombinationConsiderationTransferred1_c20220101__20221231_zOCjnBggXNzj" title="Business combination consideration transferred">2,125,000</span> is contingent upon the consummation of the Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October, 8, 2021, the Company entered into an agreement with a financial advisor (the “Exclusive Financial Advisor”) for financial advisory services such as financial and transaction feasibility analysis, assistance in negotiations, assistance in capital planning, and other customary services in connection with a Business Combination, pursuant to which the Company will pay the Exclusive Financial Advisor a fee of $<span id="xdx_907_ecustom--AdvisorFees_iI_c20211008__srt--TitleOfIndividualAxis__custom--ExclusiveFinancialAdvisorMember_zLSPb8RmE5cj" title="Advisor fees">1,500,000</span> contingent upon the consummation of the Business Combination. This agreement was terminated on January 31, 2023 as a result of the termination of the merger agreement between the Company and Suneva.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 1, 2021, the Company entered into an agreement with a financial advisor (the “Second Financial Advisor”) for financial advisory services such as guidance on valuation and transaction structure and terms, assistance in negotiations, coordination of due diligence, documentation, and transaction closing, and introduction of the Company to institutional investors in connection with a Business Combination, pursuant to which the Company will pay the Second Financial Advisor a fee of $<span id="xdx_906_ecustom--AdvisorFees_iI_c20211101__srt--TitleOfIndividualAxis__custom--SecondFinancialAdvisorMember_zBFsygYcnbFf" title="Advisor fees">400,000</span> contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on January 31, 2023, and there are no related contingent fees for the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 2, 2021, the Company entered into an agreement with a financial advisor (the “Third Financial Advisor”) for financial advisory services such as market related advice and assistance in connection with a Business Combination, pursuant to which the Company will pay the Third Financial Advisor a fee of $<span id="xdx_909_ecustom--AdvisorFees_iI_c20211102__srt--TitleOfIndividualAxis__custom--ThirdFinancialAdvisorMember_zJwLDoa3T66h" title="Advisor fees">500,000</span> contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on June 9, 2023, and there are no related contingent fees for the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 5, 2021, the Company entered into an agreement with an advisor (the “Advisor”) for services such as assistance in refining strategic objectives, preparation or refinement of solicitation materials, identification, contact, and solicitation of or potential investors and other sources of capital, and assistance in review, selection, negotiation, and closing of a transaction in connection with a Business Combination, pursuant to which the Company will pay the Advisor a fee of $<span id="xdx_905_ecustom--AdvisorFees_iI_c20211105_znLJKZRaN4u8" title="Advisor fees">200,000</span> contingent upon the consummation of the Business Combination. As a result of the termination of the merger agreement between the Company and Suneva, this agreement was terminated on June 19, 2023, and there are no related contingent fees for the agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--BusinessCombinationIndemnificationAssetsDescription_c20211115__20211115__us-gaap--BusinessAcquisitionAxis__custom--PlacementAgentsMember_zHURLSBhvpud" title="Business combination assets description">On November 15, 2021, the Company entered into an agreement with two placement agents (the “Placement Agents”) for services such as analysis of potential contributions and assets of a target to the Company’s future prospects, assistance in negotiations, and assistance in preparation of presentations to investors, lenders, and/or other financial sources in connection with a Business Combination, pursuant to which the Company will pay the Placement Agents a fee equal to the difference between 5% of the total aggregate sales price of the securities sold as part of the Business Combination and 5% of any securities sold as part of the Business Combination to investors identified by the Advisor, contingent upon the consummation of the Business Combination. This agreement was terminated on February 15, 2022, as a result of an automatic termination provision upon the earlier to occur of three months or the final closing of Business Combination and there are no related contingent fees for the agreement.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2022, the Company entered into an agreement with a broker-dealer (the “Broker-Dealer”) for services such as providing the Company with capital markets advisory services with regard to a forward purchase agreement, convertible private investment in public equity (“PIPE”), secured credit facility, and any other capital structure topics in connection with a Business Combination, pursuant to which the Company will pay the Broker-Dealer a fee of $<span id="xdx_903_eus-gaap--FloorBrokerage_c20220217__20220217_zBDkuKl3haw1">250,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. This agreement was terminated on June 9, 2023, as a result of the termination of the merger agreement between the Company and Suneva. Pursuant to the terms of the agreement the Broker-Dealer will remain entitled to the fee of $<span id="xdx_90A_eus-gaap--FloorBrokerageExchangeAndClearanceFees_c20220217__20220217_zTNBhT5su71g" title="Broker dealer fee">250,000</span> if a Business Combination is consummated within 24 months after the termination date. The Company is pursuing a waiver from the Broker-Dealer to waive the $<span id="xdx_90A_eus-gaap--FloorBrokerageExchangeAndClearanceFees_c20220217__20220217_z4naEXeLgXR6" title="Broker dealer fee">250,000</span> fee upon a Business Combination. As such, the fee remains contingent upon the consummation of the Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--BusinessCombinationIndemnificationAssetsDescription_c20230509__20230509__us-gaap--BusinessAcquisitionAxis__custom--PlacementAgentsMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zxvvgdrD2II6" title="Business combination assets description">On May 9, 2023, the Company entered into an agreement with a placement agent (the “Placement Agent) for services such as advising and assisting the Company in identifying one or more investors that are “accredited” or “qualified institutional buyers. Pursuant to which the Company will pay the Placement Agents a cash fee upon closing equal to eight percent (8.0%) of the gross proceeds received by the Company, contingent upon the consummation of the Business Combination.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Extension</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2022, the Company held its 2022 Annual Meeting of Stockholders for the purpose of approving: (i) a proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to (i) extend the date by which the Company has to consummate a Business Combination for three months, from March 28, 2022 (the “Original Termination Date”) to June 28, 2022 (the “Extended Date”), and (ii) allow the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with Suneva Medical, Inc. or any potential alternative initial Business Combination shall have occurred (the “Extension Proposal”); (ii) a proposal to re-elect five current directors to the Company’s Board of Directors (the “Director Election Proposal”); and (iii) a proposal to ratify the appointment of Marcum LLP as the Company’s independent registered certified public accountants for fiscal year 2020 (the “Auditor Ratification Proposal”). Stockholders voted to approve the Extension Proposal, Director Election Proposal and Auditor Ratification Proposal.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 18, 2022, stockholders elected to redeem <span id="xdx_907_eus-gaap--ExcessStockSharesIssued_iI_pid_c20220318_zT609Y1pBn07" title="Redemption payment shares (in Shares)">15,092,126</span> shares of the Company’s common stock, resulting in redemption payments out of the Trust Account totaling approximately $<span id="xdx_902_eus-gaap--AssetsHeldInTrust_iI_c20220318_zAiOnDpWADel" title="Trust account balance">152,451,819</span>. Subsequent to the redemptions, <span id="xdx_905_eus-gaap--TemporaryEquitySharesIssued_iI_pid_c20220318_zVzS19BdIHSe" title="Temporary equity shares issued">5,032,874</span> shares of common stock remained in the Trust Account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9, 2022, October 27, 2022, and November 25, 2022, the Company entered into the Note Agreements (see Note 6). The Note Agreements included Subscription Warrants (see Note 9). The entry into the Note Agreements and the terms of the Notes and Subscription Warrants was approved by the Audit Committee of the Board of Directors of the Company at a meeting held on March 21, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 23, 2022, the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State (the “Amendment”) The Amendment (i) extends the date by which the Company has to consummate a Business Combination for three months, from the Original Termination Date to the Extended Date and (ii) allows the Company, without another stockholder vote, to elect to extend the date to consummate a Business Combination on a monthly basis for up to six times by an additional one month each time after the Extended Date, upon five days’ advance notice and the deposit of $<span id="xdx_90B_eus-gaap--TimeDeposits_iI_c20220323_zoppxuIsZ6L3" title="Deposit amount">240,000</span> prior to the applicable deadline, for a total of up to nine months after the Original Termination Date, unless the closing of the proposed Business Combination with any potential initial Business Combination shall have occurred. The Amendment was approved by the Company’s stockholders at its Annual Meeting of Stockholders held on March 18, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2022, the Company held its 2022 Annual Meeting of the Stockholders in which they voted to extend the date to consummate a business combination on a monthly basis for up to six times by an additional one month each time for a total of up to six months from December 28, 2022 until June 30, 2023, upon three calendar days’ advance notice and the deposit of $<span id="xdx_90D_eus-gaap--TimeDeposits_iI_c20221231_z83DMEDxdeQa">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prior to the applicable monthly deadline, unless the closing of any potential initial business combination shall have occurred prior to the Second Extended Date. On each of December 27, 2022, January 26, 2023, February 27, 2023, March 27, 2023 and April 28, 2023, the Company deposited $<span id="xdx_903_eus-gaap--Deposits_iI_c20230428__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8HQTthyBMBa">100,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">into the Trust Account to extend the date to consummate a Business Combination through January 31, 2023, February 28, 2023, March 31, 2023, April 30, 2023 and May 31, 2023, respectively. The Company made a deposit of $<span id="xdx_903_eus-gaap--Deposits_iI_c20230524__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z16ax7bgWSg7">100,000</span> on May 24, 2023 for a one month extension until the Second Extended Date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 23, 2022, stockholders elected to redeem <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221223__20221223__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3RT7Buz1Nv2" title="Shares new issues">3,188,100</span> Public Shares, resulting in a redemption payable as of December 31, 2022 of $<span id="xdx_903_ecustom--CommonStockTenderedForRedemption_iI_c20221223__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjYYaCjA2s5c" title="Redemption of common share, value">34,004,514</span> included in common stock tendered for redemption on the consolidated balance sheet. On January 25, 2023, redemption payments out of the trust account totaled $<span id="xdx_904_ecustom--CommonStockTenderedForRedemption_iI_c20231223__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zmEhYCoYUoG4" title="Redemption of common share, value">34,004,514</span>. Subsequent to the redemptions, <span id="xdx_908_eus-gaap--TemporaryEquitySharesOutstanding_iI_c20231223__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7YKfWJAgGIe" title="Temporary equity shares outstanding">1,844,774</span> Public Shares remained.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 22, 2023, the Company held a stockholder meeting (the “June 2023 Stockholders Meeting”) in which stockholders voted to (A) amend the Company’s Amended and Restated Certificate of Incorporation, to allow the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $<span id="xdx_909_eus-gaap--Deposits_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zFzAVbcNImr6" title="Deposits">85,000</span> for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, with no additional deposits to be made into the Trust Account during such period, each such extension for an additional one month period, (the “Third Extended Date”), upon one calendar day advance notice to the Trustee, prior to the applicable monthly deadline, unless the closing of the proposed initial business combination with Clearday, Inc., or any potential alternative initial business combination shall have occurred prior to the Third Extended Date; and (B) to amend the Company’s Investment Management Trust Agreement, dated as of December 22, 2020, by and between the Company and the Trustee, allowing the Company to (i) initially extend the date by which the Company must consummate an initial business combination up to six times, each such extension for an additional one month period, until December 31, 2023, by depositing into the Trust Account, the amount of $<span id="xdx_902_eus-gaap--Deposits_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z1s0h3GMzI4a" title="Deposits">85,000</span> for each one-month extension until December 31, 2023, and (ii) further extend the date by which the Company must consummate an initial business combination (without seeking additional approval from the stockholders) for up to an additional three months, from January 1, 2024 to March 31, 2024, each such extension for an additional one month period, with no additional deposits to be made into the Trust Account during such period from January 1, 2024 through March 31, 2024. In connection with the stockholders’ vote at the June 2023 Stockholders Meeting, <span id="xdx_90D_eus-gaap--SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zHYMlsYGB1qh" title="Redemption payment shares">227,359</span> shares of common stock were tendered for redemption. As a result, approximately $<span id="xdx_904_eus-gaap--RepaymentsOfRelatedPartyDebt_pp2d_c20230622__20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zf13iEIZQ4R8" title="Repayments of related party debt">2,498,947.09</span> (approximately $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z7v5MRN8oqQ6" title="Share price">10.99</span> per share) were removed from the Company’s Trust Account to pay such holders, without taking into account additional allocation of payments to cover any tax obligation of the Company, such as franchise taxes, but not including any excise tax, since that date. Following redemptions, the Company has <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zdqc3ZNzH4Oj" title="Common stock outstanding, shares">1,617,415</span> shares of public common stock outstanding, and approximately $<span id="xdx_906_eus-gaap--AssetsHeldInTrust_iI_pp2d_c20230622__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvj1GPZYVY4g" title="Asset, held-in-trust">17,777,323.54</span> will remain in the Trust Account. <span style="background-color: white">On June 27, 2023, and July 27, 2023, the Company deposited $<span id="xdx_904_eus-gaap--Deposits_iI_c20230627__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zaUAJVntbN1e" title="Deposits"><span id="xdx_901_eus-gaap--Deposits_iI_c20230727__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zZBKopwe2n4" title="Deposits">85,000</span></span> in the Trust Account, to extend the date by which the Company can complete an initial business combination by one month to July 31, 2023 and August 31, 2023, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> 2625000 0.20 4025000 0.35 7043750 875000 500000 500000 2625000 500000 500000 2125000 1500000 400000 500000 200000 On November 15, 2021, the Company entered into an agreement with two placement agents (the “Placement Agents”) for services such as analysis of potential contributions and assets of a target to the Company’s future prospects, assistance in negotiations, and assistance in preparation of presentations to investors, lenders, and/or other financial sources in connection with a Business Combination, pursuant to which the Company will pay the Placement Agents a fee equal to the difference between 5% of the total aggregate sales price of the securities sold as part of the Business Combination and 5% of any securities sold as part of the Business Combination to investors identified by the Advisor, contingent upon the consummation of the Business Combination. This agreement was terminated on February 15, 2022, as a result of an automatic termination provision upon the earlier to occur of three months or the final closing of Business Combination and there are no related contingent fees for the agreement. 250000 250000 250000 On May 9, 2023, the Company entered into an agreement with a placement agent (the “Placement Agent) for services such as advising and assisting the Company in identifying one or more investors that are “accredited” or “qualified institutional buyers. Pursuant to which the Company will pay the Placement Agents a cash fee upon closing equal to eight percent (8.0%) of the gross proceeds received by the Company, contingent upon the consummation of the Business Combination. 15092126 152451819 5032874 240000 100000 100000 100000 3188100 34004514 34004514 1844774 85000 85000 227359 2498947.09 10.99 1617415 17777323.54 85000 85000 <p id="xdx_80A_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z2Ymsw2JJah1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8. <span id="xdx_826_zEhFs5ExhCdj">STOCKHOLDERS’ DEFICIT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Preferred stock </i></b>— The Company is authorized to issue <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_ztoOTAOkIjHk" title="Preferred stock, shares authorized"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20211231_z0yzUqQcf2U3" title="Preferred stock, shares authorized">1,000,000</span></span> shares of preferred stock with a par value of $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231_ziWBkufhpBtg" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20211231_zcyUIFMxx9e7" title="Preferred stock, par value">0.0001</span></span> and with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of December 31, 2022 and December 31, 2021, there was <span id="xdx_901_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20221231_z4xGl7d8BQol" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20221231_z26bTRLpiQkg" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_iI_pid_do_c20211231_zORdJnO6gM39" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20211231_zS5nczU12Gdk" title="Preferred stock, shares outstanding">no</span></span></span></span> preferred stock issued or outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common stock </i></b>— The Company is authorized to issue <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_zHIXH7V2FpW3" title="Common stock, shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20211231_ze4imj1r0mY" title="Common stock, shares authorized">60,000,000</span></span> shares of common stock with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zmxnOzbs1qRi" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20211231_zKnNFAI1H8ek" title="Common stock, par value">0.0001</span></span> per share. <span id="xdx_909_eus-gaap--CommonStockVotingRights_c20220101__20221231_zDKYnrfXPkM7" title="Voting rights">Holders are entitled to one vote for each share</span> of common stock. As of December 31, 2022 and December 31, 2021, there were <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pid_c20221231_zkJN0yexWxOk" title="Common stock, shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20221231_zYyOkmEzXL77" title="Common stock, shares outstanding"><span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20211231_zQdfSsYItaQe" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20211231_zknBsgKYh5fl" title="Common stock, shares outstanding">5,031,250</span></span></span></span> shares of common stock issued and outstanding, excluding <span id="xdx_904_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20221231_zk5tmmFrJIy6" title="Temporary equity shares outstanding">1,844,774</span> and <span id="xdx_90F_eus-gaap--TemporaryEquitySharesOutstanding_iI_pid_c20211231_zpaJ7uP1ef2h" title="Temporary equity shares outstanding">20,125,000</span> shares of common stock subject to possible redemption, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Rights </i></b>— Except in cases where the Company is not the surviving company in a Business Combination, each holder of a Right will automatically receive one-twentieth (1/20) of a share of common stock upon consummation of the initial Business Combination. In the event the Company will not be the surviving company upon completion of the initial Business Combination, each holder of a Right will be required to affirmatively convert his, her or its rights in order to receive the one-twentieth (1/20) of a share underlying each right upon consummation of the Business Combination. The Company will not issue fractional shares in connection with an exchange of Rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of the Delaware General Corporation Law. As a result, holders must hold Rights in multiples of 20 in order to receive shares for all Rights upon closing of a Business Combination. If the Company is unable to complete an initial Business Combination within the required time period and the Company redeems the Public Shares for the funds held in the Trust Account, holders of Rights will not receive any of such funds for their Rights and the Rights will expire worthless.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1000000 1000000 0.0001 0.0001 0 0 0 0 60000000 60000000 0.0001 0.0001 Holders are entitled to one vote for each share 5031250 5031250 5031250 5031250 1844774 20125000 <p id="xdx_805_ecustom--WarrantsAndRightsDisclosureTextBlock_z4iqje4oLBll" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9. <span id="xdx_82A_zv7JQ59P1211">WARRANTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each Public Warrant entitles the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221231_znonZtPVCUO2" title="Exercise price of warrants">11.50</span> per whole share, subject to adjustment. Pursuant to the warrant agreement, a warrant holder may exercise its s only for a whole number of shares. This means that only an even number of s may be exercised at any given time by a warrant holder.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may call the Public Warrants for redemption (except the Private Warrants):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: top; text-align: left"> <td style="width: 0.25in"> </td> <td style="width: 0.25in">●</td> <td>in whole and not in part;</td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td>●</td> <td>at a price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZNrX4RF7sjj" title="Price per warrant">0.01</span> per warrant;</td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td>●</td> <td style="text-align: justify"> upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and</td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top; text-align: left"> <td> </td> <td>●</td> <td style="text-align: justify">if and only if, there is a current registration statement in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading period referred to above and continuing each day thereafter until the date of redemption.</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company calls the Public Warrants for redemption as described above, its management will have the option to require all holders that wish to exercise Public Warrants to do so on a “cashless basis.” In such event, each holder would pay the exercise price by surrendering the Public Warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the Public Warrants, multiplied by the difference between the exercise price of the Public Warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the Company’s common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of Public Warrants. Whether the Company will exercise its option to require all holders to exercise their Public Warrants on a “cashless basis” will depend on a variety of factors including the price of our common shares at the time the Public Warrants are called for redemption, its cash needs at such time and concerns regarding dilutive share issuances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--BusinessCombinationControlObtainedDescription_c20220101__20221231_zaI7OFpQdiK" title="Business combination equity description">If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZdx49x6Heak" title="Shares issued price">9.50</span> per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its Sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial Business Combination on the date of the consummation of our initial Business Combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $<span id="xdx_908_eus-gaap--DebtInstrumentConvertibleStockPriceTrigger_pid_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zrUbCl5VWH53" title="Redemption price per share">16.50</span> per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value.</span> The Public Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to the Company, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of holders of shares of common stock and any voting rights until they exercise their Public Warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the Public Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Private Warrants are identical to the Public Warrants except that the Private Warrants will be non-redeemable and may be exercised on a cashless basis, in each case so long as they continue to be held by the initial purchasers or their permitted transferees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subscription Warrants</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Subscription Warrant term commences on the Exercise Date (as hereinafter defined) for a period of 49 months. The Subscription Warrants are exercisable commencing on the date of the initial Business Combination (the “Exercise Date”) and have a cashless exercise feature that is available at any time on or after the Exercise Date. Commencing on the date 13 months following the Exercise Date, the subscribers have the right, but not the obligation, to put the Subscription Warrants to the Company at a purchase price of $<span id="xdx_906_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEYLRy1A2QI5" title="Purchase price per warrant">5.00</span> per share. The Company has agreed to file, within thirty (30) calendar days after the consummation of an initial Business Combination, a registration statement with the Securities and Exchange Commission to register for resale the shares of common stock underlying the Subscription Warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and December 31, 2021, there were <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMIsg8atdkCg" title="Warrants outstanding"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zNzN6tZTIzvl" title="Warrants outstanding">20,125,000</span></span> Public Warrants and <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zpu8BvVY2tyl" title="Warrants outstanding"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zirqDFiG6d5j" title="Warrants outstanding">18,000,000</span></span> Private Warrants outstanding. As of December 31, 2022, there were <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20221231_zwUqCB9NnVk5" title="Warrants outstanding">2,000,000</span> Subscription Warrants outstanding. The Company accounts for the Public Warrants, Private Warrants, and Subscription Warrants in accordance with the guidance contained in ASC 815-40. The Public Warrants qualify for equity treatment under ASC 815-40. Such guidance provides that because the Private Warrants and Subscription Warrants do not meet the criteria for equity treatment thereunder, the Private Warrants and Subscription Warrants must be recorded as a liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  </span></p> 11.50 0.01 If (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of its initial Business Combination at an issue price or effective issue price of less than $9.50 per share of common stock (with such issue price or effective issue price to be determined in good faith by its board of directors, and in the case of any such issuance to its Sponsor, initial stockholders or their affiliates, without taking into account any founders’ shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial Business Combination on the date of the consummation of our initial Business Combination (net of redemptions), and (z) the Market Value is below $9.50 per share, the exercise price of the Public Warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional shares of common stock or equity-linked securities and the $16.50 per share redemption trigger price described above will be adjusted (to the nearest cent) to be equal to 165% of the Market Value. 9.50 16.50 5.00 20125000 20125000 18000000 18000000 2000000 <p id="xdx_80D_eus-gaap--FairValueDisclosuresTextBlock_zWBikx9RnR9k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10. <span id="xdx_827_zTjlfBLZRwmf">FAIR VALUE MEASUREMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 and December 31, 2021, and indicate the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zj49GTvpo3Pe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zcsZCkCPrWZk" style="display: none">SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amount at</p> <p style="margin-top: 0; margin-bottom: 0">Fair Value</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 40%; text-align: left">Money Market Account</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoYVJ2LiiqI2" style="width: 11%; text-align: right" title="Assets">6,346</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8BJHgQFItLk" style="width: 11%; text-align: right" title="Assets">6,346</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zn60VVHFUXGj" style="width: 11%; text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0989">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLAuPBUUIPma" style="width: 11%; text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0991">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Money Market Funds held in Trust Account</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketFundsHeldInTrustAccountMember_z4sVH3fMZFl" style="text-align: right" title="Assets">53,815,395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketFundsHeldInTrustAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z0AdRGQXy9al" style="text-align: right" title="Assets">53,815,395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketFundsHeldInTrustAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEmW9xf58ai" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0997">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketFundsHeldInTrustAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlrWnvxwmk85" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Private Warrant Liability</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember_zV8vYb6jCz2k" style="text-align: right" title="Liabilities">900,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxdZgvTbnq56" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1003">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z69oqQ55DtF7" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1005">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3Gl2g6WTbM4" style="text-align: right" title="Liabilities">900,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Subscription Warrant Liability</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantLiabilityMember_z2jh3u7DDJE6" style="text-align: right" title="Liabilities">1,635,515</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEAN9P2QvH84" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1011">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUOBz0Thbwnl" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1013">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSAVshzqIU76" style="text-align: right" title="Liabilities">1,635,515</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Money Market Account</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_znzFfvDrelG9" style="text-align: right" title="Assets">350,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTZMceeTB1N4" style="text-align: right" title="Assets">350,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zodUdxN6RJg" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl1021">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAuQz89U8Vv1" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl1023">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Mutual Funds held in Trust Account</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MutualFundMember_zOrkk5Gar7Ld" style="text-align: right" title="Assets">203,282,989</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MutualFundMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zV2YR7Ddytsa" style="text-align: right" title="Assets">203,282,989</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MutualFundMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUZszGPbwYq" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl1029">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MutualFundMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z306bmgyoqI1" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl1031">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Private Warrant Liability</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember_zFiJRaY7r97f" style="text-align: right" title="Liabilities">4,188,221</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zN1OX7ZlgQX" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1035">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztbygXytbWF8" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1037">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEDBBGmTtyrd" style="text-align: right" title="Liabilities">4,188,221</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zpQXlyoPz2u1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Private Warrants and Subscription Warrants are accounted for as liabilities in accordance with ASC 815-40 and are presented within warrant liabilities on the consolidated balance sheets. The warrant liabilities were measured at fair value at inception and on a recurring basis, with changes in fair value presented within change in fair value of warrant liabilities in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company established the initial fair value of the Private Warrants on December 28, 2020, the date of the Company’s Initial Public Offering, and revalued on December 31, 2022 and on December 31, 2021, using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement date, on December 31, 2022 and on December 31, 2021 due to the use of unobservable inputs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zjMyyZ1iCXgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The key inputs into the Monte Carlo simulation for the Private Warrants as of December 31, 2022 and December 31, 2021 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z457I3Wl9kSd" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Inputs</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">As of</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">As of</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjeamdHFZaNg" title="Warrants and rights outstanding, measurement input">4.39</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdpXTwO56DOe" title="Warrants and rights outstanding, measurement input">1.30</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term remaining (years)<sup>1</sup></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--WarrantsAndRightsTerm_dtY_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyxBI7V18AY7" title="Warrants and rights term">2.11</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--WarrantsAndRightsTerm_dtY_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUYI0Slw0a2d" title="Warrants and rights term">5.50</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zneWVB7vL9Ng" title="Warrants and rights outstanding, measurement input">0.01</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zllzPOlp6eI8" title="Warrants and rights outstanding, measurement input">7.6</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zls5z98mV1s5" title="Warrants and rights outstanding, measurement input">10.650</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zQxu0wIwFsm6" title="Warrants and rights outstanding, measurement input">10.020</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A8_zmMN2St6mgri" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company established the initial fair value of the Subscription Warrants on March 21, 2022, March 23, 2022, April 4, 2022, April 27, 2022, May 9,2022, October 27,2022, and November 25,2022 the dates of issuance, and revalued on December 31, 2022, using a Monte Carlo simulation model. The Warrants were classified as Level 3 at the initial measurement dates, and on December 31, 2022 due to the use of unobservable inputs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt"> </div></div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1 </sup>The contractual term of the Private Warrants is <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivateWarrantMember_zibBR8m7FVe7" title="Contractual term">5 years</span> from the closing of a Business Combination. As of December 31, 2022 the expected term remaining of the Private Warrants was calculated based on assumptions for both a successful and unsuccessful Business Combination resulting in a weighted expected term remaining of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivateWarrantMember_zvBNhhQx9j6f" title="Exercise price">2.11</span>. This was calculated using an expected term remaining with an unsuccessful Business Combination of <span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_dtY_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivateWarrantMember__us-gaap--BusinessAcquisitionAxis__custom--UnsucessfulBusinessCombinationMember_zKGCdEewxEq1" title="Contractual term">1.00</span> year (weighted at <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivateWarrantMember__us-gaap--BusinessAcquisitionAxis__custom--UnsuccessfulBusinessCombinationMember_zKro2aRXmGn8" title="Probability">75.5</span>% probability) and a successful business combination term remaining of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivateWarrantMember__us-gaap--BusinessAcquisitionAxis__custom--SuccessfulBusinessCombinationMember_z09oKpxMQSe4" title="Contractual term">5.52</span> years (weighted at <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20221231__us-gaap--SubsidiarySaleOfStockAxis__custom--PrivateWarrantMember__us-gaap--BusinessAcquisitionAxis__custom--SuccessfulBusinessCombinationMember_zNruPidZabak" title="Probability">24.5</span>% probability). Prior to December 31, 2022 the expected term was calculated using only assumptions for a successful Business Combination. The change in the calculation was made as using an expected term that was calculated based only on the assumption that the Business Combination would be successful as an input under the Monte Carlo simulation model resulted in an unsolvable expected volatility under the Monte Carlo simulation model.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember_zyexreLvWtrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The key inputs into the Monte Carlo simulation for the Subscription Warrants as of December 31, 2022 and the issuance dates were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zoho1K9Y1Sz8" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-size: 8pt">Inputs</span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">December 31,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">November 25,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">October 27,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">May 9,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">April 27,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">April 4,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">March 23,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">March 21,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left"><span style="font-size: 8pt">Risk-free interest rate</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">               <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z3LkM9st199k" title="Warrants and rights outstanding, measurement input">4.04</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">            <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zeyNxWeInJj5" title="Warrants and rights outstanding, measurement input">3.90</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">            <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvavKs88Nzs2" title="Warrants and rights outstanding, measurement input">4.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">            <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zFSdu80hFmOf" title="Warrants and rights outstanding, measurement input">2.92</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">           <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zo3YgRYvlPse" title="Warrants and rights outstanding, measurement input">2.80</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">           <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBk67jJqWUt8" title="Warrants and rights outstanding, measurement input">2.57</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">           <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z3Ho7NxYUm55" title="Warrants and rights outstanding, measurement input">2.33</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">            <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zPLiy9XH9YX5" title="Warrants and rights outstanding, measurement input">2.33</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Market debt rate<sup>1</sup></span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____zEkA3BoGg4Ii" title="Warrants and rights outstanding, measurement input">9.19</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____zyHUJibvclPh" title="Warrants and rights outstanding, measurement input">8.70</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____z2Wqs5PPMs79" title="Warrants and rights outstanding, measurement input">9.64</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____zFlLywpYpKBc" title="Warrants and rights outstanding, measurement input">7.49</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____z2yoBItP7E4" title="Warrants and rights outstanding, measurement input">6.75</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____zdQRvvDVxbcg" title="Warrants and rights outstanding, measurement input">6.09</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 8pt">Expected term remaining (years)</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--WarrantsAndRightsTerm_dtY_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfo9ZnoITeGb" title="Warrants and rights term">4.60</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--WarrantsAndRightsTerm_dtY_c20221125__20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zIx93owEU3u2" title="Warrants and rights term">4.70</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90E_ecustom--WarrantsAndRightsTerm_dtY_c20221027__20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zosAMPpzoxhc" title="Warrants and rights term">4.78</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90F_ecustom--WarrantsAndRightsTerm_dtY_c20220509__20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_ztEUgSwU4vD9" title="Warrants and rights term">4.56</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_901_ecustom--WarrantsAndRightsTerm_dtY_c20220427__20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zigXXDrqXSbd" title="Warrants and rights term">4.60</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90A_ecustom--WarrantsAndRightsTerm_dtY_c20220404__20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zLScUdItQag3" title="Warrants and rights term">4.66</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_900_ecustom--WarrantsAndRightsTerm_dtY_c20220323__20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgHZ9DuPPPV6" title="Warrants and rights term">4.44</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_905_ecustom--WarrantsAndRightsTerm_dtY_c20220321__20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfi6HGeFCG2" title="Warrants and rights term">4.44</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 8pt">Expected volatility</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zUggz7ubJHCe" title="Warrants and rights outstanding, measurement input">0.01</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zsR58sfCVHDi" title="Warrants and rights outstanding, measurement input">1.38</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221027__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7Urbi67DMEj" title="Warrants and rights outstanding, measurement input">4.89</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zXcMByIy9aFe" title="Warrants and rights outstanding, measurement input">1.0</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zujEhiDNwn4i" title="Warrants and rights outstanding, measurement input">1.0</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbWItbxxFpth" title="Warrants and rights outstanding, measurement input">1.0</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEb9kB6oQi5" title="Warrants and rights outstanding, measurement input">2.5</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zH91NU7xeKs8" title="Warrants and rights outstanding, measurement input">2.4</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 8pt">Probability of completing a Business Combination</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zIdgtVzJTx49" title="Warrants and rights outstanding, measurement input">24.5</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_znhoX55zwt3e" title="Warrants and rights outstanding, measurement input">23.9</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zVR7KaRf0LZ6" title="Warrants and rights outstanding, measurement input">14.4</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zlXbcPl4Q6qd" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zVYbH8HHV40h" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_z5446rNmAdvi" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_z87eAEL6yo0a" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zmdmdWbQ4lo3" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 8pt">Stock price</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zcz8Pa2bgST4" title="Warrants and rights outstanding, measurement input">10.650</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPdNZ8iupY07" title="Warrants and rights outstanding, measurement input">10.470</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zHcyQWJBDXEd" title="Warrants and rights outstanding, measurement input">10.400</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zEHHDc3KY0bd" title="Warrants and rights outstanding, measurement input">10.220</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zmyialsNqjbb" title="Warrants and rights outstanding, measurement input">10.220</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uShares_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zQsKt5KGAZIj" title="Warrants and rights outstanding, measurement input">10.170</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z3ee3TeQ3XOh" title="Warrants and rights outstanding, measurement input">10.080</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z4bKjTHphHHk" title="Warrants and rights outstanding, measurement input">10.080</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right"><span id="xdx_F00_zU7ARoLI4k46" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_zartoDiiKF02" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company changed its valuation technique to incorporate the market debt rate as a significant input to the Monte Carlo simulation for the valuation of the Subscription Warrants as of December 31, 2022, November 25, 2022, October 27, 2022, May 9, 2022, April 27, 2022, and April 4, 2022. In the case that the Subscription Warrants were exercised, the risk-free interest rate was used. In the case that the put option was exercised, the market debt rate was used. The risk-free interest rate was used in both scenarios in the Monte Carlo simulation for the valuation of the Subscription Warrants as of March 23, 2022 and March 21, 2022.</span></td> </tr></table> <p id="xdx_8A6_zYWdkKU378P8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zrpPvcZ7kE43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables presents the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zgpxgCNriCOb" style="display: none">SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value as of December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20210101__20211231_zbk0KhejtI03" style="width: 16%; text-align: right" title="Fair value as of beginning">10,763,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20210101__20211231_zhBO6Xcy82Y6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(6,575,140</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20210101__20211231_zRXQ4UVokKck" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value as of ending">4,188,221</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231_zDsM3ezjMYRf" style="width: 16%; text-align: right" title="Fair value as of beginning">4,188,221</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on March 21, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnMarchTwentyOneTwentyTwentyTwoMember_zwmOVOl2DoI4" style="text-align: right" title="Fair value of Subscription Warrants">5,370,185</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on March 23, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnMarchTwentyThreeTwentyTwentyTwoMember_zisGyeyAZ5qh" style="text-align: right" title="Fair value of Subscription Warrants">337,991</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on April 4, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnAprilFourTwentyTwentyTwoMember_zGCOuxNEuLDh" style="text-align: right" title="Fair value of Subscription Warrants">341,967</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on April 27, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnAprilTwentySevenTwentyTwentyTwoMember_zn8FegD5Amf5" style="text-align: right" title="Fair value of Subscription Warrants">417,037</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on May 9, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnMayNineTwentyTwentyTwoMember_zmzwzwnjHupa" style="text-align: right" title="Fair value of Subscription Warrants">162,003</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on October 27, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnOctoberTwentySevenTwentyTwentyTwoMember_zr7UW7mc4lMe" style="text-align: right" title="Fair value of Subscription Warrants">65,326</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on November 25, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnNovemberTwentyFiveTwentyTwentyTwoMember_zWKgU6u76jsi" style="text-align: right" title="Fair value of Subscription Warrants">121,093</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231_zDVkNBLHKzC3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(8,468,308</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20220101__20221231_zLGtF5n8X8n4" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value as of ending">2,535,515</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zKdUKNoB5PH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VIVEON HEALTH ACQUISITION CORP.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized a loss in connection with changes in the fair value of the Private and Subscription Warrants of $<span id="xdx_905_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateAndSubscriptionWarrantsMember_zDPRi2CsXkHk" title="Recognized gain (loss) in fair value">8,468,308</span> for the year ended December 31, 2022, within gain on change in fair value of warrant liabilities in the statements of operations. The Company recognized gains in connection with the changes in the fair value of the Private Warrants of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_iN_di_c20210101__20211231__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateAndSubscriptionWarrantsMember_zurodKAnDD17" title="Recognized gain (loss) in fair value">6,575,140</span> for the year ended December 31, 2021 within gain on change in fair value of warrant liabilities in the consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zj49GTvpo3Pe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zcsZCkCPrWZk" style="display: none">SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amount at</p> <p style="margin-top: 0; margin-bottom: 0">Fair Value</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; width: 40%; text-align: left">Money Market Account</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_zoYVJ2LiiqI2" style="width: 11%; text-align: right" title="Assets">6,346</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z8BJHgQFItLk" style="width: 11%; text-align: right" title="Assets">6,346</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zn60VVHFUXGj" style="width: 11%; text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0989">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zLAuPBUUIPma" style="width: 11%; text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0991">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Money Market Funds held in Trust Account</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketFundsHeldInTrustAccountMember_z4sVH3fMZFl" style="text-align: right" title="Assets">53,815,395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketFundsHeldInTrustAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z0AdRGQXy9al" style="text-align: right" title="Assets">53,815,395</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketFundsHeldInTrustAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zEmW9xf58ai" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0997">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__custom--MoneyMarketFundsHeldInTrustAccountMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zlrWnvxwmk85" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl0999">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Private Warrant Liability</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember_zV8vYb6jCz2k" style="text-align: right" title="Liabilities">900,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zxdZgvTbnq56" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1003">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z69oqQ55DtF7" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1005">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z3Gl2g6WTbM4" style="text-align: right" title="Liabilities">900,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Subscription Warrant Liability</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantLiabilityMember_z2jh3u7DDJE6" style="text-align: right" title="Liabilities">1,635,515</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zEAN9P2QvH84" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1011">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUOBz0Thbwnl" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1013">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSAVshzqIU76" style="text-align: right" title="Liabilities">1,635,515</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">December 31, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Money Market Account</td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember_znzFfvDrelG9" style="text-align: right" title="Assets">350,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTZMceeTB1N4" style="text-align: right" title="Assets">350,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zodUdxN6RJg" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl1021">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zAuQz89U8Vv1" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl1023">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Mutual Funds held in Trust Account</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MutualFundMember_zOrkk5Gar7Ld" style="text-align: right" title="Assets">203,282,989</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MutualFundMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zV2YR7Ddytsa" style="text-align: right" title="Assets">203,282,989</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MutualFundMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zUZszGPbwYq" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl1029">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--AssetsFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByAssetClassAxis__us-gaap--MutualFundMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z306bmgyoqI1" style="text-align: right" title="Assets"><span style="-sec-ix-hidden: xdx2ixbrl1031">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left">Private Warrant Liability</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember_zFiJRaY7r97f" style="text-align: right" title="Liabilities">4,188,221</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zN1OX7ZlgQX" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1035">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ztbygXytbWF8" style="text-align: right" title="Liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1037">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_c20211231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByLiabilityClassAxis__custom--PrivateWarrantLiabilityMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zEDBBGmTtyrd" style="text-align: right" title="Liabilities">4,188,221</td><td style="text-align: left"> </td></tr> </table> 6346 6346 53815395 53815395 900000 900000 1635515 1635515 350455 350455 203282989 203282989 4188221 4188221 <p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember_zjMyyZ1iCXgi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The key inputs into the Monte Carlo simulation for the Private Warrants as of December 31, 2022 and December 31, 2021 were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_z457I3Wl9kSd" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Inputs</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">As of</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2022</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">As of</p> <p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Risk-free interest rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjeamdHFZaNg" title="Warrants and rights outstanding, measurement input">4.39</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zdpXTwO56DOe" title="Warrants and rights outstanding, measurement input">1.30</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term remaining (years)<sup>1</sup></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90E_ecustom--WarrantsAndRightsTerm_dtY_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zyxBI7V18AY7" title="Warrants and rights term">2.11</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_ecustom--WarrantsAndRightsTerm_dtY_c20210101__20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zUYI0Slw0a2d" title="Warrants and rights term">5.50</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zneWVB7vL9Ng" title="Warrants and rights outstanding, measurement input">0.01</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zllzPOlp6eI8" title="Warrants and rights outstanding, measurement input">7.6</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Stock price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zls5z98mV1s5" title="Warrants and rights outstanding, measurement input">10.650</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20211231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivateWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zQxu0wIwFsm6" title="Warrants and rights outstanding, measurement input">10.020</span></td><td style="text-align: left"> </td></tr> </table> 4.39 1.30 P2Y1M9D P5Y6M 0.01 7.6 10.650 10.020 P5Y 2.11 P1Y 75.5 P5Y6M7D 24.5 <p id="xdx_89A_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember_zyexreLvWtrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The key inputs into the Monte Carlo simulation for the Subscription Warrants as of December 31, 2022 and the issuance dates were as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zoho1K9Y1Sz8" style="display: none">SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="font-size: 8pt">Inputs</span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">December 31,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">November 25,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">October 27,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">May 9,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">April 27,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">April 4,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">March 23,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">As of</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">March 21,</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 8pt">2022 (Initial Measurement)</span></p></td><td style="font-weight: bold"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 28%; text-align: left"><span style="font-size: 8pt">Risk-free interest rate</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">               <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z3LkM9st199k" title="Warrants and rights outstanding, measurement input">4.04</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">            <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zeyNxWeInJj5" title="Warrants and rights outstanding, measurement input">3.90</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">            <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zvavKs88Nzs2" title="Warrants and rights outstanding, measurement input">4.11</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">            <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zFSdu80hFmOf" title="Warrants and rights outstanding, measurement input">2.92</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"><span style="font-size: 8pt"> </span></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">           <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zo3YgRYvlPse" title="Warrants and rights outstanding, measurement input">2.80</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">           <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBk67jJqWUt8" title="Warrants and rights outstanding, measurement input">2.57</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">           <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z3Ho7NxYUm55" title="Warrants and rights outstanding, measurement input">2.33</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td><td style="width: 2%"><span style="font-size: 8pt"> </span></td> <td style="width: 1%; text-align: left"></td><td style="width: 5%; text-align: right"><span style="font-size: 8pt">            <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zPLiy9XH9YX5" title="Warrants and rights outstanding, measurement input">2.33</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 8pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Market debt rate<sup>1</sup></span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____zEkA3BoGg4Ii" title="Warrants and rights outstanding, measurement input">9.19</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____zyHUJibvclPh" title="Warrants and rights outstanding, measurement input">8.70</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____z2Wqs5PPMs79" title="Warrants and rights outstanding, measurement input">9.64</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____zFlLywpYpKBc" title="Warrants and rights outstanding, measurement input">7.49</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____z2yoBItP7E4" title="Warrants and rights outstanding, measurement input">6.75</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputMarketDebtRateMember_fMQ_____zdQRvvDVxbcg" title="Warrants and rights outstanding, measurement input">6.09</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 8pt">Expected term remaining (years)</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--WarrantsAndRightsTerm_dtY_c20220101__20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfo9ZnoITeGb" title="Warrants and rights term">4.60</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90B_ecustom--WarrantsAndRightsTerm_dtY_c20221125__20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zIx93owEU3u2" title="Warrants and rights term">4.70</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90E_ecustom--WarrantsAndRightsTerm_dtY_c20221027__20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zosAMPpzoxhc" title="Warrants and rights term">4.78</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90F_ecustom--WarrantsAndRightsTerm_dtY_c20220509__20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_ztEUgSwU4vD9" title="Warrants and rights term">4.56</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_901_ecustom--WarrantsAndRightsTerm_dtY_c20220427__20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zigXXDrqXSbd" title="Warrants and rights term">4.60</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90A_ecustom--WarrantsAndRightsTerm_dtY_c20220404__20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zLScUdItQag3" title="Warrants and rights term">4.66</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_900_ecustom--WarrantsAndRightsTerm_dtY_c20220323__20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zgHZ9DuPPPV6" title="Warrants and rights term">4.44</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_905_ecustom--WarrantsAndRightsTerm_dtY_c20220321__20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfi6HGeFCG2" title="Warrants and rights term">4.44</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-size: 8pt">Expected volatility</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zUggz7ubJHCe" title="Warrants and rights outstanding, measurement input">0.01</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zsR58sfCVHDi" title="Warrants and rights outstanding, measurement input">1.38</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221027__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z7Urbi67DMEj" title="Warrants and rights outstanding, measurement input">4.89</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zXcMByIy9aFe" title="Warrants and rights outstanding, measurement input">1.0</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zujEhiDNwn4i" title="Warrants and rights outstanding, measurement input">1.0</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zbWItbxxFpth" title="Warrants and rights outstanding, measurement input">1.0</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zEb9kB6oQi5" title="Warrants and rights outstanding, measurement input">2.5</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zH91NU7xeKs8" title="Warrants and rights outstanding, measurement input">2.4</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-size: 8pt">Probability of completing a Business Combination</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zIdgtVzJTx49" title="Warrants and rights outstanding, measurement input">24.5</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_znhoX55zwt3e" title="Warrants and rights outstanding, measurement input">23.9</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zVR7KaRf0LZ6" title="Warrants and rights outstanding, measurement input">14.4</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zlXbcPl4Q6qd" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zVYbH8HHV40h" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_z5446rNmAdvi" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_z87eAEL6yo0a" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt"> </span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__custom--MeasurementInputProbabilityOfCompletingABusinessCombinationMember_zmdmdWbQ4lo3" title="Warrants and rights outstanding, measurement input">90</span></span></td><td style="text-align: left"><span style="font-size: 8pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-size: 8pt">Stock price</span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20221231__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zcz8Pa2bgST4" title="Warrants and rights outstanding, measurement input">10.650</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20221125__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPdNZ8iupY07" title="Warrants and rights outstanding, measurement input">10.470</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20221027__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zHcyQWJBDXEd" title="Warrants and rights outstanding, measurement input">10.400</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20220509__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zEHHDc3KY0bd" title="Warrants and rights outstanding, measurement input">10.220</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20220427__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zmyialsNqjbb" title="Warrants and rights outstanding, measurement input">10.220</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uShares_c20220404__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zQsKt5KGAZIj" title="Warrants and rights outstanding, measurement input">10.170</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td><span style="font-size: 8pt"> </span></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uUSDPShares_c20220323__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z3ee3TeQ3XOh" title="Warrants and rights outstanding, measurement input">10.080</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td><td></td> <td style="text-align: left"><span style="font-size: 8pt">$</span></td><td style="text-align: right"><span style="font-size: 8pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20220321__us-gaap--ClassOfWarrantOrRightAxis__custom--SubscriptionWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z4bKjTHphHHk" title="Warrants and rights outstanding, measurement input">10.080</span></span></td><td style="text-align: left"><span style="font-size: 8pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: right"><span id="xdx_F00_zU7ARoLI4k46" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1</sup></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span id="xdx_F13_zartoDiiKF02" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company changed its valuation technique to incorporate the market debt rate as a significant input to the Monte Carlo simulation for the valuation of the Subscription Warrants as of December 31, 2022, November 25, 2022, October 27, 2022, May 9, 2022, April 27, 2022, and April 4, 2022. In the case that the Subscription Warrants were exercised, the risk-free interest rate was used. In the case that the put option was exercised, the market debt rate was used. The risk-free interest rate was used in both scenarios in the Monte Carlo simulation for the valuation of the Subscription Warrants as of March 23, 2022 and March 21, 2022.</span></td> </tr></table> 4.04 3.90 4.11 2.92 2.80 2.57 2.33 2.33 9.19 8.70 9.64 7.49 6.75 6.09 P4Y7M6D P4Y8M12D P4Y9M10D P4Y6M21D P4Y7M6D P4Y7M28D P4Y5M8D P4Y5M8D 0.01 1.38 4.89 1.0 1.0 1.0 2.5 2.4 24.5 23.9 14.4 90 90 90 90 90 10.650 10.470 10.400 10.220 10.220 10.170 10.080 10.080 <p id="xdx_890_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zrpPvcZ7kE43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables presents the changes in the fair value of the Company’s Level 3 financial instruments that are measured at fair value:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zgpxgCNriCOb" style="display: none">SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value as of December 31, 2020</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20210101__20211231_zbk0KhejtI03" style="width: 16%; text-align: right" title="Fair value as of beginning">10,763,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20210101__20211231_zhBO6Xcy82Y6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(6,575,140</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2021</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20210101__20211231_zRXQ4UVokKck" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value as of ending">4,188,221</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%">Fair value as of December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_c20220101__20221231_zDsM3ezjMYRf" style="width: 16%; text-align: right" title="Fair value as of beginning">4,188,221</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on March 21, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnMarchTwentyOneTwentyTwentyTwoMember_zwmOVOl2DoI4" style="text-align: right" title="Fair value of Subscription Warrants">5,370,185</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on March 23, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnMarchTwentyThreeTwentyTwentyTwoMember_zisGyeyAZ5qh" style="text-align: right" title="Fair value of Subscription Warrants">337,991</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on April 4, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnAprilFourTwentyTwentyTwoMember_zGCOuxNEuLDh" style="text-align: right" title="Fair value of Subscription Warrants">341,967</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on April 27, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnAprilTwentySevenTwentyTwentyTwoMember_zn8FegD5Amf5" style="text-align: right" title="Fair value of Subscription Warrants">417,037</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on May 9, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnMayNineTwentyTwentyTwoMember_zmzwzwnjHupa" style="text-align: right" title="Fair value of Subscription Warrants">162,003</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on October 27, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnOctoberTwentySevenTwentyTwentyTwoMember_zr7UW7mc4lMe" style="text-align: right" title="Fair value of Subscription Warrants">65,326</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of Subscription Warrants at issuance on November 25, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_c20220101__20221231__us-gaap--FairValueByLiabilityClassAxis__custom--SubscriptionWarrantsAtIssuanceOnNovemberTwentyFiveTwentyTwentyTwoMember_zWKgU6u76jsi" style="text-align: right" title="Fair value of Subscription Warrants">121,093</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Change in fair value</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_iN_di_c20220101__20221231_zDVkNBLHKzC3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Change in fair value">(8,468,308</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Fair value as of December 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_c20220101__20221231_zLGtF5n8X8n4" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value as of ending">2,535,515</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10763361 6575140 4188221 4188221 5370185 337991 341967 417037 162003 65326 121093 8468308 2535515 -8468308 -6575140 <p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zzC1sM9oeVkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11. <span id="xdx_820_zQ4Fsd8ps6Na">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzQ3yLcof409" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s net deferred tax assets (liabilities) as of December 31, 2022 and December 31, 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zLUKfDR0vjJ" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zqjJAAfgUbqe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231_zeL7yKf5d6I2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zbOAUQSYcIDc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredCostsAndOtherAssets_i01I_maDTAGzikP_znDMzghLbL7e" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Start-up costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,097,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">791,079.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsAccruedInterest_i01I_maDTAGzikP_zlONE65YBzBd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DeferredTaxAssetsGrossTransactionCosts_i01I_maDTAGzikP_zt4a7ShTYz4g" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Transaction costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzikP_zwLJ43tiMEG3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net operating loss carryforwards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">704,303</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,259</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzikP_maDTANzPgc_zVhsKX3Vnfdl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,901,876</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">830,338</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzPgc_zw4Jx6CJJJP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,862,617</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(830,338</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzPgc_zSe9TS9kPHRc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39,259</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1224">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zRG6w7mYcS4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zjVhzH6OWO9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income tax provision for the year ended December 31, 2022 and December 31, 2021 consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zfKkRxymor28" style="display: none">SCHEDULE OF INCOME TAX PROVISION</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zXTNt3lsnIHg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210101__20211231_zPwlnJIqOoV5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_z3iOFSA4NZIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maITEBzCny_zzmgzJZqiDkh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maITEBzCny_ztD8tWG9AdGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%">Deferred</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(1,071,538</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(824,916</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zEGbaOGWO5Ci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maITEBzCny_zx9QgTXdPnql" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1240">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maITEBzCny_zUh7SQaqUz4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i01_maITEBzCny_ziaP07ymDBB4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,279</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">824,916</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzCny_zHggvOkT9q9h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">61,310</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A5_zSbsMWeGQSUc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022 and 2021, the Company has available U.S. federal operating loss carry forwards of approximately $<span id="xdx_90A_eus-gaap--OperatingLossCarryforwards_iI_c20221231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zXaaDutnzHkh" title="Operating loss carry forwards">3,354,000</span> and $<span id="xdx_90E_eus-gaap--OperatingLossCarryforwards_iI_c20211231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zNj9ekQf5on" title="Operating loss carry forwards">187,000</span>, respectively that may be carried forward indefinitely.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a partial valuation allowance. For the year ended December 31, 2022 and December 31, 2021, the valuation allowance was $<span id="xdx_905_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20221231_zLVRA22k9vAk" title="Valuation allowance">1,862,617</span> and <span id="xdx_902_eus-gaap--DeferredTaxAssetsValuationAllowance_iI_c20211231_z22B0xjF8eol" title="Valuation allowance">830,338</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z0FnJpvePef6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal income tax rate to the Company’s effective tax rate as of December 31, 2022 and December 31, 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zkYyFSCqaWNg" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zRTMnvkwq93d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zKRi6uKkKtXc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_zNU1zqAEcuwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_zYHJlR7fuy7j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeWarrantLiabilities_pid_dp_zRjc355wFj8j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of derivative warrant liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(55.5</td><td style="text-align: left">)%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleTransactionCosts_pid_dp_z8o6l1wygwXj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-deductible transaction costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32.8</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_zAOb90oTNJUh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.3</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_zyEOzHqiLjnj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other permanent items, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.2</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationWarrantIssuanceCosts_pid_dp_zzpTRXthqzp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant issuance costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(177.8</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_zXCtvD17oHZ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(242.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">33.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zXLwPRDvN1Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(14.4</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A2_zE3pBcSJiC24" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were unrecognized tax benefits as of December 31, 2022 and December 31, 2021 of $<span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefits_iI_c20221231_zrBjxBBJ0TC8" title="Unrecognized tax benefits">765,613</span> and $<span id="xdx_906_eus-gaap--UnrecognizedTaxBenefits_iI_dxL_c20211231_zJbd7O7R9KM7" title="Unrecognized tax benefits::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1291">0</span></span>, respectively. The Company’s unrecognized tax benefits as of December 31, 2022 related to uncertain tax positions would impact the effective income tax rate if recognized. The Company’s management determined that the United States is the Company’s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties for the year ended December 31, 2022 and December 31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-size: 10pt">Below</span><span style="font-size: 8pt"></span> <span style="font-size: 10pt">is a tabular reconciliation of the total amount of unrecognized tax benefits as of the years:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zP16PajTKPoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zzAV3xFboPFa" style="display: none">SCHEDULE OF UNRECOGNIZED TAX BENEFITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_z0QUkT4G05ga" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210101__20211231_zMZjM7IPN3j5" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefits_iS_zrLyAyWgL4Zi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Uncertain tax benefits - January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1295">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1296">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zveX9mK7qXGa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Gross increases - Tax positions in prior period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">765,613</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--UnrecognizedTaxBenefits_iE_z5m2xuGlwwji" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Uncertain tax benefits - December 31</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">765,613</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1302">—</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A3_zzFI9Q6f1dQl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files income tax returns in the U.S. federal jurisdiction and Georgia. Tax returns since inception remain open and subject to examination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_89D_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zzQ3yLcof409" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s net deferred tax assets (liabilities) as of December 31, 2022 and December 31, 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BC_zLUKfDR0vjJ" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20221231_zqjJAAfgUbqe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231_zeL7yKf5d6I2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGrossAbstract_iB_zbOAUQSYcIDc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredCostsAndOtherAssets_i01I_maDTAGzikP_znDMzghLbL7e" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left">Start-up costs</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,097,004</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">791,079.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DeferredTaxAssetsAccruedInterest_i01I_maDTAGzikP_zlONE65YBzBd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DeferredTaxAssetsGrossTransactionCosts_i01I_maDTAGzikP_zt4a7ShTYz4g" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Transaction costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_maDTAGzikP_zwLJ43tiMEG3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net operating loss carryforwards</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">704,303</p></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,259</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsGross_i01TI_mtDTAGzikP_maDTANzPgc_zVhsKX3Vnfdl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,901,876</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">830,338</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_di_msDTANzPgc_zw4Jx6CJJJP4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,862,617</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(830,338</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_mtDTANzPgc_zSe9TS9kPHRc" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of allowance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">39,259</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1224">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1097004 791079.00 100569 704303 39259 1901876 830338 1862617 830338 39259 <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zjVhzH6OWO9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The income tax provision for the year ended December 31, 2022 and December 31, 2021 consist of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_zfKkRxymor28" style="display: none">SCHEDULE OF INCOME TAX PROVISION</span> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20221231_zXTNt3lsnIHg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210101__20211231_zPwlnJIqOoV5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB_z3iOFSA4NZIe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Federal</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--CurrentFederalTaxExpenseBenefit_i01_maITEBzCny_zzmgzJZqiDkh" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">100,569</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1232">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_i01_maITEBzCny_ztD8tWG9AdGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 60%">Deferred</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(1,071,538</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(824,916</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zEGbaOGWO5Ci" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>State</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_i01_maITEBzCny_zx9QgTXdPnql" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Current</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1240">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1241">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_i01_maITEBzCny_zUh7SQaqUz4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Deferred</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1243">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1244">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_i01_maITEBzCny_ziaP07ymDBB4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,279</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">824,916</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxExpenseBenefit_iT_mtITEBzCny_zHggvOkT9q9h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">61,310</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1250">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 100569 -1071538 -824916 1032279 824916 61310 3354000 187000 1862617 830338 <p id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z0FnJpvePef6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A reconciliation of the federal income tax rate to the Company’s effective tax rate as of December 31, 2022 and December 31, 2021 are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zkYyFSCqaWNg" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_zRTMnvkwq93d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49B_20210101__20211231_zKRi6uKkKtXc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_zNU1zqAEcuwi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Statutory federal income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_zYHJlR7fuy7j" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State taxes, net of federal tax benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40B_ecustom--EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeWarrantLiabilities_pid_dp_zRjc355wFj8j" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Change in fair value of derivative warrant liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">418.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(55.5</td><td style="text-align: left">)%</td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationNondeductibleTransactionCosts_pid_dp_z8o6l1wygwXj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Non-deductible transaction costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(32.8</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_pid_dp_zAOb90oTNJUh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.3</td><td style="text-align: left">%</td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pid_dp_zyEOzHqiLjnj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other permanent items, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(0.2</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40C_ecustom--EffectiveIncomeTaxRateReconciliationWarrantIssuanceCosts_pid_dp_zzpTRXthqzp3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrant issuance costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(177.8</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_zXCtvD17oHZ3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(242.6</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">33.2</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_zXLwPRDvN1Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Income tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">(14.4</td><td style="padding-bottom: 2.5pt; text-align: left">)%</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 0.000 0.000 4.180 -0.555 -0.328 0 0.000 0.013 -0.002 0 -1.778 0.000 -2.426 0.332 -0.144 0.000 765613 <p id="xdx_891_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zP16PajTKPoc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zzAV3xFboPFa" style="display: none">SCHEDULE OF UNRECOGNIZED TAX BENEFITS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_492_20220101__20221231_z0QUkT4G05ga" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_490_20210101__20211231_zMZjM7IPN3j5" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefits_iS_zrLyAyWgL4Zi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Uncertain tax benefits - January 1</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1295">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1296">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_zveX9mK7qXGa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Gross increases - Tax positions in prior period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">765,613</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1299">—</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--UnrecognizedTaxBenefits_iE_z5m2xuGlwwji" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Uncertain tax benefits - December 31</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">765,613</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1302">—</span></td><td style="text-align: left"> </td></tr> </table> 765613 765613 <p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zUpJiDpZfZ9g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12. <span id="xdx_821_zHTqprVFZaKl">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated subsequent events and transactions that occurred after the consolidated balance sheet date up to the date that the consolidated financial statements were issued. Based upon this review, other than as described in Note 1, Note 2, Note 5, Note 7, and below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated financial statements.</span></p> The Company changed its valuation technique to incorporate the market debt rate as a significant input to the Monte Carlo simulation for the valuation of the Subscription Warrants as of December 31, 2022, November 25, 2022, October 27, 2022, May 9, 2022, April 27, 2022, and April 4, 2022. In the case that the Subscription Warrants were exercised, the risk-free interest rate was used. In the case that the put option was exercised, the market debt rate was used. The risk-free interest rate was used in both scenarios in the Monte Carlo simulation for the valuation of the Subscription Warrants as of March 23, 2022 and March 21, 2022. EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

    VSGR9VZ))U4;VJ8A!%NT.?$O6-J9[$>5XV#-=RS8 F."G3QW)FT8L93Q[.7D2S8YGX,YU6D.1EK0N^ M:S^ +Z[7<6[LO1>8^,1-_)D>)1;XF-;^+)J]F&'WV/D4_QZ%?[_.$PL313"=KB)@L;^%UT)=L02N,UT0)26PY!_.2N+X6*B:C MHB8.9R]\JB!_55<C$)^N62. : MXBS2GET>!/G+4.75IZ;F"9Y M=102W?QV_MO9Q8?@E[.37S_]$IZ<_N?G\ZMSUB-/+RX_'H;0,*^"3Q?0$Z\N M?CU_=_+I[%WX\_F'DP^GYR>_AE>?Z(?W9Q\^7='Y!D3=A5I_C'38$2$"U+#T MS@WTF02#4U68@^F$A(OY&K(B=EWF1,TXTJJD+6%#!,OKG;%]-0E;ALHG)YT0 M!JB2R$]:+9%N$A13&>--!PK;RB+X; NB6SY_ J\B\Q44R1JZX)(P*\?NRD6P MN3:\!_IG&]Z4C2@Q]%^\).N]%AQR\!F'"VNL,A?=&9(8B%5M55+ISCM>@0;P M8P'IG)(<)"TV4#G>(Y3P #2*$>);XO[K> O4G6!M![,)9KH!W1-#&H4''R[S MSC5D;5M H-$Z:\C1$<#0-9]S@;FN3%S4C) A4VLEFEMXH.R@,G13?%-FJ;(4 M/;2XAP@ ZD1^+^S^S>\M8<(>J 4/A%KX#5##(84F)MPASDE\K)U_\3@M2WZE M4J=F!MA@IFI@'U3>XR2YS4K$$2O.9'N4%1@;(:MW36@;<"-I3V)[D;$517!= MP:8B-9I @A-J26 -M,7@'KD%RR'!K,SXW+G_[+0MSW*_(F&0$OK7X=N2_CCY M9&V8GT^NWCK;<.PYHMH40DG(UCYVIB7$ENM5J S %CL(]YD#PLCX0T]Q+0\GE2Q-FE::%5U M*:* SWZ73IAMZ!B0$L!2$9+7&?$*< ;HCD1C?0P@;!6N03A=0]5V*,R*K0CJ MX1",W:2FGL/:+=OE=9]B=1E,$D&MF%;N2#*(NK:P8JRF@Z@76V;CJB?@BE5Y MB!.FXB* U4Q$V%Q;LDG-@EGR#2BM,J*<5*0,-R*6:<7!W?*@;^WUUP7?9T/_ MLZ)!R+/,<(&-][HGXQZ'5F.<#A%!65S]S8RMMAR--G$'(XMPF7%FD6'5WJ4@ M+9,6$/'F(]U:Y0\_0Z#E#?95+-&2""$Z8P=4+^Z&K!"/,4N\.6EN?/M=0(;E M0W"MP!V SJU%D5 U?:9> M3M-JS:7+'+!R)D8KU7,@,M[Q7Z04_H=^8!SS.J M/+$+(@.\5_&7LL()*1.#N@I> N348Z(KQ.Q6;#FQ(P>^LX+9.]F[M?AKYMM M=MG3%,K^7B%R(6Y8\UR09*KL'>.JXX>RP>G:!05J2YME*8:\8]\5_-A$S-GW MA*W3JH<^!NAH*3$P;P48*1RJ;O=.0(I3W<:%DW,]9LGH$K'Q>+(291P+NC1L MOZ;!*6E0PNE9CSEW_C^9GS#!JB#,H>(1[DK84RY%OW*Z9KP@8LMT4&;A/OQ8 M2]@JN!)H?1@#O@F53AN8<6PK4]S#KN2\NB- R.!P_L08@#[VC 9UV0=/\K263 MRSY._&Z7,,"S>.'UCMVRBE.8?)T*J:315R+I8!Z'+V?JQR !]7H636GX\C5Y-7X>SYW*YYU!YMA?D0!+>[TE10/E]W[&P*T^\@62@[^**JAAT%_W< M.YF ;S)]_N'$P1@YAW>1<\3CY7FYZ:U[Y/@'I[R/^X-%(YI%4F >UYEX[=HU M8UAV&S;9BH@$Q@/=F8J"0IN"*:,I&>&HWQDJB98Q10X?63'VO MC"GJ:GK6]Y,9\%@B=75#^#@6!:J$DU($6]1 \Z7M;VN%,*WYAG5MXM59 MTO M@RHDB.0I818$J8E3Q(IH56QVLGK?^:18U2&IQ2J$8^B6?@*??DAB$C.ZCDEG M*Y.DK: 2]&8?VQ?[_!BB-%D'JI<65?\6$T*2!3)[(8"*PI_-O)*?7NI/RE+< M=\:M$YHZMS!_UL=Y)3!:PF,P.%!*L(?81M$LN!_-Z(!8B;;KUU!&;_UN;;+^ M[A99N\,-;.=][(^AW)O4XWQ[&*CK6+G'@GF4Y2',+'2/ +7PI]D85(3Y!GN8 M[_>DZ'",HB-FCZ2"!7&A ;"!H<[/<7K 0ZA_E,<_F/J#'O6''?4+\0Y#5 3* MN<,K0.QQ^.KXP3 ?%7@^1Y 1@ L^.[9LNHN7%B+_@IY-(DHG[>_@9/*O/T:> M*)M8ZXR]Y0^0TNJW[,ZOV&$VO8,8ZS M!SE,]0 QJ>FIZY\9\:1GQR2.H^>O7T6OG[^$/_[UZW :O9B^C)Y/CQ&D>/F2 M;IH][S"EQ\?^UN8^J]O'QG3"@9':LWJ=5_A>U5QC/)^NLVK KH=A?/?(1P9G M)Z6&[MB_ "G"Q,#!Q4Z,+I1L;A.S;L;"[IM,;+%V'='C]'S,YB19'8@7P/*, M20>G_4%&U35;\7,R7!$*A58;L%:[X+"5W2=$I?@'.<08J:K,BNZGSIS<"0_W M2(I]$DQ3FQBCBV4OAAA^S3,RB5.)AJ8(OF6T+-ZLBV;TQM R+T#W ''T^$@\B!K88FX"+.\OK;CAX+41^,;^G+\1Z&OY0;<\/.B47/ M/="'3L(.@8'9D;&I_("0.'N[K;>,$QERAG7PST)5V,-@57\$8L']$ LMQ-YS MJDAPXKQ89 )9I6 Z&]/(.=F$#YES362 L!N@9Y/0X0]O<.* ==A4%79?T@:_ M_7)R:I^[:N<1&/MA+][LV],\"(Q<"N91 M).@%_L,YO.AX,"5J3)JRLN#IY?J +XOIIL+?!?W)DLAJD1Z(-H^@6C2\8KU& M:AY6<5''B= H7)*&B(K]-RY 0_WQ1"WBU+29-C$#Y0A96/3)>?^1)>!\ MQXS[NX$!9NR/$6A^=A1.#X\!Y ^$J3SK].B?!K2H. ^# M&ML+*MH,$QC0B3H:./03B-1]0G^>$%\G2:E;*]45BXDWFO4 ?_1C4CZ/7\VB MHY<,O,[ZM$HFYS^%$)BUR7DFM2?9SQW3]:9QX0$.MSE&S I2_WD&@@Y C(2P MAG1LEST49$37*1RL^9;-A[;(0+B:5J%^M?W\IN.OT^9FH M=^4BXO3O5,*6L"HJ$N+!O(*I8.H[>-Y_!0>2(]B"*G5BLC ES;% M:0E#XA3;U$;L!"2,G($G*7#K;N97>- EPOIY8A/GZR<.G:UJG0D@A0EDF!"/"4?,)%)=<4 B)='699,Q;/?D%*05Z;K(D6\>-RZ:Q MD@S)0RTG@,D:&1\EQ:@6%8#UYA2)@V9$1^*I3G-#\BO> FW%(W(\9D)_B[JT M>]5.8GWP$U^.Z\?O*"-."2)$$ZK:Z+[[/\(($9=BTOM=DI'6<<;A>\LJQW;7 M'V]V?!2\)S6&=:EUWM;WLIH ..N@/\985,$8G<^J3)K= ,SH8FECC@<_OA8! MJR0A(7@<(FOO:!JLC49-([F2"E^;'G57#L.SN"K@//H8;R4T>EX$UO 7A/%4 M +>07@L%FD>]3ZX;,+@6S:8%4'_ 'I' MJ-NPYLFI''/ MK>]=I9GRTRS0,7,<)?HH W-4Y!YM8B"10GOC-4R=2RQXW&: MSCD+.6_C2WOGB(2M2E*^!J$X.EHT59GS5:0;=0Q>Q@^LW37R2"Q!\>&F8;YO M3<.@QLFP7QE*N'Q7M,^08@B?0QJP)H'TF7*C6FY.'*@2C?.N M\:(N%+IOQFZ%##5QMWCLD6F 8!#LP,!76,?-U3YL)*-W "]'<2ZQT=LG7P1$ M/6"$/C#$ <9&-QNRQ"H^MF(1%*SJ;.JEZNJ27[$9IPIQ*W38G$!A&,--C"9(WJ: EB)G7M::ST<[7- )9+-$B&)E6<1 MVBJP'\RFI\#:T2(7@5[87!)K'V;J(&K@$FNKK9:=V%J2#?'WR2YM6M3OLKLY MK-6WH?OLR=WY"7=^M.PS8+_T87C2,'/KWZ;.V:RN6X7Z3J*%#S3'-Z\,[^OG M\+1=M0#[#8#$V9-,9&YV\8KOR@Y/=#@W@G^R.OQ@%_"3<[B/4T?MZCZ*]8*S MV7U0%A"R=#UX.T'54LLF"CTXP//=A#AA,(.L/R=Z4,H6!3L)4CN*C*+@'P7R MR0,A&WX#9$_^*&1/_LT@^UT50.@"_Q)RV:-'/>C$9%D*;'::M%RT\YBTQU"U MQRB\2WLD;B*9S=#Z ]$EN9*H6_K.BI5)C5FN!^;6VB\MC5J#7_LWVL]EU3VC M;C>WIJ"WIM"MZ7%XC'*0*Q&7T)!X!=.5(D^^RE'#?4K"2P*;H\WKHV%=2 M4C#V@#LQSS7HU4Y)@ 2)3^D^?)Z\(?-,[B#!6KU'#\[9@,7(8%QM\L4I5J-9D>)! M9JW .J 8HIP[[:5.2%B&M3-[]CUQ.MQKSSK8"3#UT@O]W'./T]F$6W\+;O8[ M93D)SB:3^A6G9C@JO80J$W'68C&T SMN\0"KIK_NNT8:/=X:D]QEPU4!GGCG+W; MYNPI55^?#-7MP_D*;"#4-QZ# 2HTFK40IU_:NI%]%J7G4G-0D033/4O\KDK* MI=$T9XG0,^24U"!D/HWX$&W&>:T],+# JC^,+^"SSEO"=K)11$=$O6\%1Z,) MAW#WNI+_P-QF))4+/8YUN4&$&I*-++_KLK*5]>SI$%^V(NJ#8TEO>J86#9Y, M%!OQ&/+H_9FBX""=<%$T&\#Q#:+84* .R H;EO\?++RM:(D.9EA.V $H+M.# MZXF7M.^*>'$EFTAIM93"NZ(8-;U)PSWX0H"8U]9P1QHR\%BL=(SPE0NVUH;/ MX4W( 7=&7RZ(H!OR28C*F*5=\6KBW.DR#T$)]Q6X+]$*;)P$W.9\I9P$7;W!E+L*[N)$XD3IER$)8H)+E>3$/'$I2[LAB$._X[-K%P8!M=F MX@5460%<+&C7//XMHA!-IJ&9/&95 <>A@VZQ6RT#I9/YQ\1A&\A@V\,YL5X. M8J"ZGMF0HKR*&$\)I+E$E93&"(,*4<1\O8RH:H36.R*-O#@": Y&2:R(5&O- M(@BMX;R+18NN!Z"-7(JKZ L1@L2A;2Q7J #U*ET9"R8=1>^ J4-W[W)XUD X M KF2B:VQQV)3,R> \%U=:4ONU78Q3(F:YE7YU6*,W,7A;CI3B%JB6-;C1UF= M@,3XK"YQ3PRXVM"GY_*>.B=.E\SI-_%PXMHEQ7G5=EZTG80/6:^U7V[E::^# MY_NNG9X3W^.!>5UV[-Q#%;?)H+])#TEZW+KF!@J<5%SZY441C=3!0<6W<'+9W^#[ZC( 59&OC)\P-6H+=0%H":^@UBH=*V<90!TG.6>D M)!,BX$&0B>>0G/% ROI UTZM\L[:3TOH4R@F<)HC!R-X)#Z7+O-,L;"#7Q\B M D!-I'!@13:3CV],F>*-; :E;)H3XM?E2ZEQ+!E2/L1G?P[2;_K:[S;8U%YVN8%BPT>92_TR/ KCW4^/X"4E9$WBUA);C M:,&'>*O1K*+!)K3*-1L4PK@"W[@9U@QA^6!Z]7BYKR2[+3G1)U M$4:$RZ?W M:ZA<#MO0T!HIH!ZN0WDG$1X=T;**@?TW<9;;U$^G?';I=QH-B@;54MV]W)U- M$C5$ST2I$+K.2;5HB1)VHC/O6(C:;DQ>KAG_EB7AR6YGH0$2V^8\L98)>OBK M]3[L;AH4KO7PU/=/G[G4WX^*JJ[AB$MAQP"##D*=(.KGO4B.,.,I;&D?61$% M ]ZEKE;KSG&!D.>J%=HR-QZJD3D*_O" MM,V34Y?B8P6F"U!)3EP7I\0C1:F*$>,.UZ+4C1L$XGY5N(KOH"1"$265,$\; MDMDR;E):"N8!'_.XV$5+AY&.[4&!2LNU^$8L9["#K#%(+S(RF.!5^!]62NZX M<1[B4-GC_;75UAZ(:#)= S)SL0_;V$NHFCT]-N"T:J%DYWJBECWL/?L>;[ H M:*-I $?%"=W:%6"15<3\.&= A=\BJQ-"533WLG'O'6ATC&K!G9!4P>R*B0>0 MC;U=N&K\81"MMPW4TA9/KD0V"*9<:KTD0G?@=B;6A3T249!?O&'/&<@.^PPM-5C(.:A)MH [#"+$M\X^UVG568 MLMB&L$4^T&?8EF09[@>GH6$YY0JH=*]J)6WHK+G-0.V7\MNR3G9_..4B2L,:3>O!7T2[*37_UOBTE[.H>A6-'.''$G%.OV.FVT.@KC%V. MK&J/J]K6R>WJ5SY'O-$@M\V=WXI?F>7;V(C[5LH-QSIO-''9LD4) *"!5#"4 M/E6^?M5GTAZ/'&OLA.YY1"RU1RQAY1'+=PZ&64,E8,5#F!IX\WZC!:CG#!Q- M[MOC(\HF MW.]S%H1 %#F1OJ@-7P+DFC9Z6(D/$ZF[.L@Q\W6ZTMP_7,*\OW M[ECL/G^2UK,,()J"59! MSU^Q[ M?^F!7ZY@03+J+A:OBTI)1@=1XS6.2'MKN6]CK0TXW;E;!]]-9F$T[O (YC#C M\7"G2NR)H#B%SP'%2U]R7.#9,Y\+=-D @WM)83+Y-ACK_N?+I6&VTCT<\9O8 MM[-;E3^DJ*\@/JB=>IE>5A+=%*TF=S:B+^I>2*F9;=)45?,]VX7:]EHFA@*TEM4*4 BB" M4I!?^<62P].!^9:_P,H8K7QT:!$X8V1\ FZ@/ MG. .X(3W :=W+F3)$#%EI&K1;3%R&N-$EW:#H$V(%KF-E4BNDP%4MT"@JFF1 MW/5K'] >#(^;#LNE9 RW:)##;N+B;OVKSX=E7V/D).J7[(;*9 M:UIM=;8=3!PT4",#Y5C>HG4A;-3;T%(G(.O!\@[WL96.AKXG ]':BET^96'Z M0(ZRXZG_;NSEG@#,F"7@<]M_&X8C G;GJ>_ AX*.I'Q(T%"#(]4\;3HHVR.Y M[V-[J%X^SJ"&89+>BA<0#P.@2N?UVS3O9W'BN9IT$I-KKAZ/TD5E]?>C6 M9?^K%JU&8WY.+2R5,?PVN*X[!'.F6%PX7:&$&RKHAD+F$@=[!+P,3/N2DCYY M1I[*OE]]UF8F>W2XP8/!-YL@D0*7?7'-3N/[AS5*\0OMN'2A@]L; >Y;P01' MK=;I0-O+RMQQ;GDU@$\YSB^\C9P;F,UPQU+OX*B!JN+BNT*$0+U(_>+!'4)! MN1X0DH5+W')_B4C8$80YD[ SC(T/5E;: 7S#+J H''@H;&MCO7K:UPS&Z]A MN]*AMH_#^M]\3V<*".:!5,R"Q)GLU]S&4=W-6]<_*"'01>(;B<(O;;K44D&T MO@;R?FF+1(X3S?K4=JTY&0V.OSBQ+X;(XTUDU:F.$7%%,)U97(BM:XHO)3M? M,)+G?KE''8BZ?%<-T%GD"$:1@PQ+)XRT$C3]%GM!$LH)SQ7=-UPHXR64]K&K MEVD:]'!-W)Z)WW#%G-6+">3W"0=5!R MTUV_4<#AN+CQDB6ZK+S!NR\\WX>&J#72IRVA.86ZM+U2_:ZCTOQ:S[RWQ( = MW+RHK9,M?IMV.WJ7S0V+O.6696-M31V_]I7T/G5Z.6D]SA Q-C)5GE7)WPYT\4[1"503\3)Y8Y<;UDI2 M#S=IQ@A69H#[T&86A@M V*N_07QEQ0F4--I-9C92C.;$#&<^* HQB:ULM@!0 M+FBYO&VWE1#Z5"7Z#I2L_MKK^Z&G?T; 7,V0/W:0@<50^QZ:C&@QN8X! M"F-]J$ZS[^ CLGS!T8 _BJI608&.%W11!L8JOQI,JR19.^>&N!SLB"TZ6.;N M-31NADV"=WH_^PG/J_BKL:D+Q/FZ()]DL2%A(_(2O3S.T@7-)1G';W%\1YY, MQU=X9P,+6D^$())5Z1-1'B1/,-'JN?T\_Y"[H)'Z%URJJGO2,3\I7@JN6N[W M[%\Y]3RYP0A9[>U4,W[HM@A57_'BOMOD0R'30:.789%\H$7RM2[7\PTT7BQ; M*[)V-N7>5_'_LUUKA T]SUT=;K_T?V=7O70T^\#CC=0L/-DR7J4QQ>=E\1E#TH'-#$J64F5MB#2!SS@WN&6 ME4I>3)ZC&,NDRP%1$Y]7AAVZR^"$G>3':GMER9[G MRU7&<[V,*'+69![$>NM-O$:#>7^-?A\(91^89\$93=R\L!1-,A-Q&WG5KB&Z MVY2K+.'8H/F]14R/T0%%M%5]G:WMG=C=$[>]'H34R^?U[<=2.9D)KX^IQY!*\\RO!!J9BL9Z5O15%P*NJB_;(EY4.Y$/5 C9R62D$ /!\,SE%VU M-FL$+J_#:SJ[D^*UV[C/(KRME)[.#H^/_/I 3A%&/8(*4XFAU.L\$[:-\A8I MSBG2>O@&.]N6I)_H7MO7;&S15IIVGDHGH6UM6Y/@TK.C)]XEFX"UOX]!%!P? M=9DVO^J9#.KB^V7O'H:(..'J 0ZO2$'\;A#ESLB2;<"G9!WL\H&N<$3._KO& MT+5M)[L-7=O.2S^0="EM"3UYIC5Y+JKH2PKA7#XMCP=!>[$J[7RX1YR,=A;U MEQ@,EQC^%4WN4=1%4"W"$\XXWNDV-6BE&G,[W]?1J^^D:M. MYW@BTX1VFDM2#.O@S_%J_2;\7.AYLG+UWKTA*[ A/R/DJV;2M;Q%"&I2(Z]6V&UPR>P8 M ]UD58NG'6/&NS*7DOLRZC)U^-NEVDM_4WD+)6S3VH7/7'].CE(^!1,PW*98 MLF9M(B.,,[#JPE3VC71:2V5?$*9@R<3_ ATS\S*W8HGT6ZAY"56UF/UECI:/ M9KP^0 C8ORT8NXUT2K48)66:E4>OWJKIC Z-[3A.05IX4MJ>"-Q.U>*%E%4$ M"2D@7L:Q3"TOS:HU>?L6; SB*H7W$<'?\(8]9&P B=Y65ZWF >/]@;94710J M;'!!8J5Q5LOGK\A4$27^$HV68GD=HKLQJW<]ZXNV8LFVS,LYK='*T]"7IWZ] MA^VD:E\]J(L21)2U(XL/68>H $PS>*UKDOC:J--NSD)(3 !^,.(F@_P6';$W M:E+YV8&T@$Q)3/\&M]0E\6>4]=O,0[Y*-HFZ&^5EE)C3.Z9 3"DWAI2(H1HD M$221)0T2U+%3O%"/JSG=L+90G*0P&PT,5TX.0I^:N%#O-Y@NGXJ&TMQRF6[9 M_F24DYLBVVP%PC(F[7VK;J&(;5L4$:'8<3L'139Q\K7NO?^KM\J(B;>K3 .H M%E7LWCF$701=E0F)@D[!ZEXNL@\CM).8\Z)M^3U]Z.+9R%K5]]5V+ZWU7ZSI MPG:.VX"M>YV K4WC=0^HQM(X-#"4\PL[&,F_JT@]MPA%!A]>=0+4TN0)U^3P M[)8KG#_%M]R>3-XL/'UA!1/D#[_:-7R+/Z2?+0MKJ"#K#+MTTX2CT^@K"\=C MFX)S0)MI./9"ZJ?>"\:Y)QM>HUX+YLJ[QMVO[DWM)_*"\NYV>X8_7A.7-Q5NH.N+LFSL%TS@WE__T_\! M4$L#!!0 ( -RN%U<@:?0L.Q0 #(Y 8 >&PO=V]R:W-H965T&ULO5MK;]O(DOW.7]'P'5PD &V+E/S*"Y!E9:)9OS9R9G"QV \M MJF7UA"(U?-C6_OH]5?T@:P0!"+5'=U=3U/5;<^W.?%]W*I5"4>5FE6 M?MQ95M7ZW?Y^F2S52I9[^5IE^&:1%RM9X;&XW2_7A9)SGK1*]^->[W!_)76V M\^D#O[LN/GW(ZRK5F;HN1%FO5K+8G*HTO_^X$^VX%U_U[;*B%_N?/JSEK9JJ MZMOZNL#3OJ&T;O3 8WG ;]K=5^V/@O:R2S/O]/#9/YQ MIT<,J50E%5&0^'.G1BI-B1#8^,O2W/%+TL3V9T?],^\=>YG)4HWR] \]KY8? M=XYWQ%PM9)U67_/[+\KNYX#H)7E:\O_BWHP=]'=$4I=5OK*3P<%*9^:O?+!R M:$TX[CTS(;838N;;+,1BH-&@1A]XJSP;S.F,E#*M"GRK,:_Z M-/UV<3'\^B]Q]5E,)[]>3CY/1L/+&S$QX_8T_B'%,Y7LB7X4BK@7 MQS^@U_>[[S.]PV?H#9,DK[-*9[?B.D]UHE4I_FLX*ZL"UO+?VW9LZ/6WTR,/ M>E>N9:(^[L!%2E7 M>/G"XE26N@SRA;@F*EDEV?=NEBJ0D/5J+;,-23O)LQ("G\M*S<5"9S)+M$Q% MB?$*+E^5 B2JI1(C,T?(0HFU(8D9.B,*%))TM8''5$LA&U6N"PURZQ3*O%69 M*F2:;NA[M<;< '.)\+=,$Z4IKJT(D4;_[YC^,X[KW_=3B\YH_1^[=" M9G.QKHNREEDEJIPI%#6M0-\4ZK9.>:>>[V][4\A-)76A*VV'C1^2I5,K M75)<"][08+OB=#QR"^Y!?FX3),V1EY<3Y\\EB/EI/5?,CI7.4[&"+8W7*_EG M#DXWN_E]!GKT&@M419ZF>$0**"2+MJQGI9YKA.\PN$KGXD(5MZH0TWHFY*+" M)Y5J1"G#)M:"Z,$'OK"Z%_"LK)2)D14M,Y,I6"<),7/P<+6:@9#S M&$-#M^ B^!6. Y6[39 XW&=-5)U E9T@;LT$RX05AM=-+O\TP)*2.JA:*C0C\^P'BG31Z_RN=ZH;'4;,.D?ZM7:VBK MJ,1I78*'LB1C+*IZ[=>*>U'E4="FS!J% 4)7?H>GY'6P4^90()*JH MD)@#]:!6:R/S19&OQ)TL=%Z7,-QU7K!B"_57K0MK.=525NQQ61YM8YBDO*B&8;'>F,_,TO]-E7FS$75Z!S>PYGF@5 M (GD.Y&!!J'5(K]#L" 'A<_C+*,D#1TQYT9%"-+\!$94>[-[8I(%<@X%XBGT:HIZ1TY-SM81 M1,JGY][<7NCC(L'(IWY!Y-5#Q0X<<$AB-JS:W%J=J'"$J/ F?OOF]+G8 M@(U: R5NV$8S@%*\)0&6%%6;% 4CR.:P)!:#<:P \'7.-O&*KOR%U(IG>P6 ;#^XJGX)[AOF4 M$[>*>88,O- N\R \.[F+)W+?$[]/?A]?709?QL/SFR_ %__Y;3*=W$RN+L7H MZNOUGB! ,@UNKO!X.07D.!O>C,_$Y\GE\'(T&9Z+Z0U>7(PO;Z;B&S:!)<=E MI5>,'.9X@&^5X M"<@C98E"R 9E8].+!6S-^C]%#3*9E4_;&*]L($FUG.FT 1;M8,6[(I73RL_- MX54"VK=3T\]%042>XTT]4+0!Y3D\ M;6C&,\9K5[(;]3]O9B: 38%1:"1)%H M,D]]FR%G)@2Z_JSGMS0 #E-QED?"4+*L0$26>883\ MD_TBI^1LTX>W1I]HG[)B Y?GA:8 J)9)H0V-'W)Y^#;PT..%YFE&6 30DMA( MEDMV>?H@QB *9MFGVLC564/)H+E1<1'> M2%.G31O)EG81>M5=Z!Y^Y+^6) 5 NY4LOL.;;1[D15 MH_L-Q90:P*KT*9Z08;E6W$-*-\8++$^\,B#^/C.#PY/FG,N6U5OO C>'+O70'VJ1G- MD[I1]B4IEC/E"1F.S16=]SHKJZ(V9CAC6V(W9#[+DDW?ZLHNXU)A0'(C/^%X M9?RP55C(&B$&0I8,7&]KQ%!$7-KW<#H2@^,>3Z#/-_D:1&CKD!E[-V88>E_4 MG)'2Y[P(4%G79A^^Y/(;YS"^HF9GR[80$,"9EBPC(Q#A-IY(DR%:^RJYV&G7 M)3-ZI,!*N0%?,UB"MK.*C-^!7%C=6NKY+F$*N<:&4Y=($"DXD1#GM/D]VH?X MZ3[F.0-TOYT7[B5X^5Z8/5WX>+^0>*!(R^5&.PC1"1&CBI.R_WT&C>D?2K\YEC .GI?PP+5#9R>+^%:$URR,EO MG1K;\"7H=N%L\X=+MC,UJXRZ1CF"9E&Z5'S%P>3*PMEV@= )0!(1M="FWU9G M'%W!7ZDRC2]1=5%7C K:C,0L;Y'.3&Y!$ 7Y)@9P9#CJ[<;X=[ ;AR]E;-<, MG+1"&4\Z4Q5*7PY'7HA_8RTR8CP33!G/3!L\<^WPZM<&V S3-+ :/PA[_3@\ M/AIT(KI7;&DA(5M/"QH9J]&KE9IK*#)E\P0]8(0$ CY09Y* @AT2PTPR1)*KHIM<*[<@\URGI4F MW36\=&$AMZ<8S9N6&F11D"PD6WCU..J*=M3-N!:O&6Y3KP?^G6@3&PH*C>0O M+;S=[#0P.R53)G8W!,)-,?L$RW!A#[?*;/^ [EPR7CE0=Z,*WT0] M(Y\W'>=@[$KG,ZX+VHW<.21=KR?BP+K*Q&\U2I'XB,709RZ#IUPR=C=M)@-JC@^8AU?B16>( M6ZR5C@QM5TH_#7*N[RSXZ*P)F2C;4I[!67*1IVE^S_HB^N_$=/1E?/;M?$Q' M(5_'9^/QQ? 43Z.KBPL$ANG-U>@_\/[S^7A$P6!R*6Z^C+L!XG1XC@ Q%M,O MX_'-E%K9 .D(?8E2 (J_4,\WC ]8(<$Y@-6[X',G%3Q.@K)J#@][ MX(?)%)P-88Q2,7K'\]E.$R #EPYA$ M$[2B+;=+6M1GFW:G%.D_.HA1Z40 W"?83H<3MGO&^]SC:R30'T![T$(TP)1_ M9^_>$?^&K<>PJ>@D'$0H&HY.Q!55]M2%&1DU(]\FFO7LN^H3"_:LI;D9CXK5 M%0"\*IM9CUO63;+N(\S8/#QL^E%GRE9+AI&QZR!AJE\Q@MS[,.F#0P&1QB9" M'(6]09^-]N@P@J .1;-859 M$]\%>,M']ZA39F2:3BH&6RSQ#45;@\I$.UC*JL*4NFH UY;&:H<:-WBZX1:< M"@8=?,)&9Q3J/,9H2V2@VM%/<&F)%7:F9 M,IW85'\G"X?!9JPVGAV4&&)*W'K-QW;2PSTZ')8/#(%M7\0=N1 RI?_JK&55 MM+)G[6T462NO,X!J,V"3&\=,,27F(I0HZ/@GS$-@P>4MMD?UY,D>EKH7;/6KX6>\B:#?&'U?YX:OZ$N9$^8?-=5%J"BDFZME&MN$QN&]W M%AQ>-.<([D")[97FUO$<=@[/&9P\#7)E^'7,:-?6RXYQV2 <9EGN\4SW_T; M6"7O@LMZ19VQO,#')^-^01D0'Z+<.!1O MZ2$"0(V/8WZ D1X-PN.#8WP>1(13H^!,93DG 2+WAXMG0QO/.ELX1F%T$L9Q MOP6*4?%']J-_^>+]=.P0O/;V>@/#M?_4VXMZ[L\(13+\W#0%^7(:!*HK^&?Y M77QV&3IHGQI,$E?ZJ<^)W76@Z4T_-:;J_F^W.QI2])\F78P #2@?36QRV M4%X@^9(686?V:=4[@V$7_9:5O8_=$YF>?V MN2M8A*O]X7JPY1CN28>Z]!&<;3K;=8^^9P.[YS8;?U]1MC>'?N"@LG>D_+).9]BTTK:7UIO+?'TL'R[7W<:Z]S*>&QPYJC\.;N/>T],L2$> MM"K^UQCBTXZ<(<]G4\\W(8^!'[?#&G-WH*UA0FST*X.YS1:"=]N85NN^OSU9 M,'=N3';B%EGJCAE^U'QV-:75;G"=RH2W'!(^<15D^]!BJRVTVYNZ,(N3(;45 M:0\0JYS."MW)3.@O-C2'ZJV]!69OKXL27SG]!ZT?(4W]?=Q6Y-YVI=2W'&8* MT/).N5O1FP93F.LCS?7Z#2$K[DE@P^'6N\$AQ7P;5:@O2U>*02(P)3JW:"7= M.*,+)JEO<&3^%R8O_WG/GMCV>ZC]UN_8Z.XS_UJ/; R,FI^T^;?^!X%#\SNX M9KCY->&%I*O3P)AJ@:F]O:.#'101_ L]\U#E:_Y5W"ROJGS%'Y<***R@ ?A^ MD2/DV =:P/],\M/_ E!+ P04 " #E(" !*!0 & 'AL M+W=OMB])O8X1L7@!=*T;U_ B3>5DDA[ PS,?/P##*.-TJ^F1+3P7@EI MQE%I;7T9QR8KL6*FJVJ4;J50NF+6F7H5FUHCRT-0)6)*R#"N&)=1.@IS"YV. MU-H*+G&AP:RKBNF/"0JU&4=)M)MXY*O2^HDX'=5LA4]H7^J%=E;<4G)>H31< M2=!8C*.KY'+2]_[!X3?'C=D;@\]DJ=2K-V;Y.")>$ K,K"Y+)G!J1)_>&[+<70108X%6PO[J#:_<)O/P/,R)4QH M8=/XTGX$V=I856V#G8**RZ9G[]MSV NX($<"Z#: !MW-1D'E-;,L'6FU >V] M'9L^SJSM8O$SN9E.8W][>/,X>?HYBZ^#> M)(U9EWH)1V@A-(3O%Z; M:B_PAL=2E=QR)F"Q7@J>P;PH4'.Y.I1J ^H=!ODZN30URW = 2$=0@@DI.M:WY $DJ0[(%\@/7(40CM#.@@,.NS008,[ M=(+QWONN4*]"%1O(U%K:YJFWL^U'<=74QS_WYI>Y9WK%I0&!A0LEW?-!!+JI MW,:PJ@[5LE36U5X8ENZS0^T=W'JAE-T9?H/V^TP_ 5!+ P04 " #S932Z)A6-GMD/AO]_9:;-.*]4> MDOA\=Q]_S_%YNE'ZV=2(%EX;(&%PE:Z6>G7%3 MS(+("4*!N74$1I\7O$(A'(AD_-HR@V%)E[@_WM&_^MJIEC4S>*7$3U[8>A9< M!%!@R3IA']3F&V[K.7.\7 GCW[#I8V,*SCMC5;--)@4-E_V7O6[W82_A(GHG M(=DF)%YWOY!7>;I[FCTO( MOL^OEK?+N\=I: GKG&&^12QZ1/(.(D[@5DE;&UC* HN_ 2'I&40E.U&+Y"CQ M&O,1C.-32*(D.<(;#T6./>_\O2(U?V$6(1,L1SI1]E"1/6)\&.%ZX]*TE#X+ MZ/ ;U"\8I!\_Q.?1ER,")X/ R3'Z__V%HXC# N_N'Y2&XY$Y!U:\%SN"]+U.0^]0>B$9G$7P>S#AV]J&M"_<.=M/VY M'F:'6V'>-\.?\/Y*N66ZXM* P))2H]&GLP!TWZ:]857K6V.M+#6:']9TLZ%V M >0OE;([PRTPW)7I;U!+ P04 " #&5+R2QSO+M /B2V)',[+,\_, MR&\>C?WF%DI5XD>>%>[MWJ*JRM].3ERR4+ETQZ94!9[,C,UEA4L[/W&E53+E M37EVTNMTSDYRJ8N]\S=\[\Z>OS%UE>E"W5GAZCR7]NF=RLSCV[WN7G/CLYXO M*KIQ]!YEY[)&U<_=Y(_\"VPY:I M=.K"9%]U6BW>[HWV1*IFLLZJS^;QHPKV#$A>8C+'_\6C7]O'XJ1VE916%H-:?2%3>7=4$X7%)1) M9?%48U]U_OGR>GQ_^5[W-Y,W)Q7DTZJ3),AZYV7U M7I#5[8E/IJ@63EP6J4K7!9Q L5:[7J/=N]Y.B>]5#GG]UMH^ MRSM[R5J5R4JEXD[:ZDG<6UDXR>APXM_CJ:LLKOZSS7 OMK]=+"7.;ZZ4B7J[ MA\QPRCZHO?-??^F>=5[O4/JT5?ITE_2_&:*=LK9K>G-[?QD-CL7+!XD/ID9( M;3192&P35T4TKN= )P6F$XMJH<2DA!N-%:74J=@7O4'#,_[L0H3_-AIZ<F(J*N9"NE3K'WN-H MT/F',#/RIE/"!5UTEHG"5&*J1!6$6I7&V.WTO*!OSF2I@.B5.K$?K=W#!24T)OWB /X4J;_A9/)?*ST.UV9 MZXDL-4+8W#V,2!(%K-1!K3(*H(6;5RBX1D^?PHF7@" M>!D T2X+8@Z0QU@,6X6"DR WP?&XGD&G>NH02T!=(*<0F)T>B5N[)Q.#[CYD2QD,5>DF&%=G,YU)JUWFF?^@%&X%76<-!(2SH6] MI!_+6<"5RCJQD \4%@X2U?H(1K1'X*ZV2P"+-0 3C."&!11326UALW)+I4J+ M%@OUZ%B\Q[-B'G&R^DAY.'E7-'KL8@@YS10Y%VU/1B1JG=6/Q"4 M[HA#:(=,' M#5V\WJT5T*-_B(00,H14:,<5!EE9/5$2XTFJT8WH:R8U(E*R3AP=DAR7.U+((7J,#HF09- MIB;'T3HAX@RUP=B4..5@R.A/ R2W'JB$\M0]XXF5$:5+Z..J2]F&,6\_PM.?DB7V*Q M9EE]W4I?8T!>H-@,X6PTX4IQ\.J0/<_<+XL$#-)R?UV2G4WS=5M$:,Q]1'O] M>$L/N%*4Q*C+G5MON/KQ!W>3X\F%&'9'(=^/IJP*F!,3IPM5T3F3:.[9V7<@ M?>3(49)1I>. R4=IT1$ <3D*74TGPO291!(_R P(X=L3@>-1K+WYBZW]CX*HQ$HAKE,-8^,0%]$BL#XI?%9&S MLNTX@!2UVB?PI@R&A5,/RL+$3'FOM34DP-C4MLF56'R!YP&)CTIF>'1]?4&P MBZZ*"E"OG?C=&J0?;GMB7";UQ4(K8 *YC$83A]WZ$K3!*I09G)HFH_)KP X* MU8EE^;0FV,UAP)R $Z!1&>J#T0$@"/&K@1^^EM\@)]=(3?L4D?WNF<=HJ&HK M,3F' 9 93U'+06CUZ)9G]M'Z=CQ;]$:8&D>,MK]H+IVATK5;^R),CY7!8('( M-)GH/,M[Y= 6&*HTU(QY%H^#LPF=,P)V2JF[I+ZA?R]!R0 GLW&:*+DXTHP6 M1RV9M#P$H!Z5'ET1$]*V\6JS#NSJCGT&\IFR 1\KN@;4[>J.'0UY[8/F_0K3 MW;/;7<]MIJY0D0N>E%Q$;;$+O$Z1B9GHD!*];WL?6W/ [ZC"#GPP>&0GWX,^2* M;Y_7R+A>5K\9^(PJ^\&\EQ#4'ZJJ(&HQS M1\+=*>%DQAFCUF;;Q#@_TV[VH'+'R-WP-@]1R]+5^*B!,@U#33/\ H$U0U%H MQ\-<)'*)]$5?'D"'X=!WSHSJ^'F5($P[:L.PD1H#2UT@N?:@<=QV5XU3M!,T M!$@*8311]H$ZXP^*18?W,U'HQE9??6S:0:[-*) ,A]JMAWY! UM;XY KN]Q& MPQ/55KJ]#QSY,G>Z_CGP'UW_\;Y61#;/"^RFFDL/D[^7SK?D,IU/,?*$MV.^ M2Y48]SFOD1%'9G94H@E7U9)JVB$& PA,R+< *6H0P+^NA!<;!8*TD-GL&653 M&TUQI+=PE9X]-?SBZ9*')QKU#'I[?H\A[1SZ3 -2P_S? #=: 2X:T@^AWR=:C8X98D% MC!^AG?:NG5$+%=Z%_\S>==L/"RO"R7!1;0 SV<&'!8N MZ(#V9\;S_P-02P,$% @ W*X75]5NPVYP!0 C0L !D !X;"]W;W)K M&ULE599;]LX$'[7KQBXV:(%5%N'CSB' <5V-P92 M.QN[+1:+?: EVF(KD2I)Q=5.OBHM=3<4ISHKJBH!Q/=D+F1.-2[GNJD)0D5BG/>H'G#7LY8;PSN;)[ M]W)R)4J=,4[O):@RSXE\OJ&9.%QW_$ZS\<#VJ38;OB M)"RG7#'!0=+==2?R+V[Z1MX*?&/TH(Z^P7BR%>*G62R2ZXYG"-&,QMH@$/QY MI%.:908(:?RJ,3NM2:-X_-V@?[:^HR];HNA49-]9HM/KSGD'$KHC9:8?Q.&6 MUOX,#%XL,F7_PZ&2#48=B$NE15XK(X.<\>J7/-5Q.%(X]UY1"&J%P/*N#%F6 M,Z+)Y$J* T@CC6CFP[IJM9$GBQ7FSE$?S[,YU_FR\T:[J._ MHYN[^55/([@1Z<4UT$T%%+P"Y ?P17"=*ICSA":G #UDU5(+&FHWP9N(,QIW M(?1="+P@> ,O;%T-+=[P5;RMAAE3<294*2G\$VV5EE@6_[[D;845OHQE6N5" M%22FUQWL!47E(^U,WK_SA][E&TS[+=/^6^C_)REO KU,TZ [PRZ\8@56W/E" M9)Q"4,?>A7H=-NNHD"R#_NDR&/T6?X9QLUC%6FRI/#HF/(&E>*2YW1XTVXQ# M+#BOVM4Y,)V"3BG0)UW/ +&S&PG1%+;/<$A97(E,15X0_@PI4:"%0;$S!L4( MW)0*@Z*4$=HR3NPL^* H10HH,/KHGD!0KJFD"9+1PB& (6-4&PEI3BNM((/[]^=!X%W:2U$[;[=]2\_ LY2* M#E>!< MVJ/ WI+-1Y[][K=?]Z54)>':06H6DLI<':,<>5/%395;%4N&F52@ M4I)E.*ECBH,6#D1*8J*!6$6)]8.S$P2G1@R[#T&;F,5NFDV1-Y1 MILW0:ZO4,6V4 +$FHG*/W,$?VE[$-C=Y.HV:H>R/+A4D##.L!>;;8B7&=FW MNG!B_7SL>L&X@6H(5FD!DU&9/9M2/S[%IBHK6-,=NQW+F.D.G6)>4 R[6TN\ M]4[G!;3SHJJ$A%9EB1YN<=1T8<$=$L=")H9>)1VMI] ?>9\"_!M\P@ED;PA[ M-!4<:U U 5PAL(25#;^"3Y7@@N/U458=;Y5F5!,L\VU&VQ2Y,'##D>?ZYP,( MPY$['OL0]K$-AR/H^R/7"T<8=5.P(0Q1-!B"CV/7&X<0NH$W1L40-BEUCFJW MR,Q(:CW8B(+%;6XBF?WU= MK!>;Q6H)T]7#?74=K)W-"I?+]>IN,8LV\QE\7BRCY701W<%Z@QO536$([42& M#SJ;.^NQO5]LN[YNH%[1T^DG,J]?0@JL/#5:ZG= M;=^:4?7$^BU>/53Q,MPS+(.,[E#5ZXX&'9#5XZ]::%'8!]=6:'R^V<\4W\M4 M&@$\WPFD7"^,@?8%/OD/4$L#!!0 ( -RN%U&PO=V]R:W-H965T&HW M+;/]8;__Z/*(I.YN-+,E,LEU^OW(E/W;W<&.^&':SE? M%/3#_KLW*SX7-Z+X?76E\6V_HI+*IYH[U9&TL?DY4/]@98+MSM,-2,>-E5ERK^U^%EV=,]!*5&?N7W;NUX^$.2TI3J*7? M# Z6,G?_^1>OA\:&H_Z6#4._86CY=@=9+D]YP=^]T>J>:5H-:O3!BFIW@SF9 MDU%N"HVG$ON*=R>7GSZ=WWXZN[B]89.+4W9R>7%[?O'OLXN3\[.;-_L%CJ"% M^XDG]]Z1&VXA-QBR3RHO%H:=Y:E(VP3VP5O%X# P^'[X*,53D?38P2!FP_YP M^ B]@TK@ TOOY3:!U7(I"\"J,(SG*3L!NS*?BSR1PK!3:9),F5(+]M_)U!0: MJ/E?EQK<(0?=AY GO3(KGHBW.W 5(_2=V'GWKY\&+_NO'Q%A5(DP>HSZ\VWV M*+EN9B\N;\^BPQY[]"SV.XRL[[4D#4:3N1:"%,MN%R*"GE<\7[.YYGDA4E8L M!"O#2$"(3!@(Z75#G[C['UI8#ICB)>IS.V3 M..),4^2A)3.I34&ALC3@ ,( O0RZHJ#X0I=Y3OI9\IS/Z4-3H^!ME0$"UGP( MQGD1(Q 5"\8+E@D.J@?]7P)G JRII4R,%PI6AB=%/,O8K"S(=U9.>/*OE99W M))7XNY3%.B:Q[J!B./! MH+\[V]L=[NV>[>W*/3)=LMC00!0T8!;$4ZX*MN!W.(ZEI:[TN51@M%AP0&\! MX+*UX+#B3*NE$Q(LV8S1,HH6D_ MK=LX\\K9,_J3:_($PW:)OCTW6Q-Y(Y*27%&8/9@/=*90)F)LD3D%M52HG6SP M?%."FL5LWE *OF.[D?-<6"@!;J1C[86(NJPD34/CMVT)..#_EP)[:R\/HDW- M,(/:6KPN^><0C8I[!:S">5)2"]RB&12<3'2&A6--\0$#M&N#A4VS)=" K5KH M6/%%Z$0:X7GM4AYX(1'"O@HNWR%Y(XB&S%,%4&&B[N#9 M:V>!)MIMP BY@!QLV'^]DO/Y^L64)Y_M#X/7G4S9D 5=KKP)#?5FHE;XRVS%]G,%/9142,3*O0R/;%'W5"%;M&!YOD/3:YBN$UR^2D(BP_S,[.G05R;C?M__K M0J?^9>!_@5(ODT)-A8[9MREV!L81$4BI3ATM!9Y]23)(";!_J-9MJ)*2?/2 M2D.I%BC<-$^"^1H&14W&C9P"7065"CQ;&VD3#?X5-L]#_;F8*V1-7W*UGR5\ M)0M*J!FW14SLDAKDT+Y)XDV&OMJ8<2OS5/&P[4 M3DT,#/\!#-PNI'X" E\5!N"+GT5=$]/"Q!EZPZF?[Z+1$^K<(D)3F^,.;8Z_ M19MYIQ*[_.:!AEIZH&Y%VLZL3GC*MJ,(-8 ^>O(5#VV+9G:UXP/R&(4&0SK< M,THP&F)C$]H(E+$SF7@=0M<%G,%Y0&L3B%#SIPK: ->N$5^'6(.F)O'5H8O$ M<8<]M;B3XAX=61BYQ4TG=CN\)[HZINFB+3Q$/RID=]A_V&'_P;< @!J"C9[9 MM*!P53V=F(@J3/BT2%Q6UK!VTW)JPY$).A>%+[8+KN=B:^$8>G'?VCT> M8:.']FP!;\;L;,B'6.,BI4=*S#)!!;VQ-MZG[LS"I@X6 4!?[_71,ZR\J6AO M;I35;@IB>QY)+2%E"]3%Q;T0.1M7 XU"%131YC#PG)H5PS-A>Z9$A#ZFT23" M?4A5.%X7@4*7#-9<[A!;3G\#A::6H^#3=?'JX>WHZSL/N#F.J2*BSO*$,[).#4Y919X01DO*0RK$#T"IOI8* //-*G MBC&T)9D4.J)&/H%.''.-9E5IWXU0!FY$C*U*)K0)VZOFJLH[#9T #<9Z'9&M M!.U1#*A%.PRB/2NE3K7Z+/2+5 R[4SPWCTYM4\>S0>155+JFO8FQG&"C[<^ MJ9J.M.O[S3G7=F3!Z8A[^E*-4QO]27/ZYB=S/N);HO8;HAEYU=G M08;809E4C#\2ZN6)+>U]4@#KOC+WO-?57J%6,ND* UL:]&<%^Y;"6R%_[$)^ M+WH2Z;^5N6#'%@D'#T!N0T4#VV&<(Q"%=8-L"#!-3FE >@/B=WRS@70TJ^%0 M8_;U0"8KKA9TU]8:4UEOV90V_/=M>274L^"]D> >RV_;:AT"+%T/U EF$^B0 MQL>VM9M/"@H!=CY;5R-VYD8N[D_GB4.?2,,P!GO\,PK\+E"VJ_EIN4:6ZD57 MWY5;[)4#J=M&M!"?JFQC[P%ISI]8A1WU^K_L!>/.D8OML#41(C6H_!*!(F]S M&/&]\?SL2^%O3:WM$07"4&8CNBT$\I"$4/2(3?*<1/@D1.$#[@W- ,-$+,1/ M>.1*&0LV.]BXP^)7;%?N$5RTPC-_]V ?"@LK*# E)49;2I4)+?"CZFMAQTPI M.Z% 94M8>]AYGBB6TC=H>Z,;88K(>H;?VTU+"E]HHHJSH-9&NZ\I;.^&X.;N07.W U MI&M>CT^A W)VV@K,Y!DIP;I976]8M%M$PT*=@+%1 MTH5U^$T*[M 9 :@]YN_%ZDJ>9^"#MMV)<#_4#4)W:67GS[8\HOC\ #/DW=&5 M][8 G-<>-"TWU.*%0X/5M:6'J))*Q!X75[L]\KVB$@)*.*U6-ID(O[(SW^MU M,.-1_) C3I$^F%0A]X1NEARM7+*/'Z_"Y=,F6Q((6A&,[*6;NW2A0L2%"I@I MW#PFB2K1K-A!NQU=&=C&WO&1%_;;/7L)"&/1-:];9K8I3Z\=# M,DW,'FBJHFP5].C9O1\\0MS,!:8ID45)N*)+4090M=\_IE'T2WPC",CPY'(!EBXR"0]-\/PO<)7#ACH_;7X6&]G"J3R'WQ@^[&8])0/?,: M/UFATX,+6(8UKB5VC? _OMQSMR2;*V2>9"5%)KJ>3;1T+R34-U:!0'3L"6"7 M7F\_T;JQ5/=W! [FWE@I1+B$CCI\:13=$HNV2 MXJU\;N=\\-_EORWI;DO^CF2-$SU9NVTC?YIGY._K>_,U^3/Z.OC]_ M5YZ H(VL6O@&950U)J$WGMOA MS?!ET$XUS_&+#JJ4Y+^[K.O2T%%73^P5!0YJ/56A_E:7!JV@JRZZH14][:"P MGBKGBXI]_WICB_VC-OOU$L=[P(,5A[)HO<"_>P#7S-8T\JA%6_+4O@75 84M MWOA$A7 0#XZ.8I!@!R-0&<7CP:CY$07#:!0?NE+!M4'#+IU;1^>M6!BR5S,K M. HD=]5&-(J=L]C9BZBF '1QMRU&N?<18Q]J*@34:)I6'D'6Z'8$9TR^M$YA M477DWE[P_X9POH/Q,4,->7P4'X\.>_UC *]WC+_QR\%A/!J,:0![>(AUPX/> MN(&7RHW)(+^56<.SHVUNZX_M>M5VO_&JM!WM MZ^7NA74X)JH"PS(QP]9^[W"\X]X!"E\*M;(O7D]54:BE_;A 0!6:%N#Y3 &2 M_@L=4+V)_^[_4$L#!!0 ( -RN%U=5[;I-;@( %(% 9 >&PO=V]R M:W-H965TER&40C_S:0LS*4NBW"19J/PZBX'WA(=]DUBV$\6@K-KA$^VV[T#0+&TJ:ERA- MKB1H7(^#R^A\TG7VWN![CGMS, :7R4JI)S>Y2<J^)&G-AL'PP!27(M=81_4_AKK?'J.EZC" M^#?L*UO. TAVQJJR=B8%92ZKKWBM_\.!PY!]XL!K!^YU5X&\RIFP(AYIM0?M MK(GF!CY5[TWB;D9^/EX_WTR_7][6S^L#P['?)H< &S^=7-].9Q M%%H*X,S"I(9-*AC_!!9QN%/29@;F,L7T;T!(RAIY_%W>A!\ESC!I0R=J 6>< M'^%UFG0[GM?_A#=_WN7V#7Y>KHS5="-^?91DA>A\C'!52)XA:C#'W M &O3.P*I8*K*4LG:H,_^M;A618K:G B-@-+FML 4K (E$5Z41:#> 2B2#$SF M;'HM1D?*>XR"#;O=UF#0I?-M1;SGJ;XQF(_^97APSTO4&U_-!A*UD[:Z\LUJ MTS NJSKY8UYUFSNA-[DT4.":7%E[T M 5Q5<3:S:^JI9*4LUZ(<9-3W4SH#V MUXHRJRJ?@DL!P )A$ !D !X;"]W M;W)K&ULC5A;4]LZ$'[WK]"D9SHP$Q([ ZW%^5B)=6SSADSY*4L MA+[LY<949\.A3G)64CV0%1.PDDE54@.OZFFH*\5H:H7*8C@*P^-A2;GH75W8 M;P_JZD+6IN""/2BBZ[*D:GW-"KFZ[$4]_^&1/^4&/PRO+BKZQ.;,_*P>%+P- M6RTI+YG07 JB6';9FT1GUX>XWV[XQ=E*=YX)6A)+^8POL_2R%R(@5K#$H 8* M_Y;LAA4%*@(8?QJ=O?9(%.P^>^U?K>U@2TPUNY'%;YZ:_+)WTB,IRVA=F$>Y M^L8:>XY07R(+;?^2E=L;C7LDJ;6192,,"$HNW'_ZTOBA(W 2OB,P:@1&%K<[ MR**\I89>72BY(@IW@S9\L*9::0#'!09E;A2LM=??X4'8?G'^ Z M;'$=?J3]0Y]_+'EWOY@&IP/B-9 I3?+@H8X+GI#&7,*$X:9@FIB$2I2(J3!#Q55YKS=L0TK'(217PSJ"HY" M,? $NH(*,@Y)2M?Z\Z>34?3E'"4!V$IQ8YC=VBCJ0D6,N'\4GH_# Y#NKE8, M-*1V.3K?1]\R" =9-7%PKC\/ /^K49DU1XIB#<]]%Q?"-1B2U$I!Z." )ZZ- MHO8(;< [)7X&ZUF602V# F%RV*4K?(%#$:.-FWX3N!HR4Q5K+IZ@ZKY"TP%U M[C=07[=,1G@8,%Q&)@&\QG+ E*(F9S969 :(4X1 8[ET@4J@)'!1XS[K#"N( M1M+, ]K6'4D2<&P8./H 9EE 2YY4B&A]/]A%-50B'6B> QP+)8^X;"MI (: MBW7?B@,Y^YPM$3$1=QJ 0?/H.&\!46GC&_*F!\.@9&1OHW> X."SE2VYCO/>R;W=5 M2J9U8C!0^/K7(SJ$VX&U3TIHEKPJN#O.\H #J\%"R+V8F16#5'SK".+.#[9M M1\9U4C2C7$'0U3,,,TM:U,S[?P_ZM+,1IY!]/'MO[2Q\(S/ PO8WC0'8#XPI M&75P@5@*J 9TJJ0R<%!!M2&:%IL&>&HW)4AO.L^G712VN8;U"M+0/DMWE,FY M2OV& //+%;(FKIA7N'65Z7M:J=;4C;K< [LHJ;(-8?UBZ56Q<94&$1#"66DTVMZVJI@0F3 D=0"6G MRH61%S5.GTU_Y5K7%#9I6_)\KGG?XBHB3%..!T+*OI-L@ M=;=8',"<\ U+- MH(F $'-5(:$5-R"N*->V<->JDAH6H9< 2-$,QMA/;-U-"FGWP3EH(Q>@"L2O M:_B*T0" ,1>N,6'O%0ZJ=[-J&A3:N;&0=7KP/^049X?H&/_^FOV:WM\%WZ:3 M[XMO9'+S[\_9?+:8W=^1F_O'AP'!<6<>+.[A]6Y^_WUV.UE,;\G7V=WD[F8V M^4[F"_CP8XJ#4#-(!&T <3K9GBYL5'F*;2UYK83;H6_'$[I[1G%$C#&QQ $2 M ZY)<3.GX!P4OU8O)&I R2:?^[:78PM(< R##E)(\#JUK6[M.RA#>* J9T5; M*WU$_ B'":N:?(*N7.(D8TN#T%A3D5_S.L;&:*F[Z9SN2CL[0H\N+0-0/3TEI;PBNI.XZ$"81U;K+>K$Y MO%/P7$7+-CRPDY/=:6T#:>7/=5]B7&3L[\(=$;HHT$8DHG&?@^W,6:[O;^16>]M M?XW\#+O"/Z.P'XV.^B$HB4[PGWT<^:===Z=AY^Y:,O5D;^C8&&%4=-?8]FO[ M(\#$W7U?M[M?$'Y0]<2%AFJ3@6@X^'+4B:E\2]X0/O3R-5_4$L#!!0 ( -RN%U>G_&_/H0@ ,4: 9 >&PO M=V]R:W-H965T:J?(:WX&9)%4. M(1NJ$I(%DGTX=1Z$+8(JQF(E.9GLK]^6;(,!0RY[S@-8UT^M;O77+?ODA?$G ML2!$HA_+-!.GK864JV_MMH@79(F%Q58D@YXYXTLLH%' M,B'R?G7'H=9>HR1T23)!688XF9^V(N?;N:_&ZP$/E+R(6AFIGU*587+: MLI5 )"6Q5 @8'L^D3])4 8$8?Y68K?62:F*]7*%?ZKW#7F98D#Y+_Z2)7)RV MNBV4D#G.4SEF+U>DW$^@\&*6"OV/7HJQGM]"<2XD6Y:308(ES8HG_E'JH3:A M:Q^8X)837"UWL9"6\@)+?';"V0OB:C2@J8+>JIX-PM%,&64B.?12F"?/+J/A M&#U$U_<#=#.()O?CPVBJF'#W@-"?H@HHX92+G M1*#_1#,A.9R._S9MNH#TFB&5QWP3*QR3TQ:XA"#\F;3.?OW)">WO1P3VUP+[ MQ] _8INC0,UBCFZG \.Q+71@&31=$&/.4G!;FCTBB68$+0E61D@0 MU.?*/,_:/ H3/#[..8>E#? ZJK 0FR,X%&0Y(WQ],#3X;BO\JV::)33&DFC9 M:O@+2CCF\>)5(:H^U5SLA6:K7(KZ9E N0>Z_26)(!OXN"0#B_OK@7%[65=I-)D,0)G1Z )=#Z/SX?5P.AQ,*DU?H-L1&@_Z]^/Q25W2# M^1/0?!3'&O-G%)J>']:>VF[N]TUI>^)EGB4"+4BJ-(NF'-BI!A9X9M<)3*\7 M[%;V8:\WA\&XX_19V>A/S#D&I*KO%<;W;-NT;;L)8]-K3/+91F%-,(X9>H$9 M.(W"U/OW-.B\H4$OL$T_"+9*#5K,98[3-_3GVI[I=EVSU^WMU3ZO0=]TNEW3 M=9T#6]_T*W??02H\MTF]0KLO+H0'_P4R4 Y:=W*:Z7Z>X"PF$-7D GRAC^!8 M_.;;&EA!E'P"$&H$S'DI%C#J4+"NR)7PS;&04LTR0:;=B6D/" MI$=JMH/*C9H5)1$A*)C"GM/- 3- !%.V/::JF?/HK#%]2%WN_J0VZ8> MJ@2HINT2^;!LDS-E.Q4P7",DX45GD"9BCC!LW*.0?VI/RDT2P?BFZ%&F!*$9[% MP>!3B^=H.+J[+P.1ZHRF0P@]TT'_:C3\XWXP,8;%#J(#@C2W.\:8BJ??YIPH ME4!LA).)N-J9;WD]] MR+,]&OQB#'RM(P]5IA? )!T9=%Y3QO[P2S,57B&6N MY3@HL )[,_:9*:UI(K,MVP&TCA4"V$2R^ EM#Z6'X,+@=&5>#Z'IZA:+^'_?#R5"?W/[M^,Y"*HF=&--;J(XF MM]?#BV@*.=7EBWQ%WU5HK[59:LO17X__BK\8! M?U7M]=-59(1?*BJ_V1CT:SFZ/*!&=7R/#H:3;?3>,4Y[Q/L@BZ'^NQ8'+S0J M+WS/4.?8T",L9OO .Y[5 Q:#FJ-8R+5ZKGYT;?T(.OKA>>N'42:*"9F50 [J M68XBQ*[54;-Z5NAK0O-58VAU OVP56W4CM3O3=+TK="&OX[^Z\)?$%9MH2KY MOOX[1JA SUV]L6Y!UO;./VQ._X.LD!RR6958@EYCX-B4R()RSA7W$"%4XC"C M6>%"VH-A-FA/ ?H*!6E%-OP=876_4Q7LLN"ZNP6G&F-W-P5#9[7KBUR1FR4& M!;?9W/@DB1<9_:N@+$@'&5\Q7ET:E[MV!,?'0!./&?!EC/5%>*4NO^_BDLVB M;&Y\F%S,?6_>BBGK *4B3G,XTORT%;$LX)$B"\6"%!?SPX)I&B,_"(^I($F1 M-?(#GO,"NP#R3RS4N(!2&BO@8:2Q [JG]@W:]!UKJLQZQB!I%S'),*=LG6L? M-Y!1-]";[+^="6C5;B<+UM%7*,5+AMJU8N;XL M(0^\63$:WE+TKZ+1[X,)1)IZ#%(1:1T_AZ/)='RO ZAQ6;LX-9[0PO',3NB9 M7N@8_::KT)?0##J!Z< 5\.O;B$[]AOHOAL/8 Y:4FU"]E^RAP/0Z-N %_P*K M.AZ>US%[O4])M>6PR/,=LQ=V/@]4L0'RG8YI>Y]"JI$,]Z!<]@U_;!K>G;W/>?056]DS*!\B?0_3DJK\,1)S""N M_*V<%J5,:%*(69:5'S!V7T,T\T5ULSS\Y@8&_HPVV]\X9-,KZW;MT\*2\$?] M 44@_=ZG^,JP;EU_HXF*3Q.;X<4''G"(1^ JE)(Y3+4AY6D!D^N/)D5%LI7^ M4 '4+=E2%Q<$)X2K = _9TQ6%;7 ^LO5V3]02P,$% @ W*X75QK#BQ>B M!P A1( !D !X;"]W;W)K&ULE5A;<]K($G[7 MK^ABDRVGB@A=N-B)[2J,Y2RG$IPR.'LN=1X&:8"))0UG9F3L_?7;/9*P' LG MYP6$-'W_^NM&ISNI[O2&X'G#7L9$WGG_-3>^ZK.3V5A4I'SKPITD65,/5[P5.[..GZG MOG$CUAM#-WKGIUNVYG-N;K=?%?[J[;4D(N.Y%C('Q5=GG;'_X:)/Y^V!;X+O M=.,:*)*EE'?T8YJ<=3QRB*<\-J2!X=<]G_ T)47HQO\JG9V]21)L7M?:KVSL M&,N2:3Z1Z9\B,9NSSG$'$KYB16INY.X/7L4S('VQ3+7]A%UY-@P[$!?:R*P2 M1@\RD9??[*'*0T/@V#L@$%0"@?6[-&2]O&2&G9\JN0-%IU$;7=A0K30Z)W(J MRMPH?"I0SIQ/9Y/K+Q$LQO^,YJ<]@QKI?B^NI"]*Z>" M!_ %YF;C88H3WCR M7$$/7=G[$]3^7 2O:KSDL0NAWX7 "X)7](7[^$*K;W@HOCR6&8<%>X!+H>-4 MZD)Q^,]XJ8U"1/RW+>928]BND;KD@]ZRF)]UL TT5_>\<_[[;_[0^_B*O_V] MO_W7M/^T'J]*M_LVNUY$CN^[T-0-BPUW)C+;LOSQ]]^. W_T44..)("(YDKQ M! RFC&G-C8:C5+"E2(417+_#FR!7@(7BV9*K?;& Y'8)GZ?CB^GGZ6(:S9V7=E[8 MP#,O?/[@S U3YGVQA5AJC.$-^%WO9-3UO#Y>CT[PU^C$]3QG',>J0%F1&XXY M,^![7G

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

    &PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " # XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 237 286 1 true 77 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://viveonhealthacquisitioncorp.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://viveonhealthacquisitioncorp.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit Sheet http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit Consolidated Statements of Changes in Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN Sheet http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN Notes 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - INITIAL PUBLIC OFFERING Sheet http://viveonhealthacquisitioncorp.com/role/InitialPublicOffering INITIAL PUBLIC OFFERING Notes 9 false false R10.htm 00000010 - Disclosure - PRIVATE PLACEMENT Sheet http://viveonhealthacquisitioncorp.com/role/PrivatePlacement PRIVATE PLACEMENT Notes 10 false false R11.htm 00000011 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 11 false false R12.htm 00000012 - Disclosure - NOTE AGREEMENTS PAYABLE Sheet http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayable NOTE AGREEMENTS PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS??? DEFICIT Sheet http://viveonhealthacquisitioncorp.com/role/StockholdersDeficit STOCKHOLDERS??? DEFICIT Notes 14 false false R15.htm 00000015 - Disclosure - WARRANTS Sheet http://viveonhealthacquisitioncorp.com/role/Warrants WARRANTS Notes 15 false false R16.htm 00000016 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://viveonhealthacquisitioncorp.com/role/FairValueMeasurements FAIR VALUE MEASUREMENTS Notes 16 false false R17.htm 00000017 - Disclosure - INCOME TAXES Sheet http://viveonhealthacquisitioncorp.com/role/IncomeTaxes INCOME TAXES Notes 17 false false R18.htm 00000018 - Disclosure - SUBSEQUENT EVENTS Sheet http://viveonhealthacquisitioncorp.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - NOTE AGREEMENTS PAYABLE (Tables) Sheet http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableTables NOTE AGREEMENTS PAYABLE (Tables) Tables http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayable 21 false false R22.htm 00000022 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://viveonhealthacquisitioncorp.com/role/FairValueMeasurements 22 false false R23.htm 00000023 - Disclosure - INCOME TAXES (Tables) Sheet http://viveonhealthacquisitioncorp.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://viveonhealthacquisitioncorp.com/role/IncomeTaxes 23 false false R24.htm 00000024 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS (Details) Details 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE (Details) Details 26 false false R27.htm 00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 00000028 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative INITIAL PUBLIC OFFERING (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/InitialPublicOffering 28 false false R29.htm 00000029 - Disclosure - PRIVATE PLACEMENT (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative PRIVATE PLACEMENT (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/PrivatePlacement 29 false false R30.htm 00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactions 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF NOTES (Details) Notes http://viveonhealthacquisitioncorp.com/role/ScheduleOfNotesDetails SCHEDULE OF NOTES (Details) Details 31 false false R32.htm 00000032 - Disclosure - NOTE AGREEMENTS PAYABLE (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative NOTE AGREEMENTS PAYABLE (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableTables 32 false false R33.htm 00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingencies 33 false false R34.htm 00000034 - Disclosure - STOCKHOLDERS??? DEFICIT (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative STOCKHOLDERS??? DEFICIT (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/StockholdersDeficit 34 false false R35.htm 00000035 - Disclosure - WARRANTS (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative WARRANTS (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/Warrants 35 false false R36.htm 00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) Details 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) Details 38 false false R39.htm 00000039 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative FAIR VALUE MEASUREMENTS (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables 39 false false R40.htm 00000040 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) Details 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails SCHEDULE OF INCOME TAX PROVISION (Details) Details 41 false false R42.htm 00000042 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) Details 42 false false R43.htm 00000043 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details) Sheet http://viveonhealthacquisitioncorp.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details) Details 43 false false R44.htm 00000044 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://viveonhealthacquisitioncorp.com/role/IncomeTaxesTables 44 false false All Reports Book All Reports form10-k.htm ex-32.htm ex10-19.htm ex10-20.htm ex10-21.htm ex10-22.htm ex10-23.htm ex31-1.htm ex31-2.htm ex4-7.htm vhaq-20221231.xsd vhaq-20221231_cal.xml vhaq-20221231_def.xml vhaq-20221231_lab.xml vhaq-20221231_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 19, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 611, "http://xbrl.sec.gov/dei/2022": 47 }, "contextCount": 237, "dts": { "calculationLink": { "local": [ "vhaq-20221231_cal.xml" ] }, "definitionLink": { "local": [ "vhaq-20221231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "vhaq-20221231_lab.xml" ] }, "presentationLink": { "local": [ "vhaq-20221231_pre.xml" ] }, "schema": { "local": [ "vhaq-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 473, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 70, "http://viveonhealthacquisitioncorp.com/20221231": 9, "http://xbrl.sec.gov/dei/2022": 3, "total": 82 }, "keyCustom": 40, "keyStandard": 246, "memberCustom": 46, "memberStandard": 26, "nsprefix": "VHAQ", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://viveonhealthacquisitioncorp.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "VHAQ:PrivatePlacementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - PRIVATE PLACEMENT", "menuCat": "Notes", "order": "10", "role": "http://viveonhealthacquisitioncorp.com/role/PrivatePlacement", "shortName": "PRIVATE PLACEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "VHAQ:PrivatePlacementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "11", "role": "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - NOTE AGREEMENTS PAYABLE", "menuCat": "Notes", "order": "12", "role": "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayable", "shortName": "NOTE AGREEMENTS PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "13", "role": "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - STOCKHOLDERS\u2019 DEFICIT", "menuCat": "Notes", "order": "14", "role": "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficit", "shortName": "STOCKHOLDERS\u2019 DEFICIT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "VHAQ:WarrantsAndRightsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - WARRANTS", "menuCat": "Notes", "order": "15", "role": "http://viveonhealthacquisitioncorp.com/role/Warrants", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "VHAQ:WarrantsAndRightsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - FAIR VALUE MEASUREMENTS", "menuCat": "Notes", "order": "16", "role": "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "17", "role": "http://viveonhealthacquisitioncorp.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "18", "role": "http://viveonhealthacquisitioncorp.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "19", "role": "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://viveonhealthacquisitioncorp.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "20", "role": "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TemporaryEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - NOTE AGREEMENTS PAYABLE (Tables)", "menuCat": "Tables", "order": "21", "role": "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableTables", "shortName": "NOTE AGREEMENTS PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "menuCat": "Tables", "order": "22", "role": "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "23", "role": "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative)", "menuCat": "Details", "order": "24", "role": "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "shortName": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "lang": null, "name": "VHAQ:InitialBusinessCombinationPercentageOfTrustAccount", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS (Details)", "menuCat": "Details", "order": "25", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails", "shortName": "SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:TemporaryEquityTableTextBlock", "us-gaap:SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31", "decimals": "0", "lang": null, "name": "VHAQ:FairValueOfWarrantsAtIssaunce", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE (Details)", "menuCat": "Details", "order": "26", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails", "shortName": "SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_RedeemableCommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - INITIAL PUBLIC OFFERING (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "shortName": "INITIAL PUBLIC OFFERING (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - PRIVATE PLACEMENT (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative", "shortName": "PRIVATE PLACEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "VHAQ:PrivatePlacementDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_PrivatePlacementMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF NOTES (Details)", "menuCat": "Details", "order": "31", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfNotesDetails", "shortName": "SCHEDULE OF NOTES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - NOTE AGREEMENTS PAYABLE (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "shortName": "NOTE AGREEMENTS PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "VHAQ:UnderwritingFeePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "VHAQ:UnderwritingFeePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 DEFICIT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "VHAQ:PrivatePlacementDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - WARRANTS (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative", "shortName": "WARRANTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "VHAQ:WarrantsAndRightsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:BusinessCombinationControlObtainedDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_PrivateWarrantLiabilityMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)", "menuCat": "Details", "order": "36", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "shortName": "SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember_custom_PrivateWarrantLiabilityMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-10-27_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES (Details)", "menuCat": "Details", "order": "37", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails", "shortName": "SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-10-27_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputPriceVolatilityMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "menuCat": "Details", "order": "38", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails", "shortName": "SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31", "decimals": "0", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - FAIR VALUE MEASUREMENTS (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "shortName": "FAIR VALUE MEASUREMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-12-31_custom_PrivateAndSubscriptionWarrantsMember", "decimals": "0", "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingCostsAndExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCostsAndOtherAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)", "menuCat": "Details", "order": "40", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredCostsAndOtherAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (Details)", "menuCat": "Details", "order": "41", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails", "shortName": "SCHEDULE OF INCOME TAX PROVISION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)", "menuCat": "Details", "order": "42", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)", "menuCat": "Details", "order": "43", "role": "http://viveonhealthacquisitioncorp.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails", "shortName": "SCHEDULE OF UNRECOGNIZED TAX BENEFITS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2022-12-31_us-gaap_DomesticCountryMember", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Deficit", "menuCat": "Statements", "order": "5", "role": "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:AmortizationOfFinancingCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN", "menuCat": "Notes", "order": "7", "role": "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern", "shortName": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "VHAQ:InitialPublicOfferingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - INITIAL PUBLIC OFFERING", "menuCat": "Notes", "order": "9", "role": "http://viveonhealthacquisitioncorp.com/role/InitialPublicOffering", "shortName": "INITIAL PUBLIC OFFERING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-01to2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "VHAQ:InitialPublicOfferingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 77, "tag": { "VHAQ_AdvisorFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advisor fees.", "label": "Advisor fees" } } }, "localname": "AdvisorFees", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VHAQ_AgreementFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Agreement fees.", "label": "Agreement fees" } } }, "localname": "AgreementFees", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VHAQ_BusinessAcquisitionPercentageOfVotingInterestsAcquired1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Percentage of outstanding voting securities" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired1", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "VHAQ_CleardayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clearday [Member]", "label": "Clearday [Member]" } } }, "localname": "CleardayMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_CommonStockTenderedForRedemption": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock tendered for redemption.", "label": "Common stock tendered for redemption", "negatedLabel": "Redemption of common share, value", "verboseLabel": "Redemption of common share, value" } } }, "localname": "CommonStockTenderedForRedemption", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets", "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "VHAQ_CommonStockTenderedForRedemptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock tendered for redemptions.", "label": "CommonStockTenderedForRedemptions", "verboseLabel": "Common stock tendered for redemption" } } }, "localname": "CommonStockTenderedForRedemptions", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "VHAQ_DebtInstrumentForfeitForCancellationShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, forfeit for cancellation shares.", "label": "Debt forfeit for cancellation" } } }, "localname": "DebtInstrumentForfeitForCancellationShares", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "VHAQ_DebtWithConversionAndOtherOptionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt with Conversion and Other Options [Policy Text Block]", "label": "Debt with Conversion and Other Options" } } }, "localname": "DebtWithConversionAndOtherOptionsPolicyTextBlock", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "VHAQ_DeferredTaxAssetsAccruedInterest": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets accrued interest.", "label": "Accrued interest" } } }, "localname": "DeferredTaxAssetsAccruedInterest", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "VHAQ_DeferredTaxAssetsGrossTransactionCosts": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets gross transaction costs.", "label": "Transaction costs" } } }, "localname": "DeferredTaxAssetsGrossTransactionCosts", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "VHAQ_DeferredUnderwritingFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fees.", "label": "Deferred underwriting fees", "verboseLabel": "Underwriting expense" } } }, "localname": "DeferredUnderwritingFees", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VHAQ_DipakVashirMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dipak Vashir [Member]", "label": "Dipak Vashir [Member]" } } }, "localname": "DipakVashirMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_DisclosureInitialPublicOfferingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Initial Public Offering" } } }, "localname": "DisclosureInitialPublicOfferingAbstract", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "xbrltype": "stringItemType" }, "VHAQ_DisclosurePrivatePlacementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placement" } } }, "localname": "DisclosurePrivatePlacementAbstract", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "xbrltype": "stringItemType" }, "VHAQ_DisclosureWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "localname": "DisclosureWarrantsAbstract", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "xbrltype": "stringItemType" }, "VHAQ_EarnoutSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Earnout Shares [Member]", "label": "Earnout Shares [Member]" } } }, "localname": "EarnoutSharesMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeWarrantLiabilities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation change in fair value of derivative warrant liabilities.", "label": "Change in fair value of derivative warrant liabilities" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeWarrantLiabilities", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "VHAQ_EffectiveIncomeTaxRateReconciliationNondeductibleTransactionCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation nondeductible transaction costs.", "label": "Non-deductible transaction costs" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleTransactionCosts", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "VHAQ_EffectiveIncomeTaxRateReconciliationWarrantIssuanceCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation warrant issuance costs.", "label": "Warrant issuance costs" } } }, "localname": "EffectiveIncomeTaxRateReconciliationWarrantIssuanceCosts", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "VHAQ_EmergingGrowthCompanyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Emerging Growth Company [Policy Text Block]", "label": "Emerging Growth Company" } } }, "localname": "EmergingGrowthCompanyPolicyTextBlock", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "VHAQ_ExclusiveFinancialAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exclusive Financial Advisor [Member]", "label": "Exclusive Financial Advisor [Member]" } } }, "localname": "ExclusiveFinancialAdvisorMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_ExpensedIssuanceCostsOnIssuanceOfSubscriptionWarrants": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expensed issuance costs on issuance of subscription warrants.", "label": "ExpensedIssuanceCostsOnIssuanceOfSubscriptionWarrants", "negatedLabel": "Expensed issuance costs on issuance of subscription warrants" } } }, "localname": "ExpensedIssuanceCostsOnIssuanceOfSubscriptionWarrants", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "VHAQ_FairValueOfRightsAtIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of rights at issuance.", "label": "Fair value of Rights at issuance" } } }, "localname": "FairValueOfRightsAtIssuance", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "VHAQ_FairValueOfWarrantsAtIssaunce": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of warrants at issaunce.", "label": "Fair value of Public Warrants at issuance" } } }, "localname": "FairValueOfWarrantsAtIssaunce", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "VHAQ_FounderSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Founder Shares [Member]", "label": "Founder Shares [Member]" } } }, "localname": "FounderSharesMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_IncreaseDecreaseInUncertainTaxPosition": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in uncertain tax position.", "label": "Increase decrease in uncertain tax position", "verboseLabel": "Uncertain tax position" } } }, "localname": "IncreaseDecreaseInUncertainTaxPosition", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "VHAQ_InitialBusinessCombinationPercentageOfTrustAccount": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial business combination percentage of trust account.", "label": "Initial business combination percentage of trust account" } } }, "localname": "InitialBusinessCombinationPercentageOfTrustAccount", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "VHAQ_InitialPublicOfferingDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Disclosure [Text Block]", "label": "INITIAL PUBLIC OFFERING" } } }, "localname": "InitialPublicOfferingDisclosureTextBlock", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/InitialPublicOffering" ], "xbrltype": "textBlockItemType" }, "VHAQ_InterestEarnedOnMoneyMarketAccount": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest earned on money market account.", "label": "Interest earned on money market account" } } }, "localname": "InterestEarnedOnMoneyMarketAccount", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "VHAQ_MeasurementInputMarketDebtRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Market Debt Rate [Member]", "label": "Measurement Input Market Debt Rate [Member]" } } }, "localname": "MeasurementInputMarketDebtRateMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "VHAQ_MeasurementInputProbabilityOfCompletingABusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement Input Probability Of Completing A Business Combination [Member]", "label": "Measurement Input Probability Of Completing A Business Combination [Member]" } } }, "localname": "MeasurementInputProbabilityOfCompletingABusinessCombinationMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "VHAQ_MoneyMarketFundsHeldInTrustAccountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Money Market Funds Held In Trust Account [Member]", "label": "Money Market Funds Held In Trust Account [Member]" } } }, "localname": "MoneyMarketFundsHeldInTrustAccountMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "VHAQ_NewMergerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New Merger [Member]", "label": "New Merger [Member]" } } }, "localname": "NewMergerMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_NonRedeemableCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Redeemable Common Stock [Member]", "label": "Non Redeemable Common Stock [Member]" } } }, "localname": "NonRedeemableCommonStockMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "domainItemType" }, "VHAQ_NoteAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Note Agreements [Member]", "label": "Note Agreements [Member]" } } }, "localname": "NoteAgreementsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_OfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Offering costs.", "label": "Offering costs" } } }, "localname": "OfferingCosts", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VHAQ_OfferingCostsPaid": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Offering costs paid.", "label": "OfferingCostsPaid", "negatedLabel": "Offering costs paid" } } }, "localname": "OfferingCostsPaid", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "VHAQ_OtherOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other offering costs.", "label": "Other offering costs" } } }, "localname": "OtherOfferingCosts", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VHAQ_OutstandingPublicSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding public shares percentage.", "label": "Outstanding public shares percentage" } } }, "localname": "OutstandingPublicSharesPercentage", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "VHAQ_PercentageOfCommonStockIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of common stock issued and outstanding.", "label": "Percentage of common stock issued and outstanding" } } }, "localname": "PercentageOfCommonStockIssuedAndOutstanding", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "VHAQ_PercentageOfExciseTax": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of excise tax.", "label": "Percentage of excise tax" } } }, "localname": "PercentageOfExciseTax", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "VHAQ_PercentageOfLockUpSharesReleasedFromTheLockUp": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of lock up shares released from the lockup.", "label": "Percentage of lock up shares" } } }, "localname": "PercentageOfLockUpSharesReleasedFromTheLockUp", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "VHAQ_PercentageOfRedemptionOfCompanysOutstandingPublicShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of redemption of companys outstanding public shares.", "label": "Redemption percentage of outstanding public shares" } } }, "localname": "PercentageOfRedemptionOfCompanysOutstandingPublicShares", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "VHAQ_PlacementAgentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement Agents [Member]", "label": "Placement Agents [Member]" } } }, "localname": "PlacementAgentsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_PrivateAndSubscriptionWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private And Subscription Warrants [Member]", "label": "Private And Subscription Warrants [Member]" } } }, "localname": "PrivateAndSubscriptionWarrantsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_PrivatePlacementDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement disclosure [Text Block]", "label": "PRIVATE PLACEMENT" } } }, "localname": "PrivatePlacementDisclosureTextBlock", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/PrivatePlacement" ], "xbrltype": "textBlockItemType" }, "VHAQ_PrivateWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Warrant Liability [Member]", "label": "Private Warrant Liability [Member]" } } }, "localname": "PrivateWarrantLiabilityMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "VHAQ_PrivateWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Warrant [Member]" } } }, "localname": "PrivateWarrantMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_PrivateWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Warrants [Member]", "label": "Private Warrants [Member]" } } }, "localname": "PrivateWarrantsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Member]", "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_PromissoryNoteRelatedParty": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Promissory note related party.", "label": "Promissory note - related party" } } }, "localname": "PromissoryNoteRelatedParty", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "VHAQ_PublicSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Shares [Member]", "label": "Public Shares [Member]" } } }, "localname": "PublicSharesMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Warrants [Member]", "label": "Public Warrants [Member]" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_RedeemableCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable Common Stock [Member]", "label": "Redeemable Common Stock [Member]" } } }, "localname": "RedeemableCommonStockMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "domainItemType" }, "VHAQ_RedemptionOfPublicSharesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redemption of public shares percentage.", "label": "Redemption of public shares percentage" } } }, "localname": "RedemptionOfPublicSharesPercentage", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "VHAQ_RemeasurementOfCommonStockSubjectToPossibleRedemptionToRedemptionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Remeasurement of common stock subject to possible redemption to redemption amount.", "label": "Remeasurement of common stock subject to possible redemption, to redemption amount" } } }, "localname": "RemeasurementOfCommonStockSubjectToPossibleRedemptionToRedemptionAmount", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "VHAQ_SecondFinancialAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second Financial Advisor [Member]", "label": "Second Financial Advisor [Member]" } } }, "localname": "SecondFinancialAdvisorMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_SeriesACumulativeConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A Cumulative Convertible Preferred Stock [Member]", "label": "Series A Cumulative Convertible Preferred Stock [Member]" } } }, "localname": "SeriesACumulativeConvertiblePreferredStockMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_SeriesFCumulativeConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series F Cumulative Convertible Preferred Stock [Member]", "label": "Series F Cumulative Convertible Preferred Stock [Member]" } } }, "localname": "SeriesFCumulativeConvertiblePreferredStockMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm", "verboseLabel": "Contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "durationItemType" }, "VHAQ_SponsorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sponsor [Member]", "label": "Sponsor [Member]" } } }, "localname": "SponsorMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_StockIssuedIssuanceCostsCommonStockSubjectToPossibleRedemption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stock issued issuance costs common stock subject to possible redemption.", "label": "StockIssuedIssuanceCostsCommonStockSubjectToPossibleRedemption", "negatedLabel": "Issuance costs allocated to common stock subject to possible redemption" } } }, "localname": "StockIssuedIssuanceCostsCommonStockSubjectToPossibleRedemption", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "VHAQ_StrategicAdviserMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic Adviser [Member]", "label": "Strategic Adviser [Member]" } } }, "localname": "StrategicAdviserMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_StrategicAdvisorAccruedFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Strategic advisor accrued fees.", "label": "Accrued advisor fee" } } }, "localname": "StrategicAdvisorAccruedFees", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "VHAQ_StrategicAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Strategic Advisor [Member]", "label": "Strategic Advisor [Member]" } } }, "localname": "StrategicAdvisorMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrant Liability [Member]", "label": "Subscription Warrant Liability [Member]" } } }, "localname": "SubscriptionWarrantLiabilityMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantsAtIssuanceOnAprilFourTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrants At Issuance On April Four Twenty Twenty Two [Member]", "label": "Subscription Warrants At Issuance On April 4, 2022 [Member]" } } }, "localname": "SubscriptionWarrantsAtIssuanceOnAprilFourTwentyTwentyTwoMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantsAtIssuanceOnAprilTwentySevenTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrants At Issuance On April Twenty Seven Twenty Twenty Two [Member]", "label": "Subscription Warrants At Issuance On April 27, 2022 [Member]" } } }, "localname": "SubscriptionWarrantsAtIssuanceOnAprilTwentySevenTwentyTwentyTwoMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantsAtIssuanceOnMarchTwentyOneTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrants At Issuance On March Twenty One Twenty Twenty Two [Member]", "label": "Subscription Warrants At Issuance On March 21, 2022 [Member]" } } }, "localname": "SubscriptionWarrantsAtIssuanceOnMarchTwentyOneTwentyTwentyTwoMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantsAtIssuanceOnMarchTwentyThreeTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrants At Issuance On March Twenty Three Twenty Twenty Two [Member]", "label": "Subscription Warrants At Issuance On March 23, 2023 [Member]" } } }, "localname": "SubscriptionWarrantsAtIssuanceOnMarchTwentyThreeTwentyTwentyTwoMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantsAtIssuanceOnMayNineTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrants At Issuance On May Nine Twenty Twenty Two [Member]", "label": "Subscription Warrants At Issuance On May 9, 2022 [Member]" } } }, "localname": "SubscriptionWarrantsAtIssuanceOnMayNineTwentyTwentyTwoMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantsAtIssuanceOnNovemberTwentyFiveTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrants At Issuance On November Twenty Five Twenty Twenty Two [Member]", "label": "Subscription Warrants At Issuance On November 25, 2022 [Member]" } } }, "localname": "SubscriptionWarrantsAtIssuanceOnNovemberTwentyFiveTwentyTwentyTwoMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantsAtIssuanceOnOctoberTwentySevenTwentyTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrants At Issuance On October Twenty Seven Twenty Twenty Two [Member]", "label": "Subscription Warrants At Issuance On October 27, 2022 [Member]" } } }, "localname": "SubscriptionWarrantsAtIssuanceOnOctoberTwentySevenTwentyTwentyTwoMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SubscriptionWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Warrants [Member]", "label": "Subscription Warrants [Member]" } } }, "localname": "SubscriptionWarrantsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "VHAQ_SuccessfulBusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Successful Business Combination [Member]" } } }, "localname": "SuccessfulBusinessCombinationMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_ThirdFinancialAdvisorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Financial Advisor [Member]", "label": "Third Financial Advisor [Member]" } } }, "localname": "ThirdFinancialAdvisorMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_ThreeInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Investors [Member]", "label": "Three Investors [Member]" } } }, "localname": "ThreeInvestorsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_TransfereeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transferee [Member]", "label": "Transferee [Member]" } } }, "localname": "TransfereeMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_UnderwritingFeePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriting fee per share.", "label": "Underwriting fee" } } }, "localname": "UnderwritingFeePerShare", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "VHAQ_UnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Units [Member]", "label": "Units [Member]" } } }, "localname": "UnitsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "VHAQ_UnrecognizedTaxBenefitsNonCurrent": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Uncertain tax position.", "label": "Uncertain tax position" } } }, "localname": "UnrecognizedTaxBenefitsNonCurrent", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "VHAQ_UnsecuredPromissoryNoteAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured Promissory Note Agreements [Member]", "label": "Unsecured Promissory Note Agreements [Member]" } } }, "localname": "UnsecuredPromissoryNoteAgreementsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_UnsecuredSeniorPromissoryNoteAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unsecured Senior Promissory Note Agreements [Member]", "label": "Unsecured Senior Promissory Note Agreements [Member]" } } }, "localname": "UnsecuredSeniorPromissoryNoteAgreementsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_UnsuccessfulBusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unsuccessful Business Combination [Member]" } } }, "localname": "UnsuccessfulBusinessCombinationMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_UnsucessfulBusinessCombinationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unsucessful Business Combination [Member]" } } }, "localname": "UnsucessfulBusinessCombinationMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_ViveonEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Viveon Equity Incentive Plan [Member]", "label": "Viveon Equity Incentive Plan [Member]" } } }, "localname": "ViveonEquityIncentivePlanMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "VHAQ_WarrantsAndRightsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants and rights disclosure text block", "label": "WARRANTS" } } }, "localname": "WarrantsAndRightsDisclosureTextBlock", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Warrants" ], "xbrltype": "textBlockItemType" }, "VHAQ_WarrantsAndRightsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants and rights term.", "label": "Warrants and rights term" } } }, "localname": "WarrantsAndRightsTerm", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "durationItemType" }, "VHAQ_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants [Member]", "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://viveonhealthacquisitioncorp.com/20221231", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r437", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r437", "r439", "r440" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r437", "r439", "r440" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r437", "r439", "r440" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r437", "r439", "r440" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r225", "r226", "r227", "r228", "r291", "r386", "r393", "r400", "r401", "r416", "r422", "r425", "r469", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r225", "r226", "r227", "r228", "r291", "r386", "r393", "r400", "r401", "r416", "r422", "r425", "r469", "r515", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r225", "r226", "r227", "r228", "r284", "r291", "r300", "r301", "r302", "r385", "r386", "r393", "r400", "r401", "r416", "r422", "r425", "r465", "r469", "r516", "r517", "r518", "r519", "r520" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r225", "r226", "r227", "r228", "r284", "r291", "r300", "r301", "r302", "r385", "r386", "r393", "r400", "r401", "r416", "r422", "r425", "r465", "r469", "r516", "r517", "r518", "r519", "r520" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r292", "r460" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r193", "r292", "r447", "r460" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r193", "r292", "r447", "r448", "r460" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r463", "r511" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndNotesReceivableNet": { "auth_ref": [ "r218", "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable.", "label": "Notes receivable" } } }, "localname": "AccountsAndNotesReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r14", "r424" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued costs and expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r8", "r424" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r304", "r305", "r306", "r457", "r458", "r459", "r508" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r75", "r76", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "verboseLabel": "Stock compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r61", "r66", "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Subscription warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net (loss) income to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdministrativeFeesExpense": { "auth_ref": [ "r116" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for administrative services provided to the limited liability company (LLC) or limited partnership (LP) by the managing member or general partner, affiliate of managing member or general partner, or affiliate of LLC or LP, for example, but not limited to, salaries, rent, or overhead costs.", "label": "Administrative service fees" } } }, "localname": "AdministrativeFeesExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r32", "r45", "r110", "r262" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Interest expense - amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r27", "r262", "r367", "r450" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Expensed issuance costs on issuance of subscription warrants" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r118", "r134", "r153", "r175", "r212", "r214", "r216", "r219", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r238", "r239", "r341", "r343", "r358", "r424", "r467", "r468", "r513" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r149", "r160", "r175", "r219", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r238", "r239", "r341", "r343", "r358", "r424", "r467", "r468", "r513" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrust": { "auth_ref": [ "r451" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.", "label": "Asset, held-in-trust", "verboseLabel": "Investment held in Trust Account" } } }, "localname": "AssetsHeldInTrust", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldInTrustNoncurrent": { "auth_ref": [ "r451" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.", "label": "Investment held in Trust Account" } } }, "localname": "AssetsHeldInTrustNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r339", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r86", "r87", "r339", "r420", "r421" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r92", "r93", "r95" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business combination consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r91", "r94", "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationControlObtainedDescription": { "auth_ref": [ "r85" ], "lang": { "en-us": { "role": { "documentation": "This element represents a description of how the entity obtained control of the acquired entity.", "label": "Business combination equity description" } } }, "localname": "BusinessCombinationControlObtainedDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationIndemnificationAssetsDescription": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "For indemnification assets recognized in connection with a business combination, this element represents a description of such assets.", "label": "Business combination assets description" } } }, "localname": "BusinessCombinationIndemnificationAssetsDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r88", "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business combination net tangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r0", "r50", "r56" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r47", "r151", "r403" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r40", "r47", "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash - end of period", "periodStartLabel": "Cash - beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r40", "r109" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r449" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Federal depository insurance coverage amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r155", "r156", "r157", "r175", "r195", "r196", "r198", "r200", "r203", "r204", "r219", "r229", "r232", "r233", "r234", "r238", "r239", "r268", "r269", "r271", "r275", "r281", "r358", "r402", "r446", "r452", "r461" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/Cover", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r69", "r71" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Exercise price of warrants", "terseLabel": "Price per warrant", "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Warrants exercisable to purchase shares of common stock", "verboseLabel": "Warrent purchases" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r69", "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r23", "r124", "r138" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies (see Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r59", "r223", "r224", "r399", "r466" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockConversionBasis": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Description of basis for conversion of convertible common stock.", "label": "Common Stock, Conversion Basis" } } }, "localname": "CommonStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockConvertibleConversionPriceIncrease": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.", "label": "Common Stock, Convertible, Conversion Price, Increase" } } }, "localname": "CommonStockConvertibleConversionPriceIncrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common stock dividend declared per share", "verboseLabel": "Common Stock, Dividends, Per Share, Declared" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockDividendsShares": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock issued as dividends during the period. Excludes stock splits.", "label": "Common stock dividend declared shares" } } }, "localname": "CommonStockDividendsShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r457", "r458", "r508" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/Cover", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r66" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding", "terseLabel": "Common stock outstanding, shares", "verboseLabel": "Common stock, shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7", "r424" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock not subject to possible redemption, $0.0001 par value; 60,000,000 shares authorized; 5,031,250 issued and outstanding (excluding 1,844,774 and 20,125,000 shares subject to redemption as of December 31, 2022 and 2021, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Voting rights" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r131", "r207" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r97", "r407" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.", "label": "SCHEDULE OF NOTES" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r28" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "verboseLabel": "Accrued costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesRelatedParty": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.", "label": "Costs and expenses, related party" } } }, "localname": "CostsAndExpensesRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal" } } }, "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r455", "r503", "r505" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r455", "r503", "r505" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Current State and Local Tax Expense (Benefit)", "verboseLabel": "Current" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r62", "r173", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r256", "r263", "r264", "r265" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTE AGREEMENTS PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r2", "r3", "r4", "r119", "r120", "r133", "r179", "r240", "r241", "r242", "r243", "r244", "r246", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r368", "r411", "r412", "r413", "r414", "r415", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r4", "r120", "r133", "r266" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfNotesDetails": { "order": 1.0, "parentTag": "us-gaap_NotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Note" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.", "label": "Redemption price per share" } } }, "localname": "DebtInstrumentConvertibleStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r2", "r4", "r67", "r119", "r120", "r130", "r133" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt instrument description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r111", "r113", "r240", "r368", "r412", "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r21", "r111", "r267", "r368" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r22", "r179", "r240", "r241", "r242", "r243", "r244", "r246", "r252", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r261", "r262", "r368", "r411", "r412", "r413", "r414", "r415", "r453" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r110", "r113", "r470" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r110", "r113" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfNotesDetails": { "order": 2.0, "parentTag": "us-gaap_NotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "negatedLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredChargesPolicyTextBlock": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.", "label": "Offering Costs associated with the Initial Public Offering" } } }, "localname": "DeferredChargesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).", "label": "Deferred underwriting fee" } } }, "localname": "DeferredCompensationLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsAndOtherAssets": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost assets and assets classified as other.", "label": "Start-up costs" } } }, "localname": "DeferredCostsAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r455", "r504", "r505" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "State" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r312", "r313" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r45", "r84", "r325", "r331", "r332", "r455" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred tax expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r455", "r504", "r505" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "verboseLabel": "Deferred" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r321" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r501" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net of allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r82", "r502" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r322" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Valuation allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Deposits": { "auth_ref": [ "r122" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.", "label": "Deposits" } } }, "localname": "Deposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r161", "r162", "r357", "r406" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Warrant liabilities" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r98", "r99", "r100", "r101", "r102", "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "verboseLabel": "Warrants" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativesReportingOfDerivativeActivity": { "auth_ref": [ "r98" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.", "label": "Derivative Financial Instruments" } } }, "localname": "DerivativesReportingOfDerivativeActivity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r158", "r231", "r232", "r233", "r237", "r238", "r239", "r376", "r404", "r456" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from related party" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToOtherRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r14", "r115", "r456" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties classified as other, due within one year or the normal operating cycle, if longer.", "label": "Due to related party" } } }, "localname": "DueToOtherRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r14", "r231", "r232", "r233", "r237", "r238", "r239", "r376", "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "verboseLabel": "Due to related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarlyRepaymentOfSubordinatedDebt": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of long-term borrowing where a lender is placed in a lien position behind debt having a higher priority of repayment (senior) in case of liquidation of the entity's assets before its maturity.", "label": "Net of repayment subordinated convertible promissory note" } } }, "localname": "EarlyRepaymentOfSubordinatedDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r170", "r185", "r186", "r187", "r188", "r189", "r194", "r195", "r198", "r199", "r200", "r201", "r347", "r348", "r388", "r391", "r408" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted net (loss) income per common share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails", "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r51", "r52" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net (Loss) Income Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax provision" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r176", "r315", "r333" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r498", "r506" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "verboseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": { "auth_ref": [ "r498", "r506" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.", "label": "Other permanent items, net" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r498", "r506" ], "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "verboseLabel": "Stock compensation expense" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r498", "r506" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State taxes, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r66", "r147", "r166", "r167", "r168", "r180", "r181", "r182", "r184", "r190", "r192", "r202", "r220", "r283", "r304", "r305", "r306", "r327", "r328", "r346", "r359", "r360", "r361", "r362", "r363", "r364", "r372", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Redemption payment shares (in Shares)" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r45", "r63" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Gain on change in fair value of warrant liabilities", "negatedLabel": "Gain on change in fair value of warrant liabilities", "negatedTerseLabel": "Recognized gain (loss) in fair value", "verboseLabel": "Fair Value Adjustment of Warrants" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows", "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r349", "r350", "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "SCHEDULE OF FAIR VALUE MEASUREMENT INPUTS AND VALUATION TECHNIQUES" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r103", "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r254", "r285", "r286", "r287", "r288", "r289", "r290", "r350", "r382", "r383", "r384", "r412", "r413", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r349", "r350", "r352", "r353", "r356" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r254", "r285", "r290", "r350", "r382", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r254", "r285", "r290", "r350", "r383", "r412", "r413", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r254", "r285", "r286", "r287", "r288", "r289", "r290", "r350", "r384", "r412", "r413", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r105", "r108" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r105", "r108" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "SCHEDULE OF CHANGES IN FAIR VALUE OF FINANCIAL INSTRUMENTS" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency." } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair value of Subscription Warrants" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)", "negatedLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r105" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value as of ending", "periodStartLabel": "Fair value as of beginning" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfChangesInFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r254", "r285", "r286", "r287", "r288", "r289", "r290", "r382", "r383", "r384", "r412", "r413", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r354", "r356" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FloorBrokerage": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Broker-dealers often use other brokers to execute trades on their behalf. The trading broker-dealer becomes a customer of the executing broker-dealer and pays a floor brokerage fee. Such fees are paid periodically either directly to the executing broker-dealer or through a clearing house.", "label": "Floor Brokerage" } } }, "localname": "FloorBrokerage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FloorBrokerageExchangeAndClearanceFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense during the period for floor brokerage fees paid to other broker-dealers to execute trades on their behalf, stock exchange fees, order flow fees, and clearance fees.", "label": "Broker dealer fee" } } }, "localname": "FloorBrokerageExchangeAndClearanceFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FranchisorCosts": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate costs incurred that are directly related to activities, including but not limited to, generating franchise revenues from franchisor owned outlets and franchised outlets.", "label": "Franchise tax" } } }, "localname": "FranchisorCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_HealthCareOrganizationExpensesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of health care costs, net of recoveries of stop-loss insurance. Costs of services rendered (including costs of services rendered but not yet reported).", "label": "Company expenses and parent expenses" } } }, "localname": "HealthCareOrganizationExpensesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r25", "r117", "r125", "r141", "r212", "r213", "r215", "r217", "r389", "r410" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "(Loss) income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r176", "r316", "r319", "r324", "r329", "r334", "r336", "r337", "r338" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r177", "r191", "r192", "r211", "r314", "r330", "r335", "r392" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense", "totalLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails", "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r165", "r310", "r311", "r319", "r320", "r323", "r326" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r498" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r44" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueFromRelatedParties": { "auth_ref": [ "r44" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.", "label": "Increase (Decrease) in Due from Related Parties", "negatedLabel": "Due from related party" } } }, "localname": "IncreaseDecreaseInDueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r44" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties", "verboseLabel": "Due to related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r44" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accrued Liabilities", "verboseLabel": "Accrued costs and expenses" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r44" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPropertyAndOtherTaxesPayable": { "auth_ref": [ "r44" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount of cash payments due to taxing authorities for non-income-related taxes.", "label": "Increase (Decrease) in Property and Other Taxes Payable", "verboseLabel": "Franchise tax payable" } } }, "localname": "IncreaseDecreaseInPropertyAndOtherTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r112", "r127", "r169", "r210", "r366" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense - amortization of debt discount" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r123", "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest expense" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r30" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Interest and dividends earned on investments held in Trust Account", "negatedLabel": "Interest and dividends earned on investments held in Trust Account" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows", "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r45" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "verboseLabel": "Loss on issuance of subscription warrants" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r18", "r175", "r219", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r238", "r239", "r342", "r343", "r344", "r358", "r409", "r467", "r513", "r514" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities [Default Label]", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r12", "r121", "r137", "r424", "r454", "r464", "r510" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 Deficit:" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r20", "r150", "r175", "r219", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r238", "r239", "r342", "r343", "r344", "r358", "r424", "r467", "r513", "r514" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "auth_ref": [ "r15" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.", "label": "Commitment fee amount" } } }, "localname": "LineOfCreditFacilityCommitmentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of credit facility maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LoansPayable": { "auth_ref": [ "r4", "r120", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Loans payable" } } }, "localname": "LoansPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Investments Held in Trust Account" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r509" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MutualFundMember": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.", "label": "Mutual Fund [Member]" } } }, "localname": "MutualFundMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r171" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r171" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r40", "r43", "r46" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r26", "r46", "r126", "r140", "r148", "r163", "r164", "r168", "r175", "r183", "r185", "r186", "r187", "r188", "r191", "r192", "r197", "r212", "r213", "r215", "r217", "r219", "r229", "r230", "r232", "r233", "r234", "r235", "r236", "r238", "r239", "r348", "r358", "r410", "r467" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net income (loss)", "totalLabel": "Net (loss) income", "verboseLabel": "Net (loss) income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails", "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows", "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit", "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r4", "r120", "r135" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/ScheduleOfNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable", "totalLabel": "Carrying value of notes" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Note Agreements payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r13", "r116", "r456" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Note Agreements payable \u2013 related party", "verboseLabel": "Notes payable, related party" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OfferingCostsPartnershipInterests": { "auth_ref": [ "r142" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Costs incurred in connection with the offering and selling of additional partner interest.", "label": "Offering Costs, Partnership Interests", "verboseLabel": "Other offering costs" } } }, "localname": "OfferingCostsPartnershipInterests", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating costs" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r212", "r213", "r215", "r217", "r410" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating loss carry forwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expenses):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rent paid" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r37" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Payment to redeeming stockholders" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForUnderwritingExpense": { "auth_ref": [ "r42" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.", "label": "Cash underwriting fee", "verboseLabel": "Underwriting expense" } } }, "localname": "PaymentsForUnderwritingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r39" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r34" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Cash deposited to Trust Account for extension contribution" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockConversionBasis": { "auth_ref": [ "r6", "r67" ], "lang": { "en-us": { "role": { "documentation": "Describe the conversion features of preferred stock if preferred stock is convertible. That is, shares of preferred stock into which another convertible security was converted, or shares of preferred stock into which another class of preferred stock was converted.", "label": "Preferred Stock, Conversion Basis" } } }, "localname": "PreferredStockConversionBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r6", "r268" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value", "verboseLabel": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r6", "r268" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r6", "r424" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r159", "r221", "r222", "r405" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDecommissioningFund": { "auth_ref": [ "r33" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of assets held in a decommissioning trust fund.", "label": "Cash withdrawn from Trust Account for payment to redeeming stockholders" } } }, "localname": "ProceedsFromDecommissioningFund", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Gross proceeds", "verboseLabel": "Proceeds from initial public offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r35" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Warrent purchases price" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Proceeds from Loans" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r36" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Note Agreements payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r36" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from promissory note- related party" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Proceeds from (Repayments of) Notes Payable" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from Note Agreements payable \u2013 related party" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r35", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Gross proceeds of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyExpense": { "auth_ref": [ "r44", "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.", "label": "Agreegate warrants value" } } }, "localname": "ProductWarrantyExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r143", "r144" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTaxExpenseDueToAffiliatesDeferred": { "auth_ref": [ "r500" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of any deferred tax-related balances due to affiliates as of the date of each statement of financial position presented.", "label": "Related Party Tax Expense, Due to Affiliates, Deferred", "verboseLabel": "Due to related party" } } }, "localname": "RelatedPartyTaxExpenseDueToAffiliatesDeferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r145", "r375", "r376", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "auth_ref": [ "r146", "r154", "r369", "r370", "r371", "r374" ], "lang": { "en-us": { "role": { "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.", "label": "Founder shares related description" } } }, "localname": "RelatedPartyTransactionDescriptionOfTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Incurred expenses" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r373", "r374", "r376", "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfOtherDebt": { "auth_ref": [ "r38" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other.", "label": "Repayments of Other Debt", "negatedLabel": "Payment of other payable - related party" } } }, "localname": "RepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfRelatedPartyDebt": { "auth_ref": [ "r38" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.", "label": "Repayments of related party debt", "negatedLabel": "Payment of promissory note - related party" } } }, "localname": "RepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r68", "r136", "r397", "r398", "r424" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r147", "r180", "r181", "r182", "r184", "r190", "r192", "r220", "r304", "r305", "r306", "r327", "r328", "r346", "r394", "r396" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A security giving shareholders entitlement to acquire new shares issued by the entity at an established price in proportion to the number of shares already owned. Generally, rights expire within in a short time after issuance.", "label": "Rights [Member]" } } }, "localname": "RightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of units, value", "verboseLabel": "Fair value of founder shares" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of shares", "terseLabel": "Number of stock transferred", "verboseLabel": "Sale of stock" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "Aggregate percent of shares sold" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Share price", "terseLabel": "Purchase price per warrant", "verboseLabel": "Founder shares, per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "SCHEDULE OF INCOME TAX PROVISION" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "SCHEDULE OF BASIC AND DILUTED NET (LOSS) INCOME PER COMMON SHARE" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "SCHEDULE OF FAIR VALUE ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r423", "r499" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "SCHEDULE OF UNRECOGNIZED TAX BENEFITS" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r44" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock compensation expense", "verboseLabel": "Share based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StatementsOfCashFlows", "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Additional Shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r294", "r297", "r298", "r299", "r300", "r303", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangements" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "verboseLabel": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r73" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r72" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Shares issued price" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognition of changes in redemption value of mandatorily redeemable shares. Provides the period over which changes in redemption value are accreted, usually from the issuance date (or from the date that it becomes probable that the security will become redeemable, if later) to the earliest redemption date of the security.", "label": "Common Stock Subject to Possible Redemption" } } }, "localname": "SharesSubjectToMandatoryRedemptionChangesInRedemptionValuePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.", "label": "Redemption payment shares" } } }, "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r50", "r172" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r155", "r156", "r157", "r175", "r195", "r196", "r198", "r200", "r203", "r204", "r219", "r229", "r232", "r233", "r234", "r238", "r239", "r268", "r269", "r271", "r275", "r281", "r358", "r402", "r446", "r452", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/Cover", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r66", "r147", "r166", "r167", "r168", "r180", "r181", "r182", "r184", "r190", "r192", "r202", "r220", "r283", "r304", "r305", "r306", "r327", "r328", "r346", "r359", "r360", "r361", "r362", "r363", "r364", "r372", "r394", "r395", "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/Cover", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails", "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r180", "r181", "r182", "r202", "r387" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/Cover", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails", "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Number of shares issued to sponsor, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r6", "r7", "r66", "r68" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Purchase units", "terseLabel": "Share issued", "verboseLabel": "Sale of stock" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares (or other type of equity) forfeited during the period.", "label": "Shares cancellation common stock subject to forfeiture" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Number of shares issued to sponsor" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r6", "r7", "r66", "r68" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Additional offering costs related to the Initial Public Offering" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Redemption of common stock by stockholders" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r10", "r11", "r57", "r424", "r454", "r464", "r510" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, value", "periodStartLabel": "Balance, value", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets", "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Deficit:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r70", "r174", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r283", "r345" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r365", "r380" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r365", "r380" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r365", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r365", "r380" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r379", "r381" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/InitialPublicOfferingDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/PrivatePlacementDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Franchise tax payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityAccretionToRedemptionValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of accretion of temporary equity to its redemption value during the period.", "label": "Remeasurement of carrying value to redemption value", "negatedLabel": "Remeasurement of common stock subject to possible redemption, to redemption amount" } } }, "localname": "TemporaryEquityAccretionToRedemptionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails", "http://viveonhealthacquisitioncorp.com/role/StatementsOfChangesInStockholdersDeficit", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r229", "r232", "r233", "r234", "r238", "r239" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Common Stock subject to possible redemption, 1,844,774 and 20,125,000 shares at redemption value as of December 31, 2022 and 2021, respectively", "periodEndLabel": "Common stock subject to possible redemption as of December 31, 2022", "periodStartLabel": "Common stock subject to possible redemption as of December 31, 2021" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheets", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfRedeemableCommonStockReflectedInConsolidatedBalanceSheetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares issued", "verboseLabel": "Temporary equity shares issued" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary equity, shares outstanding", "verboseLabel": "Temporary equity shares outstanding" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/BalanceSheetsParenthetical", "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/StockholdersDeficitDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityTableTextBlock": { "auth_ref": [ "r1", "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "SCHEDULE OF REDEEMABLE COMMON STOCK REFLECTED IN THE CONSOLIDATED BALANCE SHEETS" } } }, "localname": "TemporaryEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TimeDeposits": { "auth_ref": [ "r122", "r129" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of time deposit liabilities, including certificates of deposit.", "label": "Deposit amount" } } }, "localname": "TimeDeposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UnrealizedGainLossOnDerivatives": { "auth_ref": [ "r45" ], "calculation": { "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.", "label": "Loss on issuance of subscription warrants" } } }, "localname": "UnrealizedGainLossOnDerivatives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r309", "r317" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized tax benefits", "periodEndLabel": "Uncertain tax benefits - December 31", "periodStartLabel": "Uncertain tax benefits - January 1" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/IncomeTaxesDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails", "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r318" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Gross increases - Tax positions in prior period" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r53", "r54", "r55", "r205", "r206", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/NoteAgreementsPayableDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and rights outstanding, measurement input", "verboseLabel": "Probability" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/FairValueMeasurementsDetailsNarrative", "http://viveonhealthacquisitioncorp.com/role/ScheduleOfFairValueMeasurementInputsAndValuationTechniquesDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r194", "r200" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average shares outstanding, basic and diluted", "verboseLabel": "Weighted Average Common Stock" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails", "http://viveonhealthacquisitioncorp.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://viveonhealthacquisitioncorp.com/role/ScheduleOfBasicAndDilutedNetLossIncomePerCommonShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.D.Q1)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=126898976&loc=d3e600348-122990", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "https://asc.fasb.org/extlink&oid=123395306&loc=d3e36975-112693", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918703-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919370-209981", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128295416&loc=SL77919784-209982", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r426": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r432": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r433": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r434": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r435": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r436": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r437": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r438": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r439": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r441": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r442": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r443": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r444": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r445": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(b))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3,4))", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 70 0001493152-23-030029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-030029-xbrl.zip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�![0&#<@@CVH+8-?-V@^,];^'WQ!_X1R^U1[_ M $DR+%F1MVT'[I![&NS^-MWXHT[0HM3TG5F@TO*K+%$-K\]#NZX]J /7MV1G M/% <'HP)]C7SIX&N/'WC#PD-(TV^^QV<3MOU"1F:23/;.:YW7D\9_"OQ-;// MK%Q<*V'5S*Q20=P02: /JTMMQNX_E0&ST(->*36GCOXJ:?%>+>?V!IFT>7$I M;=,)!%$_#MSJMP-PB&%7^\W85Y?X>T"_\ B'$VO^(O$=S:PSD_9[.TN-BQ M@]/>@#VI7STP:-V/<>U?-.JZMKGPG\>0PPZ[/J6F2$,8YYR^$)P=W/6O4?B- M>ZW=^ _[:\,ZF;6)(?.D\L %EQG@T >B[P>AHW\XR*^8OASK'Q UZTO]-T>^ M=DF;=+=W#%VB/^R3TIOC+1/&WPYN;+6)_$5S=I)+U$SX##G!&<<\T ?3Y?C( MQQUKR_6/B$9_B9H_AS2KR(VXD_TQQ@@^P-=/IT\7CWP!#+]HFMQ?0J))(#M8 M'O@U\YV'@BWN/B\_AB.]N8H4F<+W':M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MI",TM(>M 'S1\?9"/%X /2%/Y5YC!)OC!/7%>E_'P$>-D'K"G\J\TVA< <#% M(?0E4C<,T\D \"F+SZ\=Z7WIDBJN1G-%,W <Z-ZKQQK&9!Y>"P' M3'O7MM>3_M!S>7\/HTW &2[08]<9/]* ,/X/_#[3M2\,6'B&>\U%+HSLPCCG MVQ_*V/NXJ']HR3;^TY M?-C(%SNUN3^IKT$ M_!'P6YR;:ZSWQ/\ _6H$>D^,U\+W-R;VRG=XU9I-VPKDAE//!QTK MZ/7[HKA-$^%WA/PUK<%_90LMVI/DB23/.."?M'ZF^W0]- MC]$!_^O7RCZDUM/(L<;.Y"J!DEN,5Y!^ MT%?NO@.RC@D!CN+Q0<'(90K'^>*!&9X3T"[^+,T_B#Q/>72Z9YA6VL87VH1[ MGO6;\0_"%S\-&MM?\)WMU!:APLL+2%@#_45Z'\&-@^&FG;<$Y;/UI_QCACE^ M&VI;\97:1[&@?4O^&M?#^*\L[LV-Y/$8WE50WER#@G'OU_&OG_2[OQ79 M?%?[):7S:CJL4SPA[@DI@C&[;GC ->K?L_6US'X"FED!V37CO%GIMV@''X@U MRGPP1;[XY:[<<,8DF?)_W@O]: '>-_A%JT.A7GB&[\2RWUY;Q-/+$\1"\#.% M._BJGP]U'QKXU\.MX:L[U+2QMB%EU$@LZH?X!ZG\>]>S?$9MOP[\08')L9?_ M $$UPO[.T07P5J#@9+WQ/_CBT MKGGWQ#^'U_P##M['6K/6)[H-)CS'!5T<< M\_,<@U[SHUQ?>+?AS97$=V;&[O;4'SU7>4/3..,UY[^T9,5T'1K?<0)+AV(] M< ?XUZ1X MS9^ M%@8@LELH.WI0'0^9T;Q19?$Z73M.U"XO]3M;IX$EZDJF66+:P.>I"MG^E+X%'VG]HO59EX7S;E^ M??-?1)"LA4@%2#D'TH!GA?P(\:W]_>7/AO5)GE\N(S0M(WS+A@"OOU_2JGBN M[U7QW\6U\)2R7-IID,I5UB.-R@9W5E_"ZQ,OQOU"2#*PVCW#G'3!.W!_,'\* M[77?'* ,7XG_#3P_P"&/"1U;0Q+97<+ MJ,B8_O,_4UV'PFU2_P#$_P ,@MU<2)<1M);+<9RV, @_AG]*X7XE^"=2TWP9 M<:OKWB&YU'4!*B^6.(ER>U=W\#H#!\,[1VP!--+(/^^MO]*!VT/$-:M->TOX MJ1Z9'J4NIW]M>(;>28D!CP1QDXKT/Q-\(/$&L:?^T M'?\ TK#^SF__ &G6BS_J[TN#_NQ[OZ5]!ZU(8=%OI!U6!R/RH!O8\7_9ZUZ_ MO%U31KF4R06X26/>22I.00/;BLCXX^!?['NT\1::TBV]U)LN8P3\DG9LYZ'] M,>]3?LY+_P 3G72>JPQ\_P# FKVSQAH,?B7PIJ&E28!FB.QB.C#D'\Q0+J2 *MTW(!HW ].:!#J*04M 'AGQX\*:-9 M:(_B%+=O[3N+I(RYA+C'^CY/_?1H'T/-?VBI@/["M%' M.6< ]/2M'2OAGK'C'P]82^)M9EMX([6.*VLK8855"C!8YY/X5A_M$.Q\3>'X ML<&%C^.^O?;5!;V$$07A(U ]@* Z'S1X+&H^!/C0/#R73RP-+Y$N>!(I3E>P?%;QLW@[PJQM7 U&[/E6_MZM^%>72_Z1^U%@G(^U#I[0U>_: FC'BK MPZER,VJJQ=3T(WKG]* +V@Z%\.#IB7/B76X-3U:Y3?/+/.?D8]0 #QBN'T[7 MH_!'Q36#P[>O=:0UPB&,.2KJW&/PS^E>Y6?PW\#7EI#.F@VDD4B!D89.[(]J MF;P)X#T*>"^?2;"T99 (Y7./G[8R>M ;':9Z'MBG4T<>XIU @KY3U/64LOCU M';)O,GB)+JIS\S8 ''TKV3P1H">&O"-CI@"B2- TN/[QZT#Z'S]\;2]S\ M4DA@&^01Q!5]23TKTE[WXQQ6K,=/\/\ RI_ '+']:\_\7;+S]HBQB(R/M]M& M0?\ >%?3.,>E ,\@^!DES=P^)+W4&SJ,FH%;CGH0.@]@2'("0.Q/T4T"/E+X;ZCJFG_$ M5[S2])_M*Y_>CR?-\OKD9W8/\JZKQM\5/%=[??\ "/26":$92(Y=S[S@G&0V M!Q4'P"0R^.M2D SM@8[OJ:[WXU>!G\0:-'JUC%OO[$?, .9(_P#ZU!6G4T_A M_P#"O1O"PCU(S-?ZBZ@FX?[HSS\HY_/->BJ,<5XK\#_B ;VU/AC4Y#]IMQ_H MSN>67G*GW']:]J#9[4$CJ#[4F:6@#ROXX^%XM7\'R:K%'_IFGD.& Y9"<,#] M.M+\"M6BO_ @M0JI-9RE& [YZ&O2;^RBU'3[FSN%#17$;1N/8C%?,W@7Q3'\ M,O&.NV6I;UM]KJ$ ZNO*_P"% =#1_: DT\^([$6N&OHXMUP%' &>,U[)X%UV MWU/X?:9J"@*D5J$EP?NE!@_RKC?#W@>?7/!6L:MKD&_6-;1I?F',:GE5'I7E MWA'QA>Z3X:UCP:L-0,[5 KYYU-#=_M-6V/^6=Q$?^^0*^B%.%7@]ABOGC1F6]_:6N'+ M9"328/\ NB@$?1)ZTM-SDCTYIU @KYD^(]A'XA^/$6D2$K'-)!$[#DX*@FOI MNOFZ\87G[3<;?W+Q%.?]E0* /:8OA]X8M]*;3H]'MO(9,,2F7)]=W6OG^UL+ MGX?_ !PM;"R8B-[E(T']Z-SCFOJ0NHY) P,_A7@D5F?&G[0CW=M^\LM,92TH M^[\G(&?J:!H;\5=:O-7^)FFZ!:V)U".S*2FT$FT3,><$UUD_C+QU';M;Q?#K M$979@7J[0,8X&WI7G_CW4&\(?'.'69$)A_=RG"]5Q\V,U]!:1K6GZYID=]IU MS'/;R#<&5@"?#GP9XQT[XE1:S=:2UA:R.YF!8$;6!XX/K7T8HP*Y/ M_A.+&X\9P>&].3[7/L:2XD0_+"!C&3ZG-=8I)H <:X3XOQQ-\-=7E>)&=(AM M9ER1\PZ5W1K@/C/)L^&.ICIN*KS]: .(^ _A#2=0\,WFLWMK%\D;CL,+ M_A3/CYI\]WX%6YA7=':SJ\@']WIF@.IS'PZNO'FC^$K1-)\+6=Q:S?O5G:;8 MT@/()JCXV\(?$+QYJ-M=76@6EH\$?EYCF&3SGDUUGP;\?Z5>^&K70;NX2WOK M1/+5)/E#J.F#78>,/'NE>%M-,@GCN+Z4A+:VB<,SL>.F>E %S3+"?3/ $5EJ M.V2:WLF$G<$A37D'[/D>?$&O3K]W;M '^]FO8M3NYSX$N[FYC$<[:>[NB] 2 MO2O*?V=$!AUR;N9%% SJOCMM7X;3%^3Y\8!_.F_!'0;&T^']IJ*VZ&ZO&9WD M*@M@,0!G\/UJK^T%,%\ 11$\R728'KC_ /772_"A!#\,-# _YY,?S=J Z'E? MQ_M85\5:#Y:".25"&*@#/S+7K_BK1;C7/A_=:9:N5FEM=JD]SCI7D?QV<3?$ M#P[!G!&T<^[K7L7B?Q1:^#M"@O[Q6:$R1Q?)VSQF@1X7X$^(]W\.!)X>\0Z9 M+]F24E2O#)ZX_O?I7LNA'PSXKUN'Q9I$ZRW20&%MIP0"0?F'X5\9Z M6K7=I'-'.@9)T'S#/?->+^ M(N_"?QSET*SN6GM41_,P>"N,C/N* -+]HZSVNKV,6@0R6 M]U#(5M1(BJXRP"^E =#AM8T;PGX+\;7/C'5M3E-[<E+OB-J>I>()HY[P_:9&:%#DHHYY]* .B^"4#1?#*QW?Q22$#V+ M5P6/MO[3XBO);:1780N&P5ZCBN"^ M$7Q2T[1M.'A_Q!+]E6$D0SN/E7G[K>E %WQ5\+/'WBQH3JWB'3K@1<(JH4QG M\*?\3YK_ ,%_"32?#PO1)/*!!+(JXW(.WZBNQ\1?%?P]86?E:1?0ZGJ_W36I\(/'^DZAX6M=(N+M(M1M$V>7*X M7>OJ.:X[]H#Q-I6JKIVF6-W'<3V\I>7RV#!>",9% UN>Q?#R+ROAYH"9_P"7 M&(]/]D5T]^.U>7^*H?!'A M?QA_PDVI/<3ZR^/*M(F#DG'&%QD?G7I[G SC..P[U\V>!=9T^Z^,>H7OB6>- M9O,=8/M!^5&SQUX% &UX^\0>-O$G@R\NGT6'2=%( D2XDW32#L1P-M=/\ HM MGPY8@Y#WLA_#:HK(^-/C[0I/"\VA6-]'=7D[KN$#!E0#U(XJS\%-?TNW\"II M:7D7]I[YI5MBWS$ #F@?0X_QCHGBCX:>.+CQ-HN9K2Z"!0(^CE'"XQ@#C%.JIIL;PZ; M:12[C)'"BMGU"C.:MT 8R>S#D5Y-\ =>ATYM0\.W[B" MY\S?&DGRY/<N>-=/AU/P;JUM<#*&W=\]<%1FO)OV;YI"NO0;B85,; 'U M^:O0_B?XFMM!\%WH>11=7:&""($%F)XX%97P7\*3>&_!YN+N/R[R_/FLIX*K MV!_G0!YWXZABO_VA+*W>,-'YL 8?WO6OHP0QMC*J=I^4$=/I7SCJE_:7/[1\ M$OG*8DN8T+=LCBOI!?E'/.2:!GB/[1[A=%T1.I,\A_(+_C7JWA&/RO"FEIZ6 MR?RKQG]HJ_@N+C0M/CD#31M*\B@YV [ ,_D:]M\/M')X>T\QD-']G09!]A0( M\&\/7!\-?M W8UF3RS<22*DK#@AA\M>J_%;5[+3_ (?:HEQ.B2W$7EP)U+DD M=*\?\1>(?#/B+XIWTGBR6>STZQ!A@\E#N9@<9.T$UT&EZA\(5NX[F75[J[9# M\BWPE94_-<4 =+\"=#N](\$/+>1M&UY/YJ(W7;CK7,_M'39LM%C]79L5[!H6 MO:/K=KOT>\@N(D &V(_='TKPO]H;4;:YU+2K2"99'B5BX4YV_6@#W7PM&8O" MFE1XP5M8UQ]%%>& _:OVH)25#A9EX(SC$*BO=M)U&PDT&WNX+F)K18A^\##: M !ZU\]>%M7L;C]H.\U%KJ-;>2>01R,< D?*.?PH&CZ(UMA#H&H.WS!;:3K_N MFO&/V=H_F\03C^^H _6O6/&6H6MAX1U2:YFCC0VD@7 /6O)OV=]1LX M[?5[-ID6[EE5T0L,LN.U CK?&GB/PSH?B:*:+2/[5\5%0L,4(Y'IN/;\JYGQ M[:>/]8\$WVHZO=6FFV4<89M/@!9G4D<,^?IVKDM,\21>&/CIJFH^(59(S/,A M9ESL!/RG\JZSXE_$W3O$'A&]TSPW'9/B#HR_P#3)0/^^JZ/X%^,](AT"V\-&25M3>:1_+6) MB N,Y+8P.E*V5$ED#@JISSS0!],1KMC0>@ _2OG$$7 M/[40]KHC\H37T)'J]A+IG]I)=PFSV;_-#C:!]:^:M UO3I_VAFU=[J-+-[F0 MK([ _NRHY^M 'U#C(KYU^*MA)X*^)6G>*+%-D$SJS!.!N'WA^-?12.KQAU8 M,I&0P/!%<'\6?#D7B'P+>!@%GM%,\;'L1UH Q?'>KCQ?_P (SX=TY]\>K,EW M<%#G;" #@_7->I6]M%:VL=O H2.- B@=@*\9^ 7AV2/1)O$%T2\TY\BW+G.R M->N/QKVM?NB@!13')4@@9'>GTAZYH \;^*OPOU#6-53Q-X^*,%I\0O$&AZ]J" MQVPG LI'P%7 .X$_EBLKXXZEX>UG1;2STZ6VO=9EG41+;$.V.^<4 >M-?65_ MX3DO;)E:UDMF:,J,#&*\:_9M3Y]?DQU,0_\ 0J]%\-Z%>:1\)X]+F!%T+-@5 M/8D=*\7^#_CS2? QUBVU=9EEE9?+")DLPR-OUH ]Q^(>N^'-%T$3>(;>.[0/ MN@MSR7<=*Y/3;?QWX\L4N%O(?#6BOCR8(8RTQ3Z\8KC_ (X7-Q>OX9U[[#/' M;M&S-#,. <@@-CH2*["W^->DW&EVUGH.F7FH:JT85+**(@*<8Y/I]* //_A1 M8M:_&VYM9Y3++;&X5I",%R">:[G]HEB/!UBF.&NP?R!_QKR_P+XM7PW\3;K5 M=8M+@W$QE5X8TR^]CTP:]-^/27&I^ -+OX;>1(Q()9%LVNL2S(K2RE1'(58D'@9KNOAM\4-.O--T+P MU:6EU+?A/+E(4;4 R2Q.>E<)\3?#FJ^!?'1\3:;N%M-,)DD7.%;J0: /5Q\& M?";Q%7_M$AA@[KH_RJ]HO@3P[X%M[VZTB)A>_97),C[F*@9Z?E7!6/[1-JVE MK'=:/<2:F1@>25,;-^>?TKK_ (?:;KNJ7&I^)/$BF)]1B6*"UR?W48SG\\C\ MJ .%^ 5PMUXN\13S'-Q*A?)ZD;QG^E>\7QQ87'M&W\J^8K[^U_@U\2I;V* O MI\[$9Q\LL1()4'U%>B:S\;M'U'0)H-#M+NZOYH3^Z$?^K&.23[4 INXP/R-<%^SQK6GZ;JFK65W(].?P_!H<5PKWWVE9'C7JH /7\Q0!VOP>A\KX9:41_P M%+]/6O-_ MC^X;Q=X=@QU53^FX.2<4 ?3=HGE6<$><[8U7\A4U9N@ZS8Z]I$&H:=,LM MO(HP1V/H:TJ \BOG'4D\[]I^.-6QMN8SG'_ $R!_K7T:3@9KYF\::BW@[X^ M/KM[;RFU\R.4;1RR^6%./Q% 'TQG(%?//P:D:-\4+ M+4M#O_$%Y93Z?I-N0L4UQP9B>P%>._!WQ/I6D?$+4KG4+I8H[Q&CB<],E\C- M 'OOCZ7R? .MR%)-+@T*YT":=4OY+EIEC88W*54?TH Y;X9^']$ M\5>.]?M=;$DDH:5H@)"I/S\]*];'P9\$%?FTZ5E_VKAS7D'Q"\.ZM\.O'?\ MPD.DB1;624S)(H^523RK5TUE^T/)-91VYT)YM2;Y5\IAM+?SH ]3\+^"/#OA M*YNO[&@\J:95\T%]QP.GTKJ!GG(KA/AUHFL0"^\0:[+_ ,3#5&#^1DXA3LN# MWKNP,4 +7F/QYC+?#.Y< G9/$<#_ 'J].K#\8:%_PDGA34-*&W?/$1&6Z!NQ MH XWX#2*_P -;<*8M',RG:#W M/TXKURZ^*/@RUMC.VOVC+C(5'W,?H!0!B_'*?R_A=J"9&9)(E'/7YP:[;P_9 M?V=XS231VT#2 M2,J1QKEF)P% H ^>OBK^\^.&AH?NB. #_OXQKZ)'RC Z5\K>/?%VEZO\7++5 M;:??96K1HT@Z?*Q)(KZ./B_0D\.#7CJ$/]G8R)MW!/I]: /#? 28_:*U%=V0 MLEQS_P !-1_%J>2?XR:9;7!VVT7DHA/0@\D_F:RO 'BK2[3XQW.M7EPL-G'8K37;>Y:_MU" Q*#YO8#KG->=>-?%%]JO MQ%LM=NM,N+4QO$\$#I\[(K9Z>IH ]?\ C]+*GP^A1<[&N%#D?I4'@3X:>#]< M\$Z9?/!++)+$#*RW#+\_<8!KI?$>GM\2/AM-$EI/:32()(4G7#;UY'2O"_!O MQ!UKX97LVD7UHTMLKY>WD.UE/-A[UYW/\ $S5OB6PT#PQILUFEQA;JZD/W$[XQGM73 M_$/4M,\)?"NYT&YO0UW-9-;PH6R[DC&?I0!@_LXJ'\-ZL^T BZ"Y Y/R@U[; MCWKY_P#V>_$FEV%G?Z-=74<-Y<3B2)78#?\ *!@>]?0(Y XQ[4 ?-?QCTZ3P MG\3--\2V:^6D[+(=O&74_-S[@UWOQ \32:[I6E>&=#F#WNN*,R1MGRX_XB:T M?C3H"ZSX O)Q&K36.)D/?&<-^E60?X#]*R_ MVA/#WVG0;+6XD)FM'\MV _@/3]S/PK$\X M!-?-'PP/VKXZW\JY3:]RQ'7CZC34OAUK<5HOG/)9N4"<[N,\5XA\(_B7IG@[0KS3;ZWN M9KF6X#PQVZ;BW &/K0![7\3/^2,#P->2#&YKP@_@H_Q MK0^*_B:TA^&4L-U)]FOM0A4QVTA&\9P<$5B_L]:KIZ^&+G2S=Q+??:6E\DN- MS*5'('?I0!2_:03_ (EVBMGCS6&/P->K^"(!!X&T.,=/L,)_'8*\6_:%U[3M M0FTNPL[N*>:W=FF6-@=G;!]Z]>\"^(-)U/PA8_8KV*46EK''-AO]60@SF@#Q M#XIIYOQTT^(9^9K;O_MFO=/'.C7&M^!=3TVV8B:2W(3'\6.K3I9W FW1K,=OU&32_&O58/%-_I/AG1&2]N]^YS"VX)VQD5P7AC MQ3X107D_BS2;J_U"XE,IFB(X]ASFO0O"WQ*^%^CS^;:Z;-83$\RR0EVQ]1FF M!Z_X7TR31_#&FZ=(Z9J;6OA>QOXS')<#[=, MK JH!QM)% &5X*3QY>Z]J/C/2]'M+G[>2J-=N1\F?X?RKI]?E^)_B#1;W2;C MPWIB17$94LDQXKTSPN^E_P#"-V46CSQ36<481&B8$9 YK6)X/K0!\P?!O6[C MPIX]ET._'DK/I7R?\7;G3[3XGRW^C7,2"YC-\L8\^'<-X(X)QZ4 >,^-X[OP9\:[;7[F(F MSFG61)#]TCH>?;->T:_XRT&T\+76H-J5I)$83M19 2Y(Z8'->-_%/Q/!=?%" MVT[Q!;RMH=@X)A0?R4_P"-=KX8^(WA+Q%,+#1[ M]/,482%HS$3[ ,!7F7[1&NV%W;:7IEM=12SQ2N\J(X)3@#F@#U7X<6J6_P / M]&6-0@-N&P!W->6_M$3[KO1+-BPC?+,<^^*],^&VN:9JG@[3K>QO(9I;:!4E M16Y0CU%M '/?'TH-= M\.Z?-(\=F$)9AU7D#^5=I;?!7PW+"D@U76W5D4AEO, \=1\M4?CCX-N-;\/V M^IV2-+<:=D.J\DIWKD/ GQS30]'CTS7K2YN3 -DP/_UJS1X^U'XFZE::9X6L M[NSL89UEO+R8 ?*.BC!/7FD_: U6R3P?;:2+J-KTW",8MXW;0#R1_GK0!T7P M3@6/X9:>P'WW=OKDUPW[1GS7F@IZAOYUV?P4UFPN_ %E807$;75L")(MPW#\ M*\^^/^L:?=Z]I%M;W4&=-B7HMK'_Z#7@7CC$O M[1&E+R,75KG\'!_"O=?#&M:;J?AFTNK.\ADAB@19&#C"$+SGTKYX\3Z]ILGQ MZM=3^U1FR@NX=\H;( 5N>E 'H/[0UPT?A/3[<$A);GYL'K@5%X4^$/A_5?"^ MG7ZZUK&^>%78PW(50Q'( P<>99)K_ %>0@_,);E6W#Z[: MZ/QI:0Z/\+=4M+4-Y$%DT:!CSC&*XC4OBC=^/670?!5C="6<@7%W*NT1)WQ7 M2?$W5+'0OAEU=MHR;E>?^ +6G^T)% MGX?V[ XVWRZ%OUKR;2@TO[207&LV_A#X_76IZJLD=N MLS_,%[,, _2@#Z=%+7,^$?&NG>,XKJ?2XKC[/!)Y8ED3:LGNM=-0 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4A]:6D;[I^E 'S7\?8]WBV)A][REKRZ M ^;'ENH[5ZI^T H/B2$@X/E+^->4VS 0@=Z13V+ 4+DC);T[4[K\K#WIB.S@ MG;CZTIR%XR3WID,0]:*,&BJ ^X:***D84444 %%%% !1110 4444 %%%% !1 M110 4444 %>1_M"VMQ<>!K22")G6&\#R;1G:NQAG]:]-QD,* /&?AC\2HKC2M(\.V^F7$MQ!&(YI@?W:(HY8FN!^+GBC3M<^(EG< M64ZRVUDB1/(G(R')-?2>D>&M'T*W:#3=.M[>-R2X5!\V:A?P;X8<[F\.Z46) MR3]CCY_2@.I4MO&WAY/",>NG48OL"(%,G^UC[N/7VKP+P3XMTE/C57 A MM+EY=DCC'+ @9].M?27]@:2=..G?V79"R)R;;R%\LGUVXQFJH\&>&%(*^&]) MXZ?Z''_A0!Y+\>?"E[P1F$";)BAY7!R&K*\._'Z[L-)BL]4T\WEQ$H M1)4;:6P,#([U]"RV\<\+0RQJ\3#:489!'O7/1?#SPG%=K=)H%FLRG(;9GGZ4 M#OH<1X%M?$/C/Q3%XTUS?:V5N&6QM.@.003C\:]> P,4R.)8D5$554# "C ' MT%/7ITQ0(#7-^.O"<'C+PS-I$/%FL_"/7 M;G1];M97T]W^8 9"G/WE]>*]>C^,O@E[7S_[5*C^XT9W?E79:AHNFZL@34+& M"Y4=/-0-6-%\.O!\$WFIX=L ^<@F('^= '&76O:G\4F.D:';7%GH+D?:KZ8; M6E3KA0>:Z3QGX&AUKX=OH5L/WMM$&MF;D[E&0,^_3\:[*""*WB6*")(HEX5$ M7 'X"I* /GGX2^-[;P6][X=\2S-:*LF83(IP&[C-:?Q!\6)\0VM_"GA0M=I- M*#3^M>%?!_P 2:7IGQ/U.[OKD0P7R2QP. M_P#$6E5A^@-?2]WI]GJ-J;>]M(;F$]8YHPZ_D:SHO"/AN"19(O#VE(ZG*L+. M,$?0XH$<7\9/%^FZ9X.O-+^TJ;V^A*1QCD[2.M<]^S_XCTR+P_=:+)<+'>BX M:58VXW)@R?#C7]/UKP? M9"QG$CV\*QRJ1@JPK8;PMX?,[SMH6FM+(+J.H3)MAB@&[!/]['2O/O@%:6]]XCU^.ZMX9U, ($BAARW(P:]VLO"N MA:9,9['1K&WF/.^.!0?SQ0#.%^%7@N[T/P[?:C?IMU/509&]4!R0/S->.>$/ M$TOPZ\<7\NJ64D@D+Q2(!AAD]1ZU]9@$#I6?>>']'U&=9[W2K*XF7H\L"L?S M(H$> _$CQCKGC/PAY]MHLUIH<8]N/2MKX5_$>#2_#5II-WI\T5G91 MR-)?'E,EBP ]>M>VW-A:WMJUK,T5E-/(=[+T!0HO\ 2O- M?#KW-W&JW=N_ER%1@&D^(7B'1+"W&GW&F1ZMJKKFUM#!YA!/&23T%2?"_P ( MR^%?#T@O%5+V^E-Q*B_=C]%'TS0!W5%%% CQG]H:QN;GPOIUS"C/';SMYA ^ M[D#'\JS_ (:_$N\N--TGP]9:,\BVB8NKHM\JQC))'^%>WW5I;WMN]O=0I-"_ M#(ZY!JMINBZ;I$31:?86]K&W58HPN?KZT!<^8OBUXMM/$_C2UN;#?+:6**JD MH1DYRW%?0EOXYT67PG_PD(DD^Q!?F_=G<#Z;>M:[:%I1DW_V79%NY-NO/Z59 M2PM%MC;"U@$!ZQB,!?RH&?*NC>*[-?C0OB:Y27[$]RYW",DX*E1Q^5>L?&+P MC-XS\,6FK:1'YL]J"X3'S/&>H'OT/X5Z2FAZ4A)72[,?2!?\*T @4!54!1T M[4!<^4O"OQ9\2>#+$Z4;2.ZCCX2*X!#)[<HR^'M'GNOM$NE63S'GS# I/YUHI&J*JJH"CHH& *!7N* 0< M=O6G444 V-QY4[ M2-)MB)*EV)_K7UNT:OC>H;!XR,U$+6,$XC09]%'^% 7*^EZC;ZUI<%_;*_D7 M"[E$B[3CW!KYT^*7@R_\*>+TUS0HI5MY7$J>4"3&_4CCL:^F47:H%#*#U4$4 M >8>!?BJWB&]MM*U'1[RUO709EV'8Y ZGTJ_\4?ARGCG28Y+8K'J=KGRF/&] M3U4_B!7?[6 //TXI<-B@#P7PU\0]?\ V*Z+XJT2]GBMSY<5Q&"<#TSW%:]_\ M8M1U6W^S>%_#=_+C $4L<0C "*$7^ZH % 'EGP] M^%\VG:@_B/Q.4N=:F?S0""]=EO#X5O[A+A-D@,1&WGKFOI: M=6J/+&T9D3YXFZC M(Z5/R>M** W/G#QS\,O$>@>,?[:\*6<\D+OYJ&WY9'SR"!V/%>H>!/$WBO5I M_LGB'PU<6/EQ\W4B[0S>F*[\Y[4@4@Y[T ZTZBB@ /2O'O$GPJEU[XK6^L2 M1(=(<*]P"PR7';'O7L-)0 U4"*%48 & *\?T3X7SV?QBU'6YH%_LQ6,]N20= MTC8)X[IKY[^(7A#X@>-M<2^?288X+8&.%%E!X MSUKZ'YQQ^M+@YH Y3PU/XG_X11O[5TZ&+4XEV0QB0$. ."3VKQG5? 'Q(U+Q MJ/$DFGVPNUE5T'GK@!>@KZ1 Z]:"/\YH YJ2Y\4+X/$HL8&UW9CRA(-@;UST MKQ;0?A_\2M*\9_\ "1I86ANG=F?S)UQ\W6OH^B@""U\XVT37"*LY4&15/ ;' M-3T44 %>*^,?A/KLGC-_%7AJ\C6[:7S0DC;=K?6O:J* /(/L_P 7=;@.F7K6 M&G0.NV2ZC8,Y'?&/6NX\&>"['P9I1M;7,D\AW3SM]YV]:Z>B@#AOB/\ #JU\ M=:I6LNDY+"%5^;O1[ZPM]2L)K*[B66"9" MCHPR"#5FB@#Y\UG]G>]_M*1]%U2&.U9LHLH.Y/;-=7X%^#%OX:U%=3U:Z74; MI!^Z4@[8S[9KUBB@#C_'GAG7/$^EC3]+U:.PMY 5G4IDN#VKD_ ?PM\1>"=5 M\V'78&LY"//A$?\ K *]7_D_RKN** /$=;^"&MZ_K3:I?>)P]P7W(Q0_(,Y M%=;K?P[OO$?@>+0=5UIIKB.16%R%]/:O0:* /)+'X8^,M'M/L.F^-Y([/&W8 MR$E1[>E=1X)^'UGX0$URTK7FJ7!S->2\LWM79T4 <1\1?AY;^/-.AC,WV>YM MSF*7&<55\!_"NP\'%[B:X>^O73RS(Y^4+Z 5Z#10!XSK'P!LKSQ!)J&G:I)8 MPRL7:)!R"3DX-;EU\%O#DOA>32H49;IR&^VO\TFX=\UZ510!PG@3X8:5X'+3 MPN]S?.-K3OV'L*R_&/P9TWQ3XA;6([V:RFEQYPC_ (CZ_E7I]% &'X9\+Z?X M6T1-+L8L0C)V%R]A)(V9%49!^E>MT4 >>^"?A%H MG@ZZ%X&:]O!]V:8#*_05WEU;17MK);7$2R12 JR.,@BIJ* /(+S]G_0[C5GN MH+^ZMH')+01XQSZ&KU]\"/"MV+98Q- L(P^QN9/J:]1YHYH Q?#WA;2/"]F; M72;18(SRV.K'WK:HHH 0CFO,_$WP4T+Q)KIU-IY[4NV9HXB,/_A7IM% '%1_ M"[PQ%XF_99+6]/6: [2:[RB@#S_ $3X1Z!I5U%= MW1GU&YBY1[IRP4^P-=GJ6F0:KI<^GW 803(4;8VT@>Q'2KM% 'FO_"B_!1Y- MIQ8X^IJ]10!Y_?_ ;\(:E?SWMS M:3R3S/O=FG8\^W/%;5IINE?#SPI=O:*Z6=K&TS*[ECP,XYKIJIZMIMOK&E7. MG72EK>XC,<@!YP1VH \+\!>#M!^),VJ^(M:P\MS<-LMD?;Y8S[5UTOP'\$JC M-Y-PGOYYX_6N4O/@AXAT?47F\*:X\$+$D*TA4C\JNVOPL\>ZCB+7?&%R+NY+K1X[4_:6+956/09[FNYN/@[X-NKF6XGTYI M)96+,S2GJ:Z#PQX3TSPEIHLM,@V*3NED)R\C>I-;U '/67@O1-/\/R:);VI6 MQD!#(7)_6L%/@UX*CV,FE[70@A@YSD5W]% '/:UX+T/Q!:6UKJ5GY\-O]Q2Q M %4]+^&OA71=1CO]/TN.&XC.5=2>*ZVB@#D_$'PZ\->)[Y;S5-.22X4 ;U., M_7UK3MO"^CVFCR:3!801V,B;'C5?O#WK9HH P-#\&:%X;ADBTK3HH%E!#DO-9C_"SP;([,^@VI+'))'4UV5% &0GAG28]$;1DLHQ8,NTQ#IBN>_X5)X* M#(PT2$%&W @]Z[B@]* ,75=?^//'VG:WH::#X M;O$O=0U0B("$Y\M">2?2NA^)?@23QUHD-I!"42(SC*GVJ#P!\+].\$Q> M>V+K46^].R@8^GI0!U/AS0H/#OA^RTJW&([:()G^\>Y_/-:PX HQP*6@ I#F MEHH Y34?AOX3U66>:[T>!Y9V#R/C#$_6ET3X=>%_#]V+K3]*A2<=)&&XK],U MU5% #=OM]:YE/A]X9CUV365TF#[:[;B[#(SZX]:ZBB@#.UC0]/UW37L-2M4N M+9\$QM_2JFB>$=#\.KC2].@M_P#:5?F_.MRB@#&'AC1QJSZG_9EL;USEIB@+ M'WJ]?:=;:E8R6=["D]NXPR.,@U;HH Q=&\*:+X?W'2].@MF;@LB\D?6K][IU MKJ-L;>\MHIX3U21^%;2\6[AT.S2=#E2(QP?6NE52H &!CTZ M4X=*6@#/U71--UNW$&IV4%U&#D+*@./I5;3O"NAZ0CI8:7;0+(-K[$ R*V:* M ,S3/#^E:.[O8:?;6S.(#$=5T^"Z,1RA=G)I\]C;R6:XQ"R J,=.*J1^$/#T$BRPZ-9*Z?=/E#BMNB@#/OM%TW4S$U] M8V]RT?W#*@;;45IX:T:QO/M=KIEK#<8QYB1@&M6B@"K?:?:ZG:/:WMO'/"_5 M)!D&L>P\#>&M+NOM-EHUG%..CB,9'TKHJ* $ Q2T44 %(:6B@#,U3P_I6M1E M-2L+>Y!&/G0$XK"M/A=X-LIA-#H5J9 <@NF[%=A10!!;6=O9PB&W@CBB'\"* M *?+$DL;1R(&C8893T(J2B@#G/\ A!?#)+$Z'8<]?W(YK1?0-*DTM=-?3[8V M:G(@\L; ?I6E10!@?\(5X:^7_B1V'!R/W(K:\E/(\DHA3&W;CC'IBI:* .U:%% # F" M,<_TK$U7P;X?UNX^T:EI5K<3?WV09-;U% &;I>A:;HT;)I]C!;*W7RD S2:E MX?TG5Y8Y=0TZVNI(ON--&&V_G6G10!AV_@[P[9SQSVVC64UO($F@?[R,,@U+! EO"D,2!(HU"JH[ #I4M% &-JWA30= M=N8Y]5TFTO)8QA'FC#$?G3++P=XX7[LL<*AA^-;E% %+4M*L M=8M3;:C:17,.<[)%R,UBCX>>$PZR#0K(.I#*1$."*Z>B@!BQJB"-5&P#&W' M%8-GX(\.6.I'4;?1[6*Z)W%T0#GVKH:* ,C5/#.C:W(DFIZ;;73H,*94#8J# M3/!?AS1[P7EAHME;W(&/-CB 8#V-;U% '-3?#_PE'["6:0DN[P@DD MU=TSPMH>CVT]OIVEVUI#'3]+M5A%V?LT008$8())_(5ZD:Q?$_AC3/%>DMI^IP>9&>58' M#(V,9'O0!YIX(\!> M7\(V=C'ZUQD_[/.JV]S(=-U]8X2?D!4@X]\&M?1/@05NDE\2:S-?QH1M@4D* M?KS3$7_@=IHM(M=GLS(=+DN0MJ9,C(&HMJ&A:@VGS.Q9U8$C/M@@BJ M-G\%O%N5BN_'%X+;H4BDD''XMB@1G:]X5\-Z3\0M @\(R9U W ::-'+JBCKG MTKUJ_P#AUX4U.\DN[O1K>2XD.6D*\FD\'_#[1?!L!^Q1&:[?_67MTKD8(SG@BG44 <3JOPG\'ZO=M=7&DQB M9F+,8R5W$^N*Z'0_#NF>';$6>EVB6\74A>I^IK5HH :RAT*L 01@@]*XS4?A M5X0U2]>ZN=(B,KMN8KP#^%=K10!F:+H.F^'[/[)IEI';0 YVH.OUK/U;P)X: MUR]^V:CI4$\^,;V'-='10!S^C>"_#_A^>2;2],@MGE&'*CK6;=_"WP?>WWFN'&&=EY-=-10!A:'X/T+PU M-++I&G16K2C:Y08R*K^(O ?A[Q3=Q76JV"331C ;H2/0UTM% %+3=,M-)LX[ M.QMHX+>,85$&,5=HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]Z6 MCO0!\Y?M![1KUGP,M$,Y^M>1PJJ=,&O8OVAE)U>P8(.(N6/UKQZWR8LD @'J M*0V7,?)D4RGC+(<<#')I"&"J.PZU1 P@D]:*7-% 'V_1112*"BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHJ.6:*+;YCJN3@;CC)H DHI >E+0 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AKDO&WA"_P#%MG': M6NOS:7%R)1'"'\P'MU&*ZZB@#QSPO\$;WPKKL>HV7BN5 K?/&EMCS%]#\U>P M\Y!/ZTZ@]* "BH&N(4FCB:5 \A(52>6QSQ4] !1110 4444 1RQ+-&\;C*LN MTCV->50? C0(_$CZG+M>LT9H"Y%;P1VT*0PQJD:#"JHP M*D)]J6D9@HY(% $!LK9KH71MXC/C D*C=CZU*!M/UIP93T(-+0 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 44'I6!X@\8:#X8C)U;4[>V?;N6-F^=A[+U- &_17.>$O%^F^, M;":^TOS##%+Y9+H1FNCH **** #-%^&?#)9=4U>"*5?^6*-OD_[Y'- M8=G\:O UY.L0U1HBQZS0.BC\2,4 >AT9'K7/+XU\.OJ%G90ZM;3W%YQ"L3AM MWY52\7?$7P_X.(CU&YW7++N6"/EB* .NHKF?!'C&U\:Z.^H6EO+!&K[-L@Y- M=-0 4444 %%%% !1110 4&BN6\9^.=(\%6J3:D9&>0?)'&A)- '4 8I:X/X= M_$B+Q])J0AL7M5LS'C>P)8-N_+[M=Y0 4444 %%%% !1110 4444 %%%(>U M"YHKE?''C$>#='%^=/N;PD[0(5R!QU8]A6!\+OB->>.[C45N+..WCML; C9Z M^M 'I-%%% !1110 4444 %%%% !1D>M(:\^^)?C77?!]D+C3-'-S !\]RWW4 MH ]"HK@OA1XMU/QCX:EU'5!%Y@F9%\L8&*[V@ HIDI<0N8U#/M.U2< GL*\2 M\3_%SQ9X0U VVJ^';:/>286\WAE% 'N%%>0:;XU^)FM6,=[9>$K1K:0;E+SA M=P_&HKSXM^(_#5VB>)?";O2IRVSB2)Q MAD^HKHA0 4444 %%%% !1110 4444 %%%% !1110 4F1ZT-TKRGXP:]XQ\/: M?]MTEH8=*&$EE',@+E '1T5\Z MRZA\8/$<+ZKI\=S;6K_-'$F%)7VSUJ;P)\9-8MM?CT/Q4AD+R>7YKC#HW3F@ M#Z$HS5'5-2M=)TNXU"\D"6T*%V?MBO#KOQA\1?',\TWA*TE@TN-]J2J-N_\ M.@#W^BOF6#XJ^.?!FN)9^)HGGC4_O(I!AB/8U]%Z/JMMK>CVNI6C;H+F,2(? M8B@"_10.E% !117*^//&5MX+T/[;(OF7$AV01#JS4 =517SO/-\9-=#:K:Q7 M%I"PW)"C!#M[8!ZT[P1\7=>TWQ)%H/BQ7;S91$9)1AXV)P,^U 'T-132UJV\0:#::I:D>7.@? /0]Q0!JY&<9YI,UX?XB\>^*?%6 MM7.D> 8'>VMCLEND7'/U-<=J5[\5/ ;)J&I7-T8&;)#2!T/L<=* /J*C(KBO MAQXZB\<^'FNBHCO(&"3H.Q/0CVK0\:>+['P;H4FHWF6;[L48ZNW84 =+29&2 M,CBO%=)\->-_&VG?\)!=^)KC26NB9+:TB'RJIZ9K0^'GCG58O%-UX+\3NLE_ M #Y-Q_ST ]?P(H ];HI /$*6MEXFOIHKJ(RY=_N_,1BN^TOX=>*+W2[2\;QYJ2-/$LC(.0,C/ M% 'KM%>">,O#/CGP=IZDM[ID=BYPPV M\''OQ0!]1T4@Z4M !1110 4444 %%%% !1110 445EW^NZ=I^JV.FW-PJ75\ MQ$$>>6VC)H U.M-$B%R@=2XY*@\BL#QAI^J:EH$T.D:D;"X"EO,4O&-'TSXC>/;==1O M=;;1M.G^>%(/O$9]*O7'@7QUH<3WNA^+KB]EC&?L]T.'QV% 'KHI:\,^&?Q! M\1^(/B5<:;KC"+$#AK<+MV,M>Y @\B@!:*** "BBB@ HHHH **** "BBB@!" M<"DSGCI3J:5YS0 H-(5R:4#K[TU0P/)H ?1110 4444 %%%(2!0 M%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1136XH =15:TOK M6^$AM9XYA&Y1]C9VL.QJS0 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !2'TI:1NA]: /GW]H>8+J%@F.L1[>YKQ>T!^SX]3R*]?_:%NLZ] M90KR4AY_.O)+8855 /(R2:170M(P$6U<@GMBF1%\'S$VGM2C&" >>E%*4?/R]**";'V]11104%%%% !1110 4444 %%%% !1110 4444 M%%%% $-RC2VTD:2&)F4@..JGUKY;\5:;JUI\7-*TK5M7FU%S=P&.21B<*SCB MOJ@]J^;O%\L,G[0EF\\T<,5M<0N\DAX4*V[^E T?1\0"J%'0#%/KQO6?V@=% MT^_>VL-/FO8T8@SB3:/P&*[_ ,'>,=+\9Z7]NTZ4AAQ+"Q^9&H$=-17/>*O& M&F>$M.^U7\C,[G;#!'S)*W8 5Y_<_&Z\TYHY=2\&7UK92'Y;AYN@]2-E 'L% M8NO^)]-\-_9/[0E*-=S"&$#JS''^-9UOXYL-1\)/XATN&>^B5?\ CWC WAO2 MOGC7_&^L^(_B!97=]I\V+.<&'3A]X$<_GTH&D?60Y I<5YVWQ&U.V\)SZW<^ M$;Z+R7"M"THSM_O=*H>$?C&GB[Q!#I=GH4Z!AN>0S [![C% K'J?>DKA/''Q M(3P-=Q1W6C75S;2)G[1&P"@Y(Q]>*M^ _'MMXZMKN>UL+FVCMF";I2"')ST^ MG]: .QHKSSQS\3QX*U6WLYM%N;E)Q^[E1L!F]!6[)XRL;+PG#K^JJ]C%)&'\ MI^7R>V.YH Z:BO(+[XVW5O;M?6_@[49-,SQ=2OLX]<;3Q^-=KX,\>:1XVT]K MC3W99HP/.@;[R$_S% '545S7BSQMI'A"V1]0DD::7B*WA&Z1S["N%NOC9>:8 MLHT5X_KGQ]T;2[Z2VT_3Y]1CC.&F$ M@5?PX-=_X/\ %NG^,]%74K!B!G;)$3S&V,X_6@#H:0]*!535;PZ?IEQ>""2? MR4+^5']Y\#H* ,WQ-XJT[PKIZ7>H.56241(HZLQ/:KFKV++GQ,D_G:#= MZ8(307$BM.YR7_ '3$5]0]Z^9]#U&S M7]H"_P!5N9T@M;:2>1I&/]V,J)]%@U73W+6\PR >JGT-97B[Q[I/A'RX;KS;B]F'[JUMQN= MOKZ4$G645X]=?&F^TEDEUCP??6=J[ +*TN>/IBO2]!\06'B32HM1TZ;S()./ M<'T- &M33GM2@Y%4M6OH]+TRXOICB.WC:0_@.E '%?$CXEVO@NV%M;A9]4E' M[J+KM]S7':5X \5^/[3^T_%&OW=K#/\ -':PG QVXKB/!=I+\1?BV+R^9GA2 M4W+JQR-BG@<]LXKZFB14555=H X Z#VH&U8\>D^#%]HEN]QX:\3ZC#=(-RQR M-\KM[XK,^&'B+Q%?_%>^L/$EU(;B&Q:/R3]W(=#FO=R,]A7!GP-\BYDMI#S^![TOC7 MXD:1X(6-+Z.>:XE7,<<:X!^K=J .TS17E-E\;M$N/#\ MGISCBLK3_C_;RZO':7VA2VD3N$\QILE0>F1B@+'M=%><>*?BSI^A7*V6E64V MMWFT/)';-Q&O4$D U2\#?&2W\7:\='NM,?3KE\^43)N!(YVD8&#C- 'J=%:=X)MHY;^&YE:4'8(DR,^Y[5QVE_'G2;K3;^[O+)[=H& @A5]SS9'TXH M!(]>HKP:W_:)==15+[0#%:,WWEE.\+GK@BO:=)U>SUK2X=0LI?,MY5W*U 6- M"BO)]0^+-[J6N2:/X,T\2>&-;M['QAH,%M%-TE@8 M],]1S0![717/:]XGAT/PTVN?9KB[AVJZQ0+EF!]?2O,M$^/MOJ&MS1:A9+9: M:L9*8)>1F]* /;J,5X%K/QQ\46DJ7EKX:6#22<+)N00!7K'@_Q5#XQ M\+QZM:*%=LH\9/"R =/IR* .EQ17@/B3XR^-/#&LSZ;?Z/IJ2ACY1*O\R]C] MZO7/"-SX@O-$CG\1QV:73_,!:9V[3TZT =%17D?BOQQXWT[XA1^&](LM.F2< M+)$S(Y(3ON(/'0UZM:FW M)(AASC\30!W%%>,R7?Q??1VUS[3IL,7E^<+/RLMMQD9]\>];?PL^)4_C:.YL M]1MT@U"U&6\O.UAG&<'I0!Z7BBO(_B;\3-?\(R&WLM%$<4AV1WTS[E+8[+61 MIWQ5\5:YX9M(-#TB2]UE@?M%R(]L*-8=(\ M7QJ(Y6$901A2A8\'(ZU[Y/=0V]J]S+($@1=SLQQ@4 3GD5Y=\:_#FD77@V\U MJ>TC.HP*JQSX^8#/2J$/C'Q;\0=5NK3PE+!I>E6S[6U"2/S';'H#Q7&?%";Q MYH6AC2==U*'4]-NWW"[6$(=P_AXZ4#6YWWP$C\OX?%_^>EX_\A7JU>>_!>W6 M'X9::0 "Y=S[\]:]"H$]Q*\=^+GQ(N-'E'AK0VSJ8@W 4>YKUF^N1 M:6,]R>D<;/\ D*^5? 1D\7_&"&]N,OYEP]RV[G@=!SZ4#2ZGKW@/X1:7IM@F MH:];QZCJDX$C>>H81$\X&:[N]\*>']2L3:76DV'-+U74[+4;RT62ZLB6@D)P5-<)\>)1#\.&7H37$+R .KMN1U)QD>E V?3=%8OB77$\/\ AV^UDH9$MX/,"YZ\_P#U MZ\C\*6?B;XK07&M:EXEOM.LHY#';P6)\O\21C- CW:BOG>VU_P 2?#SXI6N@ M7FLW&HZ='GNO#4MO&\2EYFE&6V^PZ4 =K M17S#X$\:>/M8_M:QTN26_O;L*WGSN=MKUS@=!FNZ^$?_ EMGJ.N-XKN+L6\ M*=;ER0"#R5)[8H ]CSC.:Y3XC^0WP]UMI$1PMLQ&>QKS\:IXB^*WB*]LM)U. M32?#UF^QYX,B24^S5E?$?P'JWA7PU<7FG>)M5N[%D"74%Y,9-P]10!H_LXVD M:Z+K-W_RTDGC0_102/\ T*O;SZUY!^SS$%\#WT@_BOW4#V")_C61XN\0Z]XO M^)F3222)"-SNJCH"QQ7RMXKU;Q?I/Q,AL;W5Y[ZX@N8WCBBD9(WRV0I4<<]*[ MS7?A_P"/_&-I)J.I:\MI)C=#I\.Y44>A(/)H ]N4JXRIR#T(-.[5X9\!_%>I MW=U>Z!J,SSK OF1R2,68<],FO<^U ,6BBB@ IDDBQ*6=@J@9+,< 5'=3QVT# MS2MMBC4L[$] *\5M)=5^,/BBZ5KN>T\*6,GEE(6*F<^A(H ],\7:E9MX+UQD MN87VV$WW7#=4->9_LY19TG6IB.3<*N?^ TSXA_"72M"\)WVI^'[BZLC#$6GB M$S%94[@^M7_V=XR/".H28QONL\?2@?0]@EECAC+RNJ(.I8X%5$UG39&"I?VS M-G&!**\6\7S:QXU^+B>$Q/M EJ>X%E"ER0$ SDUXS\1?B5;RZSI^@:-?L&^TH;JXB M?"@9Z9]*W_A9J$_B_P"&?DZM)))DM;M('*N5]<]:!GU-;W,%PF89XY !R48'^5-N;RVL8?,NKB.&,?Q2-@5SNF M>'- ^'NC7MS8Q-#"J^9*TDI8D@>]>9>'IM'^(&I7NO>,-6B%B)3%::=)<[$ M'0D C- CV>SUW2]0DV6E_;S./X4D!-:(KY>^)MGX<\-ZG8:AX+O8[>=C^\CM MIV91CWKV3PSX[%S\+HO$NH@JT4+>9VW,,CC\J L=E?ZI8Z9%YU[=PV\8_BD< M 5YY\5O$&F:E\+]4_L^_MKDN8U^20'^-36%X(\+O\29IO%OBUY+FUDD9;.Q+ MD1JH[X'X?E6/\9_AWHOA[0H=9T2V-HOFK'-"C$HP/?!/KB@#M/@-$8_AO Q) MP\\A _X$:]0KS_X,1"+X8Z6,%=)C_NVD8_\=%6=2TVTUC3[BQO(A)!,NUE M8<4_3H?(TRUAZ>7$J_D*M8H$?)]\E]\(_B@8[&8BU+JP!Z-"QYS^M?4]G<)> M6<-RAW)*@4C.QGYQ4VD^)=%US(TS4K>Z88)5'R1^%>. M^#KOX9V>AQ7?B+4+:^UBZC$MR]VC2%689*C([5Y_J^K:7H?Q)AU3P7,[60=6 M"(&4,2<%?I0(^MSQTZ^E9/+<('()';/2@#L]#\3Z-X MCB,NE7\5R!U"GD?A6L[K&C.S!54$DGH!7@.E^ O$'A;XRQRZ5;NNCR3;RRMA M1&<\$5T'QK\7M8G3_#,-VUJ+]P;J:,G0YQ7E=AXA^$=CI"Z64M91LV/))9DO(?7 M=C-<#\)-2DTKXG"STYYVTJYD>,!@0"O8F@#Z*U?Q1HN@QL=2U""!E&2C-\WY M5!<>,] M-(AU:XU**.TG7=&S-]\>PKQ_]H7P[96J:?K4(87%Q(T@#T;0?''A_Q/.\.DZC'<2IR4 MZ'\*9X@\?>&_"\ZP:IJ*1S$?ZL?,WXU\]:SX/KG^E<9\!YY[#QUKVB"5VM8T;:FX[5*/@'' MK\WZ5T_[0TFSP+:IUWWB@9/HK'^E BS\/_$>B^$?A5I$NK7L<"NI903DG)[" MNH\._$;PUXGO/L>F7X>XZ[&&"?I7F_P]^$FEZ[X2L-1U^>XNQ+'OAB$I"QJ> MP%<=\1/!,GPRU^QU?1+F46KONC.[#(1VSWXH&?4I.%)KC-6^)_A?1KM[6>^: M69.'6!#)L_*N=\=^/)++X1VVI0,8[S5(5B0@G*Y'S$>^*Q/!?BGP;X7\-VP? M2K^XO+A=]Q,;,R,S=_F/.*!'I'AOQ[X>\4OY>F7RM,.L3C:WY5?UKQ3HWAV, MOJE_#;G&=K-\Q'L*^9];OO,^)D>L^%=,O[6W:2-B@A9,GC/ [5ZG\<=!TV\\ M%G7I[8_VC%L1&#$8SV(H ['_ (6/X:'AT:X]^J6;.40D?,S#T%:WAWQ)I?BC M3O[0TJX\ZWW%2<8P17B7PQ^%VG^*?!#7NLRW#F5V%J%D(6/C[VWIFO7? _@V MT\$Z%_9UM,\V7+O(_+^%M,E^(_P 29O&-W"RZ19MLLT?^,CH?IWH ]+U[PK#XE\(Q:)>2,B%8 M]Y7J2HK7TS3[?2M/M["UC"00H$11Z"K:Y[]:4\*<8Z=Z /(_V@;>V;P,EQ)& MOVA;A0A[UO\ P=LYK3X9:4EQGP8DBN/\9R'XF>/[+PG8LQTJP?S+V9 M.F1U ->SVMM#9VT5O!&L<42A551@ #M0!/1110 5@:UX3T_7=:TW4[W>[Z>2 MT49/R;CWQZUOT4 ,QQR!TP:^<_CKID,_C[1([5!]LNE"R >NX ?S-?0FHW]M MIEC+>7/>"],G^(/Q!N/&NHQ%=.M&*6,;C[Q'0X/YT >A^,- M7?PWX"U#44/[^&VPO^]C KRW]G;3?-;6M;E4F1W$0;WZM^IKM/C=(\7PPO\ M:.LD8./]ZLO]GR(+X GD[O>/G\A0!V/Q$L5O_AYK<+_PVS2 ^Z_-_2O/?V>[ MY;SPIJ>FR$GRI?T8&O1O'\HM_A]KCYX%HX_/C^M>6_LXPNMKK,^/W;.BCZT M>M^%O"VF^$-(&G::C"/<69F.2Q-+XNAAE\(:LDV/+-L^?RK;%>6_%CQ)-)!% MX/T7,NJZD0L@0_ZJ/U- '-_LX6DL5KKMUM_<2/&B'U(W?XUE?&S4FUKX@:9X MT^"?"]OX0\,6FE0@%U7=,^.7<]37A?B:/SOVB[=&&?\ 3(1S MZ4 ?2%K;K;6<-N/NQHJ ?08KYZ^+DO\ 87QHT74X3M8PPLW_ 'VX/Z8KZ* W M?3)KYM^.KFY^*.DVJC)%M"H_&5O\* /HZVD$T*2KT=0WYBIJKV">786Z?W8E M7]!5B@ HHHH *04M H ^U9?BCQA8?#ZRM8Y-,N'L$C"*T"_+$!P!^E(3;F'W M0:YK2OB[X:UG6GTZRGD(2)I6G==J8%:_@ZP@E\ Z59W,$AK MY^\-^%;/7?C3J6C/E-/ANIV>*,[045_N\=L]J!6/6/\ A>WA2NK% M4*)GS#Z"O*?&OC^^\1>-M--]ITL-C97"/'9.,,_/<>]>Z6?PM\+:?XAMM:L[ M'R9X!\L8;Y.G7'K7D'CI//\ VBM*BQD&ZM01Z@N*!H]M\)>*G\313,=(O+!8 MC@?:1RU>&Z/<11_M%WMW N*^F,<8KY=T30[;Q+\>-4M+O<; M=;N9V53C=@XP?:@#TS5?CUX9T^[:&&"ZNE5MIE087\/6O0/#WB+3O$^DQZEI MDPD@?CW4^AKGO%O@CP_+X'U*VATJTMS%:N\;I"H92H)ZXSVKB/V>&-1M]/8X M%PXP#^':N,U/Q)/K?QLN9FT:;68=*9HH+6%P "I^\<\=01O*G"H<]ZXKX#:/KFFZMJL&HZ?<0Z;);'"3+\IDW+V^F:YGXJZ# M9GXOP:;9Q1V\=UY*E8E"@%@,G H ]:+E%)KT:-U MEB21.5=0P/J#7G,_P5\*3V]BBV\EO):E271O]81Z^M>BPQ+%$D:C"(H5?H* M)**** ,/Q1KZ^&]$EU%K2:Z*':L40R6)KYKM_B#?:M\4[/7M4M)IA:NPAM(A M\R#&, 5]7]>,?G7S7X)3SOVA;S,:C;+,< <#B@:/&++Q/XNNA?KYEK;Q^8T7\+Y)P#ZB@2V/59/C[X634%@6*Z:(MM,V, >_P!* M].L+ZWU.RAN[219+>90R,.A%>7?&3PGH=M\.[B[L]+MK6:U="KPQ*AP3C!(' M-6/@A?,?A<)IV9E@GEZGHJ@'% '6>*_'6C>#XU%_*SW$A_=V\0W.WX5QY^.6 MF6US&NI:+J-E%(<"61<"O._#WC=KSQ_JVO77AVYUV?<5MDC/$"Y]"".E;_CK MQG>^,?#4^G-X#U&*Y;_53R?-Y9]1\M 'N.FZE:ZO817UE,LT$HRK*:N5XS\ M[?6[+3=3L]2M[B*U613")@00>>3>"9H/C!;^*+*-%M MI+9EN3W+GC^0%=QJ&H6NEV4EW>3I#;QC+.QX%66&<#WS7@'Q8UZY\1?$+3O! M4,S)9+(@G"'[[-SS]!_.@#K;GXY:%&S-:Z=J-U;H2&G2,[?SKK?"WCK1/&%N M&TVX'F_Q0O\ ?'X5JZ;HFGZ9I$6F06D(MHT"^64&&^H[U\Y_$"QE^''Q1M]4 MT@M;V]PPF"1\+C/S+@=J /H+Q#XKT?PQ LNK7J6P;Z"LC1/B7X=US2 MK[4H[GR+:S?:[2\9^E0>.]/TWQ)\.KF^N[:-W^QB>*1ARA(!X/:O(O@?X*L? M$RZC=ZH9)[2V= MKO(1G.2"PZ'IWH ]*C^.?@][_ .S&>8+G'G%/EKJO$'C/ M0_#.G)>ZC>(L%+QW9%4RHI;_5LK;6Q['(_*MV MX\ :QJ?QF?7=5B231X&WHTC K@#@8- &Q'\=?"[7"QW$-];!NCRPD#ZUZ);W M]I>:='?P3J]JZ>8)0>"M>.?'#5?"\_A?['!-:2:HLJ^6(1DA0>1D>U;GP/SJ M'PN2"[W2QF62/#G/RYZ4 ;\GQ0\)IK$&EC45EN9G$:[%R-Q. ,U#KWQ7\+>' M;PVMS>M+,#ADB&[;7@OC/PO;VGQA&AZ5(]K'<31;7C/S1ENI&*]R@^#_ (3A MTB:TELO/N9H\27CR,96;U&3Q0!T_AWQ3I/BG3_MNDW(GC!PPZ%3[BL?5_B=X M7T/4Y=.U#4&@N(_O*8Z\B^!$TNG^/=5TH.S0%&!&>,J3S7=_&GP;!K7AB75[ M>W4:C9X;>J\NG<$T!;4[/PQXRT;Q6)FTF625(CAF,>T'Z&H/%'CS0_"$\4>K M321F897"9%<=\!=>@U#PC)IBHB7%C)\P48+J>A/XYJ+X@6L'C/XE:#X94[XK M7-Q>8&=J]0* /3=!URS\1:5%J5@S-;RC*EEQ6E4%I;P6EK';VT*0PQC:B(H M ^@J>@"*XGBMH&FFD6.)1EG8X"CUK@;_ .,WA*QN6A6>XN-IPSP1%E_.CXS: M;K>K>!S::'%)),\Z^:L9P2G.?UQ3O"6E:+X1\!6%KK<5A;S>4#<>&7\*Z!B I). !R:^7_ =[:6_QWD&D/C3I[F5 M4"'"E2^'MW-:OLGN&%N&] V,6DE M8 M],UYC\QN;:W6.._0-(B #G.#QVH ^BHO$&DW%G)=P:A;/;QG M#R!QM6LG3_'_ (9U/4;BRM=3CDEMXS)(U)M.T[ M4XI[E<_(O7CTJ[K?B32/#EMY^JWT=LI&0&;YC]!7G^@_"/2_!7B#_A([;4+E M[>TB9_(<#/3U[UYWHOB_1?$OC>\\0>*H+VZAC(%I:QP>;&H]QTI#/7+'XQ^# M-0OQ9Q:A)$YX#S1E5/XFN\BDCFA5XV5T<9#+T(KYW^)OB+P9KWA[R-(T2>'4 M4<-%*EB(OJ#@T6G'>DDH.2FTD@9],4 >D:]XGT?PW; M^=JE[' O92&1CA?.CV@UY'H7C70M9\>:CK_BF"YN MXT8K9P)%YL:#I]T\58^)WB?P1XBT0#2=*N(=41AY;_9!$,>^.M 'T;%-'<0K M-"X>-QE64\$5S&O_ !%\->'+C[-?Z@!/WBB7>P_ 5QGP*UW4;_PG=V=XLK_8 MGQ"SYRP(ZJ RRL$$;+@Y-=R#D9KR7Q]\-H=8U72=7\.V=M'<1W"^>8<*I4'K@=Z]:H$% M>=?$CXF67@VWDM$1I=1EC_=KCA.=$TG1[BPU"Y9-0N[PN%VYW9 KWB25%C\PL @&2Q. ![UY)\! M]%T^;P&E]-8VTD[W,A$CQ*S#!P,$C/:J_P ;?%ES%/IWA73KAH9+U@;ED)#! M20% (^C4 =;J?Q:\):5=FWDU!Y77[Q@C+J*W/#?C'1/%<)ETF\67;]Y#PP_" MJOAGP5H>B:%!9KIUM,QC!EDEA5F)_$K26^&GC>QUK0&>V@N&WM&C84 MD'D8';VH ^E:*SM!U6#7-#L]3MSF.YB63Z$CD?G6C0 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4AY-+10!\[?M!VP&LVD^!EH0/UKR*W_U0]<5ZY^T+ M+(NMV0(^01#'NI[/J'PZ\,WGA]M(72X(8BFU'1/G4]CGK7BGPC:;P_\ %V_T192T ,T##^\4 M8 &OHZYN8K6TDN9I%2.-=S,?0#FO!?A+9?VU\4]>\11\VJ22^6^.&+MG^0H! M;%$^(-6U[XQZAJ6G:*VO)I^Z."V:0(L6"!NYXZYKH_%FO>.?$F@W.D7'P_:( M7"[1)]I5MGN*Y?P)KR>#?C!K%IJI$,-W))$6;HA+[E/XU]%K?VC6ZSK<1& C MB3>,4"/)?@IX8\2>''U./5[22UM)54QH[@_-W.!7(Q?Z5^TXVT#:+K!&.,"( M?UKVSPOXOM_%5YJ26,+&TLY?*6Y_AE(Z[:\4\&G[;^T-J4K')CGG.0.X.W^5 M TSZ+FMX[B*2*504==K C((-?-O@2X/@OXTW.EW"E(IYG@Y&.I^4U]+J0V2/ MI7S]\<=*DT;Q7I7B>VX>1E5O]Y>AH")W7QJO+.#P)):3PF:ZNW\NU0#)WCN* MY/\ 9YUMOLVKZ!*0DL+K/&K#DYR'S[ A?SK4\'RW/Q-\7#Q9>Q-'I-@OE6<# M="^!N;WYS7GFO37GPN^+UUJ%O&3!+OD51TD5^H_!L4!Y'I;1R^,_C04EC$ND M>'DRX;[IF(X_$=?PKDOB5JU[K'Q7L-%M=/;48=/*/]A#;1*<9->E_"K1YK+P MP^HWL96_U28W,Y8Y)!^[^AKR7Q7JK^$/CZVJ3MB(R*S-C^!AS0)';7OC/QM/ MITMB_P -66WDC,0'VD$ <]L5S/P@\(^*=#\;R7MYI,UE8R1.'WL,<\@>]>[V M.IVNHV<=W:SI+#(N]6!' K"LO&MIJGC2?P[8QFX%O;F6:X0Y16R %SZT"/%X MO$.JZ]\6K_5M.T$ZZ+(E(('E"+$ <;N?>ND\8:OXZ\4Z#-I-U\/C$)A\D@NU MDVGUKC/AGXEM_!GQ&U.UU9C!'=NT#.>D;;\@FOIAKVV2W-P\\8MPN[S"PP!3 M8SR3X(^%/$'AU=5@US3V@M)PAC21@V3SGC\JX0^'K+7OVA+O2+B$):-=.S1( MN!A8\XX^E>\^%_%UOXJN]3%E XLK.40QW)^[,W.[;]*\?\#E;_\ :&U.Y8EF M1IF!!SSMVTAH]5\5>&-$C\$:C;1Z9:I%%:,4Q$ 00.#GK7GO[.&_^SM9RQ,8 MF7 [9VBO4/'DGE^!-<=205LI"/8[37FO[.28\/:L_8W0 /\ P$4"Z'MP[T,, MC% I&) X]10(^<_$P6?]IC3X\!E%U;A@>G05]%@!5/'3FOG*('4?VF&+X_=7 M18?\!'%?0]U+Y=G/+G&R-C[C S3&?,_PZ\/67B7XN:K#J$0E@MY+BX,;=&(E M '\Z]<^*GA_2/^%;ZFPL;>(V\.Z)DC VD?2O._@6PN?B1K]SG.;>7!^LJFO2 MOC'<&W^%^KD'[ZJGYL!1U&]SE_@%<31>!=3FE=O(BN69 >P"Y('XYKC_ EX M@U_7O'NM>(M/\.QZ].I"QB2X6(6\9)VXW=\ 5W'P4M9'^%EPJ#YY7F ]^"!7 MG_P9\2VOA'Q;?Z3JI$1NF$)E8\*Z$C!H ZKQIJWCOQ7X:NM)G\!-;[MN)4N5 MD*X/:M3X&:!X@\/V>I0:O92VL#N&B63CGZ5ZG+?VUO:&ZFN8D@5=QD+C&*Q/ M"?C"#Q:;^6TMI%L[:811SMTE/C7EBY^6>%H_P 2* /GK]G;8WC'4^ 3_9Y(_P"_B5])\9KY/^'^J-X M^)Y@OV\F%G:VF+C'RDY!^F0*^JH9TEC22-P\;#*NO((H*EJ3&@C-,:0(K%B% M"C)R:YC1O&MOK_B:^TK3X6FM;./][>J?D\PG&P'N:"3R#4=1/C?X[6NEW;&3 M3K.XPL#C@@' M]:^GMV.3TH*D?+OB&VE\#?''.F@QQS7,=NWYL?F:[+X]3^5\/ M@?\ UUS'&1ZXY_H*:!="G\#?"6EKX136KFRCEO9Y&&^50VU0<# KGOVA--LK M?4-&GMH(XKB96C?8H&5SP>/J:]+^$=J+7X:Z0%)^>+S#D]SR:\S^/N^"/#>FZ#X5L([:UC$LD*/+*5RSL0,Y/6O#]1MA# M^T9;160\L?;8V8)P,?Q?IFOHZR7RM/M8L9V1(N!["OGRPQ<_M-,I.0ES)C\( MR: 1Z_\ $N*!_AUKK31JY2T=D)&<''&*\L^ ?A73-3L[_6;^SCGEAG$,7F+G M9A03_.O3/BO)Y?PUUG!^_"5_.N5_9YV?\(1J#!@7:_8L,]/E6@70O?&/PCIU M]X%O+Z"SABN[$)*DD: $KN (X]CG\*R_@!>3WG@Z]LWD8)#-B,_W0?2NB^,F MM1Z3\.[Y/,437>V&-3U;)Y_3-F!FO/?BWXOG\7S:6W]D7-A:1!_L\MPF#- MDCI[<5W_ ,%=%T_5M+F\2ZDZW^KR2D,\QW&,?C7,?&W5K'4O'&BV%M6\"[QXYD(AT]L$'./W?&:\?\ V=H0U_K<^?F*A?PSF@%L MST/XO6\#?#'5,QJ!& R #&"#6+^SV?\ BW=RQZG49?\ T".M+XV7(M_AI>#. M!+(B?7-5O@/"(_ANA48WW:KIT>K:3>:?*!LN87B.1TR"/ MZU\I:%!K^G^(M1\%V1V-J$GV2?Y?X0>6]N.](>ZL>S_#*WG\2>)-8\=7F[;< M2M;6*GM"O&1]<5ZMBLW0]*M]$T:STRV&(K:)8E]\#D_G6E3)"O//B+X5\.:G M<6>N^(-0:UBL1P,C#\YQBO0Z^;/%VNKXA^-UMI6K2D:/;7:PF%CA3CKG\: . MXU#XCZKK&F7$?A'PU=75FD3!KZYQ'&%"G.,]:Y/]GI))_$&O7;X#>2%..Q+9 MKU'QAXF\/>'O"5U"]U;1+);/%!#&1\V5P *\P_9^U*PT^+7FO;J*!G>+;YC M 9'S?_6H'T-G]HU]GAG2%'4W9)^FTUWWPUT^"S^'6AI%"J>;9QROM&-S,H8D M_B:\S_:,O8I+71+5&#$LTN,]1C%>M^"L#P-H(!! T^ <=/\ 5K0+H>'?&&%/ M^%T:$$ ^=;;&+/1[V[ MAMKZRC$01VP'0# (-?&&F:G8V6BV%U%5))/]:[:@1EZ_ ] MSH&H0H2&>!P"/I7S+\#YH[;XCPI-\KO \8SV;-?5A164J1P>#7RSXWT.^^&? MQ(36[*!C923F>!R,KRGPR6E["+DH#) S@ M,I[BM;5?$6DZ+;M<:CJ-M;Q*,DR2 ?E0(U#]ZO'_ -HB7;X%LH<_?OU;\D?_ M !K=T+Q+K/C7Q"M[I\3V?ANT)'FR+AKIO]G_ &<8KD/VB;^!])TBQ613,9WD M* Y( '/YT MST3X:6ZV_P .=%55 )M@3@=^:\;^.S"7XBZ7 ><1IG\37M?@ M2:W;P3I:6TZ2)';*I*GH<=Z\*^*MY;7_ ,8[53,IAB,*,X/ Z9H&?0VO1:4? M#]U#K!C&F>7MF\TX&!V_2O,M$\4ZCJ*_V1\-M"CBTJW8AKV[RL>?4=S3/C_> MW!\(:SGG)D:,Y#C''/YU?\ !OQ)\&:7X%LD^V1V[PQA7M\?.S>P[T"/ M,-CV6MW\=]>O=6V]X@0JJ7' S7T#X_F^R^ -;E!VE+1\&OG;4/%M MKJ'QGLO$-_'):V4=U$P\Q2"$4Y#$5Z_\0O%^D:I\*M1N+2Z#I=Q%(E/RL_N! M0-F)^SG9QKX7U2^\L"22\\O?W*JBD#\R:ZWXP:E+I?PWU*6!RCRA8MR]<,<& MN7_9ZOK;_A#;JR\Z/[2MZS^7N^;:47G%=M\2O#\OB;P+J-A ,S[1+$/4JN>*M_&680?#+4B?XRJ_G7E'PJ^)EOX-6XT37 MA)%;>82K!23&V>.5_N';D].:X+X;>,K+P;XUU>?Q"KJ\P:-I<9*MN!Z?A0)G4?$WP M_P"*V\&2ZKXBU]"N^/\ XEUM'^Z4D_WO:NU^!\0C^&=B=N"[R,3Z_,:\Z^*G MQ(C\5>&?L>DV%T=-:16DNY(RJD@\"NF^$7CS2(_#%EHA\U9;6-FGF9<1QC)/ M+=* Z')ZJHO_ -IF*)AO5+I.#_LQ[OYU]'N,(Y]J^7],\0:9+^T$=8EN46R: MZ;$NX;3^[*CGZU]">(_%6E^'M#EU"\NX4C,9,0+C,AQQCUH!GBO[/R"3Q7K- MP!TB S^-?1-?-O[/^JV%CK>HV]UL0KY:W"Y*'^$YY%;0H XKXK7LEA\. M]5EB+!FBV CMFN<_9]*'X=R8V[_ML@8=_NKUKN?&6AGQ'X5U#2U^_-$0OU[5 M\Y^!/&M_\+-;O=*U6S7%SXK;0/!6G076KX(N+MT&V'UR M>^*Y;XE>![ZS\$SZWKNNWFH:BC(IC!Q$N3T KDO#'BY_A[\1M8GU*SDE6:61 M7P/F'S$C%=#\1?%^O>./"$LUAHDUMH4,BM+/+PSG/''I0"/0_@A"(_AO9G&- M\C-7 ZCBZ_:?B[A)HC]-J 5T'P2\4W5QHMGH4>C7/D0!C)>D8C%<;XLOY?!/ MQSFUN^MI)XF?S45!C<".,4!U/7_B\SQ?##6&C)W%%''IN%^#7<>)/A_% M>_#/_A&;)OF@4,CMU=QR3^)S0(N?"DQM\--&,;*?W1W8['E>@F@0'I7S+\;G,OQ3LHNH6.( >F37T;JNJ6^C MZ9/?W;,((%W/M7)_*OE?QSKY\3_$%==L["YDLXF15S&P+!30-'UH@ C4>U([ M[%+'[H&2?05YFGQO\/\ DC=9:D),?<^S-_A7-:[XF\@K1^(O@]/&?AB33P^RX0^9 MW;=CI0 OA31_#E_X4TRXM],LGB>!#GRE/.T9R?K6C>:9XE>'++Q=\1=2MM1\41_9-%M MV$D=HHV^8PZ$^N,4#,#]H>63[9H#IS:;'8$=,Y&/TS7MWAJ\BU#PYI]W RLD MD"%2.W'2N;^)W@5?&GAE;: [+JU8RP #J<$;?IS7AOA[QCX[\"!M%CLI716( M$,L)8@^Q]* /IG5]=T_1((9+^7RQ-*(8^.68]A7A/Q&O+>S^/>D37Z!K18X5 M<2#*X+-_7%=;X+T+Q-XLUF'Q+XS^6.#FSL]NU5/][;4OQB^'%QXJM(=4TL;K M^T4AHR>9$Z\>XH$>BII.CRJKQZ=9,K#*D0+R#Z'%,(T/2[VV@,=I;W4QVPJ( MU#-CTQ7SCH'C?XE>'[8:3;V4\RQG:JS6Q8K^)KU?P%X1UJ34AXH\83F;577$ M$)/$(]AV- '-?M(R8TG1(AWED(_):]:\*1F+PGI*'J+6//Y"O"?C-?:OXKUV M#3['1+YH--9E,GDDAV..0?3BO7?"WB6:7P&E_<:3=P26< 0P,A#.5&.!0!Y3 MXJVR_M)V [![?\P*^@91B"5O]EOZU\RW[N;FXC(6!4R4)'>@+GE/P002_$?Q3.HX4L,_60_X5J_M M'28\-:3'ZW9;_P <:L/X26OB7PMXKO7U#P_>B'4L;Y#&0$.XG/\ X]7=_&?P M;J?B_P /6O\ 9:AYK60R&,]6&TCC\Z .B^'*;? &B*>UJG\J\^_:(D632-%L M5YFFN&(4=<<"H?"7Q%U_0=#AT:^\):C-#==\8>+(O%' MC"!;6&#!L[!3ROINH Y'XR6DNF^ ?"-IL;RH5&[ _BVC_P"O7L/@K4-+USPG M875DD+*(E1AM&5('(-'C?P?;>,/#CCUQTH&?1^N:MH_ANR%[J/E0Q;PB?(-S,>@ KA?CK.V:S_"G@CQ3XFU>VU[QS<,4A(>&R/ R.Y7M53XO+XJ\4N-!TSP M]%II75(T!9F8X 'K3R:\9^+D?CS7KS^Q- M#TV<:6JAI)8O^6Q/8GT'I[T 7M2FU+XJZD^FZ=(]KX6MY,7-U@@W)'\*^HKT MC3M/L- TB*TM8TMK2W7 !. H'%&,NIS#%U=Q_]>/Z+ MX2^+.@M\"M_=F ->M^ O"<_A;P4+)W M/]I3J99Y"/QKZFA8M"C,,,5!(H >>E07%PEK \TTBQQ(I9W)+YM)T?3W&D*!ET8#S3WS[>U %F[?4OBUK!MK8R6W@^T?\ >RD%3>L# MT4=U&/UKTZ"*QT335CC6*ULX$X)^55 ]N_$:Q7Q#\-]3CLV2B7PEJ-F6^>&[+8] 5']+>*,1A?48KR*[\+ M^(_AQXNN=8\*:>=0TN\&9;4'E30!TOQKU4:;\-;U <-=.D(!/.,Y/\J@^"6A MOI'@"*:9"LMX_G8(YQVK D\)>*_B7K5O?^*8AIFDV[!H[//++_ /"#?%9]=?6O*G34&)_?"4 CV'I6J- ^ M-80J+Z[P1C'VD?XT ?07VZU-^;$7$1N]OF>3O&[;D#./QKP'XH64GAWXP:1K MV[]S<2QL#[J<&NT^$W@36-!N+_6?$CM)J=POE*7?0EW'\]O*?X6H ZE'#(&4G:WS ]L'FOG;48SX[_:"C6%?,MK(H';' "$GK M]3716UY\5X=%'AU=&B+QKY/V]F_AZ9_*NS^'/P_A\&V$TMP_GZI=G=<39S^ M_.@#MF9(8R68(@_B8X I4=9 &1PRGH0<@UQ'Q7T'6?$'@Q[/0RQN?-5F0-@N MHZBI/A=H6K>'O!T-GK+LUUN+;6;.P>E ';4444 %%%4-6DU"+2YGTR&.:\"_ MNTD;:I/UH ^??C5(9OB[HB+SL@@0_P#?UC_(U]&P*!!& .-H_E7SCX@^'/Q& M\2^)&UV\M+5;I64HJRJ IR *]O\(3>(Y-*">)+2""X0!08GSO\ ?VH&= D, M4;LZ1JK,>0H;Z9KT"LOQ'HL/B'0+S2I_N7$97/H:!' M"? @*GPTAVG.;F3=@=_E_I7&_M%WD+OHUFLJ&=69F0') Z57T#P=\3_"E_/H MVBR"/3Y7R9VP5 /&1GO@5+XS^"VMW?V*:RNI-2O9V^'HA! MX;T]!QMMD ^F*\,^%($OQS\0RG'W[HC\9*]'TC0_&'AKP7):Q746I:EM"Q)( MVU4'3K7F/ASP!\1O"OB3^WK6PMY9Y'8RQF4$,&.2* /I C@XZU\X>('%U^TI MIZAZ18YR@,B*<@&O%/B9\.=?;QC!XJ\,J9K@R*[ M(.J,.A^E 'N);*G!Z"OG'X9.)OC[K;-SN:Z/X^8*]&TS2_'FD:)?ZA<74>JZ MW=8"VK2;8X1[=J\_\*_#[XA^'O%S>)$L;5KB=V\Y&E7H[9;% 'MWC)_*\$:Z MPXVV$V/^^#7E7[.*;M!UI_6X0?CMKL_B*/%U_H1TOP_IT,HO83''^-@9_VC=.B;!'GVR\_05Z[X3\'?\ "#>&[J'3S]LU&8>8[N?]8X'' M->/:IX&^)&L>,1XGETV%+Z.5710X ^7I0"/I(D\]JCDNK>%U6::*-FZ!W )_ M"LWPY/K%QHL$FNVT=O?D?.D;9%>*?&+P?XJO_$\^M6*2R:?;P;]ZO@1A>2: M/H//>EKAOA3K-YK7@"PN;\EIQF/>?X@.AKN: $[U\X_#B19OC]JCN1N+3X_# MBOHZOGS7/AMXRT3X@SZWX5566=V=)-P_=[NNZ:U\NAWQXP('_D:\)_9P MASJ>O2%>!'&OZFNTO=-\>:;X)EL8?^)OJM]N6>1W $(/I7*?"WPIXZ\$:Y(L MFDQM8W9"3LT@RH'0B@#OOC.0/A;JH/?8!_WT*Q?@S;&?X.SPJ/FF>X7'J2H% M+\7++QEXBM&T/1=)673GP\D^\98CM3O@[IGBOPY82:+K6F""Q4M+%-N&=QQD M&@#@O@=KMIH/BS4](U"1+>2?*QM(=OS ],FOHYG^7)QCKGMCZUX7\4/@_?WF MKR:]X94M-*V^6W4X8-ZK7.:/X?\ BSJ;1Z5-P62=1\C,>P/>NEKG_"7A6P\(Z)'IUFF3]Z:0_>D?U-=!0! M5O[1+^QGM)0&CF0HP/N*^5?"=Q-\-OBW]FO@8HTE:VE9NAC8_*P^O!KZSQ7G M?Q*^&%OXWCCNK9UM]2A&!)C[X[ T >@Q.DT22(P9& (8=P:<21VXKY]TG5OB MEX#SITFCW&K6<1VIF-F 'LP[5O1^,OB=XE0V=AX932W?AKB8'Y >^&H ]*N/ M%6EV_B:WT!IBU_.F\1J,[1[^E?//C=F\/_'Y;^X/[MKB&8$]E("_T->X^"?! M">&H);J^N&OM7N&WSW4G)SCH#Z5F?%#X;0^-K&.YMB(M4MU(C?\ OKQP?RH M[^*5)HDE4@HX#*1WS7@'[0 ^T^(- L8^9V0C Z\FM3PYXM\?^&],72+[PG=7 M[0'RX944@8'3)K6\-^!=9USQ;_PEOC&...91_H]FAR$],_2@#J_$%L++X7W5 MM/\ \LM."-GU"@5PG[.4 7PSJLP/W[E5Q]!_]>NF^*DWB6XT271M"T9[Q+V( MK),I_P!6/3%%KR;2M2T2>+3KIO,\UEQL8#% &W^T /^+>*,X_TI M,#UYKHOA,@C^&>BK@#, -<7\9;7Q5XF*:)I>@7$MG"XE-PHR'/I6]\)I?$5C MX932-7T6:V6R3$,C#'F#TH X?]H!6;QEX< &5\H#_P B&O=[4;-&A]!;KQ_P M&OGWXA:9XX\;>)8KV+PU<0PV!VQ C[P#$Y_&O:/"^I:G?^$?,U;3I+&ZBB*M M&W\6%ZT >,? 5?.\?ZY<-RRPL0/4EZ^A[@K'!([' 5223TP!7R?\.+SQ)IOB M^^OO#MB;PIN^TP@ DQ[NU>EZU\0/%WB>S?1=)\*7MG<7"^7)+.IP@/!Q0!SW MP=M7N_BIX@U>-?\ 1(1,'?M\[Y_]E-:;Z]JWQ:\;7'A^POI--TBS#-,\9^:1 M0=O]:]%^'?@E/!_A8Z=,RO=W!+W#KW)&,9KQVX\.>+_AGX]EU/0["6\MYV8# M8A8.K')4_I^5 '8?$GP5X?\ "_PONOL5D@G$D0-P_+N=PYS6U\"%Q\,[;/>: M0_K7*>)O#'Q \=^&IKO5GCLUB_>6^FHN"WU]34GPMB\>^'M$:.?3"NEVVYA: MM%B64G^[WH Q/$$BR_M+6:J.1-&I_P"^":^C2!WKY;U"W\8)\2AXP?PK?C$X MD6'RCG &W^5>]ZOXFU*U\'+JMKHEU->21Y%J%^9#[T >._ I1-\1-;E/)$9( M/U8U]#W%O%A!KYI^&L'BKP;XI>\G\-7TD-[B.0B(_+DYS7 MTTAW(K$%I_"O3'OGU/ MQC=Q%9M6F+0JWWDBSP*Y;XY:/::IXL\,VD0_TV[D\J3:>?*R/_KU[7IEC%IV MFV]G"NV.&,(H'H!0!:48%!I:0\-8O MAGX9_P!N6D6M>,[V74[NY42"'<1&@/08JO\ '3P9J7B"PL=4TY&FDL@PDB7K MM.#D?B!^=9'A3Q3\2-9TN+1;71U@:-!&;ZX0J$7Z&@#GO#MC9VG[1+6EC (+ M:"Y<1QIT KV[XB^&8?%7@R]L)9$B=!YT4CG 1EZ9/IU%>"0^%/'/A'XCK=V MEA)J%X)"XGVDQR;NN3VKU+XE'Q#-\(7EO)8K:_!1KI(SC*D_='YT >@-)+HVM?%?Q];ZG=:5'E%,# M\J8'T3= 1:?-CHL3?H*\!^ P27QUXA$O%LU[<>'K]K>_)C8^21M);.:0'T-XKAEF\*: MK'!GS&M9 N.N=IKQC]GG4K 1ZEI%TD7VMI!(@D49(P 1S]*]\7$\*LRD!EY4 M^]?,WCSX=Z[X-\32:WX>BFDM7D,J-""3&2>AH ^DFL+)L!K2 D=O+!_I6+JT MMC=^%=>M]*:$R16TL;B$#A]AP..]>)Z/XT^*WB&-=,MK=@LGR&X:U"E1W.:] MJ\%>%(O"V@"R9S-/,3)>3.6DD9"*\T\!>/]<\ M%Z:--U_1-0DLD),EZK+)-9E@"CME&7^\IKZ?M; MB.[LX+F+F.:-9%^A&17@6NR7OQC\1Z;#I^DW%KIEHV9+F=,9%>^6=LMG8V]J MARL,:QCZ 8_I0(GKSOXW _\ "KM2PVXY _6NOJ*")(8(XHUVI&H51Z <"I: "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "D/>EI#SQ0!\W?M#70D\265L ?DB&37E=N<0 M@+^=>M?M O;CQ!:]/-$(!KR2V7$2X]*0RQ'D9).32AB3G/-*,[!Z'M28Q3$! M&3DCFBDS10!]OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$ ]J M\,\2_"3Q#IOB_P#X27PC?*9VF,I25@I4GJ!ZCM7NE(0#UH \=U#0_B7XV5-. MUR>RTC2VXN!9DEI /KSS7I'AKPUIWA;18=-TV/RXD7EB/F<^I]ZV0@'89]<4 MN/>@#Q_XH?!]_%%ZVLZ1,JW[@>;#)PLF!C.1WKB=!^"OC"]D6WU:_>QT]6^9 M5E+9'L*^EL?2C:* ,W0]!L/#NDP:;IT0BMH5P%'<]R?>O$_$WPD\4P^.[C5_ M#%V(([J0R&59"K1EC\W3M7O](5SU_"@#G/!GAVY\.Z&MO>ZG2,9)IYG+ M98]AGM6?\2?!DGC7PU]@MY(X[E)%>-Y!P/7]*[/%&* ,CPSH-OX<\/V>E6^- MEO&%+ 8W-W-<=\1_AS<>,=?T&^@DC$5I(PN5?JR94C'Y&O2<4A&: (X(5MX4 MB081%"J!V KS[XG_ UC\:6"3V;K#JD(PCMC:Z]PU>C=Z0C/6@+GS#I7PE^( M45V+-+EK*TD.UY$N#M"_2O=?!'@C3_!>CFSM"9+B0[KBX8?-(U=1MY_QI2,] MZ N>-?$[X._V_<2ZQH.U-0AKF-$^#/C2[GCL]"K>TBGCX3[0< 9ZM_O5Y-X>^&?Q%\ M.>*$URV.G/.SLTH:?(<,>./!5W);7,=A_95P^^9?,)96P!E?R%>R^6M 4 <=?6@!1 M0PS@'UH%*>: /!?'GPI\377CR37O#DX3SW\PR"78T;=^G:NGB\'^-M'\+7-M M9ZS'J.JWY/VJ6]D;$8QC"<_SKU+:._-&W/6@#PGP!\-O''@OQ']O2337CF C MN TA.4+ DC'?BNH^*'AGQGXLMCI6E_V>-+?:S&1RKE@<\]>,UZ;L7.DVFZJME_9K$NNR0NRMZ#MBL7XC?!2;6]6?5_#IBBGG;=/ M#(VU=W]X>YKV_%!&>] [GS?I'P7\97\\=EKFIF'3$/SHEP7R/8=*]_T/1;+0 M='M]-L(_+@A7"C&,^Y]ZT-HS3@,4" "@C-%% 'G?Q!^%&F>,Q]KBD^QZD!_K M5&1)[,*X72O#'Q>\+@VFF7T,UJG""1U9/?\(I\3?%2 M"W\1:_'8V)^66&T55+KWY %>E^'?#NG^&-'ATW3H1'"G4XY=N['U-:^WW-&/ M>@1Y?\3OA4?%\D>J:9.MOJD0QDC ?'3IWK%M%^,DMDNC2_98 1M.H$ N!7M6 M/>C![F@#B? 7P\M/!T,]Q+.UYJETWF7%U)@G=WP?3.:YOXD^!O&/C:]%M%=V M,>DQ2!XHSG)..K<]>37K6/>EQ0!P/P^\.^*_#.DMINIWUI<6T4>VV55Y4^A/ MI7GWB+X3>.?%NO2:KJ>IV8G4XB"@@(H.0!7OV.?Z48H Y"PL/%UMX'-C+>6C MZTB[(YR#MV^IYZUYE:?"'QM9>)1K\6N6@U(LSF4J3R1@_I7OF/>D( Z=: /, M/C%+=VWPDF%[(CW1>))6C& 23SBN(^&OA'QC!X1M];\+ZY#;"]+,UM+&&4E6 M*YY_W:T/C?XNAU/3F\-V5C>O-%.#,Y@(3CI@]ZZ/X(Z_#<>$+;06L[J"YL@Y M=I(B$8,Y;@_C0/H16OPUU_Q#KUMJ?CO5DO8[4AX;2!0J;O<"O0/$7ART\1>& M[O1)QL@GCV J!E/0CW%;.*,4"/GO2?@CXKL+^6VC\1&TT^0_.]N[*T@^F>M; M/B?X#6E[%8_V!,<<\5%X(^$.N>#M92\M_$T?D,1YT,=OCS!Z> -5\#F:"77S>6# [;8 M1;0K'OS7H6VLWQ!'=R:!?I8%A=M _E%3@[L<4 7Y)%BCWLZJB\LQ/ '>O*/A M]9V_B3XB^(/&*0*( YM[1\=<<%A[FO-?#?A3XB>(]3ET^>^U.SM&)6ZEN)&P M%SSM!/-?1_ASP_9>&M%MM,L5Q# N,GJQ[D_6@#6"X[TM%% !7E7Q"^#=OXOU M-=4L+P6-XW^N)3*R>_'>O5:3'YT >8Z%\$/#.F6,BW@DU"ZEC*F>!74^'?!*^&_#L^C6^L:A+"XVQR2LI>$8Z+@8KJL>]+0! MX]$[W3;&QB2:U2U; M3WW[/_ (6N9VEM;K4+'/\ #!(,?J#5S1O@9X2T MN6.6X2YU!T.1]JDR/^^1@5Z910!'%;Q00K#$BQQ*,*B# ]L5P&H_!CPEJNJ M7&H7L5U+-.VYLW#X!]N:]#HH Y;1/ &A^'M)N]-TY+B.WNE*R SN3R,<9/%< M\/@7X*+[I+2XD/??$O#E^;VUT\2S9RAN/GV?3-=Q10!R>L_#CPUKVO1ZQJ%B)KE5"D%CM8 M#ID=*77/AOX6\0O$^H:8K-$NV/8[(%'T! KJZ* .5T7X<^%_#UZMYIFFK!<* MN-X=CG]:ZC8"_K6Y10!R@^&G@U45!X>L<#I^Z%:5_X4T+5(;>&_TNUN M8K?_ %*21@A/I6S1GF@# M?!/AFRNTNK;0[&*=/NR+ H(_2N&^*%UX6N1)8- MIL&J>(Y%$4,2)ETSW8CM7K%4(=%TVWOI;Z&RA2[E.7F"#>?QH R? ?A]O#7@ MS3],D.943=)CLQYQ72B@<44 )BLK4?#&AZO,)=0TJTN9!_%+$&-:U% % Z)I MC6'V$V-O]D_YX^4-OY8JU#;16\*PPHL<:#"JHP!^%2T4 9=WXF6 MLTX.?,>($YJ[)96LUHUI+;Q/;L-IB9 5(],5/10!!;6=M90""U@C@B'1(T"@ M?@*KWVB:9J MT@EE'\;Q@G\\5))9V\H020QN(SE R@A?I4]% "!0/PI>M%% #6C5T*, RGJ" M,TP6\*@!8D7'3"CBI:* &>5'_<7\J=BEHH 3;[YI-@_Q]Z=10!$]M#*VZ2-' M/^TH-2!0.!T]*6B@!,>],:&-V#.BL1T) .*DHH 3;[FC:,8[4M% !BDV^AYI M:* $VX/!-&WD')R/>EHH ;L&[.3^= 4 DY/YTZB@!-ON?SI0,444 &*3 SFE MHH 3:*"N>Y_.EHH 3'Y^M&/#R/2@*!_3VI:* $*@]ASUHVCL *6B@!," M@C//>EHH 3:#UYI N._%.HH 3:,D]Z-HI:* $QW[^M&*6B@!,<<<4FP9S^=. MHH ;M '&!^%>=^*K#Q?XHUB30X533] 8#S;I23)*O=1VY%>C4F/4\^U %'2- M)MM%TNWT^T0)#"FU1C]?K5^DQ2T )BC;CIQ2T4 )@#IQ1M&,4M% " 8'4T%< MG/>EHH ;M&,9/YT8R>IXIU&* $VTM%% !2 8-+10 4FWW/YTM% !BBBB@!, M?7\Z,4M% "$9&.:,?6EHH 3;[FC'7KS2T4 -VCU/YUEZ_JMEH^CW5Q?7$<48 MB?;O;DG'05K5C>(O"NC^*K1+;6+07$2-N4;BN#^% '@?P&UFPLO&&JQ7$R1& M[C(A+D $[LXKZ3 R*X>V^$'@NTNTNH=+*R(P=?WK8!%=RJ[5Q0 !=O Z48YZ MFEHH ;M'J>OK1L'J>N:=10 F..IHQ[FEHH 3&1U->/\ B_XUS>$_&%UHS:0L M]O;[/WF\ACD _P!:]AKF=9^'_AO7]634]1TY);INKP.N:CM[>.V@2&%%CC0;51!@ ?2I0 M,"@ I",TM% "%/>D*Y'))IU% #=@]3[5XK\>M4U.PET$1PR2:8DWGS@9 MVNRE2%;'XU[95:\T^TU&V>VO+>.>%QADD7(- 'G>A_&GP=>V$*W%U]BE50#% M(O"GV-0:[\4?#-]"VF:3;-J]Y=(45(H^ 3ZFM*[^"G@FZN'F.G21%CDK'*0O MY5O>'O GA[POEM+L(XY#UD;YF_/M0!0^&?AB3PGX/@LKA=MS*S32I_<+'A?P M&*[+&: N!CM2T (!BC%+10 W8!P.!Z"EV\Y]*6B@!-HSWI!&JDE0!GK@=:=1 M0 FVD9%888 CT(IU% #5C5%VHH4>@&*=110 4A7/.<'UI:* &B-020 "W4@8 MS2XI:* $VC=NP,^N*,#(..1TI:* #%%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !2$X%+2'H10!\R_M ,A\81*O)$2YS]*\UC?$2$KC KTCX^J@\: M+C[[1)Q^%>;Q-F'G\12*Z%E2-JMG/%!8$=*;@;%*^E /'2F1<48Q10O(ZT4! M<^W:***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 444E "T9I"P%M:T_QF\') MI\5W%J!D+RB/R0A$BY[E>H% 'H.[GGBC/(KE_%?CG2/!]E'<:@9V\T$QB*,M MGZGM6;\//B/!X]DOQ#826WV4KDLV=P/3^5 '=T444 %%%% !1110 4444 (: M0')QT-E^"+>,WD<\LTH)C2-#@X]3VJ/X<^/%\>6%[=K9FV%O/Y6TG M.>,T!8[6BBB@ HHHH **** "BBB@ I",BEHH @DL[>7)D@B8GJ60'-+%;10X M$44:#_97%344 %%%% !29I:X[XD>,I?!/AH:C#:BXE>41J&^ZN>YH [ '/8T M Y%<;\-O&4OC?PR=0N;7[/.DAC<+]UO<5V.X"@!U(:6B@!H7&>G-*!2T4 '2 MDW#..:#TXKS_ ,;?$+4?!UTY;PYET %(3BC<*Y/QYXZL? VCB]NHS-+(^R*%3@L>O MY4 =9GV-+7DGA7XF>*O&5XC:3X;A6P$@$L\TA&!WQV)KUG(4<_I0 XG%&>:X M[QS\0-.\%V<7FJUQ?3\06R=7-_$3Q]INCKKUYX3LX]+!!8"5O-"GN1VH M]@HK&\,>(K3Q3H5MJUGGRIA]T]5/<5LT %%%&: $) I4'[LAY KONHS0 M%%% !1110 44 YHH "<"DW"E/2N%^)=]XITSP_) M>^&V@18$:2Y9P-P4#J* .XW>QIU>1_ _7M9\0:=JUSJU[)Z: M&1E$"W).[<.I /;I0!ZT#G/M2TG3K1F@!:*3(QFC- "T8YI,TN: "BC(HS0 M4444 1RS1PKND=57U8@#]:>"& (((/(([UY3\:_#GB+Q%:Z5%H<Z3X4TZQU*7S+J&(+(V<\^F: -RBDR,9I*AN;B*VMI9YF"1QJ68GL!0!-NSV-9^L:[IV@ M6#7VJ726ULI \QSP3SP/?BL_PCXHM_%NCMJ=K$R0^>\:%OX@IQFLWXC^#)/& M_AY--CN1;R1S+,KL,C@$8_6@#IM*U:QUO3XK_3KA+BUE&4D3H:NUS/@?PLO@ M_P ,V^DK.9F0EGDZ DUTN0* %HI,CZ_2EXH ,T4F1C-&1G% "T4FX49% "T4 M'BDW =: %HHS2;A0 M%%)N&: .:\3^/?#_A">WAUB[,,EP?D4(6X]3CH*Z"U MNHKRUCN8'#PRJ&1AW![UPGQ#^&=KX[N[*YEO&MGM\JV!G>I[5VNFV,.E:;;V M, /E0($7N<"@"WD51U?6M.T*R-YJ=W';6X.-\AP,UR^J^/([;Q_IOABR19Y) M@6N6!_U8]/K6WXKT;3M;\/W<6I6J3Q1Q.ZAAT(4\B@#/\,?$70/%VKW.G:1- M)-);Q^:SE"%*Y X)^M=97SM^SPBIXIUS:OR+;[5/H-XX_2OHC.: %HHS10 4 MF:"0!DG KA]"\K;%P2B'E MFQZ 5%X/\:Z7XUL[BZTL2^5!)Y9,BXS[BL#XMZ%INH>"-2O[NU1[BUAW128Y M7D#^M8/[.ZX\%7TAZM=D$_0"@#V&BD!%&>: %HI,C..]+F@ I"<#-+0>E '+ M>*?B#X=\($1ZI>A;AEW+ @RY']*O^%_$UEXLT2/5;!9%A%F_"@#T.BDSQ2YZT %%)D M8SFC<,X[T +12;A1F@!:RO$?B"S\,:%.[&:YTZ.:%H7V/#-CM!('4T +129'K1D>M "T4 MA.*,B@!:*0'-&X9QWH 6BDR*,T +11FB@ HI-PH# ]/7% "T4FX&C(% "T4F MM "T4=*3(H 6LS6_$&E^';$WFJWD=M .[GDGT [UI9K$ M\4Z78:KH-VE_:17*1Q,P#KG!QU% &9X3^(^A^,]1N[/23,YME#,[)A6!)Z=^ MU=?7SG^SB@;6M'/$\>@WK3?:FV; MF1=^)OA+I'B7QBGB"YN)$<[#)$O1RHP/T H ]#1Q(@=3E M6&0?44ZHXD6&-8USM4 #V IX=6Z'- "T4A('6C- "T4F106 ZT +29]C1D5P M_CKQV/"U[I-C;1I-=W\X38Q^ZF<9H [@G S7'ZG\3?#6D^*8_#UW=LEXQ )V M'8I/0$UUJ'<@)QG'('K7G.M?!_2]:\:KX@ENY@#())+<=&84 >E YHIJ (, M8["ES0 M%)FC( SF@!:*3-&X<>] "T49HH *Y_Q-XTT+PA' ^MWGV83L5C_= MLV.>))8F#1R ,C#D$>M>8_%# MX77?CG5;&\M;R. 0IY;JX[9SD5Z!HFF_V3H]EIXX_Q8QS0!I44F11 MN'3OZ4 +11FB@ HHHS0 444$XH **3(I&;2PFL=;@DE\^[=XY49B5. , M8].IH ^@[6[@O;:.YMI%E@D7U35S7@!&C\!Z*C#D6RUTN: "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#2TT]#0!\O?'N17\=E0' 09&:0^A.IR6';'!H!XP*;G!^M M.7&".],0J@!:*0$ 44 ?;U%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 9Q36D1?O.J_4XKC_ (C^,X_!OAW[3'M>_N&\JUB)^\W<_0 O&^K>%_'W M_"+ZI>/>64EP8%=WR03PISZ5H?''4O%FD7D1353'I%WD11V^492N,AC^M [' MOY8 9)XI/,3&=P]*\"T>S^(_CSPI90072Z3IT46//FE;S;D]CP"0*Q_ .N^( MO"'Q.B\.:M['I7G'@KP)=>.M&_X2/Q)K>H>==LS01V\Y58P#B@1[@& M!Z'-!91WKY?U+5/&WA+QR/"5GXCN!%).D<$LH#?*Q !Y'^<5['J>JZKX#^'% MS?:QJ/\ :FH0 @3!-N2Q^48]J!M6.\+J.K ?4TNX8SGBO _ ?A75/B-I5QKW MB#7=3@\Z0I!';S%%('?\ZI>%M5UOP9\7U\+SZA=7=E*_EA9G+D@@D'G\: /H MG(I&D1/O.J_4XK \:>(X_"?A:]UEU+^0OR+ZL3@#\S7E?@OPOJ?Q)L)?$'B3 M7-0ABN'*V\%K+L H$>Z!E(R""#W%&X>M?,6OZEXS\ ^+!X9L=?N/LLSH;:2 M?#G:QP,GDU[+:7NJ^!_ U[J'BW4TU"X@)D5T&-V?NKT'>@9VYD102S =R<4 MH=6&0P(]C7BFA>&_$GQ+M6UG7M=N;#3YB3:VMHV"!VR:Y*?7/$/PH\=+ILFK M2WVFEE)$[%LH>_<@T!8^F)8UQZ 8H*> MPY;*W2/RTMH0HXVB,8QZ5\^_&[P';:-<6WB33H!%;RS*D\: *3SN_/C\:^C M*I:MI5EK6GO8ZA;)<6[D%HWZ'!R/Y4$G->/%MI_AIJES)$DNRP9XRZ@X^7M7 MGW[.4#+IFLW)QL:=4'U S_6O0OB3LM?AGKRHNU/L3HH].,"O%?A>/&%_X5OM M&\-6\5M#/<[I=1E8C8=H! XYZ4QK8^FMP]:-P]:^6M=/C/X4>*;&YO=8>\6; M+ F9G20 C<-K8P>?UKZ+O=>BL?",VO.A:.&T-TR#N N<"D!M%U R6 ^M('4@ MD,"!Z5X#X,T_6_BQ)?:OJ^OWEI;1R;(X+(E!^!JAJ5YKGPT^)6G:/;:WP6HMT:6X+@[B M@4_=XKQ/P-XA\WNE32*D\%RY9@J;A2>8F<;AGTS7A/C+Q!KOBKXI#P9IMY-9V4;JDKPDAONY)R.E5?B+X+ MNO VAP:YHWB+57FCF5)?/N202?04$GT#N7UI/,3@;AD]!7#> ]?O_%GP[BOD ME5-2*/$)77(WCO7A\GB#QMI?Q-CM+NZEU+4;>?8+:.3"2>U TCZI,B#JX'U- M*&!Z'-?/_B3P%\1-7M[SQ!J&M0VCK&95LX)W_=KUV\#&0/Y5M? CQ=>ZO8WN MC:A,\[V8#Q2,23MS@@GZT"/9PF* '%E49) 'J:8L\+_O;>8X M]2!7DO@]7^+_ (HU:ZUS4[JWMK;'V>SMI]G&3S^@H ^@1(A4,'4@]#FG5\\> M*?"FI^#O&OAQ+#5]2GTBZOX@4DF9MA#KP3TQ7T,.E "UEZ]HNF:_IS:+I6FZ)I M4-EI<,<-I&/E"'/Z]Z\S^+GQ#CTRVBT/1=0VZC-*@DDB;/E+GO\ 6NE^&]JU M]\*M+BN)YBUS;,'EWG?R2.":\,\;^"M-T?XF6.A6=S=2QW31^8TC[I 6/K04 MD?4MM*C0QJ)0YV YSDD8ZTES?V=F%-U=0P;NGF.%S^=\$Z?X.DN[^VO- M1N&:+D74^]0!D\"O*O"-G8_%;QIK4_B6\G(MI +.T67:I3+ \>VU?SH)L>^Q M:G83J&AO;>0,< I*#D^E6LBOG_Q5\-V\(^)_#MUX?>^;3IM1B26$.6\L[LY. M!P, ]:]_7[HH #T-,GD?E7V/'*DL2R(P96 8$=Q7A/ MQ?\ "P;X?:-JD$69;&)%DVC^ CO[5UWP6\3?VYX*CM[B7==6!\J3*]H^*WB M*XTW2(-$TS)U75W\B+;R47/+8KA_B]H#G],5PWP=@%O\,M*']]#(?Q.:Z+Q)XETSPOIK M7^J7 BB4?*H^\Y] .] /<^>?B5>2VGQTMY[\DVT,L#IGH(\CD?CG\J])^*_C MS3[;PU)HFGNMYJ&HQA(XHSN*@]^*\P^)MQJGC2WB\6Q^');'2X?W"7$C?/,# MT8CL!CK_ +5=[\$/#WAZ[T(:T4^U:LC[)6F.XQ>F : MH=;\-]/A\'>#++2M M2N[>&[P99$>15(+'..379V^HV5V[);7EO,Z]5CD#$?E7A/QJTA-;\;:-IVE MOJTZ[9A&2=J9X+8Z5Z?X(^'^E>"[7-JC/>R(HGGJ7+*/*C;RT/\ &^.%'U-;IKQSQ9(?B#\2;'PS"!)I.F.+B^96X;'\- 'C M6NV.OZ%K&F^)-3+BZU!OM:MG!SNSC\J^N-#U:#6]#LM3@8&.YA63CL2.1^!X MKS_XV^&%U?P4;N"+-QI_S)CCY>XJC\ ?$*7_ (3GTA\^=8R$\G(*-R/ZT#/7 MZ*0=*6@0A('>N=U[QUX<\.R>3J.IQ1W&,B%\'3&2QP>@^[S0!Z#HGQ-\*:Y.+>VU-$ MN"<"*8%&-==N7'6OF+XWOH$7B#3Y]!EM?M)4F=[1P0I!'7'>O>=9U^/PSX); M5;MP&AMUQO\ XGQP/SH E\1^-?#_ (60?VMJ,<$C+N6+J[?05P'BOXM>%M8\ M#ZQ;6%ZPNY(#&D4J;6?<<''X9JK\*_#A\4-<>-?$D2WEU=RG[/'*-R1J.. > M*L?&_P ):1_PA,NJ6UE!;7-M(GS11A[/>]$UNR\0:7%J-A(7MI2=K%<9P<5SNL?%#POH6L2:7?74L= MU&0"HB)!)K1\$7]IJ/@G1[FS"I";5%*J.%91AA^8->?6=E9>/?C-=:E]F5]. MT6+8'QQ+-GUZDZIXLT/1K&*\U'48;6*90R&3JP^G6H_"_B[2?%MOE77@2\U"\ME-S:I^Y<'&PFLS]GJW,?@:ZG M*X,UXQW>N !_2@#T3Q'XGTKPOIXOM4N5BC)PBXRSGT KBQ\;_#:G_2[35;-# M]V66VP#^-<+\7=6;3/BYH]QJL#SZ1;QI(L;#Y2GS2>&?B7X3N;2 MPGM;CS86$8QAX6QQQU&* .B\/>(;'Q-H\6J:>7-O(2%+C!.*SO%'CO1?"7E) M?2O)<2_ZNVMUWR,/7%8^FP/\-?A2R7CQM-8Q.=R]"W:N,^"M@?$^H:GXOUAF MN;WSS%$7&0@P#QZ=: .GC^-OAM;J."[LM3LA(0%DN+?:O\Z]$M+RWO;5+FVE M26!UW!E.17(?$OPG:>)/!M\C1(+BWB:>%@O.5!./QK@?V?=>NIX=1T*X8R); M@2QY.<6 MXN&P7\G!$>>@)KQWXRZ-8VOQ&LK/3+=+9Y?]\GK7J\GP4\+W.GVL4L< MRW,;!YK@-EI6QSG\: /1K6X2[M8KB/.R5 ZY]#4N:AM;=+6TBMXP0D2!%!]! MQ4I]* ."\3_%WPOX:O6LI9I;J[4[7C@3.P^A)KJTUBT_L)-7F8PVIA$Q+#E5 M(S7A/Q\LK*#Q1HOD6Z1S3KND*KC=\^.?>O>-/MXVT.T@DC5H_LZ(R,."-HH' M;0X:Q^-7AO4O$=OI%LLQ$CE?M$F%08'6J.L_'?0=-NY(+2TNKY(VPTZ#"'Z& MO++?PY9:U\=Y](=-EE]K8E(^/E5_:YX1T(>$KZRBTZVBA\AMNV, @@ M<'- %_PIXMTOQ?I0O],EW*#MD1NJ-Z&MZO /V;68R:ZFYO+41$+VR=V?Y5[_ M -J!!FN/\7>/].\)M%:^6]]J)?!N-?%?BC6_%>JJ);L/MCSR$SZ4 ;ES\8[_0[B'_A(O"-YIMM,<)(9@YKT MS1]8LM=TJ#4;"82VTPRK5A>/_!J^-O#+:9YRPSA@\23; SC)3/)Q7J'C#1K77O"]_97 M*!@T3,K8Z$#(- %S1M>T_P 0:4FHZ;.);=A]X#D$=0:\WUWXZZ9I.LMIL.E7 M,SK*(V>1M@ZXSTKF/V>]7GAU;5]#DD+0*GF1J>Q#$'^8K-^-]M#ST>86^CZ9+JL@4,TD6?+3/;(%:7P^^*5GXY>6U M:U-I?Q#+1%L@CVKJ=(T'3-*TR.UM;&&.$(,@)G=QWS7AO@2WCM_VA]7@MALB M1KCY1[,*!'I/Q ^)]IX&*0-I]Q=3OT ^5!^-9 ^-5F?"UOJ,6GR3ZE,Q464) M+;?PRS100O+*X1$4EF)X [FOG;XY6D= MO\1=%EMT59)(T)VX'(?%=[\;]9GT?P((;73$(Y']W%4=(^,EQ:^(QH/B[21IUVSA5DC)*\],U6\(I\2] M*\(Z=;:=I>BBV$8*&25@[ \Y; Z\U@>*?AM\0/&7B"/4=0BTRVE4!=T$IP,= M^F: />=0U&UTRPEO;J98K>)-[.?2O-(O'/C'Q2D]WX/T&S.F1,52XOF8-,?] MD#_/-8'QNO;NRT/PYX>:Z;?*%6X93C> O\ ,&O7O#=A!I?AW3[*V14CB@0? M*.IVC)_6@#@/!/Q8GU;Q"WASQ#9)9:F&**8_NLP[?SK%^-^K^+K2QEAAC2VT M%F"/-$WSR9['TKN#\,]'_P"$[3Q6LDJW*$OY0Z%L=:P/C^^/AZ%'\5RG\Z!F M1\([WQG!X=TFTMM(LFT4NQ^T,Y#A2Q)./7-;7Q&^*U]X,NC:VVBL^[ 6YF8^ M63UP*Z#X5P^1\-]#7!&8"Q_$FN,_:+*#PEIPVC>;S@XY^Z: /2_"&KS:]X5T M[5+B-(YKJ(.RH.*P?&7Q 70KR+1](MO[1UVY.V*V_A3W:M#P.Z6?PWTB1R%$ M5D'.>,8%>2?!N=O$WQ$UC7[X!IU3U '3ZMKWQ8T"Q;5;RSTBXM8QO MEA@#%E%=7\/_ (@67CK2VFC7R;V'B>WS]WW'M7720QSPO#*H:-@5*GG(-?-/ MPTN&T?XV7%A;N5MIYIXBF>#C)% CTKXG?$G5O!4JPV6C!TD "WDS9CR>V!WK M-@^+&LZMX:M)- T)[_5G3]^R)^[C;/3K3?VB9]GA#3$"_P"MNR/IA2:[GX;Z M;;Z=\/=#6")4,UE%-(0,$LR DG\Z /.?"'QAUMO%ZZ%XLLXK=IF"*53:8V/3 M/KFO<5ZFOF_XGPJ?CKHZQ<.PMRV!WWFOI!!P/I0-BMTKQ[XF>,?&O@?41>V_ MV*72)CMB5H\E6]Z]B-<=\3M!3Q!X!U*V,8,T<9EB/HP_R:!#?AUKNK>)/!L6 MJZFT)N+AF,8C7"J!TS^->8^-?B/\0/!^OMIER; K+EK>40]5K8_9\\0?:M!O M=#F?$MFXD0$\[6X/Y'^=<;\7)KWQ?JNHZG81 Z5H0\EIQT=B1G![XH&?1=@; MU]&@^TR1M>&(;Y$7Y2^.H'IFO*O#VN^/]4\?:EI)U*SGL=+E'GLL(4.&Y"@X MZCI6OX0\=I_PII=?%3QEH_B6+2X[&/3$,B['6;?P1?+KMQ%-?"VF+O$,+]T]*\5^$Y^T_ M&_6KDG/S7)R/=S7N_BJ;RO"&L2>EG+_Z": 9\Z_"3Q%-H4^M+IVG37^K7("V MT2#(/))S[5L^(?&WQ7\*W%MJ>M+'%8228\A8DV?0D#/ZUH_LWV\;V^N73QKY MRO$JOCG!#$C]*Z+X_LH^':J>"US'C\Z!'H'AG7(?$?AZRU> ;4N8PY7T/'M4CL2@"S/+&'W?G7TCXJE\GPCK$G]RRE;CV0UX]^SFA-KK4F M.KJ* .[^)K7%K\(M42ZE$ES]G1)' P&;<,G'YUY3\-?$FO0^"SH7A'3'FU.6 MX:2:YD'[N)2!W]:]5^,I_P"+8:K@C^$?K69\!K6.'X.OB!X"\46L/BF4SV\Y!*-@@J>N"/2OH2?4[:VTEM2ED"6RQ>:3_ +., MUX5^T8 VI:$H8;RK<8]ZZCXL7\^E_""VBC!4S)#$YST&T4 06&K>,OB;=W%S MHVHG0] B;RXI5C#23GN2". MXJWX"\ ^(;_P9I]U9>,[FQMID+K!%""%Y(ZD^U6-;^!FK:[+#+J'BU[IT!7= M-!SCVP:!'L=A?0:E907ELX>&:,.A'<&K597A[25T+0[/2UD:46T0C\PC&<5J MT >6_'R7R_AJ4Z>;=QI^C'^E<'X6\1^.=0\#V&D>#]+>*.V4K->'!R?;-=A^ MT3)M\ 6BC^+4$_\ 0'KK_AC;I;?#K1!&BKOME=MHZDT >-Z5\5/&?A#Q$FG^ M*]TL)8!Q,@#*/4$5[%XR.JW_ (5&J>']9-B8X#6QZ%@:Z/3)9X?@%'+.Y\W^S6&3UQR!^F* *OP4\::SXNL=6_M>Y M%Q):R1A'"!20V[/ ^E1_&'4O%/A>W37=(UPPVA98FM#$I&?7)K)_9P@\O1=; MF/&^:,<^P;_&M?\ :#<+X C7(RURH H Z?X=:[?:S\/;'5]7E62Y=':1@N,@ M,<=/85P.FZQXJ^*>NZN-(UXZ-IVGN$1(T#-)DMR?^^?UKN?A?;(_PMTJ!N%D MMV!^A)KQS7- \6_"/Q#/J^BEY=,G#?&'A[2]0U MY[VPO;R*,R^4!N!< J3]":[/XK>)/%GAO23?:%! +1%_?SL-SIVZ'BL+PG\3 MO#WC^\L-/U^Q6VU*"59K=FY0R+TP>QKJ/C ^SX8ZK@#)50?Q- %'X+^(M5\3 M>$[N\U>Z-S,+QD5R,?* /2N-^+?CSQOX:UE;..2&RL9LM;R1+EG QGD_4?G7 M4?L_Q>7\.=Y_Y:W4C?R']*X_]I(9U+P\!R?+G'ZQT ;+^(?B-XTT.T?PU;?8 M+<1@27/O$5KXV;PKXKG:6:1MJ&0#!ZDRO^TY;% JW46<>NT9H ]J\9>*K7PCX>FU*>)CI*S_ +R&UAC'R ] 3WK&_:!G>?5?#VEB,QX4\6SI>(T@ M1+G: PST)Q76?%?QQ<^%-.M;+360:A?ML25NB#UK#_X44DNM1ZE?^([JZD1U M&./QK6^+7P]N/%FC6]QIK?Z?8+\BL?\ 6KZ?6@#(?P1\0+/1QJUIXUN9 M[\Q^8T#*#&PQG !K>^#OB'5]?\.7LFMW+SW,%P8\LH!&.HXKS+PS\8_$/@^8 M:1XHT^6>"([,LNV1 .,#/45[EX.U#0-6T@W_ (?6-+>XRE]=3X9^+FA^-; MNWTCQ-IR6]QYH:%BP*%QT^E 'M"%B%#*DIBD9X(/O3Z .&^(GCM/!V MG1K;1B?5+KY;:'WZ9KDSX8^(]]H,FL7_ (LN+2\$1E6S@C "]]IKF?%]^+_] MH73K6[^>UMYXHU!/ R <_G7T3@,A##@C!!H \?\ @_\ $G4_$5[98)R%X^8NRG^5 'KGQ4\2>*/#6@MJ&AV]L;>,8GFD^9H\G ( M'3O7">$_B7XTU_P[-8:;9O?ZP)/^/MT"QQK[XKOOBK,3\)=5D8!2T,61]76L MCX!P1I\/5G$>)))WW-CDX- ' :MXR^)'@'7K4Z_=^=!,V_:5!1QW Q7::AXV M\:>,HH3X&T]K>SV9DO)U'+=PH.>E9W[1Q4:3HBD R&:3#>WR\5Z?X$MDL_ V MD(J!,VR,<#J2,T >1^#OB+XMT;Q[%X:\8.93=2+&"ZJ"I8X4C;C@U[CK6/[$ MOA_TP?\ E7S]\4>?CQHPC'S>9:GCKG>*]^ULXT"_.?\ EW?_ -!H ^7/A7XH MU'P^NLV^C:;)>ZI>QQK"%Z)MW9)_,5LZIXS^*WA6X34=6,R0M_!)$IC^G%:_ M[.%DCSZU=E 74)&I(Z=!?&Z^-/ M"C:C%"HOHLI)!GC?V_.O*K_XF^.X?'MIHU^(K#-PJM L8)*GID_2IOVFX-C\ZH?$CYOC[8@+R&@Z=_E% 'N_B:]U:PT&>ZT>S2ZO8QE8 MW. >.37A7A?XS>)I/%LT6J1M=[U:.&Q@B 'F=N>M?1%T?]#N,_W&_E7SG\$[ M*"[^*NK32QJYMH9I(R1G!\Q5S^1- &CXG\3_ !=TJV?7)XDL=.5LFW6-&V#M MN)&?UKU3X<^,/^$U\*QZBZ".Y1C%.HZ;Q_\ K!IOQ/('PUUTNH;%H^ ?7'6N M)_9S/_%':IDG_C_.<_[BT .\:_$?6;CQG#X,\*A(;MW"2W+C)4XR<#V'-9WB MQ_B3X!TT:R_B1-0MT8"5&@7 R<5T/B67P1X,\8'Q%,);G7Y@1';6YWL6P!T' M0FN.^(VN>-]>\$7EY>Z1#I6AED_=RO\ OG^88R.U CU7PKXFN?&W@9-4L-EM M?2H4^9=RI(.,XKYR\46WBB'XF+::EJ N=969/+ES\@S@C [5[9\! 1\-X<]Y MY,?F:\Y\=?-^T/$!S^_M_P#T 4%(]D\,P>-K"POI?$-W:7\OE9MH88POS8Z$ MUYE'\6/&BGK5/X!V$%M\.QF2: %U_XS^)=# M\:IIU_ID5C9QR@2(5W.T9/!!^E:7B/XA^.K_ ,R;PKX>E33%&X74B99QUR 3 MP*Y;XDV\-_\ 'BPM;C'DNT*O],5]')%''"L"1J(@NW;CC'I0!YA\*?B==>,9 M+C3-5A2/4(%+;T&-X'7BO5*^W/TKUSP.H3P M/HJC) M4Y_"O"/'MHE_^T'%:RJ"CRP#"C)/R*: .F\0?%/QM>R/<>&/#\D>F M1@G[1-#N+CUYZ"NJ^%?Q);QO;S6E^D<>J6R[G"+@,N0"?S(KOI;>-;*2W6,+ M&4,84 8QBOGGX+HUM\6]7A7H(I@V/3>* .Q^)'C[QGX'U/SXK"QFTF1ML4C( MQP?0D$5TGPS\5Z[XNT1M4U:VLX(97(@$ ;) .#G)/>M+X@^'5\3^"]0TXYWE M/,C./XEY%>7_ +/?B(K'J'AJZ9A+$QEB5NPZ,/S_ )T ==\5O&'B/P='87>D M1VI^)C;VLPC\R78"%1?>N+U@KXT^+VFZ M4@$FG:"C7-P1RK2G 4?44SX]:W+IO@R.PA.W[;*(V8'&%'.* (1\1/%OB_49 MXO NF6S6$)VF[N\X8U4/Q3\4^$=9AL?&^DVR0SGY+BV! QW-==\(;&VLOAQI M36Z@-/$))& ZDUG?'#2H=2^']S=,B^;9,LJ.>N"<$4 >C6%[;ZC8PWEK*)() ME#HX[@U\]_$[]Y\>=&3K\]N/U%=A^S_J-S?>"KB">1G2VGV19Z!<9Q7'?$52 MW[0FC#J/-M>G;D4 >V>+;W6].T9[K0;*"\N4.6BF)Y7VQWKRSP[\:O$'B#Q3 M::+'H-G%*\NR7);9B."RO/*QWH>V15;6?CGJD4IN=(\.22:6G_+>X1AG\17,P M:+9:K^T9<:?<0)):BYD=HR.#M0MC]*]_UC2[23PY>69MXUMS X**H"CB@&97 M@#QY:>.M%-W!'Y-S$0L\.<[3[>U6O&OC&Q\&:(U_=J978[(H5/+L>E>1?LW/ MFZ\0("=@$)QV_BI/C=-(OQ"\/1W8?^SU*,?[I.Z@1V$?B?XEW.FC5X= TQ+8 MKO6V>1O-*UEZ5\?(;YEMW\.7C7W(:.!MPR.M>NVWER6<7E[3$4!7'3&*^=O M$1/Q[U9;",?98Y[@' RH7<0#0!]#Z7>G4M-M[TP20&9 WE2=5^M6STI%&!^% M*>G'6@#B?'OC^'P=';6L-M]MU2[8+;VH.,^YKDM2\;_$_0;-M0U'PU8/: ;B M(BQ,8_VN:SOCAH6LQ:UIWBK38WFBLU 954L4(.@H ZGPCXOU+Q?X%;6;2Q@2^W,J1,QVL17*^%OB[JVI^.H_ M"^JZ+!;7!=HY&A8_*0,]Z]!\)>'M/\-Z*+33)O-M7D:8/G(.[T]J\)T@M#^T MS(#_ ,_7$?S-'.Q'R^V.]<;\-OBO<^-]8NM M,N]-CM9(8]^Z-B<\].:]*OL?8;C=]WRVS^5?._P! /CG6F"Y C./IN.* /;O M%OB[3?!VD/J&H2E;T%<%+XW^)-UIIUFP\,6$6GE/,"S,QD*^O!KDO M&]Y-XH^.VG:'<'_1+6=$6,G@\;B37T+Y$7V3[.5'E;=FT#C'2@#SOX=?%FS\ M:3_8+FV^R:EM+!%)*OCKBN<_:.;_ (D&C*!R;ESGT^45TWACX3:?X6\82Z_; M7DC!@P2$K]W=7,_M&[3H.C*5^A:[IGV&YE;8C D#=V!!]:['X>:%9:/X,TT6 MT"HTL(>1\#))KQWXPQ"P^+&DW-E'MN&\M_D');(H ^D,\TM,3)52WWL#-/H M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6B@#Y6^-X ^(,QW=0O'X M5PD77/:NT^-A8?$BX9B"O&!7#JW Q2&39#'K3BHR,DX]JM+2&@#YV^.\POOB+H.D7$ACM!"C%LXQO<@_^@BNWB^"N@O%&RZIJH4J.!$+F]BLO$EBA9K53%.%&2!G*G\.:R/"7QZ^P:5'8Z[92320J%C MFB."P'K0!WVF?!;PMINJ07Z"YDFA<.IDDW'M/;>H)P9G[?A7%_'S7=/U+7-,LK.X6:2T5C-L.0I M)Z?6@?4]X\*1+;^$M(A&!BTC_5G2_'YM7EN56Q-R^V4].010!ZA\=M)N]2\" M^9: L+:422*/[OK5CX2^*=-O?AY9(]U;Q26$;1W"%P-@!."?PJ+XR^*KW0O! M\8TU?EOB8VN%Y"*?\:\GTK5OA/'IMFE_H-^]VB+YK"9\,V.3C/3/:@.AT'V8 M?$3XYIJ.F@R:9I[QL]PO*ML.1@_4U[/XLO-%LO#UQ/KXC;3@!O1QG<>U<;X4 M^)_P]C\G2=))T]&P%5X?+4GW-8O[0[7#^&=*,))MC<$N5Z'CC- MR?1=6\5^ M+K%(O"%C!H'AY"4CN95^9QZJ/ZUP6BV-U8?M"6=E?WSWUS#<$/;V7BT6?QD'B36K62UVREI(4 M7YES&0!CWS04E:Y[E\9=,NM5^&FI1V:-))#LF*+W56!;\@"?PK&^!OB&PG\# M1Z>;B-;FR=_,1C@A220:N?$;QQ=:9\.(M9T>%T:\81!Y5P8E8'G!_+\:\GT7 M4_A2-!LDUG3KV7454&X>/>-S=SP:"4;_ (I@3XB_&FQCT7=/;6 C6YG3[J;6 M)_\ K5T_[0T\L/@2SC1B$EOD63W&QR/U%/\ "_Q-^&NF&+3M%C>R$K 9^S;1 MG_::MGXN^'Y/%GP^D6Q EE@D6[C"\[P 0AZGX6TV\EO]2#S M0!F\JY*HIQZ5IM\"?#$DOFS7%],W',LNZO./A]\89/"5@-'UNUDFMHCB-EX: M/V-=9=>-M0^*Q30?#5G<6ED[ WMX[?=7NHH"Y[19VL5C8V]I",101+&@/]U1 M@?RJ4GFHK.V2RL;>UC)9(8UC4MU( QS^53T"/E;XLQKI/QADN67 M37U':7$=W:17$3!HI4#J1W!%>7_&GP&_B725U73X]VHV2$E1UDC[CZUS/PP^ M+4.EV,7AWQ.6MFMALBN)/EPO96'J*!W/?**Y6?XA^$H8?/;7K+8!GY9,G\JY M#^W-:^).L00Z$UQI_AVWE$EQ>Q126-GX(C;5& M1;%+(>>9.FS;S7A7Q^URQU36]-L[*=96LDD\TH<@,Q7C]*Z_XJ7BZK\(;2XT MN<36RF+S_*/8 9!I#ML1Z+XEU?6M^G?#C1(=/TA&(:^G0A2?6N \7:3JNF_% M/1[76-3_ +0NY7@E:4# &9"<#VKMOAW\5?#.A>![/3KMYH[NV&PQ1IDR&N \ M2>,&O?BK!KU_92V]O#)&8X)5PPC'?'ZT MSZ.\?2>3\/]<8=K*0?IBO-?V<4 M']A:U)M&[[2@!]MM:7COQ_I&K_"C4I[*-2L(]$O[ M SQI>/P^&UR;=B&GF2%B/0Y_PJ?X+6L%M\,M.>$8 M,Y>5_KN*_P#LM7?B?X;D\3^![RR@&ZY3$T7N5[5Y%\*?B?!X3M9O#NO1O'") MBTJG\J 2/0?CU*$^'+J?X[F,?^/9_I5OX)Q"+X7Z<.[-(_YL:\W^,7 MQ%TSQ1HEOIFD":2);D,]R4PK<$8!_&NR^$'B2TU'P&-(M4E%[9P,2#'A<\XP M>] ^@NO>+=-M_&TMEX4T*/4O$T@V33 86/\ WFKC_BMHOBR+PHFI^)=:AE_T ME42SMU.Q20QY]QBL7X4^,;/PCXKU0:^SQO<_*\S#)5E)Z_G6K\7?'T'BW0X+ M+2K*X.GIR(55V"L,#\Z 2U1ZG\'K5+7X:Z7MZR@R'\37EVDA;W]I6[9A MGR[N4C_@)Q78?"GQ]HC^&+/2)'D@>RMP)99>(P?K7G7@S7M/D^.UYJKSJMG< MW,[1R2<##L2* ZGT=XC.WPSJI]+.4_\ CAKP_P#9PAW7NM3GO$J_K7JOQ U[ M3]'\'7SW5S&KW%LZ0KGF0D=J\H_9VU*QM9M7LYITCNKEHO*5CRX&[(% CZ&' M2F2.$!9CA0,D^E2=JP?&4$]SX0U2*VSYS6[!<#K0(\VF\8QW7BJ]T_X>:'!/ MJ4S8NK\KA%QW]^IKD_C#X:U[3-!L=3US7WOYIK@QFW"XCC.QCE?RQ^-4OA)\ M0M*\%1:G9ZS&\1E=2LL4>6R,@@_I4GQ;\;7/BW3K$6VFW,.BK+NBGFCV^9)M M('Z$F@:6I[7\-(%/PVT>)QE7M0"/8BO(/%OPQ\2>#-\!?&=M4U2VT?Q5:QBX>7RX;G;P'Z $=CFO=001D5\Y>(; M73O&_P 8M+D\+0+,L$DTJV M'_+:X=C_ ,!4?XU[4> :^U M^ H!:^!-%A'06R_KS_6O%O&A,O[1^E)V$]J/Y5[#X U_3==\*V+:?<+(8($C ME0'E& QS^5>)?$J^G\-?&R'6KB%FAC>*5#CA@!R!0-;GTJX5T*$9!&"/:O _ M'?PBU?3M6DU[PA)(2S%V@A)$BG_9 ZUVA\>'Q)X(U_4[+3[JSM8+<^3.PPSL M>\\/V]CK]\+748%V-)*>)!V.:"3GO GQ>U6SUR'0/&$9P7$ M0FD7:\;]MP->_H=W/^37SOXC2S^)?Q8T]=!B\ZUMBIN;E5PI 8'K7T0B[55> MP&!0-CCTKROX^2LOP_AA7_EO?11G\F/]*]4;[IKP3XU^-M'O5TW2+67SY;/4 M$GN0H^Z%!&/UH$>QW.E6^L>$QI=TNZ&>U$;#_@-?.7PNUM/ ?CZ^TW6IEM8" M&AF+G@.M?0OA+Q3I/BC25GTJ;>D0".I&"IQTKQWXN> KO5?B!I\]A!(RZEM2 M9T&0I'!- '2^![6X\9^.-1\:7H$EC [6VF#/! ."X^O7\:R_VC+C_B3Z-;#^ M*=I#^"G_ !KUK2["S\,>'+>RCVQVUE 2!UP/F;\3S7SG\:?&6G>,-3T^'2# M)-'9B17;9P2Q7&*!GNGPW1;;X9Z$2< 62.?IC->&2ZT?B/\ &"VBO'8Z:+@I M#$Q^7:OM7K?PN\6Z7KGA6RT:-W6]M;41RQNA&,#&K:II(L MUN)I7\I59L!9,X#&O1M.^-.K:]9I9Z1X:FGU:0 !FSY0/=C^E<[XK^$7BC4] M*F\17MT+C6G8R2VR]%0#HOO0"/5? 7@Z32O.UW691=:Y?_O)9#R(P?X5]J[@ ML,[<\]:^5/#OQ.\9^%K=-->V:ZAC.U8KB$DK[ UZCX%M?$VO:PWC+Q-));0Q M1%+:R3*A1UY% ':^._$R>%/"5]J;;3*JA(E)^\YX%>5^#/AGXFNK$Z_'XDGT MJ[U$&21(5Y*GFL+X@>/CXJ\2Z?:MI]V-#L+D/,OEL3(0>?TKZ$T#4K35M&MK MRQ1TMW0;$==I4?2@1YY=_##Q/>VLD%QX]U":*1<%'3@UYA\.+^7P'\6)]'O' M81/(UK(?[QSE3^7\Z^GKNZ2SLYKAPQ6)2Q"C)P*^2?'E_=>)_&]QK6EZ3>1+ ME=I,3 L5[_I0!]?#IQ17"?#/QE<>)]&2&\L+BVN[:,+(TB$*YZ<9KNAS0!B^ M*_$-MX7T"YU:Z&4@7*J#]YNPKRWPYIGB#XL1/J^N:C+9:)O*PV=NVTR#OD_E M79_%KP]=^)O US8V0S/&ZSJO][;GBO(_AUXL\D6.DV20*\3,S Y9CD=:].^..\_#$*OW?.AS^8KS'XC^#/ M&D>M6>JZB6U.:X(.((SMB.AN]4L/+LQ.OEV4*_-D@\F@#TOX)Q>7\ M-K$_WW9JW/B%X<3Q/X.OK#&90ADC/HPKF_A)IGBS1M#6RUV&&*RC7, /,BD^ MM>F,H92&&0K/\I ^AR?QKV[X>^&%\ M,>$[:W;YKN?]_8_^/D5F_&8>)M/TKPGQ?\,=?^'9.MZ)?2/91R ET;#1C/5AZ=OQ MKI;Q/&OAOXM:[K.D:-U^)9UMO"^K3,V EI*?_ !PUXU^SQI'? M%<+-\;-+13R!%G]*^CP, "OFO6_"'Q#UKQDOB:718UN%=&6(-P-M>_Z!=:I= MZ5%-K%HEI>'AHD;(H UJ**CFWB-RBAG RJD\$T ?/GQY?S?B#X=@'_/%#_Y% M-?0,*!((E_N@?RKY^\6^"_B'XL\5)K4^FVL9MF"V\8EX"*Q(']?QKUFXN_%P M\&"2'3;7^W"-GD^8=@&.N?6@=SR'P&GVG]H._DQQ&TS?^.D?UKW3Q3-Y/A75 M)/[MLY_2O#O"G@3XB:%XK.OQ6=I]HE9O-$LO!#'FO3_B#IWBW6?#RZ9H:VJ& MY3;=.\F"!W"^U C@?V;8=MGKDW]Z1%_('_&O>*\:^%O@GQEX'U-X+A;1M+N& M!EP^67CJ*]EH RO$MK)>^%]4M(/];-:2QI]2I KP#X"^([?2==OM*O)1$+K# M1ANF:^E*\-^(?P0DU34VU/PV8XGE.9;=C@9]10![)J6J6>DZ?)?7MS%#;QC) MD=@!BN$UV\E\?_"K69K:V>&.5&:VW=940YS^AKB?#?P2UJZFA/BG46-E"P*V MJ2$@U[M:6=O9V,5I#$J01IL5,< >E 'B/[.VJ+]DU;2G.)5D6;\.AKU_Q)?Q M:7X;U"[F($<4#Y_+ KR_6_A;K>@^*3XA\$7"QR2,6>WDZ<]?PJW/X3\>^-8( M[/Q5J-K9:8'S)!;*-TOL30!B_L\:&[#5O$4J\2O]GB/T.YOYK6/\3E%U\>=% M@'.)+8'_ +[KWBUTA-&\/C3=%BC@$,16 $_6 M02+*1]T@Y% SWT-MCS_=%?//PQ;[9\>]?N3V>Z_]&5[#?6'B:?P?]CM]1@36 M"H5IRGR^]>9^%OA!XM\.>(%U:'7;9)W)\\A,[P3DB@1>_:.(_P"$/TQ>YOA_ MZ U=[\.(_*^'>A+Z6BUPOC[X8>*?&VHQ27.MV@M(1^[C\K&#W-==X,\/:_X; M\-R:9=ZI!=2(F+5A'@)Z4 >4?&4FY^+6AV_94C'YMFNO_:#TZ:Z\%VEU$I9; M6YR^/0C_ .M6+J7P3\4:SK9UF^\2VK7I97#>0W!'XUZ];:5/=^'#INOR17KR M(8YG5Z=X?$=I:R MQWFJW#+'!:1MN8DGJ0.U>8ZS^SS.VHO)H^IQI:LV1',N2@]*[7X?_"/3O!\W M]H74JWVH#[DA7"Q_04#9Q_[0MEE CT36OB'#+XAT_0/#CQW]]-<*+AHCN6&,'YB37-_M$28\(Z< MA;&ZYY_*NU\$> -)\%6I6R027+KB2Y;[S>U6/'7@^U\:>'WTZY8QOG=%(/X6 MH 9X#N;6+P%H 69=K6D:K[MMKSC]HR=1I.BVQ/S-.['Z8K;\!_!V+PQ>Q7^H MW[WES"H?%OP>O_ !AKDE]J/B*0P@_N8@G""@#O="LHW\&6=G_ M]FL?YK7@?PHO3X.^)MWHNH@QM,QMN?[P/%>Y>"O#-_X6THV%WJ\FH1KQ#O'W M!61X[^%MAXPF6_AF:RU-,%9TH&=M>W4=C9374K )$C2$^P%>#_!G1SKGCO5_ M%4B?Z/%(XAS_ 'F/^%=(GPJ\1:E#'8:_XPNKK34(S;*2 P'8UZ;HNB6&@:9# MIVG6ZPVT0PJ@=3ZF@1Y%^T9*/[$T.$GDW1;_ ,=(KU7PJ@A\&Z,@Z)8PK^2 M5P7B[X-R>+]'9=)?6[BZXVPRMUB&.@H M \<\9N+O]HG3T[1O"GY9/]:^CEYZ=N*\9F^ <5UJ+:A/XEOVNS)O\X8W9^M> MMZ592:=IL%I+=2W3Q*%,TIRS?6@;+M,FC6:%XG&5=2I!]#3Z0]*!'RAJ']K> M _BEJ>E:&0LE^?L\8_V9,8Q]#7OVF^!;&W^'TOAF7E;B$B>7NSL.6_.KE[X' MTB^\96GB:6,_;;="H]#Z'ZBNFH ^2/!^CZS=^*9/ K2LMFMWONT[?(>?Y5]: M11)!"D4:A8T4*H'8#@5S>E>"[#2?%NI>(8&8W-]]]3T%=#<0^=!)$)'0LI = M3@C/I0!\Y?%FYBE^-VD*6&V(VRL/?>:^C00;4X.1LX_*O)[KX!Z3>ZA)>7&L M:A)-(V]W9\L3]:],T32ET728=/6XFG2(8#S'+$>E 'SI\)M8T_1_B7JTFH7, M5LDGFJLDK!1G<:]L\4:YI^H?#G6KZSNHY[?[.\8D1L@G Z?G7.Z[\$/#^L>( M)-4:>>!9GWRPH>&/>MG7/AAI.LZ)9Z.EQ=6>GVN<06[X5R>Y]>E '%_LX%?[ M"UG!&XSQ_P FJS^T7;P;K,4?WFLI0/\ O@UXI\"/$NC: M'H^KPZC?PVLC3"0>8V,K@5]!.BR(46V?P+\,6FN+?YGDB#[UMG.4 MS0 GQGUFVE^%PF@17%^]THBC"1QQR$*H'0 59\'_#O3?!4TTFG7-VRRC!BDD)4>] 'E'[0\\;> M)]$BWI_!#PWK&I3W]Y<7TDTS MEF)F/'M]*[/PUX:M/#&EC3K22>6!>GG/N(&.GTH'<\)^%'Q8L_#=@=$U]G2W MC(?C#I=U9#3O"B6MQ9:/:6]W, M99TB D=NI;O6C2#TI3TH$>,_M&R,/!^F1J,AKT$_@C?XUV7PNU.SU#X?:4MO M.CF& 1R 'E2*Z+6M#T_Q!IDFG:E;)<6\G57&>?4>]><'X$Z-!.[6.JZE:1/U MCAEP* ,+XFWY\?>+M/\ "&C'SXX'#74BH- 'SU\#O&&A^'M,U+3M M6OXK.5I0ZF9L9Q5/XV>/K#Q-96NFZ23/;12[VN5^XQQC ->DZM\$_"FK:VVI MR12Q;VW/#$V$8_2MK5_AOX?N,H[UK> ?&=CX]\+ W?DO=K\EU;GG'H<>AK9L/!NAZ9H=QHUC9 M);VDZE9 G!;/VL@)):.4Y- '"?$?PWIMK\3]#M/#<:1W MVO MG7%XZE3/.VXXI/%7PO\ #_C#4UO]46X:8+L!24@ ?2@#&^ \\+_#:WA1QYD< MT@8>^XUP/[0E]!/XGT6U5A^YC9I#Z98?X5ZKX7^%OA_PA?O>Z8+E9F38VZ8X M(K/O_@IX1U+49KZY@N6FFEII[J9K<1B(K*=V5QCG->>:M\"_".I7K74<'-7\(7UW?BW4>27CN1C.[!*X-<'\ 8KNT\.:_=! M6^S[@UN6Z$A6_P#K5O+\"/#8N49KF^>T4Y%L\I*YKT6STBSL=+&FVT"16@C, M>Q>.",4 *-&?1T2.^N9 M!OAB['(P>*[R;X$^%6E,EO)>VTI);?%,1BMCPW\*O#WAK5%U.))KJ^7E9KA] MS*?44 =?IZ2Q:=:I,>'/CGX9O-(C;5KDV=Y&@$J,A.]L488&O M,1^S]X934$F2XNC &W&!SE3[4 6_#GBF]\?^.?MFFM+#XN?F%?1FDZ38Z'8QV.G6\=O;)]U$&!46N^ M'=,\2Z>UEJMJD\1'&X<@^HH DTS5K34]+BU*"5#;31B0-GH",\UX3>6\7Q$^ M.Z36<9FT[3E19I1]WY"3U^IKJT^ VCQ.XBU?4DM7/,"R87'I7H7AWPWIGA?3 M%T_3+988!R6_B8^I- '(_&R:.'X5ZG%N ,C0(N/^NJG^0-0? =T/PSMU# E9 MY<_]]&M;QM\,]+\;W4$]_$=(V,"/L<7_ *"*Y+6_@SX9U_5K MC4[YKQYYVW-B4X'TK=\,^!M/\*:5=:=I]Q=&"<$'?(25R,<4 >)_$6^A;]H# M2I/,79#/:JY],.#7T!XA/_%-:B1_S[OC\J\[O/@'X:NKE[A[N_WN2SDR9)-> MC:3H\.DZ/%I@EEGAC78#.VXD>AS0!XA^SA?012ZU9R2A9Y#&ZH>XYKU#XC^* M+3PUX1OY)9E%S/$T5O%W9F&.EZ7=7.ESLQ8F!L 9.>/2K>@? M!_3-,U9-3U._NM8NHO\ 5&[;<%- %?X*^$KCP_X8EOKV-HKO4&WLC?PKVKS? MQK_#S2F5]4U M-I">) M9CYB0R3GY X8<9/M78_&SQIHEYX/DT:ROXKF[ED0E8&# $&MSQ=\$M$\2ZN M=2BN);*:0YE$0&&]ZVK#X6^'-.\+7&B);!H[A,2S, 7;WS0!S'P.U[28/!-I MI4E_ M\9I/W!<;CECVKA_&TL%E^T1'<7K^7;B6!BQZ#]V!7J_@OX4:'X-O7O M83)F^.;J"]EN)+:ZC789$'WA[T ==8:WIFIW,MO97T, M\L0#.D;@E0?6OG[7)DD_:1MSNR%NHU//I7L'ASX=:;X7\.7>F:9/-#/=)MDN MU/[SZUQ,G[/=C)<&Z_X2"_\ M);=YAQG/KG&:!G9_%'PW+XH\#7EG;KNN(SY MT8]2O:N!_9\\20QV6H>&;MQ'=1S&>)'/+ @!@/IM'YU['HNFOI.D6UC)>3WC M1)M,\[;G;ZUP?BCX.:=K6M'6=+O9M*OV.YGM^ 6]?K0(W_B7K5OHG@/59IY% M4S0-!&I_B9@1C\B:X_X">')=+\,3ZG_8% ?[@Z58M_@U]MOX+CQ-XAO] M82+E8)G)7(KTMK)5TXV=LQMT$?EH8^-@QQB@#YQ\=S(/V@;=GD"*DT +'H/E M%?2Q(VY!XQG->,7?P!BOK][Z?Q)>2W+OO,K\MGZUWUQX2OIO!0T#_A(+U9<; M6O ?WC+TV_3% 'BWPB*M\9=18N.D_P#6OI6O&+'X"_V5?QW^G^)KVWNT;=YJ M@!J]D165 &$?M(S?Z%H<&N)MX(AD8X:Y+^89]OSEO7- 'M5RVVVE M?^ZI/Z5\\?!*03_%7793_%!*?_(JU[#J?A?4[_PBFC1Z_W$ C!Y!KY>\;I'_?5?3L098T4DL0,%CU/O7'^.OA[:^-;G2YIIVA-E+O./XESG'Z4 M 5OA7H+Z;X=;5+T;M2U5_M,[=P#T%8OQYT*34O! OH1DV,OFL/\ 9Z'^=>J1 MQB*)(UX5% 7Z 4RX@BNX)()D62&12KJPR&!ZT >:? S7(=1\#Q6&\">R;8R^ MU3_&_5+>P^'\]I*?WMZPCC [X.:QYO@WJ.BZY)J/A#7FTQ9.J.-V*T+#X67^ MI:K!J7C/7)-8: YBM\8C'H<4 6_@GH4NB> (3.NV2\D,^T]AT'\J\]\:.MS^ MT3IL8_@DMP:^@)[=SI\EO:R>0_E[8V4?8I'4H&;75;+0K>WU MJ]6\OT&))E&-U7=0M4OK">TD^Y-&T9]@1B@#YX^'UUJ'Q&U+0])U $Z?H*F> M;/(E(P$S],U]'#Y0!T&,8]*XSX=> 8/ UG>1B199[F3*^*O@[XF\4>()=1N_$$,GS M9@W)RB9R!7H>B:)XET[P=-IEUK23:GM*PW.S[@Q@4 >1^%?WO[3%\2>DTY_\ MAFO?=7<1Z->L>@A<_I7AUK\%/%6GZX-9M/$-N-0#F3SBG.:]*\6>'O$NN>&H M=-L=7BMIW7;=R&/_ %@[T >8_LVG-YXB(Z%8?YO6Y\=;G2KRVT[1616UB>8& MW?./+'"]3-SIWB6U6*4J)XC;DF10>F3TK*^+&A)XT^(NEZ+I M!!U)(&^UOGA$!&,CZT =-HWAWQXGAHZ6/$^F&,Q[%<*6=!CIFNC\ _#^R\%6 MU>.-^S[XIAF#V^I6OKN#%327WA[Q_\,S#K+ZF\]HC* ML@64D8)Z$4 ?3%(?7TJGI-[_ &AI-I>%=K3PI(0>V15QL%<'H>* .<7Q1I=U MXMN?"DH)NTA$A5URKJ1FN!^(WPAT&ZT:\U;2HA97<*&4B/[CX[>U3>,_A;K. MO>.3XCTG5HK.0(FS*\@@4E[X3^)^MVAT[4_$5I'92?+*88P'9?J* #X :M?Z MEX2O(+R5I([6<)"S?W2#Q^E<3I\D5G^TM.U^X0&YDVD^I0@5[MX5\,6'A+18 MM,T^,+&OS.YZNW3 M+'"D3 DGJ2*\(_9X=&\6ZTX;AH01]-QKLM ^#]PMO*_B;5Y=4G,1CAC=F*1' MU )K*\*_ -]+U5+[4=6;,3YC2W&W('3)H X[XJPW?A7XNQZXJMMD=+F-AWQ@ M$?D*^A/#7BO3/$VDQ7MA=12 J#(FX;D/?(JKXP\%:?XQ\/G3;S*L@S#.>6C; MUKQG_AG?6A<[5U:W\C/WPN&Q0!ZY+XTCO_&-IH.B2PW31Y>^=2"(E]/K7GO[ M2#D67A\ \%YR?P\O_&O0O GP]TOP18NMKF6[E $L[#D__6KBO&GPF\3>,]7: MXO=?A:WC9OL\1C_U:G_]0H ]+\(R"3P=I3#O;+_*O$_BVV?C)H2CL8OYBO3O M OAGQ+X:TB73=2U:&XB1=MJ5CYCKA=:^#/B?6/$+:O/XBMWN0^Z-WBR5QTH M]S%.K*T"UU.TTF"'5KQ+N\08>9$VAJU: "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BCO2&@#Y(^,GF#XD7Q?D;_ )1[5R,:J0#WQ75_&*5'^(FH[3NP MV*Y&U)*#(^E(994>O2E &[H:=C R>E&>0.U,0UAS10PVG!HIV$?;]%%%(844 M44 %%%% !1110 4444 %%%% !1110 4444 ,EB29"DBJZ,,,K $$>AKBKSX3 M^![R\>YFT"'S'.3LD=!G_=! KN*,4 4K+3K/3K%+*SMD@MD7:L48P *Y6;X3 M>!KB:6:;08VDF=*,D_1J[? HQ0!SD/@GP[;Z)+HD.E0IILO,D&6(8_7. M:S8/A5X'@.4\/P9]ⅅ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